<SEC-DOCUMENT>0001657312-22-000016.txt : 20220503
<SEC-HEADER>0001657312-22-000016.hdr.sgml : 20220503
<ACCEPTANCE-DATETIME>20220503082455
ACCESSION NUMBER:		0001657312-22-000016
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		56
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220503
DATE AS OF CHANGE:		20220503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Verona Pharma plc
		CENTRAL INDEX KEY:			0001657312
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38067
		FILM NUMBER:		22884701

	BUSINESS ADDRESS:	
		STREET 1:		3 MORE LONDON RIVERSIDE
		CITY:			LONDON
		STATE:			X0
		ZIP:			SE1 2RE
		BUSINESS PHONE:		011-44-0-2032834200

	MAIL ADDRESS:	
		STREET 1:		3 MORE LONDON RIVERSIDE
		CITY:			LONDON
		STATE:			X0
		ZIP:			SE1 2RE
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>vrna-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:8fe8cf0b-7d67-4c56-b99e-508dc94a315d,g:47f0dc6b-9fdd-4cb6-bded-b1ab0e3af7d2,d:1386bbda6db741028e2d0ab6d6a3d0c9--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:vrna="http://veronapharma.com/20220331" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vrna-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80L2ZyYWc6YzAxZTE2YWU3YzRjNGE3YWI5ZTliNmJhMzc5ZmVhN2IvdGFibGU6MGI4ZmI3OTRiYTM3NGIwY2JjMTA3YjIyNTRhY2YyMjIvdGFibGVyYW5nZTowYjhmYjc5NGJhMzc0YjBjYmMxMDdiMjI1NGFjZjIyMl8zLTEtMS0xLTUwOTQw_2b1d1f7c-8d8c-476d-bd37-86dd436126dc">false</ix:nonNumeric><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80L2ZyYWc6YzAxZTE2YWU3YzRjNGE3YWI5ZTliNmJhMzc5ZmVhN2IvdGFibGU6MGI4ZmI3OTRiYTM3NGIwY2JjMTA3YjIyNTRhY2YyMjIvdGFibGVyYW5nZTowYjhmYjc5NGJhMzc0YjBjYmMxMDdiMjI1NGFjZjIyMl80LTEtMS0xLTUwOTQw_7c952a29-2167-4f24-9155-15a4940e0927">2022</ix:nonNumeric><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80L2ZyYWc6YzAxZTE2YWU3YzRjNGE3YWI5ZTliNmJhMzc5ZmVhN2IvdGFibGU6MGI4ZmI3OTRiYTM3NGIwY2JjMTA3YjIyNTRhY2YyMjIvdGFibGVyYW5nZTowYjhmYjc5NGJhMzc0YjBjYmMxMDdiMjI1NGFjZjIyMl81LTEtMS0xLTUwOTQw_957df4fa-f6b1-42a0-a37d-5a623509ab93">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80L2ZyYWc6YzAxZTE2YWU3YzRjNGE3YWI5ZTliNmJhMzc5ZmVhN2IvdGFibGU6MGI4ZmI3OTRiYTM3NGIwY2JjMTA3YjIyNTRhY2YyMjIvdGFibGVyYW5nZTowYjhmYjc5NGJhMzc0YjBjYmMxMDdiMjI1NGFjZjIyMl82LTEtMS0xLTUwOTQw_b519558e-952b-4e0d-a4d9-25cb3354f98c">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80L2ZyYWc6YzAxZTE2YWU3YzRjNGE3YWI5ZTliNmJhMzc5ZmVhN2IvdGFibGU6MGI4ZmI3OTRiYTM3NGIwY2JjMTA3YjIyNTRhY2YyMjIvdGFibGVyYW5nZTowYjhmYjc5NGJhMzc0YjBjYmMxMDdiMjI1NGFjZjIyMl83LTEtMS0xLTUwOTQw_89e060c8-1951-42d2-8694-5a36bcd19763">0001657312</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vrna-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13a74a89113848ab9989e148e632f317_I20220429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i568425c4e3c7431599d8b1aa195d0e85_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i43f3fd81e5634600b3df44427e14839e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbpPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i3fd060aa5bbb47278b27ef1634cafe13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee10beb5614d4c36a49b38b0408c3c77_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie034936385eb4829a4a09ca135e0d332_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i487b969ea66c4193b79846ba2684834b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia76cefe1174549e7b4d4eb6f368d6bb9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a41f83bf2f147cca904ad371dd3c80f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i406e2d71f2494b7586c12bf94c99c19a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c4f42981f7a4b07b3f072092f9d25ee_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c8f3273cca84e1fb9b901be94b1d3de_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccf8c5dacaee4f44963a79b7f359f4ea_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27b5bd780a9d45798cffb2697ac8ade3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic919c5d0bdfd4afaa416dbe6e26c0669_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14c4574a519449c29bf55707447cb27d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00c370453f2b4f5db71678b478ddbbe0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief871dca18cb4d72a122e673f25d7055_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5415b7e84bdf40e388391917c6fb0a3c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17b773074fa84265a6b1dcd53b75176c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89039648129e48e19231c6fcf8cd7c46_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84db4d73c9c5454584348de0514aa545_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i753d3703301043ad8197826c3029e966_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8c845ed47cd447f83b0049bc8df056e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62831f3f81ff424dbd8b50fd58c3cd6c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i764cecabbeee41a19da9bdf3d8c3566e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia488af7353324c8197666eef6a12f7bf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87de327ddb3f41e7ba3457265e088033_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a61756845fa41f2bdc2a4c25489a95a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7370fb3dc73448d91fdc9fe7f5ffd30_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie94feae856cc4ea5ac4eff16299f3bbf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic509b8fcd7664f3594ed0ab72f0e609f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="subsidiary"><xbrli:measure>vrna:subsidiary</xbrli:measure></xbrli:unit><xbrli:context id="i22ba9f263b564af695f8fba5e244c5fa_I20210319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14b59a9e0309440bbd87ed4bea74076d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b1d9925838f4f4e8d46dce269a2578c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>vrna:segment</xbrli:measure></xbrli:unit><xbrli:context id="ib5e3071b65394dcb9eeb62c562c7fadf_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e36e2a2c0ee4200aa8e95a2881303c4_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d316fcf04fa4e9886bc433d175709c7_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermBLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5ebcd401a344004af7b7053e2853059_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermCLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e7ac21ebac441969276519788ca0689_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47479f2645fe48afa643ac8df2b7b1c4_I20210609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:NuanceShanghaiPharmaCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85587e1e0a8f439d8aebd8e3ae70349a_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:LigandUKDevelopmentLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ccfc42928504d8bb11c9856cb8aae45_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:LigandUKDevelopmentLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="vrna:BenchmarkAchievementAxis">vrna:FirstCommercialSaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="tradingday"><xbrli:measure>vrna:tradingDay</xbrli:measure></xbrli:unit><xbrli:context id="if0331ecacba24ab991d409deb3d7c0d6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:LigandUKDevelopmentLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26149cf54682400fabed175e2aa6fa8c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:NuanceShanghaiPharmaCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf656cb200bb45b582e522a818bd7960_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08b14602cfda47eaa4b3fbe624c9a1cf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f4ede3c3b79413cac4812d5477bb459_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3718066b40d6491eb81e069865deddc4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82b2bb68605b4efca32316b1da619988_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5bbf2f1a066455386dcb6d6e2137c08_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica753976be2b4f4bae0fa0b52b8c63a0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c92777eba5f49eca3791c762fd6c083_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Washington, D.C. 20549 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yNTI1_5228f0ef-7804-4473-90c0-2bf0abfabd20">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yNTIy_bfa611e8-919e-4108-8fd2-5275d962c289">&#9746;</ix:nonNumeric>&#160;&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yMTI_dbfe63bd-96c9-494c-9060-0cc6fae79e9a">March 31, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OR </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yNTI2_bff39252-e3f0-4e0c-8ba6-cb1b6988541f">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FOR THE TRANSITION PERIOD FROM __________ TO __________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yNTI3_431387bd-77d5-4340-963f-884622930edc">001-38067</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yNTI4_2d6f40a4-8e4c-4b41-8b3b-ce031cecb90e">Verona Pharma plc</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its Charter) </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGFibGU6ZmNlOTEzNGVjNjFjNGY3YTk2NTJkNjQwZTc3M2I3YTUvdGFibGVyYW5nZTpmY2U5MTM0ZWM2MWM0ZjdhOTY1MmQ2NDBlNzczYjdhNV8wLTAtMS0xLTUwOTQw_7b984d7b-c037-47f3-b8a4-817530ab1119">United Kingdom</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGFibGU6ZmNlOTEzNGVjNjFjNGY3YTk2NTJkNjQwZTc3M2I3YTUvdGFibGVyYW5nZTpmY2U5MTM0ZWM2MWM0ZjdhOTY1MmQ2NDBlNzczYjdhNV8wLTMtMS0xLTUwOTQw_7a2e0d29-6eea-40e6-a056-bb897ba019f2">98-1489389</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer Identification No.)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGFibGU6ZmNlOTEzNGVjNjFjNGY3YTk2NTJkNjQwZTc3M2I3YTUvdGFibGVyYW5nZTpmY2U5MTM0ZWM2MWM0ZjdhOTY1MmQ2NDBlNzczYjdhNV8zLTAtMS0xLTUwOTQwL3RleHRyZWdpb246ODZmNTU0MGY0ZDBiNDc5OThmNjkwODRiM2E3MWY3YmJfNQ_12c9579b-1171-4fda-acc8-469bf5ffbc05">3 More London Riverside</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGFibGU6ZmNlOTEzNGVjNjFjNGY3YTk2NTJkNjQwZTc3M2I3YTUvdGFibGVyYW5nZTpmY2U5MTM0ZWM2MWM0ZjdhOTY1MmQ2NDBlNzczYjdhNV8zLTAtMS0xLTUwOTQwL3RleHRyZWdpb246ODZmNTU0MGY0ZDBiNDc5OThmNjkwODRiM2E3MWY3YmJfOA_cdcfa3d5-4959-4812-843f-6935949afd79">London</ix:nonNumeric> <ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGFibGU6ZmNlOTEzNGVjNjFjNGY3YTk2NTJkNjQwZTc3M2I3YTUvdGFibGVyYW5nZTpmY2U5MTM0ZWM2MWM0ZjdhOTY1MmQ2NDBlNzczYjdhNV8zLTAtMS0xLTUwOTQwL3RleHRyZWdpb246ODZmNTU0MGY0ZDBiNDc5OThmNjkwODRiM2E3MWY3YmJfMTE_d633ddf4-6b99-455e-b02e-78fb7ebb4665">SE1 2RE</ix:nonNumeric> <ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGFibGU6ZmNlOTEzNGVjNjFjNGY3YTk2NTJkNjQwZTc3M2I3YTUvdGFibGVyYW5nZTpmY2U5MTM0ZWM2MWM0ZjdhOTY1MmQ2NDBlNzczYjdhNV8zLTAtMS0xLTUwOTQwL3RleHRyZWdpb246ODZmNTU0MGY0ZDBiNDc5OThmNjkwODRiM2E3MWY3YmJfMTQ_c11b99a3-89d8-4988-93d7-edf5662fb62a">United Kingdom</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Zip Code)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: +<ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:CountryRegion" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yNTI5_1d38bca4-acc9-4e27-a107-f3aba0ddee50">44</ix:nonNumeric> <ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yNTMz_5b3ce4ce-b7ca-49e2-9977-133fdcb46347">203</ix:nonNumeric> <ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yNTM0_47952a8b-61b4-4666-8043-0130cc5ffa25">283 4200</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:42.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGFibGU6MjIzNWRkMDgxNzQ0NDc2MzlkNmYzY2YxNzNmMDg2MTAvdGFibGVyYW5nZToyMjM1ZGQwODE3NDQ0NzYzOWQ2ZjNjZjE3M2YwODYxMF8xLTAtMS0xLTUwOTQw_d215cedc-fcd6-47fd-ae3d-04fb47914378">Ordinary shares, nominal value &#163;0.05 per share*</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGFibGU6MjIzNWRkMDgxNzQ0NDc2MzlkNmYzY2YxNzNmMDg2MTAvdGFibGVyYW5nZToyMjM1ZGQwODE3NDQ0NzYzOWQ2ZjNjZjE3M2YwODYxMF8xLTEtMS0xLTUwOTQw_4f3b9e96-3ad3-46e1-8910-f78f19407633">VRNA</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Nasdaq Stock Market LLC (<ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGFibGU6MjIzNWRkMDgxNzQ0NDc2MzlkNmYzY2YxNzNmMDg2MTAvdGFibGVyYW5nZToyMjM1ZGQwODE3NDQ0NzYzOWQ2ZjNjZjE3M2YwODYxMF8xLTItMS0xLTUwOTQwL3RleHRyZWdpb246NGQ2NzJkZjFjZTExNDRhODk1ODg0NGQ2MzNkODEwNjFfMzM_0b69a915-470a-42fe-918d-b918fa5035d2">Nasdaq Global Market</ix:nonNumeric>)</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* The ordinary shares are represented by American Depositary Shares (each representing 8 ordinary shares), which are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder.</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    <ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yNTMw_7b00e412-79d9-4cde-865f-9ee8c471d69b">Yes</ix:nonNumeric>  &#9746;    No  &#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    <ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yNTMx_fec4ec8d-7358-4de6-a3f7-0c0c0e51d1f6">Yes</ix:nonNumeric>  &#9746;    No  &#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.397%"><tr><td style="width:1.0%"></td><td style="width:43.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.812%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGFibGU6NDZiMjBlNmI3ZTc1NDQ2ZWE4ZDQzYTAxMzlkM2EwZjMvdGFibGVyYW5nZTo0NmIyMGU2YjdlNzU0NDZlYThkNDNhMDEzOWQzYTBmM18xLTAtMS0xLTUwOTQw_bfabe132-1781-4719-b787-9303fd6b036e">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGFibGU6NDZiMjBlNmI3ZTc1NDQ2ZWE4ZDQzYTAxMzlkM2EwZjMvdGFibGVyYW5nZTo0NmIyMGU2YjdlNzU0NDZlYThkNDNhMDEzOWQzYTBmM18xLTQtMS0xLTUwOTQw_e3df6238-d512-4181-adce-e254b041b02d">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGFibGU6NDZiMjBlNmI3ZTc1NDQ2ZWE4ZDQzYTAxMzlkM2EwZjMvdGFibGVyYW5nZTo0NmIyMGU2YjdlNzU0NDZlYThkNDNhMDEzOWQzYTBmM18yLTQtMS0xLTUwOTQw_fd837bf9-eb86-4200-a596-dd430665fcef">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yNTI0_74e73cf3-82ca-4603-b904-c02645351f71">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes <ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yNTMy_c306c680-6d60-403a-b733-b8d2581cdace">&#9744;</ix:nonNumeric>    No &#9746;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of April 29, 2022, the registrant had <ix:nonFraction unitRef="shares" contextRef="i13a74a89113848ab9989e148e632f317_I20220429" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yMzI4_1c48bd1a-a592-41ef-9e2e-1fa36a476cad">482,944,390</ix:nonFraction> ordinary shares, nominal value &#163;0.05 per share, outstanding, which if all held in ADS form, would be represented by 60,368,049 American Depositary Shares, each representing eight (8) ordinary shares.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.516%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I - FINANCIAL INFORMATION</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1386bbda6db741028e2d0ab6d6a3d0c9_25">Item 1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Statements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1386bbda6db741028e2d0ab6d6a3d0c9_25">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1386bbda6db741028e2d0ab6d6a3d0c9_91">Item 2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1386bbda6db741028e2d0ab6d6a3d0c9_91">15</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1386bbda6db741028e2d0ab6d6a3d0c9_94">Item 3</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quantitative and Qualitative Disclosures About Market Risk</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1386bbda6db741028e2d0ab6d6a3d0c9_94">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1386bbda6db741028e2d0ab6d6a3d0c9_97">Item 4</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controls and Procedures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1386bbda6db741028e2d0ab6d6a3d0c9_97">26</a></span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II - OTHER INFORMATION</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1386bbda6db741028e2d0ab6d6a3d0c9_103">Item 1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal Proceedings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1386bbda6db741028e2d0ab6d6a3d0c9_103">27</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1386bbda6db741028e2d0ab6d6a3d0c9_106">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk Factors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1386bbda6db741028e2d0ab6d6a3d0c9_106">27</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1386bbda6db741028e2d0ab6d6a3d0c9_109">Item 2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unregistered Sales of Equity Securities and Use of Proceeds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1386bbda6db741028e2d0ab6d6a3d0c9_109">27</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1386bbda6db741028e2d0ab6d6a3d0c9_112">Item 3</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1386bbda6db741028e2d0ab6d6a3d0c9_112">27</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1386bbda6db741028e2d0ab6d6a3d0c9_115">Item 4</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mine Safety Disclosure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1386bbda6db741028e2d0ab6d6a3d0c9_115">27</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1386bbda6db741028e2d0ab6d6a3d0c9_118">Item 5</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1386bbda6db741028e2d0ab6d6a3d0c9_118">27</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1386bbda6db741028e2d0ab6d6a3d0c9_121">Item 6</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1386bbda6db741028e2d0ab6d6a3d0c9_121">28</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1386bbda6db741028e2d0ab6d6a3d0c9_124">Signatures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1386bbda6db741028e2d0ab6d6a3d0c9_124">29</a></span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_25"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 1. Financial statements</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts and par value of shares)</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNC0yLTEtMS01MDk0MA_31513e44-54e9-4106-8fda-5e1c2b04f50d">132,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNC00LTEtMS01MDk0MA_645b02a3-a49c-4467-ad42-a313f62741c5">148,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNy0yLTEtMS01MDk0MA_da91cf90-2c19-4c94-b2a2-ccba65878a4e">1,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNy00LTEtMS01MDk0MA_877aa5aa-a75e-4a03-8c8c-9360dc2e3e29">4,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax and tax incentive receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="vrna:TaxCreditAndIncomeTaxesReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfOC0yLTEtMS01MDk0MA_401fbb38-07da-415b-8cf3-5629009b05ee">16,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="vrna:TaxCreditAndIncomeTaxesReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfOC00LTEtMS01MDk0MA_f14be353-f638-41dc-ab02-7ca5604edc87">15,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTEtMi0xLTEtNTA5NDA_519136de-9860-40b7-8d53-3a3ab7d32612">2,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTEtNC0xLTEtNTA5NDA_8edfedbb-651a-4c72-8695-b9123aaf43e5">2,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTItMi0xLTEtNTA5NDA_859c2fbe-261e-463b-801c-8249a4a43e49">152,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTItNC0xLTEtNTA5NDA_100ca487-57da-4346-a14f-802c71ad495d">170,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTUtMi0xLTEtNTA5NDA_fc888ef8-4335-47cd-a2c4-0f62c121c40d">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTUtNC0xLTEtNTA5NDA_2ecb510a-1489-42b3-82ec-caf873990965">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTYtMi0xLTEtNTA5NDA_869f0f44-da9c-412a-b253-11f48a8443ee">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTYtNC0xLTEtNTA5NDA_f4b967b0-529d-482f-8ce6-6540a6e2c6ae">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTctMi0xLTEtNTA5NDA_2afec541-cc54-4105-b190-33163e5fb154">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTctNC0xLTEtNTA5NDA_ff2d908d-d53e-4971-8116-9948d50c56c2">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTgtMi0xLTEtNTA5NDA_747756c9-8bd3-46d2-a75a-3177feb31627">744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTgtNC0xLTEtNTA5NDA_8616c8bf-0299-45b4-8570-654c67c3a27f">899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTktMi0xLTEtNTA5NDA_6cf6e88c-13c2-466a-b3e0-11ac8ad9bbcc">16,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTktNC0xLTEtNTA5NDA_d7f2552a-6b7b-4bf4-aefd-e4b51d1e2c5f">16,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMjAtMi0xLTEtNTA5NDA_0bf7ec26-059f-4603-b4ea-cab897d7935b">169,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMjAtNC0xLTEtNTA5NDA_e61de9b4-461d-4194-84a4-f70934ab8eda">186,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMjQtMi0xLTEtNTA5NDA_22e0ac93-9365-49a7-b892-638985181b80">8,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMjQtNC0xLTEtNTA5NDA_3207f28f-0f4d-41df-bbd4-f859ac3c78e9">10,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMjUtMi0xLTEtNTA5NDA_a57d5ee5-30df-4af3-a143-b530e22543eb">28,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMjUtNC0xLTEtNTA5NDA_266b49f4-2510-4112-96b5-c770dfece619">22,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMjctMi0xLTEtNTA5NDA_f6855d1f-670c-4e42-86fd-6c7a68886d46">583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMjctNC0xLTEtNTA5NDA_9f5d53ee-c555-48f5-aa6f-8ea57e0f25e1">648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMjktMi0xLTEtNTA5NDA_b42afc02-331c-406a-9142-3f0546d6c608">235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMjktNC0xLTEtNTA5NDA_f3f20243-d7d0-4dd7-bcd2-59bbaca9b21f">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMzAtMi0xLTEtNTA5NDA_fbe32614-57f3-4c0f-aa27-66e9a780eea6">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMzAtNC0xLTEtNTA5NDA_eafb6d09-d519-4bb9-a057-74ef8d1842fc">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMzEtMi0xLTEtNTA5NDA_40949909-2e3f-4a8c-9866-8c6606110eb5">37,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMzEtNC0xLTEtNTA5NDA_86f5a000-03c3-4228-8cc8-2e787f8e262e">33,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMzUtMi0xLTEtNTA5NDA_c88987be-4bfe-4a32-9149-f2f26ad41ddc">4,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMzUtNC0xLTEtNTA5NDA_55a5164f-2971-4903-a4fc-83ef8ecc91f2">4,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMzYtMi0xLTEtNTA5NDA_3cf319a6-60db-419d-afd9-bad7cd079d66">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMzYtNC0xLTEtNTA5NDA_47509077-6f2d-4b46-bbec-9fdd7ab57edc">286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMzctMi0xLTEtNTA5NDA_b3862b9a-8428-4578-acee-c7fa73e04e52">5,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMzctNC0xLTEtNTA5NDA_0b7d6359-851e-4004-8764-b0d8b22741cb">5,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMzgtMi0xLTEtNTA5NDA_1660b7b2-952a-4ee3-99a0-c92586ccffb0">43,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMzgtNC0xLTEtNTA5NDA_4a1bad0b-52e2-4a2e-b99d-50a56a512103">38,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitments and contingencies </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDAtMi0xLTEtNTA5NDA_3dab0410-be52-4a03-98ab-5d902e729886"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDAtNC0xLTEtNTA5NDA_d9b5a678-0435-4181-ba1d-2aac1652df87"></ix:nonFraction></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordinary &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDMtMC0xLTEtNTA5NDAvdGV4dHJlZ2lvbjoyNDhkZDgzNzhlMjQ0YzNiOGE0NTVkOTM0MzE4ZmE5YV8xMw_7635d412-c513-4e0d-bd4b-73b268d498cb"><ix:nonFraction unitRef="gbpPerShare" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDMtMC0xLTEtNTA5NDAvdGV4dHJlZ2lvbjoyNDhkZDgzNzhlMjQ0YzNiOGE0NTVkOTM0MzE4ZmE5YV8xMw_bf678216-cf85-4afe-8b83-1dffe5852bb1">0.05</ix:nonFraction></ix:nonFraction> par value shares; <ix:nonFraction unitRef="shares" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDMtMC0xLTEtNTA5NDAvdGV4dHJlZ2lvbjoyNDhkZDgzNzhlMjQ0YzNiOGE0NTVkOTM0MzE4ZmE5YV8zNA_58da56db-b641-45c4-9f03-eb1ea7e3f7f9">494,058,246</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDMtMC0xLTEtNTA5NDAvdGV4dHJlZ2lvbjoyNDhkZDgzNzhlMjQ0YzNiOGE0NTVkOTM0MzE4ZmE5YV80MQ_85b756d8-6f28-4528-9acc-e0ba57e61004">489,177,550</ix:nonFraction> issued, and <ix:nonFraction unitRef="shares" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDMtMC0xLTEtNTA5NDAvdGV4dHJlZ2lvbjoyNDhkZDgzNzhlMjQ0YzNiOGE0NTVkOTM0MzE4ZmE5YV81Ng_74dd5531-4552-4d4c-ab7d-ff0443a10db8">482,944,390</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDMtMC0xLTEtNTA5NDAvdGV4dHJlZ2lvbjoyNDhkZDgzNzhlMjQ0YzNiOGE0NTVkOTM0MzE4ZmE5YV82Mw_0aa263d3-0516-412a-8221-13895828f36e">480,082,966</ix:nonFraction> outstanding, at March 31, 2022 and December 31, 2021, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDMtMi0xLTEtNTA5NDA_e731554a-dd42-4950-987d-3c0b57644385">32,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDMtNC0xLTEtNTA5NDA_6942a264-f495-4068-856d-5140f4b8bb8b">31,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDQtMi0xLTEtNTA5NDA_e6a23ebf-214b-4a2b-8454-206160fe09c0">388,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDQtNC0xLTEtNTA5NDA_12e30d83-07a4-4c46-b7e0-953ef9fa5798">385,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordinary shares held in treasury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDUtMi0xLTEtNTA5NDA_519e6947-4a07-424a-90da-79b1dc9539da">739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDUtNC0xLTEtNTA5NDA_2d35c83e-8c50-47f5-8ed1-35e99a1c2c96">603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDYtMi0xLTEtNTA5NDA_f4cc2969-d71d-4f98-9732-6b5c1df669f5">4,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDYtNC0xLTEtNTA5NDA_fc2eedf3-9905-4bc8-bfd8-4b2fa21b6d9e">4,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDctMi0xLTEtNTA5NDA_a735e4c3-1afb-4310-bcd6-4226e33ff220">288,739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDctNC0xLTEtNTA5NDA_756faeb4-f649-4e81-ae17-696fad65ac91">263,716</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shareholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDgtMi0xLTEtNTA5NDA_2ee74dd6-8f9c-4d7f-a882-c1c53dea5eec">126,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDgtNC0xLTEtNTA5NDA_8b721dff-f190-4bf6-81f7-ef6d7a704842">148,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and shareholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDktMi0xLTEtNTA5NDA_9b417e76-c5ab-4480-839b-b5cd83969e90">169,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDktNC0xLTEtNTA5NDA_b02f2810-67a8-42d8-9b10-5a168f76953f">186,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfNi0yLTEtMS01MDk0MA_7c2c2c9d-1462-4d6a-8baa-5e7799379023">17,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfNi00LTEtMS01MDk0MA_564cd20c-6622-4868-966e-49e2a978fd4d">13,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfNy0yLTEtMS01MDk0MA_8a91c255-a264-4d44-8fd1-5f17fcd3b83b">7,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfNy00LTEtMS01MDk0MA_cdebf955-1604-467f-ae26-3547124e24d0">9,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfOC0yLTEtMS01MDk0MA_75cdb941-3080-4f11-9d36-900bcdab8f44">25,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfOC00LTEtMS01MDk0MA_ca713ecd-b33a-42ac-b224-c7f9ed7a37ec">22,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfOS0yLTEtMS01MDk0MA_5f6963f4-b48d-4957-ae1f-bea425741b5b">25,065</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfOS00LTEtMS01MDk0MA_683420f3-5aea-4989-a5e8-f46a7c7eb9cf">22,856</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income/(expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="vrna:GainLossFromResearchAndDevelopmentTaxCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTEtMi0xLTEtNTA5NDA_0723bf88-9ded-4d1b-bd32-420943649c1b">1,302</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="vrna:GainLossFromResearchAndDevelopmentTaxCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTEtNC0xLTEtNTA5NDA_877b6828-d8f6-4aac-a708-c1c3d3a51510">2,070</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTItMi0xLTEtNTA5NDA_68e4f9d7-e1a8-49fc-aac8-bb90b216071a">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTItNC0xLTEtNTA5NDA_89cd4cdb-368e-4378-8a55-40f11c6352f0">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTMtMi0xLTEtNTA5NDA_473cb567-3ad5-4a65-a643-5b4a22f0ff48">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTMtNC0xLTEtNTA5NDA_e3ea9cd4-9c80-4015-b254-07f86c110316">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value movement on warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="vrna:UnrealizedGainLossOnWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTQtMi0xLTEtNTA5NDA_3933ad74-6734-4fca-8e3e-f5e9dc98ebb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" sign="-" name="vrna:UnrealizedGainLossOnWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTQtNC0xLTEtNTA5NDA_d7f63ba7-d673-4451-998f-6129014eec27">507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange (loss)/gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" sign="-" name="vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTUtMi0xLTEtNTA5NDA_a95de505-6558-49f2-aea4-47f9887f2e81">923</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTUtNC0xLTEtNTA5NDA_2142ee9d-cada-4d5e-909e-1ddf60d21826">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTYtMi0xLTEtNTA5NDA_572ab943-76f6-4e95-ac93-5e8a6936f9ed">310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTYtNC0xLTEtNTA5NDA_32a7b012-20ee-4b22-a461-f2dd258a2216">1,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTctMi0xLTEtNTA5NDA_948e264f-47da-4f12-b6e8-3ff6300bd70a">24,755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTctNC0xLTEtNTA5NDA_b5f4fd20-f265-4f75-9512-92f427643b06">21,210</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTgtMi0xLTEtNTA5NDA_bbb31232-155b-404a-862f-3247c393c10f">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTgtNC0xLTEtNTA5NDA_24c213e1-70f7-4fbc-a7e1-3746df28f7cb">80</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTktMi0xLTEtNTA5NDA_44b02f1a-bd30-458a-83bf-b3fc35e602f2">24,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTktNC0xLTEtNTA5NDA_6bacdebd-719d-4993-bb4f-9b7ff321a62a">21,290</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per ordinary share - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMjQtMi0xLTEtNTA5NDA_277ba617-86b8-4a05-96cf-910318484dab"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMjQtMi0xLTEtNTA5NDA_35ed8f25-4204-4c5a-a285-a26a9eef9ce2">0.05</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMjQtNC0xLTEtNTA5NDA_0a2e9213-74db-407e-ae22-2118f36f8705"><ix:nonFraction unitRef="usdPerShare" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMjQtNC0xLTEtNTA5NDA_5d8952db-d22f-4eed-8a60-b1835ff8016c">0.05</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Shareholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands except share data)</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.282%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ordinary shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ordinary shares held in treasury</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total shareholders' equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3fd060aa5bbb47278b27ef1634cafe13_I20211231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMi0yLTEtMS01MDk0MA_24ff9b9d-a801-4e63-91c0-f50e135d2b67">489,177,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fd060aa5bbb47278b27ef1634cafe13_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMi00LTEtMS01MDk0MA_70008bec-eaf7-4f32-b9ee-97ebeb183954">31,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee10beb5614d4c36a49b38b0408c3c77_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMi02LTEtMS01MDk0MA_7714ebde-70ad-4780-b5c2-5f5158f5c88e">385,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie034936385eb4829a4a09ca135e0d332_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMi04LTEtMS01MDk0MA_ee182ece-81d7-482b-8601-971ab1af7205">603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i487b969ea66c4193b79846ba2684834b_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMi0xMC0xLTEtNTA5NDA_411af8c5-7a99-4d80-8f56-2ffd1aa94302">4,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia76cefe1174549e7b4d4eb6f368d6bb9_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMi0xMi0xLTEtNTA5NDA_861d897e-6c92-4ac2-b8af-49d5e21db206">263,716</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMi0xNC0xLTEtNTA5NDA_48d62fb3-1814-4ea3-96f6-b5d3a627a0ab">148,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a41f83bf2f147cca904ad371dd3c80f_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMy0xMi0xLTEtNTA5NDA_41eef1b3-b2b7-4834-9d92-84ee7e917dc7">24,837</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMy0xNC0xLTEtNTA5NDA_752c7232-05d3-435e-a740-2f7120ce379d">24,837</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common shares under at-the-market sales agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i406e2d71f2494b7586c12bf94c99c19a_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfNi0yLTEtMS01MDk0MA_80a59027-bd7e-4654-a62e-969e7d1b3b84">80,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406e2d71f2494b7586c12bf94c99c19a_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfNi00LTEtMS01MDk0MA_c6f3c54f-6442-4d63-b852-fdbfc651b8f2">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c4f42981f7a4b07b3f072092f9d25ee_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfNi02LTEtMS01MDk0MA_c1bc1fbe-aa5b-410e-b023-724750a51768">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfNi0xNC0xLTEtNTA5NDA_6729f378-931f-4c8a-b765-fb3d9b60c2ef">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted share units vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c8f3273cca84e1fb9b901be94b1d3de_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfNy04LTEtMS01MDk0MA_93ebc91b-263d-4caf-891b-f23cc927f4e4">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a41f83bf2f147cca904ad371dd3c80f_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfNy0xMi0xLTEtNTA5NDA_305dad92-b55a-4558-8f75-49a572defe91">186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of ordinary shares to treasury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i406e2d71f2494b7586c12bf94c99c19a_D20220101-20220331" decimals="0" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfOC0yLTEtMS01MjM4MA_5de3db56-ba4c-4abe-98bf-35a37f2526c5">4,800,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406e2d71f2494b7586c12bf94c99c19a_D20220101-20220331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfOC00LTEtMS01MjM4MA_f24f4c02-6e70-4e52-9ef5-613ecea16d2c">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c8f3273cca84e1fb9b901be94b1d3de_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfOC04LTEtMS01MjM4MA_d472c535-9ae4-4fd0-9756-2ba4d05c91f1">322</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares withheld for taxes on vested stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c4f42981f7a4b07b3f072092f9d25ee_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfOS02LTEtMS01MDk0MA_af545cab-a49d-4176-aff6-2323a675a69d">793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfOS0xNC0xLTEtNTA5NDA_627a20ec-e403-4db6-b4df-0c2d667f3831">793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity settled share-based compensation reclassified as cash-settled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c4f42981f7a4b07b3f072092f9d25ee_D20220101-20220331" decimals="-3" sign="-" name="vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMTAtNi0xLTEtNTA5NDA_782d19b1-5598-403b-8477-b8da7b5026df">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" sign="-" name="vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMTAtMTQtMS0xLTUwOTQw_0f3c8cc6-1da8-4c25-a065-64731b7a7eef">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c4f42981f7a4b07b3f072092f9d25ee_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMTEtNi0xLTEtNTA5NDA_45a5f57c-0501-4057-b992-222dd1ec5969">3,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMTEtMTQtMS0xLTUwOTQw_d8cb6f8e-fe4b-455b-8486-aa5c64aa90b2">3,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iccf8c5dacaee4f44963a79b7f359f4ea_I20220331" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMTMtMi0xLTEtNTA5NDA_fb0f8dcd-b249-4c0d-a620-04d1d4c10264">494,058,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccf8c5dacaee4f44963a79b7f359f4ea_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMTMtNC0xLTEtNTA5NDA_79b2a509-dd39-4ae0-8462-d11d66789c20">32,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27b5bd780a9d45798cffb2697ac8ade3_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMTMtNi0xLTEtNTA5NDA_de1943c2-592f-405d-b339-212634823800">388,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic919c5d0bdfd4afaa416dbe6e26c0669_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMTMtOC0xLTEtNTA5NDA_5a973849-ef7a-41ca-aa06-3ae0fa470566">739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14c4574a519449c29bf55707447cb27d_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMTMtMTAtMS0xLTUwOTQw_0b1c3d7d-780e-4fae-9e8e-2bfb06cd6288">4,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00c370453f2b4f5db71678b478ddbbe0_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMTMtMTItMS0xLTUwOTQw_6a51a539-25fb-41fa-9715-c7a88a64893f">288,739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMTMtMTQtMS0xLTUwOTQw_dd7ac381-98b6-4abb-8d6e-9ae85c5eb7c3">126,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Shareholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands except share data)</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.282%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ordinary shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ordinary shares held in treasury</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total shareholders' equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief871dca18cb4d72a122e673f25d7055_I20201231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMi0yLTEtMS01MDk0MA_6dd3df2f-1e4a-4f1e-842a-908d4fe6c64d">488,304,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief871dca18cb4d72a122e673f25d7055_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMi00LTEtMS01MDk0MA_139cff80-e832-49da-af28-351fdaac2fb9">31,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5415b7e84bdf40e388391917c6fb0a3c_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMi02LTEtMS01MDk0MA_0b78e914-6646-4a03-acf5-aa70bbc486f0">366,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17b773074fa84265a6b1dcd53b75176c_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMi04LTEtMS01MDk0MA_dd1317a8-2336-4ddd-bb5b-b44097aafebe">1,700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89039648129e48e19231c6fcf8cd7c46_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMi0xMC0xLTEtNTA5NDA_d1fc9089-a61b-42da-a6e3-2721be959739">4,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84db4d73c9c5454584348de0514aa545_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMi0xMi0xLTEtNTA5NDA_47785e3b-af74-4139-b6ff-f88a73ba36ce">207,050</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i753d3703301043ad8197826c3029e966_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMi0xNC0xLTEtNTA5NDA_cdab0647-8bb7-417d-9b5a-481c72edda9c">184,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8c845ed47cd447f83b0049bc8df056e_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMy0xMi0xLTEtNTA5NDA_3d9b7db5-8ba3-403b-8736-642985028c4d">21,290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMy0xNC0xLTEtNTA5NDA_0130b8a6-1c63-49af-89ab-f247d67b56a3">21,290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted share units vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62831f3f81ff424dbd8b50fd58c3cd6c_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfNy04LTEtMS01MDk0MA_394e1f37-54b6-4f3f-a2ec-c1aa3dce012e">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8c845ed47cd447f83b0049bc8df056e_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfNy0xMi0xLTEtNTA5NDA_d1b2975b-4408-442c-8e5a-8700c8cd68dd">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764cecabbeee41a19da9bdf3d8c3566e_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMTEtNi0xLTEtNTA5NDA_ab801b96-7abb-47c8-a298-99cef6ad7ce2">8,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMTEtMTQtMS0xLTUwOTQw_b5c392d9-0f73-4862-9eac-aca91635b421">8,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia488af7353324c8197666eef6a12f7bf_I20210331" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMTItMi0xLTEtNTA5NDA_da732570-de3e-451a-8c00-5f9e6adbb134">488,304,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia488af7353324c8197666eef6a12f7bf_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMTItNC0xLTEtNTA5NDA_fe15bccd-3bc8-485b-b993-4b11c2f91952">31,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87de327ddb3f41e7ba3457265e088033_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMTItNi0xLTEtNTA5NDA_73bcdc47-dc02-404c-a6de-9615a3ac2333">375,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a61756845fa41f2bdc2a4c25489a95a_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMTItOC0xLTEtNTA5NDA_5f35098a-3dd0-4653-a8d1-384f10a4aeaa">1,670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7370fb3dc73448d91fdc9fe7f5ffd30_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMTItMTAtMS0xLTUwOTQw_f427e2f4-461f-4e29-bc63-a69ee1ca4f03">4,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie94feae856cc4ea5ac4eff16299f3bbf_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMTItMTItMS0xLTUwOTQw_5d0846c2-e8cf-455c-81a2-f144e7e0556b">228,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic509b8fcd7664f3594ed0ab72f0e609f_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMTItMTQtMS0xLTUwOTQw_face36b4-1bf8-4c45-a1b4-7fe4cd8ef937">172,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_40"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMy0yLTEtMS01MDk0MA_a173ddff-a3aa-45e3-8d89-ce56dc5631e3">24,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMy00LTEtMS01MDk0MA_5ffa51eb-2d05-43fe-9806-6d9bd17b7621">21,290</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange loss/(gain)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNS0yLTEtMS01MDk0MA_b29d5384-0365-41e7-975e-73b53694e3e2">1,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNS00LTEtMS01MDk0MA_451ee0d3-6132-45ee-8bcd-e2e37f16d943">155</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issue costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNi0yLTEtMS01MDk0MA_400e09b9-a15a-4643-9c69-c52ca78fc2ed">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNi00LTEtMS01MDk0MA_f6ea796e-0917-41b0-afa0-5cc0f53dbf99">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of redemption premium on debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNy0yLTEtMS01MDk0MA_aba668f1-2471-4f8f-8b85-6ecbf218b40b">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNy00LTEtMS01MDk0MA_01bb8b19-bf06-491d-bb57-b68763c19a11">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value movement on warrants </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfOC0yLTEtMS01MDk0MA_f6e94328-d269-4b62-8205-f4f2792550ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfOC00LTEtMS01MDk0MA_80dd59dc-c245-4df9-be19-f7d158e88def">507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMTAtMi0xLTEtNTA5NDA_35eee905-7a11-4d61-b30a-8a1a92828cd2">3,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMTAtNC0xLTEtNTA5NDA_86986ee2-51f4-4843-8a08-ae6cecb8f564">8,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMTEtMi0xLTEtNTA5NDA_7de35c95-ae2c-4fc2-94ff-7d573f2b6f8c">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMTEtNC0xLTEtNTA5NDA_8a70ffce-2327-44e3-a5dd-7711c7f45d2a">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMTYtMi0xLTEtNTA5NDA_20ce0a87-d64f-4527-9620-c250f9a18b96">2,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMTYtNC0xLTEtNTA5NDA_a3e4fb6a-0dc8-4573-81d2-e44000465e83">2,709</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax incentive receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMTctMi0xLTEtNTA5NDA_842e2e77-edb1-49e8-985a-b86d71ceb1b0">1,578</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMTctNC0xLTEtNTA5NDA_aef4e07a-f4ec-4f7a-8310-a34e8b57446b">2,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMTgtMi0xLTEtNTA5NDA_18078a11-2de0-4a69-8a33-4cf422e3c086">462</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMTgtNC0xLTEtNTA5NDA_b387a2c6-57a8-4a71-8b7a-f0977ba2b96d">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjAtMi0xLTEtNTA5NDA_57aa804c-34e3-4054-bf9f-b3bb342d5048">1,980</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjAtNC0xLTEtNTA5NDA_3003ef0e-004c-4aec-b8e7-7c4dbd7b36aa">363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjEtMi0xLTEtNTA5NDA_d45b1c1f-427c-44ad-81d1-7897ef52c5c6">6,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjEtNC0xLTEtNTA5NDA_775e34f6-2c92-4d47-b0c6-fc0e866fb1c0">2,349</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" sign="-" name="vrna:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjItMi0xLTEtNTA5NDA_d41a5231-9983-464b-8a1a-1f6fa0ad54f4">174</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" sign="-" name="vrna:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjItNC0xLTEtNTA5NDA_3c0bd5a9-1390-4e1e-a3ec-203b1b80ce88">210</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjMtMi0xLTEtNTA5NDA_927c7cb5-4d20-4145-a533-08c69809fdde">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjMtNC0xLTEtNTA5NDA_988197fd-a4d7-415b-8217-7ff9ca0d98c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjQtMi0xLTEtNTA5NDA_bca32496-2221-477d-94d6-11530424b750">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjQtNC0xLTEtNTA5NDA_f7c3543b-a6c3-4c43-b68e-2bc4a9dd2be3">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjUtMi0xLTEtNTA5NDA_75f435e3-06fc-4c13-810e-1d469742ec46">14,512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjUtNC0xLTEtNTA5NDA_db464314-1f6c-4b82-aeb0-011251058e51">18,551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjktMi0xLTEtNTA5NDA_6ef9d32e-967c-4c7c-ad0f-708d44c1512c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjktNC0xLTEtNTA5NDA_bbfef4ab-ef1c-46d4-8996-ff5070f59016">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments of withholding taxes from share-based awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMzUtMi0xLTEtNTA5NDA_28e227b3-a2bd-471d-b6ff-9ca935da8d5f">793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMzUtNC0xLTEtNTA5NDA_2630514f-79c5-475b-ba18-84de4f25383d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from at-the-market sales agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMzctMi0xLTEtNTA5NDA_fbe8ce30-846d-4caf-ae92-f5507f2a9e68">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMzctNC0xLTEtNTA5NDA_41ed8aa2-2ac5-422b-a271-4dad76172fbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMzgtMi0xLTEtNTA5NDA_2c6caf4c-60ab-4c37-ac6c-45d62e7dfdb7">726</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMzgtNC0xLTEtNTA5NDA_0bf23f69-112c-4d06-83cb-20cb9c82006e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMzktMi0xLTEtNTA5NDA_b1ebf5a2-1625-42d6-b9ce-cb935108497d">378</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMzktNC0xLTEtNTA5NDA_7c728f44-1db7-4a7f-ab2c-3387a34acdcc">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNDAtMi0xLTEtNTA5NDA_51ea1dfe-bedb-4256-a839-55abdaec35d5">15,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNDAtNC0xLTEtNTA5NDA_a43a53e6-dc33-4883-8cb0-e661cd8cda00">18,388</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at beginning of the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNDEtMi0xLTEtNTA5NDA_f561797b-d23e-42d5-8ae2-29ce69fef211">148,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i753d3703301043ad8197826c3029e966_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNDEtNC0xLTEtNTA5NDA_d7818cbf-f6fe-4494-a31f-64a493065ca0">187,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNDItMi0xLTEtNTA5NDA_a0e07492-3b81-4054-97fe-a62aa07438eb">132,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic509b8fcd7664f3594ed0ab72f0e609f_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNDItNC0xLTEtNTA5NDA_21bd89c6-844f-4fe0-bc21-0730fa75f654">169,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNDQtMi0xLTEtNTA5NDA_b007797e-903a-47d9-92c0-4e94cf379855">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNDQtNC0xLTEtNTA5NDA_f317c673-7092-451d-afa8-2de354d1fc6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNDUtMi0xLTEtNTA5NDA_5bca871e-fdd4-4412-b405-4f0fe62cc71e">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNDUtNC0xLTEtNTA5NDA_fa017807-cdbb-4070-9c1b-8a21694883ec">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_46"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 1 - <ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="vrna:OrganizationAndBusinessDescriptionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80Ni9mcmFnOmZhNGYxYTU1YzcwNjQ3NjY5MWZhZjAwOGM0NTZkYjhhL3RleHRyZWdpb246ZmE0ZjFhNTVjNzA2NDc2NjkxZmFmMDA4YzQ1NmRiOGFfMjA1OQ_197af163-f27e-45b6-a8cf-f8488076a61a" continuedAt="i839d289bc9ab4439b1d507999ba3a21b" escape="true">Organization and description of business operations </ix:nonNumeric></span></div><ix:continuation id="i839d289bc9ab4439b1d507999ba3a21b"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Verona Pharma plc (the &#8220;Company&#8221;) is incorporated and domiciled in the United Kingdom. Verona Pharma plc has <ix:nonFraction unitRef="subsidiary" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="INF" name="vrna:NumberOfWhollyOwnedSubsidiaries" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80Ni9mcmFnOmZhNGYxYTU1YzcwNjQ3NjY5MWZhZjAwOGM0NTZkYjhhL3RleHRyZWdpb246ZmE0ZjFhNTVjNzA2NDc2NjkxZmFmMDA4YzQ1NmRiOGFfMjA2MA_7b2f9cce-460e-4771-a195-8def6398188e">one</ix:nonFraction> wholly-owned subsidiary, Verona Pharma, Inc., a Delaware corporatio</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">n. Rhinopharma Limited, a Canadian company that was previously a non-operating, wholly-owned subsidiary, was dissolved in June 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The address of the registered office is 1 Central Square, Cardiff, CF10 1FS, United Kingdom.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company is a clinical-stage biopharmaceutical group focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The Company&#8217;s American Depositary Shares (&#8220;ADSs&#8221;) are listed on the Nasdaq Global Market (&#8220;Nasdaq&#8221;) and trade under the symbol &#8220;VRNA&#8221;.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has incurred recurring losses and negative cash flows from operations since inception, and has an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80Ni9mcmFnOmZhNGYxYTU1YzcwNjQ3NjY5MWZhZjAwOGM0NTZkYjhhL3RleHRyZWdpb246ZmE0ZjFhNTVjNzA2NDc2NjkxZmFmMDA4YzQ1NmRiOGFfOTI0_7e8a44bf-65e9-4e9b-9973-1a0685219598">288.7</ix:nonFraction>&#160;million as of March 31, 2022. The Company expects to incur additional losses and negative cash flows from operations until its products potentially gain regulatory approval and reach commercial profitability, if at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company expects that its cash and cash equivalents as of March 31, 2022, will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In March, 2021, the Company entered into an open market sale agreement with respect to an at-the-market offering program (the &#8220;ATM Program&#8221;) under which the Company may issue and sell its ordinary shares in the form of ADSs, with an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i22ba9f263b564af695f8fba5e244c5fa_I20210319" decimals="-5" name="vrna:SaleOfStockMaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80Ni9mcmFnOmZhNGYxYTU1YzcwNjQ3NjY5MWZhZjAwOGM0NTZkYjhhL3RleHRyZWdpb246ZmE0ZjFhNTVjNzA2NDc2NjkxZmFmMDA4YzQ1NmRiOGFfMTYzNw_89b179af-57b2-4d9a-bc84-175ae21b9ca2">100.0</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During the three months ended March 31, 2022, the Company sold <ix:nonFraction unitRef="shares" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80Ni9mcmFnOmZhNGYxYTU1YzcwNjQ3NjY5MWZhZjAwOGM0NTZkYjhhL3RleHRyZWdpb246ZmE0ZjFhNTVjNzA2NDc2NjkxZmFmMDA4YzQ1NmRiOGFfMTcwNw_2219a8bf-be2f-4825-9fd8-8970292f1ecf">80,696</ix:nonFraction> ordinary shares (equivalent to <ix:nonFraction unitRef="shares" contextRef="i14b59a9e0309440bbd87ed4bea74076d_D20220101-20220331" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80Ni9mcmFnOmZhNGYxYTU1YzcwNjQ3NjY5MWZhZjAwOGM0NTZkYjhhL3RleHRyZWdpb246ZmE0ZjFhNTVjNzA2NDc2NjkxZmFmMDA4YzQ1NmRiOGFfMTc0MQ_215d8c19-65d8-4da4-b44c-733fca6167bb">10,087</ix:nonFraction> ADSs) under the ATM Program, at an average price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80Ni9mcmFnOmZhNGYxYTU1YzcwNjQ3NjY5MWZhZjAwOGM0NTZkYjhhL3RleHRyZWdpb246ZmE0ZjFhNTVjNzA2NDc2NjkxZmFmMDA4YzQ1NmRiOGFfMTgxMA_831fb03f-03aa-4298-89ef-44cc3c8f955f">0.86</ix:nonFraction> per share (equivalent to $<ix:nonFraction unitRef="usdPerShare" contextRef="i9b1d9925838f4f4e8d46dce269a2578c_I20220331" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80Ni9mcmFnOmZhNGYxYTU1YzcwNjQ3NjY5MWZhZjAwOGM0NTZkYjhhL3RleHRyZWdpb246ZmE0ZjFhNTVjNzA2NDc2NjkxZmFmMDA4YzQ1NmRiOGFfMTgzOA_d6c8fd12-a3e8-40c9-a4d2-039c24bf002b">6.86</ix:nonFraction> per ADS), raising aggregate net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80Ni9mcmFnOmZhNGYxYTU1YzcwNjQ3NjY5MWZhZjAwOGM0NTZkYjhhL3RleHRyZWdpb246ZmE0ZjFhNTVjNzA2NDc2NjkxZmFmMDA4YzQ1NmRiOGFfMTg5OQ_ebc263d0-2b03-4a51-b452-ee648b39e319">0.1</ix:nonFraction>&#160;million after deducting issuance costs. As of March 31, 2022, there remained ordinary shares, in the form of ADSs, with a value up to $<ix:nonFraction unitRef="usd" contextRef="i9b1d9925838f4f4e8d46dce269a2578c_I20220331" decimals="-3" name="vrna:CommonStockSharesAvailableForSaleValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80Ni9mcmFnOmZhNGYxYTU1YzcwNjQ3NjY5MWZhZjAwOGM0NTZkYjhhL3RleHRyZWdpb246ZmE0ZjFhNTVjNzA2NDc2NjkxZmFmMDA4YzQ1NmRiOGFfMTk3NQ_939c526e-973a-4e28-9e0c-82e82a87d968">99.2</ix:nonFraction>&#160;million available for sale under the ATM Program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s commercial revenue, if any, will be derived from sales of products that we do not expect to be commercially available for several years, if ever. Additionally we may enter into out-licensing transactions from time to time but there can be no assurance that the company can secure such transactions in the future. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives including to further advance clinical and regulatory activities, to fund prelaunch and launch related costs and to create an effective sales and marketing organization to commercialize ensifentrine. We will need to seek additional funding through public or private financings, debt financing, collaboration or licensing agreements and other arrangements. However, there is no guarantee that we will be successful in securing additional capital on acceptable terms, or at all.</span></div></ix:continuation><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_49"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 2 - <ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80OS9mcmFnOmU3NmUzNWZkZWI5YTQ2OTg5N2IxYzkyN2FlZGYyYzIwL3RleHRyZWdpb246ZTc2ZTM1ZmRlYjlhNDY5ODk3YjFjOTI3YWVkZjJjMjBfNzgzMw_c7042b24-86ac-4948-b31b-ab17cccdcd76" continuedAt="i42731bb4d0a043629e1dca801d55eb21" escape="true">Basis of presentation and summary of significant accounting policies</ix:nonNumeric></span></div><ix:continuation id="i42731bb4d0a043629e1dca801d55eb21"><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80OS9mcmFnOmU3NmUzNWZkZWI5YTQ2OTg5N2IxYzkyN2FlZGYyYzIwL3RleHRyZWdpb246ZTc2ZTM1ZmRlYjlhNDY5ODk3YjFjOTI3YWVkZjJjMjBfNzgzNA_d430cecf-ab87-43f2-8c6c-6fd1f6f5a71e" continuedAt="ibaa76cef0e014f7489054e999482a1df" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Basis of presentation and consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The unaudited condensed consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiary Verona Pharma, Inc. All inter-company balances and transactions have been eliminated. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with accounting principles generally accepted in the U.S. (&#8220;U.S. GAAP&#8221;).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 3, 2022 (the &#8220;2021 Form 10-K&#8221;). The Consolidated Balance Sheet as of December 31, 2021, was derived from audited consolidated financial statements included in the 2021 Form 10-K but does not include all disclosures required by U.S. GAAP for complete financial statements. The Company&#8217;s significant accounting policies are described in Note 2 to those consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"><ix:continuation id="ibaa76cef0e014f7489054e999482a1df">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. The unaudited condensed consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and shareholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year.</ix:continuation> </span></div><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80OS9mcmFnOmU3NmUzNWZkZWI5YTQ2OTg5N2IxYzkyN2FlZGYyYzIwL3RleHRyZWdpb246ZTc2ZTM1ZmRlYjlhNDY5ODk3YjFjOTI3YWVkZjJjMjBfNzgzNQ_8982d9a9-252d-4d9c-b8d7-71c7ec2b1256" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Segment reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has <ix:nonFraction unitRef="segment" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80OS9mcmFnOmU3NmUzNWZkZWI5YTQ2OTg5N2IxYzkyN2FlZGYyYzIwL3RleHRyZWdpb246ZTc2ZTM1ZmRlYjlhNDY5ODk3YjFjOTI3YWVkZjJjMjBfOTM0NTg0ODg0OTA5MQ_5f457c82-a04c-4731-9e28-f78d117fc30a"><ix:nonFraction unitRef="segment" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80OS9mcmFnOmU3NmUzNWZkZWI5YTQ2OTg5N2IxYzkyN2FlZGYyYzIwL3RleHRyZWdpb246ZTc2ZTM1ZmRlYjlhNDY5ODk3YjFjOTI3YWVkZjJjMjBfOTM0NTg0ODg0OTA5MQ_7862f634-e4ee-48ef-9586-f49e3b76951c">one</ix:nonFraction></ix:nonFraction> operating and reportable segment, pharmaceutical development.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80OS9mcmFnOmU3NmUzNWZkZWI5YTQ2OTg5N2IxYzkyN2FlZGYyYzIwL3RleHRyZWdpb246ZTc2ZTM1ZmRlYjlhNDY5ODk3YjFjOTI3YWVkZjJjMjBfNzgzNg_d982fbb6-f423-44b3-ae75-cc5a450d61a8" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, the fair value of share-based compensation, the fair value of warrants, research and development tax credit and the carrying value of the equity interest in Nuance Pharma (as defined below). Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company&#8217;s estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80OS9mcmFnOmU3NmUzNWZkZWI5YTQ2OTg5N2IxYzkyN2FlZGYyYzIwL3RleHRyZWdpb246ZTc2ZTM1ZmRlYjlhNDY5ODk3YjFjOTI3YWVkZjJjMjBfNzgzNw_ebe2093b-9ac9-435c-9cd7-0f4cc5b67e85" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Recently adopted accounting standards and recent accounting standards not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">There are no recently adopted accounting standards and recent accounting standards not yet adopted that the Company believes will have a material impact on the Company&#8217;s consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_52"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 3 - <ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="vrna:PrepaidExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81Mi9mcmFnOmQ0MzgyNDAyN2M3NTRjNzQ5MTg0ZThmZGM5ZjMwMjQ3L3RleHRyZWdpb246ZDQzODI0MDI3Yzc1NGM3NDkxODRlOGZkYzlmMzAyNDdfOTM_7abd3dc9-29ac-483a-8131-77b1d6fa808f" continuedAt="icdc520c85c444d278f954918a8b401f3" escape="true">Prepaid expenses </ix:nonNumeric></span></div><ix:continuation id="icdc520c85c444d278f954918a8b401f3"><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81Mi9mcmFnOmQ0MzgyNDAyN2M3NTRjNzQ5MTg0ZThmZGM5ZjMwMjQ3L3RleHRyZWdpb246ZDQzODI0MDI3Yzc1NGM3NDkxODRlOGZkYzlmMzAyNDdfOTQ_791005d0-7858-4ded-955f-ca84afb005ad" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Prepaid expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and other development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="vrna:PrepaidResearchAndDevelopmentFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81Mi9mcmFnOmQ0MzgyNDAyN2M3NTRjNzQ5MTg0ZThmZGM5ZjMwMjQ3L3RhYmxlOjNlMzhlZDkwMjU4NjRiMGE5NDUwM2Q4YjhiZmJmOTAxL3RhYmxlcmFuZ2U6M2UzOGVkOTAyNTg2NGIwYTk0NTAzZDhiOGJmYmY5MDFfMi0yLTEtMS01MDk0MA_e3aea34d-c209-4e51-a118-04925e8334c4">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="vrna:PrepaidResearchAndDevelopmentFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81Mi9mcmFnOmQ0MzgyNDAyN2M3NTRjNzQ5MTg0ZThmZGM5ZjMwMjQ3L3RhYmxlOjNlMzhlZDkwMjU4NjRiMGE5NDUwM2Q4YjhiZmJmOTAxL3RhYmxlcmFuZ2U6M2UzOGVkOTAyNTg2NGIwYTk0NTAzZDhiOGJmYmY5MDFfMi00LTEtMS01MDk0MA_2f84e161-60df-45eb-94f7-82f25f74964f">2,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81Mi9mcmFnOmQ0MzgyNDAyN2M3NTRjNzQ5MTg0ZThmZGM5ZjMwMjQ3L3RhYmxlOjNlMzhlZDkwMjU4NjRiMGE5NDUwM2Q4YjhiZmJmOTAxL3RhYmxlcmFuZ2U6M2UzOGVkOTAyNTg2NGIwYTk0NTAzZDhiOGJmYmY5MDFfMy0yLTEtMS01MDk0MA_c91a7cae-efc9-428a-84a5-7891976134dd">435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81Mi9mcmFnOmQ0MzgyNDAyN2M3NTRjNzQ5MTg0ZThmZGM5ZjMwMjQ3L3RhYmxlOjNlMzhlZDkwMjU4NjRiMGE5NDUwM2Q4YjhiZmJmOTAxL3RhYmxlcmFuZ2U6M2UzOGVkOTAyNTg2NGIwYTk0NTAzZDhiOGJmYmY5MDFfMy00LTEtMS01MDk0MA_598d1eac-b811-47aa-b652-68e74e6ef5e0">1,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81Mi9mcmFnOmQ0MzgyNDAyN2M3NTRjNzQ5MTg0ZThmZGM5ZjMwMjQ3L3RhYmxlOjNlMzhlZDkwMjU4NjRiMGE5NDUwM2Q4YjhiZmJmOTAxL3RhYmxlcmFuZ2U6M2UzOGVkOTAyNTg2NGIwYTk0NTAzZDhiOGJmYmY5MDFfNC0yLTEtMS01MDk0MA_405945de-3628-49dd-be53-206f59ae12f0">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81Mi9mcmFnOmQ0MzgyNDAyN2M3NTRjNzQ5MTg0ZThmZGM5ZjMwMjQ3L3RhYmxlOjNlMzhlZDkwMjU4NjRiMGE5NDUwM2Q4YjhiZmJmOTAxL3RhYmxlcmFuZ2U6M2UzOGVkOTAyNTg2NGIwYTk0NTAzZDhiOGJmYmY5MDFfNC00LTEtMS01MDk0MA_f841ef7e-f7a8-4fac-aff0-53296723ccca">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81Mi9mcmFnOmQ0MzgyNDAyN2M3NTRjNzQ5MTg0ZThmZGM5ZjMwMjQ3L3RhYmxlOjNlMzhlZDkwMjU4NjRiMGE5NDUwM2Q4YjhiZmJmOTAxL3RhYmxlcmFuZ2U6M2UzOGVkOTAyNTg2NGIwYTk0NTAzZDhiOGJmYmY5MDFfNS0yLTEtMS01MDk0MA_507f0faa-3937-48c8-92ff-abcfc282df8e">1,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81Mi9mcmFnOmQ0MzgyNDAyN2M3NTRjNzQ5MTg0ZThmZGM5ZjMwMjQ3L3RhYmxlOjNlMzhlZDkwMjU4NjRiMGE5NDUwM2Q4YjhiZmJmOTAxL3RhYmxlcmFuZ2U6M2UzOGVkOTAyNTg2NGIwYTk0NTAzZDhiOGJmYmY5MDFfNS00LTEtMS01MDk0MA_79d6428a-b30e-4372-917a-3328ccfe827e">4,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_55"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 4 - <ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81NS9mcmFnOjgyY2JiMzFiMWFiMjQ3YzViYTFhZWRjNzUxOGI1ODFmL3RleHRyZWdpb246ODJjYmIzMWIxYWIyNDdjNWJhMWFlZGM3NTE4YjU4MWZfMTI1_8cca2f87-0ac7-4578-914a-28207e92e64b" continuedAt="ied1d1f779afe4425a64c53c7a36e26e5" escape="true">Tax and tax incentive receivables</ix:nonNumeric></span></div><ix:continuation id="ied1d1f779afe4425a64c53c7a36e26e5"><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="vrna:ScheduleOfNontradeReceivablesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81NS9mcmFnOjgyY2JiMzFiMWFiMjQ3YzViYTFhZWRjNzUxOGI1ODFmL3RleHRyZWdpb246ODJjYmIzMWIxYWIyNDdjNWJhMWFlZGM3NTE4YjU4MWZfMTI2_53669730-04d6-4462-b0b8-c59da10ea93d" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Tax and tax incentive receivables consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit receivable - U.K.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="vrna:ResearchAndDevelopmentTaxCreditReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81NS9mcmFnOjgyY2JiMzFiMWFiMjQ3YzViYTFhZWRjNzUxOGI1ODFmL3RhYmxlOjA5NWRjNjIxMGQyZDRiOWJiYTlhNDcxNDRkYzMxNTBjL3RhYmxlcmFuZ2U6MDk1ZGM2MjEwZDJkNGI5YmJhOWE0NzE0NGRjMzE1MGNfMi0yLTEtMS01MDk0MA_73f9abec-0129-4b6e-8795-fd5019832e01">16,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="vrna:ResearchAndDevelopmentTaxCreditReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81NS9mcmFnOjgyY2JiMzFiMWFiMjQ3YzViYTFhZWRjNzUxOGI1ODFmL3RhYmxlOjA5NWRjNjIxMGQyZDRiOWJiYTlhNDcxNDRkYzMxNTBjL3RhYmxlcmFuZ2U6MDk1ZGM2MjEwZDJkNGI5YmJhOWE0NzE0NGRjMzE1MGNfMi00LTEtMS01MDk0MA_ca6e70e3-4e71-4083-a521-0d077914df06">15,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total tax receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="vrna:TaxCreditAndIncomeTaxesReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81NS9mcmFnOjgyY2JiMzFiMWFiMjQ3YzViYTFhZWRjNzUxOGI1ODFmL3RhYmxlOjA5NWRjNjIxMGQyZDRiOWJiYTlhNDcxNDRkYzMxNTBjL3RhYmxlcmFuZ2U6MDk1ZGM2MjEwZDJkNGI5YmJhOWE0NzE0NGRjMzE1MGNfNC0yLTEtMS01MDk0MA_37359eb5-82c4-48d4-835e-306e30cbc1d8">16,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="vrna:TaxCreditAndIncomeTaxesReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81NS9mcmFnOjgyY2JiMzFiMWFiMjQ3YzViYTFhZWRjNzUxOGI1ODFmL3RhYmxlOjA5NWRjNjIxMGQyZDRiOWJiYTlhNDcxNDRkYzMxNTBjL3RhYmxlcmFuZ2U6MDk1ZGM2MjEwZDJkNGI5YmJhOWE0NzE0NGRjMzE1MGNfNC00LTEtMS01MDk0MA_be4f0cc7-f24e-4e54-b9e9-a7c4c854df5f">15,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company conducts research and development activities including, but not limited to, developing ensifentrine for various indications and delivery methods, and as a result the Company benefits in the U.K. from the HM Revenue and Customs, or HMRC, small and medium sized enterprises research and development relief, or SME R&amp;D credit, which provides relief against U.K. Corporation Tax.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Effective for accounting periods starting after April 1, 2021, new rules were introduced whereby the amount of SME R&amp;D tax credit that a business can receive in any one year will be capped at &#163;20,000 plus three times the company&#8217;s total Pay As You Earn (&#8220;PAYE&#8221;) and National Insurance contributions (&#8220;NIC&#8221;) liability. Exemptions to the cap have been introduced which are available to companies that meet certain conditions. The Company believes it may be eligible for an exemption and has requested feedback from HMRC. If the cap does not apply the Company would have recorded $<ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-5" name="vrna:GainLossFromResearchAndDevelopmentTaxCreditExcludingAnnualCap" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81NS9mcmFnOjgyY2JiMzFiMWFiMjQ3YzViYTFhZWRjNzUxOGI1ODFmL3RleHRyZWdpb246ODJjYmIzMWIxYWIyNDdjNWJhMWFlZGM3NTE4YjU4MWZfMjc0ODc3OTA3NzUzNQ_15e04386-5372-4138-a309-aed88fb6c7ee">3.6</ix:nonFraction> million relating to the quarter ended March 31, 2022 instead of the $<ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-5" name="vrna:GainLossFromResearchAndDevelopmentTaxCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81NS9mcmFnOjgyY2JiMzFiMWFiMjQ3YzViYTFhZWRjNzUxOGI1ODFmL3RleHRyZWdpb246ODJjYmIzMWIxYWIyNDdjNWJhMWFlZGM3NTE4YjU4MWZfMjc0ODc3OTA3ODAwMA_008b86e9-3d43-47a5-ba99-9a3e238c9d70">1.3</ix:nonFraction> million reported in the condensed consolidated statements of operations. Until we receive this feedback the Company is accounting for the credit as if the cap applied.</span></div></ix:continuation><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_61"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 5 - <ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82MS9mcmFnOjg3YzI1YjlmMjYyNjQ1YjBiMDQ3NDg2NjE1MzQ4OGNiL3RleHRyZWdpb246ODdjMjViOWYyNjI2NDViMGIwNDc0ODY2MTUzNDg4Y2JfOTE_8010bb6b-2547-4f2f-abf3-25be7ff885e6" continuedAt="i2498e5018bab4c4baebc15bb9dd74f51" escape="true">Accrued expenses</ix:nonNumeric></span></div><ix:continuation id="i2498e5018bab4c4baebc15bb9dd74f51"><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82MS9mcmFnOjg3YzI1YjlmMjYyNjQ1YjBiMDQ3NDg2NjE1MzQ4OGNiL3RleHRyZWdpb246ODdjMjViOWYyNjI2NDViMGIwNDc0ODY2MTUzNDg4Y2JfOTI_70eb7b5a-8386-4d92-9c4f-329a94dab638" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and other development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="vrna:AccruedResearchAndDevelopmentFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82MS9mcmFnOjg3YzI1YjlmMjYyNjQ1YjBiMDQ3NDg2NjE1MzQ4OGNiL3RhYmxlOjY2OWY4YTg3YmNkNzQ0ODdhZTk0NDdhYzgzYTAwZGQwL3RhYmxlcmFuZ2U6NjY5ZjhhODdiY2Q3NDQ4N2FlOTQ0N2FjODNhMDBkZDBfMi0yLTEtMS01MDk0MA_6a52011e-e5c1-465b-a41d-0b3628182012">27,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="vrna:AccruedResearchAndDevelopmentFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82MS9mcmFnOjg3YzI1YjlmMjYyNjQ1YjBiMDQ3NDg2NjE1MzQ4OGNiL3RhYmxlOjY2OWY4YTg3YmNkNzQ0ODdhZTk0NDdhYzgzYTAwZGQwL3RhYmxlcmFuZ2U6NjY5ZjhhODdiY2Q3NDQ4N2FlOTQ0N2FjODNhMDBkZDBfMi00LTEtMS01MDk0MA_86b2c6ea-8e6b-4e63-a96f-25e3388b062c">21,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and general corporate costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82MS9mcmFnOjg3YzI1YjlmMjYyNjQ1YjBiMDQ3NDg2NjE1MzQ4OGNiL3RhYmxlOjY2OWY4YTg3YmNkNzQ0ODdhZTk0NDdhYzgzYTAwZGQwL3RhYmxlcmFuZ2U6NjY5ZjhhODdiY2Q3NDQ4N2FlOTQ0N2FjODNhMDBkZDBfMy0yLTEtMS01MDk0MA_281432b8-04ac-49c0-a350-eb8aa9120a7b">846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82MS9mcmFnOjg3YzI1YjlmMjYyNjQ1YjBiMDQ3NDg2NjE1MzQ4OGNiL3RhYmxlOjY2OWY4YTg3YmNkNzQ0ODdhZTk0NDdhYzgzYTAwZGQwL3RhYmxlcmFuZ2U6NjY5ZjhhODdiY2Q3NDQ4N2FlOTQ0N2FjODNhMDBkZDBfMy00LTEtMS01MDk0MA_764d9aba-9c0d-4056-bb9d-5c8dea75cdaf">919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82MS9mcmFnOjg3YzI1YjlmMjYyNjQ1YjBiMDQ3NDg2NjE1MzQ4OGNiL3RhYmxlOjY2OWY4YTg3YmNkNzQ0ODdhZTk0NDdhYzgzYTAwZGQwL3RhYmxlcmFuZ2U6NjY5ZjhhODdiY2Q3NDQ4N2FlOTQ0N2FjODNhMDBkZDBfNC0yLTEtMS01MDk0MA_d396f7a4-37f8-46b6-a99d-221739a0cf63">511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82MS9mcmFnOjg3YzI1YjlmMjYyNjQ1YjBiMDQ3NDg2NjE1MzQ4OGNiL3RhYmxlOjY2OWY4YTg3YmNkNzQ0ODdhZTk0NDdhYzgzYTAwZGQwL3RhYmxlcmFuZ2U6NjY5ZjhhODdiY2Q3NDQ4N2FlOTQ0N2FjODNhMDBkZDBfNC00LTEtMS01MDk0MA_7347ccea-0fe7-48d4-ac51-73e007f9a89c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82MS9mcmFnOjg3YzI1YjlmMjYyNjQ1YjBiMDQ3NDg2NjE1MzQ4OGNiL3RhYmxlOjY2OWY4YTg3YmNkNzQ0ODdhZTk0NDdhYzgzYTAwZGQwL3RhYmxlcmFuZ2U6NjY5ZjhhODdiY2Q3NDQ4N2FlOTQ0N2FjODNhMDBkZDBfNS0yLTEtMS01MDk0MA_9111ab61-2f3d-4a97-ba61-cc01dab0b23e">28,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82MS9mcmFnOjg3YzI1YjlmMjYyNjQ1YjBiMDQ3NDg2NjE1MzQ4OGNiL3RhYmxlOjY2OWY4YTg3YmNkNzQ0ODdhZTk0NDdhYzgzYTAwZGQwL3RhYmxlcmFuZ2U6NjY5ZjhhODdiY2Q3NDQ4N2FlOTQ0N2FjODNhMDBkZDBfNS00LTEtMS01MDk0MA_f886a403-18ae-4d09-a96d-7e04b7de74d5">22,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_67"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 6 - <ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82Ny9mcmFnOmYwMTU3MmQwNzRlYjQ3M2VhNDk4ZGIwYzQ0Mzg0N2IxL3RleHRyZWdpb246ZjAxNTcyZDA3NGViNDczZWE0OThkYjBjNDQzODQ3YjFfNzA4_5082b112-6b05-478b-b18d-f20a90efd841" continuedAt="i556519cbb5fd4078a825a25f8d7bffae" escape="true">Term loan</ix:nonNumeric></span></div><ix:continuation id="i556519cbb5fd4078a825a25f8d7bffae" continuedAt="i0f1a97b08b6c4c3b82767dfcd833942b"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In November 2020, the Company entered into a term loan facility of up to $<ix:nonFraction unitRef="usd" contextRef="ib5e3071b65394dcb9eeb62c562c7fadf_I20201130" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82Ny9mcmFnOmYwMTU3MmQwNzRlYjQ3M2VhNDk4ZGIwYzQ0Mzg0N2IxL3RleHRyZWdpb246ZjAxNTcyZDA3NGViNDczZWE0OThkYjBjNDQzODQ3YjFfOTc_71f0a457-01ee-41f8-82dc-4bba1d4e4dee">30.0</ix:nonFraction>&#160;million (the &#8220;Term Loan&#8221;), consisting of advances of $<ix:nonFraction unitRef="usd" contextRef="i3e36e2a2c0ee4200aa8e95a2881303c4_D20201101-20201130" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82Ny9mcmFnOmYwMTU3MmQwNzRlYjQ3M2VhNDk4ZGIwYzQ0Mzg0N2IxL3RleHRyZWdpb246ZjAxNTcyZDA3NGViNDczZWE0OThkYjBjNDQzODQ3YjFfMTQ1_6843a3e9-d346-46a2-b20f-3ca3e299cdb1">5.0</ix:nonFraction>&#160;million funded at closing and $<ix:nonFraction unitRef="usd" contextRef="i9d316fcf04fa4e9886bc433d175709c7_I20201130" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82Ny9mcmFnOmYwMTU3MmQwNzRlYjQ3M2VhNDk4ZGIwYzQ0Mzg0N2IxL3RleHRyZWdpb246ZjAxNTcyZDA3NGViNDczZWE0OThkYjBjNDQzODQ3YjFfMTcw_8a56479e-f444-4c18-8d63-55756885ba92">10.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia5ebcd401a344004af7b7053e2853059_I20201130" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82Ny9mcmFnOmYwMTU3MmQwNzRlYjQ3M2VhNDk4ZGIwYzQ0Mzg0N2IxL3RleHRyZWdpb246ZjAxNTcyZDA3NGViNDczZWE0OThkYjBjNDQzODQ3YjFfMTc3_0d7c3505-1ab6-439b-92a6-323f9911054e">15.0</ix:nonFraction>&#160;million&#160;contingent upon achievement of certain clinical development milestones and other specified conditions. As of March 31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="i9e7ac21ebac441969276519788ca0689_I20220331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82Ny9mcmFnOmYwMTU3MmQwNzRlYjQ3M2VhNDk4ZGIwYzQ0Mzg0N2IxL3RleHRyZWdpb246ZjAxNTcyZDA3NGViNDczZWE0OThkYjBjNDQzODQ3YjFfMzI1_b48f7e06-4ca5-4993-9397-922f7bd9289e">5.0</ix:nonFraction>&#160;million principal outstanding under the Term Loan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Term Loan is governed by a loan and security agreement, dated as of November 19, 2020, between the Borrowers and SVB, as amended (the &#8220;Loan Agreement&#8221;). The Term B Loan will be available, subject to and customary terms and conditions, only during the period commencing upon the achievement of a specific clinical milestone relating to ensifentrine through and including September 30, 2022. The Term C Loan will be available, subject to customary terms and conditions, only during the period commencing upon the achievement of an additional specific clinical milestone relating to ensifentrine through and including June 30, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Term Loan will mature on November 1, 2024. Each advance under the Term Loan accrues interest at a floating per annum rate equal to the greater of (a) the sum of the prime rate reported in The Wall Street Journal plus 1.00% and (b) four and one-quarter of one percent (4.25%). The Term Loan provides for interest-only payments on a monthly basis until the payment date immediately preceding December 1, 2023. Thereafter, amortization payments will be payable monthly in equal installments of principal plus monthly payments of accrued interest. Upon repayment (whether at maturity, upon acceleration or by prepayment or otherwise), the Borrowers shall make a final payment to SVB in the amount of 10% of the aggregate Term Loans advanced (the "Final Payment"). The Borrowers may prepay the Term Loan in full but not in part provided that the Borrowers (i) provide ten days&#8217; prior written notice to SVB, (ii) pays on the date of such prepayment (A) all outstanding principal plus accrued and unpaid interest, (B) a prepayment fee of $450,000 plus 3.0% of the Term C Loans advanced if paid on or before the </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i0f1a97b08b6c4c3b82767dfcd833942b"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">first anniversary of the closing date; $300,000 plus 2.00% of the Term C Loans advanced if paid after the first anniversary of the closing date and on or before the second anniversary of the closing date; and $150,000 plus 1.00% of the Term C Loans advanced if paid thereafter and prior to maturity, (C) the Final Payment and (D) all other sums, if any, that shall become due and payable with respect to the Term Loan Advances, including interest at the Default Rate with respect to any past due amounts. Amounts outstanding during an event of default are payable upon SVB's demand and shall accrue interest at an additional rate of 3.0% per annum.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Term Loan is secured by a lien on substantially all of the assets of the Borrowers, other than the equity interests of Verona U.S. and other than intellectual property, provided that such lien on substantially all assets includes any rights to payments and proceeds from the sale, licensing or disposition of intellectual property. The Borrowers have also granted SVB a negative pledge with respect to its intellectual property.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Loan Agreement contains customary covenants and representations, including but not limited to financial reporting obligations and limitations on dividends, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. The Loan Agreement also contains other customary provisions, such as expense reimbursement, non-disclosure obligations as well as indemnification rights for the benefit of SVB. The Loan Agreement includes a minimum cash covenant triggered when Borrowers' consolidated cash and cash equivalents drop below $45.0 million at any time after the earliest to occur of any of the following: (i) the release of negative data from ENHANCE-2 and/or ENHANCE-1, which in the reasonable business discretion Borrowers&#8217; senior management, would be considered insufficient to support submission of an NDA to the FDA, (ii) the FDA issues a complete response letter with respect to an NDA submitted for ensifentrine, or (iii) failure to achieve a specific regulatory milestone relating to ensifentrine by June 30, 2023 (extendable to March 31, 2024 upon the Borrowers receiving a specified amount of new cash proceeds after September 8, 2020 from the sale of equity securities in one or more public financings or other bona fide equity financings, subordinated debt and/or upfront/milestone payments from one or more collaboration agreements not prohibited in the Loan Agreement). Upon such trigger, Borrowers must cash collateralize an amount equal to the outstanding obligations to SVB plus the amount of any prepayment penalty and Final Payment which would be due in the event the Loan Agreement were prepaid in full with respect to the Term Loans advanced as of such time.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of March 31, 2022, the carrying value of the Term Loan was approximately $<ix:nonFraction unitRef="usd" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82Ny9mcmFnOmYwMTU3MmQwNzRlYjQ3M2VhNDk4ZGIwYzQ0Mzg0N2IxL3RleHRyZWdpb246ZjAxNTcyZDA3NGViNDczZWE0OThkYjBjNDQzODQ3YjFfNDUx_cb7a6e9a-4a32-411e-be64-d9ea8a5a1ca7">4.9</ix:nonFraction>&#160;million, of which all was due in more than 12 months. The debt balance has been categorized within Level 3 of the fair value hierarchy. The carrying amount of the debt approximates its fair value based on prevailing interest rates as of the balance sheet date.</span></div></ix:continuation><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_412"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 7 - <ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MTIvZnJhZzoxYzQ0Mzc0YWRmZmQ0Mzc5YWQxNjg5OTNkMWM4MGVhYy90ZXh0cmVnaW9uOjFjNDQzNzRhZGZmZDQzNzlhZDE2ODk5M2QxYzgwZWFjXzEwOTk1MTE2MjgxOTI0_b08aff67-1d59-40a0-ae8d-19d6d2921e67" continuedAt="ibd6267e566ba41f998d85c2171aaa01b" escape="true">Equity interest </ix:nonNumeric></span></div><ix:continuation id="ibd6267e566ba41f998d85c2171aaa01b"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company entered into a collaboration and license agreement (the &#8220;Nuance Agreement&#8221;) with Nuance Pharma Limited (&#8220;Nuance Pharma&#8221;) effective June 9, 2021 (the &#8220;Effective Date&#8221;), under which the Company granted Nuance Pharma the exclusive rights to develop and commercialize ensifentrine in Greater China (China, Taiwan, Hong Kong and Macau). In return, the Company received an unconditional right to consideration aggregating $<ix:nonFraction unitRef="usd" contextRef="i47479f2645fe48afa643ac8df2b7b1c4_I20210609" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MTIvZnJhZzoxYzQ0Mzc0YWRmZmQ0Mzc5YWQxNjg5OTNkMWM4MGVhYy90ZXh0cmVnaW9uOjFjNDQzNzRhZGZmZDQzNzlhZDE2ODk5M2QxYzgwZWFjXzEwOTk1MTE2MjgxOTQx_11f5c28c-6fbd-4592-96a1-b00aaf606776">40.0</ix:nonFraction>&#160;million consisting of $<ix:nonFraction unitRef="usd" contextRef="i47479f2645fe48afa643ac8df2b7b1c4_I20210609" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MTIvZnJhZzoxYzQ0Mzc0YWRmZmQ0Mzc5YWQxNjg5OTNkMWM4MGVhYy90ZXh0cmVnaW9uOjFjNDQzNzRhZGZmZDQzNzlhZDE2ODk5M2QxYzgwZWFjXzEwOTk1MTE2MjgxOTU2_282d373a-0979-4606-afa6-43755cf9fb46">25.0</ix:nonFraction>&#160;million in cash and an equity interest, valued at $<ix:nonFraction unitRef="usd" contextRef="i47479f2645fe48afa643ac8df2b7b1c4_I20210609" decimals="-5" name="vrna:EquityInterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MTIvZnJhZzoxYzQ0Mzc0YWRmZmQ0Mzc5YWQxNjg5OTNkMWM4MGVhYy90ZXh0cmVnaW9uOjFjNDQzNzRhZGZmZDQzNzlhZDE2ODk5M2QxYzgwZWFjXzEwOTk1MTE2MjgxOTI2_38c6d866-bc48-4ced-93ff-4018bcee5aa8">15.0</ix:nonFraction>&#160;million as of the Effective Date, in Nuance Biotech, the parent company of Nuance Pharma.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company follows guidance from ASC 321-10-35-2 and uses the fair value measurement alternative and measures the securities at cost, which is deemed to be the value indicated by the last observable transaction in Nuance Biotech's stock, subject to impairment. The valuation will be adjusted for any observable price changes in orderly transactions for an identical or similar investment in Nuance Biotech, or if there is an indicator of impairment. As of March 31, 2022, there had been no observable transactions to indicate any price changes in the value of Nuance Biotech&#8217;s stock, nor had there been any indications of impairment. The equity interest is therefore recorded at a value of $<ix:nonFraction unitRef="usd" contextRef="i47479f2645fe48afa643ac8df2b7b1c4_I20210609" decimals="-5" name="vrna:EquityInterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MTIvZnJhZzoxYzQ0Mzc0YWRmZmQ0Mzc5YWQxNjg5OTNkMWM4MGVhYy90ZXh0cmVnaW9uOjFjNDQzNzRhZGZmZDQzNzlhZDE2ODk5M2QxYzgwZWFjXzEwOTk1MTE2MjgxOTcx_33b4258a-9cd2-4079-962d-07d229888c58">15.0</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 8 - <ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfNjk5OQ_d8af9b55-cac1-4f68-96d5-6101db650c01" continuedAt="i95a74cbf284d49c0bc142546c16a8dec" escape="true">Significant agreements</ix:nonNumeric></span></div><ix:continuation id="i95a74cbf284d49c0bc142546c16a8dec" continuedAt="i60e214f1ffab4103a959cdc59ea7a5ca"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Ligand agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In 2006 the Company acquired Rhinopharma and assumed contingent liabilities owed to Ligand UK Development Limited (&#8220;Ligand&#8221;) (formerly Vernalis Development Limited). The Company refers to the assignment and license agreement as the Ligand Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ligand&#160;assigned to the Company all of its rights to certain patents and patent applications relating to ensifentrine and related compounds (the &#8220;Ligand Patents&#8221;) and an exclusive, worldwide, royalty-bearing license under certain Ligand know-how to develop, manufacture and commercialize products (the &#8220;Ligand Licensed Products&#8221;) developed using Ligand Patents, Ligand know-how and the physical stock of certain compounds.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The contingent liability comprises a milestone payment (the &#8220;Milestone Payment&#8221;) on obtaining the first approval of any regulatory authority for the commercialization of a Ligand Licensed Product, low single digit royalties based on the future sales performance of all Ligand Licensed Products and a portion equal to a mid-twenty percent of any consideration received from any sub-licensees for the Ligand Patents and for Ligand know-how.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At the time of the acquisition the contingent liability was not recognized as part of the acquisition accounting as it was immaterial. The Company will therefore record as a research and development expense the Milestone Payment or royalties when they are probable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In March 2022 we entered into an Amendment Agreement (the &#8220;Amendment&#8221;) with Ligand whereby the Ligand Agreement was amended to clarify certain ambiguous terms in the Ligand Agreement. Pursuant to the Amendment:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the Company agreed to pay to Ligand (i) $<ix:nonFraction unitRef="usd" contextRef="i85587e1e0a8f439d8aebd8e3ae70349a_D20220301-20220331" decimals="-3" name="vrna:SublicensePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfMTA5OTUxMTYzMTg4MTk_7a799338-11e0-473c-bef4-8564e3a08776">2.0</ix:nonFraction>&#160;million within five business days of the date of the Amendment and (ii) $<ix:nonFraction unitRef="usd" contextRef="i8ccfc42928504d8bb11c9856cb8aae45_D20220301-20220331" decimals="-3" name="vrna:SublicensePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfMTA5OTUxMTYzMTg4MzM_6090abdc-e7b5-48c9-92c7-5a27df047752">15.0</ix:nonFraction>&#160;million upon the first commercial sale of ensifentrine by the Company or a sub-licensee, which amount is payable in cash or, at the Company's discretion, by the issuance of Company equity of equivalent value, as determined based on the volume-weighted average price of the Company's American Depositary Shares on the Nasdaq Global Market over the ten (<ix:nonFraction unitRef="tradingday" contextRef="i85587e1e0a8f439d8aebd8e3ae70349a_D20220301-20220331" decimals="INF" name="vrna:SublicensePaymentEquityIssuanceThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfMTA5OTUxMTYzMTg4NDg_a4dc01b1-9874-4d04-93ab-f574000f9364">10</ix:nonFraction>) trading days including and prior to such milestone event;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the Ligand Agreement shall expire on March 24, 2042 unless terminated earlier by either party in accordance with its terms;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">upon termination of the Ligand Agreement, any Sub-licensee (as defined in the Amendment) shall have the right to enter into a direct license agreement with Ligand for the portion of the Program IP (as defined in the Amendment) that was sub-licensed by such Sub-licensee;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the Milestone Payment may be paid in cash or, at the Company&#8217;s discretion, by issuing to Ligand shares in the Company of equivalent value; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">each party&#8217;s right to terminate the Ligand Agreement is conditioned upon such party obtaining a final judgment of the English High Court declaring that the other party is in material breach of its obligations under the Ligand Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company accounted for the $<ix:nonFraction unitRef="usd" contextRef="if0331ecacba24ab991d409deb3d7c0d6_D20220101-20220331" decimals="-3" name="vrna:SublicensePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfMjc0ODc3OTExMDMxOA_f48390db-f1a0-41a5-844d-d0c72a3c54a8">2.0</ix:nonFraction>&#160;million payment at execution as selling, general and administrative expense in the condensed consolidated statements of operations as the payment is related to a contract modification.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i60e214f1ffab4103a959cdc59ea7a5ca"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Nuance agreement </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company entered into a collaboration and license agreement (the &#8220;Nuance Agreement&#8221;) with Nuance Pharma Limited (&#8220;Nuance Pharma&#8221;) effective June 9, 2021 (the &#8220;Effective Date&#8221;) under which the Company granted Nuance Pharma the exclusive rights to develop and commercialize ensifentrine in Greater China (China, Taiwan, Hong Kong and Macau). In return, the Company received an unconditional right to consideration aggregating $<ix:nonFraction unitRef="usd" contextRef="i47479f2645fe48afa643ac8df2b7b1c4_I20210609" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfMTg1MA_2593fc08-b17e-4379-9113-1b14af5534b3">40.0</ix:nonFraction>&#160;million consisting of $<ix:nonFraction unitRef="usd" contextRef="i47479f2645fe48afa643ac8df2b7b1c4_I20210609" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfMTg2Nw_b370b234-4085-44f8-82f2-251ce6cefe0b">25.0</ix:nonFraction>&#160;million in cash and an equity interest, valued at $<ix:nonFraction unitRef="usd" contextRef="i47479f2645fe48afa643ac8df2b7b1c4_I20210609" decimals="-5" name="vrna:EquityInterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfMTkxMg_b0bec1db-c785-43f0-8c98-855a9c85e8f5">15.0</ix:nonFraction>&#160;million as of the Effective Date, in Nuance Biotech, the parent company of Nuance Pharma. The Company is eligible to receive future milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i47479f2645fe48afa643ac8df2b7b1c4_I20210609" decimals="-5" name="vrna:ContractWithCustomerFutureEligibleMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfMjA2Nw_97c4b340-95d9-420d-926c-8b539f9e867f">179.0</ix:nonFraction>&#160;million triggered upon achievement of certain clinical, regulatory, and commercial milestones, as well as tiered double-digit royalties as a percentage of net sales of the products in Greater China.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of March 31, 2022, the $<ix:nonFraction unitRef="usd" contextRef="i26149cf54682400fabed175e2aa6fa8c_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfMjI5MQ_77e98360-fb11-4720-aaf2-86bc1283b256">25.0</ix:nonFraction>&#160;million cash payment and $<ix:nonFraction unitRef="usd" contextRef="i26149cf54682400fabed175e2aa6fa8c_I20220331" decimals="-5" name="vrna:EquityInterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfMjMxMQ_5d424ca0-8439-47ab-92f8-56662da5e168">15.0</ix:nonFraction>&#160;million equity interest had been received and the holding in Nuance Biotech was recorded as Equity Interest on our unaudited condensed consolidated balance sheets included elsewhere in this Quarterly Report on Form 10-Q. The Company follows guidance from ASC 321-10-35-2 and uses the fair value measurement alternative and measures the securities at cost, which is deemed to be the value indicated by the last observable transaction in Nuance Biotech's stock, subject to impairment. The valuation will be adjusted for any observable price changes in orderly transactions for an identical or similar investment in Nuance Biotech, or if there is an indicator of impairment. As of March 31, 2022, there had been no other transactions to indicate any price changes in the value of Nuance Biotech&#8217;s stock, nor had there been any indications of impairment. The Equity Interest is therefore recorded at a value of $<ix:nonFraction unitRef="usd" contextRef="i26149cf54682400fabed175e2aa6fa8c_I20220331" decimals="-6" name="vrna:EquityInterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfMjg2NA_c79e634e-39b4-41aa-9da9-3e3989aa78b1">15</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the terms of the Nuance Agreement, at any time until three months prior to the expected submission of the first New Drug Application in Greater China, if (i) a third party is interested in partnering with the Company, either globally or in territory covering at least the United States or Europe, for the development and/or commercialization of ensifentrine or (ii) the Company undergoes a change of control, the Company will have an exclusive option right to buy back the license granted to Nuance Pharma and all related assets. The price is agreed to be equal to the aggregate of (i) all prior amounts paid by Nuance Pharma to the Company in cash under the agreement and (ii) all development and regulatory costs incurred and paid by Nuance Pharma in connection with the development and commercialization of ensifentrine under the Nuance Agreement multiplied by a single-digit factor range dependent upon achievement of certain milestones, subject to a specified maximum amount.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Nuance Agreement will continue on a jurisdiction-by-jurisdiction and product-by-product basis until the expiration of royalty payment obligations with respect to such product in such jurisdiction unless earlier terminated by the parties. Either party may terminate the Nuance Agreement for an uncured material breach or bankruptcy of the other party. Nuance Pharma may also terminate the Nuance Agreement at will upon 90 days' prior written notice. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company reviewed the buy-back option and determined that because it is conditional on a third party the Company does not have the practical ability to exercise it and, accordingly, the contract is accounted for under ASC 606.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The transaction price at the Effective Date of the Nuance Agreement was $<ix:nonFraction unitRef="usd" contextRef="i47479f2645fe48afa643ac8df2b7b1c4_I20210609" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfNDYxMg_9be414ba-fae1-4fd7-9de6-56bfbaacaf97">40.0</ix:nonFraction>&#160;million consisting of the $<ix:nonFraction unitRef="usd" contextRef="i47479f2645fe48afa643ac8df2b7b1c4_I20210609" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfNDYzMw_f0284409-425d-4479-a050-970f9a6aba95">25.0</ix:nonFraction>&#160;million upfront cash payment and $<ix:nonFraction unitRef="usd" contextRef="i47479f2645fe48afa643ac8df2b7b1c4_I20210609" decimals="-5" name="vrna:EquityInterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfNDY2MQ_d1236b73-96a3-4851-8176-929dd24997da">15.0</ix:nonFraction>&#160;million equity interest. Developmental and regulatory milestones, and the manufacture and supply of ensifentrine drug product, were not included in the transaction price as management determined that it is not probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Commercial milestones and sales royalties were also excluded and will be recognized when the milestones are achieved or the sales occur in Greater China.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The performance obligations in the Nuance Agreement include the grant of the license (including the right to commercialize ensifentrine until the end of the term, the sharing of certain know how, and the sharing of certain clinical and regulatory data), and manufacture and supply of ensifentrine drug product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has determined that the license and the know how shared with Nuance Pharma constitutes functional intellectual property and that revenue relating to this should be recognized at a point in time. Consequently, the Company determined that it fulfilled its obligations to Nuance Pharma after it delivered the know how that will allow Nuance Pharma to file an investigational new drug application in Greater China. This know how was delivered in the year ended December 31, 2021, and the $<ix:nonFraction unitRef="usd" contextRef="i47479f2645fe48afa643ac8df2b7b1c4_I20210609" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfNTkzNg_2e8e4375-3e50-41c1-8ed1-019420802221">40.0</ix:nonFraction>&#160;million revenue was therefore recognized as revenue in the year ended December 31, 2021. Revenue relating to the manufacture and supply obligations will be recognized when the drug product is delivered.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 9 - <ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RleHRyZWdpb246ZjExOTIzYTM1OGRmNDhiN2I1MmIzNzNlZDg2ZDg1MThfMzk5_112456bd-d996-4aa9-a629-4e11919d3dcd" continuedAt="i5d38d53996a746dba9c5732702a06331" escape="true">Share-based compensation</ix:nonNumeric></span></div><ix:continuation id="i5d38d53996a746dba9c5732702a06331"><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RleHRyZWdpb246ZjExOTIzYTM1OGRmNDhiN2I1MmIzNzNlZDg2ZDg1MThfNDAx_0af59d18-55db-48cc-b70a-3b864a61f3d9" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows the allocation of share-based compensation between research and development and selling, general and administrative costs (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf656cb200bb45b582e522a818bd7960_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjZjNWNhMzJlMjA2ZDQ4YTNhNzZjZjhjN2Q2NDlhNzVjL3RhYmxlcmFuZ2U6NmM1Y2EzMmUyMDZkNDhhM2E3NmNmOGM3ZDY0OWE3NWNfMi0yLTEtMS01MDk0MA_2af192fd-acd1-44e5-b473-49a0b0754e44">1,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08b14602cfda47eaa4b3fbe624c9a1cf_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjZjNWNhMzJlMjA2ZDQ4YTNhNzZjZjhjN2Q2NDlhNzVjL3RhYmxlcmFuZ2U6NmM1Y2EzMmUyMDZkNDhhM2E3NmNmOGM3ZDY0OWE3NWNfMi00LTEtMS01MDk0MA_f8bbc804-627d-4923-9f01-38e55d5655e8">3,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f4ede3c3b79413cac4812d5477bb459_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjZjNWNhMzJlMjA2ZDQ4YTNhNzZjZjhjN2Q2NDlhNzVjL3RhYmxlcmFuZ2U6NmM1Y2EzMmUyMDZkNDhhM2E3NmNmOGM3ZDY0OWE3NWNfMy0yLTEtMS01MDk0MA_75490a55-5f24-494b-ba47-4ba67269d37e">2,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3718066b40d6491eb81e069865deddc4_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjZjNWNhMzJlMjA2ZDQ4YTNhNzZjZjhjN2Q2NDlhNzVjL3RhYmxlcmFuZ2U6NmM1Y2EzMmUyMDZkNDhhM2E3NmNmOGM3ZDY0OWE3NWNfMy00LTEtMS01MDk0MA_a1192aa8-9d23-4b6e-b850-47d14c903c10">5,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjZjNWNhMzJlMjA2ZDQ4YTNhNzZjZjhjN2Q2NDlhNzVjL3RhYmxlcmFuZ2U6NmM1Y2EzMmUyMDZkNDhhM2E3NmNmOGM3ZDY0OWE3NWNfNC0yLTEtMS01MDk0MA_4bbaccb9-6f0a-42bf-9b38-445c74a2fe8a">3,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjZjNWNhMzJlMjA2ZDQ4YTNhNzZjZjhjN2Q2NDlhNzVjL3RhYmxlcmFuZ2U6NmM1Y2EzMmUyMDZkNDhhM2E3NmNmOGM3ZDY0OWE3NWNfNC00LTEtMS01MDk0MA_ff28ab61-b0db-46e3-a558-de9396e34c60">8,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Share options</span></div><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RleHRyZWdpb246ZjExOTIzYTM1OGRmNDhiN2I1MmIzNzNlZDg2ZDg1MThfNDAy_14c05412-8429-4b18-ba24-8d26c29436ca" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows share option activity, in ordinary shares, in the period:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of share options outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average exercise price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjhhZjExNmNiYjdmZjQ4Y2E4ZTRkZjY2NTY1ZTg5N2E1L3RhYmxlcmFuZ2U6OGFmMTE2Y2JiN2ZmNDhjYThlNGRmNjY1NjVlODk3YTVfMi0yLTEtMS01MDk0MA_3e65f365-164f-4797-9299-e1eb4b91d407">12,695,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjhhZjExNmNiYjdmZjQ4Y2E4ZTRkZjY2NTY1ZTg5N2E1L3RhYmxlcmFuZ2U6OGFmMTE2Y2JiN2ZmNDhjYThlNGRmNjY1NjVlODk3YTVfMi00LTEtMS01MDk0MA_8ae4f1f0-b1f1-4da4-b21a-9aeeffe3ab9d">1.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjhhZjExNmNiYjdmZjQ4Y2E4ZTRkZjY2NTY1ZTg5N2E1L3RhYmxlcmFuZ2U6OGFmMTE2Y2JiN2ZmNDhjYThlNGRmNjY1NjVlODk3YTVfMy0yLTEtMS01MDk0MA_dc44633d-8dc5-4914-9f51-f418675224d3">608,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjhhZjExNmNiYjdmZjQ4Y2E4ZTRkZjY2NTY1ZTg5N2E1L3RhYmxlcmFuZ2U6OGFmMTE2Y2JiN2ZmNDhjYThlNGRmNjY1NjVlODk3YTVfMy00LTEtMS01MDk0MA_c358cb21-bfd5-4ad6-8e1a-b7abd51ccee7">0.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at March 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjhhZjExNmNiYjdmZjQ4Y2E4ZTRkZjY2NTY1ZTg5N2E1L3RhYmxlcmFuZ2U6OGFmMTE2Y2JiN2ZmNDhjYThlNGRmNjY1NjVlODk3YTVfNy0yLTEtMS01MDk0MA_44cc24ae-8335-49f9-927c-76686f96f56b">13,303,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjhhZjExNmNiYjdmZjQ4Y2E4ZTRkZjY2NTY1ZTg5N2E1L3RhYmxlcmFuZ2U6OGFmMTE2Y2JiN2ZmNDhjYThlNGRmNjY1NjVlODk3YTVfNy00LTEtMS01MDk0MA_a1f4fb0f-069f-4463-ad46-ec35ca2694d9">1.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Restricted stock units activity</span></div><ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RleHRyZWdpb246ZjExOTIzYTM1OGRmNDhiN2I1MmIzNzNlZDg2ZDg1MThfNDAz_7edccc1c-ff58-44f2-b68c-2d7e8f0e28e1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows restricted stock unit (&#8220;RSU&#8221;) activity, in ordinary shares, in the period:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.241%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of RSUs outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term (years)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82b2bb68605b4efca32316b1da619988_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjdkMzJkMzU5ZjcyZDQwMzE5YThlMjAwMjg5NTZkZWQwL3RhYmxlcmFuZ2U6N2QzMmQzNTlmNzJkNDAzMTlhOGUyMDAyODk1NmRlZDBfMi0yLTEtMS01MDk0MA_f4532747-e5b4-4c8b-bc67-0a9bfccead23">38,347,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia5bbf2f1a066455386dcb6d6e2137c08_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjdkMzJkMzU5ZjcyZDQwMzE5YThlMjAwMjg5NTZkZWQwL3RhYmxlcmFuZ2U6N2QzMmQzNTlmNzJkNDAzMTlhOGUyMDAyODk1NmRlZDBfMi00LTEtMS01MDk0MA_95d2e84e-d5d3-45b0-83ba-dfc262802188">1.2</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica753976be2b4f4bae0fa0b52b8c63a0_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjdkMzJkMzU5ZjcyZDQwMzE5YThlMjAwMjg5NTZkZWQwL3RhYmxlcmFuZ2U6N2QzMmQzNTlmNzJkNDAzMTlhOGUyMDAyODk1NmRlZDBfMy0yLTEtMS01MDk0MA_bb79361f-5a85-4c81-9019-79c1162e153a">468,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ica753976be2b4f4bae0fa0b52b8c63a0_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjdkMzJkMzU5ZjcyZDQwMzE5YThlMjAwMjg5NTZkZWQwL3RhYmxlcmFuZ2U6N2QzMmQzNTlmNzJkNDAzMTlhOGUyMDAyODk1NmRlZDBfNS0yLTEtMS01MDk0MA_ff3e1d74-777f-4857-9d42-d6f1e0d9efe4">3,943,144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at March 31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c92777eba5f49eca3791c762fd6c083_I20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjdkMzJkMzU5ZjcyZDQwMzE5YThlMjAwMjg5NTZkZWQwL3RhYmxlcmFuZ2U6N2QzMmQzNTlmNzJkNDAzMTlhOGUyMDAyODk1NmRlZDBfNi0yLTEtMS01MDk0MA_38259c55-5ce2-4c7c-ba6e-2eeebf85d7bd">34,872,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ica753976be2b4f4bae0fa0b52b8c63a0_D20220101-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjdkMzJkMzU5ZjcyZDQwMzE5YThlMjAwMjg5NTZkZWQwL3RhYmxlcmFuZ2U6N2QzMmQzNTlmNzJkNDAzMTlhOGUyMDAyODk1NmRlZDBfNi00LTEtMS01MDk0MA_fd07456c-82f8-4b0d-98c4-b4c275c70cbc">1.1</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_79"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 10 - <ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RleHRyZWdpb246NDY0NDI0NjYyNTJlNDA3MmFhNzQxN2EzN2Q3ZGY3MDNfOTUx_a92aa1be-7113-401a-aa57-479933627848" continuedAt="i8a7e507ca8964a2c96bb7cb9272e994b" escape="true">Net loss per share </ix:nonNumeric></span></div><ix:continuation id="i8a7e507ca8964a2c96bb7cb9272e994b"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Net loss per share is calculated on an ordinary share basis. The Company&#8217;s ADSs that are listed on the Nasdaq Global Market each represent eight ordinary shares. <ix:nonNumeric contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RleHRyZWdpb246NDY0NDI0NjYyNTJlNDA3MmFhNzQxN2EzN2Q3ZGY3MDNfOTUy_0dc46810-943b-4ee0-82b3-fda13f75a842" continuedAt="i12b7260ef1a040f5b2f1678fb8126617" escape="true">The following table shows the computation of basic and diluted net loss per share for the periods ended March 31, 2022 and 2021 (net loss in thousands, loss per share in dollars):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><ix:continuation id="i12b7260ef1a040f5b2f1678fb8126617"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RhYmxlOjZlYjY4NDUzMzlkNDQ1ZjdhMDg4Yjk4NzY2ZjE3YThlL3RhYmxlcmFuZ2U6NmViNjg0NTMzOWQ0NDVmN2EwODhiOTg3NjZmMTdhOGVfMy0yLTEtMS01MDk0MA_5145b1cb-735e-450d-b11c-a306eff8c39e">24,837</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RhYmxlOjZlYjY4NDUzMzlkNDQ1ZjdhMDg4Yjk4NzY2ZjE3YThlL3RhYmxlcmFuZ2U6NmViNjg0NTMzOWQ0NDVmN2EwODhiOTg3NjZmMTdhOGVfMy00LTEtMS01MDk0MA_2fad3338-1e5e-4ab7-835c-22ce0e03e123">21,290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RhYmxlOjZlYjY4NDUzMzlkNDQ1ZjdhMDg4Yjk4NzY2ZjE3YThlL3RhYmxlcmFuZ2U6NmViNjg0NTMzOWQ0NDVmN2EwODhiOTg3NjZmMTdhOGVfNi0yLTEtMS01MDk0MA_53ce9628-05ba-4cb1-840e-04cf4f13c4de"><ix:nonFraction unitRef="shares" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RhYmxlOjZlYjY4NDUzMzlkNDQ1ZjdhMDg4Yjk4NzY2ZjE3YThlL3RhYmxlcmFuZ2U6NmViNjg0NTMzOWQ0NDVmN2EwODhiOTg3NjZmMTdhOGVfNi0yLTEtMS01MDk0MA_73c9355d-9e98-458c-814b-afd1dd6bc8ad">481,941,527</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RhYmxlOjZlYjY4NDUzMzlkNDQ1ZjdhMDg4Yjk4NzY2ZjE3YThlL3RhYmxlcmFuZ2U6NmViNjg0NTMzOWQ0NDVmN2EwODhiOTg3NjZmMTdhOGVfNi00LTEtMS01MDk0MA_25a6adf2-648f-4c4d-b1ab-e9425ad32880"><ix:nonFraction unitRef="shares" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RhYmxlOjZlYjY4NDUzMzlkNDQ1ZjdhMDg4Yjk4NzY2ZjE3YThlL3RhYmxlcmFuZ2U6NmViNjg0NTMzOWQ0NDVmN2EwODhiOTg3NjZmMTdhOGVfNi00LTEtMS01MDk0MA_b562caf5-175a-4702-bdd2-f9c58ae5acdb">469,465,085</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RhYmxlOjZlYjY4NDUzMzlkNDQ1ZjdhMDg4Yjk4NzY2ZjE3YThlL3RhYmxlcmFuZ2U6NmViNjg0NTMzOWQ0NDVmN2EwODhiOTg3NjZmMTdhOGVfNy0yLTEtMS01MDk0MA_277ba617-86b8-4a05-96cf-910318484dab"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RhYmxlOjZlYjY4NDUzMzlkNDQ1ZjdhMDg4Yjk4NzY2ZjE3YThlL3RhYmxlcmFuZ2U6NmViNjg0NTMzOWQ0NDVmN2EwODhiOTg3NjZmMTdhOGVfNy0yLTEtMS01MDk0MA_35ed8f25-4204-4c5a-a285-a26a9eef9ce2">0.05</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RhYmxlOjZlYjY4NDUzMzlkNDQ1ZjdhMDg4Yjk4NzY2ZjE3YThlL3RhYmxlcmFuZ2U6NmViNjg0NTMzOWQ0NDVmN2EwODhiOTg3NjZmMTdhOGVfNy00LTEtMS01MDk0MA_0a2e9213-74db-407e-ae22-2118f36f8705"><ix:nonFraction unitRef="usdPerShare" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RhYmxlOjZlYjY4NDUzMzlkNDQ1ZjdhMDg4Yjk4NzY2ZjE3YThlL3RhYmxlcmFuZ2U6NmViNjg0NTMzOWQ0NDVmN2EwODhiOTg3NjZmMTdhOGVfNy00LTEtMS01MDk0MA_5d8952db-d22f-4eed-8a60-b1835ff8016c">0.05</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During the three months ended March 31, 2022 and 2021, outstanding share options, RSUs and warrants over <ix:nonFraction unitRef="shares" contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RleHRyZWdpb246NDY0NDI0NjYyNTJlNDA3MmFhNzQxN2EzN2Q3ZGY3MDNfNTI4_147c0918-f4d1-4584-bcfd-9262ea394d04">60,576,894</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RleHRyZWdpb246NDY0NDI0NjYyNTJlNDA3MmFhNzQxN2EzN2Q3ZGY3MDNfNTM1_47188750-8d7c-4cc2-a980-18dc37eb4923">77,584,846</ix:nonFraction> ordinary shares, respectively, were not included in the computation of diluted earnings per ordinary share, because to do so would be antidilutive.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_91"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 2.&#160;&#160;&#160;&#160;Management&#8217;s discussion and analysis of financial condition and results of operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and related notes as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission on March 3, 2022 (the &#8220;2021 Form 10-K&#8221;).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">In addition to historical information, this Quarterly Report on Form 10-Q contains statements that constitute forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including without limitation statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, the development of ensifentrine or any other product candidates, including statements regarding the expected initiation, timing, progress and availability of data from our clinical trials and potential regulatory approvals, research and development costs, timing and likelihood of success, potential collaborations, our estimates regarding expenses, future revenues, capital requirements, debt service obligations and our need for additional financing, the funding we expect to become available from cash receipts from U.K. tax credits, and the sufficiency of our cash and cash equivalents to fund operations, are forward-looking statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of known and unknown risks, uncertainties, assumptions, and other important factors including, but not limited to, those set forth under Part I, Item 1A of the 2021 Form 10-K under the heading &#8220;Risk Factors&#8221;. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. We intend the forward-looking statements contained in this Quarterly Report on Form 10-Q to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical need. Our product candidate, ensifentrine, is an investigational, potential first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 (&#8220;PDE3&#8221; and &#8220;PDE4&#8221;), which is designed to act as both a bronchodilator and an anti-inflammatory agent. In the third quarter of 2020 we commenced our Phase 3 ENHANCE (&#8220;Ensifentrine as a Novel inHAled Nebulized COPD thErapy&#8221;) trials and, if approved, we intend to commercialize ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (&#8220;COPD&#8221;) for the nebulized formulation in the United States.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have incurred recurring losses and negative cash flows from operations since inception, and have an accumulated deficit of $288.7 million as of March 31, 2022. We expect to incur additional losses and negative cash flows from operations until our product candidates potentially gain regulatory approval and reach commercial profitability, if at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">continue to invest in the clinical development of ensifentrine for the treatment of COPD;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">manufacture ensifentrine and engage in other Chemistry, Manufacturing and Controls activities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">maintain, expand and protect our intellectual property portfolio; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">build out infrastructure and prepare for commercial launch.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We believe that our cash and cash equivalents as of March 31, 2022, expected cash receipts from U.K. tax credits and funding expected to become available under the $30.0 million debt financing facility secured in November 2020, will enable us to fund our planned operating expenses and capital expenditure requirements through at least the end of 2023. The Term Loan advances are contingent upon achievement of certain clinical development milestones and other specified conditions. See &#8220;Indebtedness&#8221; for additional information.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Clinical development update</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During the first quarter of 2022, we continued enrollment in our Phase 3 ENHANCE clinical program and we are now close to completing enrollment for this program. As of May 2, 2022, approximately 90% of subjects were randomized into ENHANCE-1, and complete enrollment in ENHANCE-1 is expected in the second quarter of 2022. This would conclude enrollment in the Phase 3 ENHANCE program. The Company projects approximately 55-65% of subjects will be receiving background therapy in each study.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Based on our current models of forecasted recruitment and study progress, we expect to report top-line data for ENHANCE-2 in the third quarter of 2022 and for ENHANCE-1 around the end of 2022. The top-line data from both ENHANCE trials will include the primary endpoint, improvement in lung function as measured by average forced expiratory volume in one second (&#8220;FEV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:1.41pt;vertical-align:baseline">1&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">) area under the curve (&#8220;AUC&#8221;) 0-12 hours post dose at week 12, as well as key secondary endpoints comprising measurements of COPD symptoms and health-related quality of life, including E-RS and SGRQ endpoints, as well as overall safety data.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The design of the ENHANCE program was based on analysis of our two Phase 2b clinical trials, which both enrolled 400 subjects with moderate to severe COPD. This includes similar entry and exclusion parameters as well as key study endpoints. To date, overall population attributes including demographics and baseline COPD characteristics including smoking history, lung function, symptoms and quality of life for subjects in the ENHANCE program are similar to those seen in the Phase 2b trials.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Board update</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In March 2022, James Brady joined our board as a Non-Executive Director. Mr. Brady has extensive experience in the biopharmaceutical industry, serving in multiple leadership roles across the U.S., Europe and China during his 30-plus-year career at AstraZeneca. Most recently, he served as Chief Financial Officer of MedImmune, the biologics discovery and development division of AstraZeneca.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">COVID-19 impact</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Verona Pharma continues to monitor the impact of the COVID-19 pandemic on its operations and clinical trials, in particular the timelines and costs of its Phase 3 clinical program ENHANCE. The pandemic and government and other measures in response continue to impact a number of clinical trial activities and the Company will provide an update if it becomes aware of any meaningful disruption caused by the pandemic to its clinical trials. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To help protect the health and safety of the subjects, caregivers and healthcare professionals involved in its clinical trials, as well as its employees and independent contractors, the Company continues to follow guidance from the FDA and other health regulatory authorities regarding the conduct of clinical trials during the COVID-19 pandemic to ensure the safety of study participants, minimize risks to study integrity, and maintain compliance with good clinical practice (GCP).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The COVID-19 pandemic is disrupting supply chains, and employee retention and recruitment, globally and the Company is closely monitoring this situation and will provide an update if it becomes aware of any meaningful disruption caused by the pandemic to the supply of ensifentrine and drug-related products, equipment and services for its clinical trials. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Russia-Ukraine Conflict</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Verona Pharma is conducting its ENHANCE-1 program at a number of clinical trial sites in Russia and Europe (but not including Ukraine). The sanctions and other restrictions imposed by the U.S. and other countries as a result of the current conflict between Russia and Ukraine may impact our outsourced clinical research vendor&#8217;s ability to pay the clinical trial sites in Russia, to supply ensifentrine and equipment to the sites, or validate their trial data. If the conflict extends into other countries in Europe where our clinical trials are being conducted, our clinical trial activities in those countries may also be impacted. The Company is closely monitoring the Russia-Ukraine conflict and will provide an update if it becomes aware of any meaningful disruption to the cost and timelines of our Phase 3 program or our plans to submit an NDA for ensifentrine.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Significant agreements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Ligand agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In 2006 we acquired Rhinopharma and assumed contingent liabilities owed to Ligand UK Development Limited (&#8220;Ligand&#8221;) (formerly Vernalis Development Limited). We refer to the assignment and license agreement as the Ligand Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ligand&#160;assigned to us all of its rights to certain patents and patent applications relating to ensifentrine and related compounds (the &#8220;Ligand Patents&#8221;) and an exclusive, worldwide, royalty-bearing license under certain Ligand know-how to develop, manufacture and commercialize products (the &#8221;Ligand Licensed Products&#8221;) developed using Ligand Patents, Ligand know-how and the physical stock of certain compounds.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The contingent liability comprises a milestone payment (the &#8220;Milestone Payment&#8221;) on obtaining the first approval of any regulatory authority for the commercialization of a Ligand Licensed Product, low single digit royalties based on the future sales performance of all Ligand Licensed Products and a portion equal to a mid-twenty percent of any consideration received from any sub-licensees for the Ligand Patents and for Ligand know-how.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At time of the acquisition the contingent liability was not recognized as part of the acquisition accounting as it was immaterial. We will therefore record as a research and development expense the Milestone Payment or royalties when they are probable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In March 2022 we entered into an Amendment Agreement (the &#8220;Amendment&#8221;) with Ligand whereby the Ligand Agreement was amended to clarify certain ambiguous terms in the Ligand Agreement. Pursuant to the Amendment:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">we agreed to pay to Ligand (i) $2.0 million within five business days of the date of the Amendment and (ii) $15.0 million upon the first commercial sale of ensifentrine by us or a sub-licensee, which amount is payable in cash or, at the our discretion, by the issuance of Company equity of equivalent value, as determined based on the volume-weighted average price of the our American Depositary Shares on the Nasdaq Global Market over the ten (10) trading days including and prior to such milestone event;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the Ligand Agreement shall expire on March 24, 2042 unless terminated earlier by either party in accordance with its terms;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt"> upon termination of the Ligand Agreement, any Sub-licensee (as defined in the Amendment) shall have the right to enter into a direct license agreement with Ligand for the portion of the Program IP (as defined in the Amendment) that was sub-licensed by such Sub-licensee;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the Milestone Payment may be paid in cash or, at our discretion, by issuing to Ligand shares in the Company of equivalent value; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">each party&#8217;s right to terminate the Ligand Agreement is conditioned upon such party obtaining a final judgment of the English High Court declaring that the other party is in material breach of its obligations under the Ligand Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Nuance agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We entered into a collaboration and license agreement (the &#8220;Nuance Agreement&#8221;) with Nuance Pharma Limited (&#8220;Nuance Pharma&#8221;) effective June 9, 2021 (the &#8220;Effective Date&#8221;) under which we granted Nuance Pharma the exclusive rights to develop and commercialize ensifentrine in Greater China (China, Taiwan, Hong Kong and Macau). In return, we received an unconditional right to consideration aggregating $40.0 million consisting of $25.0 million in cash and an equity interest valued at $15.0 million as of the Effective Date in Nuance Biotech, the parent company of Nuance Pharma. We are eligible to receive future milestone payments of up to $179.0 million, triggered upon achievement of certain clinical, regulatory, and commercial milestones as well as tiered double-digit royalties on net sales in Greater China.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of March 31, 2022, the $25.0 million cash payment and $15.0 million equity interest had been received and the holding in Nuance Biotech was recorded as Equity Interest on our unaudited condensed consolidated balance sheet included elsewhere in this Quarterly Report on Form 10-Q. The equity interest is recorded at the fair value indicated by the last observable transaction in Nuance Biotech&#8217;s stock, which was a fund raising in November, 2020. As of March 31, 2022, there had been no other observable transactions to indicate any price changes in the value of Nuance Biotech&#8217;s stock, nor had there been any indications of impairment. The equity interest is therefore recorded at a value of $15.0 million.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Nuance Pharma will be responsible for all costs related to clinical development and commercialization of ensifentrine in Greater China. A joint steering committee has been established between us and Nuance Pharma to oversee and coordinate the overall conduct of such clinical development and commercialization. We intend to use the joint steering committee to help ensure the clinical development of ensifentrine in Greater China aligns with our overall global development and commercialization strategy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the terms of the Nuance Agreement, at any time until three months prior to the expected submission of the first New Drug Application in Greater China, if (i) a third party is interested in partnering with us, either globally or in territory covering at least the United States or Europe, for the development and/or commercialization of ensifentrine or (ii) we undergo a change of control, we will have an exclusive option right to buy back the license granted to Nuance Pharma and all related assets. The price is agreed to be equal to the aggregate of (i) all prior amounts paid by Nuance Pharma to us in cash under the agreement and (ii) all development and regulatory costs incurred and paid by Nuance Pharma in connection with the development and commercialization of the ensifentrine under the Nuance Agreement multiplied by a single-digit factor range dependent upon achievement of certain milestones, subject to a specified maximum amount.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Nuance Agreement will continue on a jurisdiction-by-jurisdiction and product-by-product basis until the expiration of royalty payment obligations with respect to such product in such jurisdiction unless earlier terminated by the parties. Either party may terminate the Nuance Agreement for an uncured material breach or bankruptcy of the other party. Nuance Pharma may also terminate the Nuance Agreement at will upon 90 days' prior written notice.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We reviewed the buy-back option and determined that because it is conditional on a third party we do not have the practical ability to exercise it and, accordingly, the contract is accounted for under ASC 606.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The transaction price at the Effective Date of the Nuance Agreement was $40.0 million consisting of the $25.0 million upfront cash payment and $15.0 million equity interest. Developmental and regulatory milestones, and the manufacture and supply of ensifentrine drug product, were not included in the transaction price as we determined that it is not probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Commercial milestones and sales royalties were also excluded and will be recognized when the milestones are achieved or the sales occur in Greater China.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The performance obligations in the Nuance Agreement include the grant of the license (including the right to commercialize ensifentrine until the end of the term, the sharing of certain know how, and the sharing of certain clinical and regulatory data), and manufacture and supply of ensifentrine drug product. We have determined that the manufacturing and supply was not at a discount.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have determined that the license and the know how shared with Nuance Pharma constitutes functional intellectual property and that revenue relating to this should be recognized at a point in time. Consequently, we have determined that we fulfilled our obligations to Nuance Pharma when we delivered the know how that will allow Nuance Pharma to file an investigational new drug application in Greater China. We delivered this know how in the year ended December 31, 2021, and the $40.0 million revenue was therefore recognized as revenue in the year ended December 31, 2021. Revenue relating to the manufacture and supply obligations will be recognized when the drug product is delivered.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On the Effective Date, $4.0 million of costs of obtaining the contract were recorded as a contract asset. The entire cost had been recognized as Selling, General and Administrative expense in the Consolidated Statement of Operations, in line with recognition of the revenue relating to the contract in the year ended December 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For additional information regarding the Nuance Agreement, see Note 7 to our unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Warrants</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On July 29, 2016, as part of a private placement we issued warrants to investors. The warrant holders can subscribe for an ordinary share at a per share exercise price of &#163;1.7238. They can also opt for a cashless exercise of their warrants whereby they can choose to exchange the warrants held for a reduced number of warrants exercisable at nil consideration.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If, after a transaction, should the warrants be exercisable for unlisted securities, the warrant holders may demand a cash payment instead of the delivery of the underlying securities. Accordingly, they are accounted for as a liability under ASC 480 &#8220;Distinguishing Liabilities from Equity&#8221; and recorded at fair value using the Black-Scholes valuation methodology, on recognition and at each reporting date. The warrants were exercisable by the holders until May 2, 2022 the warrants are now expired. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Loan and security agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In November 2020 we and Verona Pharma Inc. entered into a term loan facility of up to $30.0 million with Silicon Valley Bank (the &#8220;Term Loan&#8221;). See &#8220;Indebtedness&#8221; for additional information.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Critical accounting estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the recognition of revenue, the accrual and prepayment of research and development expenses, the fair value of share-based compensation, the carrying value of the equity interest in Nuance Pharma (as defined below), research and development tax credit and the fair value of warrants. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from our estimates. The accounting policies considered to be critical to the judgments and estimates used in the preparation of our financial statements are disclosed in the Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our 2021 Form 10-K. There have been no material changes to that information disclosed in our 2021 Form 10-K during the three months ended March 31, 2022.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Components of results of operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We anticipate that our expenses will increase substantially if and as we:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">conduct our ongoing Phase 3 clinical trials for ensifentrine for the maintenance treatment of COPD;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">continue the clinical development of our DPI and pMDI formulations of ensifentrine and research and develop other formulations of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">initiate and conduct further clinical trials for ensifentrine for the treatment of acute COPD, CF or any other indication;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">initiate and progress pre-clinical studies relating to other potential indications of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">seek to discover and develop additional product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">seek regulatory approvals for any of our product candidates that successfully complete clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">potentially establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any products for which we may obtain regulatory approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our product development and potential future commercialization efforts and to support our continuing operations as a U.S. public company; or</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">experience any delays or encounter any issues from any of the above, including but not limited to failed studies, complex results, safety issues or other regulatory challenges.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Operating expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Research and development costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Research and development costs consist of salary and personnel related costs and third party costs for our research and development activities for ensifentrine. Personnel related costs include a share-based compensation charge relating to our stock option plan. The largest component of third party costs is for clinical trials, as well as manufacturing for clinical supplies and associated development, and pre-clinical studies. Research and development costs are expensed as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We expect our research and development costs to essentially remain at current levels through at least the first half of 2022 as we progress our ENHANCE program. Until we add new compounds or develop ensifentrine further in other delivery methods or indications, we expect our research and development costs to begin to decrease in the second half of 2022. Due to the nature of research and development, the expected costs are inherently uncertain and may vary significantly from our current expectations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Selling, general and administrative costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Selling, general and administrative costs consist of salary and personnel related costs, including share-based compensation, expenses relating to operating as a public company, including professional fees, insurance and commercial related costs, as well as other operating expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We expect commercial costs to increase as we continue to develop our potential commercial operations and, in the event of successful regulatory approval, we expect to incur sales force, marketing and other launch related costs. As we develop our knowledge of the market and refine our commercialization plans, expected costs may vary significantly from our current expectations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Other income/(expense)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other income/(expense) are driven by interest income and expense, the fair value movement of the warrant liability, foreign exchange movements on cash and cash equivalents and taxes receivable, and the U.K. research and development tax credits.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are entitled to participate in the U.K. Small and Medium Enterprises research and development tax relief program. The tax credits are calculated as a percentage of qualifying research and development expenditure and are payable in cash by the U.K. government to us. Credits recorded in the 2021 financial year are expected to be received in the 2022 financial year.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Effective January 1, 2022, this tax credit will be subject to a cap equal to a multiple of employment taxes the entity pays in the year in question. We are currently reviewing the impact these changes could have on our tax credit for the 2022 financial year, receivable in 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Taxation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are subject to corporate taxation in the United States and the United Kingdom. We have generated losses since inception and have therefore not paid United Kingdom corporation tax. The income taxes presented in our consolidated statements of operations and comprehensive loss represents the tax impact from our operating activities in the United States, which generates taxable income based on intercompany service arrangements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">United Kingdom losses may be carried forward indefinitely to be offset against future taxable profits, subject to various utilization criteria and restrictions. The amount that can be offset each year is limited to &#163;5.0 million plus an incremental 50% of U.K. taxable profits.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_392"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Results of operations for the three months ended March 31, 2022 and 2021</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows our statements of operations for the three months ended March 31, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,842)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,065&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,856&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,065)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,856)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,209)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income/(expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(768)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value movement on warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(507)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange (loss)/gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(923)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,086)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,646&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,336)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,755)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,210)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,837)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,290)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,547)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Research and development costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Research and development costs were $17.6&#160;million for the three months ended March 31, 2022, compared to $13.6&#160;million for the three months ended March 31, 2021, an increase of $4.0&#160;million. This increase was primarily due to a $5.6&#160;million increase in clinical trial and other development costs, as we progressed our Phase 3 ENHANCE program, offset by a $2.0&#160;million decrease in share-based compensation charges.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Selling, general and administrative costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Selling, general and administrative costs were $7.4&#160;million for the three months ended March 31, 2022 compared to $9.3&#160;million for the three months ended March 31, 2021, a decrease of $1.9&#160;million. This decrease was driven primarily by a $3.1&#160;million decrease in share-based compensation charges and a $0.6 million decrease in professional fees, partially offset by a $2.0 million charge related to the modification of the Ligand Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Other income/(expense)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The research and development tax credit for the three months ended March 31, 2022 was $1.3&#160;million compared to $2.1&#160;million for the three months ended March 31, 2021, a decrease of $0.8&#160;million. The decrease is due to changes in the SME R&amp;D tax credit program that established a cap limiting the research and development tax credit to &#163;20,000 plus three times UK pay as you earn and national insurance taxes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We recorded no income in the three months ended March 31, 2022, compared to a charge of $0.5&#160;million in the comparative period relating to the fair value movements of the warrants. In the three months ended March 31, 2021, there was a loss due to a rise in the share price in that period and greater volatility.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Net loss</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Net loss was $24.8&#160;million for the three months ended March 31, 2022, compared to $21.3&#160;million for the three months ended March 31, 2021, because of the factors outlined above.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Cash flows</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table summarizes our cash flows for the three months ended March 31, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at beginning of the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,986&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,606)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,512)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(726)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(726)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(378)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(541)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,764&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,598&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,834)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Operating activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Net cash used in operating activities was $14.5 million in the three months ended March 31, 2022, compared to $18.6 million during the three months ended March 31, 2021, a decrease of $4.1 million. This decrease is predominantly due to timing of supplier payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Financing activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Net cash used in financing activities was $0.7 million in the three months ended March 31, 2022, compared to $0.0&#160;million provided in the three months ended March 31, 2021. This consisted of $0.8 million for payment of withholding taxes due on the net-settling of certain employees&#8217; RSU awards, partially offset by $0.1 million generated from the issuance of ADSs under the ATM Program.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_386"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Liquidity and capital resources</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We do not currently have any approved products and have never generated any revenue from product sales. To date, we have financed our operations primarily through the issuances of our equity securities, including warrants, from borrowings under the Term Loan and upfront payments from the Nuance Agreement. See &#8220;Significant Agreements&#8221; and &#8220;Indebtedness&#8221; for additional information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have incurred recurring losses since inception, including net losses of $24.8 million for the three months ended March 31, 2022, and $55.6 million for the year ended December 31, 2021. As of March 31, 2022, we had an accumulated deficit of $288.7 million. We expect to continue to generate operating losses for the foreseeable future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have no ongoing material financing commitments, such as lines of credit or guarantees, that are expected to affect our liquidity over the next five years, other than leases and the Term Loan with Silicon Valley Bank.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Open market sale agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In March 2021, we entered into an open market sale agreement with Jefferies LLC (&#8220;Jefferies&#8221;) to sell shares of our ordinary shares, in the form of ADSs, with aggregate gross sales proceeds of up to $100.0 million, from time to time, through an &#8220;at the market&#8221; equity offering program under which Jefferies will act as sales agent (the &#8220;ATM Program&#8221;).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During the three months ended March 31, 2022, we sold 80,696 ordinary shares (equivalent to 10,087 ADSs) under the ATM Program, at an average price of approximately $0.86 per share (equivalent to $6.86 per ADS), raising aggregate net proceeds of approximately $0.1&#160;million after deducting issuance costs. As of March 31, 2022, $99.2&#160;million of ordinary shares, in the form of ADSs, remained available for sale under the ATM Program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Indebtedness</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In November 2020, we and Verona Pharma, Inc. entered into a term loan facility of up to $30.0&#160;million with Silicon Valley Bank, which we refer to as the Term Loan, consisting of term loan advances in an aggregate amount of $5.0&#160;million funded at closing, a term loan advance of an aggregate amount of $10.0&#160;million available subject to certain terms and conditions and the achievement of a specific clinical milestone, and a term loan advance of an aggregate amount of $15.0 million contingent upon achievement of a specific clinical development milestone and other specified conditions. As of March 31, 2022, the Company had $5.0 million principal outstanding under the Term Loan. Additional detail surrounding the Term Loan is included under the caption &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2021 Form 10-K. There have been no material changes to that information disclosed in our 2021 Form 10-K during the three months ended March 31, 2022. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Funding requirements</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We believe that our cash and cash equivalents as of March 31, 2022, expected cash receipts from U.K. tax credits and funding expected to become available under the Term Loan, will enable us to fund our planned operating expenses and capital expenditure requirements through at least the end of 2023. The Term Loan advances are contingent upon achievement of certain clinical development milestones and other specified conditions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We will require significant additional capital to further advance clinical and regulatory activities, to fund prelaunch and launch related costs and to create an effective sales and marketing organization to commercialize ensifentrine. We will need to seek additional funding through public or private financings, debt financing, collaboration or licensing agreements and other arrangements. However, there is no guarantee that we will be successful in securing additional capital on acceptable terms, or at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our shareholders and ADS holders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect such holders&#8217; rights as a shareholder or ADS holder. Any future debt financing or preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute our security holders&#8217; ownership interests.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our future capital requirements for ensifentrine or any future product candidates will depend on many factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the progress, timing and completion of pre-clinical testing and clinical trials for ensifentrine or any future product candidates and the potential that we may be required to conduct additional clinical trials for ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the number of potential new product candidates we decide to in-license and develop;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the costs involved in growing our organization to the size needed to allow for the research, development and potential commercialization of ensifentrine or any future product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the costs involved in filing patent applications and maintaining and enforcing patents or defending against claims or infringements raised by third parties;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the time and costs involved in obtaining regulatory approvals for ensifentrine or any future product candidate we develop and any delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to ensifentrine or any future product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">any licensing or milestone fees we might have to pay during future development of ensifentrine or any future product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">selling and marketing activities undertaken in connection with the anticipated commercialization of ensifentrine or any future product candidates, if approved, and costs involved in the creation of an effective sales and marketing organization; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the amount of revenues, if any, we may derive either directly or in the form of royalty payments from future sales of ensifentrine or any future product candidates, if approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for several years, if ever. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Recent accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For a discussion of pending and recently adopted accounting pronouncements, see Note 2 to our consolidated financial statements included in the 2021 Form 10-K.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_94"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item 3.</span></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_97"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Limitations on Effectiveness of Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) under the Exchange Act as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our principal executive officer and principal financial officer have concluded that, as of March 31, 2022, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the quarter ended March 31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_100"></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_103"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 1. Legal Proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are not currently subject to any material legal proceedings.</span></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_106"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our securities. Our risk factors have not changed materially from those described in Part I, Item 1A of the 2021 Form 10-K under the heading &#8220;Risk Factors&#8221;.</span></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_109"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">None.</span></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_112"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">None.</span></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_115"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 4. Mine Safety Disclosures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Not applicable.</span></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_118"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 5.&#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">None.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_121"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 6. Exhibits</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.999%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by Reference to Filings Indicated </span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit&#160;Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">File No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit No. </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filing date</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed/Furnished Herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000110465920140541/tm2039594d1_ex1.htm">3.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000110465920140541/tm2039594d1_ex1.htm">Articles of Association, as amended and as currently in effect</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/30/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="svb-second_amendmentxtox.htm">10.1&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="svb-second_amendmentxtox.htm">Second Amendment to Loan and Security Agreement, dated as of March 2, 2022, by and among Silicon Valley Bank, Verona Pharma plc and Verona Pharma, Inc. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1657312/000110465922040140/tm2210807d1_8k.htm">10.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1657312/000110465922040140/tm2210807d1_8k.htm">Amendment Agreement by and between Verona Pharma plc and Ligand UK Development Limited dated March 24, 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/30/2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q122.htm">31.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q122.htm">Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q122.htm">31.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q122.htm">Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q122.htm">32.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q122.htm">Section 1350 Certification of Chief Executive Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q122.htm">32.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q122.htm">Section 1350 Certification of Chief Financial Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">**&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8224;             Portions of this exhibit (indicated by asterisks) have been omitted pursuant to Regulation S-K, Item 601(b)(10). Such omitted information is not material and the registrant customarily and actually treats such information as private or confidential. Additionally, schedules and attachments to this exhibit have been omitted pursuant to Regulation S-K, Items 601(a)(5).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i1386bbda6db741028e2d0ab6d6a3d0c9_124"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.664%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">VERONA PHARMA PLC</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: May 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ David Zaccardelli</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">David Zaccardelli, Pharm. D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">President and Chief Executive Officer</span></td></tr><tr style="height:36pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: May 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Mark W. Hahn</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Mark W. Hahn</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>svb-second_amendmentxtox.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>svb-second_amendmentxtox</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- svb-second_amendmentxtox001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="svb-second_amendmentxtox001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">297684974.1 SECOND AMENDMENT  TO  LOAN AND SECURITY AGREEMENT This Second Amendment to Loan and Security Agreement (this &#8220;Amendment&#8221;) is entered  into this 2nd day of March, 2022, by and between (a) SILICON VALLEY BANK, a California  corporation (&#8220;Bank&#8221;) and (b) VERONA PHARMA PLC., a company registered under the laws of  England and Wales with company number 05375156 (&#8220;Parent&#8221; or &#8220;UK Borrower&#8221;) and  VERONA PHARMA, INC., a Delaware corporation (&#8220;US Borrower&#8221; and together with UK  Borrower, each a &#8220;Co-Borrower&#8221; and collectively &#8220;Co-Borrowers&#8221;).  RECITALS A. Bank and Co-Borrowers have entered into that certain Loan and Security  Agreement dated as of November 19, 2020, as amended by that certain First Amendment to Loan  and Security Agreement dated as of January 28, 2021 (as amended, and as the same may from time  to time be further amended, modified, supplemented or restated, collectively, the &#8220;Loan Agreement&#8221;).    B. Bank has extended credit to Co-Borrowers for the purposes permitted in the Loan  Agreement.    C. Co-Borrowers have requested that Bank amend the Loan Agreement to the Loan  Agreement as more fully set forth herein.  D. Bank has agreed to so amend certain provisions of the Loan Agreement, but only  to the extent, in accordance with the terms, subject to the conditions and in reliance upon the  representations and warranties set forth below.  AGREEMENT NOW, THEREFORE, in consideration of the foregoing recitals and other good and valuable  consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be  legally bound, the parties hereto agree as follows:  1. Definitions.  Capitalized terms used but not defined in this Amendment shall have  the meanings given to them in the Loan Agreement.  2. Amendment to Loan Agreement. 2.1 Section 13.1 (Definitions).  The definition of &#8220;Term B Availability  Period&#8221; set forth in Section 13.1 of the Loan Agreement hereby is amended and restated in its  entirety and replaced with the following:  &#8220;Term B Availability Period&#8221; is the period of time commencing on the date  Borrower publishes a press release that states that it has received positive Enhance 2 pivotal  data for Ensifentrine, through and including September 30, 2022.  DocuSign Envelope ID: 9FF3261D-0D20-412B-884B-4C5114DC38A9 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- svb-second_amendmentxtox002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="svb-second_amendmentxtox002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">2  297684974.1 3. Limitation of Amendments. 3.1 The amendments set forth in Section 2, above, are effective for the purposes  set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent  to any amendment, waiver or modification of any other term or condition of any Loan Document,  or (b) otherwise prejudice any right or remedy which Bank may now have or may have in the  future under or in connection with any Loan Document.  3.2 This Amendment shall be construed in connection with and as part of the  Loan Documents and all terms, conditions, representations, warranties, covenants and agreements  set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and  shall remain in full force and effect.  4. Representations and Warranties.  To induce Bank to enter into this Amendment,  Co-Borrowers hereby represent and warrant to Bank as follows:  4.1 Immediately after giving effect to this Amendment (a) the representations  and warranties contained in the Loan Documents are true, accurate and complete in all material  respects as of the date hereof (except to the extent such representations and warranties relate to an  earlier date, in which case they are true and correct as of such date), and (b) no Event of Default  has occurred and is continuing;  4.2 Co-Borrowers have the power and authority to execute and deliver this  Amendment and to perform its obligations under the Loan Agreement, as amended by this  Amendment;  4.3 Except as has been delivered to Bank pursuant to Section 6.2(e), the  organizational documents of each Co-Borrower delivered to Bank on the Effective Date remain  true, accurate and complete and have not been amended, supplemented or restated and are and  continue to be in full force and effect;   4.4 The execution and delivery by Co-Borrowers of this Amendment and the  performance by Co-Borrowers of its obligations under the Loan Agreement, as amended by this  Amendment, have been duly authorized;    4.5 The execution and delivery by Co-Borrowers of this Amendment and the  performance by Co-Borrowers of its obligations under the Loan Agreement, as amended by this  Amendment, do not and will not contravene (a) any material law or regulation binding on or  affecting Co-Borrowers, (b) any material contractual restriction with a Person binding on Co- Borrowers, (c) any order, judgment or decree of any court or other governmental or public body  or authority, or subdivision thereof, binding on Co-Borrowers, or (d) the organizational documents  of Co-Borrowers;   4.6 The execution and delivery by Co-Borrowers of this Amendment and the  performance by Co-Borrowers of its obligations under the Loan Agreement, as amended by this  Amendment, do not require any order, consent, approval, license, authorization or validation of,  or filing, recording or registration with, or exemption by any governmental or public body or  DocuSign Envelope ID: 9FF3261D-0D20-412B-884B-4C5114DC38A9 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- svb-second_amendmentxtox003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="svb-second_amendmentxtox003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">3  297684974.1 authority, or subdivision thereof, binding on Co-Borrowers, except as already has been obtained  or made; and  4.7 This Amendment has been duly executed and delivered by Co-Borrowers  and is the binding obligation of Co-Borrowers, enforceable against Co-Borrowers in accordance  with its terms, except as such enforceability may be limited by bankruptcy, insolvency,  reorganization, liquidation, moratorium or other similar laws of general application and equitable  principles relating to or affecting creditors&#8217; rights.  5. [Reserved].    6. Integration.  This Amendment and the Loan Documents represent the entire  agreement about this subject matter and supersede prior negotiations or agreements.  All prior  agreements, understandings, representations, warranties, and negotiations between the parties  about the subject matter of this Amendment and the Loan Documents merge into this Amendment  and the Loan Documents.  7. Counterparts.  This Amendment may be executed in any number of counterparts  and all of such counterparts taken together shall be deemed to constitute one and the same  instrument.  8. Effectiveness.  This Amendment shall be deemed effective upon (a) the due  execution and delivery to Bank of this Amendment by each party hereto and (b) Co-Borrowers&#8217;  payment of Bank&#8217;s legal fees and expenses incurred in connection with this Amendment.  [Signature page follows.]  DocuSign Envelope ID: 9FF3261D-0D20-412B-884B-4C5114DC38A9 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- svb-second_amendmentxtox004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="svb-second_amendmentxtox004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">297684974.1 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly  executed and delivered as of the date first written above.  BANK:  SILICON VALLEY BANK  By:    Name:  Mike McMahon  Title:  Director  CO-BORROWERS:  VERONA PHARMA, INC.  By:    Name:  Mark Hahn  Title:  Chief Financial Officer  VERONA PHARMA PLC.  By:    Name:  Mark Hahn  Title:  Chief Financial Officer  DocuSign Envelope ID: 9FF3261D-0D20-412B-884B-4C5114DC38A9 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exhibit311q122.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iba5134eb1665466e9981d9399c269224_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David Zaccardelli, Pharm.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Verona Pharma plc&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in&#160;Exchange Act Rules 13a-15(e)&#160;and&#160;15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.215%"><tr><td style="width:1.0%"></td><td style="width:36.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; May 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47;&#160;David Zaccardelli, Pharm.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">David Zaccardelli, Pharm.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer </font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(principal executive officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exhibit312q122.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i04ec35a5b65c410fac7bceecf983dc36_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark W. Hahn, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Verona Pharma plc&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in&#160;Exchange Act Rules 13a-15(e)&#160;and&#160;15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.381%"><tr><td style="width:1.0%"></td><td style="width:26.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; May 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47;&#160;Mark W. Hahn</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Mark W. Hahn</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">principal financial officer</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exhibit321q122.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1e5845c51b0147a8901008ab5d7491e1_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Verona Pharma plc (the &#8220;Company&#8221;) for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.215%"><tr><td style="width:1.0%"></td><td style="width:36.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; May 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; David Zaccardelli, Pharm.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">David Zaccardelli, Pharm.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">principal executive officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>exhibit322q122.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0dee4f6e3a864786b63d2965e502c792_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Verona Pharma plc (the &#8220;Company&#8221;) for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.381%"><tr><td style="width:1.0%"></td><td style="width:26.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; May 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47;&#160;Mark W. Hahn</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Mark W. Hahn</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">principal financial officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>vrna-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8fe8cf0b-7d67-4c56-b99e-508dc94a315d,g:47f0dc6b-9fdd-4cb6-bded-b1ab0e3af7d2-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vrna="http://veronapharma.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://veronapharma.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrna-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrna-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrna-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrna-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://veronapharma.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquity" roleURI="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity">
        <link:definition>1004005 - Statement - Consolidated Statements of Shareholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organizationanddescriptionofbusinessoperations" roleURI="http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations">
        <link:definition>2101101 - Disclosure - Organization and description of business operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationConsolidationandPresentationofFinancialStatementsDetails" roleURI="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails">
        <link:definition>2402401 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Basisofpresentationandsummaryofsignificantaccountingpolicies" roleURI="http://veronapharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies">
        <link:definition>2103102 - Disclosure - Basis of presentation and summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies" roleURI="http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies">
        <link:definition>2204201 - Disclosure - Basis of presentation and summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpresentationandsummaryofsignificantaccountingpoliciesDetails" roleURI="http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesDetails">
        <link:definition>2405402 - Disclosure - Basis of presentation and summary of significant accounting policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Prepaidexpenses" roleURI="http://veronapharma.com/role/Prepaidexpenses">
        <link:definition>2106103 - Disclosure - Prepaid expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidexpensesTables" roleURI="http://veronapharma.com/role/PrepaidexpensesTables">
        <link:definition>2307301 - Disclosure - Prepaid expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidexpensesDetails" roleURI="http://veronapharma.com/role/PrepaidexpensesDetails">
        <link:definition>2408403 - Disclosure - Prepaid expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Taxandtaxincentivereceivable" roleURI="http://veronapharma.com/role/Taxandtaxincentivereceivable">
        <link:definition>2109104 - Disclosure - Tax and tax incentive receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxandtaxincentivereceivableTables" roleURI="http://veronapharma.com/role/TaxandtaxincentivereceivableTables">
        <link:definition>2310302 - Disclosure - Tax and tax incentive receivable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxandtaxincentivereceivableDetails" roleURI="http://veronapharma.com/role/TaxandtaxincentivereceivableDetails">
        <link:definition>2411404 - Disclosure - Tax and tax incentive receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Accruedexpenses" roleURI="http://veronapharma.com/role/Accruedexpenses">
        <link:definition>2112105 - Disclosure - Accrued expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedexpensesTables" roleURI="http://veronapharma.com/role/AccruedexpensesTables">
        <link:definition>2313303 - Disclosure - Accrued expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedexpensesDetails" roleURI="http://veronapharma.com/role/AccruedexpensesDetails">
        <link:definition>2414405 - Disclosure - Accrued expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Termloan" roleURI="http://veronapharma.com/role/Termloan">
        <link:definition>2115106 - Disclosure - Term loan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TermloanDetails" roleURI="http://veronapharma.com/role/TermloanDetails">
        <link:definition>2416406 - Disclosure - Term loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityInterest" roleURI="http://veronapharma.com/role/EquityInterest">
        <link:definition>2117107 - Disclosure - Equity Interest</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityInterestDetails" roleURI="http://veronapharma.com/role/EquityInterestDetails">
        <link:definition>2418407 - Disclosure - Equity Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Significantagreements" roleURI="http://veronapharma.com/role/Significantagreements">
        <link:definition>2119108 - Disclosure - Significant agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantagreementsDetails" roleURI="http://veronapharma.com/role/SignificantagreementsDetails">
        <link:definition>2420408 - Disclosure - Significant agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Sharebasedcompensation" roleURI="http://veronapharma.com/role/Sharebasedcompensation">
        <link:definition>2121109 - Disclosure - Share based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationTables" roleURI="http://veronapharma.com/role/SharebasedcompensationTables">
        <link:definition>2322304 - Disclosure - Share based compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationShareBasedCompensationExpenseDetails" roleURI="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails">
        <link:definition>2423409 - Disclosure - Share based compensation - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationShareOptionActivityDetails" roleURI="http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails">
        <link:definition>2424410 - Disclosure - Share based compensation - Share Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationRSUActivityDetails" roleURI="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails">
        <link:definition>2425411 - Disclosure - Share based compensation - RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Netlosspershare" roleURI="http://veronapharma.com/role/Netlosspershare">
        <link:definition>2126110 - Disclosure - Net loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetlosspershareTables" roleURI="http://veronapharma.com/role/NetlosspershareTables">
        <link:definition>2327305 - Disclosure - Net loss per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetlosspershareComputationDetails" roleURI="http://veronapharma.com/role/NetlosspershareComputationDetails">
        <link:definition>2428412 - Disclosure - Net loss per share - Computation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="vrna_CommonStockSharesAvailableForSaleValue" abstract="false" name="CommonStockSharesAvailableForSaleValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" abstract="false" name="ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_SublicensePayment" abstract="false" name="SublicensePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_GainLossFromResearchAndDevelopmentTaxCredit" abstract="false" name="GainLossFromResearchAndDevelopmentTaxCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_TaxCreditAndIncomeTaxesReceivableCurrent" abstract="false" name="TaxCreditAndIncomeTaxesReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_NuanceShanghaiPharmaCoLtdMember" abstract="true" name="NuanceShanghaiPharmaCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_ScheduleOfNontradeReceivablesTableTextBlock" abstract="false" name="ScheduleOfNontradeReceivablesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vrna_SublicensePaymentPercentage" abstract="false" name="SublicensePaymentPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vrna_EquityInterestReceivable" abstract="false" name="EquityInterestReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_NumberOfWhollyOwnedSubsidiaries" abstract="false" name="NumberOfWhollyOwnedSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vrna_AmericanDepositorySharesMember" abstract="true" name="AmericanDepositorySharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_TermCLoanMember" abstract="true" name="TermCLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_FirstCommercialSaleMember" abstract="true" name="FirstCommercialSaleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_BenchmarkAchievementAxis" abstract="true" name="BenchmarkAchievementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" abstract="false" name="IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" abstract="false" name="AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_PrepaidExpenseDisclosureTextBlock" abstract="false" name="PrepaidExpenseDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_SaleOfStockMaximumAggregateOfferingPrice" abstract="false" name="SaleOfStockMaximumAggregateOfferingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_BenchmarkAchievementDomain" abstract="true" name="BenchmarkAchievementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_ContractWithCustomerFutureEligibleMilestonePayments" abstract="false" name="ContractWithCustomerFutureEligibleMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent" abstract="false" name="ResearchAndDevelopmentTaxCreditReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_LigandUKDevelopmentLimitedMember" abstract="true" name="LigandUKDevelopmentLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_OrganizationAndBusinessDescriptionTextBlock" abstract="false" name="OrganizationAndBusinessDescriptionTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vrna_UnrealizedGainLossOnWarrants" abstract="false" name="UnrealizedGainLossOnWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_AccruedResearchAndDevelopmentFeesCurrent" abstract="false" name="AccruedResearchAndDevelopmentFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_PrepaidResearchAndDevelopmentFeesCurrent" abstract="false" name="PrepaidResearchAndDevelopmentFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_TermLoanFacilityMember" abstract="true" name="TermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_GainLossFromResearchAndDevelopmentTaxCreditExcludingAnnualCap" abstract="false" name="GainLossFromResearchAndDevelopmentTaxCreditExcludingAnnualCap" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_TermBLoanMember" abstract="true" name="TermBLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_SublicensePaymentEquityIssuanceThresholdTradingDays" abstract="false" name="SublicensePaymentEquityIssuanceThresholdTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>vrna-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8fe8cf0b-7d67-4c56-b99e-508dc94a315d,g:47f0dc6b-9fdd-4cb6-bded-b1ab0e3af7d2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vrna-20220331.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0e31cd31-8b49-4932-aba6-dcf03d92e45d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_9c1ee408-3fae-4473-abc0-9f430238ca80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0e31cd31-8b49-4932-aba6-dcf03d92e45d" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_9c1ee408-3fae-4473-abc0-9f430238ca80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4b790991-4232-4220-875f-575047c70d80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0e31cd31-8b49-4932-aba6-dcf03d92e45d" xlink:to="loc_us-gaap_LiabilitiesCurrent_4b790991-4232-4220-875f-575047c70d80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_a344ecc4-61ac-45fc-a773-9ccbd2cf9de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3b4ac5ed-ca77-436b-ab7c-770e5d803f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_a344ecc4-61ac-45fc-a773-9ccbd2cf9de2" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3b4ac5ed-ca77-436b-ab7c-770e5d803f0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_65bc08c0-baa6-48ce-872b-d48b4fbab642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_a344ecc4-61ac-45fc-a773-9ccbd2cf9de2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_65bc08c0-baa6-48ce-872b-d48b4fbab642" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a4fef46d-2ef5-4552-ba26-22ae3a360af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_367161a5-37b1-498a-8190-2e0065050ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a4fef46d-2ef5-4552-ba26-22ae3a360af0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_367161a5-37b1-498a-8190-2e0065050ad9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_0f9a6717-20ce-4aca-9b4b-1bc08e4704c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a4fef46d-2ef5-4552-ba26-22ae3a360af0" xlink:to="loc_us-gaap_AdditionalPaidInCapital_0f9a6717-20ce-4aca-9b4b-1bc08e4704c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_e783d1bd-8219-4e86-9d86-0d944c957076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a4fef46d-2ef5-4552-ba26-22ae3a360af0" xlink:to="loc_us-gaap_TreasuryStockValue_e783d1bd-8219-4e86-9d86-0d944c957076" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_117edee8-f172-458f-a81f-6d7813c8f6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a4fef46d-2ef5-4552-ba26-22ae3a360af0" xlink:to="loc_us-gaap_CommonStockValue_117edee8-f172-458f-a81f-6d7813c8f6c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_18ab679d-ff37-4ae4-ac60-ac6db35de6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a4fef46d-2ef5-4552-ba26-22ae3a360af0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_18ab679d-ff37-4ae4-ac60-ac6db35de6b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_38ab4c9b-ea9b-4881-b932-e9aeb7c5a73d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_22e49f1c-a01d-4b48-86ad-918eadbcc7ce" xlink:href="vrna-20220331.xsd#vrna_TaxCreditAndIncomeTaxesReceivableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_38ab4c9b-ea9b-4881-b932-e9aeb7c5a73d" xlink:to="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_22e49f1c-a01d-4b48-86ad-918eadbcc7ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_aabb2fd8-8f60-46d3-b102-9624ffab30fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_38ab4c9b-ea9b-4881-b932-e9aeb7c5a73d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_aabb2fd8-8f60-46d3-b102-9624ffab30fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_cb91996a-8c2f-4960-b8df-ec23cf99b0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_38ab4c9b-ea9b-4881-b932-e9aeb7c5a73d" xlink:to="loc_us-gaap_OtherAssetsCurrent_cb91996a-8c2f-4960-b8df-ec23cf99b0cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_afd08878-68ae-46c1-a3a2-68e44895bd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_38ab4c9b-ea9b-4881-b932-e9aeb7c5a73d" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_afd08878-68ae-46c1-a3a2-68e44895bd6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0ecb03c2-6af0-4d78-ba9e-59b4fc781a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_68894a28-8c64-4b15-ac63-6583b03d7512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0ecb03c2-6af0-4d78-ba9e-59b4fc781a3b" xlink:to="loc_us-gaap_AssetsNoncurrent_68894a28-8c64-4b15-ac63-6583b03d7512" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1302c964-2e7b-4aaf-96ce-96fbe81062f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0ecb03c2-6af0-4d78-ba9e-59b4fc781a3b" xlink:to="loc_us-gaap_AssetsCurrent_1302c964-2e7b-4aaf-96ce-96fbe81062f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_d5e66ffb-57a8-4b74-b83c-a00cfb81fce4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_0d02343e-591f-4ae1-b115-57276fac58b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_d5e66ffb-57a8-4b74-b83c-a00cfb81fce4" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_0d02343e-591f-4ae1-b115-57276fac58b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_28f345c2-25e1-4deb-b8d3-e04cb4ce5f71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_d5e66ffb-57a8-4b74-b83c-a00cfb81fce4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_28f345c2-25e1-4deb-b8d3-e04cb4ce5f71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_98af56b1-1a7e-4ba8-a7cf-3d569a97c291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_d5e66ffb-57a8-4b74-b83c-a00cfb81fce4" xlink:to="loc_us-gaap_Goodwill_98af56b1-1a7e-4ba8-a7cf-3d569a97c291" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_739feee7-d5a9-4d95-827e-d4c7208e6653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_d5e66ffb-57a8-4b74-b83c-a00cfb81fce4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_739feee7-d5a9-4d95-827e-d4c7208e6653" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_767bf666-bdd4-4dc1-a7f3-cceded0f21ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_781b7037-ada0-4441-89fe-3724d57928b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_767bf666-bdd4-4dc1-a7f3-cceded0f21ca" xlink:to="loc_us-gaap_Liabilities_781b7037-ada0-4441-89fe-3724d57928b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_58c151c1-cd0a-4bc7-961f-80a42ac34504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_767bf666-bdd4-4dc1-a7f3-cceded0f21ca" xlink:to="loc_us-gaap_CommitmentsAndContingencies_58c151c1-cd0a-4bc7-961f-80a42ac34504" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a0e626d6-e2f2-4d4c-9325-03d205a3f372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_767bf666-bdd4-4dc1-a7f3-cceded0f21ca" xlink:to="loc_us-gaap_StockholdersEquity_a0e626d6-e2f2-4d4c-9325-03d205a3f372" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5a190d63-d7bd-484e-91bc-659f39a434d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5450dfb2-ee86-4745-8636-500ea4f5a591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5a190d63-d7bd-484e-91bc-659f39a434d6" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5450dfb2-ee86-4745-8636-500ea4f5a591" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a943d992-a9e1-4a58-9aeb-9f3bbcc79787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5a190d63-d7bd-484e-91bc-659f39a434d6" xlink:to="loc_us-gaap_AccountsPayableCurrent_a943d992-a9e1-4a58-9aeb-9f3bbcc79787" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_f3a881d6-32bf-4447-a542-29c0b3a995ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5a190d63-d7bd-484e-91bc-659f39a434d6" xlink:to="loc_us-gaap_TaxesPayableCurrent_f3a881d6-32bf-4447-a542-29c0b3a995ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b52a69af-8cf5-4341-b156-644f8e880eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5a190d63-d7bd-484e-91bc-659f39a434d6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b52a69af-8cf5-4341-b156-644f8e880eda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bb732168-0cb8-4478-b57b-49340d8610bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5a190d63-d7bd-484e-91bc-659f39a434d6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_bb732168-0cb8-4478-b57b-49340d8610bb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="vrna-20220331.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d9d54a8c-dfd1-463e-91eb-565297fd4639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_adbc5515-711c-4a20-b1a2-13158075937b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d9d54a8c-dfd1-463e-91eb-565297fd4639" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_adbc5515-711c-4a20-b1a2-13158075937b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9233a5e2-123c-48da-87fe-88bbd087b982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d9d54a8c-dfd1-463e-91eb-565297fd4639" xlink:to="loc_us-gaap_OperatingIncomeLoss_9233a5e2-123c-48da-87fe-88bbd087b982" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_edcc4d95-3948-4d7c-8e30-b3851442d829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_0cdc0aa3-e62a-415b-b9e9-20c41528686e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_edcc4d95-3948-4d7c-8e30-b3851442d829" xlink:to="loc_us-gaap_InvestmentIncomeNet_0cdc0aa3-e62a-415b-b9e9-20c41528686e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit_2f805ceb-b1fd-4f54-8c0b-a9325a8262e6" xlink:href="vrna-20220331.xsd#vrna_GainLossFromResearchAndDevelopmentTaxCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_edcc4d95-3948-4d7c-8e30-b3851442d829" xlink:to="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit_2f805ceb-b1fd-4f54-8c0b-a9325a8262e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_UnrealizedGainLossOnWarrants_082d8c3b-b6d4-4f36-a804-10f49aa9aa86" xlink:href="vrna-20220331.xsd#vrna_UnrealizedGainLossOnWarrants"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_edcc4d95-3948-4d7c-8e30-b3851442d829" xlink:to="loc_vrna_UnrealizedGainLossOnWarrants_082d8c3b-b6d4-4f36-a804-10f49aa9aa86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases_a1d9dd96-cd37-4208-8a37-059aff8175b2" xlink:href="vrna-20220331.xsd#vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_edcc4d95-3948-4d7c-8e30-b3851442d829" xlink:to="loc_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases_a1d9dd96-cd37-4208-8a37-059aff8175b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_551a013f-2196-4a3c-8659-16b75ee9b94c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_edcc4d95-3948-4d7c-8e30-b3851442d829" xlink:to="loc_us-gaap_InterestExpense_551a013f-2196-4a3c-8659-16b75ee9b94c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_39d383f6-594c-4e87-93ae-0ab9bb29c8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_afdb9441-4f82-49ae-892e-e2fa0285a3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_39d383f6-594c-4e87-93ae-0ab9bb29c8ff" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_afdb9441-4f82-49ae-892e-e2fa0285a3dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_be2fc666-907c-4df0-9d8c-8154cd1d8434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_39d383f6-594c-4e87-93ae-0ab9bb29c8ff" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_be2fc666-907c-4df0-9d8c-8154cd1d8434" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_90e52ac7-a870-47e2-b780-1cfe77d97c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7815f23d-2b0c-47dd-bcc7-c01cef7fee8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_90e52ac7-a870-47e2-b780-1cfe77d97c49" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7815f23d-2b0c-47dd-bcc7-c01cef7fee8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0cf3639b-26f5-4939-842a-beb93e63c13c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_90e52ac7-a870-47e2-b780-1cfe77d97c49" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0cf3639b-26f5-4939-842a-beb93e63c13c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_48d9e6e1-ed19-4acc-a3a7-41efa0ef027f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_6237692d-d1c8-47c6-a2b1-9e716b5d5dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_48d9e6e1-ed19-4acc-a3a7-41efa0ef027f" xlink:to="loc_us-gaap_OperatingExpenses_6237692d-d1c8-47c6-a2b1-9e716b5d5dc8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="vrna-20220331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6cebdf-54dd-48b7-8938-0c32715c52c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_1201fb22-5412-489c-be48-e2932a8d0b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6cebdf-54dd-48b7-8938-0c32715c52c5" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_1201fb22-5412-489c-be48-e2932a8d0b8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_8c39c5d3-cd98-4bd1-853b-d6b057eb5ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6cebdf-54dd-48b7-8938-0c32715c52c5" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_8c39c5d3-cd98-4bd1-853b-d6b057eb5ae4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_5c362c67-cd71-42ff-bf7a-612814b738bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6cebdf-54dd-48b7-8938-0c32715c52c5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_5c362c67-cd71-42ff-bf7a-612814b738bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c8ad42e6-745d-4016-82df-891e617fd32b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6cebdf-54dd-48b7-8938-0c32715c52c5" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c8ad42e6-745d-4016-82df-891e617fd32b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2f056518-e404-4514-9031-a4cecae68360" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6cebdf-54dd-48b7-8938-0c32715c52c5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2f056518-e404-4514-9031-a4cecae68360" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_398f5a5e-0a4c-4188-8fe3-96bb23eb62e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6cebdf-54dd-48b7-8938-0c32715c52c5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_398f5a5e-0a4c-4188-8fe3-96bb23eb62e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6b2d2b30-dc4a-4d1e-8252-e83ef53afad1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6cebdf-54dd-48b7-8938-0c32715c52c5" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6b2d2b30-dc4a-4d1e-8252-e83ef53afad1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cef671af-58a6-4783-9f65-9a12031c1eff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6cebdf-54dd-48b7-8938-0c32715c52c5" xlink:to="loc_us-gaap_NetIncomeLoss_cef671af-58a6-4783-9f65-9a12031c1eff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_31f3e5d5-0cec-4f42-9fae-66ff3a058903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6cebdf-54dd-48b7-8938-0c32715c52c5" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_31f3e5d5-0cec-4f42-9fae-66ff3a058903" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_103bf43c-581f-4976-9ea9-e34a284d0c67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6cebdf-54dd-48b7-8938-0c32715c52c5" xlink:to="loc_us-gaap_ShareBasedCompensation_103bf43c-581f-4976-9ea9-e34a284d0c67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7261d5f0-6a6d-449f-ae4c-c6ebf5dcb35e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6cebdf-54dd-48b7-8938-0c32715c52c5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7261d5f0-6a6d-449f-ae4c-c6ebf5dcb35e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e071105c-3498-462c-882b-e5c552785cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6cebdf-54dd-48b7-8938-0c32715c52c5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e071105c-3498-462c-882b-e5c552785cdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_f8ce3374-8244-428d-a9e7-54bc371cde3e" xlink:href="vrna-20220331.xsd#vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6cebdf-54dd-48b7-8938-0c32715c52c5" xlink:to="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_f8ce3374-8244-428d-a9e7-54bc371cde3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_5c035733-10a8-4661-af07-0a088354f00e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6cebdf-54dd-48b7-8938-0c32715c52c5" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_5c035733-10a8-4661-af07-0a088354f00e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_62c11b0a-94e0-4d15-b444-09b681751ce1" xlink:href="vrna-20220331.xsd#vrna_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6cebdf-54dd-48b7-8938-0c32715c52c5" xlink:to="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_62c11b0a-94e0-4d15-b444-09b681751ce1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_67847095-b945-48a5-a544-24ff0c91a0de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1833610e-82ec-447a-919e-5a027bde689d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_67847095-b945-48a5-a544-24ff0c91a0de" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1833610e-82ec-447a-919e-5a027bde689d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0baa567a-5a4a-42d4-9368-28f760cc871d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_67847095-b945-48a5-a544-24ff0c91a0de" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0baa567a-5a4a-42d4-9368-28f760cc871d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_86cc0c5d-2fe2-4414-a636-803639371d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_800c238e-4758-47d0-aefa-5c1c8a50f808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_86cc0c5d-2fe2-4414-a636-803639371d96" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_800c238e-4758-47d0-aefa-5c1c8a50f808" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_65e2f67d-e382-4485-ba69-d5509bccd741" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_86cc0c5d-2fe2-4414-a636-803639371d96" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_65e2f67d-e382-4485-ba69-d5509bccd741" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_12ee50eb-9902-42a3-9044-73f0007d2b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_86cc0c5d-2fe2-4414-a636-803639371d96" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_12ee50eb-9902-42a3-9044-73f0007d2b68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9c92c09e-e36b-4988-9b01-801f99885891" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_86cc0c5d-2fe2-4414-a636-803639371d96" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9c92c09e-e36b-4988-9b01-801f99885891" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/PrepaidexpensesDetails" xlink:type="simple" xlink:href="vrna-20220331.xsd#PrepaidexpensesDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/PrepaidexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_836ddc46-1090-40d9-81e1-9804c03e9f27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_83e254c2-a585-4b76-af0e-7f710684dd17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_836ddc46-1090-40d9-81e1-9804c03e9f27" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_83e254c2-a585-4b76-af0e-7f710684dd17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PrepaidResearchAndDevelopmentFeesCurrent_83b54d13-ef04-4258-86a8-42b8af9a766b" xlink:href="vrna-20220331.xsd#vrna_PrepaidResearchAndDevelopmentFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_836ddc46-1090-40d9-81e1-9804c03e9f27" xlink:to="loc_vrna_PrepaidResearchAndDevelopmentFeesCurrent_83b54d13-ef04-4258-86a8-42b8af9a766b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_405efade-3471-44ef-827b-645a5e334353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_836ddc46-1090-40d9-81e1-9804c03e9f27" xlink:to="loc_us-gaap_PrepaidInsurance_405efade-3471-44ef-827b-645a5e334353" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxandtaxincentivereceivableDetails" xlink:type="simple" xlink:href="vrna-20220331.xsd#TaxandtaxincentivereceivableDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/TaxandtaxincentivereceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_626ec345-cd18-40cf-b763-7ecfca62fcde" xlink:href="vrna-20220331.xsd#vrna_TaxCreditAndIncomeTaxesReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent_c90480a2-8649-48a5-86e4-4a508350f626" xlink:href="vrna-20220331.xsd#vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_626ec345-cd18-40cf-b763-7ecfca62fcde" xlink:to="loc_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent_c90480a2-8649-48a5-86e4-4a508350f626" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/AccruedexpensesDetails" xlink:type="simple" xlink:href="vrna-20220331.xsd#AccruedexpensesDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/AccruedexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8bd60078-cedc-457b-9d1e-ad24599f83ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_02476302-dab6-4d03-b5f2-fce35618e599" xlink:href="vrna-20220331.xsd#vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8bd60078-cedc-457b-9d1e-ad24599f83ac" xlink:to="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_02476302-dab6-4d03-b5f2-fce35618e599" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent_2c7c84a6-fa0a-4f23-b03c-dea1b59261d9" xlink:href="vrna-20220331.xsd#vrna_AccruedResearchAndDevelopmentFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8bd60078-cedc-457b-9d1e-ad24599f83ac" xlink:to="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent_2c7c84a6-fa0a-4f23-b03c-dea1b59261d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f2982730-3ffb-47f3-87b4-516cdfc75f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8bd60078-cedc-457b-9d1e-ad24599f83ac" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f2982730-3ffb-47f3-87b4-516cdfc75f26" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>vrna-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8fe8cf0b-7d67-4c56-b99e-508dc94a315d,g:47f0dc6b-9fdd-4cb6-bded-b1ab0e3af7d2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="vrna-20220331.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended" id="i719311905ecc45a89ea6009cfabe9cd5_ConsolidatedStatementsofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ab258761-6955-452e-afd3-4c5825584ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab258761-6955-452e-afd3-4c5825584ad6" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4f595576-df90-4a9c-bae4-b7db45cc62c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4f595576-df90-4a9c-bae4-b7db45cc62c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e40b9972-fd5e-47ed-a599-1b7819ee0c96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:to="loc_us-gaap_StockholdersEquity_e40b9972-fd5e-47ed-a599-1b7819ee0c96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_495d3c26-61d8-4bcb-b485-1ced92a31c65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:to="loc_us-gaap_NetIncomeLoss_495d3c26-61d8-4bcb-b485-1ced92a31c65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e960ba79-56cd-40a6-a62a-ab74d5fc1f00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e960ba79-56cd-40a6-a62a-ab74d5fc1f00" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8fad5bc7-2db1-4bb7-86ce-857af13c352b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8fad5bc7-2db1-4bb7-86ce-857af13c352b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_e8c68301-776c-44ed-91e2-3c2d7b0abb83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_e8c68301-776c-44ed-91e2-3c2d7b0abb83" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_e9fcedeb-b4b5-49ad-892c-7458c1083493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_e9fcedeb-b4b5-49ad-892c-7458c1083493" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_8e66a77d-4572-41f1-9c25-caec9e408d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_8e66a77d-4572-41f1-9c25-caec9e408d8c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_4e7c7f77-d220-4936-b944-7eab892b55ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_4e7c7f77-d220-4936-b944-7eab892b55ec" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_cf8bff40-fe73-4108-9712-aed58fd3731a" xlink:href="vrna-20220331.xsd#vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:to="loc_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_cf8bff40-fe73-4108-9712-aed58fd3731a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5ed9d47a-f152-4c14-a731-886528b61b13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5ed9d47a-f152-4c14-a731-886528b61b13" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e6cbd6af-685c-4c00-8691-1bca5cf50ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_26d0865f-366f-4161-bb6e-30fb2b5315f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fe337a4b-3fdf-424a-9c8a-346f496fdb9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ab258761-6955-452e-afd3-4c5825584ad6" xlink:to="loc_us-gaap_StatementTable_fe337a4b-3fdf-424a-9c8a-346f496fdb9d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e22f1acf-e33c-454c-ae00-9dfb6e8efe70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_fe337a4b-3fdf-424a-9c8a-346f496fdb9d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e22f1acf-e33c-454c-ae00-9dfb6e8efe70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e22f1acf-e33c-454c-ae00-9dfb6e8efe70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e22f1acf-e33c-454c-ae00-9dfb6e8efe70" xlink:to="loc_us-gaap_EquityComponentDomain_e22f1acf-e33c-454c-ae00-9dfb6e8efe70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ee012ed6-83b1-4430-8d0f-becac171bacd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e22f1acf-e33c-454c-ae00-9dfb6e8efe70" xlink:to="loc_us-gaap_EquityComponentDomain_ee012ed6-83b1-4430-8d0f-becac171bacd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d98270b8-3c53-4707-83a4-ea5c1bda77a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ee012ed6-83b1-4430-8d0f-becac171bacd" xlink:to="loc_us-gaap_CommonStockMember_d98270b8-3c53-4707-83a4-ea5c1bda77a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0aedf169-2102-413d-8423-8b5352143695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ee012ed6-83b1-4430-8d0f-becac171bacd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0aedf169-2102-413d-8423-8b5352143695" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_d389e1fc-23b4-483b-8bd2-fcd7ebfd5551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ee012ed6-83b1-4430-8d0f-becac171bacd" xlink:to="loc_us-gaap_TreasuryStockMember_d389e1fc-23b4-483b-8bd2-fcd7ebfd5551" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4fad8129-5f65-4153-9713-6efe7826e98b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ee012ed6-83b1-4430-8d0f-becac171bacd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4fad8129-5f65-4153-9713-6efe7826e98b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5f940e9d-338b-4b69-af7a-7778eb128461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ee012ed6-83b1-4430-8d0f-becac171bacd" xlink:to="loc_us-gaap_RetainedEarningsMember_5f940e9d-338b-4b69-af7a-7778eb128461" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails" xlink:type="simple" xlink:href="vrna-20220331.xsd#OrganizationConsolidationandPresentationofFinancialStatementsDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails" xlink:type="extended" id="i725047548869413899bf23f49a39fabd_OrganizationConsolidationandPresentationofFinancialStatementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_30b382b9-e635-4b0c-a94d-fb6aa9da9410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e794b28f-e375-4beb-9f0e-4c179319f6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_30b382b9-e635-4b0c-a94d-fb6aa9da9410" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e794b28f-e375-4beb-9f0e-4c179319f6cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SaleOfStockMaximumAggregateOfferingPrice_0a5bc9cf-23bb-48ac-9460-f643c4b7fecc" xlink:href="vrna-20220331.xsd#vrna_SaleOfStockMaximumAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_30b382b9-e635-4b0c-a94d-fb6aa9da9410" xlink:to="loc_vrna_SaleOfStockMaximumAggregateOfferingPrice_0a5bc9cf-23bb-48ac-9460-f643c4b7fecc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_729964a0-79e5-41ec-b457-c6ca3ce6f9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_30b382b9-e635-4b0c-a94d-fb6aa9da9410" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_729964a0-79e5-41ec-b457-c6ca3ce6f9f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_a862b13f-b6ba-4515-8321-c4005626e362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_30b382b9-e635-4b0c-a94d-fb6aa9da9410" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_a862b13f-b6ba-4515-8321-c4005626e362" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ca0ab44f-9fb3-4942-a9ff-155a43e18a48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_30b382b9-e635-4b0c-a94d-fb6aa9da9410" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ca0ab44f-9fb3-4942-a9ff-155a43e18a48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_CommonStockSharesAvailableForSaleValue_77a2660e-dfe1-47bf-a6eb-4507e2e76fa6" xlink:href="vrna-20220331.xsd#vrna_CommonStockSharesAvailableForSaleValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_30b382b9-e635-4b0c-a94d-fb6aa9da9410" xlink:to="loc_vrna_CommonStockSharesAvailableForSaleValue_77a2660e-dfe1-47bf-a6eb-4507e2e76fa6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b87b168a-621b-44ac-a836-8ec3bbc21511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_30b382b9-e635-4b0c-a94d-fb6aa9da9410" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b87b168a-621b-44ac-a836-8ec3bbc21511" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_06496512-0d28-4ad7-9fca-96b84f28f38f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b87b168a-621b-44ac-a836-8ec3bbc21511" xlink:to="loc_us-gaap_StatementClassOfStockAxis_06496512-0d28-4ad7-9fca-96b84f28f38f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_06496512-0d28-4ad7-9fca-96b84f28f38f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_06496512-0d28-4ad7-9fca-96b84f28f38f" xlink:to="loc_us-gaap_ClassOfStockDomain_06496512-0d28-4ad7-9fca-96b84f28f38f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cd90ad94-d417-46dc-b172-3f19377b32c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_06496512-0d28-4ad7-9fca-96b84f28f38f" xlink:to="loc_us-gaap_ClassOfStockDomain_cd90ad94-d417-46dc-b172-3f19377b32c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AmericanDepositorySharesMember_a78516d9-859a-4974-977f-b4dd5f0ae5f8" xlink:href="vrna-20220331.xsd#vrna_AmericanDepositorySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_cd90ad94-d417-46dc-b172-3f19377b32c1" xlink:to="loc_vrna_AmericanDepositorySharesMember_a78516d9-859a-4974-977f-b4dd5f0ae5f8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TermloanDetails" xlink:type="simple" xlink:href="vrna-20220331.xsd#TermloanDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/TermloanDetails" xlink:type="extended" id="ia74c34b0f32b43a292078087f434a327_TermloanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2871c4dc-c8d4-4872-a825-5cc31470d0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1614326f-ce4f-40be-bc9b-353c458e958e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2871c4dc-c8d4-4872-a825-5cc31470d0ff" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1614326f-ce4f-40be-bc9b-353c458e958e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_00f71123-ac66-4d65-9459-67943bcf4ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2871c4dc-c8d4-4872-a825-5cc31470d0ff" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_00f71123-ac66-4d65-9459-67943bcf4ecd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_fc1647da-c636-4347-a005-775e0663f615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2871c4dc-c8d4-4872-a825-5cc31470d0ff" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_fc1647da-c636-4347-a005-775e0663f615" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_62358f4c-16b0-45f8-b1dc-4de4e013b12a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2871c4dc-c8d4-4872-a825-5cc31470d0ff" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_62358f4c-16b0-45f8-b1dc-4de4e013b12a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d99ea950-1252-4287-bd7c-263131add3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2871c4dc-c8d4-4872-a825-5cc31470d0ff" xlink:to="loc_us-gaap_DebtInstrumentTable_d99ea950-1252-4287-bd7c-263131add3fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c5aaf37d-2d18-46dc-9d93-4f2f8ca21ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d99ea950-1252-4287-bd7c-263131add3fe" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c5aaf37d-2d18-46dc-9d93-4f2f8ca21ee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c5aaf37d-2d18-46dc-9d93-4f2f8ca21ee0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c5aaf37d-2d18-46dc-9d93-4f2f8ca21ee0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c5aaf37d-2d18-46dc-9d93-4f2f8ca21ee0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4b405d68-f3ff-4494-b82c-7b0ef088ab1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c5aaf37d-2d18-46dc-9d93-4f2f8ca21ee0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4b405d68-f3ff-4494-b82c-7b0ef088ab1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_858443dd-ba83-4b77-b513-2d08e88b49f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4b405d68-f3ff-4494-b82c-7b0ef088ab1f" xlink:to="loc_us-gaap_SecuredDebtMember_858443dd-ba83-4b77-b513-2d08e88b49f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_950d1078-c6a9-4dba-8476-30a03aa23b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d99ea950-1252-4287-bd7c-263131add3fe" xlink:to="loc_us-gaap_DebtInstrumentAxis_950d1078-c6a9-4dba-8476-30a03aa23b5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_950d1078-c6a9-4dba-8476-30a03aa23b5e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_950d1078-c6a9-4dba-8476-30a03aa23b5e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_950d1078-c6a9-4dba-8476-30a03aa23b5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4aa58000-8998-40d7-9a3a-33e1129eb5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_950d1078-c6a9-4dba-8476-30a03aa23b5e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4aa58000-8998-40d7-9a3a-33e1129eb5fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermLoanFacilityMember_5850c06e-7113-4778-9cdb-366813991872" xlink:href="vrna-20220331.xsd#vrna_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4aa58000-8998-40d7-9a3a-33e1129eb5fe" xlink:to="loc_vrna_TermLoanFacilityMember_5850c06e-7113-4778-9cdb-366813991872" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermBLoanMember_c50634a6-e416-477f-a6f0-2ef282c7f807" xlink:href="vrna-20220331.xsd#vrna_TermBLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrna_TermLoanFacilityMember_5850c06e-7113-4778-9cdb-366813991872" xlink:to="loc_vrna_TermBLoanMember_c50634a6-e416-477f-a6f0-2ef282c7f807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermCLoanMember_660a9ad6-d713-4547-b52e-da2726c5c35c" xlink:href="vrna-20220331.xsd#vrna_TermCLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrna_TermLoanFacilityMember_5850c06e-7113-4778-9cdb-366813991872" xlink:to="loc_vrna_TermCLoanMember_660a9ad6-d713-4547-b52e-da2726c5c35c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/EquityInterestDetails" xlink:type="simple" xlink:href="vrna-20220331.xsd#EquityInterestDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/EquityInterestDetails" xlink:type="extended" id="ifa891f074e9549e38a9934f2873f043d_EquityInterestDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b87f4d09-a8d0-4180-845c-74b00664a611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_1771ff3d-3905-4d5f-b41d-af68369661d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b87f4d09-a8d0-4180-845c-74b00664a611" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_1771ff3d-3905-4d5f-b41d-af68369661d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ae4678c0-04b9-42ae-807d-a337ecf54394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b87f4d09-a8d0-4180-845c-74b00664a611" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ae4678c0-04b9-42ae-807d-a337ecf54394" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_EquityInterestReceivable_e61065e5-61f1-46bd-862b-5b7cc60509bf" xlink:href="vrna-20220331.xsd#vrna_EquityInterestReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b87f4d09-a8d0-4180-845c-74b00664a611" xlink:to="loc_vrna_EquityInterestReceivable_e61065e5-61f1-46bd-862b-5b7cc60509bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d076e7a0-55b9-4121-b4a2-5e3223693721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b87f4d09-a8d0-4180-845c-74b00664a611" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d076e7a0-55b9-4121-b4a2-5e3223693721" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2d18bb1a-8bff-4a0e-9cb4-c81b0b3c337b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d076e7a0-55b9-4121-b4a2-5e3223693721" xlink:to="loc_srt_CounterpartyNameAxis_2d18bb1a-8bff-4a0e-9cb4-c81b0b3c337b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2d18bb1a-8bff-4a0e-9cb4-c81b0b3c337b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2d18bb1a-8bff-4a0e-9cb4-c81b0b3c337b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2d18bb1a-8bff-4a0e-9cb4-c81b0b3c337b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7990d708-97fb-4ca1-8113-9c3be1905897" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2d18bb1a-8bff-4a0e-9cb4-c81b0b3c337b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7990d708-97fb-4ca1-8113-9c3be1905897" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NuanceShanghaiPharmaCoLtdMember_dca5e7d9-2992-4c5b-aef1-9646ca38237d" xlink:href="vrna-20220331.xsd#vrna_NuanceShanghaiPharmaCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7990d708-97fb-4ca1-8113-9c3be1905897" xlink:to="loc_vrna_NuanceShanghaiPharmaCoLtdMember_dca5e7d9-2992-4c5b-aef1-9646ca38237d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SignificantagreementsDetails" xlink:type="simple" xlink:href="vrna-20220331.xsd#SignificantagreementsDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/SignificantagreementsDetails" xlink:type="extended" id="i1ce8217635fb4a2d85df0363541685fb_SignificantagreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems_7fe6b067-22d3-4d65-a27c-a35f1dc46a26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SublicensePaymentPercentage_1ef95173-2fe1-45ba-a180-8a34d95681c1" xlink:href="vrna-20220331.xsd#vrna_SublicensePaymentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_7fe6b067-22d3-4d65-a27c-a35f1dc46a26" xlink:to="loc_vrna_SublicensePaymentPercentage_1ef95173-2fe1-45ba-a180-8a34d95681c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SublicensePayment_599beeed-6473-40a4-958b-f32b9e3ca8dd" xlink:href="vrna-20220331.xsd#vrna_SublicensePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_7fe6b067-22d3-4d65-a27c-a35f1dc46a26" xlink:to="loc_vrna_SublicensePayment_599beeed-6473-40a4-958b-f32b9e3ca8dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays_4d59f1fd-894f-4cf5-9279-fec3917e4c6e" xlink:href="vrna-20220331.xsd#vrna_SublicensePaymentEquityIssuanceThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_7fe6b067-22d3-4d65-a27c-a35f1dc46a26" xlink:to="loc_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays_4d59f1fd-894f-4cf5-9279-fec3917e4c6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_d99aff42-a2c1-42b8-b552-c0fc6ee1e9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_7fe6b067-22d3-4d65-a27c-a35f1dc46a26" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_d99aff42-a2c1-42b8-b552-c0fc6ee1e9d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7209cc88-03ba-40ec-8d90-d6f720a1d836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_7fe6b067-22d3-4d65-a27c-a35f1dc46a26" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7209cc88-03ba-40ec-8d90-d6f720a1d836" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_EquityInterestReceivable_ac3ffc25-6d79-47b7-a0fd-b137114c8944" xlink:href="vrna-20220331.xsd#vrna_EquityInterestReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_7fe6b067-22d3-4d65-a27c-a35f1dc46a26" xlink:to="loc_vrna_EquityInterestReceivable_ac3ffc25-6d79-47b7-a0fd-b137114c8944" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ContractWithCustomerFutureEligibleMilestonePayments_327d8896-e35d-4994-8e4a-be3c87d2825d" xlink:href="vrna-20220331.xsd#vrna_ContractWithCustomerFutureEligibleMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_7fe6b067-22d3-4d65-a27c-a35f1dc46a26" xlink:to="loc_vrna_ContractWithCustomerFutureEligibleMilestonePayments_327d8896-e35d-4994-8e4a-be3c87d2825d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_ba80564b-b833-45d6-b525-a0f9d3c19eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_7fe6b067-22d3-4d65-a27c-a35f1dc46a26" xlink:to="loc_us-gaap_ContractWithCustomerLiability_ba80564b-b833-45d6-b525-a0f9d3c19eeb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable_47575074-eb90-4bef-b415-ded732de6059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_7fe6b067-22d3-4d65-a27c-a35f1dc46a26" xlink:to="loc_us-gaap_CapitalizedContractCostTable_47575074-eb90-4bef-b415-ded732de6059" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0cd72eb0-7f2c-4cb5-9d39-88f8586d650d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CapitalizedContractCostTable_47575074-eb90-4bef-b415-ded732de6059" xlink:to="loc_srt_CounterpartyNameAxis_0cd72eb0-7f2c-4cb5-9d39-88f8586d650d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cd72eb0-7f2c-4cb5-9d39-88f8586d650d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0cd72eb0-7f2c-4cb5-9d39-88f8586d650d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cd72eb0-7f2c-4cb5-9d39-88f8586d650d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_89f811ad-f4cc-4822-ab19-556d0ba85374" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0cd72eb0-7f2c-4cb5-9d39-88f8586d650d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_89f811ad-f4cc-4822-ab19-556d0ba85374" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_LigandUKDevelopmentLimitedMember_067caf76-2611-4beb-912f-21df30d6499a" xlink:href="vrna-20220331.xsd#vrna_LigandUKDevelopmentLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_89f811ad-f4cc-4822-ab19-556d0ba85374" xlink:to="loc_vrna_LigandUKDevelopmentLimitedMember_067caf76-2611-4beb-912f-21df30d6499a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NuanceShanghaiPharmaCoLtdMember_931998b7-5a5e-4bca-81d7-c41c77771c8b" xlink:href="vrna-20220331.xsd#vrna_NuanceShanghaiPharmaCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_89f811ad-f4cc-4822-ab19-556d0ba85374" xlink:to="loc_vrna_NuanceShanghaiPharmaCoLtdMember_931998b7-5a5e-4bca-81d7-c41c77771c8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_487d511d-b9c6-4bbd-be63-a18dddbf7b55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CapitalizedContractCostTable_47575074-eb90-4bef-b415-ded732de6059" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_487d511d-b9c6-4bbd-be63-a18dddbf7b55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_487d511d-b9c6-4bbd-be63-a18dddbf7b55_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_487d511d-b9c6-4bbd-be63-a18dddbf7b55" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_487d511d-b9c6-4bbd-be63-a18dddbf7b55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a9316247-8af9-4d04-b0d0-f955350482ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_487d511d-b9c6-4bbd-be63-a18dddbf7b55" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a9316247-8af9-4d04-b0d0-f955350482ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0d35bf35-3455-4eec-93f7-385c16f6fbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a9316247-8af9-4d04-b0d0-f955350482ca" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0d35bf35-3455-4eec-93f7-385c16f6fbc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_BenchmarkAchievementAxis_1b9e2851-2307-48a7-8006-8c209d0a3bea" xlink:href="vrna-20220331.xsd#vrna_BenchmarkAchievementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CapitalizedContractCostTable_47575074-eb90-4bef-b415-ded732de6059" xlink:to="loc_vrna_BenchmarkAchievementAxis_1b9e2851-2307-48a7-8006-8c209d0a3bea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_BenchmarkAchievementDomain_1b9e2851-2307-48a7-8006-8c209d0a3bea_default" xlink:href="vrna-20220331.xsd#vrna_BenchmarkAchievementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_vrna_BenchmarkAchievementAxis_1b9e2851-2307-48a7-8006-8c209d0a3bea" xlink:to="loc_vrna_BenchmarkAchievementDomain_1b9e2851-2307-48a7-8006-8c209d0a3bea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_BenchmarkAchievementDomain_9518aea5-ef3a-41d1-b08a-2adb23c7ef8f" xlink:href="vrna-20220331.xsd#vrna_BenchmarkAchievementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_vrna_BenchmarkAchievementAxis_1b9e2851-2307-48a7-8006-8c209d0a3bea" xlink:to="loc_vrna_BenchmarkAchievementDomain_9518aea5-ef3a-41d1-b08a-2adb23c7ef8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_FirstCommercialSaleMember_b57d12f4-67eb-44ff-a7ad-47452cb9a773" xlink:href="vrna-20220331.xsd#vrna_FirstCommercialSaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrna_BenchmarkAchievementDomain_9518aea5-ef3a-41d1-b08a-2adb23c7ef8f" xlink:to="loc_vrna_FirstCommercialSaleMember_b57d12f4-67eb-44ff-a7ad-47452cb9a773" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="vrna-20220331.xsd#SharebasedcompensationShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails" xlink:type="extended" id="ifd437b0f613541ec945625bd26087d0d_SharebasedcompensationShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_02d4dd56-bb35-4220-846b-d4940a57c76d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f42baa49-98ed-4cf2-9b17-8e84aef9e959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_02d4dd56-bb35-4220-846b-d4940a57c76d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f42baa49-98ed-4cf2-9b17-8e84aef9e959" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e253a3a4-e860-4b23-a510-615e959cf53c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_02d4dd56-bb35-4220-846b-d4940a57c76d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e253a3a4-e860-4b23-a510-615e959cf53c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_daffe5b9-cedb-40ce-b1d9-5201c025102e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e253a3a4-e860-4b23-a510-615e959cf53c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_daffe5b9-cedb-40ce-b1d9-5201c025102e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_daffe5b9-cedb-40ce-b1d9-5201c025102e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_daffe5b9-cedb-40ce-b1d9-5201c025102e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_daffe5b9-cedb-40ce-b1d9-5201c025102e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3cc25ea7-bb5d-4e4c-b541-dd1e817ca615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_daffe5b9-cedb-40ce-b1d9-5201c025102e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3cc25ea7-bb5d-4e4c-b541-dd1e817ca615" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9b58fb75-4cf2-4638-a9f8-6db5d8cc7072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3cc25ea7-bb5d-4e4c-b541-dd1e817ca615" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9b58fb75-4cf2-4638-a9f8-6db5d8cc7072" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7676e53d-e6e1-4429-8f34-850bd914e4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3cc25ea7-bb5d-4e4c-b541-dd1e817ca615" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7676e53d-e6e1-4429-8f34-850bd914e4bf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails" xlink:type="simple" xlink:href="vrna-20220331.xsd#SharebasedcompensationRSUActivityDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails" xlink:type="extended" id="ic2c631a14d1a4f51b5c266c8412a1f9a_SharebasedcompensationRSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50ff3269-a44b-4bc2-addc-f8d8a8d9ebff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0f331780-b1b1-4216-abb9-b11b61671fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50ff3269-a44b-4bc2-addc-f8d8a8d9ebff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0f331780-b1b1-4216-abb9-b11b61671fc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1d8644d9-3fc6-4f84-a47b-bd797800209f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0f331780-b1b1-4216-abb9-b11b61671fc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1d8644d9-3fc6-4f84-a47b-bd797800209f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9f3f12a8-4526-4e2a-9b24-58502fb9299f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0f331780-b1b1-4216-abb9-b11b61671fc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9f3f12a8-4526-4e2a-9b24-58502fb9299f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_230116dd-5fdc-4e5c-aa38-22975f08bb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0f331780-b1b1-4216-abb9-b11b61671fc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_230116dd-5fdc-4e5c-aa38-22975f08bb3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_035a04ac-f2b0-440e-85ea-ec9c20e64025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_c171a41c-d54c-4c7f-870f-455fdc9a61a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50ff3269-a44b-4bc2-addc-f8d8a8d9ebff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_c171a41c-d54c-4c7f-870f-455fdc9a61a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_de0a7136-56b7-4023-91fa-ac59d8095f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50ff3269-a44b-4bc2-addc-f8d8a8d9ebff" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_de0a7136-56b7-4023-91fa-ac59d8095f3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_30fe0cbf-812a-4753-bf68-3b51e862cf7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_de0a7136-56b7-4023-91fa-ac59d8095f3c" xlink:to="loc_us-gaap_AwardTypeAxis_30fe0cbf-812a-4753-bf68-3b51e862cf7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30fe0cbf-812a-4753-bf68-3b51e862cf7e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_30fe0cbf-812a-4753-bf68-3b51e862cf7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30fe0cbf-812a-4753-bf68-3b51e862cf7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0f39443-3fc1-4c94-953b-8f9d08c88092" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_30fe0cbf-812a-4753-bf68-3b51e862cf7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0f39443-3fc1-4c94-953b-8f9d08c88092" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b336674d-556f-466a-af57-736bd65a4016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0f39443-3fc1-4c94-953b-8f9d08c88092" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b336674d-556f-466a-af57-736bd65a4016" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>vrna-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8fe8cf0b-7d67-4c56-b99e-508dc94a315d,g:47f0dc6b-9fdd-4cb6-bded-b1ab0e3af7d2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_dace8cfd-a8f6-4e4d-ac6a-b3fa93da293f_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_bd4dfd49-521c-459e-b305-0b655f2f64a6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a80b1798-8393-4687-946d-718d2e259089_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_eba8d5bd-b2c2-4680-b528-982aafa42dfd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_711591c9-4765-43b9-acee-dde81fa2b712_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_75af3209-d50d-40bf-9ba6-15ee1557e246_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4096a89f-5dcc-4e66-bb98-ae5dd3fc7aaa_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_bb0feaed-f033-426c-b33e-728543e9a4c9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3c596637-e589-492d-bccb-dde6de45c58f_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_29f2f698-ae1a-406e-a13f-26be022c952f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_5c47c6a4-aa93-43eb-9fb2-6b99dace1dcb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_409960bf-1f3e-4885-b53e-5c5d17743eca_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">People related costs</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_da4df198-7ef6-4732-9d0b-623ed0391664_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_703da9cd-6c8a-467f-baae-df39f3d3b9d6_negatedTerseLabel_en-US" xlink:label="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax incentive receivable</link:label>
    <link:label id="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_label_en-US" xlink:label="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Tax And Tax Credit Receivables, Current</link:label>
    <link:label id="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_documentation_en-US" xlink:label="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Tax And Tax Credit Receivables, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:href="vrna-20220331.xsd#vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:to="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e1cb40d0-c861-4218-8fd5-e061162d9a61_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3360c5fa-425e-4bcb-a55e-b244d6ea4a6c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_54b3bcb1-c97e-4b53-b965-2fc4fa54e332_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_7d13d98c-d299-4002-a84c-c0aa00ad8508_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_da8ff4b4-3093-45ab-9555-dc042b674d00_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7a0db9fa-6733-4c56-a4c3-ef9226738437_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4c7d2982-a842-4990-812e-4efb169caba6_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_1a1f7b6d-d34f-4111-82d3-473b271acea0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_PrepaidExpenseDisclosureTextBlock_2133115e-bebc-4fde-a62a-4622e5308f7d_terseLabel_en-US" xlink:label="lab_vrna_PrepaidExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_vrna_PrepaidExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_vrna_PrepaidExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Disclosure [Text Block]</link:label>
    <link:label id="lab_vrna_PrepaidExpenseDisclosureTextBlock_documentation_en-US" xlink:label="lab_vrna_PrepaidExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PrepaidExpenseDisclosureTextBlock" xlink:href="vrna-20220331.xsd#vrna_PrepaidExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_PrepaidExpenseDisclosureTextBlock" xlink:to="lab_vrna_PrepaidExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent_de476c88-6e4a-4b67-8198-af3fc8050af4_terseLabel_en-US" xlink:label="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial and other development costs</link:label>
    <link:label id="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent_label_en-US" xlink:label="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Fees, Current</link:label>
    <link:label id="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent_documentation_en-US" xlink:label="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:href="vrna-20220331.xsd#vrna_AccruedResearchAndDevelopmentFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:to="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_d30ee3b7-acb2-4d5c-bda9-c464d8618ae1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2ca5960-4872-4b65-b85b-3f48b8921ea7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_9acf4ad2-b4ca-41a8-a64a-da91f31202c6_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation and summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c8b8dec2-42ad-46f4-86b2-55e2d9f9d9d3_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3b10d2be-0f7f-49a0-9c17-433bd25bb7e3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5b5a7168-7629-43b4-a077-f0b49f9ea816_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_be9862f8-4c53-416c-9376-6cad5e24a8f3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_5071fcf0-ff75-4ec6-9b83-52b741245d33_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2c42fa89-1989-4cca-bc77-13576b1e791f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_a40cd1ff-7bec-4d2e-a16d-1b410db76f69_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded advances</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_87aa7937-ada8-4064-b62e-4e2149636ce5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_9360c731-fe34-4367-bec1-f2859a428450_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_80811afa-4500-427b-8c74-4ba331f31ae7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_54b973ff-2f2b-476d-8fd6-3650fa1dc3d0_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_f5c52903-a977-4649-9463-b2d1df45c410_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0d259d4b-a09a-45eb-9507-e49370dd54ca_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit_8b491761-d40a-4947-81a6-143d940170be_terseLabel_en-US" xlink:label="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit</link:label>
    <link:label id="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit_label_en-US" xlink:label="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) From Research And Development Tax Credit</link:label>
    <link:label id="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit_documentation_en-US" xlink:label="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) From Research And Development Tax Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:href="vrna-20220331.xsd#vrna_GainLossFromResearchAndDevelopmentTaxCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:to="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_e3d41d7d-c741-49fe-8c70-c570a81cec59_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c27ee03b-6ee7-4652-9268-52ff3f5d8a02_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_dff3aa86-fa29-44c4-818b-61e0d2b00a16_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_AmericanDepositorySharesMember_35dccbcb-b017-4e47-acb9-361a005cf1ea_terseLabel_en-US" xlink:label="lab_vrna_AmericanDepositorySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depository Shares</link:label>
    <link:label id="lab_vrna_AmericanDepositorySharesMember_label_en-US" xlink:label="lab_vrna_AmericanDepositorySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depository Shares [Member]</link:label>
    <link:label id="lab_vrna_AmericanDepositorySharesMember_documentation_en-US" xlink:label="lab_vrna_AmericanDepositorySharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depository Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AmericanDepositorySharesMember" xlink:href="vrna-20220331.xsd#vrna_AmericanDepositorySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_AmericanDepositorySharesMember" xlink:to="lab_vrna_AmericanDepositorySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_bd6b27b8-f970-416f-a141-b59a37b25342_terseLabel_en-US" xlink:label="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:label id="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="vrna-20220331.xsd#vrna_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ec72acd1-63ab-468b-85b4-59d42af19fcd_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c05fc21c-7268-4174-8967-9c0c5b70a910_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c75faed8-b40a-4365-8785-cf66f6b91fab_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_11fb0b36-5867-4724-9f76-9f48dc71fd09_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_f69a9327-973b-48a2-aab0-cd4555dd16f9_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of redemption premium on debt</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_baada3b0-e9d7-4682-be26-142e1796f022_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_8fb19720-8a70-4654-8ff0-bdd45d70dab4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_988f0867-0f49-4020-826a-2c4de2c71452_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6b3c99d5-c3d7-47e3-8666-22630b9433e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4a4189a7-1096-43ef-ab30-884b1348578a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_6e091d78-6dbc-4801-88a7-4f581245eb86_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a9bcfc5c-c023-487a-b960-3f4f1bf8d202_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5f562df9-fd2e-45d7-8593-fd0d1d59e33d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ContractWithCustomerFutureEligibleMilestonePayments_0aeeee21-c08a-4712-ab79-016430fb3101_terseLabel_en-US" xlink:label="lab_vrna_ContractWithCustomerFutureEligibleMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future eligible milestone payments</link:label>
    <link:label id="lab_vrna_ContractWithCustomerFutureEligibleMilestonePayments_label_en-US" xlink:label="lab_vrna_ContractWithCustomerFutureEligibleMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Future Eligible Milestone Payments</link:label>
    <link:label id="lab_vrna_ContractWithCustomerFutureEligibleMilestonePayments_documentation_en-US" xlink:label="lab_vrna_ContractWithCustomerFutureEligibleMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Future Eligible Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ContractWithCustomerFutureEligibleMilestonePayments" xlink:href="vrna-20220331.xsd#vrna_ContractWithCustomerFutureEligibleMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ContractWithCustomerFutureEligibleMilestonePayments" xlink:to="lab_vrna_ContractWithCustomerFutureEligibleMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_12c33b71-d162-45ff-b9b9-084f501a9b4a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted share units vested</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_61efb908-9a26-48b7-84b0-c8694f534f40_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_b37d71e9-b31a-48f0-a48a-47f9354fa07d_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_ed069d45-7ed3-4de1-8506-31460879a015_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_GainLossFromResearchAndDevelopmentTaxCreditExcludingAnnualCap_70c5b472-17cd-40e5-9341-c8cbfdcd5038_terseLabel_en-US" xlink:label="lab_vrna_GainLossFromResearchAndDevelopmentTaxCreditExcludingAnnualCap" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit excluding annual cap</link:label>
    <link:label id="lab_vrna_GainLossFromResearchAndDevelopmentTaxCreditExcludingAnnualCap_label_en-US" xlink:label="lab_vrna_GainLossFromResearchAndDevelopmentTaxCreditExcludingAnnualCap" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) From Research And Development Tax Credit, Excluding Annual Cap</link:label>
    <link:label id="lab_vrna_GainLossFromResearchAndDevelopmentTaxCreditExcludingAnnualCap_documentation_en-US" xlink:label="lab_vrna_GainLossFromResearchAndDevelopmentTaxCreditExcludingAnnualCap" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) From Research And Development Tax Credit, Excluding Annual Cap</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_GainLossFromResearchAndDevelopmentTaxCreditExcludingAnnualCap" xlink:href="vrna-20220331.xsd#vrna_GainLossFromResearchAndDevelopmentTaxCreditExcludingAnnualCap"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_GainLossFromResearchAndDevelopmentTaxCreditExcludingAnnualCap" xlink:to="lab_vrna_GainLossFromResearchAndDevelopmentTaxCreditExcludingAnnualCap" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_054ce0f8-017e-4b2e-b143-40fef48ed709_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_BenchmarkAchievementDomain_cbc021f5-7cb1-4999-aff6-78ff1763ba2d_terseLabel_en-US" xlink:label="lab_vrna_BenchmarkAchievementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benchmark Achievement [Domain]</link:label>
    <link:label id="lab_vrna_BenchmarkAchievementDomain_label_en-US" xlink:label="lab_vrna_BenchmarkAchievementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benchmark Achievement [Domain]</link:label>
    <link:label id="lab_vrna_BenchmarkAchievementDomain_documentation_en-US" xlink:label="lab_vrna_BenchmarkAchievementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benchmark Achievement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_BenchmarkAchievementDomain" xlink:href="vrna-20220331.xsd#vrna_BenchmarkAchievementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_BenchmarkAchievementDomain" xlink:to="lab_vrna_BenchmarkAchievementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_41e42fce-8473-438b-bcad-d84d45ca288f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_FirstCommercialSaleMember_5284d4b7-d6d0-44d1-b8ac-20459d38cc83_terseLabel_en-US" xlink:label="lab_vrna_FirstCommercialSaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Commercial Sale</link:label>
    <link:label id="lab_vrna_FirstCommercialSaleMember_label_en-US" xlink:label="lab_vrna_FirstCommercialSaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Commercial Sale [Member]</link:label>
    <link:label id="lab_vrna_FirstCommercialSaleMember_documentation_en-US" xlink:label="lab_vrna_FirstCommercialSaleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Commercial Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_FirstCommercialSaleMember" xlink:href="vrna-20220331.xsd#vrna_FirstCommercialSaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_FirstCommercialSaleMember" xlink:to="lab_vrna_FirstCommercialSaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_7345bc58-ecf1-4e7b-8e1c-c5ac2114a9ca_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_OrganizationAndBusinessDescriptionTextBlock_d4192121-fff3-46ab-b2c8-66c721d0c36d_terseLabel_en-US" xlink:label="lab_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and description of business operations</link:label>
    <link:label id="lab_vrna_OrganizationAndBusinessDescriptionTextBlock_label_en-US" xlink:label="lab_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Business Description [Text Block]</link:label>
    <link:label id="lab_vrna_OrganizationAndBusinessDescriptionTextBlock_documentation_en-US" xlink:label="lab_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Business Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:href="vrna-20220331.xsd#vrna_OrganizationAndBusinessDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:to="lab_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_5b9d56c8-206d-4e75-994c-3198f29ba814_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_bb5c0215-fd81-4855-86cd-b2b950719e8e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of Basic and Diluted Earning Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_36d2c800-00b2-4ef1-b241-9e5617431c7f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e7581c30-15fa-45aa-82d8-b2c24482b7da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocation of Share Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_6195f5cb-6213-4bbf-97c2-d91575be518e_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7602a2ac-205a-449f-a626-c3c3f03c2825_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_52149156-b962-4a39-8cf2-d88e690144cf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0b999dbd-f120-4f34-96c4-71af84b5ea73_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from at-the-market sales agreement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_dbe5dc84-d64a-4e9f-af43-cf7a1ab0778d_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_9b9c261c-846e-4e9b-8a27-94f142bafd43_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_902fa497-28a8-407a-8b2d-2c1a5d540bc4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_47b669de-08f4-4929-9843-f09858c373e9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit/(loss) per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_9653ed2e-c58f-49dc-b7ba-03e4aa29d4bf_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_b3b322ec-815f-4d39-a1c7-5e44e2e96ae5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent_9ebf9dc0-b806-4942-8cb8-4f9ac6b772cc_terseLabel_en-US" xlink:label="lab_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit receivable - U.K.</link:label>
    <link:label id="lab_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent_label_en-US" xlink:label="lab_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit Receivable, Current</link:label>
    <link:label id="lab_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent_documentation_en-US" xlink:label="lab_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:href="vrna-20220331.xsd#vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:to="lab_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9dc129aa-4adf-49e9-9807-4a845c9054fb_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_51bc9a17-3df6-4bd6-acca-5b1f5ee033ea_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant agreements</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4ec0a52a-dea6-4db4-ae59-546beea068f7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ce5c85e5-76ce-4543-b572-cf175e812b38_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b86fe67d-9a63-4e34-8ef5-aa95ceb3c0b7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_TermBLoanMember_adb2d6a1-3d9c-40ae-964f-263730f76e88_terseLabel_en-US" xlink:label="lab_vrna_TermBLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B Loan</link:label>
    <link:label id="lab_vrna_TermBLoanMember_label_en-US" xlink:label="lab_vrna_TermBLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B Loan [Member]</link:label>
    <link:label id="lab_vrna_TermBLoanMember_documentation_en-US" xlink:label="lab_vrna_TermBLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermBLoanMember" xlink:href="vrna-20220331.xsd#vrna_TermBLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_TermBLoanMember" xlink:to="lab_vrna_TermBLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_NuanceShanghaiPharmaCoLtdMember_0d154d0e-066f-4056-8614-3556adfbfc35_terseLabel_en-US" xlink:label="lab_vrna_NuanceShanghaiPharmaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuance (Shanghai) Pharma Co Ltd</link:label>
    <link:label id="lab_vrna_NuanceShanghaiPharmaCoLtdMember_label_en-US" xlink:label="lab_vrna_NuanceShanghaiPharmaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuance (Shanghai) Pharma Co Ltd [Member]</link:label>
    <link:label id="lab_vrna_NuanceShanghaiPharmaCoLtdMember_documentation_en-US" xlink:label="lab_vrna_NuanceShanghaiPharmaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuance (Shanghai) Pharma Co Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NuanceShanghaiPharmaCoLtdMember" xlink:href="vrna-20220331.xsd#vrna_NuanceShanghaiPharmaCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_NuanceShanghaiPharmaCoLtdMember" xlink:to="lab_vrna_NuanceShanghaiPharmaCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_3ad112e8-7235-4bdf-a25b-cc5822cfbbac_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_fe7074e7-921e-4cd8-ba19-62749f02960c_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_0dce2695-187a-4f3d-8d1d-c32b0b6b8c50_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c47b461-9df5-40db-8dd6-b7faf7d2a600_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_SublicensePaymentPercentage_f8c45d35-cb88-43b1-9a39-82697b43905f_terseLabel_en-US" xlink:label="lab_vrna_SublicensePaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublicense payment percentage of payments received</link:label>
    <link:label id="lab_vrna_SublicensePaymentPercentage_label_en-US" xlink:label="lab_vrna_SublicensePaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublicense Payment, Percentage</link:label>
    <link:label id="lab_vrna_SublicensePaymentPercentage_documentation_en-US" xlink:label="lab_vrna_SublicensePaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublicense Payment, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SublicensePaymentPercentage" xlink:href="vrna-20220331.xsd#vrna_SublicensePaymentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_SublicensePaymentPercentage" xlink:to="lab_vrna_SublicensePaymentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_523ac96e-5feb-45b4-9ae1-1e02a406ca4b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_c4651c81-54cf-4b8b-84e9-65c582e38d45_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_78756b5d-00b2-4dc6-a005-9dc4b4c45df8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares withheld for taxes on vested stock awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_35e1c0e1-d743-4dc1-9a36-c08c4cfcb6e7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_8cf66442-4aca-4fd0-879d-5a4a223ba610_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit/(loss) per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e375687b-9cd2-4db7-8efb-3d06c2c276b3_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_2dfc7fb7-0918-4978-a5d7-687fb40f3d61_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_EquityInterestReceivable_28f51265-0967-44a7-a6eb-7f04e09800bd_terseLabel_en-US" xlink:label="lab_vrna_EquityInterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest receivable</link:label>
    <link:label id="lab_vrna_EquityInterestReceivable_label_en-US" xlink:label="lab_vrna_EquityInterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Receivable</link:label>
    <link:label id="lab_vrna_EquityInterestReceivable_documentation_en-US" xlink:label="lab_vrna_EquityInterestReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_EquityInterestReceivable" xlink:href="vrna-20220331.xsd#vrna_EquityInterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_EquityInterestReceivable" xlink:to="lab_vrna_EquityInterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_b8b2318c-b572-4c25-a4fe-e22bb48f306b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_TermCLoanMember_b6e356c7-1bce-44ba-80af-d2602b060d79_terseLabel_en-US" xlink:label="lab_vrna_TermCLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term C Loan</link:label>
    <link:label id="lab_vrna_TermCLoanMember_label_en-US" xlink:label="lab_vrna_TermCLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term C Loan [Member]</link:label>
    <link:label id="lab_vrna_TermCLoanMember_documentation_en-US" xlink:label="lab_vrna_TermCLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term C Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermCLoanMember" xlink:href="vrna-20220331.xsd#vrna_TermCLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_TermCLoanMember" xlink:to="lab_vrna_TermCLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_202f4425-bf2c-490a-b670-646b3dcd67a5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_7db23894-fd3e-4a4b-b64c-204b64d696af_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_809680fb-3a53-4778-8090-c570c141d0a2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_bb7d83b1-a322-47eb-92fb-e783c73a65a3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_04edd359-1157-4960-b5b1-ecefba5dbc76_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares held in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_33826c17-fb0c-4a72-ac66-05f38a30ac5d_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_106ee67a-cd0c-4b1d-8da8-4ad3e525838b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_a8ad5c4c-59c3-4f0b-bf08-f56e6d923036_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_bcc69f77-ee7b-4e00-8e5e-7e50d186bafe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ScheduleOfNontradeReceivablesTableTextBlock_01c9d21e-b552-4ed9-bc42-555b192be000_terseLabel_en-US" xlink:label="lab_vrna_ScheduleOfNontradeReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Taxes Receivable</link:label>
    <link:label id="lab_vrna_ScheduleOfNontradeReceivablesTableTextBlock_label_en-US" xlink:label="lab_vrna_ScheduleOfNontradeReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Nontrade Receivables [Table Text Block]</link:label>
    <link:label id="lab_vrna_ScheduleOfNontradeReceivablesTableTextBlock_documentation_en-US" xlink:label="lab_vrna_ScheduleOfNontradeReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Nontrade Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ScheduleOfNontradeReceivablesTableTextBlock" xlink:href="vrna-20220331.xsd#vrna_ScheduleOfNontradeReceivablesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ScheduleOfNontradeReceivablesTableTextBlock" xlink:to="lab_vrna_ScheduleOfNontradeReceivablesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_8d7cc7ce-07ff-4e32-a9e7-9bc4b8cc6819_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income/(expense)</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_836062a6-780c-4cfc-a51d-597e03afde1e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_PrepaidResearchAndDevelopmentFeesCurrent_30cdc060-d972-4e9b-9015-544310cd4ada_terseLabel_en-US" xlink:label="lab_vrna_PrepaidResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial and other development costs</link:label>
    <link:label id="lab_vrna_PrepaidResearchAndDevelopmentFeesCurrent_label_en-US" xlink:label="lab_vrna_PrepaidResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research And Development Fees, Current</link:label>
    <link:label id="lab_vrna_PrepaidResearchAndDevelopmentFeesCurrent_documentation_en-US" xlink:label="lab_vrna_PrepaidResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research And Development Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PrepaidResearchAndDevelopmentFeesCurrent" xlink:href="vrna-20220331.xsd#vrna_PrepaidResearchAndDevelopmentFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_PrepaidResearchAndDevelopmentFeesCurrent" xlink:to="lab_vrna_PrepaidResearchAndDevelopmentFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_3fd32690-ebdf-4d86-81ae-f2d8c287d943_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_d21d5a08-015d-4fdd-a087-92722511aa26_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases_6f3549e1-9928-4960-a304-dd5baeef54da_terseLabel_en-US" xlink:label="lab_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange (loss)/gain</link:label>
    <link:label id="lab_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases_label_en-US" xlink:label="lab_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases</link:label>
    <link:label id="lab_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases_documentation_en-US" xlink:label="lab_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" xlink:href="vrna-20220331.xsd#vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" xlink:to="lab_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_db5c10d7-c6eb-40d1-a73a-8e1d67198c11_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_af758a72-7f3b-4788-a451-0c03abfa605d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bc3b59f9-9506-4bfe-933f-6e9b8f3d9c69_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_SublicensePayment_3770c27b-cead-4912-928b-710b54f15b73_terseLabel_en-US" xlink:label="lab_vrna_SublicensePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublicense payment</link:label>
    <link:label id="lab_vrna_SublicensePayment_label_en-US" xlink:label="lab_vrna_SublicensePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublicense Payment</link:label>
    <link:label id="lab_vrna_SublicensePayment_documentation_en-US" xlink:label="lab_vrna_SublicensePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublicense Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SublicensePayment" xlink:href="vrna-20220331.xsd#vrna_SublicensePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_SublicensePayment" xlink:to="lab_vrna_SublicensePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9ecb297a-b61d-4eb6-b5ae-f781ca12418e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7927bd4e-a094-43ec-b29d-43949a56eced_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8d09ac7d-9f84-4fa8-be75-df909793715c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_5e2ecc15-3a33-44cb-8a10-d69e4bdc55cc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_49a2afa1-e214-4b9e-b37c-7a4607eb211c_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares to treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_2360ee73-87a1-4b79-aef3-debd51c72d9a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_d958f52d-4525-487c-ac81-52f15309e08a_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_TermLoanFacilityMember_7626dc96-6eee-4036-8022-96289c86a218_terseLabel_en-US" xlink:label="lab_vrna_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility</link:label>
    <link:label id="lab_vrna_TermLoanFacilityMember_label_en-US" xlink:label="lab_vrna_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:label id="lab_vrna_TermLoanFacilityMember_documentation_en-US" xlink:label="lab_vrna_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermLoanFacilityMember" xlink:href="vrna-20220331.xsd#vrna_TermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_TermLoanFacilityMember" xlink:to="lab_vrna_TermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_1fb75282-1d68-42bb-a8ef-33f9fb08829f_terseLabel_en-US" xlink:label="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees and general corporate costs</link:label>
    <link:label id="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_label_en-US" xlink:label="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Listing, And General Corporate Costs, Current</link:label>
    <link:label id="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_documentation_en-US" xlink:label="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Listing, And General Corporate Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:href="vrna-20220331.xsd#vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:to="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostTable_ca74e338-8f88-44e7-8fc7-8c4479a48c05_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Table]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostTable_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostTable" xlink:to="lab_us-gaap_CapitalizedContractCostTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_SaleOfStockMaximumAggregateOfferingPrice_7a45b1e2-a857-40d9-aa6f-0f737834d00a_terseLabel_en-US" xlink:label="lab_vrna_SaleOfStockMaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate offering price</link:label>
    <link:label id="lab_vrna_SaleOfStockMaximumAggregateOfferingPrice_label_en-US" xlink:label="lab_vrna_SaleOfStockMaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Offering Price</link:label>
    <link:label id="lab_vrna_SaleOfStockMaximumAggregateOfferingPrice_documentation_en-US" xlink:label="lab_vrna_SaleOfStockMaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Offering Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SaleOfStockMaximumAggregateOfferingPrice" xlink:href="vrna-20220331.xsd#vrna_SaleOfStockMaximumAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_SaleOfStockMaximumAggregateOfferingPrice" xlink:to="lab_vrna_SaleOfStockMaximumAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_716d8c62-5528-403b-9198-4f215d032d78_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c7719b32-0ad6-4819-81ae-7483bbbdfdea_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22852437-4d65-411b-a0ee-ad7b04d01595_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee74edc6-fb09-4bb3-b4cf-a7978bff3bb1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_ff38dfd5-0ecc-4256-b6e3-338c7403bff1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_42597a6f-eb30-4eb5-995a-ece1fc61c87b_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b7977024-7e3b-4106-bbde-fe89385d4663_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_79e553c5-cc87-4a38-86ed-fd8c2dddb4cd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_57274f02-4335-4147-acc4-7cec67b2907f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_5a1ebaaf-c24b-4e8f-bb16-fd9a7801f7d5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_f9a387e7-121d-4bb4-a99b-24dacc181191_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares under at-the-market sales agreement</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_8dbc5839-c482-4db6-b569-316670a44d3b_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_ae8495fd-5876-4f46-baf0-18636e9222dc_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares to treasury (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_UnrealizedGainLossOnWarrants_2eb56b60-0577-4680-9654-d017ac95536b_terseLabel_en-US" xlink:label="lab_vrna_UnrealizedGainLossOnWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value movement on warrants</link:label>
    <link:label id="lab_vrna_UnrealizedGainLossOnWarrants_label_en-US" xlink:label="lab_vrna_UnrealizedGainLossOnWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) On Warrants</link:label>
    <link:label id="lab_vrna_UnrealizedGainLossOnWarrants_documentation_en-US" xlink:label="lab_vrna_UnrealizedGainLossOnWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) On Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_UnrealizedGainLossOnWarrants" xlink:href="vrna-20220331.xsd#vrna_UnrealizedGainLossOnWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_UnrealizedGainLossOnWarrants" xlink:to="lab_vrna_UnrealizedGainLossOnWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0b29fe0-4c3b-4ef2-a0bf-c43412db81c9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_7e670534-768a-41f5-b13a-da72dd0f7af2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_a7841bd2-10cc-4460-88ab-e05c775dda99_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_240094da-d383-4c49-a3b5-dc121ea3e9d2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_eeacf7f6-eb94-4a31-b71e-a45deae34585_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_aa0569b4-f6cc-4ddc-bf99-a61c8af76a08_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostLineItems_eca4c610-facd-4ce5-aa86-7e48a7cd341e_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostLineItems_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems" xlink:to="lab_us-gaap_CapitalizedContractCostLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_17995d68-8acf-4b3f-ac39-4b53422c951c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares under at-the-market sales agreement (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_9c8d5525-6758-4817-89fd-70ef5ff71b01_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays_4b109122-afd2-4747-b7b9-4de92c0fbecb_terseLabel_en-US" xlink:label="lab_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublicense payment, equity issuance, threshold trading days</link:label>
    <link:label id="lab_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays_label_en-US" xlink:label="lab_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublicense Payment, Equity Issuance, Threshold Trading Days</link:label>
    <link:label id="lab_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays_documentation_en-US" xlink:label="lab_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublicense Payment, Equity Issuance, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays" xlink:href="vrna-20220331.xsd#vrna_SublicensePaymentEquityIssuanceThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays" xlink:to="lab_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_10980f3a-4ead-4bfd-8dbe-7960f1a7bcad_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_80acd1aa-3de7-43e6-ac5e-24c14f4ffdd9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange loss/(gain)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a00a941e-beda-4cab-969d-cf3dd0ea9c8c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning Balance, Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_56e30105-5cf2-4c61-984d-ab01c4e5be7b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending Balance, Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_36fcc51f-903f-4504-8bda-14a81e6fe792_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary &#163;0.05 par value shares; 494,058,246 and 489,177,550 issued, and 482,944,390 and 480,082,966 outstanding, at March 31, 2022 and December 31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_8bfeca85-40f4-4cb6-a7a1-d6caae8802c6_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_70c06aa8-6801-48dd-87fc-3c271aa9aeed_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_5f39441b-ccda-4904-ae68-2f8a4d7ee832_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of term loan</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_8dc0efdb-c2b6-4bd6-b48d-e6557e224bc5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_9e0f595b-9ed7-48f9-a7b7-7b8d6dbbb9a1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5b376530-9eff-472d-9bfd-b339beabb4d3_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_CommonStockSharesAvailableForSaleValue_a2cdad7f-8038-4a13-abab-1b0ccbc0395f_terseLabel_en-US" xlink:label="lab_vrna_CommonStockSharesAvailableForSaleValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for sale</link:label>
    <link:label id="lab_vrna_CommonStockSharesAvailableForSaleValue_label_en-US" xlink:label="lab_vrna_CommonStockSharesAvailableForSaleValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Available For Sale, Value</link:label>
    <link:label id="lab_vrna_CommonStockSharesAvailableForSaleValue_documentation_en-US" xlink:label="lab_vrna_CommonStockSharesAvailableForSaleValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Available For Sale, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_CommonStockSharesAvailableForSaleValue" xlink:href="vrna-20220331.xsd#vrna_CommonStockSharesAvailableForSaleValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_CommonStockSharesAvailableForSaleValue" xlink:to="lab_vrna_CommonStockSharesAvailableForSaleValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_90fc13de-b052-4820-9b12-0755c703d6f3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b5b1058f-f240-48c1-8afd-709578087951_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_8d98571a-e47e-48db-9ded-27339cc21eba_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_f20dd38e-f3c3-4b07-b67f-a2523549af10_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issue costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_363a58e2-cf79-4d5e-ba7b-439714573aae_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15011a37-5487-48f1-9813-41a6b1eedb5e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cd1094e3-09d7-4260-a412-d923325581d9_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_94a2cad4-2405-4118-aa3a-c888fe9dd181_verboseLabel_en-US" xlink:label="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax and tax incentive receivable</link:label>
    <link:label id="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_3a6a3808-8dd0-4ba4-ace2-91b1b4cba2da_totalLabel_en-US" xlink:label="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total tax receivable</link:label>
    <link:label id="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_label_en-US" xlink:label="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit And Income Taxes Receivable, Current</link:label>
    <link:label id="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_documentation_en-US" xlink:label="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit And Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:href="vrna-20220331.xsd#vrna_TaxCreditAndIncomeTaxesReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:to="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_17e832cf-c8c6-46c4-b636-7c06f83a1590_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_92debdc1-bc45-4162-8ce4-f7e902ac410e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in sale</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_93c04cad-785e-4cf0-8edd-6b19f416fee7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in pounds sterling per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_636ba86c-2ccc-418d-bca8-eae073053897_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_9eb94c9a-6644-4909-a5b6-87c4d8597306_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_e0e70d50-98cd-42b3-acdc-8792e00b7024_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_820ea251-128d-4031-88aa-c438955719a3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2748f062-5036-4244-8bd6-a2758ac8eded_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b178072c-6aea-48c8-a915-2286819a659e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ffb8e8d2-bc73-4db4-8222-49ba9d1f389f_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b857a3b2-8864-479d-a341-8277e3a58424_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_038514db-6c7d-4187-9066-d7296b288a68_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_c3cd7aa8-0cdf-4e42-974b-bb69bccb88d8_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_ea897121-64d6-4270-9557-88fb718bea0d_negatedTerseLabel_en-US" xlink:label="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity settled share-based compensation reclassified as cash-settled</link:label>
    <link:label id="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_label_en-US" xlink:label="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Reclassification from Share-based Compensation</link:label>
    <link:label id="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_documentation_en-US" xlink:label="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Reclassification from Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" xlink:href="vrna-20220331.xsd#vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" xlink:to="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CountryRegion_53ba9f80-3363-463d-badf-5ff661a45d45_terseLabel_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Country Region</link:label>
    <link:label id="lab_dei_CountryRegion_label_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Country Region</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CountryRegion" xlink:to="lab_dei_CountryRegion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d2f7ecd7-fcc3-4927-b340-10d42b326398_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_c224897e-d88e-4884-a588-e086702d881b_terseLabel_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax and tax incentive receivable</link:label>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_BenchmarkAchievementAxis_0f31c7b2-daa0-4b6f-b71f-bfbe4d899326_terseLabel_en-US" xlink:label="lab_vrna_BenchmarkAchievementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benchmark Achievement [Axis]</link:label>
    <link:label id="lab_vrna_BenchmarkAchievementAxis_label_en-US" xlink:label="lab_vrna_BenchmarkAchievementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benchmark Achievement [Axis]</link:label>
    <link:label id="lab_vrna_BenchmarkAchievementAxis_documentation_en-US" xlink:label="lab_vrna_BenchmarkAchievementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benchmark Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_BenchmarkAchievementAxis" xlink:href="vrna-20220331.xsd#vrna_BenchmarkAchievementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_BenchmarkAchievementAxis" xlink:to="lab_vrna_BenchmarkAchievementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_75118bfd-6398-40c3-b49c-0135d3bb32d7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_90d505f0-5f99-4924-b251-66d5f79d8dde_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_67583942-1e47-4ba9-a305-103cbc384ef5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value movement on warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_8173633f-665c-4b32-8f67-f5e71cc782d1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_3c0a6276-08d7-4d29-ae25-250b8955ecef_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a7a486b8-fdb1-4ab3-876f-f42b6c1887d2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_c3237421-8ca2-4e35-bce8-9ac559ef1671_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_adaa24f9-a73f-4d8e-a53b-34dd0c498e7c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_35da3f2e-e018-4631-84a4-1d7af60cc654_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_1dbb911a-2d82-44b7-a8cb-418bb2c94090_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Prepaid Expenses</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_253be440-1235-414a-b2a8-1bc92b5f2243_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_36003933-e6a3-4733-a8c9-320708abef9c_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_ab4a83e4-36de-4296-b150-f81d86db9e58_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation and consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_7bd79429-8ce2-4d5e-9fba-22410eb02290_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_fd1ef508-9209-424d-b1b0-de98f1dd34d6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_91b687bd-ebfc-4188-8895-a020442f4474_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_25694c3b-d7cf-4b26-9f0b-6056a05314a0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_45a1381c-0a3c-40c3-8194-11e59b5b0dfe_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_91459fa2-6b4c-419e-85f4-45dedcd4f17d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of withholding taxes from share-based awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7293b661-ce9e-4739-a38e-5b2d214b75c5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f85fb654-3258-48a4-b888-8b88b9ef7997_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_c038ed1e-a9d8-4c8b-b6f3-443c827c039f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_36b8d888-217d-496c-a080-022a9deb2031_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7fd8f66f-4765-4c54-a616-fdc8cb8794a6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_67f59752-9cfa-4c0f-ac48-d5854fd9887e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_fabe1449-9d4f-459a-9404-ae3d6ad4eafa_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares held in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_5344a726-75ca-4497-ae43-f55ccc83ed19_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_2a86bf60-e598-4945-91cc-8f8c95336fbd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_dd2fb0f7-d20e-47c6-b8ea-6c356192f2e2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_aca6a1c8-7cc7-49b9-bd37-35bf49db2afa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_c3de4b67-ac37-4bc0-a6c4-141a6760fc32_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_c4a094c1-b511-4cc8-b36f-3dbbaad353f2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_LigandUKDevelopmentLimitedMember_e0e4f18e-5411-46c9-ac9f-b01d8c28b82f_terseLabel_en-US" xlink:label="lab_vrna_LigandUKDevelopmentLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ligand UK Development Limited</link:label>
    <link:label id="lab_vrna_LigandUKDevelopmentLimitedMember_label_en-US" xlink:label="lab_vrna_LigandUKDevelopmentLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ligand UK Development Limited [Member]</link:label>
    <link:label id="lab_vrna_LigandUKDevelopmentLimitedMember_documentation_en-US" xlink:label="lab_vrna_LigandUKDevelopmentLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ligand UK Development Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_LigandUKDevelopmentLimitedMember" xlink:href="vrna-20220331.xsd#vrna_LigandUKDevelopmentLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_LigandUKDevelopmentLimitedMember" xlink:to="lab_vrna_LigandUKDevelopmentLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8c72cccb-e960-4e9a-b225-2aae0daa48a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2e96589c-2abf-4744-9d5f-65bc54bcffe1_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently adopted accounting standards and recent accounting standards not yet adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_432ffdb6-6190-4c2d-a640-8a2e6f915320_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_05b13ae1-5e31-4db0-9b84-a53eede1eb2b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_d6b51218-b045-46c3-b5f1-f9fc21248abd_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_747528f0-a67f-4a4d-8fb5-f5be24cfe262_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_a429b364-5cba-4f76-a4dc-1f695f681a78_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d92776a1-6835-4d8b-a377-97fda857b4da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, Weight average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_14d676ed-9cf9-4418-965e-ad3bdf15ec1d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_258cee94-af9d-4c38-aa5d-8f541375d969_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_27370c55-0dfd-4813-bb47-b2888bb53def_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_cba7ec23-d9d5-4609-9357-045a2d908b82_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b79ab605-f1d5-41da-86a5-07fa26a14b2c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_NumberOfWhollyOwnedSubsidiaries_f158c1fc-f90b-40c2-9286-1501f38af625_terseLabel_en-US" xlink:label="lab_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of wholly owned subsidiaries</link:label>
    <link:label id="lab_vrna_NumberOfWhollyOwnedSubsidiaries_label_en-US" xlink:label="lab_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholly Owned Subsidiaries</link:label>
    <link:label id="lab_vrna_NumberOfWhollyOwnedSubsidiaries_documentation_en-US" xlink:label="lab_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholly Owned Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:href="vrna-20220331.xsd#vrna_NumberOfWhollyOwnedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:to="lab_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_f2d0d5d9-da82-4d32-a352-5ec0cec03eee_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a3f4336e-9c09-46de-8f3f-e0571723eb96_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d567b000-2732-444f-a42e-e04d1adcd6db_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_34da99e7-1684-4bde-a872-c3b45e33eff3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_fc4c9563-d190-4c94-a860-21f3e28c28bd_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f42c8cb2-e7d5-41d1-a263-c0ad0b531f96_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>vrna-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8fe8cf0b-7d67-4c56-b99e-508dc94a315d,g:47f0dc6b-9fdd-4cb6-bded-b1ab0e3af7d2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://veronapharma.com/role/Cover" xlink:type="simple" xlink:href="vrna-20220331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c80c9676-f65f-41bf-991c-ea05d9b135b6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_DocumentType_c80c9676-f65f-41bf-991c-ea05d9b135b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_b812ce15-1a02-436a-b995-61b5234d67f3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_DocumentQuarterlyReport_b812ce15-1a02-436a-b995-61b5234d67f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_53a3632e-f0bd-40b4-82e8-105706310702" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_DocumentPeriodEndDate_53a3632e-f0bd-40b4-82e8-105706310702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_21303e5c-85cd-4dd4-bd9d-29ef3c67fa94" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_DocumentTransitionReport_21303e5c-85cd-4dd4-bd9d-29ef3c67fa94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_dfc1b5ff-5799-4af1-8af6-cf6ae491bfa2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_EntityFileNumber_dfc1b5ff-5799-4af1-8af6-cf6ae491bfa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_cb4bcb6e-6ddd-4c0d-9139-1d594594140c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_EntityRegistrantName_cb4bcb6e-6ddd-4c0d-9139-1d594594140c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_18424a7c-e43e-48a9-9ae2-43899964fbf9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_EntityIncorporationStateCountryCode_18424a7c-e43e-48a9-9ae2-43899964fbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1bf59837-15b7-47fa-95d3-5c3795a64c23" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_EntityTaxIdentificationNumber_1bf59837-15b7-47fa-95d3-5c3795a64c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d43ae9c2-0b1d-4175-9f3d-f7cc0925e0e3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_EntityAddressAddressLine1_d43ae9c2-0b1d-4175-9f3d-f7cc0925e0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a4348643-f116-47a6-a0f5-6a388ac01ca6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_EntityAddressCityOrTown_a4348643-f116-47a6-a0f5-6a388ac01ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_119b675b-70ae-4273-ab26-6d7d5527471b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_EntityAddressPostalZipCode_119b675b-70ae-4273-ab26-6d7d5527471b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_6e1019ce-7d31-4444-a0a7-09cfad574116" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_EntityAddressCountry_6e1019ce-7d31-4444-a0a7-09cfad574116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion_4ad2454c-d563-4835-99ee-f120ab4b2f63" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_CountryRegion_4ad2454c-d563-4835-99ee-f120ab4b2f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_57dc421e-a358-4985-979d-1755eddb694a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_CityAreaCode_57dc421e-a358-4985-979d-1755eddb694a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5e036b92-535b-419d-8fdc-8e0727bf1a84" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_LocalPhoneNumber_5e036b92-535b-419d-8fdc-8e0727bf1a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_7f8c4cdb-135c-4bcd-ad1c-3a61f935af5b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_Security12bTitle_7f8c4cdb-135c-4bcd-ad1c-3a61f935af5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_26f33973-bca2-4972-a588-5724b7678a46" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_TradingSymbol_26f33973-bca2-4972-a588-5724b7678a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3f2ce408-8b49-4403-97b3-f5eddf0f5ec1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_SecurityExchangeName_3f2ce408-8b49-4403-97b3-f5eddf0f5ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d43c3d9d-da47-4f90-862e-9c419cb048bc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_EntityCurrentReportingStatus_d43c3d9d-da47-4f90-862e-9c419cb048bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_9c003960-23e9-466d-9430-fad5ab499a4e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_EntityInteractiveDataCurrent_9c003960-23e9-466d-9430-fad5ab499a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_5840c534-6eb6-4e06-b2d8-6346c0fd6866" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_EntityFilerCategory_5840c534-6eb6-4e06-b2d8-6346c0fd6866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_b052dd98-28d4-444f-ac52-f24a09fcadc2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_EntitySmallBusiness_b052dd98-28d4-444f-ac52-f24a09fcadc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a042da63-8b18-4b74-b554-7517fab37f02" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_EntityEmergingGrowthCompany_a042da63-8b18-4b74-b554-7517fab37f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_77944f0d-59bc-4862-bc99-d7a400f4895f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_EntityExTransitionPeriod_77944f0d-59bc-4862-bc99-d7a400f4895f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_44b18683-2da5-4cd0-875b-30d4a075ad50" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_EntityShellCompany_44b18683-2da5-4cd0-875b-30d4a075ad50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f278ddc4-dcec-497b-b577-b38dfcf15dfe" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f278ddc4-dcec-497b-b577-b38dfcf15dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e8df114b-e382-4c47-a0cc-809677511b15" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_AmendmentFlag_e8df114b-e382-4c47-a0cc-809677511b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_2f979f56-46e4-4be4-b362-327c55df779d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_DocumentFiscalYearFocus_2f979f56-46e4-4be4-b362-327c55df779d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_07ac9664-47bc-4d43-bd7a-a81e46176c47" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_CurrentFiscalYearEndDate_07ac9664-47bc-4d43-bd7a-a81e46176c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_a21bb24f-8673-438e-95cd-f3bb43c30b3d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_DocumentFiscalPeriodFocus_a21bb24f-8673-438e-95cd-f3bb43c30b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6cfe76a3-52aa-4039-a309-bcc750967bee" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e3bac04-f9d5-4d73-89f8-afbd683b9418" xlink:to="loc_dei_EntityCentralIndexKey_6cfe76a3-52aa-4039-a309-bcc750967bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vrna-20220331.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6ae15609-1701-40be-b25a-fb03032f1f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4d4880de-96b4-43dd-a6bd-7e0a4612ace6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6ae15609-1701-40be-b25a-fb03032f1f96" xlink:to="loc_us-gaap_AssetsAbstract_4d4880de-96b4-43dd-a6bd-7e0a4612ace6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9a951e66-2a25-4baf-b9c2-030ed54b6a86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4d4880de-96b4-43dd-a6bd-7e0a4612ace6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9a951e66-2a25-4baf-b9c2-030ed54b6a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b14f4628-3fb2-4db3-8693-f79b3d734e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9a951e66-2a25-4baf-b9c2-030ed54b6a86" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b14f4628-3fb2-4db3-8693-f79b3d734e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_d4e518e2-57b7-4a7a-80e1-7de7ac8aa5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9a951e66-2a25-4baf-b9c2-030ed54b6a86" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_d4e518e2-57b7-4a7a-80e1-7de7ac8aa5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_74f36a22-4ddf-4ff5-a582-208e3dc0840f" xlink:href="vrna-20220331.xsd#vrna_TaxCreditAndIncomeTaxesReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9a951e66-2a25-4baf-b9c2-030ed54b6a86" xlink:to="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_74f36a22-4ddf-4ff5-a582-208e3dc0840f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_66af235e-624e-414a-a23b-995df517ad2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9a951e66-2a25-4baf-b9c2-030ed54b6a86" xlink:to="loc_us-gaap_OtherAssetsCurrent_66af235e-624e-414a-a23b-995df517ad2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_eae303a5-5ed0-44d6-aa5d-16b4891ff753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9a951e66-2a25-4baf-b9c2-030ed54b6a86" xlink:to="loc_us-gaap_AssetsCurrent_eae303a5-5ed0-44d6-aa5d-16b4891ff753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_373047a5-7e83-43fd-84a9-e41c1793b52c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4d4880de-96b4-43dd-a6bd-7e0a4612ace6" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_373047a5-7e83-43fd-84a9-e41c1793b52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1cced0ca-f66b-449d-a614-e6c28c3141d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_373047a5-7e83-43fd-84a9-e41c1793b52c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1cced0ca-f66b-449d-a614-e6c28c3141d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_38278842-d46c-4656-9940-df0d4259d75f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_373047a5-7e83-43fd-84a9-e41c1793b52c" xlink:to="loc_us-gaap_Goodwill_38278842-d46c-4656-9940-df0d4259d75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_a675fa3c-911f-4b2e-b00d-d3dcea6abe13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_373047a5-7e83-43fd-84a9-e41c1793b52c" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_a675fa3c-911f-4b2e-b00d-d3dcea6abe13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_608dc9b0-6a34-41ef-9e53-f5b725f3dd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_373047a5-7e83-43fd-84a9-e41c1793b52c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_608dc9b0-6a34-41ef-9e53-f5b725f3dd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_ba93df1a-e148-488b-b436-3debe727a128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_373047a5-7e83-43fd-84a9-e41c1793b52c" xlink:to="loc_us-gaap_AssetsNoncurrent_ba93df1a-e148-488b-b436-3debe727a128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_93453a8c-9e08-4192-b3b1-c10f9709d454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4d4880de-96b4-43dd-a6bd-7e0a4612ace6" xlink:to="loc_us-gaap_Assets_93453a8c-9e08-4192-b3b1-c10f9709d454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6eea4d1a-4059-49d1-abe1-271a63387930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6ae15609-1701-40be-b25a-fb03032f1f96" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6eea4d1a-4059-49d1-abe1-271a63387930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_6c0acb49-e751-4d9d-bfb6-8fe8f112201e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6eea4d1a-4059-49d1-abe1-271a63387930" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_6c0acb49-e751-4d9d-bfb6-8fe8f112201e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9e2d5c5e-d328-43b6-8ccf-6d49014d70b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6c0acb49-e751-4d9d-bfb6-8fe8f112201e" xlink:to="loc_us-gaap_AccountsPayableCurrent_9e2d5c5e-d328-43b6-8ccf-6d49014d70b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e6d01c79-3485-466c-961d-5f77650a7956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6c0acb49-e751-4d9d-bfb6-8fe8f112201e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e6d01c79-3485-466c-961d-5f77650a7956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8142bb66-f595-4ece-88cd-13203a4adaa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6c0acb49-e751-4d9d-bfb6-8fe8f112201e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8142bb66-f595-4ece-88cd-13203a4adaa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_5826fbda-6842-4ddf-bd27-3f4b3eb36871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6c0acb49-e751-4d9d-bfb6-8fe8f112201e" xlink:to="loc_us-gaap_TaxesPayableCurrent_5826fbda-6842-4ddf-bd27-3f4b3eb36871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ae22bca0-fd41-4993-a428-c2f9533c0130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6c0acb49-e751-4d9d-bfb6-8fe8f112201e" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ae22bca0-fd41-4993-a428-c2f9533c0130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_61e28d50-9be8-4991-802b-d012653b86e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6c0acb49-e751-4d9d-bfb6-8fe8f112201e" xlink:to="loc_us-gaap_LiabilitiesCurrent_61e28d50-9be8-4991-802b-d012653b86e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_d8d02cbb-37ee-4857-8eda-43b724abe6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6eea4d1a-4059-49d1-abe1-271a63387930" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_d8d02cbb-37ee-4857-8eda-43b724abe6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_2bd38500-7dc6-4a37-b063-a21b3e9d11b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_d8d02cbb-37ee-4857-8eda-43b724abe6e2" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_2bd38500-7dc6-4a37-b063-a21b3e9d11b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_55ea2387-56c3-4bf9-a1ae-632cf9b3559e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_d8d02cbb-37ee-4857-8eda-43b724abe6e2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_55ea2387-56c3-4bf9-a1ae-632cf9b3559e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_18403ba0-6ec7-4a3e-a6ff-d3ae5adc0972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_d8d02cbb-37ee-4857-8eda-43b724abe6e2" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_18403ba0-6ec7-4a3e-a6ff-d3ae5adc0972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e1515b92-613e-488c-b9ce-9fe922d9888d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6eea4d1a-4059-49d1-abe1-271a63387930" xlink:to="loc_us-gaap_Liabilities_e1515b92-613e-488c-b9ce-9fe922d9888d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7406b634-e3ad-4f0a-849a-920738e94ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6eea4d1a-4059-49d1-abe1-271a63387930" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7406b634-e3ad-4f0a-849a-920738e94ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_57575de1-e42e-44f4-ab9d-64699474397e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6eea4d1a-4059-49d1-abe1-271a63387930" xlink:to="loc_us-gaap_StockholdersEquityAbstract_57575de1-e42e-44f4-ab9d-64699474397e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d24bc9b9-ff0b-4d62-9ddb-cd6d43ff2c81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_57575de1-e42e-44f4-ab9d-64699474397e" xlink:to="loc_us-gaap_CommonStockValue_d24bc9b9-ff0b-4d62-9ddb-cd6d43ff2c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d86247f5-93f3-4793-98ae-1237c0bf59da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_57575de1-e42e-44f4-ab9d-64699474397e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d86247f5-93f3-4793-98ae-1237c0bf59da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_8d3d25bb-5914-45cf-b005-2d04b4069286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_57575de1-e42e-44f4-ab9d-64699474397e" xlink:to="loc_us-gaap_TreasuryStockValue_8d3d25bb-5914-45cf-b005-2d04b4069286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c2f1d15d-9003-4335-b00e-02054e9c246f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_57575de1-e42e-44f4-ab9d-64699474397e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c2f1d15d-9003-4335-b00e-02054e9c246f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fd7015eb-429e-4968-8862-a53db8ba583c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_57575de1-e42e-44f4-ab9d-64699474397e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fd7015eb-429e-4968-8862-a53db8ba583c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e5aa6042-39e7-4307-8c8d-e83fa1f832fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_57575de1-e42e-44f4-ab9d-64699474397e" xlink:to="loc_us-gaap_StockholdersEquity_e5aa6042-39e7-4307-8c8d-e83fa1f832fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_73752cc5-c552-43fc-a6f1-16d5892ca052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6eea4d1a-4059-49d1-abe1-271a63387930" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_73752cc5-c552-43fc-a6f1-16d5892ca052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="vrna-20220331.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1f9c8c31-ad9b-4374-ab37-b15ce2b8e162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c35e78ab-a274-4b12-ab95-40a69462d317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1f9c8c31-ad9b-4374-ab37-b15ce2b8e162" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c35e78ab-a274-4b12-ab95-40a69462d317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cbcb939d-acdd-44af-8379-b0c2f03972e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1f9c8c31-ad9b-4374-ab37-b15ce2b8e162" xlink:to="loc_us-gaap_CommonStockSharesIssued_cbcb939d-acdd-44af-8379-b0c2f03972e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_71a21d51-12f8-4894-b4f7-489151a5c966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1f9c8c31-ad9b-4374-ab37-b15ce2b8e162" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_71a21d51-12f8-4894-b4f7-489151a5c966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="vrna-20220331.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_db17cd51-e9ba-41d6-b182-ed16b3e78975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_bf4a2085-7d67-4412-9e37-de803b59a807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db17cd51-e9ba-41d6-b182-ed16b3e78975" xlink:to="loc_us-gaap_OperatingExpensesAbstract_bf4a2085-7d67-4412-9e37-de803b59a807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b9a49739-df32-4a18-9cba-244c9ea72b13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bf4a2085-7d67-4412-9e37-de803b59a807" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b9a49739-df32-4a18-9cba-244c9ea72b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ec04ad85-53ac-4dfe-89d0-ce92c95b1686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bf4a2085-7d67-4412-9e37-de803b59a807" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ec04ad85-53ac-4dfe-89d0-ce92c95b1686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_dc87a44b-4435-4964-9240-61db34e2fe25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bf4a2085-7d67-4412-9e37-de803b59a807" xlink:to="loc_us-gaap_OperatingExpenses_dc87a44b-4435-4964-9240-61db34e2fe25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4f700466-6604-4a4e-ba88-048227dbac85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bf4a2085-7d67-4412-9e37-de803b59a807" xlink:to="loc_us-gaap_OperatingIncomeLoss_4f700466-6604-4a4e-ba88-048227dbac85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_ea87c7ed-fb62-4e92-91ae-36f84c1889bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db17cd51-e9ba-41d6-b182-ed16b3e78975" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_ea87c7ed-fb62-4e92-91ae-36f84c1889bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit_68e68b7e-ca8d-4a24-95fd-e0559cbdfc10" xlink:href="vrna-20220331.xsd#vrna_GainLossFromResearchAndDevelopmentTaxCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ea87c7ed-fb62-4e92-91ae-36f84c1889bd" xlink:to="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit_68e68b7e-ca8d-4a24-95fd-e0559cbdfc10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_271f8b8d-1bd8-4b2e-9dc9-e1602ab7ad87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ea87c7ed-fb62-4e92-91ae-36f84c1889bd" xlink:to="loc_us-gaap_InvestmentIncomeNet_271f8b8d-1bd8-4b2e-9dc9-e1602ab7ad87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_32ed22b7-d58c-42a3-8c95-196582696e25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ea87c7ed-fb62-4e92-91ae-36f84c1889bd" xlink:to="loc_us-gaap_InterestExpense_32ed22b7-d58c-42a3-8c95-196582696e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_UnrealizedGainLossOnWarrants_841d6bbd-82cb-4ae5-9ead-b843b60af156" xlink:href="vrna-20220331.xsd#vrna_UnrealizedGainLossOnWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ea87c7ed-fb62-4e92-91ae-36f84c1889bd" xlink:to="loc_vrna_UnrealizedGainLossOnWarrants_841d6bbd-82cb-4ae5-9ead-b843b60af156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases_5f255f41-8149-478c-9227-4fc3ce54b3ba" xlink:href="vrna-20220331.xsd#vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ea87c7ed-fb62-4e92-91ae-36f84c1889bd" xlink:to="loc_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases_5f255f41-8149-478c-9227-4fc3ce54b3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ea21207f-8380-4e79-9776-b5b950e3d90b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ea87c7ed-fb62-4e92-91ae-36f84c1889bd" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ea21207f-8380-4e79-9776-b5b950e3d90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_975a6075-5cf0-4c26-bda0-36494a2d6e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db17cd51-e9ba-41d6-b182-ed16b3e78975" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_975a6075-5cf0-4c26-bda0-36494a2d6e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_41d2e31e-44f0-4321-9152-58e2dbb72af7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db17cd51-e9ba-41d6-b182-ed16b3e78975" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_41d2e31e-44f0-4321-9152-58e2dbb72af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_150c1269-7795-4ddd-a8d8-2f25cb3f7064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db17cd51-e9ba-41d6-b182-ed16b3e78975" xlink:to="loc_us-gaap_NetIncomeLoss_150c1269-7795-4ddd-a8d8-2f25cb3f7064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_81098439-d717-490c-9263-cde4fdfd7e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db17cd51-e9ba-41d6-b182-ed16b3e78975" xlink:to="loc_us-gaap_EarningsPerShareBasic_81098439-d717-490c-9263-cde4fdfd7e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b3ed7ee8-dde5-48e3-8eff-eef2c42f81bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db17cd51-e9ba-41d6-b182-ed16b3e78975" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b3ed7ee8-dde5-48e3-8eff-eef2c42f81bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="vrna-20220331.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_b2f48d3b-2f67-4683-a8b7-b6f0b7cf4043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fe337a4b-3fdf-424a-9c8a-346f496fdb9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_b2f48d3b-2f67-4683-a8b7-b6f0b7cf4043" xlink:to="loc_us-gaap_StatementTable_fe337a4b-3fdf-424a-9c8a-346f496fdb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e22f1acf-e33c-454c-ae00-9dfb6e8efe70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fe337a4b-3fdf-424a-9c8a-346f496fdb9d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e22f1acf-e33c-454c-ae00-9dfb6e8efe70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ee012ed6-83b1-4430-8d0f-becac171bacd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e22f1acf-e33c-454c-ae00-9dfb6e8efe70" xlink:to="loc_us-gaap_EquityComponentDomain_ee012ed6-83b1-4430-8d0f-becac171bacd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d98270b8-3c53-4707-83a4-ea5c1bda77a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ee012ed6-83b1-4430-8d0f-becac171bacd" xlink:to="loc_us-gaap_CommonStockMember_d98270b8-3c53-4707-83a4-ea5c1bda77a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0aedf169-2102-413d-8423-8b5352143695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ee012ed6-83b1-4430-8d0f-becac171bacd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0aedf169-2102-413d-8423-8b5352143695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_d389e1fc-23b4-483b-8bd2-fcd7ebfd5551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ee012ed6-83b1-4430-8d0f-becac171bacd" xlink:to="loc_us-gaap_TreasuryStockMember_d389e1fc-23b4-483b-8bd2-fcd7ebfd5551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4fad8129-5f65-4153-9713-6efe7826e98b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ee012ed6-83b1-4430-8d0f-becac171bacd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4fad8129-5f65-4153-9713-6efe7826e98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5f940e9d-338b-4b69-af7a-7778eb128461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ee012ed6-83b1-4430-8d0f-becac171bacd" xlink:to="loc_us-gaap_RetainedEarningsMember_5f940e9d-338b-4b69-af7a-7778eb128461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ab258761-6955-452e-afd3-4c5825584ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fe337a4b-3fdf-424a-9c8a-346f496fdb9d" xlink:to="loc_us-gaap_StatementLineItems_ab258761-6955-452e-afd3-4c5825584ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab258761-6955-452e-afd3-4c5825584ad6" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4f595576-df90-4a9c-bae4-b7db45cc62c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4f595576-df90-4a9c-bae4-b7db45cc62c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e40b9972-fd5e-47ed-a599-1b7819ee0c96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:to="loc_us-gaap_StockholdersEquity_e40b9972-fd5e-47ed-a599-1b7819ee0c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_495d3c26-61d8-4bcb-b485-1ced92a31c65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:to="loc_us-gaap_NetIncomeLoss_495d3c26-61d8-4bcb-b485-1ced92a31c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e960ba79-56cd-40a6-a62a-ab74d5fc1f00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e960ba79-56cd-40a6-a62a-ab74d5fc1f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8fad5bc7-2db1-4bb7-86ce-857af13c352b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8fad5bc7-2db1-4bb7-86ce-857af13c352b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_e8c68301-776c-44ed-91e2-3c2d7b0abb83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_e8c68301-776c-44ed-91e2-3c2d7b0abb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_e9fcedeb-b4b5-49ad-892c-7458c1083493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_e9fcedeb-b4b5-49ad-892c-7458c1083493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_8e66a77d-4572-41f1-9c25-caec9e408d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_8e66a77d-4572-41f1-9c25-caec9e408d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_4e7c7f77-d220-4936-b944-7eab892b55ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_4e7c7f77-d220-4936-b944-7eab892b55ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_cf8bff40-fe73-4108-9712-aed58fd3731a" xlink:href="vrna-20220331.xsd#vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:to="loc_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_cf8bff40-fe73-4108-9712-aed58fd3731a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5ed9d47a-f152-4c14-a731-886528b61b13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5ed9d47a-f152-4c14-a731-886528b61b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e6cbd6af-685c-4c00-8691-1bca5cf50ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e6cbd6af-685c-4c00-8691-1bca5cf50ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_26d0865f-366f-4161-bb6e-30fb2b5315f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f55806b-8a50-4781-b720-503e1f67fd2c" xlink:to="loc_us-gaap_StockholdersEquity_26d0865f-366f-4161-bb6e-30fb2b5315f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="vrna-20220331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f7209143-a74a-451d-a7d2-414e043989ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8ce1556d-2db9-4d01-ae57-0ff59909275b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7209143-a74a-451d-a7d2-414e043989ed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8ce1556d-2db9-4d01-ae57-0ff59909275b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4a007f9c-2e46-40dc-8469-045124a9ba82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8ce1556d-2db9-4d01-ae57-0ff59909275b" xlink:to="loc_us-gaap_NetIncomeLoss_4a007f9c-2e46-40dc-8469-045124a9ba82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_75cd6f6c-ed87-442d-924b-0a795b28e6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8ce1556d-2db9-4d01-ae57-0ff59909275b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_75cd6f6c-ed87-442d-924b-0a795b28e6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_42867252-c97b-4d8d-a2bb-b7c9c1f0986d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_75cd6f6c-ed87-442d-924b-0a795b28e6f1" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_42867252-c97b-4d8d-a2bb-b7c9c1f0986d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_16edff2f-48d1-4eec-9b36-368971edb081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_75cd6f6c-ed87-442d-924b-0a795b28e6f1" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_16edff2f-48d1-4eec-9b36-368971edb081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_6920559c-526d-45df-b699-d9f46a6a2d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_75cd6f6c-ed87-442d-924b-0a795b28e6f1" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_6920559c-526d-45df-b699-d9f46a6a2d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_9767ef7c-0249-4b2a-951a-34dd1eb327df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_75cd6f6c-ed87-442d-924b-0a795b28e6f1" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_9767ef7c-0249-4b2a-951a-34dd1eb327df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1e916953-e625-40d4-981d-6e7106d644d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_75cd6f6c-ed87-442d-924b-0a795b28e6f1" xlink:to="loc_us-gaap_ShareBasedCompensation_1e916953-e625-40d4-981d-6e7106d644d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_97617181-2e78-47a7-bcb9-c1c7bdf66578" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_75cd6f6c-ed87-442d-924b-0a795b28e6f1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_97617181-2e78-47a7-bcb9-c1c7bdf66578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a3ee5e3c-ef72-4474-a5da-c65718be4e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_75cd6f6c-ed87-442d-924b-0a795b28e6f1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a3ee5e3c-ef72-4474-a5da-c65718be4e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_9ebc72de-7783-4471-b0cf-8c467d8b4736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a3ee5e3c-ef72-4474-a5da-c65718be4e88" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_9ebc72de-7783-4471-b0cf-8c467d8b4736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_ab9f4f07-711e-4190-aa3f-4bf3e1efa377" xlink:href="vrna-20220331.xsd#vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a3ee5e3c-ef72-4474-a5da-c65718be4e88" xlink:to="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_ab9f4f07-711e-4190-aa3f-4bf3e1efa377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_048d05ec-3b85-443d-be28-d19cf7ef2a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a3ee5e3c-ef72-4474-a5da-c65718be4e88" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_048d05ec-3b85-443d-be28-d19cf7ef2a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_27f16773-68da-4366-9aaa-c3ba1837c89b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a3ee5e3c-ef72-4474-a5da-c65718be4e88" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_27f16773-68da-4366-9aaa-c3ba1837c89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_fd2ec075-5a91-40c3-abae-efa0565bda12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a3ee5e3c-ef72-4474-a5da-c65718be4e88" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_fd2ec075-5a91-40c3-abae-efa0565bda12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_bbb701c3-6577-405d-8c2a-709dfd232cfd" xlink:href="vrna-20220331.xsd#vrna_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a3ee5e3c-ef72-4474-a5da-c65718be4e88" xlink:to="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_bbb701c3-6577-405d-8c2a-709dfd232cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_5af6817f-08af-455e-bbb7-fb130a94eab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a3ee5e3c-ef72-4474-a5da-c65718be4e88" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_5af6817f-08af-455e-bbb7-fb130a94eab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_643b11bf-c036-4013-8977-72bdfe5f31d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a3ee5e3c-ef72-4474-a5da-c65718be4e88" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_643b11bf-c036-4013-8977-72bdfe5f31d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_860f8526-4766-424b-b14a-8d50d24cd356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8ce1556d-2db9-4d01-ae57-0ff59909275b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_860f8526-4766-424b-b14a-8d50d24cd356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1b833c81-8522-4711-8637-6f46b5e952d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7209143-a74a-451d-a7d2-414e043989ed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1b833c81-8522-4711-8637-6f46b5e952d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_125212f1-122b-47dc-a5f0-128c76bae6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1b833c81-8522-4711-8637-6f46b5e952d9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_125212f1-122b-47dc-a5f0-128c76bae6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a0a2f25-52db-4b5b-b0a0-84fba75768c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7209143-a74a-451d-a7d2-414e043989ed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a0a2f25-52db-4b5b-b0a0-84fba75768c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c8abf15f-a1ae-45ed-9e55-36dd3e5815b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a0a2f25-52db-4b5b-b0a0-84fba75768c8" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c8abf15f-a1ae-45ed-9e55-36dd3e5815b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b95d46e4-2049-46fb-8aac-3db9e631149b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a0a2f25-52db-4b5b-b0a0-84fba75768c8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b95d46e4-2049-46fb-8aac-3db9e631149b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_60e4981a-dff3-42f3-9d28-fd07c804cba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a0a2f25-52db-4b5b-b0a0-84fba75768c8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_60e4981a-dff3-42f3-9d28-fd07c804cba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0f2bbd0b-d41c-477f-9b61-1d417882e099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7209143-a74a-451d-a7d2-414e043989ed" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0f2bbd0b-d41c-477f-9b61-1d417882e099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b509f055-18f7-44ec-b5d6-91654a1a354b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7209143-a74a-451d-a7d2-414e043989ed" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b509f055-18f7-44ec-b5d6-91654a1a354b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dabc9433-cea1-42ae-9f5c-90f3232814fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7209143-a74a-451d-a7d2-414e043989ed" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dabc9433-cea1-42ae-9f5c-90f3232814fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_954a5690-cf47-4254-9e09-c933c6745b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7209143-a74a-451d-a7d2-414e043989ed" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_954a5690-cf47-4254-9e09-c933c6745b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_2efc8cb6-c4e6-4b76-b2e0-446bf1da9d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7209143-a74a-451d-a7d2-414e043989ed" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_2efc8cb6-c4e6-4b76-b2e0-446bf1da9d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_eb2a44fe-229b-495e-b90a-471624239df0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_2efc8cb6-c4e6-4b76-b2e0-446bf1da9d89" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_eb2a44fe-229b-495e-b90a-471624239df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_ed1fee60-e306-4c60-96f9-569bfb88620b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_2efc8cb6-c4e6-4b76-b2e0-446bf1da9d89" xlink:to="loc_us-gaap_InterestPaidNet_ed1fee60-e306-4c60-96f9-569bfb88620b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations" xlink:type="simple" xlink:href="vrna-20220331.xsd#Organizationanddescriptionofbusinessoperations"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c78472c9-25eb-4eda-bb3b-e356fe0f42d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OrganizationAndBusinessDescriptionTextBlock_8d2a5bf9-28ed-4bae-ac7f-a4a27600bccd" xlink:href="vrna-20220331.xsd#vrna_OrganizationAndBusinessDescriptionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c78472c9-25eb-4eda-bb3b-e356fe0f42d5" xlink:to="loc_vrna_OrganizationAndBusinessDescriptionTextBlock_8d2a5bf9-28ed-4bae-ac7f-a4a27600bccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails" xlink:type="simple" xlink:href="vrna-20220331.xsd#OrganizationConsolidationandPresentationofFinancialStatementsDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28479a60-2336-404a-a026-f4a9e3eed4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NumberOfWhollyOwnedSubsidiaries_0de9fab5-1177-41e9-8fe1-5da3e326ee00" xlink:href="vrna-20220331.xsd#vrna_NumberOfWhollyOwnedSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28479a60-2336-404a-a026-f4a9e3eed4aa" xlink:to="loc_vrna_NumberOfWhollyOwnedSubsidiaries_0de9fab5-1177-41e9-8fe1-5da3e326ee00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b87b168a-621b-44ac-a836-8ec3bbc21511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28479a60-2336-404a-a026-f4a9e3eed4aa" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b87b168a-621b-44ac-a836-8ec3bbc21511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_06496512-0d28-4ad7-9fca-96b84f28f38f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b87b168a-621b-44ac-a836-8ec3bbc21511" xlink:to="loc_us-gaap_StatementClassOfStockAxis_06496512-0d28-4ad7-9fca-96b84f28f38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cd90ad94-d417-46dc-b172-3f19377b32c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_06496512-0d28-4ad7-9fca-96b84f28f38f" xlink:to="loc_us-gaap_ClassOfStockDomain_cd90ad94-d417-46dc-b172-3f19377b32c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AmericanDepositorySharesMember_a78516d9-859a-4974-977f-b4dd5f0ae5f8" xlink:href="vrna-20220331.xsd#vrna_AmericanDepositorySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_cd90ad94-d417-46dc-b172-3f19377b32c1" xlink:to="loc_vrna_AmericanDepositorySharesMember_a78516d9-859a-4974-977f-b4dd5f0ae5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_30b382b9-e635-4b0c-a94d-fb6aa9da9410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b87b168a-621b-44ac-a836-8ec3bbc21511" xlink:to="loc_us-gaap_ClassOfStockLineItems_30b382b9-e635-4b0c-a94d-fb6aa9da9410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e794b28f-e375-4beb-9f0e-4c179319f6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_30b382b9-e635-4b0c-a94d-fb6aa9da9410" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e794b28f-e375-4beb-9f0e-4c179319f6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SaleOfStockMaximumAggregateOfferingPrice_0a5bc9cf-23bb-48ac-9460-f643c4b7fecc" xlink:href="vrna-20220331.xsd#vrna_SaleOfStockMaximumAggregateOfferingPrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_30b382b9-e635-4b0c-a94d-fb6aa9da9410" xlink:to="loc_vrna_SaleOfStockMaximumAggregateOfferingPrice_0a5bc9cf-23bb-48ac-9460-f643c4b7fecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_729964a0-79e5-41ec-b457-c6ca3ce6f9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_30b382b9-e635-4b0c-a94d-fb6aa9da9410" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_729964a0-79e5-41ec-b457-c6ca3ce6f9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_a862b13f-b6ba-4515-8321-c4005626e362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_30b382b9-e635-4b0c-a94d-fb6aa9da9410" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_a862b13f-b6ba-4515-8321-c4005626e362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ca0ab44f-9fb3-4942-a9ff-155a43e18a48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_30b382b9-e635-4b0c-a94d-fb6aa9da9410" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ca0ab44f-9fb3-4942-a9ff-155a43e18a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_CommonStockSharesAvailableForSaleValue_77a2660e-dfe1-47bf-a6eb-4507e2e76fa6" xlink:href="vrna-20220331.xsd#vrna_CommonStockSharesAvailableForSaleValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_30b382b9-e635-4b0c-a94d-fb6aa9da9410" xlink:to="loc_vrna_CommonStockSharesAvailableForSaleValue_77a2660e-dfe1-47bf-a6eb-4507e2e76fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="vrna-20220331.xsd#Basisofpresentationandsummaryofsignificantaccountingpolicies"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1718121f-126b-46ba-86c7-de495183ddd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_5c8cda45-d3e2-410e-ba9c-d8123bfa8bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1718121f-126b-46ba-86c7-de495183ddd1" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_5c8cda45-d3e2-410e-ba9c-d8123bfa8bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="vrna-20220331.xsd#BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2fc45f74-182c-4c90-a057-f42a3f7189d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_eeb55be3-105d-46d6-b84d-78bb68ef8072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2fc45f74-182c-4c90-a057-f42a3f7189d5" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_eeb55be3-105d-46d6-b84d-78bb68ef8072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_9bd2835d-57b7-41b9-a07c-054fbb755125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2fc45f74-182c-4c90-a057-f42a3f7189d5" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_9bd2835d-57b7-41b9-a07c-054fbb755125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_9ddb7164-ea62-4665-874d-5c9b6f877af1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2fc45f74-182c-4c90-a057-f42a3f7189d5" xlink:to="loc_us-gaap_UseOfEstimates_9ddb7164-ea62-4665-874d-5c9b6f877af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5096ca72-cc5c-4ab7-b2fc-f2e87e5b1022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2fc45f74-182c-4c90-a057-f42a3f7189d5" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5096ca72-cc5c-4ab7-b2fc-f2e87e5b1022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesDetails" xlink:type="simple" xlink:href="vrna-20220331.xsd#BasisofpresentationandsummaryofsignificantaccountingpoliciesDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_717b5d6b-3dae-43f9-8544-76e64ee50221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_b8591bc5-284c-4937-9873-22565a681bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_717b5d6b-3dae-43f9-8544-76e64ee50221" xlink:to="loc_us-gaap_NumberOfOperatingSegments_b8591bc5-284c-4937-9873-22565a681bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_1e8c7cf3-6933-441d-a357-cb5a0b1d0f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_717b5d6b-3dae-43f9-8544-76e64ee50221" xlink:to="loc_us-gaap_NumberOfReportableSegments_1e8c7cf3-6933-441d-a357-cb5a0b1d0f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Prepaidexpenses" xlink:type="simple" xlink:href="vrna-20220331.xsd#Prepaidexpenses"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Prepaidexpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_6ab99a9a-7b56-4b52-a2ec-7bcbc40c8b34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PrepaidExpenseDisclosureTextBlock_d329006d-6949-4b14-94cb-9dd35ab7961e" xlink:href="vrna-20220331.xsd#vrna_PrepaidExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_6ab99a9a-7b56-4b52-a2ec-7bcbc40c8b34" xlink:to="loc_vrna_PrepaidExpenseDisclosureTextBlock_d329006d-6949-4b14-94cb-9dd35ab7961e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/PrepaidexpensesTables" xlink:type="simple" xlink:href="vrna-20220331.xsd#PrepaidexpensesTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/PrepaidexpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_b9dd47cc-f8ce-4dad-9b89-ee7dabda3078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_c9eb6b77-dd80-479a-b78d-39acf33848bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_b9dd47cc-f8ce-4dad-9b89-ee7dabda3078" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_c9eb6b77-dd80-479a-b78d-39acf33848bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/PrepaidexpensesDetails" xlink:type="simple" xlink:href="vrna-20220331.xsd#PrepaidexpensesDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/PrepaidexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_6a8748e2-0b24-4ae8-a073-5f379e4da07a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PrepaidResearchAndDevelopmentFeesCurrent_ae9fbab3-fb7e-4118-8c81-e0490cc6ea7a" xlink:href="vrna-20220331.xsd#vrna_PrepaidResearchAndDevelopmentFeesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_6a8748e2-0b24-4ae8-a073-5f379e4da07a" xlink:to="loc_vrna_PrepaidResearchAndDevelopmentFeesCurrent_ae9fbab3-fb7e-4118-8c81-e0490cc6ea7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_d127b720-5a36-441e-b95e-a940859a5fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_6a8748e2-0b24-4ae8-a073-5f379e4da07a" xlink:to="loc_us-gaap_PrepaidInsurance_d127b720-5a36-441e-b95e-a940859a5fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_f309ca32-f65e-4e9f-81aa-44f4b293a8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_6a8748e2-0b24-4ae8-a073-5f379e4da07a" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_f309ca32-f65e-4e9f-81aa-44f4b293a8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_c0bfd866-c020-49bf-b6e3-b92daf3c94ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_6a8748e2-0b24-4ae8-a073-5f379e4da07a" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_c0bfd866-c020-49bf-b6e3-b92daf3c94ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Taxandtaxincentivereceivable" xlink:type="simple" xlink:href="vrna-20220331.xsd#Taxandtaxincentivereceivable"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Taxandtaxincentivereceivable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_9594ef28-8c1d-41e2-a16b-de266b2d2d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_ff3ed36c-0f81-41bc-98b5-2fef75c0337b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_9594ef28-8c1d-41e2-a16b-de266b2d2d2c" xlink:to="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_ff3ed36c-0f81-41bc-98b5-2fef75c0337b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxandtaxincentivereceivableTables" xlink:type="simple" xlink:href="vrna-20220331.xsd#TaxandtaxincentivereceivableTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/TaxandtaxincentivereceivableTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_e99f0d69-1efb-4d74-96a7-c261449e8331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ScheduleOfNontradeReceivablesTableTextBlock_c82bfc51-57f9-497d-865d-09617bc3fa03" xlink:href="vrna-20220331.xsd#vrna_ScheduleOfNontradeReceivablesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_e99f0d69-1efb-4d74-96a7-c261449e8331" xlink:to="loc_vrna_ScheduleOfNontradeReceivablesTableTextBlock_c82bfc51-57f9-497d-865d-09617bc3fa03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxandtaxincentivereceivableDetails" xlink:type="simple" xlink:href="vrna-20220331.xsd#TaxandtaxincentivereceivableDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/TaxandtaxincentivereceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_37c39a98-2ae6-434b-9c63-08b9d9fcf7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent_e7743b90-3629-4688-adff-74b59ed435b2" xlink:href="vrna-20220331.xsd#vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_37c39a98-2ae6-434b-9c63-08b9d9fcf7a7" xlink:to="loc_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent_e7743b90-3629-4688-adff-74b59ed435b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_882d8ca5-970b-4bb8-946b-847fc6f5ab36" xlink:href="vrna-20220331.xsd#vrna_TaxCreditAndIncomeTaxesReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_37c39a98-2ae6-434b-9c63-08b9d9fcf7a7" xlink:to="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_882d8ca5-970b-4bb8-946b-847fc6f5ab36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_GainLossFromResearchAndDevelopmentTaxCreditExcludingAnnualCap_a5445cd7-e354-4290-a88f-10ae8d2d6b63" xlink:href="vrna-20220331.xsd#vrna_GainLossFromResearchAndDevelopmentTaxCreditExcludingAnnualCap"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_37c39a98-2ae6-434b-9c63-08b9d9fcf7a7" xlink:to="loc_vrna_GainLossFromResearchAndDevelopmentTaxCreditExcludingAnnualCap_a5445cd7-e354-4290-a88f-10ae8d2d6b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit_daa7793e-7225-4f87-8b0c-f6515d0f0018" xlink:href="vrna-20220331.xsd#vrna_GainLossFromResearchAndDevelopmentTaxCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_37c39a98-2ae6-434b-9c63-08b9d9fcf7a7" xlink:to="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit_daa7793e-7225-4f87-8b0c-f6515d0f0018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Accruedexpenses" xlink:type="simple" xlink:href="vrna-20220331.xsd#Accruedexpenses"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Accruedexpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_507e9555-da23-49c9-b185-d3ed61befbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_7d78cff7-6ba3-4b8b-81a0-a8d3b0395c53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_507e9555-da23-49c9-b185-d3ed61befbc7" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_7d78cff7-6ba3-4b8b-81a0-a8d3b0395c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/AccruedexpensesTables" xlink:type="simple" xlink:href="vrna-20220331.xsd#AccruedexpensesTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/AccruedexpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_a89804af-887c-471f-b067-679dc737e935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ae438f09-5359-4e05-9b78-4eb70ff53033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a89804af-887c-471f-b067-679dc737e935" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ae438f09-5359-4e05-9b78-4eb70ff53033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/AccruedexpensesDetails" xlink:type="simple" xlink:href="vrna-20220331.xsd#AccruedexpensesDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/AccruedexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_07bd49c6-d530-4f46-80f6-d40071bbf731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent_4ae9b778-374b-40da-8146-62f02e6d9cde" xlink:href="vrna-20220331.xsd#vrna_AccruedResearchAndDevelopmentFeesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_07bd49c6-d530-4f46-80f6-d40071bbf731" xlink:to="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent_4ae9b778-374b-40da-8146-62f02e6d9cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_ef7676cb-8fb9-40c1-8715-a4219a8f0505" xlink:href="vrna-20220331.xsd#vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_07bd49c6-d530-4f46-80f6-d40071bbf731" xlink:to="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_ef7676cb-8fb9-40c1-8715-a4219a8f0505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_41d68fba-738c-474c-ade9-cba8d00e9ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_07bd49c6-d530-4f46-80f6-d40071bbf731" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_41d68fba-738c-474c-ade9-cba8d00e9ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_33436e0d-060a-441f-b943-0fdb6924d5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_07bd49c6-d530-4f46-80f6-d40071bbf731" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_33436e0d-060a-441f-b943-0fdb6924d5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Termloan" xlink:type="simple" xlink:href="vrna-20220331.xsd#Termloan"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Termloan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_efd1d556-253c-4e4f-9231-8df10285841c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_d7e04563-74c9-4c03-a8c4-790ac7158e14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_efd1d556-253c-4e4f-9231-8df10285841c" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_d7e04563-74c9-4c03-a8c4-790ac7158e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TermloanDetails" xlink:type="simple" xlink:href="vrna-20220331.xsd#TermloanDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/TermloanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6e1222e8-c29d-4707-878c-22b2f333d25a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d99ea950-1252-4287-bd7c-263131add3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6e1222e8-c29d-4707-878c-22b2f333d25a" xlink:to="loc_us-gaap_DebtInstrumentTable_d99ea950-1252-4287-bd7c-263131add3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c5aaf37d-2d18-46dc-9d93-4f2f8ca21ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d99ea950-1252-4287-bd7c-263131add3fe" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c5aaf37d-2d18-46dc-9d93-4f2f8ca21ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4b405d68-f3ff-4494-b82c-7b0ef088ab1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c5aaf37d-2d18-46dc-9d93-4f2f8ca21ee0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4b405d68-f3ff-4494-b82c-7b0ef088ab1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_858443dd-ba83-4b77-b513-2d08e88b49f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4b405d68-f3ff-4494-b82c-7b0ef088ab1f" xlink:to="loc_us-gaap_SecuredDebtMember_858443dd-ba83-4b77-b513-2d08e88b49f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_950d1078-c6a9-4dba-8476-30a03aa23b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d99ea950-1252-4287-bd7c-263131add3fe" xlink:to="loc_us-gaap_DebtInstrumentAxis_950d1078-c6a9-4dba-8476-30a03aa23b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4aa58000-8998-40d7-9a3a-33e1129eb5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_950d1078-c6a9-4dba-8476-30a03aa23b5e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4aa58000-8998-40d7-9a3a-33e1129eb5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermLoanFacilityMember_5850c06e-7113-4778-9cdb-366813991872" xlink:href="vrna-20220331.xsd#vrna_TermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4aa58000-8998-40d7-9a3a-33e1129eb5fe" xlink:to="loc_vrna_TermLoanFacilityMember_5850c06e-7113-4778-9cdb-366813991872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermBLoanMember_c50634a6-e416-477f-a6f0-2ef282c7f807" xlink:href="vrna-20220331.xsd#vrna_TermBLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_TermLoanFacilityMember_5850c06e-7113-4778-9cdb-366813991872" xlink:to="loc_vrna_TermBLoanMember_c50634a6-e416-477f-a6f0-2ef282c7f807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermCLoanMember_660a9ad6-d713-4547-b52e-da2726c5c35c" xlink:href="vrna-20220331.xsd#vrna_TermCLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_TermLoanFacilityMember_5850c06e-7113-4778-9cdb-366813991872" xlink:to="loc_vrna_TermCLoanMember_660a9ad6-d713-4547-b52e-da2726c5c35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2871c4dc-c8d4-4872-a825-5cc31470d0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d99ea950-1252-4287-bd7c-263131add3fe" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2871c4dc-c8d4-4872-a825-5cc31470d0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1614326f-ce4f-40be-bc9b-353c458e958e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2871c4dc-c8d4-4872-a825-5cc31470d0ff" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1614326f-ce4f-40be-bc9b-353c458e958e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_00f71123-ac66-4d65-9459-67943bcf4ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2871c4dc-c8d4-4872-a825-5cc31470d0ff" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_00f71123-ac66-4d65-9459-67943bcf4ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_fc1647da-c636-4347-a005-775e0663f615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2871c4dc-c8d4-4872-a825-5cc31470d0ff" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_fc1647da-c636-4347-a005-775e0663f615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_62358f4c-16b0-45f8-b1dc-4de4e013b12a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2871c4dc-c8d4-4872-a825-5cc31470d0ff" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_62358f4c-16b0-45f8-b1dc-4de4e013b12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/EquityInterest" xlink:type="simple" xlink:href="vrna-20220331.xsd#EquityInterest"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/EquityInterest" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ccc15723-9ede-410a-b739-45586f4ad809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5a853176-de80-4ec4-aa07-ecc2cad348d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ccc15723-9ede-410a-b739-45586f4ad809" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5a853176-de80-4ec4-aa07-ecc2cad348d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/EquityInterestDetails" xlink:type="simple" xlink:href="vrna-20220331.xsd#EquityInterestDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/EquityInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_05d6b46b-c630-4bb8-aba8-27756b6c284e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d076e7a0-55b9-4121-b4a2-5e3223693721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_05d6b46b-c630-4bb8-aba8-27756b6c284e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d076e7a0-55b9-4121-b4a2-5e3223693721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2d18bb1a-8bff-4a0e-9cb4-c81b0b3c337b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d076e7a0-55b9-4121-b4a2-5e3223693721" xlink:to="loc_srt_CounterpartyNameAxis_2d18bb1a-8bff-4a0e-9cb4-c81b0b3c337b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7990d708-97fb-4ca1-8113-9c3be1905897" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2d18bb1a-8bff-4a0e-9cb4-c81b0b3c337b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7990d708-97fb-4ca1-8113-9c3be1905897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NuanceShanghaiPharmaCoLtdMember_dca5e7d9-2992-4c5b-aef1-9646ca38237d" xlink:href="vrna-20220331.xsd#vrna_NuanceShanghaiPharmaCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7990d708-97fb-4ca1-8113-9c3be1905897" xlink:to="loc_vrna_NuanceShanghaiPharmaCoLtdMember_dca5e7d9-2992-4c5b-aef1-9646ca38237d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b87f4d09-a8d0-4180-845c-74b00664a611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d076e7a0-55b9-4121-b4a2-5e3223693721" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b87f4d09-a8d0-4180-845c-74b00664a611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_1771ff3d-3905-4d5f-b41d-af68369661d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b87f4d09-a8d0-4180-845c-74b00664a611" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_1771ff3d-3905-4d5f-b41d-af68369661d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ae4678c0-04b9-42ae-807d-a337ecf54394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b87f4d09-a8d0-4180-845c-74b00664a611" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ae4678c0-04b9-42ae-807d-a337ecf54394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_EquityInterestReceivable_e61065e5-61f1-46bd-862b-5b7cc60509bf" xlink:href="vrna-20220331.xsd#vrna_EquityInterestReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b87f4d09-a8d0-4180-845c-74b00664a611" xlink:to="loc_vrna_EquityInterestReceivable_e61065e5-61f1-46bd-862b-5b7cc60509bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Significantagreements" xlink:type="simple" xlink:href="vrna-20220331.xsd#Significantagreements"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Significantagreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6556663b-f6a1-4de4-8c99-920007d1752d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_56ae55d8-f8f1-44a0-8687-30be9c025336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6556663b-f6a1-4de4-8c99-920007d1752d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_56ae55d8-f8f1-44a0-8687-30be9c025336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SignificantagreementsDetails" xlink:type="simple" xlink:href="vrna-20220331.xsd#SignificantagreementsDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SignificantagreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d58349a0-25a6-42ab-b694-35df55773995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable_47575074-eb90-4bef-b415-ded732de6059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d58349a0-25a6-42ab-b694-35df55773995" xlink:to="loc_us-gaap_CapitalizedContractCostTable_47575074-eb90-4bef-b415-ded732de6059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0cd72eb0-7f2c-4cb5-9d39-88f8586d650d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostTable_47575074-eb90-4bef-b415-ded732de6059" xlink:to="loc_srt_CounterpartyNameAxis_0cd72eb0-7f2c-4cb5-9d39-88f8586d650d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_89f811ad-f4cc-4822-ab19-556d0ba85374" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0cd72eb0-7f2c-4cb5-9d39-88f8586d650d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_89f811ad-f4cc-4822-ab19-556d0ba85374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_LigandUKDevelopmentLimitedMember_067caf76-2611-4beb-912f-21df30d6499a" xlink:href="vrna-20220331.xsd#vrna_LigandUKDevelopmentLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_89f811ad-f4cc-4822-ab19-556d0ba85374" xlink:to="loc_vrna_LigandUKDevelopmentLimitedMember_067caf76-2611-4beb-912f-21df30d6499a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NuanceShanghaiPharmaCoLtdMember_931998b7-5a5e-4bca-81d7-c41c77771c8b" xlink:href="vrna-20220331.xsd#vrna_NuanceShanghaiPharmaCoLtdMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_89f811ad-f4cc-4822-ab19-556d0ba85374" xlink:to="loc_vrna_NuanceShanghaiPharmaCoLtdMember_931998b7-5a5e-4bca-81d7-c41c77771c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_487d511d-b9c6-4bbd-be63-a18dddbf7b55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostTable_47575074-eb90-4bef-b415-ded732de6059" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_487d511d-b9c6-4bbd-be63-a18dddbf7b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a9316247-8af9-4d04-b0d0-f955350482ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_487d511d-b9c6-4bbd-be63-a18dddbf7b55" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a9316247-8af9-4d04-b0d0-f955350482ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0d35bf35-3455-4eec-93f7-385c16f6fbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a9316247-8af9-4d04-b0d0-f955350482ca" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0d35bf35-3455-4eec-93f7-385c16f6fbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_BenchmarkAchievementAxis_1b9e2851-2307-48a7-8006-8c209d0a3bea" xlink:href="vrna-20220331.xsd#vrna_BenchmarkAchievementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostTable_47575074-eb90-4bef-b415-ded732de6059" xlink:to="loc_vrna_BenchmarkAchievementAxis_1b9e2851-2307-48a7-8006-8c209d0a3bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_BenchmarkAchievementDomain_9518aea5-ef3a-41d1-b08a-2adb23c7ef8f" xlink:href="vrna-20220331.xsd#vrna_BenchmarkAchievementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_BenchmarkAchievementAxis_1b9e2851-2307-48a7-8006-8c209d0a3bea" xlink:to="loc_vrna_BenchmarkAchievementDomain_9518aea5-ef3a-41d1-b08a-2adb23c7ef8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_FirstCommercialSaleMember_b57d12f4-67eb-44ff-a7ad-47452cb9a773" xlink:href="vrna-20220331.xsd#vrna_FirstCommercialSaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_BenchmarkAchievementDomain_9518aea5-ef3a-41d1-b08a-2adb23c7ef8f" xlink:to="loc_vrna_FirstCommercialSaleMember_b57d12f4-67eb-44ff-a7ad-47452cb9a773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems_7fe6b067-22d3-4d65-a27c-a35f1dc46a26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostTable_47575074-eb90-4bef-b415-ded732de6059" xlink:to="loc_us-gaap_CapitalizedContractCostLineItems_7fe6b067-22d3-4d65-a27c-a35f1dc46a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SublicensePaymentPercentage_1ef95173-2fe1-45ba-a180-8a34d95681c1" xlink:href="vrna-20220331.xsd#vrna_SublicensePaymentPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_7fe6b067-22d3-4d65-a27c-a35f1dc46a26" xlink:to="loc_vrna_SublicensePaymentPercentage_1ef95173-2fe1-45ba-a180-8a34d95681c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SublicensePayment_599beeed-6473-40a4-958b-f32b9e3ca8dd" xlink:href="vrna-20220331.xsd#vrna_SublicensePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_7fe6b067-22d3-4d65-a27c-a35f1dc46a26" xlink:to="loc_vrna_SublicensePayment_599beeed-6473-40a4-958b-f32b9e3ca8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays_4d59f1fd-894f-4cf5-9279-fec3917e4c6e" xlink:href="vrna-20220331.xsd#vrna_SublicensePaymentEquityIssuanceThresholdTradingDays"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_7fe6b067-22d3-4d65-a27c-a35f1dc46a26" xlink:to="loc_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays_4d59f1fd-894f-4cf5-9279-fec3917e4c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_d99aff42-a2c1-42b8-b552-c0fc6ee1e9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_7fe6b067-22d3-4d65-a27c-a35f1dc46a26" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_d99aff42-a2c1-42b8-b552-c0fc6ee1e9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7209cc88-03ba-40ec-8d90-d6f720a1d836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_7fe6b067-22d3-4d65-a27c-a35f1dc46a26" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7209cc88-03ba-40ec-8d90-d6f720a1d836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_EquityInterestReceivable_ac3ffc25-6d79-47b7-a0fd-b137114c8944" xlink:href="vrna-20220331.xsd#vrna_EquityInterestReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_7fe6b067-22d3-4d65-a27c-a35f1dc46a26" xlink:to="loc_vrna_EquityInterestReceivable_ac3ffc25-6d79-47b7-a0fd-b137114c8944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ContractWithCustomerFutureEligibleMilestonePayments_327d8896-e35d-4994-8e4a-be3c87d2825d" xlink:href="vrna-20220331.xsd#vrna_ContractWithCustomerFutureEligibleMilestonePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_7fe6b067-22d3-4d65-a27c-a35f1dc46a26" xlink:to="loc_vrna_ContractWithCustomerFutureEligibleMilestonePayments_327d8896-e35d-4994-8e4a-be3c87d2825d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_ba80564b-b833-45d6-b525-a0f9d3c19eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_7fe6b067-22d3-4d65-a27c-a35f1dc46a26" xlink:to="loc_us-gaap_ContractWithCustomerLiability_ba80564b-b833-45d6-b525-a0f9d3c19eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Sharebasedcompensation" xlink:type="simple" xlink:href="vrna-20220331.xsd#Sharebasedcompensation"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Sharebasedcompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63e6588e-66ba-43ee-b0d9-320dcc54e3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_067ca6e1-4e50-4e90-9951-87ec8746eb5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63e6588e-66ba-43ee-b0d9-320dcc54e3c1" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_067ca6e1-4e50-4e90-9951-87ec8746eb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationTables" xlink:type="simple" xlink:href="vrna-20220331.xsd#SharebasedcompensationTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a3f2aa21-a686-44fd-80d5-2474872e5792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8dc57c5f-9573-49da-85dd-4814e68a5861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a3f2aa21-a686-44fd-80d5-2474872e5792" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8dc57c5f-9573-49da-85dd-4814e68a5861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_880bb936-2178-4ec8-a0b0-a584d45e2fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a3f2aa21-a686-44fd-80d5-2474872e5792" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_880bb936-2178-4ec8-a0b0-a584d45e2fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_5658a611-a6b3-44df-ac3d-92dcc433a2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a3f2aa21-a686-44fd-80d5-2474872e5792" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_5658a611-a6b3-44df-ac3d-92dcc433a2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="vrna-20220331.xsd#SharebasedcompensationShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b017c1cf-3d72-414d-bbec-2a3b8ecbb7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e253a3a4-e860-4b23-a510-615e959cf53c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b017c1cf-3d72-414d-bbec-2a3b8ecbb7ae" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e253a3a4-e860-4b23-a510-615e959cf53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_daffe5b9-cedb-40ce-b1d9-5201c025102e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e253a3a4-e860-4b23-a510-615e959cf53c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_daffe5b9-cedb-40ce-b1d9-5201c025102e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3cc25ea7-bb5d-4e4c-b541-dd1e817ca615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_daffe5b9-cedb-40ce-b1d9-5201c025102e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3cc25ea7-bb5d-4e4c-b541-dd1e817ca615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9b58fb75-4cf2-4638-a9f8-6db5d8cc7072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3cc25ea7-bb5d-4e4c-b541-dd1e817ca615" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9b58fb75-4cf2-4638-a9f8-6db5d8cc7072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7676e53d-e6e1-4429-8f34-850bd914e4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3cc25ea7-bb5d-4e4c-b541-dd1e817ca615" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7676e53d-e6e1-4429-8f34-850bd914e4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_02d4dd56-bb35-4220-846b-d4940a57c76d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e253a3a4-e860-4b23-a510-615e959cf53c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_02d4dd56-bb35-4220-846b-d4940a57c76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f42baa49-98ed-4cf2-9b17-8e84aef9e959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_02d4dd56-bb35-4220-846b-d4940a57c76d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f42baa49-98ed-4cf2-9b17-8e84aef9e959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails" xlink:type="simple" xlink:href="vrna-20220331.xsd#SharebasedcompensationShareOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3e806922-feca-4b2e-a392-c6e6b6818d19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_49626e15-7fe4-4e99-b997-41d03fc1502b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3e806922-feca-4b2e-a392-c6e6b6818d19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_49626e15-7fe4-4e99-b997-41d03fc1502b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_57649283-bd43-4c8b-b947-67c54bdbb461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_49626e15-7fe4-4e99-b997-41d03fc1502b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_57649283-bd43-4c8b-b947-67c54bdbb461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d362660f-fa77-4cf1-9698-03a5eb299345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_49626e15-7fe4-4e99-b997-41d03fc1502b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d362660f-fa77-4cf1-9698-03a5eb299345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ea2f7413-b78c-44b7-85f2-43f57ab0360d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_49626e15-7fe4-4e99-b997-41d03fc1502b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ea2f7413-b78c-44b7-85f2-43f57ab0360d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c9579b85-c888-4eab-8804-ceb91890a00c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3e806922-feca-4b2e-a392-c6e6b6818d19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c9579b85-c888-4eab-8804-ceb91890a00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_01f8aea6-c8d2-4a01-89d5-078563c9482b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c9579b85-c888-4eab-8804-ceb91890a00c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_01f8aea6-c8d2-4a01-89d5-078563c9482b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fa85f8d7-8690-422d-bb80-25b3dfe2bb34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c9579b85-c888-4eab-8804-ceb91890a00c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fa85f8d7-8690-422d-bb80-25b3dfe2bb34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_122534ee-2080-4e71-82fc-b822c13fff6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c9579b85-c888-4eab-8804-ceb91890a00c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_122534ee-2080-4e71-82fc-b822c13fff6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails" xlink:type="simple" xlink:href="vrna-20220331.xsd#SharebasedcompensationRSUActivityDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_668e5728-9132-481b-960d-fa8aed457234" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_de0a7136-56b7-4023-91fa-ac59d8095f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_668e5728-9132-481b-960d-fa8aed457234" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_de0a7136-56b7-4023-91fa-ac59d8095f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_30fe0cbf-812a-4753-bf68-3b51e862cf7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_de0a7136-56b7-4023-91fa-ac59d8095f3c" xlink:to="loc_us-gaap_AwardTypeAxis_30fe0cbf-812a-4753-bf68-3b51e862cf7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0f39443-3fc1-4c94-953b-8f9d08c88092" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_30fe0cbf-812a-4753-bf68-3b51e862cf7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0f39443-3fc1-4c94-953b-8f9d08c88092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b336674d-556f-466a-af57-736bd65a4016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0f39443-3fc1-4c94-953b-8f9d08c88092" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b336674d-556f-466a-af57-736bd65a4016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50ff3269-a44b-4bc2-addc-f8d8a8d9ebff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_de0a7136-56b7-4023-91fa-ac59d8095f3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50ff3269-a44b-4bc2-addc-f8d8a8d9ebff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0f331780-b1b1-4216-abb9-b11b61671fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50ff3269-a44b-4bc2-addc-f8d8a8d9ebff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0f331780-b1b1-4216-abb9-b11b61671fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1d8644d9-3fc6-4f84-a47b-bd797800209f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0f331780-b1b1-4216-abb9-b11b61671fc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1d8644d9-3fc6-4f84-a47b-bd797800209f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9f3f12a8-4526-4e2a-9b24-58502fb9299f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0f331780-b1b1-4216-abb9-b11b61671fc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9f3f12a8-4526-4e2a-9b24-58502fb9299f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_230116dd-5fdc-4e5c-aa38-22975f08bb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0f331780-b1b1-4216-abb9-b11b61671fc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_230116dd-5fdc-4e5c-aa38-22975f08bb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_035a04ac-f2b0-440e-85ea-ec9c20e64025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0f331780-b1b1-4216-abb9-b11b61671fc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_035a04ac-f2b0-440e-85ea-ec9c20e64025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_c171a41c-d54c-4c7f-870f-455fdc9a61a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50ff3269-a44b-4bc2-addc-f8d8a8d9ebff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_c171a41c-d54c-4c7f-870f-455fdc9a61a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Netlosspershare" xlink:type="simple" xlink:href="vrna-20220331.xsd#Netlosspershare"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Netlosspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e3fe8382-d128-4017-93dc-f109b0f8590f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_85615dbb-6f7c-4e21-9d09-9920ca0b355b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e3fe8382-d128-4017-93dc-f109b0f8590f" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_85615dbb-6f7c-4e21-9d09-9920ca0b355b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/NetlosspershareTables" xlink:type="simple" xlink:href="vrna-20220331.xsd#NetlosspershareTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/NetlosspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d52b05ba-59c1-49fa-a085-074c1fb1c0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_daa18051-4b0a-42f6-8b91-26580b7cdc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d52b05ba-59c1-49fa-a085-074c1fb1c0e3" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_daa18051-4b0a-42f6-8b91-26580b7cdc9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/NetlosspershareComputationDetails" xlink:type="simple" xlink:href="vrna-20220331.xsd#NetlosspershareComputationDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/NetlosspershareComputationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c7e752c7-b200-49c1-9281-b62fa6728381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_6a0c9f2c-802b-451b-8515-314b364ebd11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c7e752c7-b200-49c1-9281-b62fa6728381" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_6a0c9f2c-802b-451b-8515-314b364ebd11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bfb9339d-4aff-4526-8d27-0d9093180e83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_6a0c9f2c-802b-451b-8515-314b364ebd11" xlink:to="loc_us-gaap_NetIncomeLoss_bfb9339d-4aff-4526-8d27-0d9093180e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_65413b16-cb3d-48e3-9565-64b3fcdead23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c7e752c7-b200-49c1-9281-b62fa6728381" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_65413b16-cb3d-48e3-9565-64b3fcdead23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ef61858f-59d0-43f9-bb83-91cbb463f10d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_65413b16-cb3d-48e3-9565-64b3fcdead23" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ef61858f-59d0-43f9-bb83-91cbb463f10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_db4b8d55-046a-4f23-9f1d-b12e5472583d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_65413b16-cb3d-48e3-9565-64b3fcdead23" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_db4b8d55-046a-4f23-9f1d-b12e5472583d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e0479f17-4903-4329-9592-12809ee6238b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_65413b16-cb3d-48e3-9565-64b3fcdead23" xlink:to="loc_us-gaap_EarningsPerShareBasic_e0479f17-4903-4329-9592-12809ee6238b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_abcf08a9-25c3-4b26-95f6-4e8665b1252e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_65413b16-cb3d-48e3-9565-64b3fcdead23" xlink:to="loc_us-gaap_EarningsPerShareDiluted_abcf08a9-25c3-4b26-95f6-4e8665b1252e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_27e10e93-5e84-400f-b461-f95d776bd3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c7e752c7-b200-49c1-9281-b62fa6728381" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_27e10e93-5e84-400f-b461-f95d776bd3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>svb-second_amendmentxtox001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 svb-second_amendmentxtox001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3W;[<TD>V3S+9XUV!6+<F0.VX#!7N: /2=/\0:/JMS+;:?JEI=31#+QPS*Q
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M',85FG3=DLG3Y 0X5<YYQZ9'&(HDC7[J*%'T% #J*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ JE=:1IE]=0W5WIUI<7$/\ JI9H%=T[_*2,C\*NT4 %
M%%% !1110 4444 %,AABMH$@@B2**-0J1HH55 Z  =!3Z* "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ J"\O;73K22[O;F*VMHAEY9G"*H]R>!4]<IX_P!&U#6-
M'L6TVUAO9K"_BO393.$6Z5,YC)/ Z@C/&0* -31_%6@>())(](UBRO9(QETA
MF#,H]<=<>]5;CQYX2M+F6VN/$FE13Q.4DC>Z0,C X((SP0:P]+UW0M8\7Z<N
MJ:!?Z+XCACD%HMW%L$JE?G5'4[9 !S@].H%<OX-U>*PG\41/X0U/5R?$%XWV
MBUM8I%'S#Y<LP.1U_&@#U32?$&CZ\DKZ1J=I?+$0)#;RAPA/3..G0U0O?'/A
M33KYK*\\1:9!<J=K1O<J"A]&YX_&N:\4^(IK/X6>(=6T[1;S0[J-/*5;B%(I
M/F*KO&PGIO.#GJ*Z3P]X2T31O#=MID&GVLD/DJ)6>)6,Y(Y9R1\Q/O0!NQ3Q
M3P+/%*DD+KN61&!5AZ@^E8/_  GWA#[;]C_X272O/W;=OVI.OIG.,UR'C;1+
M7PWX0TSPSI$D]KI^M:[#:3 2D^5%*Q9T0_PK\N,>Y]37=_\ "+Z#_9']D_V/
M9?8-FSR/)7;C\NOOUH MZAJEAI-BU]J%Y!:VB8W33.%09.!R>.214_GQ&W^T
M"1##MW^8#\NW&<Y],5X=,6?X2:YH=P[7-KI/B1=-@,IW%H%N(MJD]\!B/I77
MZ%<3>&QJ_@:_D9EM[22XTB=SS-:X/R9[M&>/I@]* .PNO%&@V.FV^I76L6,-
MC<_ZBXDG54DXS\IS@\4:7XHT#6IC#I>MZ?>2@9,<%RCMCUP#FO*HHTE\&_"6
M.1%=&OH 589!_=M78_$?PSI4O@W4M3AM8;/4M-MWO+2\@01RQ21C<,,.<'&,
M>] '=52U36--T2U6YU2_MK*!G""2XD"*6.<#)[\'\JB\/7\NJ>&M*U"=0LUU
M9PSN ,89D#']37G?B632/&?Q%GT/5;ZVATC1;)UE$LRIYEU.I48R>=B$G/9C
M0!ZKN&W=D8QG-4M*UK2]<MFN=*U"VO8$?8TEO*'4-@'!([X(_.N3^&6NOJO@
MU["YG2:_T>1]/N'1@P?9PC@]PRXY[D&N"^#\C>&?^$>D8XT[Q/:R1D]DNX9'
M ^FZ/CW(H ]IU+6M+T80G4]0MK,3OY<7GRA-[>@SU-5M5\4Z!H5REOJVLV-C
M,Z;UCN)U1BN2,@$],@_E7CWQ,D;Q)JU_J8).GZ#>6VG6_HUP\J-,P]U 5*Z3
MQ->I8?&VVE?1+O5P?#Q7[/:PI(R_Z0?FPY QQC\: .XT_P 9>&=6OH[+3M>T
MZZNI,[(8;A69L DX /H":T++5M.U*:ZAL;ZWN9+20Q7"12!C$XR"K =#P>OI
M6#H&K0W^IB)?!NIZ4RH6%S=6L4:CMC*L3DY]*\YT=9_#.I:[XWM%=[:'Q!?6
MFL0ISOMO-R)0/[T;$G_=)H ]G&H69OY+$747VN.(3/#O&]4)(#$>F0>?:L6/
MX@>#I9 B>*-'+'@#[9&,_K6):31W'Q=U6>&19(I/#T#HZG(93(Y!!]*K_";2
M-,O_ (2Z(+S3K2X$D4@?S85?=^]?KD<T =_+>6T%B][+<1):QQF5YBPV*@&2
MQ/3&.<TS3M2L=6LDO=.NX;NUDSLFA<.K8.#@CW!KR=(QHVE_%3PO:LW]E:?8
M&>TB+$B#SK=V9!GHN1D#WJQ\*9&\.7EOX?E.+/5M,M]6L">F\QJ)T'ONPV/0
MF@#TR[UK2["_M;"[U"V@N[HXMX))0KRGI\H/)JEJ/C'PUI%Z]EJ.O:=:72 %
MH9KA489&1D$^E>1:@[>(/B!HGBYB3:S>(8].T[T,$(?<X]FD+'\*W?[1CT_X
MO^,"_AR^UG?#8X%I!')Y6(SUWL,9SV]* /0]*\5^']<NFMM*UJPO9U0R-';S
MJ[!00,X!Z9(_.KFFZMIVL0//IM];WD2.8V>"0.%8=5)'?D<5D>&]2BU"XGV>
M%K_1F1!^\N[:./S 3T!1CGI7E_@-W\&:-I/BA2?[&U2:6TU9>T,@GD6*X]AT
M1O;!H ]ANO$&CV2WK76IVD(L=GVHR2A?(W_<W^F<C&>M9?\ PL3P9_T-.D?^
M!:?XUE>&XHKCXE>/HY8TEC9M/RK@,#^X/:L[4M.L1\=-$A%G;B)M'G8H(EVD
M[^N,4 =_I>L:;K=H;K2[ZWO;<,4,MO('7<,9&1WY%7:C@MX+:/RX(8XDSG;&
MH49^@J2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "L3Q+8ZW=VUK-H%_%;7MK,)?*
MN,^3<+@@QOCD#G((Z$5MT4 <3%HWB;7?$.DZAX@BTRQM-*D>>*"SF>9YI2A0
M%F95"J Q.!G-9VBZ'XZ\,SZS'IMOX?N+6^U2XOD:XNIE<"0C ("$= *]'HH
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ME:-YX:O;CXFZ;XD22 65MI\EJZ%CYA=FR"!C&/QKJJ* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXBMAG_9?_P")K-MM4L];^*OA_4["42VMUX?GDC8>AE3@^A'0CL12_$P#^VO
MG _Y&"'^1H ZK0O%FA>)FG71M1CO#;A3+L##;NSCJ!Z'\JV:  .@HH ****
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M.];.&99,XXP68CK619_#TCP%K7AJ_N(I#J%S<7$<L8.(V=MZ'GNI /X5W=%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRJJOI\_CR::SXRC18DP5]MP8B@#U31O%VAZ\]U'I][NDM &GCFB>%D4]&(<
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M\+7ND>3'9KXAN8[B9$V(]P87#'/1LGC(X)J'7+RWN_%_CP6\J2>3X7\IRIR
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M-:7U_LNHE1V@2&21]K9P0JJ2?NMTZ8YQ5-OB1X15+63^V8VBN@I258G9%W'
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M11GXM>/IMJF0#3U#8Y ,!./T'Y5RNDV\,?[.WB#9$B[A?LV!U(E< _DH_(4
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M!@<G .:@^(4:1:AX'$:*@37X$4*,;5V/P/;@53\+S11?&SQXDDB([QV&Q68
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MNY7S%263PU$(]QQEO/;IZT =%#XW\.3ZR-)CU)6NC*8%_=N(VE'5!)C86XZ
MYI9/&OAZ/65T@ZB#J!N/LWD+$[,),*<' X'S+\W3GK7F/AS2[Z^^'N@V]YXO
MTZSM%NX56V.G9G2Y28'R]_FYW[P<G;W)KK_ T$8\;^/9P@\UM1B0OCG B! _
M,F@#>3QOX<DUK^R5U)3=F8VX_=OY9E'_ "S$F-A?_9SGM3-5\;Z#IE_/IDVH
MA+Z) 7 B=EA+#Y=[A2J9_P!HBO,_#^EZA?\ PYTVTO\ Q?IUC:B\2-K=M.W3
MQW2W&=F_S0=Y<==O0^E=)X=O-/L[/XAQZI+$DBZK=/<)*0&,+1KY?!Z@KP*
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MZNY%EB=8YI%MI&BA9L;0\@4JI.1U/>@#=M+2VL+2*TL[>*WMXEVQQ1*%5!Z
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M*:]$8\^2)-J%^^T>GI7%7NK>*M3^(>IZ!H^I6%C;65I#/NN+,S,Q?.1PZ^E
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M3I90Z?IEG:&-#&A@@5-JDY*C X!(!QZU<FABN8'AGB26*12KHZAE8'J"#U%
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M?X'U4PBYT^SFN[3R23&UO*C'";N<*Y(Y]:];AABMH(X((TBAC4(D:*%55'
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M1)?7%ND!TM9,+&Y49;>,]/2K-GX_NM-\,>)+KQ!##+?:!<FV=K0%4NF(7R\
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M]V]K(MM/*,_(DI&UCP>_..,T:A\0M TZ\NK>5[R5+)]EY<V]G)+!;-Z/(JD
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MXH(C+/</@DX4>@&2> *U3X]T)-!&LS2SP6PNQ93+-"4>"8MC;(IY7&1GVYH
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M[;74S_HTZ+N0C:&W$]A@YH AN?":77C6WU.6"SDTJ/27L&M73.294<?+C;M
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MU:P^),2:W-JGFZ9:-#<W#1[KA5:0,4V*H958[<@=>]>@^+%5-=\!!0 %U(@
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MJ_-TW<#K[T >8V:J/AM\33@9.H:L3[_+5W5E5-+^&(4  7]J !V'V9Z]&%M
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M2Z5J>IVD>M216CO;/,HD8B:,LP7.2/E;GV->B?V?9&\^V&SM_M6,>?Y2[_\
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MCC,:J"0/F(Y(S7L4D:2QM'(BNC##*PR"/0BH$TZQCCBC2SMU2'/EJ(E 3/7
MQQGVH \OO55?@?X0V@#Y]*/'J9(\U>T'7-*\.ZSXXL]:NX(+M]3:Z2&5@'GA
M>) @0'E^A&!GGBO1C;0&%(3#&8DQM38-JXZ8'M39;&TGN8[F6U@DGB_U<KQ@
MLGT/44 <E\)?^26:!_U[G_T-J[2F111P1K'%&L:+T5!@#\*?0 4444 %%%%
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MK%KNEN;;4(ATW@<2*/[KC##MU]*\\UBUNI/A;XQU^[MI;7^VM3AN8()5VNL
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M;XB:3?Q[[:ZOHT<=Q^X3!'H0<$'U% &Y>:Q?1?$_3-(6?%A-ID]Q)%M'+JZ
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M0@[(]7#N0.BBY0DT =]>>,)K7XA6)>VU;[/<Z*[QZ6L696F\\#.S. 0H;DG
M'>NN\.^([/Q-8S7-I'<0M!.UO/!<Q[)89%QE6'/."#P>]<S:WUEJOQ@LKVQN
M8;JVD\.RF.:%PZMBY4'!'N"*L^!/^0WXU_[#;?\ HF*@#4\<ZE=Z/X&UK4;"
M7RKNVM'DBDVAMK <'!R#^-:6B7$MWH.G7,[;YIK6*1VQC+%02>/>L_QMIEQK
M/@C6].M%W7-Q9R)$O]YMIP/Q/%<WH7Q,\*6?A&R%_JL5I>6ELD,]C*"+A)%4
M IY?WB<CL* ,&\\;>(8O@YJ>O)J&-2AU-H(YO*3A!<!,;<8^[QTKK-?\2ZAJ
M&KOX8\)%&U-<&]OW7?#IZ'U'1I#V3\3Q7GFN:;>6'[.=W]O@DMI[N^%T87X>
M-9+D,H/H<8/XUU>H^&Y_AQ<#Q%X5@GN-."@:OIAD,C3H.LZ%CGS!R3_>% 'H
MUI#);VD4,UQ)<R(H#32!0SGU(4 #\!4U4M(U:QUW2K?4]-N$N+2X3?'(O?V/
MH1T([&KM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%<;\4=6U#1/ =W>Z9=M:W:S0(LRJ"5#2JI
MX((Z$T =@$0.7"KO(P6QR:22*.4 21JX'0,,UYAXIF\0^#-,CU6R\9SZM<"X
MBC73+N" _:]SA2BE%# X)/'I79ZWXKM]'U&WTR*QOM2U*XC:9;2R16=8P<%V
M+,JJN>.3R: -E;6W5@RP1 CD$(.*E5%3.U0,G)P.I]:Y.3XB:+#X9FUV=+N&
M"WNUL[J"2,++;RE@N'!.!C<"2">.F:CN?B-I]C8V=U?:3K%J+VX>WMHI;8"2
M4A-RD)NSANBCKG@@4 =>$4.7"@,1@MCDU&]K;RS+-);Q/*OW79 6'T-<W<>.
M(8/L%NNB:M+JEY$TZZ9'$GGQ1JVTO)EPJC/3YN<T6GQ TBZ%@/)O87N[]M.:
M.:(*UM<!2VR49X) XQD&@#J6174JZAE/8C(H(# @@$'@@UA1^+=-E\9R^%5$
MWV^*W^T%RH\LCY?E!SG=AE.,=#5&7X@:8%F6WL[^[N%U"33H;>"-2]Q+&,N4
MRP&Q>[,0.* .I6&)2I6- 5& 0HX%/KDYOB%I%KX>N-8NX+VV2UNEL[JWEC42
MV\C%0-PW8QA@<@D8/&:V=#UC^W+!KL:=?6*>851+V(1NZX!#A<G .>^#P>*
M-%$2-0J*JJ.@48%*54L&*@LO0D=*@OKVVTVPN+Z\E$5M;QM++(W1549)_*L'
M1_&MKJNHP6,VF:GILEU$TUH;Z)4%PBX)VX8X(!!VM@X[4 =-3418U"HH51T
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M$>OK4A52P8J"R]#CD4M% $8MX1.9Q#&)B,&0*-Q'IFGJBJ254 L<G ZFEHH
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MQGCO6-JOB+2_%'@_P[X?T>=9M7EN;(/:(#YMIY3*TAD7J@4*1S^%>M !0
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MG7X;Z9>20R0QZAXO^VP1R*598I))"F0>F1S^->\NB2 !U5@#D9&>:<0#U&:
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MK1%L5E:XG=VGNKEQAKB9SEW/U/;L !6S0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %4-;U>VT'0[W5KML06D+2OZG
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M(DC:FYA+F-YEM93'$P<IB1MN$^8'[V/7H<TL>LWS?%F?13<9TU=$2[$.U?\
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M# 9 R >,CBK]9'A?0XO#7A?3M'B((M8%1F'\;]6;\6)/XUKT %%%% !1110
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M[EEG%MY3VT@,4NX!EE&,H0#WQDX ZBNOT^^CU*PBO(8YXXY1D+/"T3CG'*L
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M(D-WM0%23]TG:V,UZW7,^(M O+BRACT*#2%47!FN;*]ME,%WD<[B%)5LX.X
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MVA&WCFD.$2=H8B 2> 652!ZXKU>>WANH'@N(8YH7&'CD4,K#W!ZU#-IEA<V
ML)[*VELPH46\D2M& .@VD8P* /.O[,M/&?BSQU;6TD<NGW.G6UD\\9W(;@!V
M!!'!*97/IQ5/P?J5QXY\2:"UXK?\4U8,;U6_Y_V+0X(]0L;M_P "%>J6=E::
M?;+;65K#;0+]V*&,(H^@'%$%E:VKS/;VT,+S/OE:.,*9&]6QU/N: /%-+L?M
M/@:72-5\;K81_;I+:?3A9QO*LQN"0!_&26*L"/7/05V_AN-#\0OB"Q4;C)9J
M3CJ/LPX_4UUS:/I;ZD-2;3;-K]1@71@4RCM]_&?UJPEM;QS331P1I+-@RNJ
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M$598)DP/,C8GY#G P,@Y'%9W@:2VL=9\9^);G5VO-.+P1/J<N DS1(?,9=O
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MFH6L=K>Z=:7-O'C9%- KHN.!@$8%.N-+T^\M8[6YL+6>WCP4BEA5D3 P, C
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M\4\D,;319\N1E!9,\'!ZC/>@#QKQ3%*]Q\0VBD,20ZEI4TSJF_9&JQEFV]"
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M12IB7RD)7:0""&)R#R#FKNL^.M(T2_N+2>._G:TC66\DM;1Y4M489!D8#Y>
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M[&UBA,]\7B# G>K,V2VP!<8Q4'@^:"Z\2> I(I(Y0GA9UW*0=K#RE(]B.0:
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MBSC>VWH">G<U0^'>LS:[H^IWDMVUU'_:UTEO(?\ GB'^0#VQBL'0;O3?"GQ
MUFVU;4([:.;2K V<]ZXB\V.)&1^6QSGDCKS4OPYUS3+'PKJ-_<RBVM;G7[E(
M=Z$<R2_(N,9!.0* ._U#4+72M.N-0OIEAM;>,R2R-T50,DUC:3XTTS5[F:U6
M"_M+F.W^U"&]M6A:2+.-Z@]1G _$4GCW5)]&\$:G?VR1-+&B*#,F]$#.JEV7
MN%#%OPKA(;RW3XCV:OXIDUO=H]W$+B3R1&)"8V\M#&H!;')7)(!'K0!UMO\
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MC2U9V3>JL'? PJ@,NXG&":Q/$G_)</!/_7K>_P#HLU9\)(O_  M+X@2;1O\
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MOA^ZFBF78\UN^W:D;NG#E@Q(R-WRUZ_U&#4-O:6UHK+;6\4*L<L(T"Y/J<4
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !02
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M;:MIEKJ-G(9+6ZB6:)RI7<K#(.#R.*M4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M** "BBB@ HHHH **** "BBL37O%V@^&'MTUG48[1KD,80RLV_;C., ],C\Z
M-NBL+1/&?ASQ'</;Z1J]M=3HNYH5)5P/7:<''O6[0 4444 %%%% !117,ZI\
M0_"FC:G/INH:Q%!>0;?-B,;DKD!AG"D="#0!TU%9VC:]I/B&S-WI&H07L ;:
M7A?.T^A'4'V-:- !116:NN63>)'T ,_V]+07A7;\OEER@.?7(Z4 :5%%9ZZS
M9OXADT,,_P!MCM5NV7;\OELQ4'/KE3Q0!H4444 %%%% !1110 45'!<0W4(F
MMYHYHB2 \;!@2#@\CT((_"I* "BBJ^H7L.F:;=7]R2(+:%YI"HR0J@DX'T%
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ML1TQ5?PYXBE3Q;X>M;?Q)JNL1ZFLR7C7=FT=N76(R!X&,:C&5(P">#^-;2^
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MC?\ AWQ)K'AU],U'6X U[<[KU[>(H([;C,,/?D#!9CGYC[8LZ?X2.A^*6O\
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M%"?9Q;Q[TVLNW)8A6^;(P2/3%=UK/AR;4Y?#CI/&G]DWJ7,FX']X!&R8'O\
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MK<NB>)M8T77;36M2L%:_L'L[>WLXF\J(LK R,S?,2=PXX  [GF@#FV?Q+:^
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M[%<EI 2"$SD<=^:MVF@RVWC;4]>,R&*[M(+=8@#N4QER2?KN_2@"E\/=2O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% $5M:V]G#Y5K!%!%N+;(D"C).2<#N22:EHHH
M *BDM;>6YAN)((GGA#"*5D!:/=][:>HS@9QUJ6B@ HHHH **** "D(# @@$'
M@@TM% $5O;06=NEO;0QP01C:D<2!54>@ X%2T44 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*6X+VJ+$$\F+ ^0D?>.<G)]:OT4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>5)0EO(5B,>[=O;&%Y5@,]<<4W3?B!X;U:.>:TOG:VM[;[5+<O"Z1(G!P7(
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M[33%%$P9H@I56) ^[C.TY[D"ND\'Q)_PLWX@2[1YAGLUW=\>0#C]: -D^.]
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MT ;]GH.CZ=Y?V'2;"V\MS(GD6R)M8C!88'!(XSZ4YM$TE]3&IMIEDVH+TNC
MIE';[^,_K6//XQTC2(=,MKFYNKBXO+,3VP2W:26X "CA5'+'<#C'J>@-7_#_
M (DT_P 26L\UCYZ/;RF">"XB:*6%P =K*W(X(H L3:%I%QJ2:E-I5C)?)C9<
MO;H95QTPQ&14DFE:=-J,6HRV%J]]$-L=RT*F1!Z!L9'4_G5NB@"C!HFDVNH2
MZA;Z990WLN?,N(X%61\]<L!DTV70='GOGOIM)L9+MT*/.]NAD92,$%B,D8XQ
MZ5H44 -CC2&)(HD5(T4*J*,!0.@ ["JDVD:9<7Z7\VG6DEXBE%N'@4R*I!!
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MA6=IQ$@F90K2!1N('0$]<4 >*:9(ECIGAC4[M@FF6?BB^%Q(W"1%VE5&8]
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M+*V6T7&(!$H0<Y^[C'7F@#B/B)'+#KOA&[35/[)MHKJ>)KWRT=87>(A,AP5
M.&7)Z;JYCQ+:VH\ >/[Z'Q&^N7,T=O%<S"!$173& I0!6.U@#C.,#->QW%O!
M=P/!<PQS0N,-'(H96'N#P:B33;".Q^PQV5LEIC'D+$HC]?NXQ0!P&GJK>./
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M,@C&/O$'.!0!WU%>4Z'XH\2GPCJWC#4]426UTW[7'%8+;(!<%&8(SN!D<X7
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M\P-M=R-&KK(@7<&"MAACTZ$UMZ/J]EKVEQ:EITIEM92P1RI7.UBIX//4&KU
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MQLGRKM(;.[N1_CTUCKECJ-QJ$,$D@:PD\JX,D3(JM[%@ PXZC(I;C6K"UO\
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MO[#Q?;W,^FO)K\$;+(LCJ(95 7R\;3E H^]U..G/'I,TR6\$DTF=D:EVP,G
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MAXT\2:Q*\1M]36U$*J3N7RD96W#&!R1C!-6;;Q5I%V^LI!<.[:.Q6]41-E"
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MC..V36E10!YRGA3Q3>Z9H'A[5&TP:5IDMO+-=PRN9;A8<%4V%0%Y RVXYQG
MZ58/AOQ18:CXBM=+;3#INMW#7'VF:1Q+;,\:HX"!2'^[D<CW]*[ZB@#S<^#/
M$.GV'@:?3CIT^H>'8)(9H9YG2.421!"58*3QC/2N_OK*/4M,N;&Y'[JYA:&0
M*>S*0<?G5FB@#S8^$?%=_P"&['PAJ3Z7_8ULT*37T4KF:X@B8%4$97"L=J@G
M<1UKJ-$T*ZTWQ3XEU.9XF@U.:"2%4)+*$B"'=QQR.V:Z&F&6,2K$9%$C LJ$
M\D#&2!^(_.@#S,?#K5QX6\&:9Y]EY^B:NE]<MO;:T8D9L)\O)PPZX^M)\4M+
M_M;7O#MEIMX(M5OWEL+A(^6:Q=<S,?0+M&/=J]"TO5[+68)IK&4R1PSR6SDJ
M5Q(C;6'/H1UIMKH6DV6J7.IVVG6T5_<_ZZY2,"23ZMU["@"Y!!%;6\<$*!(H
MD"(@Z*H& *DHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KS[XQ17,G@R(P7\ULOVZV21(U4B3,J
M8SD'H<$8[CG(KT&N;\=>'KOQ/X6ET^PFAANQ-%/"T^=A9'#8;'.#CM0!C3OK
M6H^+T\*0>(+NV@L-.6ZN[Z.*+[1<2.Y55Y0JH 4DX7FM+P3JVHW;:UI.JW(N
MKO2+XV_VG8$,T9571F X#8;!QQQ52?0O$\6N6_B6Q.D?VK)9?8[^TDDD$#@.
M61D<*6!&2.5Y![5J>$O#]UHD.H7.HW$4^IZG=M=W30J1&I("JB9YVJ% R>3S
M0!S_ ,7H;J7P_I?V?4)[56U6UC=8U0A]TB[2=P/*D9';US5.?2M4N/BP;"#7
M+B!U\/1?:+Y8HS/)B>3H"NQ23R3M[8 YR.I\=>'KWQ)X?2UTZ:"*\@NX;J$W
M&?+9HW#88C) /L*9INA:J/&9\0ZBUFK2:2EE)%;LS 2"5G)!8#*X8>_M0!QD
MOC;5=/\ #+65]K CNT\0RZ.VJM I984!<R; -I?:-O3&3FM_P+XD;4-=U32$
MUF76K."&*XMKV:$)(-Q97C;"J"00"#CHWM3&\"ZE':WLUM>6J:DOB"36;%G#
M&/##;Y<G&1E2P.,XR#S73:%%XB\VZN-?GL1YFT06MEN9(@,Y)=@&8G([ # ]
MZ *'C_Q!-X;\+/=VTR07$T\5M'/(F]83(X4N5[[1DX[XKF_#OB";4=?N_#^G
M^*[K4X+G3GGAOY;9%EM)U8*1]Q58$,& (/W2*['Q7H4GB#0VM(+A;>[CECN;
M69EW!)8W#J2.XR,'V)JE;1>-I([Z>[FT:*?[-Y=G;0%VB\W/^LD=E#?\! _&
M@#F](\4>(O$&K6?A</\ 8M4TN3=KUTB*59%X01Y!'[W(;./E&:S=/NK_ ,/^
M)/B/KDNK75TNF!)/L\B1A9S]GR@8A01MX VD<=<FM^W^'L^C)I&HZ-=QG7K:
M5FO[FX) U!9#F82$ GKRO!VX%/E\%ZG+XB\4K)+9/H7B*(+.2SBXA80F/Y1C
M:1G!R30!B>'O&$JZ_H,*^*I=;;4F,5];/:B-;=RA97C(12%##:02>H-5EU7Q
M;<?#B_\ %W_"2RQ3V$EPT-LEO%Y<R1S,,2?+DD@$<$8 '?)KM=#LO&4-S8P:
MM>:4+"SC*.UJ':6\(7:I8, (_P"\=I.2,=*HP^"K^/X6ZCX6-Q;&\NA=!)06
M\L>;*[KGC/ 89XH RE@O[[XX6TR:Q=PQ-H*78A5(RH0SJ&AY7.TD9)^]GH0.
M*].KBY_#.MVWCC2]?TV73WB33%TV\BN&=6""0.7CV@Y/48.*VO#EWJ=VNJ_V
MEY9\K49HK9HT*@PC&WKU(Y!/J* ,7XKZYJ7ASX=:CJFDW)MKV)H@DH16QND4
M'A@1T)[57U.[UW4?B'!H%EK$FGV,FBB[F>*)&D#>;M^0LI )R.H(P#QDY&G\
M1?#%WXP\$WNB64T,-Q<-&5>8D*-KJQS@$]!Z5/'X?N4\>IKYEB^S+I'V QY.
M_?YN_/3&,>] %3P%J6HWEKK-EJEX;V?2]4ELDN615:5 %92P4 9PV.!VJUXU
MOI=/T..2/6X-'1[A$ENY%WN$.<K$I!!D.,#@]SVI_AG0;C1+G7I9Y8G&HZG)
M>1",GY49$4 Y'7Y3TJ+Q;H>HZI+H]_I+6AO=+N_M"0WA812@HR$$J"00&R#@
M\B@#C+?QY>Z=X<\726^HRZO_ &6UNMC=7EOY4C&?"@.NU<A7/7 R*Z,V_B7P
MHEQJEYKQUG3(+&:>\CNHTC=)$7<#%L4?*<$%6/'')K.E\!:SJK>)8]7O[,QZ
M];0EY+<,&MIXC\@12/F0?*<D@DCH,\:EOHOBO5[CRO$U[I\>G"TEMY+?32Y^
MU&1=I=]X&T 9PHSR>M %;P]:>+[FUT/7G\0+<B^6.:^L)H42&.)UW8B*KN#+
MD=2=W.2*R(-0\3ZYX-U'QK:>()K0Q_:)K+3E@B:#RH68!9,KN8ML.2&&,\5L
M:+X?\962:1I5UJNGII.EL@^T6H?[1=QH,)&ZD;5!&-V"<X[54_X0[Q18Z'J'
MA;2[S2UT.[>81W,WF?:+:*5B70(!M8C<V#N'6@"M-KFO^)_&&D:;I6K/I=AJ
M/AZ/4I"D2.\9+CE2PZG*KSQC/&:T+677O$GBC7HK37Y]/M=&DCM8(XH8V$\O
MEAW>7<I)&6 PI7CN#6E8^$7T[QM9:K;R1C3K30QI4<1)\S(D# ],8VC'7KVJ
MK)X>\2Z7XFUB]\/W&F?8]79)9A>;]]M*J!"Z!1AP0 <$CGO0!RGAK49K+X4>
M&1+X@CT.&:XN1<21IYEQ)^]E(2%2K9.>IP< 5-_PF>MGP'J%Q8:F;F[LM=BL
M+>\GMPC3Q,\1'F(5&#B0J2 #QGBM'2_ >O\ A_3?##:?<:;=7^CK=PNMT[K'
M(D[[MP8*2&&!VYR:5O 6OR6.JV=Q?V$PO=6M]4$WSH0ZF,R)MP0%_=X7DGIG
MUH M?;-8\+^-["RO]=N-5L=0L;F>1)X8T,4D(5LIL484AB,'/UJ/PXOC#6M)
MTGQ1'KREKUTGFTN6)%MEMF/W58*7WA<$,2<GKQ70ZOX=EU/Q?HNK;XOLEE;W
M4,T;$[G\T(!CC&/E.>:PM(\+^,-+L]/T"+5;"+1+&92MW%O^UR0*V1$5(V#C
M"E@>G:@#E;_XA7#1ZMK$/B=X+RSNY4M-%6U#12Q1OMVNVPL7<*3D,,9%>S0R
MK/!'*N=KJ&&?0C-<5!X>\6:.]YIVB7NEQ:5<WCW,=Q,KF>U$C[W54P4?DM@D
MCKR#7<4 >:W'BK6;#1/&-E+=^9K%EJ*VNGN47(6XV?9^ ,$C>>HYV\TD7BC6
MKKP[X:T]+PKKMUJYT^\E$:[ML#/YS;<8&50=OXZU-8\$76H_$/3M>BN88].3
MRI+VW.=\LL/F>4PXQP9.<_W11IO@BZLOB/>Z_+<POIA\V:TMAG?'/*L2RL>,
M8/EG'/\ $: .7O=;UK6?#WQ0MYM5EC32Y)DMO+CC!6((Q,?W>AQC/7T(IKZ?
MJ<9^&=O!K$KW4RS,ES-%&3 AM!E54* <+G&X'G&<UT=IX!O8[;QW;S7=N%\1
MR2M R9)B#HRC<"!Z]J?I?A;7S/X1FU633%?03+&XM7D821F#RE(W*/FSDD=,
M>M %CPI=ZI:^+]?\.ZAJDVIPVD5O<6T\Z(L@$@?<K%  >5X..]2?%!)V^&NO
M-;W<MLR6DC,8PIWKM(*'(/!![8/O5^PT&XM?'&L:X\L1M[VUMX8T!.]3'OR3
MQC'S#'-6?%.COXA\*ZII$<JQ/>6SPK(PR%)'!/MF@#SN[T[5$U7X<VD&LS-=
M2PW9%Y-%&6B0P(2%4*%) R!D'D@G-3WGBK6?"=KXSM+G4VU%]*6T:RNKJ-0Z
M_:#M^?8 &"MSTZ5O:?X:UZ34/"E[JSZ:DFBI<12K:N["17B5%(W*.<@D_P!:
M35? L^K:AXJEDNXXHM7@M%MG4$M#)!N8,PZ$;MIX/8]* ,SPOXI+>,+/2;?Q
M-/X@M;VVE>1Y[81M;S)@Y!5%&Q@6X.<%>M=OXB2=_#FHBVNY;286[LD\04LA
M SQN!';'3O5'1HO%KZB)M=GTN*UCA*""PWOYTA(^=F=05  .%&?O<DX%;5Y;
MB\L;BV+;1-&T>['3(QF@#Q_2-9O/#'PH\*H==E@&K211"YE@1_L,.QF;8 OS
M'Y<#=NY;VJQ+XWOK?P[XOBTS7YM3&G64=U8ZE+;JLBEB0R,-@5B"H(.WHWM6
MQIW@OQ);>$=(T^:YTI-2T&X273IHS(T<JJK*5E! *[E8CY<XZUI:KH'BCQ'X
M3U[3M5N]-BN+^$0VL%ON,4&.I9RH9B?I@8&.] &1K%YXKT?P]H]X->\W4-7U
M6SB*/;IY5NLF<QJ ,E>1R3DXZC-/6+Q/'X]E\*_\)7=O9SZ:-0-V]O#]HB(D
M*%$PFT D@Y*G &!US71:_P"&KK5M,\/VT,T*/INH6MW*7)PRQ?>"X'4]LU/_
M &#<?\+$_P"$B\V+[-_9/V'R\G?O\W?GIC&/>@#A_P#A*-?B\(2BZU.X46&O
MS:9?ZM;VJO*EM'NQ+L"D YV*3M.,YQ7;>#;E[O2))AXAAUVT,Q^S7B!0^S ^
M63: -P.>PXQD5EV7AOQ+HEKJ+Z3>Z>;BYUJXU#R9PWE30R]$9@NY&'!RH/(Q
MR#58:9X@\-Z+K6JP_P!G1ZOJ5]!+]FM8V:!!F.,A<@%F89); Y/M0!W]>9:W
MKNH+XRU'3[GQ4_A^9&C&DPSVR?9;M2BDEW9?F)<LN RD8&,FO3:XGQ/H/BK6
MH=5TA)M&N-(U %4DO$836BE0#M55VN0<LI)!!//2@"[H6JW]WX[\4Z=<S[[6
MQ2S,$84 (7C8OSC)R0.M<#-J6LZ_I/@>Y-\!J4NO7<*W+1*=BJ9T!"@ $J@X
MSU(&:[ ^&O$>D>*+W4= N--DM]1MK>&?[>9-\3PJ5#J%&'R#R"1SWK+@^'FN
M6?A_PW9VVIVGVS1]2GO3-(&*RAVD*@@ ==X#=,<X[4 68-1UK0/$NL:!=:Q-
MJ4?]C-J=I<W$<8EB96*,IVJ PSM(X]JP[;QWJ1^&OA*YO]8^R7FLSO'<ZEY"
MLT4:&0L54+C<0JJ."!G-;UQI.I6T^O>*?$]SIL$[:2]A;0VLC&..,;G8EG"D
ML6QVX [UC^"-!OM3^$W@^\TR6&#5-,D>YM_M /EN"TBLC8Y 96/(Z<4 1Q^/
M[VSTGQ!;:?JQUA[=[6/3K^Y@"MF=_+(<!5#%",YP,@BNEGT7Q5IMO?@^*9KN
MRDL9&:>:*);B"=>08]J;2A&00W3C!J34/#>O^)O#>IV6NW]G;W-P\<EDEDI>
M.T:,AE;<P#.2P&>!QP*FLM+\6ZA>R2^(+[3[>U%H]NMKII=EE=^#(Y<#& .%
M'J>: *GPDM;BW^'&CR37\URLUNCQQR*@$(Q]U=H!(^N3[U2^*MM=S/X2%MJ=
MQ:++KUM 5B5"-QW$2?,IY7;P.G/(/%;O@+1M:\/>&K?1M7:P<6:"*WDM&<[T
M&>7# 8/3@9H\<>'M0U^PTMM*EM4O=-U*'4(ENBPCD,>X;25!(SNZ@=J ,E7U
MOQ!XNU/0H/$%W86FB6]LDD]O%$9KJ>1-VYBR$  8X4#))K7\":U?:QHMW'J<
MB2W^G7\^GSS(FT2M&V ^T=,@CCUS5!]!\3Z=K]SKND'2'N=3MH4U&UN9)%C6
M:-2 \;JI)&#C! S@<UL>$?#TGAS1GM[FX6YO;FYEO+N9%VJ\TC;FVCL!P!]*
M .7^)]K>7&J^#TM]5N;-)=8CCVQ)&=K;'(D^93R.1@\<]*KV>E:K?_$OQ9:V
MNNW%@B6NG^=<PQ1F:5A&X7[RE0/O$X'IC KI?&WA[4M<CT>XTB6T6]TS4$O$
M2[+".0!6!4E02/O>E2Z%H5_8^*=;UJ]DMB=3@LU\N$L=CQ(P?J!QEN/;KB@#
MA?\ A/=0;PQX;M]2UD:?<7UU=P7FIQ0!FV6[,N43:0&<[.<$#GBNI\ >(I-8
MDUBP;4GU6&PFC^SW[Q>6TL;KD!@% +*0PR ,\52M/ VL:7I6DRV-U9'6-+OK
MNXC$I?R98IW8LC$#<#AE.0#@KWKK-"BUQ(;B77KBT>>67='!:*?+@3  4,P#
M,20220.O H S_'&LWNDZ39PZ;(L-]J5_!I\,[H'$)D;E]IX.%!P#WQ6+K%UX
MD\":%K>J3ZL-9L(;,/;&[15G2Y+;0#L55:,[@?48Q[UT/B_P_+XBT>*&TN$M
MK^TN8KRSF==RK+&V5W =0>0?K6-<^%O$/B>RU:V\3W]G!;W=G]EAM-.+O'&V
M=WG,7 );(&!TP* *EV_B+PA>>'KN]\0W&JQ:C?Q6%[;SPQ*BM*" \6Q05 8#
M@DY!K.6[\5:OH_B[5(_$LUD-'U"^CLXH;>(AQ$20)"RDD8PH P>"23GC;'AW
MQ1K5[HJ^))]*6RTJX2[S9&1I+J9 0A8, $ )W$ MS5O3_"EY:>'O%&G// 9=
M7O+VXA92=J+,#M#<=1WQF@#&AUO6?%NN:+IEMJDNDPR:%%JUW+:1H9'>0A50
M%U8!1ACTYZ5SC:IK7ASP5\1[^*^ U6UU90MTL2_-\L*[MI! )4\CID\5U<7A
M#7]&NM#U/19M-EO;31X]*O(;MG6.14P0Z,JD@AL]1R#VJE<_#O6[OP9XMTJX
MU"RDO]<O%NEE 98T/[LD$8) !0@=>,9H K:O!J6I?$7P.XUR[MS<:?/+^[CB
M(1A&A;&5/WL\YSC'&*L)XVU.PU_XD/<S?:+30H();.W9% 4F)F(R!D@L!U)K
M6U?PMK?]K>%]5TB73VN=(MY+::*[9U1U=%4E2H)R-O0BF0> 99==\<3W\\36
M/B.***-8B?,C"QLA)R,9R<C&>E &=<W/B7PSI>B>(;WQ#/?BZN;>+4+*2")8
M568A?W6U0RE2PQDG..:6&7Q/K]SXM\KQ)/80Z5?RQ68@@B))$:L%<LIRHST&
M"<G)Z5:7PKXIU2WT?2==NM*.EZ;/#,\UJ9#-=^5R@96 5 2 6P3TXQ6WHOAR
MZTT^)O-EA;^UKZ2YAVD_(K1H@#<=<J>F: .,N/&-_>:9X7O-4UNXT#3;_3!-
M-?VMNK*UUE1L9F5@BXR1P,],\5Z/H3W,FA6;W=];W\[1@M=VX CF]' ''(P>
M./2N6T[0/%N@>']'TW3I](O(K:P6UN;6\+K&7'_+1'5"3D'!4C' Z5O^$="?
MPWX8L]*DECDDAWL[1KM0,[LY"CLH+8'L!0!C>-=2:TU&PMY?%)T6TDC=BEI"
M);J=P1C"E'P@&<D#K@5SEMXM\1:KH/A#[)J:1W5_J=Q8W%R;=?WJ1^:HDV$<
M-A V..>#QQ75:QH>O+XQ37]#?36:2P%C,E\7'E@2%PZ;0=W4Y4D9P.:Q](\!
MZS82:-%<7MG-!I>KW%ZLV6$DT<HD^\-N ^Z3L<8H B?Q!J_A'4?%-E>ZG+J\
M-AHZZG:O=1HKJV74H2@4$$J.W%9>NV&O0Z3X.O\ 4M?FU$W>M:=)<P2PQJD3
MLX8&+:H( Z8).<YXKK]5\&OK'B'6[JXGC6RU/1AIN%R9$;<Y+8QC&'&.>HK&
MD\)>,M3L_#]CJ=[HZV^C7UK<;[<R%[H0L.6RN%.W/ SDGJ * /2*\P7Q5K9O
M/BC&;X[=%ME?3QY:?N&,,C9Z?-RH/S9Z5Z?7 +X$U 77Q E^TVN/$D CM1EO
MW9$3I\_'JPZ9H HF^\2Z7!X1URZU^6Y&K7=M;75@8(UA59D)!0A=P*G')//L
M.*]-KD]3\+7=[HGA>QCF@632+VTN)F8G#K",,%XZGMG%=90!YGH>K^(+V]\4
M:Q?:S(-+T'4[R..SCA0>>B+G:S8SA01C'.<Y)K*T3QU</=>'KL^*7U*ZU.XB
MBOM+^R!8H!*./+8("-C%026.1FNX\/>%)--M/$MK?R12PZQJ5S= 1$\12@#:
M<C[W!JMH&D>,=,33-*N+_2_[*T\",W$2N;BZB5=J*RL-J'ID@D\<8S0!RGAV
M[GL+[XM7EM)Y=Q;S/+$^ =K+$Y!P>.HK0A\1W]W\.?"^H:AXG32VOE!O+I8E
M:XF^4X6) A&2<9^7@"M&Q\#W]K_PG>^YMC_PD)<VV"W[O=&RC?QZL.F:KVG@
MK7M'TSPB^GRZ;/J&AV\UM)'<NZQ2"0 %E8*2"-H[<@GI0!CCQGK;>#+V2PU4
MW-U::_#I\%Y<6P1IXG:,@2(5&#ARI( .!D8K<^W:QX6\:VUEJ&N7&JV%[IUS
M=.L\,:-%)#M)*;%'RD,1@Y^M53X"\021:C!<7]A,MYJ]KJIF^=6#H8_,3;@@
M+\F%Y)Z9]:Z?5O#<NI^,-*U5GB-G:VEU;31,3N?S=@&.,8^4YYH P/#D?C#5
M]+T;Q,FO*[7S)/<:9+$BVZ6[\[4(7>'"D8))R>M<SJ/Q!N&76=6A\4/;WEC=
MRQV>C+:AHIHXFV[7;86+/M)R&&,BNJT?PSXPTRUTW05U:PCT73YE*W<._P"U
M30*<K$RD;5R,*6!/ Z5-#X>\6:/+?V&A7NEQ:9=WCW27$ZN9[7S&W.JI@H_)
M8C)'7G- ':6\RW%M%.H(61 X!ZX(S7-^'M5O;WQEXML;B<O;6,]LELFT#RPT
M"LPR!DY))YS745Q4OA_Q+I_BW6-1T2XTS[)K A:8W>_S+=T39N15&'X ."1S
M0!S&G>)?%&K:3X#C@U;RKK6);R.[G,$;$JF\@@8P" O';.,YZ5:U'Q7K/@B3
MQ187E^^KFSTV+4+":YC17!=S%L?8 & ?!Z#C-49?#>J^')_AQHEO=VQU&TGO
MRDK!FC?]V[X;@'!!P3CC.>:Z%_ FH>(?^$AN?$T]I'=:K9I8PI8EG2VC0E@=
MS!2S;SNZ#I0 R[?Q%X0O/#UW>^(;C58M1OXK"]MYX8E16E!"O%L4%0& X).0
M:S5N_%6K:-XMU1/$LUD-'O[Z.SBAMXB'$1) D+*<C&%P,'@DDYXVQX=\4:U>
MZ*OB2?2ELM*N$N\V1D:2ZF0$(6# ! "=Q +<U;T_PI>6GAWQ1ISSP&75[N]G
MA92=J+-G:&XZCOC- &[X?U"35O#>EZE*H62[M(IW5>@+H&('YUP^I65_/\=;
M 1ZU=P1#2'G6-$C(51+&&CY4G:VT$GKZ$"NX\/Z?)I'AO2]-F='EM+2*!V3.
MTLB!21GMQ6%K'A_66\>Z;XDTF2P98K-K*YANV=3Y;.'W(5!RW'0X% '#Z9!K
MT/@WQ9K.GZ_-8#3M1U&X@MXH8V24H[.?,+*2<XP ",=>:TM6\;_;=:M+&Z\1
M2^'[8:7!>N]M )))II<D+ED8!% ],G=UXKHK3PA>V_@GQ)HC3VYN-4DOGB<$
M[5$Y;;NXSQN&< _C4*^&-?T6\LM1T*339;G^S(=/O8+QW2-S%G9(K*I.1N88
M(Y&.E &IX$URX\0^$K:^NV62Y#R0R2JA192CE0X!Z!@ V/>NDJEI$.H6^E01
MZK=QW=\ 3--''L4L23A1Z#H._'-7: "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***XWXF:MJ>C>&+
M>YTBX\F[;4+:)6(R&#. 5/L>] '945YAXAU&Y\-WNC^'K_Q5JBQ78GN[O44@
M#SD+L"QH$0A%+,3G;P!C/-9TGBS79?#\-OINJSO,GB.WL+?4+FVV-/;R#(+J
MRKD@D@X SM]Z /8**\_CEU;PSXXMM(FUN]U.RU/3[B9#>!#)#-%M)*E57Y2&
MZ8ZBN=TK7_$5E\*/^$VO]=GN+RXMEMX;=HU,,)>98Q*5"Y9^K>G.,4 >Q45Y
M5I?B2]AUE[#0M9U/7Q<Z=<2*-0M&C,-TB@IAC&@VODC;SC%3>%?$("3WA\57
MU]=6MA)/J6D:G L<T<BJ#F-=JE0#D'[PY% 'I]%>.:'XQNGF\/7Z>(=2U&_U
M&XB34-/>Q9;:-)>/W9\L;?+)7G<<@'UJVLOB35?#OBW6/^$GOK1](OK];**W
M6/81"S$"3*DL.-N..!W)H ]4:>%)XX'EC660$I&6 9@,9('?&1GZU)7DKI>:
M]\1_!U\^K7UL;S16NS' 4"QDB,LJY4_*W?//'!%1^)/%$^EWFI:A;^*[VYOK
M2_5$L+6S9K)(MZJ8I'\LC?M)R2X(/I0!ZT)X3<-;B6,SJ@<Q[AN"DD XZX)!
MY]C5/2-8M]:M9+BVCN(TCE:$BXA:-B5ZD!NH]ZX72-.N'^-NOR-J]^4@M+:0
M1;DV,K%R(S\N=JDDC!!]2:R-'\9Z_-\/;B;[>7U6\\0_V5:W,J*WD!W50<8P
M=HSC/>@#V&BN#1M3\*^-]"TV36[[5+#6%GC=;[8SQ2QIO#*RJO! ((KDX]3\
M3CX3Q^.)?$MX;VV_>):JD?D2(LVPB0;<L2,\Y&.,#CD ]HHKS#Q+K%U!XOO[
M74O$]]X=C"Q?V/*(5^R3$H"QE8J03OR"I9> ,=:])9W2S+M)$'6/)<\)G'7V
M% $U%>2:-XFGA\1>'A#XIU#6FU&X:WOEDLV2S.8W8- YC4##*  &.12+/XEU
M'P?XFU\^)[VVFTFZOOL<,"1[&6%F($F5);IMQD  #J<T >N5GZ7K-GK#7RV;
MLQL;I[2?<I&)% ) ]1AAS7%1ZCJGB_Q3::;'JUUI=G#HT%_.;'8'DFE)P,LK
M?* #QW)YJQ\+TN8H?%<=Y,)[A/$-PKRA0OF$1Q#=@< GK@4 =[17GM]XIOO#
MVI^-X;VX:5;2SCU#358#.UT*;!ZCS5Q_P*LE?$7B*V\!7.D7&H.WBA-7CTE+
MDJN[=(RNKXQCB-CV_AH ]8HKR/QEXDGTF;7+R#Q;?-?Z<0UM86=FTEM&JJI*
M7#",C<WS9)88R.E:^KW&N:U\38] LM:N=,TZ31$O93;JID#><R_*6!P3E<GT
M!]: /1:*\[TEM=UOXB^(K.37;JWTO1[JV:."%4S,6B5BC$C.S@Y Y.[J,5BZ
MGXHGT_4C?0>*[V^O$U9('L[>S8V"PM,$,>_R\!PI^]OSN&* /7JCEGAA:-99
M8XVE;9&&8 NV"<#U. 3CV->?P1:YXE\5^++#_A([[3[+3[B);5;0(&#-"K?,
M64_*#S@8SN//2N7FN=3\5VWPTU"ZUB]MKB]ED24VVQ0)$20>: 5(#'D'M@\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!!-96MQ=6]U-;
MQ27%L6,$K("T188;:>V1P<5/110 4444 %%%% !1110 4444 %%%% !1110
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MAJUU9+^^CO)[_4I+YI40KRZH",=N5/'/&*Z:B@#B_%_@>;Q)XATC48+N."&
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MVB6ZB4==X&"RY^IQ6EX NIX/ATMA8/9)KEA++'>Q7CE0DWFDNSXYY!R#WR*
M.CNO&>AVVB66L"Z>XLKZ58;9K6%YFD<YPH506S\K<8X(Q1I_C+1]1U*+3@;R
MUO)@S0PWUE-;&4 9.WS% ; YP.:X'4=8OM<T+0I;:+2X+J'Q8MO$]N&>VD95
MD^<8P2"2>E;.W6+[XBZ38>*+FRC2T1K[3190,BW4@5D<,SL2"@;.T=0V<\8H
M V_^$_T9I[B*&#5[G[/,\$CVVE7$J!T)5@&5"#@CL:L7WC32=/&GB>/43+?Q
MO+!!'I\SRE5QN+(%++C<.H'6N0\'P:Y)!K;6'B.PL8/[;OL0S6'FL#YS9.[S
M5_E5OQ''J,GCWPDMKJ]K;W@TZ\#W;VV^-R/)W83>,9/^T<>] '3P>+]-FL;^
M\>'4K:WL8&N)WN].F@ 1022-ZC<< \#)J_HVLV'B#2;?5-,G\ZTG!,;[2N<$
M@@@\@@@C!KF/$$>IQ?#[Q4-2UFTU$G2[@Q_9[7R=G[I\Y^=LYX],8]ZY2#4;
MSPA8SZ%8 B;Q!:P7&CGLEQ*$CF'_  $E9?H6H [R/Q[X=ETO5M2BOF>TTF8P
MW<BPN=K9 X&/F'(Y&:?:^,]/N[N&VCL=;5Y7"*TNCW*("3C)9D  ]R<5YC?Z
M7!HG@KXCZ7:?+#:RV<*$]3B& 9/N>IKTRP@U^.^A>\\4Z;<VX;YX8].\MG'H
M&\TX_(T 7]+\1Z5K.H:C8V-T)+K3I?)NHBI4HW/J.1P>1QQ56?QAI<,+2I'J
M%RJW$UJWV2PFGVR1-M<'8IQST)X/:N(M+.XL9=:\5:;$TEYINMW:W,"=;FT)
M4NGNR_?7W!'\5=)\-KN"_P!#U2\M9%EM[C6;V6*1>C*TS$$?4&@"[HWCK1]?
MFA33HM3D29F5)VTV=(LKD',A0*,$$<GJ,=:Z6N*^$_\ R3JQ_P"OB[_]*9:[
M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ[0>3^% $]%13W,%K&)+B:.%"P7=(P49)P!D]R:EH **** "BB@D $DX [T
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MSYPH PJ]^N:M7_@V#3-=TO7?#&EV%O<V[F&ZMXHDB6>W?[V,# =3A@>_([T
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M6Z^/"_A34=:,7G-:Q;DCS@.Y(50?;<16)J7AG4KGPGX2T^-(S<:9=V$UR"^
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MJ/&%$13&[(QM!S@ Y[8(!J7.N^(=6\:#0]'N;6QM9-(AU W,T'FO&6=EP%W
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M,RI9(5B5B<D*#V]^_7BM"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBN:\::W>Z/86$&F>4NH:G
M?16,$DJ[DB+Y)<KQG"JQQZXH Z6BN"U76/%'@K0M:OM4GMM8MX((VLKGRA"Y
MF=]GENBG!7+*<C'&12RW_B?PMJV@G6-7M]4L]4NA8S(MHL)@E924*$'E<J0=
MW- '>45Y7_;OC*_\->(]=M]7M+6/1KJ]6* V:R?:4A9CAV)&W@;>.>"<\X%K
M4_%^HW>LV-JNO6?AR*ZTR&\M7NK=9%NI7SN3>Q  7"\#YCNH [NXUK3K35[/
M29[I$O[U7:WA(.9 HRV.W JU<W,-G:S75PXC@A1I)'/15 R3^0KB;[Q%K5G\
M0?!FBW!M574;6=[Y85W*9$BW?(Q&0N[]*QK[4_$WB3PIXJUJVU&WATV#[9;0
M:>;8'S8HPR,S29W!SAB,<#CK0!Z=:74%]9P7=M()+>>-98G'1E89!_(U-7DL
M'BUK2Q\,Z"OB.P\/Q)H%M=RW=TJ,TC,H58T#D#^%B3R>G2I'\?:[?Z)X<;2Y
M[![Z]U:;2YYE3?!(5#@2KS]WA7P#STS0!ZM1G%<#KU_K&B)IUIJ/C;2M-3R7
M:6_GMXQ-<R[N%6(G:%"GDC)^E<OJ>LZUXITCX?ZC%JD5J]WJAB?RK<.AEC\U
M1*,GD':?E]_:@#U==:TY]<?15ND.I)!]H:WP<B/.-WIU(J_7"1>)M0MOBE>Z
M'=SQR:?::$+UF$0#&0. S9],9XK';Q'XOB\#+X\?4+4VI5;LZ.+4;?LY;H)<
M[M^TYSTSQB@#U.D "@   #@ 5P?]I^)->\::YHVEZK!I]C906LR7!M5ED!D1
MCM ) P<$DG., #KFMGP)K=[K_A*WO=1\O[:LLT$S1+A6:.1DW =L[<_C0!TE
M07M[;:=8W%[=RK%;6\;2RR'HBJ,DG\*GKQ2"'5VT'XIS7FKBYCC^UPR1_9E7
MS'%NH#Y!^7"@#;0![/!-'<V\<\+AXI5#HP[@C(-25YG::CXGT&U\'WEUJ5M/
M8:G-;V,FGK;!?)$D9*E9,Y8C:,YX.3@"LS4OB3<(NL:M#XGTBV&G74L4&ARA
M/,N8XFVL68MN#MABH QTZYH ]?HJ."9+BWBGC.4D0.OT(R*X6SU7Q-K7Q$UW
M2;;4;>STO1[BV=B;82/*CQJQB!)& ?FRW)&1B@#OJ*\=C^)\S6<?B#_A)](,
M;W84Z  GFBW,NS.[=N\S;\_3';%=(VH^*O$FHZ])H&IVMC;Z1<M9P6\MJ)/M
M4R(K-O8D%5RP4;?K0!WU4-1UK3M)FLH;ZZ2"2]F%O;*P/[R0]%&*X76_&5W_
M ,)"-&N/$6F>%WMK&&XN'N-DADGDS^[3>0"B[>2.3D=*JR_$'4KO2/ U[;M:
MA]4U<6-Z8U#HX5RC%">@)7(/H10!ZG1G%>?I?>*]>\7^)])T_5[?3;32Y85A
ME-HLSL7A5MIR0, Y)/7D8QBN8O\ 6M=\50> ;P:A'87$VI2PS1I;AU2XB$J&
M09/((!^7WH ]GI-H#%L#)ZFDC5EB17?>X #-C&3ZX[5Y=XL\::EX>O=1NY/%
M&CQR6DZ^3H:*LCS0Y7.]L[E<@L0 ,# ZT >IT5PLU_XEUCQUKNA:=JD&G6=C
M!;2K.;599 SJWR@$@8.,DG.,8'7(RK3QGX@U70_#FGP3VUOK>IW]S9S7@AW(
MB6Y?>ZH3C<0HP#QDF@#T1=3LVU9]+$ZF^2$7#0X.1&25#>G4$?A5NO.O#\6I
MV_Q@U.#5+J.[ECT2$1W"1>69$\YR"R@X!R2... >*[/Q!<WEGH%[<:?)9Q74
M<1,<EZ^R%#_><^@&3^% &E534-3L]*@2>^G6&-Y4A5F!Y=SM4<>I(%>=Z1X]
M>UU+5[>3Q%9^)+6TT>74_M%O$L1C:,X:,[200000>OUK-\0GQ1<>$?#VJ:MJ
MEM=17^HV$TMJEJ(Q;;I%90C Y8#A3NSG.<\<@'L-%>4:UX_N?[1U^2V\4Z/I
M9TB9X+?3;I4+WC1J"Q8E@P#,2HV^F>:UX/$.M>+_ ! EGH6HQZ590:9;WTTC
M6RSO(\X+(F&( 4*,DCF@#T"BO+K#QGXB;3K5[V6W%TWBW^R)A'&-HA!(*K^(
MX)YKJY]:OD^)$6B1E#9MH\EWL(P3*)54?-V&": .FHKRW2_&FH1>)M%L[KQ3
MI&K2ZA<-;W>GV*+BT.QF!1P<L 5"G=USVJ]8ZIXR\1V5SXAT6^LTM4O)(K32
MY;<8N(HY"A+RYRK':Q&.!QUH ]$HKD-$\27<?B/Q+H^N2QJVGE;RVDVA<VCK
MD=.NPA@35OP+J>IZWX6AU?5,*]](\\$00+Y4!;]VI]3MP<^] '24V21(8GEE
M=4C12S,QP% ZDGTKD=>U75[SQE:>%]&O(]/8V37]U>-")6";PBHBGC).<DYX
M%<[K&IZ[J'A#QQH5YJ,*W^BPN9+J.V&+JW>!G4%<X1B,@D=,<"@#O-$\3:-X
MD2=]'U"*\2!@LC19P"<XY(YZ'I6M7%?"NTOK;X?Z.]U?K<PRV4+01" 1^2NW
M[N0?FZCD^E7[[6;ZP^(FE:9*Z?V9J5E,(EVC(N(R&//H4)X]J .FJH-3LSJQ
MTH3K]N$ N3#@Y\LMMW>F,@BN \.?$"]N(_$=[JQB^QP6LFIZ:%7:3:K)*G)[
MG]VI_P"!BLO2O^$GU3QSIK-J$-GJ=SX6BFN[HVX<Q[IV;:J<#/(&3Q@'C- '
MJ&KZQI^@Z9+J.J726UG$0'E<$@9( Z>Y%758,H8'((R#7D^K^-_$&F_"[Q'?
MO<6\NK:-JAT_[3Y "S 21C>4Z E7Z5TNI:IK>K>+$\.Z-J$6FB#3UO;J[-N)
MF)=BJ(JL< ?*Q)Y[8H ZFXU.SM+^SL9YU2YO2XMXR#F0JNYL?0<U;KRS6_\
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M9M^?ICMBNEBU/Q+XBU?Q#-I6HV]I8Z1<M9PVKVPD^U2(@9][YRH); V].O-
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M*VX*<<@'C/UKRZ^\&^*9O#OB'PY:V^FQPW]U/=C4FG)DG#OYBHR;>#G"EB2
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MSN64@[!C_5MG)'8]!4M]X5U&X\#^%](3R?M6FSZ?)/E_EQ"5WX..>AQ7;T4
M<(FE>*?#6IZX-!L;"^L]5NFO8GN+HQ&UF=0'W#:=ZY4,,8/4>]9VL?#S5+?X
M?Z)I6@W,)UC2B^VXE8HK>:CK+V.,F0D?05Z910!YOXF^'EW?2^'[72WA33H;
M6/3M261L%[5)(I %&.3^[8?\"-;&H>&K^Y^*ND>(X_*^P6EA+;R9;Y]S$XP,
M=.:["B@#SW1] \2Z#!#H%GIVD/80W):/4YI-SBW,A;88MO+@$KG=CH:ECT7Q
M1H>LZ]#HUM8SZ?K-R;M+F:X*-:2.@5R4VG>/E! !'H37>T4 >4V?AS5?"T'@
MDP2Z;)K=E;7%F]A/=>4+M&PQ\M]IY7 /3H:AL-"U#Q1JOQ&L+VXMTO+H6(#P
MY>&&5$+JF2 6VD)DX&>>!TKTO6-"TKQ!:+:ZM8PW<*L'59%SM;U!Z@^XI^DZ
M-INA60L]*LH;2WW%BD2XRQZD^I]S0!SME8>(-6:>VUG2=*TRQ>TDMY?LTOG2
M3.XV[E.U=B@;N#DG-<U<^%_&U]X*L?"DMMID<.G/;K]L6Z8FZCB=2H";?D.%
M!))/*X[Y'JM% &+#J=\_C2ZTIH[?[!%8QW"NN?,#L[+AN<8(4XX[&H_&NBW/
MB+P?J.E6CQK<3H-GFDA&*L&VMCL<8/L:WJ* . &D>*;WQ1I.M7&FZ?:6\%M/
M9-8Q76XPHX4^8&V ,<KC: , #GDX9)X,U5O@Y9^%AY']HPI;JWS_ "9297;G
M'HI[5Z%10!P[:3XFT+Q7K5YHEG87EGK+1REKBY,1M9E0(20%.]2 #@8/:M/P
M!H-[X9\%6.D:@Z274#S%W0Y#;I7<'\F%=+10!Q_BSPU?ZUXN\(ZG:>5]GTJY
MEEN-[X;:RJ!M&.>AJ?0M O=.E\5-/Y6-3OWN+?:V?E,2*-WH<J:ZFB@#S%/!
M_B+2M,\"7%E;6=W?>'XY8KBV>X,:OYD>PE7VGI]*O'0_$NC7VKPZ1IFDW<&I
MW37<5U=3%3:22 ;PR;3O4,"PP1UP:] HH YJQT*\MO'M[K,AA-K-ID%JNS@[
MT=R?E[###'-<S)X(UN"Q:[L_LK:G:>(Y]7MHI)"$FBD+ H6Q\I*MZ'!%>ET4
M </I>C>([KQ])XDU>WL[2!]):QCM89S*T9\U7&6V@$GYN@XX'-8V@^ -:TWP
M%X6T:<VWVO3-:COKC;(2OEK(['!QR<,.*]1HH X_7?#$NJ>+);^>2./3)-"N
M=.F<M\RM(ZG./3:#S7":N^OR> ?#FGW$FE/8Q7UC!;W=E<F4ZAMD54VKM 7@
M;CR>5[5[76!9>"/#&G:J-3L]$LX;P,661(_N$]2HZ*?< 4 ;]><_\(9JT]UX
MQTBYAM_[(U]WGCO5G_>0NT84 Q[><, <Y[5Z-10!Y\^B^*_$ T33=<L["TL]
M,NH;JYN8+HRF[:+E0J;1M!;!.37H-%% 'EEMX9\:V/@W4/"\-KILD6I27(%X
MUT5^RQS.VX%-OSG:Q(P1R<=LG6?PSJGAS63>:%IMEJMM/8V]I+!=S^2T;P@J
MCAMK @J<$=>!7>T4 4='AO;?2+:/46MFO0G[XVJ%(]W4[0>W\^O%7J** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *\[^./\ R275_P#?@_\ 1R5Z)7)_$GPU>^+O M]HNG/ EU.T
M11IV*I\LBL<D GH#VH P?$OC$6WB=-#?Q1;^';>WL([A[AXD=YY') 0!P0%
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M$D,J%'1NC*1@@_A26MM#96D-K;1K%!"BQQQJ.%4#  ^@%2T4 %%%% !1110
M4444 %%%% !1110 4444 %%%% $%Y9VNH6DMI>V\5Q;2KMDBE0,K#T(/6J6C
M>&]%\/)(FCZ7:V(E(,GD1!2^.F3U-:E% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-I:K<W&MVD<311S*6?!9) 2A ZG(!/X&DD\=>%8GLT?7[ &]4-;_ +X$."<
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M[S#-YF#@2'^/;G;N_P!K&: .7T<#_A?7B/C_ )A-O_,5PR_\D=^)G_8?N/\
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MT=F57'DJP"D*!P 0 /PH Y33[:%OC7K,S1*9(M&ME0X^Z"[YQ^0KC4L;6'X
M>*?+@C7==7;'"]UG(7\@HQ]*]C33;./5)M22W07LT:Q23#JR*20/P)/YU5_X
M1S2/[&N-(^P1?V?<,[2P<[7+-N;/U)S0!QNKVFH6E_K.LZ+<:3J226<2ZOI5
M\<-M2,D;7&=I9&Z,,=^]=MHUU;W_ (=T^[M(3#;3VD<D,6,;$9 57'L"!5'5
M?!7AS6KQ;O4=)@GG5!&7)(W*.BM@C</8YK<1%C1410J* %51@ >@H \5DN88
M_P!F&U#RJ"\<42@GDO\ :1D?7@_D:Z/Q#;7FEW7B?6M+?2=8TN50VLZ7=\.O
MEP@$*XR,E #M8?3K72?\*^\)^=<S?V':[KDDR<'&2<D@9PI)],5/J7@KPWK&
MI'4-0TBWGNFV[W;($FWIO .'Q_M T </IXUG4?&GBJ32GT:*WF@L\QZG!([?
M9V@! &U@ F2^1ZYI/"-BNG^._#EE<7\&H1V_A=ELKF,YCD/GC)0_]<]H^E=Y
MK/A#0/$$\<^J:7#<2QIY:N<J=G7:2I&5]CD4[5?"F@ZW;6MOJ&F02Q6G%N "
MAB&,84J00, # XX% '-?#T6@\2^.19;/)_M<?<Z;O+7?_P"/;J)$M&^/<1G"
M&=?#N8-W4'SVR1[XS^&:Z[2M"TO1%E73+&&T68J9%B7 8JH4<?0 57U7PIH>
MN7)N=2TV*XG,8B$K$AU4$D $$$<L>1SR: /*;GRXIM3:#:MA'X[M"I'"JWR>
M9_X]U]Z[:]FB?XUZ7 KJ9(]$N&=0>0#+'C/Y&N@'A301X>.@#2K;^RF'-MM^
M4G.<^N<\YZYINE>$M!T2>.?3M-A@FC5D64$E\-MW9)))SM7KZ"@#G_@YC_A5
M6BXQ_P M_P#T?)2V=O#)\;-4G>-6EBT6W",1RNZ63./R%='H_AG1O#\UU+I.
MGQ6C7;;YO+)PQR3TS@=3TQUJXFFV<>IRZDEN@O98EA>;NR*20/P)/YT >-VR
M1K_9D$RJ-,3QU=(Z$?(#E_+!'3&[]<5UVL!1\6X?LP'F'P_<?:]O]SS%\O=^
M.['XUU<GAK19M-N].ETV![.\F:>>%ERKR,<EC[YYS2:-X9T;P\LPTNPCMVGQ
MYKY+.^.F68DD#TS0!A_"?'_"K?#Y&/\ CV_]F-5O#HA;XG>.OM00RA;-5\S'
M^H\GMG^'=NS[UTNB>&M&\-K.FCV$=FD[;Y%C)P3ST!/'4\"HM7\'^']>OHKW
M5-*@N;F-=@D;()7.=K8/S+['(H \@\.K<OI/@==&>Q2 ZMJ1MS>HSP;P7\O(
M4@YV[]O/6NCUC3+VS\)_$6YU#4-+N+FZM TUOIZLJPR"$@EE9B0678??%=]+
MX4T&?1FTB32[=K RF;R<<*Y8L6'<'))R,=:6U\+:'9:+<:/;Z;"EA<[O/AY/
MF[A@EB3DDCN30!YCXO&/A)\//^OS2_\ T4:ZW1;:&3XP^*KAXU::.PLD1R.5
M#"3<!]=H_*NEN?#FD7FFV6G7%A%):6+1O;1'.(B@PA'T%6H=-LX-1N=0BMT6
M[N51)I1U<)G:#],G\Z /%M,COQ#X3@TYK*)8]>U181>HS0+(#)Y8PI'.-^WG
MK5SQ-IMY9VFK7&KZCI4Z7FLZ8=1M[!65(5#@,9%9B1N'E]>N*]/F\*Z%<:3)
MI4NF0/8R3-.T1!QYA8L7!ZALDG(]:+;PIH-GHMQH\.EVXT^X),\++N$I/4L3
MDL>!R3G@4 <QKXM!\9?!OEA!=_9+WS-OWO+V#9GVSOQ^-1?''_DDFK_[\'_H
MY*Z;2_!?AW1;B"XT_2H89X"QCE!9G&X;3\Q))&!C!Z=JT=6TC3]=TV33M4M4
MNK24@O$_1L$$?J!0!QR6\,WQHLI)(U=X?#>Z,D9VL9P,CWP2/Q-6/AZJQWGC
M*- %0>(9R%'09CB)_4FNK73+)=3&I"W07BP?9A-W$6[=M^F>:6STVST][I[2
MW2)KJ8W$Y7^.0@ L?? 'Y4 <<N/^%\2=,_\ "-*?_)DURUG9VP^ 7B=Q FZ9
M]0DD.WEF69PI/N-H_*O3M1\,Z-JNJV>J7NGQ37UF08)R2&3!W <'D9YP<U(O
MA_2DT:;2%L8AI\^_S(.=K;R2V?J23^- 'GKL6^-/A%V.2= <DG\:DTU+CPTN
M@VS_ -E:YX8GU!4TZ[C&+BWDD+%&[JX!)&X8/)->@?V%IG]J6VI_8X_MMK"8
M(9N=R1G^$>U4+/P3X:L-6&J6ND6\5X'9U<9PC-U95SM4G)Y '6@!?&?B)/"O
MA+4-78!I88\01]=\K?*BX]V(_#->:1>$O&3?#63PQ)X;L6FG)N7OFU7$OV@M
MO\PCR_O X&,]!C->N:EI&GZPMNNH6J7"V\ZW$2OG"R+]UL=R,]ZNT >17NMQ
M^,O#OP^O+R(&<Z]%%>0N/NS1QR!P1]1G'H170V5I;_\ "\-5N/)3S1HD!#8Y
MR9'!/UPH'T%=)'X6T.*;SH]-A5_MIO\ (S_Q\$$&3&?O8)J\FFV::I)J:VZ"
M]EB6%YOXF122%^@)/YT >*Z>EZ+#PS!8-9QHGB;4%B%XC- L@\WRP0I!S][;
MSUQ5[Q?I-]!X9\:W&J:AI4]Q>-IXGMM/5D\IA*HW,&8D%E(Y[[:]/E\+Z'/I
M,VE2Z; ]C-*TSPD'!D9MQ8=P<\Y%1P>$/#]MH\VDPZ7"MC/())HCD^8X((9F
M)R3E1U/:@# \1P1V_P 1? :V\21[?MT2!5  46_"_3@<5Q9%@?V8;AKKRS(8
MI#(7QN^T^>>O?=N_2O9+C3;.ZOK2]GMT>YLRYMY#UC++M;'U'%8LWP_\*7%Y
M=7<NAVKS76XS$@X8L,,VW. Q!.2!GDT 86DV\4GQBN)GC5I(_#ML$8CE<R/G
M'Y5RT-C:Q? [QH([>-0UY?,<+W64A?RP,5Z]%I5C!J+:A';(MVT*V[2CJ8U)
M(7Z DU!_PCVD_P!DW6E?88OL-TSO/!SM<N<L3]2: . M4U^X^(>KG3IM)64Z
M59!?[2ADD+0D/NV;6'R[]V[WQ572='BL_$'PXLI;NSU)+>+4Y(IK;F+JI7;D
MGA00!Z;?:O0M7\(Z#KWD?VGIL4[6Z;(FR595_NY4@E?8\5;31-,BFL)H[&%'
MT^-HK38NT0HP (4#@ A1^5 'EOB9%0?%Q44!39VCD <;C <GZ\5ZEHF/[ TX
MC&#:Q=/]T4DFA:7+)J+R643MJ2+'>;AGSE52H#?@2*-&T33?#^GBPTJU6VM0
MQ81JQ(R?J2>U 'G\RS^&XI+M#I6N^%+C6/.8$8N+::2X RIY63;(?9AC':I_
M#=E;/9?$>5X$9YM4NXI&*Y+((5PI]OF/YUU7_"$^&O[:_M?^R+?[=YOG^9SC
MS/[^W.W=WW8SFM*#2+"UCO4@M41;V5IKD#_EH[ !B?J * /,_#5Y?7-IX/T_
M28=-CU&#PXERVH7\;R^7$=J;$567DE1DYX %<O?R>;\,=#/FQ2K_ ,)D</"N
MV,CSI3E5R<*<Y R>M>Q7?@GPW?V]C!<Z1!)%81^5;+R-B<?)P>5X'!R*<_@S
MP[() VDV^V2[6]91D#SUSA\9P#R>GK0!RC_\G&I_V+7_ +7-:'Q1@BNM&T2W
MG020RZ[8HZ,.&4R8(/X5U1T;3CK8UK[)'_:0@^S?:.=WEYW;?IGFI+[3;/4T
MA2]MTF6&9)XPW\,B'*L/<&@#A_$=Q!I?Q,M+YX=R1>'KUY508+HC(VW^>/K6
M!&^HI>?#I[EM&M;2:[$EE86,#AX8V@?@R%R&&&4'"C)(KU6;2K&XU"._FM8Y
M+J.%X%D89(C;!9?3!P*QH/A_X4MH###HENJ>:DHY;*LN=NTYRH&3@# Y- 'G
M>HW-QX>LO$_@*S.RYU+4(TTKT$-X3OQ[)MEYK873=5T_XE2Z=H+Z5"MIH5M#
M;+J$3O\ N0[AMFUAW"[O^ UZ!<:#I5UK5KK,]C#)J-JA2"X8?,BG.0/S/YU#
MK?AC1?$7DG5M/CN6ASY;DE64'J RD'![CI0!0\ Z<=+\)PVOV^SO4$\[))9?
MZI0TK'8O)X4DKC/&,5TU065E;:=9PV=G!';VT*A(XHUVJH'8"IZ "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *YSQGXQL?!>CK?78#O)*D4462-^64,<X., EOPKHZX3XN$+X(5B<
M:A:$D]OWRT $_C^RMO&4:3:E"F@RZ.+N-RAR\IF*#'&X\ \ =LUT</BK0KCP
M^^NQZI;G2TSNN2V%4@XP<\@YXQUYKGWABE^.,<KHK/%X=)1B,[2;C!(_#(_&
MN(O4N1'J M9;>!5\?99[B,O$A,2[2Z@C(\PKW'.* /7-&\0Z3XAAEETJ]2Y6
M)MD@ *LAZ@,I (_$4FK>(]'T.2--3OXK5Y$:1!)G+*I ./7EE&.IR*P/#VF:
MA!XXU*^U/6M,N;Y[&**:UL;=HBJAV*.X+MSRX'M4/B&&.7XN>#3(BL8[6_=<
MCH=L8S^IH T6^(WA%-/2^.N6_P!G=V0$!BP*XW;EQN7&1G('4>M:6I>)]%TC
M3[:^O=1ACMKK'V=U)?SLC(V!<EN.>!TKC] M+?\ X2#XE/Y*;I)T1SCJ/LX.
M/S8_G7,>&DU>2Y\!?V?>6-M*?#DBV[WT#2H7#Q[P@#+AMNWG/0&@#U63Q5H4
M6@IKCZI;_P!F/@)<!LAB3C: .2V>,8SQ3;?Q=H%UHLNL0ZG"UA#((I9>1Y;D
M@!6!&0<L.".XK@H8[K3#:Z=!>:)J6IZIXAFFCN3;M]GL)EB+283>3O\ E; W
M#ES6!KIEFT'XEQ7=_;W\HN=/66:WA\I&;,:G"[FY&-I.>JF@#UK3?&/A[6-4
M?3-/U6">\12WEKGY@#@E21AA[@FJ>E>(;6"SUN]U#Q%;7EK9W[Q.Z0>4+09
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M(2H;D $XPP.>@R*!XY\,-J5MIZZU:M<W6P0JK$JY8 J-P&W)!! SDY'K7/\
MAZVA?Q_\1)'C5G9K2-B1U7[,./IS7*P010_L^^&C'&JD7=G("!SN-R,GZ\F@
M#V:X;9;2OY@CVH3O(R%XZXKG-&\3:?;^%-.U#5/$=I>I<N\::@(O(CF8%S@+
MSMP%(Y/\)-;FJ?\ ()O?^N#_ /H)KQ3PY!%<?"GX9Q3(KQGQ N589!P]P: /
M7M$\5:'XBDGCTG4([F2WQYJ ,K*#T.& .#Z]*S_%OCG3/"%QI<%ZPWWURL6"
M2/+C.=TG .0, 8]ZI8"_&_( !;PY\V.^+GC^9J'XBD+JO@DD@#^WXAD_[CT
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML'!ZBM?P1HE]H^F7\VIB-+_4[^;4)XHFW+$7P @;OA549]<T <W=?\G&6/\
MV+K?^CFKT>65(87ED.$12S'T ZUYYXATKQ):?%>U\4:3H8U2TCTG[&RB[CA(
M<R,W\1]".W>MVPU7Q)JET+'5?![:?93(Z2W/]I12[!M/\*\G)P/QH YL^,/%
MG_"(?\)QLTW^R/\ 7_V9Y+^=]FW8W>;OQOV_-C;BMKQ#K>M1:DJV>JZ%HVF&
MW62*ZU(AVN7.?E5=Z[5 QDG/7BN=_L'Q<? ?_" G2(_+V?8_[8^U)Y7V?=][
MR\[]^SC;C&>]79O#VJ:;XVU:]B\-6VLP7L-O%97-Q/&%LQ&FTHP;Y@N?F^0'
M.: &2?$35KCP9X6U>PLK-[W5M3&GRPLQ,>[,B$JP/ W1@YYX/>M2SUOQ'I?C
MJPT'79M.O(-3MIIH)K2W>%HGCP64AG;(P>O6N=TOP?XCM_#_ (9TB?3U#Z-X
MB^UR3K-'LE@+RMYBC.1]\#:>?:NOU?1;^[^(WAO5X80UE96]VD\F\ J750O&
M<G.#TH Z2[NH;&SGN[F01P01M)(YZ*JC)/Y"O$8DO;*TM/BW.LBSW&HF6ZB[
MKILF(D7'?: KCZYKT?XA:3J_B'08=#TQ,0WUS''?S^8%,-MG+D9.23@# ]34
M$OPF\$26SP?V&B*R%05FDRO&./FH L^*/$&HP:EH6C:";07NKM(RW-PIDCBA
MC4,S;5(W$[E YQS6;8>*O$,>K>)]+U2*P,VCZ>EQ%- C!9V8.0Q!8X'R@;<\
M$'D\5A66C>)]&MO"4]S;V]UJFAS7-C';-=QQM?6SJ KQDG&Y55?E.#A35G2H
M]5U7QIXY6[MHX;N?2;>)+9)0_D[EE"HS]"QZGL-W?&2 6?!GBKQ7XC\/V?BB
M_P#[+L]&2*1[B)(G:68)N#,I+809' .2<'U%1:7X^U1WT/4;V_T.6RUBXCA.
MG6Q_TBT$O^K);>=YSM##:,9XZ5M>!?#5YIOPMLO#NKQ>1<_9YH9T5PVT.[]P
M<'AA63X9T#4]._L?3+CP5H\3V)1+C6&\EA*B# >,+\XD8A3E@,'/6@"M=?$;
M4$M+WQ!%?Z(NE6ET\0TQS_I4T*2;&D#;^&X+!=IXQS6N^O\ B?5O&NO>']'D
MTVU@T^*VE2[N('E/[Q"=NT,,Y(Z\8 Z'/&39>%M1T?S](B\&:1J(:]DD@U:Z
M\DHL,DA?]XI_>%E#%< 8.!S73Z)HE]9?$'Q3JLT*I97\5FMLX8'<8T8-P.1@
MD=: .3@\9^-;_P "WOB:%-'MAI7G+<6[Q22?:FB)WE6W#8,#@8)R#S6SJGC.
MZN=4T[3=,O\ 2]*:XTU-2FN=2&\*KG"1JNY<DD-DYX ]Z@T_PKJ]O\*?$&AR
M6RC4+PWWDQ^8I#>:SE.<X&<CKTJ*Z\*WMEJ&CZJWANVUT)H\6G75G(T6^)T^
M970R?*1\S*>1V/- #)?B'K$NCZ#)86NGS:A>:M)I5RNYC#O7>-Z,#G:2%;OP
M<<FM.UUKQ/8^,T\.:K<Z9<F^L);FTN8+9XQ%(A *NA<[EY!X(-5[GPWJ]W%X
M2E&CV%B]GJQO+NVLBJI!'M<#TW-@J"0.3G'%:^H:+?W'Q,T768X0;&UL;B&6
M3> 5=RNT8SD]#0!S?PGN?$-]-XBN-0U"UGMEUFZCDC$#A_, 3E&+D*GHN"?>
MO3J\Z\%Z9XD\+W7B.PET036]UJ-SJ%K>K=1['W@;$*YW DJ!G&.:[O3);R?2
M[674+9;:]>)6G@1PXC?'*AAUP>] %JBBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,S6_#^E^(K1
M+;5+;SDCD$L;*[(\;CHRLI#*?H:31/#NE^'8)8M,MC%YS^9-(\C222MTRSL2
MQ_$UJ44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%5+[5=.TL(=0O[6T$APAN)ECW'VR1FI7O+:-8F>XA59?]66< /QGCUX!/TH
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MDVF3:!P,X4GZUT_C30M+T1O!,^G6,%M<1Z_:0^?&@$C(X8.&;JV[OGK74?\
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MO^22_$[_ +"][_[)70AH+ZT\"Z7;Z';ZKJL>CK=Q"]N#';01^7&A=@%;<V2
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METZWU2RFOHL^9;1SJTB8ZY4'(K.T+QEHOB+4]1L-/O8))K*;R\+,C&4!5)=
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MVNZ1>Z?+J%KJME/919\RXCN$:-,=<L#@?C1!KND7.I-IT&JV4M\@RULEPC2
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M)U2XF@T_5+*[FA_UL<$ZNR?4 \5@>,/&]EH6@:O-IM_IMSJUA%O^QM,&8?,
M=R*P;O7.V&@:[#J7AR^CLO#5A#8Q2+%]AN9#)<1-"1L ,:AN=K=>V:YN\T[2
MI/V9Q?RPPFZ>$3M<E1YAG:;#$MUR22I]N* /<U.Y ?49K&M-3N/[:UF.\O\
M2/L-HL;1I#*?/@4J2QGR<*.,CIQ6Q'_JU^@KQ]/^1M^,/_8.A_\ 29Z /48O
M$&BSZ@NGPZO827KJ'6W2Y0R,I&00H.<8Y^E:->27FDV%AX#^'MS;6D4=P-2T
MMS,J .Q?&\ENIW9.:];H Y*7Q>NB>']:U?7+_29HK*YE2%=.FR2%&5B;<?\
M7=<@5K?\)3H*Z7!J4NLZ?#:3\1S272!&;NH;."1W%>,Q11R?"CXGET5BFNW;
M+N&=IS'R/>N\U7P_=?;](U/0K31[R>UT]HI-*O,(&C<J2\9 .ULKC)&#F@#O
MHI8YXDEAD62-U#*Z'(8'H0>XI]<_X)NK"[\)6<FG6#:?;J9(S9LV[R'61E=<
M]P&#8QQCTZ5T% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %4-7T:QURS6TU&'SH%E28+O*_.C!E.0
M1T(%7ZAN[RVL+22[O+B*WMXANDEE<*JCU)/ H FKG=7\$:%KE_)>WEO.)ID$
M=QY%U)"MP@Z+(J, X'3GMQ5ZV\2Z'>:5+JMMJ]C+I\61)<K.IC3_ 'FS@=1U
MI+;Q+H5YJDNF6VL6,U]#GS+>.=2ZXZY&<\=_2@!MQX8T>YU;2]4DLQ]KTM&2
MS9'95B5EVD!0<$8XY'%2:MX?TS6Y]/FU"W,LFGW"W5L=[+LD7H>",_0\5B:;
MX^T?Q#;:Y'I.J:>ESI_FA'FG5D*HBGSR <^4&;!/L>:U+'7;2'1-/N=5UC2S
M+<Q;A/#*%AF(4LQCW'D  GJ>!0!!K'@G1-;OWOKJ&XCN9(Q%,]K=2P&9!T63
M8PW#ZU+J/@_0M4T:TTJ>P5+2S*M:B!VB: J, HRD%3^-/N/%OAVUTVVU&XUN
MPBLKK(@G>X4++CKM)/.*I:_X[T'P]+I27=_:XU*55C?ST"K&58^:23]S@#/J
M10!-I/@O0M%U-=3L[67[>(FA:YFN))9'5B"=Q9CN/RCD],8'%=!56QU.PU-)
M7L+VWNEBD,4AAD#A'&"5..AY''O3K2_L[_S_ +)=0W'D2M#+Y3AO+D7JC8Z,
M,\B@"6:&.X@DAF19(I%*.C#(92,$$>E8&D>!]"T2^CO+2&X:6%#';BXNY9EM
MU/!$:NQ"\<<=N*NWGB;0M/U.+3+S6+&WOI<;+>6=5<YZ<$YY[>M.U'Q'HFD&
M4:CJUE:&)5:033JI4-G:2">^#CUP: ,VQ\!^'M.U.*^MK24-#(TL$+7,C00.
MV<LD1;8IY/0<9XQ5NT\*Z38>(;K7+6&6*]N^9]L[^6[8 W&/.W=@=<5:;7=)
M71_[8;4[0:;MW?:_.7RL9Q][..O'UK"T[QA%J_CF+3-,NK.\TJ326O!/ V\^
M8)@F-P.,8/3&<T ='J6GVNK:9<Z=>Q^9:W,312IN*[E88(R.1^%4+OPKHU[H
M%KHD]INL;18UMU$C!X?+&$*N#N# =\YJ_>ZE8Z:(S?7EO;"5BL9FD";B 20,
M]> 3]!5&;Q9X>M])AU6;6K"/3YR5AN6G4)(02"%.>>0>GI0!#8>#M%TZSU"V
MBMY9/[10QWDUQ<22RS+M*X:1B6P 3CGC-69_#>DW/A@>')K0/I0MUMA 7;B-
M0 HW9SD8'.<\5-)KFDQ6MO=2:G9I;W()@E:=0DH"ECM.<'@$\=@:J1>)=+U/
M1K^^T74K._\ LL;L3!*) K!20&P?:@!-.\*:3I<]E<01SM/90R0PRSW,DK!'
M(+ EB<\@=>F.*NV>D65AJ%_?6T.RXOW62Y?<3O95"@X)P. !Q7/>#_&*ZE\.
M=/\ $WB"YL[+SU<S2%O+B4B1E&-Q/H.]=#9:UI>HZ:=2L]1M9[$ EKB.53&N
M.N6S@8[T 1:YX?TSQ'9Q6FJVYGABF6=%#LN'7H<J1ZU+%I%E!K-SJT<.+VYB
M2&63<?F1"2HQG QN-1Z3XAT;75E;2=5L[X0G$GV>97V?7!XINF>)-#UFYFMM
M,U>RO)X?]9';SJ[+VR0#TSWH FTO2++1H9H;&'RDFGDN9!N+9D<[F/)[GMTJ
MKKWAC2/$L<"ZG;&1[=B\$T<C121$]2KJ01GZ\UA^,?'^G:-H.LMI6J:;/K5A
M%O\ LC2AV!# $%00>,\^E==<74%G:275W-'!;Q(7DED8*J*.I)/04 9&B^$-
M%T%KB2SMG>>Y79//<S//)(O]TLY)Q[=*ATKP+H&BZA%>V=M-YD 86R2W,DD=
ML&^\(T9BJ9'' Z<5KW.K:=9PVTUS?VT,5TZQP/)*JB5FY55)/)/8#K4>IZG;
MVD<MN+^SM[YK>26%;EP!A1RY&02HXR1VH R'^'WAN35CJ+6+[VG^U-!]HD\A
MINOF&+=L+9YSCKS5U?"NDQ^*)/$4<,L>I2J%E9)W5)<*5!9 =K$*< D<5CW/
MCW3=!T;0Y=9U73+BXU&5(O.M)@L)4DYE&XG]V,<G/4TD7CNRM_$VMVVIZCI]
MKI-I#9R6MP\@7S#,KL?F)PW"@C';- &G;^"?#UKX8?PY'IRG2F8L8'D9OF+;
MLAB=P.>00>.U/TGPAH^C37%Q;Q3RW-Q'Y,EQ=7,D\IC_ +@9V)"^PK7M;JWO
MK6*ZM)XY[>5=T<L3!E<>H(X-<W'X]T6Y\1:IH-M>VQOK*(%09E/FR8<LBKG)
M*;/F],T :+>%=&?PU#X>:T)TN$1A(?,;C8P9?FSG@J#UK9KD/"GCO3-7T;11
MJ6JZ=#K5_;)*UHLP5BS#( 4DGGL*V]1\2:'I%Y#9ZEJ]C:7,W^KBGG5&;G'
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MWO(,.<YXS[8JA>^!]!O[?289;:9!I,?E63PW,D;Q)M"[=RL"00H!R>U=%10
M5B?\(EHG_"*GPS]D/]DE2A@\U^A;=][.[KSUK;HH P=:\':-KUXEW>17"7*Q
M^29;:YD@9X\YV,48;ESV-6$\,Z/%=Z5<Q62QR:5$\-EL8JL2, K# .#P!US6
MM10!@ZUX.T;7[Q;R\BN$N1'Y+2VUS) TD><['*,-R\G@^M,O?!'A^_\ L7FV
M)C-C ;>T:"5XC F0?D*D;3\HY'/7U-=#10!S<>GVO@G1)SHFC7E_++-YDD<4
MHDFFD;^-WD;GH,DGCTJM\/\ PQ)X<T6YDO((8-1U.[DOKJ.$Y6)G.1&#W"C
M^N:ZVB@!&4.A5AD$8-<VO@+P['X?M-$ALY(;.SD::V,5Q(LD+DDEED#;@?F/
M?O72T4 9NBZ%I_A^T>VT^)U620RRO)*TDDKG +,[$EC@#J>U0:YX6TKQ#/;3
MWT<XGMMPBFM[B2!PK8W+N0@E3@9%;-% '.0^!/#ENQ\FP:./[7#>K$D\@C2:
M(81E3=@>^!S@9SBM7^R+'^W?[:\G_B8?9OLGF[C_ *K=OVXSCKSG&:O44 8<
MOA#0YM-O]/DLMUM?737DZ^8V3,Q!+JV<J<@$8(QVJ"+P+H$6DZAIS6TT\6H@
M+>27%S))+,!T!D9BV!V /%='10!0O-'L;^XL+BYAWRZ?+YUL=Y&Q]I7/!YX)
MZUBW?P\\-7U_=W4]E*?MC%[B!;F1897(QO:,-M+>^.O/7FNIHH Y^_\ !>B:
MA;6$+PSPG3X1!;36US)#*D> -F]6#$8 X)-%UX)\/W6B6>D-8F*TLG\RV\F5
MXY(7Y^97!W9.3DYYSS7044 8NB^$]&\/W4]UIUL\=Q<1K'-*\SR-*%)(+%B<
MG+'D\_D*LZWH=AXAT\66HQ,\2R+*C)(T;QNIRK*RD%2/4&M&B@#E_P#A7OAO
M;*#9S$SVK6EPQNI<SQL23YAW9<Y8_,<D9X-:]WH>GWJ:<MQ 7&G3)/:_.PV.
MJE5/!YX)ZYK1HH Y>\^'OAN^U"[O)[*4F[;?<PK<R+#*^,;VC#;2WOCKSUYK
MH;&R@T[3[:QM4V6]M$L,29)VHH  R>3P*GHH H1:-80:W<:S'"1?W$*02R[S
M\R*25&,X'4]JR;[P'X>U'4Y;ZYM)2T[K)<0I<R+#.ZXPTD0;:QX'4<XYS72T
M4 <WJ?@30-7U":]NK>??<;?M,<5U+'%<8&!YB*P5N !R.E6;OPEHU[KUKK<E
MO(E_;1B)'AG>,,@.0K*I 90>Q!%;=% '(I\-/"Z6[0"SN/+#!H1]LF_T;#!Q
MY)W?N_F /RXZ5HIX/T6/7KK64MI!=7:;+A?/?RIAMVY>/.UCMXR16[10!SNC
M^!]"T._CO+*WG,L*&.W$]U)*MNIZK&KL0@/3CMQ5*;X8^%+C[2LMA*T%PS.U
MM]JE$*NWWF6,-M5CD\@#KQ77T4 (   !T%8P\*:,+S6;L6A\[6HUBOF\UOWJ
MA2@&,_+\I(XQ6U10!ES>'=+N--T[3Y;8M:Z=)#+:IYC#8T6/+.<Y.,#KG/>M
M2BB@#"A\':#!I>JZ:EB/L>JS23WD;2,?,=\;CDG(Z#IC':J3?#S0#:VL*K?H
M]JK)%/'J$RS!&P2AD#;BO ^4G [8KJJ* *FF:99Z/IT&GZ? L%K NV.-23CG
M)Y/)))))/))JW110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7"?$Y;N2#PW!;+:N)=:A5DN\^2Q"
M.4#XYQO"_CBN[JGJNDV.MZ=+8:E;)<6LN-T;9Z@Y!!'((/((Y% 'E'B[2M6M
M="\;ZAJ<VC1R76DQ++::<[D[E=MLKA@",@E<]]OM70^(=.L].UKX?"TMXX?*
MOC"I10"$-N^1GWP,UT5OX(\.VVE7VFII^ZVOP!=^;/)(\P'0-(S%CCMSQ6G=
MZ18WTUC-<VXDDL9?-MCN(\M]I7/!YX)'- 'F6D0Q)X'^*;)&BL-0U100H! \
MD<?2LR"S@U#PK\);6ZC62![A=Z,,A@(F.".X..1WKTX>"O#XO]3O5T_;-JD;
MQ7FV:0+*KC#93=M!('4 'WJQ'X7T6&#2H([%1'I+;K%=[?N3@KQSSP3US0!Q
M=_;:L?BO<PZ1;:.3!HT0ACOPX58VEDWF,(.Y !_"L=M';2U\!V5U-I]T%UZX
MV&S;?$B'S&\L$C.%)*X[8Q7I>M^%M&\1/!)J5HTDL (CEBF>&10>HW(P.#Z9
MQ4-[X+\/:AHMGH\^FI]ALW#VT<3O&8F&<%64A@>3SGG/- '':YJL?PZ\;:MJ
M+J!I^M:<US&G8WD"XV =MZE?J176>!=#D\/>#["SN>;UU-Q>.>K3R'>^?Q./
MP%8NMZ#?>)]?T?2Y]&^RZ!HUTMT;J>9':Y*+A$0 E@N3EBV,XKO: /&?%\\]
M]X8\=7MC8:/:::D\MO<SW6^2XN)HU5-R\X3G:%'/3..:Z/2+2WO/BW=W-S$D
MTL>@VA1G&<%G?)^O'7W/K70W'@3PU=ZC=WT^EI)-=[O/5I7\MRR[2WE[MNXK
MQNQGWJ[IGAO2M'N!/8VICF%NEKO:5W/E(257+$]"QYZT >2V<47_ !*+"5%&
MF+XWNX_*(^0%?,,:XZ8W=!7800V</QZF-LD:3/X=W3A !EOM"@$^^ /P KH[
MCP?H%WI=UID^G(]I=7+7<J%VR9F.XN&SE3GT(Q1I'A#0M"O?MNG6/E71B,+3
MM*\CNI()W,S$L<JO)R> .E '-?$VT@O]0\&6MS&)()-<19$;HZ^6^0?4'H1W
M%5];MM3'Q6L8-&MM)Q!HKO;QWP98T+38D*!!][&S/L:[R_TBPU.:RFO+<2R6
M4XN+<EB-D@!&[@\\$]:K:WX:TGQ$L']IVID>W),,L<KQ21Y&#AT(8 ]QGF@#
MRZ[T06(\*V&K3Z;/!)XJED$-FQ:"+<KGR<'IB3(V^^*WM3ABMOBCJZVB)&LO
MA61[D1C +B7"%L=]NX?05>\1>"K:<>%M,T_2HVTBSOV>YB!&%C,4@+')R268
M<\G)S70:5X1T318[Q+&S*F]&VYDEFDEDD&" "[L6P 3@9XH \Q\(7&[X:> -
M-M].M+S4;FXGDM&O'80P-&96:1@O+$ D >I[8JIJ3W"V?B^WOI+,P-K^G)J'
MV)2L 1A$)."21D@!L]3FO4Y/ WAR30[+1O[.V6-BYDMDCGD1H6)))5PP89W'
MOWIT/@GPW;BZ6+2H@EW;BVN(RS%)8QTW*3@G_:QN]Z .<^(EMH]CHNM7%BL4
M'B Z).D8A8JQMAC>=HX('8D<=JJ6NBZZ-3\-7K-X;M(K*&06J6+R"2>)H2-B
MAAAA]UOPS77Z-X,\/Z"UP^GZ>%>XC\J5YI7F9H_[F9"Q"_[(XINC^"?#V@WP
MO-.T_P N=4,<;/-)((E/54#,0@]E H \MOK73&_9@6XD2(RM"LOFD#>;@S88
MYZ[B20?;(KVB^LH=2TNYL+@9AN86AD'JK*0?T-<]+\-?",\ER\FCJPN69I(_
M/D\O<WWF5-VU2?50#75@8&!0!X.L-UXN\/Z=X?9C]N\.:3=O(!SB[B<P0?C^
M[<_C6[!J">+W\5>)TP;>V\.+9P8Z!Y(3/+^(W1C\*](T[P]I.DZEJ&H6-DD-
MWJ+A[N0$DRL,X."<#J>F.M1:;X5T31]%N='T_3T@T^Y+F:%6;#[QAN2<\CCK
M0!Y5911O\/?A5O16SJ]NIW#/&)>*[#1M/M)_B[XLFEMXW>&RL8XRR@[599-P
M'UVC\JW[GP7X>N_#UKH,VG Z;:,KV\0E=3$RYP5<-N!Y/.>]7=/T+3=*NIKF
MSM_+GFABAD<R,Q9(@0@.2>@)YZGOF@#FOA4JQ^"S"@"QQ:A>)&HZ*HG? 'M6
M?I4,0^)7Q";RTW+:69!VC()A?/YUW6F:59:/:&UL(!#"9'E*AB?F=BS'DGJ2
M35&X\):)=:__ &[+9'^TO+\IIDF==ZX(PRA@K<$]0: /,#IUG:_L^:'<0V\:
M3J]C<"4*-PD-PF6SUS@D?3BKZ6.MZIK?CR**'07BEN_(N6U)I!(L/D)L^Z"
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ?\ QRUZ:^M-$N)[2.T+M*KOY,> 08<CA\<\XYKV2@!LDB11M)(ZI&@+,S'
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M*X#OCC=C;D#->AM?6:7R6+7<"WCIYBVYD D9?[P7J1[U8H X;Q=HFHZA\1/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^'=1B\7>#[U-*M;2UL;"YCNH[,JL-O)(%PJC@D9W<@5H?%#_ ))CXB_Z\VH
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MN$P&&.2<MZ$<'DU5M?'>K^(-.\*0Z-!9V^I:W;R7$\ERK216Z18#D*""Q+'
MY^M 'HU1S3Q6\32SRI%&O5W8*!^)KE/"GB'6M1\3>(-%UF"SCDTI;8+);!@)
M?,5R6Y)P" O'8Y&3UK/^(5FQUK0M2OM%N-;T&T$PNK."+SBDC!=DIB_C PP[
MXSF@#NK>Y@NXA+;S1S1GH\;!@?Q%2UYOH>K>"-,M?$'B;PU+Y2V]GOO=+B3R
M%5D#$,8BH*N?NYZ&IM'\8ZLNLZ+!JU]H=U#K!9!%IY/F6<NPNJL2[;P0I&<+
MSB@#T*BO*[;QIXTN_!$WBZ.#1UL[-IFEM#%)ON(XY&5V5]V$.%.!AN5)[X%J
M'4M=OOC'"MK?V@TQ]$CNUB>%S^X>89'#X\SC[V,8XQWH ]*HKRZW^(VHR6=M
MXA>[T4Z/<72Q?V<K'[6D#2>6LA;?@MR&*[>G>KL_B;Q=J%YXIBTD:3!%H<Y5
M'N87<SCR@X3 <8/7+>XXZF@#T2H(+VUNIKB&WN8I9+=_+F1'!,;8!PP'0X(/
M/K7GD7C3Q,=.\.>(IX--CTC5[JWMFLE1S-&)3@2>9NP>>=NWH>N:KZ1_PD\O
MB_QO%X??3H!'J"2-)>Q/()',"80!67:..6YZC H ]2HKS:+XBW>LZ;X>2PDT
M[3+W4[>6XN9K\EHK<1,(V"KN7<2_ Y' )J.[^(VJV_AI;B&WT^[U.#7(]*G$
M+$PSAL$-&<_+N#+U)P<]: /3:@EO;6"=();F&.:3[D;R ,WT'4U6T9-733E&
MMS6<M[N)9K-&6,#L &)/'K7F_CO2/".@:;K#ZO9R:CK&L&66"ZN(0S1.?E11
M,0%A13MQDC@=Z /5)[B"UB,MQ-'#&.KR,% _$TY)$EC62-U=&&593D$>QKS.
MUTL:WXTT/1/$0AU.+2_#L5TZ2XDBEN7;RS(0>&X0X)_O9K6\#Q1Z3XE\6^'K
M1?+T^QNH)[6$?=B$T09D4=EW D#MF@#N*@-[:BZ%J;F$7)&1#Y@WX^G6IZ\C
M\7^#M$T;PW'IMC%]K\7ZA=![*^< WCS>8&:4N!D*HSD_= 'O0!ZM<7=M9HKW
M-Q% K' ,KA03Z<U(\B)&9'=50#)8G  ]<UY_:Z1I_BKXD>)CKEG!J$6EQ6MI
M:Q7$8=(]\?F2,%/&XDCGK@54\,>';?Q'X<N= U">=]-T/7KB!+<ME9XHVS''
M)GEE&\<?[(H ](M[JWNXO-MIXIH\XWQN&'YBLU[/2;WQ);ZAY\<FIV,4D*HD
MP)17V[LK_P !%<9X=TJQN?&OB1O# &GZ&U@ME++9*$C:\RV7B &W**0"0,9J
MIJOA70M&UCPGHWARSB77[>\BN)KF)0)OLRY\Z29QR0_3!ZDX% 'JM%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %9XT:S'B%M<"M]N:U%H6
MW<>6&+@8]<D\UH44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M74<A2+RG4/E3@Y+ 8'-=O10!QFHZ3KL?CK4M;TRUMY VAI;6YN'PCS+,[E"
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>svb-second_amendmentxtox002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 svb-second_amendmentxtox002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3W;[<TD>V3S+9XUV!6+<F0.VX#!7N: /2=/\0:/JMS+;:?JEI=31#+QPS*Q
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M',85FG3=DLG3Y 0X5<YYQZ9'&(HDC7[J*%'T% #J*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ JE=:1IE]=0W5WIUI<7$/\ JI9H%=T[_*2,C\*NT4 %
M%%% !1110 4444 %,AABMH$@@B2**-0J1HH55 Z  =!3Z* "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *Y7Q1I-QJ-]!/?>()=*\/V\),PMKDVTDDQ8!=TG&$ [ C)-=57
M(^*M>@TW4H['7M%-UX<NK?+W0M6N5696R$DC53@8P0<=1[4 0_#F[N[FPU:.
M2_N-1TZWU!XM.OKAMSS0A5_C_C 8L W?%=I7FWA+4/["TKQ-K,6F:E'X<^UH
M^F6*V[>;LVJKF.-L%4+DD#CC/%>D@Y&: "BBB@ HHHH *\_T;4[Z;XV>)=.D
MO)WLH=/MWBMVD)C1B%R0O0$UZ!7DS:M%X:^-GB+4=0M-0^R7-C;Q12V]E+,K
M, I(RBF@#U6X*K;RLP)4(20#C(Q7G.@^.-'T7X8Z)K%CI-Y'IUW>_9([8SF:
M5"TK@G<V2W()Q[@5TFG^,M+\0/<65C%J(F$#O_I%A-"N!Q]YU SSTKS/0M,O
MT^#G@BV>QN5GB\00R21-$P9%%S(2Q&,@8YS0!W+>/]0M]<70[SPI>0ZG<PF:
MQA6YC=9P#AMS@XC(')SGIQDX!</&$&K>%_%::KI%Q:7&D6\JW]CYX)9#$7&R
M1<?>7.",$4[5+:=_B_X?N%AD,":;=*TH0[5)9, GH#6%>V-VT_Q<(M9B+FR0
M08C/[T_8R,+_ 'N>..] $.M>,]0TCP?X*E\-:9+%9ZE<VD2>9<*[;6R?()?)
MRP&-YZ>M=A?>)M7MY;*SM?"]U<ZE/ T\L7GHD4"@XPTQ^4L3T R:\_UFSO+?
MX4_#NX:RNF&F:A8W-VB0LSQ1JK;B5 SQD=N]:NN:Q::IXM@FU6;75\-S:>'L
M$LHKJ(3S^8P<.(P'W8"X#8&#GO0!9\4_$._C^&6I:[H^GRV][:RO9W(E="UE
M,KA"2#D/R1C'J#4VMZ]&=.\*3^)-#N4N;G5[>&W2.] V2$?+*Q0@,O7Y37&R
M:=>R?"3QWH<.E7\5_P#VBUU'9RH\DGDM)&R_.<[SM4YP2>*V_%5ZGB72_ ES
MI5O>31VVOV@FW6LB&/:/F)#*#@9^]T]Z .QO_%]X-=O-)T/09M6GL$1KQQ<)
M"D9<;E0%OO,1SCH,CFJ=Q\2M/32-"U&VL+RY36)VMHX4 $L<JALH0>,[EV]<
M=\XYJC:ZI%X+\8^)SJ\%XMMJ<T5Y9W$-K),LO[L(T?R X8%>A[$5@Z?HFIVE
MKX&>ZL9XII=>N+Z:$H2;=9!(RA\?=X(SGH3B@#N-(\7W5UXG;P_J^B2Z7?-;
M&[@S<),DL88*>5Z,"1Q6CXE\10^&]/BN'MY;JXN9TM;6VAQOFE?[J@G@="23
MT -86H6T[?&31;E89# FDW"-*%.T,77 )Z9J3X@VURJZ!K$%M-<QZ3J<=S<Q
M0H7?RBK(S*HY8KN!P.V: )K/Q??R:C<Z1>^'Y;365M3=VUM]J1TN4!VG;)P
M02,@COFN/^#QO=3N]4UK4=/N9+J6[N(VU"6^WJH#+^Y$6< #U K>L;M?%?Q*
ML=8TV&Y_LO3-/FB>ZEMWB6265EPBAP"<!22<8&13?A!:W%GX5OX[FWE@=M5N
M6"RH5)!88.#VH Z;Q;X@B\+^%M0UB4!C;Q$QI_?D/"+^+$"N,\"W6O>'O$P\
M.>)M1N;V;4[%-0MI;ARQ24#$\()[ X( X ^M3^-M-O?&7C/2/#,3W=IIMDIU
M*\O(D&/,!Q$BE@5)!.X@@\?2J/C+P;K.FV-MXFL]?U;6-2T2874%M<+$=Z9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPJJHY8D] *R])\;Z9JFK1Z6]MJ6GWTJ-)!#J%F\!F5?O%">#CN.M '24444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\]MT*AUPJ'/RCV%=3>:;-X9\:^%)H-5U&>34IYK>_%Q=.\<_[EG#;"=J89>
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MP")W91M!PW(Q\V>, 8Q7:VG@_4I=6TV]U_Q =433"7M(5M%@'F%=OF2$,=S
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MV,'-:MEX,FEU:\U/Q#J@U:XN+)M/1$MA!'' QRXVACDL<9.>U ')7]C=>&_
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M4 1GG@>O6J^L>$)M0\4Q^(K'69M/OXK+[''MB61"N\L=RG[P.>G'(!S74T4
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MUUIV^!()HC LZ';G#(&^XW)R1P>,CBM6XO;V+6;.TBTN2:SF5S->"50L! R
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M8H<PJOFHR!%#8/&U0.>]:FB>%8M%\2Z_K273ROK,D3O&R@"/8I P>^<UT-%
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M.)22$1%Z#))/)R:Z*L?3_$MEJ7B36-"@2<7>DB$W#.H"'S5W+M.<GCKD"@#
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M:9XDN+RT.\G!B*ML^A&X8]Z[R'P%/]OTK4;OQ+J%UJ&F2?Z/,\<041%2K1[
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MT:()O,!!+!0 , \8]*IW?P^,K:E;V6OZA8:5J<KRWEC"D9#,_P!_8[*60-W
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M-&G<) ,C<0H."3NQSG  QBMCQX\EYJ7AG0&FEBL]4OF6[,4A1I(XXF?R]PY
M8@9QV%;GA_P]!X>_M3R)I)?[0U":_?>!\K28RHQV&*3Q)X=@\1V4$3W$]I<V
MLZW-K=0$;X95S@C(((P2"",$&@#C/%.C/X-\,W\6AZE=VMIJEW:6J0B0M]BW
MR!)&C8DD;@?P/(J:ZT>S\&>-O"W]AB:WAU&::TO(#.[K,!$75R&)^92O7KR:
MU5^'MI<Z?JT6LZC=ZG>:J(UGO'VQN@C.8_+"@!-IYZ<GKFK.F^#YH=;M=6UC
M7+O5[FRC>.S$T<<:P[AAFP@&YB.,GMF@#S1-%BF^#-]XFENKQ]8M&N9;2Y^T
MN#;^7<. % .,<'.1SGV&.K@T^W\9_$/68=:\V6VTJRLQ;0+,\:J\RL[R?*1\
MW  /;%;Z>![1/ 5SX3%W/]FN%F#38&\>9(SG';@MBFW_ (+>76EU;2M<O-*N
MWMDM;EH(XW$\:_=)#J0&&3AJ /*]5:?3_@]JJQ7DS2Q^*)4,^\AW_?D$DCU[
MUVESH6G7/Q_CEE@9G&A"\R)7'[U;A55L ^@''0^E:,WPOTV7P?-X;6_NUM9+
M\WPD)#.&+;MN3U'N>:U]3\*&]\6V7B.TU6YL;N"#[+*L:(ZSP[PY0[@<<CJ.
M: /,H]:U'3_#7Q-N+6\E2X37FMX9=Q)A6254)7TP&)'I73ZKH5GX(UWPK=Z&
M;B%KS4ET^[1KAW%RCQN=SAB<L"H.:W+;X?:7%9>);.XDFN;?7[J2YN$; \LM
MSA2/0X(/J*6P\%S1ZK87^KZ_?:N=.W?8HYXXT6-B-N]MJ@N^.,GU/>@#@8]!
MM]2^'GBW6[RXO)+^QNM2DL91<NOV;RW=EV $#J,D]>W0"O6=)NY9_#=C>S?/
M+)9QRO\ [3% 3^M9D'@ZU@\+:OH(N9C#J;7322$#<GGEBV.W&[BMRPLUT_3;
M6R1BR6\*1*S=2% &3^5 'C\.DQWOPAF\<2W=U_PDK6TFHK?K<."CJQ8(%SM"
M8 7;C&*=>Z%I>L_&+P_)=VCXU'1GN[A!/(N9#Z8;(^@P*ZU_AM$;232$UR_C
M\.2S&5M*58]N"V\QB3;O"$_PY]LUMS^%;6?QG8^)?.D2:SM'M$@4#858YSZT
M 'C.YMK+P?J,EU>7=I"8Q'YMD,SY8A0L?^T20!]>W6N TE7TKQ5?V%IHVH:)
M9W&@3SM;75TLOF2(ZA9!MD?:V&(/(S7I/B+0H/$>ASZ9/-+")"CI-%C?&Z,'
M5AGCAE!K!7P'(VK1ZM=>(+ZYU$VTMI<2O'&%EA?&$"A<( 1D8YR3DG- '#+I
M$>G_  U\*^*H[F[;6Q)8$W37#DLCNBF,KG;MVMC&.<9/).>D@UH>!_$_BVSO
MY7:Q>V;7++>Q/&-LL8)_VPN /[U=#-X+M)O!NG>&C=3"WL?L^R4 ;F\EE89[
M<[>:YCQ=9V/COQIHFDVL%Q)_95R\FI7/E.D21#!,)8@!R[*G SP": .G\ :9
M=Z9X.LO[1D>34;K==W;.22))#N*\],9"_A6%X2_Y+)\0O]W3_P#T2:]#KBKO
MP#<-XIU37M,\3:AID^I^5Y\<$43*?+0*OWU/O^= $WQ*OKNR\(&.RN)+:6\N
M[>S-Q&<-$LDBJQ!['!(SVS6/>:19>"O&OA8Z+YUM;ZC+-:WD!G=UF41%U<AB
M?F4K][KR:W/^$+EO=%U#2M=U^_U:"[";6E2.-X&4Y#(44<YVGG/W1[TMAX-D
M76+?5-:UN[UBXM(GBM!/''&D0<89L(!N8CC)[9H \]CFABO- US2;#6V-WK4
M,;:Y>7*@7D4LI5E\K?G80?E^08"@\5JV7ART\1MXZFU26ZF%KJEPEJ@N'5;=
MA$C;U"D<Y(ZYQCW.=D?#+_B66FGMXCU)K?39HYM+4I'BT9'#*3\O[P@#;\W8
MGBNBTSPS!ID.M1K<RR'5KF2YE9@!L9T5"!CM\N?QH B\!WMQJ/@'0;N[E:6X
MEL8FDD8Y+':,D^YK#^'7_(=\<_\ 8=D_] 6NLT#2(M T"PTB&5Y8K.%85=\;
MF"C&3BN9'P_O+;5=4O=+\6:GIZZE<M<S0PPPLN\@#@LI/0"@#*\177]G?%Z&
M]T]0UU%X>N9;Q5_B13F/=_P(8K#N])CT[X1VWCB&ZNCXD6W@U%KYKERTCNRE
MD89VE"&*[<8KT?P]X.TWP]]LF62YOKZ^Q]KO;Z3S)9@. I.  H]  *QX_AM&
MMK#I,NNW\WAV"42QZ4ZQ[<*VY4:3;O9 ?X2>PYH H0:-:^./%OBG^V7N633Y
M(K2RC2X>/[-F(.9%"D?,6;.3Z 5;TR*ZL?BG9Z=<:A->&'PSAY9.#*PN -Y'
M3<1WK1U;P4]YK%YJ6EZ[?:1+?QK%?+;)&XG"C"L-ZG:X!QN';%1S> (8)=*G
MT+5;K2+C3K0V*21(DOF0$@[6#@@G(SGU)H X?6;B[?P]XL$5Y/%(/%T,4<J.
M<Q@F <?F>.E:MUX3TZT^)MAH]M)>1Z9J&FS37UM]KE(N6C==I8ELY^;G!YQ@
M\$YWX_AQ81:/>Z;_ &A>.MWJ<>IR2R$,YD4H3DXYR4R?J<5NSZ!#/XJL]?,T
M@GM;62V6,8VD.RDD]\_+0!Y5-=W6D>']8T&R-_+9_P#"5)I\<,$Q\Y;=T5VB
MC=F&,\J,G^(\U;F@U#3-'\7?8=#U71=$?09I%BO)U8)<J&^:/;(Q7*GGIRM=
MO-X#L+BUUB%[JY5]1OUU%9HR%>VF4+M9#CL4!Y]30/!L]SINKV^K:_?ZA-J=
MH;-I75(UBC(8?)&H"[OF)).2>* .1N=&AT.'P-KEK/='5;S4+6WO+E[AV-PD
ML;;U92=N.!@ <8&*N_#O0M.M?&7C*YAA99;?4O)B8RN=J&-21@G!Y[GFNMO_
M  O;W]AH=H]Q*JZ1=07,3*!ES$I4!O8Y[54A\(/I^NZSJEEJ][%#J@+S6:(F
M/-V;0ZN1N!XSC.,T =3167X:MKZT\,:7;ZI+)+?QVL:W#R/O8R;1NRW<YSS6
MI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !117%_$B65[+0M+6:2*WU76(+.Z:-RK-$0S,@8<C=M
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MU.G:7]O,EPL<P\]8O)C.=TGS?>QQ\HY.:\WMK^6/XGMXGDG9-.N-0GT'!;Y
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M^#["WUR.6._A#QL)I%D?8'8(69203LVY.>M=#0 4444 %%%% !1110 4444
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M69@H'4DXH X^R^'&D67@P>&5N+QK=9S<Q7!<":*7=N#JP  (/3BI;3P'9?\
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M!>,X; 9P3V/XUN^'/%>F^)X[@68G@NK5PEU9W41CF@8] RGU[$9!H YOX=Z
M$U?Q!XJ>QGLAJ]R3:6]PI5XX0<EBI^[O<LV/I7H%-#J6*A@6'49Y%*652 6
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M@K@!E(96!!P.H[5G?\*XT<Z9K-@UUJ#IJ\D,MU(\P9R\>T[@2O4E<GKU.,4
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M-9'4*9$^7<&XXYQGM6_I]FNGZ=:V2S33+;Q+$)9FW.X4 98]R<<F@"Q1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>=>*-,F@_M;5M>\9
MW>F'YSI<-G>>0D:*HQE/^6CENHYZ@"@#T6BL?PI=:C?>$M)NM7C,>H2VL;W"
ME=IWE1G(['V[5Q_BC1-5L]'\0>(]4\5ZA9W-OYLUA'97)CMX44?ND9,8=F.
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M@NK+Z$8(^G6ETGQI/>:EI]MJ.@W6F1:HC-8332H_FX7?M<*<HQ7) .>AYR*
M.LHJGJVJ6NBZ3=ZG?2>7:VL32R,!DX SP.YKGM,\9W4^I6MKJ_AZ\TF.]B>:
MUGEE216"C<0^T_NVV\X/OSF@#K:*X1/B2WV"'6Y?#]Y%X;FE5$U)I4R%9MJR
M-%G<$)(YZX.<5=O/&ET/$.J:'I/A^YU*]T\1/)MG2)-KIN!W-T/8#G.#T H
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MMW;"=S*&(!/UQFO6Z "BN-?QW/#>QO<>'KV#1Y+T6*:A(ZJ?,+[ QB/S!"W
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLI8EY=@Y\O:&&!C.01@5IZ=9W*_"SQO";>42RSZL8T*'<^XOMP.^>WK7IM%
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M:?>KXC-O#ITEHUK(!$490TC/C;LPN[=GG(KL_#=M+#\1?&<CQ2".1; 1R,I
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"[P-J[2N#N( KGH=)U(>&_A1&=/NP]I?HURODMF$9ZN,?*/K0!V6A>)=?O\
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MA);NCW+*CEBJ, V,L ..>: .FC\>W3:(NJ2^';B.*\EAATF/[0A>^:3../\
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MC,!U1) 8Y]S;DB,H#E NWKD ]#0!OZWKNJV6I16&D>'YM3F:$SR2-,((44'
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M+P<DKZ=C0!Z317*ZCXJU!]8.E^'=(CU.>*U2ZN'FNO(2-7SL4':V7;:QQ@
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MQU1CM"\ ;LC^\/3- 'H-%<))XWUZUU^#1+KPJJ7M]"TVGA+X,K;2-PE;;\A
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M;F&%=\D2X.)%3JQ#8'RD$9R.E ')^-M4U=_#6GR:MH_V>\M/$%D!';3>:EP
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M6.HWGQ/\+:P-,O8;*/0VAE>:$IY4F3\K9Z'VIUIHVI)\'O$FFM8SB]G.H^5
M4.]]\DA3 [Y!&/K0!Z/;SI=6T5Q$28Y4#J3Z$9%>9:/XVLM(\!Z]KMAX?BMD
MM-::WDMH92?.9I(T:3./O'?G'MUKT31XWAT2PBD4I(EM&K*1R"%&17D=AX<U
MJ/X7^([%]+NENY_$8N(H3&=SQ^?"V\#N,*3GV- '=6?BC6H?%=AHVN:/;6B:
MG%+)9R6]T92IC +)("H .#G()'UJI\7KK4[3X<:L^GI%L:$K<2-,4>-"0,J
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MS"WE<J0#C^'MGIQ0!Z115#3M1FOKB_BET^XM5M9S"CRC G7 .]/]GG'X5?H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHJ&[NX+"SGO+J58K>!&DDD8\*H&23^% $U%8_A?Q
M)9^+=!AUBPBN(K>5G15N%"N"K%3D GN*V* "BBB@ HHHH ***XZ\^(,-OXAU
M+1;3P]KNI7&G&,7#V4$;(N] Z\F0'H?3L: .QHKFM#\;6&M:M)I$EEJ.F:FD
M7G"TU&#RW>/.-RD$AAGT-=+0 4444 %%%% !1110 4450U/6;#1S9B^G\HWM
MTEI -I.^5\[5X^AYZ4 7Z**I:MJUEH>DW.IZC-Y-I;)OEDVDX'T')H NT5FW
M]_?0_8&T[3&OX[B=$F<3+'Y$1ZR8;[V/[HYK2H **** "BBB@ HHHH ***Q-
M&\1)J^N:[IBVQB.DSQPM(7SYFY ^0,<=<4 ;=%8UKXEL[KQ9?^'!%/'>V<$=
MP3(H"2QOW0@Y.#P<@<^M5Y/&>E1>.8O")\[^T9;?[0&"CRQU.PG.=V%)QCIW
MH Z&BL;4/$MGIWB72=!>*>6]U)96C\I05C6,9+.21@=A@'FMF@ HHHH ****
M "BBJ']LV!U\Z&)_^)@+;[68MIXBW;=V>G7C'6@"_16?I]YJ%S=WT=YI;6<,
M,NRWE,ZO]H3^_@<K]#S6A0 4444 %%4-8U)])TY[M-/O;]E('D6:*TC9.,@$
M@<?6N1C^*,<NJ3:8GA#Q.U[#&LLD M8MRH> 3^]Z&@#O:*K6%VU]80736MQ:
MM*@8P7"A9$]F ) /XU9H **STO-0;7I+-M+9=/6 2+?^>I#R9 \O9]X<<YZ<
M5H4 %%%8WA?7U\3:&FII;FW#331>67W?ZN1DSG Z[<_C0!LT444 %%%9?B+7
M;7PSX?O-9O8YI+>T3>ZP@%R,@< D#OZT :E%</+\3;6SMEN]3\-^(]/L#MW7
MEQ9J8HP>A8H[$#D<XKMHW26-9(V#(P#*P.00>] #J**AN[@6EE/<E=PAC:3;
MG&<#.* )J*RO#6MKXC\-:?K*0&!;R$2B(MN*Y[9XS5Z\NX-/L;B]N7\NWMXV
MEE<C.U5&2?R% $]%0VEU%>V<%W;MNAGC62-L8RK#(.#[&IJ "BBB@ HJ.>:.
MW@DGE8)%&I=V/8 9)J+3[^WU33;74+1S);742S1.5(W(P!!P>1P: +-%%% !
M16?:7FH3:K?VUQI;6]I!L^SW9G5A<Y&6PHY7:>.>M:% !15.VU6SO-1OK"";
M?<V)07";2-A==R\]#QSQ5R@ HJO?7MOINGW-]=R>7;6T332OC.U5&2>/85E7
M/B>"'6O#]A%"TJ:TLKQS;MNP)&'R01SD'VQ0!NT5!>RSP6-Q-;6QN;B.-FC@
M#A/-8#(7<>!D\9--T^>YN=/MY[RT-G<N@:2W,@<QMW7<.#CU% %FBBL7Q1XF
MLO">C_VC>QSS!I4@B@MD#2RR,<!5!(R>IZ] : -JBJ&B:Q:>(-$L]6L6+6MW
M$)8]W! /8^X.0?<5?H **** "BBB@ HK'T77UUC4=:M%MS$=,NQ:EB^?,.Q7
MSTX^]C\*V* "BBB@ HHJG:ZK9WM_?6-O-ON+%T2X7:1L+*& ST/!!XH N444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %><^.O$NBOXFL?#&KZE!9:
M=&JWNH&9L"<!OW<(]06&YO90.]>C4A /4"@#@?A)K&G:CX7N;>SNXII8+ZY>
M1$/*K)/(R$_4<BN_KG(O"$5KX5N="L]3O[59YI)OM<$@2:,O*9#M8#CDD?2N
MC' H **** "BBB@ KRC3;KQ#;?%7QW_86EV5\&DL?--S=F#9^XXQA&SGGTZ5
MZO6-IGARVTOQ#K>LQ32O/J[0M,C8VIY:;!MXSR.N: .*\*2ZCXL\:W7B+64M
MK*ZT%);!-+A9GD1VY+NQ R& ^7 P>O:N9T&'6-3T72O$%AX9U:3Q!-<QW4FK
MF[B\N9#)F1"IDSY>PE0NWC XKU@^&+5?&"^);>>:"Z>W^SW,28\NY4?=+C'W
ME[$=N.E9EIX#2RN(HH-<U--'AN?M46EJR+&K[M^W>%WE-W.S./PH YK0O#6G
M^)O&OC9=:$MY;07Z+#:M,XC0F(9; (Y/ ![8..IKE=>OKR/X%^(;1KN>3^RM
M<>QMYWD)<Q),NW+=3@''X5UVA^'+^]\9>-;NTU;4-'F>_1/,AC1EF3RE_AD4
M@X.<,,$9-;MY\-=(N_ 3>$1<7<=J\@FDN-P::23?O+,2,$D^U &#XHT.'PKX
M,GO].%Y+K&J26UK>7BW#>=,))5#[2S;4)R0,8 R.E06&AZW'>ZC;>'O#]_X<
ML[S29X3]IND9!=<>5(NV1B&P6!/T/45Z-K&AV>N:%-I%YYGV>5 NY&VNI4@J
MRGLP(!'N*R+?P8[QWHU;7]4U*2YM3:!W=8?)C/.5$:@;\X.XY/% '"V]W9^%
M]-UB2VT?5/#WB&#1IY/LTLOFV]V4 /FJV6#LAQSP<,<@]K'AK2]1L]9\/7FE
M^%]6L23MU2\N;R)UNXFC.7<"1BS;]K X]?I78VG@D&[:YUO6+W6V%K):1)=+
M&BQQ28#\(JY9@H!)I=&\&R:5>6<DWB#5+ZUL%*6=K.R!(P5V_,54&0A>!N)Q
M]: .$\-^%=.\0>"O$%]JWGW5Q%>WXM6:=Q]F"NQ&P X!SSGKT'0 5F:U:0:]
MX=^%=_J:-<W5W=VMM<2N[9DCP<@\]3R<]>:]:T?PM::-H=[I4$\SPW<T\KN^
M-P,I)8# [9XK*O?AU8W7A?0]&BU"\MGT26.:SNX]ID5TS@D$;3U].U &+XAT
M[1KKQ/!HL.B:GKK:?8*/[-CN%CM;568[79G9<R$# Y/ [5QVN1_VA^SYK#WR
M2M-I>H206HFF+O"HN54*6!PV%)7//M7ITG@:<ZG_ &C;^)M4MKR>W2WOIHDA
M!NE0G:QRF$8;B,J!Q4*_#32U\,:UX<^VWATG4I?.6$E<VS;@QV-C)^8 _-GI
M]<@'->,M/MM"MOA_:Z8C6T,GB&U9T61CN)QG.3^E:=CHEAXT\8^*I-?B>[CT
M^YCL[.!I658$\M6+* 1AF+9W=>!6O+X"%]9Z+#JFN7]])I.H1WT$SK&K$H!M
M0[5 *\?7GK5C4O!K7&LW6JZ5KE_I%Q>HJ7@MEC99MHPK8=3M8#C<.V* /.(9
M[W6-)\"V5UJ%V2NM7=B]PLI62:*/S%&6'.2HQGKWZUT4&C0>&_BK'IF@;K&W
MU#1)I)(@[-'YRN LF"3\PS731^!=*MX/#T%L\\,.AS-- H8$R,P(8N2.22Q)
MQCDU;OO"]GJ'B2+6II9O-CLI;'RE;"E'().>H/'8T <-X,LK/1/$&E66K:5J
MFD>(3$\;W7V@RVVJL$RY+Y.3P7 (4C'X5TGQ"EL'L=-TZ\74KE[R\41:?I[A
M6O"JEBCDD8CQRW(Z"IM,\%/9ZC87-]K^HZG%IN[[#!<B,"(E2FYBJ@NP4D L
M>Y[U>\2>&4U]K"XCOKC3[_3YC-:W5N%+(2I5@58$$$'D8H \[TGSM,U'QKI4
M.ESZ-9C1!=)8/<K*(Y"LBEU*L0N0!P#VK.U/0+2R^!UCXK22Y;7[>RM+B&_,
M[^8AR@"CG&T*=N,>_7FO0(OA[!'J5UJ!UG49;F^LGL[]Y#&?M((8!C\ORE=W
M 7 P ,=<W;SP597O@!/![W-PMDMM%;"92OF;4*X/3&?E':@#FYM/MO%_Q6U.
MPUI&N+#2M/@:WM&=A'YDA):0@'D\ 5)\-[)-.\5^.+2.626.*_A5&D<NP7RA
MA23R<# YYXK=U?P:+[78M<T[5[S2=26W^S2RVRQN)HLY 974@D'H:F\,>#[/
MPM<ZG/;75W<2:C*LT[7+AF+A<%L@#DG)/N>,#B@# \8+_8?Q'\)>)%^6&Z=]
M'NSZB3YHOP#@UR,X>71[[XE*"7B\1+=1L.K6,1^SD?BI<UZMXI\-VOBS09=)
MNY9H4=TD2: @21NK!@RD@X/'ZTR#PKIUOX*'A50YL/L9LR3C<5*X+=,;CDGZ
MT <EIEQ!J?Q'\6>)IY_+L-%LUTV&<<A,#S9F'7D'%<FT4>G0>&];TG0M8M6G
MU2U']M7UXAEO(Y7PPD0.20X/0@8XZ5ZAX?\ !&F^'_"=SX>22>ZMKKS3<R3L
M/,F,G#$D =N/PK(D^&27.E6VGWGB35KE+ QMIS-Y0^RF,@JV F'8 8RV>">F
M: .=OM)3Q%\>]2TF]GN/[-_L:.::VCF9%FPZ@*2I!QD@\=<#M3?&&C1)\3/
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M?M!:DLMH&"Z4EZ/WC<3&8?-U_3I[5WNL^%K76M&L=,GGF2*SG@F1DQN8Q$$
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M(W*0.>#UH Z:BLGPO:7UAX7TVUU.:6:^CMU$[S2>8Y?'.YOXCVS6M0 4444
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MI;QF$,2HSU)/WNO YK"\/3SV%UX8U26>26"RU>]T!II&+,\#,PAW$]<,BC-
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M:GI5R\(@F-FZ;94!)&0ZL 1N.&&#S70T4 4M(TJUT32;73+)66VMHQ&@9LG
M[D]R>IK+A\':?#X6U+P^LUR;34#<&5RR[U\XL6VG&.-QQD'\:Z&B@#F;_P %
MP7,MC<V6J:AIM[:6HLUNK5DW20C'RN&4J>1D''!)IR>"M-1=" GO&.C3O<0N
M\N]I7<$,9"1DYW$\8Y]N*Z2B@#G]:\*1ZKJ<6J6VIWVEZ@D)MVN+-DS)$3G8
MP=6!P<D'&1DU3NOA]IEU;:-$+W4HGT@R/;3I/F0R/U=F(.6SSZ<X((XKK**
M.6L](L?!<&IZY>7FHZE=W/E_:;J2/S965?E152)1A1NZ =R367\./#QM+K7?
M$<UA+8R:S=M)!;3C#PP DC(_A+,S,5[9%=[10!FZ_HMMXCT&]T>[>5+>[C,<
MC1$!@/8D$?I4&L>&K/6=(MM/EEN(3:NDMM<P.%EAD085U.,9QD<C!!/%;-%
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M!E*?)AB,8R^[C('4UT.G^&K338-7BBFG<:K<27,Y=AD,Z!3MP!@84=<ULT4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(NM1EAGF2WC+F*!-[OZ!1W)K L?%]_/?7&F7?ANZM-56T-Y;VK7$3"XC#!2
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M@,/(09'KS7#Z/#HT'P_\(P^(H=7TR>*TD-OJMFLB/;OOYC)0$@L,'##!QZT
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MBQZ=;RRS89Y))ICEY9'8LSMCN236$OQ"M1X?N;Z?3KF/4;:]&G/IFY6D-RQ
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MN%EWE5W%' ^X^WG'/0\\50T;QU-XITV\N4\.SII445PES</<J/G3<-BC[QR
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MF2TCO(Y;.1$M%B=&=RY&TCY.,$YR*]:HH XWPK:W$/B+QK)+!+&DVH(T3,A
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ML<DKRZA-=>79N5VE")FPS$,P^7/3-=7X[AEN? 'B&"")Y99-.G5(T4LS$H<
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M=V-N6B(VMR'8!3N )((- ';7>JVW_"Q?"MKJ>@HFLW-K</'<)=EA:X4[E
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=ZY97]M"(7M(S(\$L>Y64J&& P*D'IP:4:;=^&M4\,Z]:>%YX;.*RGM+O3;
M^?):F1Q(I XW?,#NQTSWH N^!;F[NO'OC=[^U6UNU>R26))-ZY$)&5; RI&"
M,@'GFNBUW4/$$5];V6A:7;3EXVEENKV9HX8\$ )\JDECGZ "L;P7#JDOB_Q9
MJVH:9<6$-^UHULDX&XHD97G!(ST)';.*I^+].^T^-H)M6\/7NNZ1_9_EVMO
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M.7+$+P!QSGH,^KC7/^*N.@FSE'^@_;%NB1L;#A"@[Y&0?QH UJ*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "@C(P>E%% ''6_PVT>WF@7[9JDFG6\
MXN(-,DNMUM&X.X87&2 >0"2/:NK%I;B\:\$*?:6C$1EQ\VP$D+GTR2:FHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^RR!6PP9W1BO(9MJ@]\'WJN^G6?@SXCZ1;Z!9F"UU*PNS<V-N<*[1!&1@I.
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M3\RZ_LYV+%MX\SF7S>N,?>]NE:=[H5I?Z[I>L2M*+G31,( K *?-4*VX8YX
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MC(5]S8.2&8# !SR>*Z71M0GU/2XKJZT^?3[@EEDMIN61E8@X(X8'&01U!!H
MOT5RWQ))7X:^(B"0182\CZ5G:;XRO[>XT&UU'0)+73M3VP6EX;E6<OY>Y=\>
M,KN"G')([XH [JBN+U;QOJ.E2WEW+X:N!H=E<"">]DG$<A&0#(D17YD!;KD9
MP2*EU#QAJ4>KZG::3X<EU.#2RBWDB7*I)N9 ^(XR"7(5AW&3P* .OHI%;>BL
M 1D9P1@UP?Q(O9-/U#PA<16\MQ(-8 2"(@-(QAD 7)X&21R>!UH [VBN.MO'
M3VUWJMGXCTLZ5<Z?8G42$N!.DMN"065@!R",8QW%/TSQC?RZGI]KK6@MI<>I
MHSV4INEER57>4D  V-MR<9(X(S0!UU%<19^/[BX^PZA+H4D/A_4+E;>VU W(
M+DLVV-VBQ\J,< ')/(R.:CF\?:G*=;_LKPP]XFC7,L-R[WBQ!@@!RF5.YL9.
MWMQSS0!W=%4M(U.#6M&LM4M@P@O($GC#=0K*" ??FJOB;7X/#&@W&J3PR3^6
M52."/[TLC,%51]210!KT5YI<ZKJUY\3O!D&KZ/\ V;.%O741W(GCD4PCC< /
MF!'(QW&":TT^(,[I'JAT-QX;DNQ:KJ7VE=_,GEB0Q8XC+\9W9QSB@#N**\W\
M.,Q^.?C5225%I9X&>G[M:@\)>--*L/"&B76G:"]CI=_JK6++]J,GV=V8@.2P
MR06&.HQF@#T^BN?U?Q5#I7B73=&\CS6NH)KF>7?M%M#&,EV&#G).!67IWCJ[
MN9=*N+W0)++2-7D$5C=M<J[DL"T?F1@?)O XP3U .,T =I17%:5X\N=6U?48
M(=#9-.TN\N+:_OY+E0L0CSA@N,L3C) ^Z".32Z;XYO+F;2I[[0)+'2=7D$=C
M=M<J[EF4M'YD8'R;P.,$\X!QF@#M**\Q\3>,[[5?!_BB6QT&2318H+JS^WBY
M4.S*K(76+'*!N^[. 3BNY\,G/A31R>OV&'_T 4 :M%<9\3M>U;P[X0>\TB$&
M9IXHVF,@4Q!I%' (.<YV^V<]JEO/%NJ0W]EH]KH"W&NSVS7<]J;P+%;1!MH9
MI=ISD\ !?7TH ZZBL/PSXC'B&"\6:S>QO[&X-M=VKN'\MP 00P^\I!!!XK<H
M **\+\+7/AR_T2YNO$7CW4;+4A=W"F,:\\3(H<A<1[O3IQ7;>$M=URU^&JZE
MJ-I?ZM=B9DLT$>)[F(R;8F?CY<@@EB.%&30!WU%<:OC>[M+?74U?1/L>H:58
M?VAY$=T)4GBPV"K[1@Y0@Y''O4,'CV^-QHL]YX=DM=(UB5(+:[-TK.'=2R;H
M\<!L<'.>F0.E '<45YCH'B*T\.3^.;Z],DA_MYHH((QNDGD,:;8T7NQ/^->B
M:;/=W.G03WUH+.YD0-);B7S/+)[;L#)_SSUH M45A^+O$D?A+PU<ZU+;M<1V
M[QJT:M@D/(J9'!Z;LX[XK-L_&&H#Q'8Z3K6@/I@U))&L9OM2R[V0;BC@ ;&V
M\]2/>@#KJ*X]?'B-\-I_&/\ 9[;(DD?[+YO)V2%/O8[XSTIFJ^-[VV\4GP[I
M6@/J-^;*.\7_ $E8DV,S*VXD< 8'KDL..] '9T5Q\?C+4KK4;C[%X<FNM)MK
MXV,MW'<*90ZL$9A#C)4-U.<X!.*T]*\2KJ;Z\HM3'_9%V]L<OGS=J*^>G'WL
M8YZ4 ;M%<A#XRU#4?#^AW^D>'IKNXU:(S")IMD5NH&3YDNT@'D #&3SZ56F^
M(JVWA^WU&71[C[4VJ_V3/9)(&>.;)!"G&'Y QTSN'2@#N**Y"R\7:M+K=WHE
M]X>6UU-;$WUI&MZLB7"!MI4OM&QLD=CUJ'X7^(-9\2>$(=0U>V53(TABN!*&
M,P\UP1M &W;@+WSUH [6BH;J2:*TFDMH!/.J,8XB^P.V.%W<XR>,UYQX5^(.
MICX>G7M=T]I7DN6AL_)F5GNY'G=%B"X&W;\JY.<@9H ]-HKE=-\5WY\0VVB:
M]H@TRZO(7EM'CNA<1R[,;T)VJ0P!!Q@C'>NJH **\Q\4WNGM\09+#Q9J]YIF
MCFSB;3A'=/;032$MYA>1"/F'RX!.,'WK:MKH>"_"]U=MJMQKUG)<*-,0R"25
MO,*JD(E)._YSPQZ#UQ0!VE%<E;>-)+6;4+;Q)I@TJXL[(ZA^[N!.DD .&*L
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M-\[!N(.6;!P,=N30!U5%9OA_6H/$.AVNJ6Z21I.#F.08:-E)5E/N&!'X5I4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 444A(&,D#- "T444 %%%)D9QD9]*
M%HHHH ***0D 9) 'O0 M>4>*O!/B2S\+>*I+/Q +P:B)KB6U72PTTV1@1APY
M/"@*,#@#I7J]% '/:=>7NDP:'I>HK=:A=78=7O(+7RXH=JEAY@R=G&%'7)':
MN0\1:W#J%AJFE>)/!]W<ZNAEAL3;:>\R3*<^6\<H!V'H3R""*]/!!&0<BEH
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M(8A.8R$+B5B5W=,XYQ7;@Y&110!Y-K*Q#7Y[C0M+UW2O%1OE5D@BE^RWB"0
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M>2VTJ6UQ;V*PS,A"2%5DW!3T.,C/UKD3HFJ_\,]S:7_9UW_:!D<BU\EO,/\
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M^$]!TRS_ +0U&33+62Y7S=B6D/E+\[M@\G^%<9/MUKNY)$AB>61@J(I9F/0
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MD3*[AE.W (R<]O6@#-^'E[)X7\":9/;^'+8ZEK30Q6S1WA+WTA#L7F)3]V%
M8_Q=:Z]O'K:;INMMKNF_9M0TD1%[:WF\U9Q*<1&-B%^\V5Y P17*OX9N)/AO
MX'DO](O;E=*96OK"(.D_EM&R$A5(;<I*G Y(!I]SX8M=3\+:W+X9\,WUC.LE
MM+ U\\JR7ODR"0J$E)91U )QDF@#J/\ A*/$]N;F"_\ "T<-S]D>YMGBO#+
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M@[2<$5KZOINFW'BZXU_6/#VMWFG:I90FW-M#.)8)(]P9)(XR&&X%2"PQP>E
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MS-&#$SKY:E &9N-V2,'IFKEEXK\0IJFE6^M:':V46L"06@2Z9Y(9%0R!)@4
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MPTD4L8)!4EE!5@0.QZT =C17GUA\0=5N/"B^)+G0HXK.YBA2P@6YS-<7$C!
MI&W"KN/!Y.!G':MO1O$&JOX@?0M?L+6UO6M?M=O):3M+')&&"L/F52&4E>V#
MF@#IJ*I:O>SZ=I%U>6UC+?3Q1EH[:+AI6[ 'M]>U<W:>*M9MM3N]+U[3+."[
M33GU&!K.Y:2-T4[61MRJ0P)7U!S[4 =C17G5O\0=;;1]&\0W.@VT.AZA)!"Y
M^UDW$9E(4/MV;2FX\<Y(P>,X&G+XKUF\UW5;;1-'MKNQTAUCNI9KDQR2R%0S
M)$H4@D C[Q )...M '81R)*@>-U=#T93D&G5Q7PD.?A9H)]86_\ 1C5VM !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %<;\3]/O=1\%2)I]I+=SPW5O/Y$(R[JDJLVT=S@'BNRHH X
M6VCO-3^*.FZZNFWMO8MH<L1:YA*%)#,I"L.Q(&<>E017&H^&_'GB:3^P=2OH
M]6:WFLY;6(-&66((5=LX3D=3VKT&B@#Q2T\'SP>&/!MUKGA^ZOXM/2[@OK*%
M&,L?F2;DD5006 *\@<X;.*ZW2;FR\)^%-2UFQ\(W6G0&Y3%LSGSIDRJ>:RG.
MS&3P3G"^^*[ZH;FU@O(?)N8EEB+*Q1QD$J0P_(@'\* )J\6\1^';K58_%MK=
M>%[W4M?N)YVL+Z9,P1V^W,81R< @# 4#.X\\<CV2*Y@GDECBGCD>([9%1P2A
M]".U2T >;6US?Z!XF;Q"=!U:YL-5TRWB>.WMM\]O-%N&UX\Y (;KZBEN7\0Q
M:QX>\8W^A3LR07-K>6-D/-F@CD8-$VW/S'Y1N Z9]J](HH \U\07'B#7=&L-
M9;P_<QQ:=KL%Y#9!?]*DMD!#,4SPV6)"]<"I(3J>M_$"?6!HM_::>= FM86N
MHMCO)YJM@K_#GL#R<$XQBO1J* /-+;2=<MO@-:Z9;6UW%JD=I&LEO&=DVT2
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M CG&:YS_ (0NZ32=!U;6]!GOD6^OKF^TZ#+2Q+<MN4@*1N*E4R!SR?2O9Z*
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M)EDBD&"IWL>E=9110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?T.]TF[:1;>[B:&1HB P!ZX)!&?PH 9H&I6FK:%9WME+YMN\8"OM*Y*_*>"
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M,DC#>3N(./O8!Z UZ#:^"UMQ=R3:]K5W=W%L;1;J:=/,@C/)\O"!03Q\Q!/
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MF13](HI/SJ3Q-<7&HWOB?5[59)HI]1L?#\0BE$;-$'5IE5^B[F?;GI7H.C>
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M'+KY@\UF9L'&.K''%1ZAX*MKN[AO+/5-2TN[CMEM'GLI55IHE^Z'#*02,G!
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M/6[>%V>*+7;U$=F+%@'P"2>I]ZK:YH^GZW\9].MM2@CN+=-#ED\B4;DD(G4
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M!]F634)A+Y<1.2B@ #!.,DY)QUJOIO@#3-+O;26.]U.:VLG+V=C/<[H+=B"
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M=9+*2S<QR6[C/S*WKR<YSG)SFI="\+V>A7%U=I<7=[?W>T3WE[+YDK*OW5X
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M2U::3=(TLLT\A>261CEF9CU)K-\2>"[#Q-J&GW]Q>:C9W>GB06\UC<>4R[P
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MB(R[]6<27.6R,A GR\<<"M:B@#EI/ >E_P!EZ39VUU?V<FDQF*TN[:8+,J$
M,I.""#@9!'85-%X)TJ*QT^UWW3_8K\:BLLDVZ26?YLM(QZYW'T[5T=% &5/X
M=T^ZUY]7G1Y)WL6T]T8_NVB9MQ!'KG]*YZ+X7Z-'%:027^KW%M8S1S65O/=[
MH[8HP90@QTXQSDXR 1FNVHH Y;5/ 6FZG?WES]MU.TCO\?;K:TN?+BNL#;\X
MQG)4 $J1D=:DU3P3I^HZG#J,%YJ&F7<=N+5I-/G\KS(@<A&X.0.Q&"/6NEHH
M R/#OAO3_"UA-9:8LBV\MP]P5=]VUFZ@'TX[U5UGP=8:UK4.L27-]:ZA!;FW
MAGM9MC1J6R2."">HYR,'I70T4 <M':6/@#0IWMK/5M4EN;@R3-%&;FXN)6'W
MGP.!\H&> .*K?#3PJWA;PN4N+9;:]O9WNYX5;<(=WW8P>X50H^N:[*B@"EJ^
ME6NN:/=Z7?(6M;J)HI IP<$=CV-9.G>#++3Y](G:^U&\FTH2K;274P=MLBJI
M!P!D *,5T=% &#=>$=-O)-?>4SYURW2WN]K@8549!MXX.&/K567P)IYLM+@M
M+[4K"73+86D%S:3A)3%@?*V00P^4'D=>F*ZBB@#/T71K30=,2PL_,,:LSL\K
MEWD=F+,[,>K$DDFM"BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "N?\ &WB(>%?"-_JH&ZX1-EM'
MC)>9OE08[\D?@#705E:SX=L->GTZ2_61QI]RMU#&'PAD7[I8=\=J /'+JRUJ
MP^&^GV-MX1UN/6M*G74Q?2"$JUP&WR,V)-Q4@L.F<8XKJ-=N=.\::S\.+LH)
M;"_>YE:)N01Y!8HWJ,C!'0X(KU"N9TSP'HFDR:<UHDZKIUQ/<6J&4E8VE4JX
M _N\G [9H Y;0?">@W'Q)\96<VE6DEE EFT-HT2F&-I8CO94Q@,=B\@9_.N6
MT9[Z]\/_  ZL%TR#5X1%?R"SN[CRXY&B?8A)*L#M5C@$?RKV>TT6SLM:U+5H
M5<76HB(3DMD'RP0N!VX)K)_X0/1ET&PTB'[5 FGR-+:7$,Y2>%F+%BKCUW$$
M'@B@#SW6="U&R\.3VM_8P:997GB.QDMK.SNO,%N&9!(%8!=N6&X  8W5MZQI
M]GX8^(-G+H5C;V+2:#>[DMH@BR&/8R9 X)![UU47@?1X],6R;[3*/ML=_)/+
M.7EFG0@JSL>OW0,=,"M.XT2RN=<M=8E5C=VL,D$?S?+M?&[([_=% 'C^J>']
M%A^ VE:K':P+J+K9SM=A1YLLDDJ%PS=6SN/!/8>@KJK#0=+UKXK>,O[4L8+Q
M(H+%4CG0.@W1MDX/&<#&>HY]:T3\+/#S6K6;2:DU@)/,@LVO',-NV[=F->@Y
MSZX!..M=+::)9V6M:CJT*N+K4%B6<EL@B,$+@=N": /%8=%T^'X 6^MBVC;5
MH;B)XKUQF:/9=B-0KGD (  !Q707MC>Z[XX\7QOX6T_6UC:&T1[R\$36\9A5
ML("C8R69MP(Y^E=S_P (5H__  AX\+;)O[,!!V^9\^?-\W[W^]2:QX*TW6=1
MDOVN-0L[B>(0W+6-TT(N$&<*X'7&2,\'!QF@#B=.T&2[\;>%M.\2QQ7EQ:^'
M)#,C'S(Y765%!;/#]<\]P#U%8'B;3K*V\!?$6RBM(%MK+687M8A&-L!?R-VP
M?PYW,..Q/K7L-MX:TNRU2SO[: Q26=D;"!%;Y$ARIQC_ (".:JWG@K1K^QUN
MSN(I'AUF42W8\PC+@* 5],;%/U% &U9V5KI]JEK96T-M;QYV10QA$7)R< <#
MDDUQ_P 6X_-^'5['N9=UQ:+N4X(S<1\@^M:"^%6M]6\.SQ7MW<1Z5]IWRW=R
MTDD@D7 !S][GG)Z!<=ZU];T6S\0:6^G7P<V[O'(0C;3E'#KS]5% '%:CI&D^
M&_B5X0?2[&WL$EM[Z.X,$83S$2-6&['WL'G)YKE4C58?">L:?X<L].L[K7('
M@U"6[WWTZRNV=^$Y#J3D%S@8]*]>O=$LM0U?3M3N$9KC3Q*(,-\N)%"MD=^!
M7.K\,-!6T2V\[4S% ZO9AKUS]B*L&'D_W>0.>3CC- '+RZQ)X!3QQH\((DW"
M_P!(0=6-R=FU1Z++V]ZK_P#"/W.D>(_#_AN#0[+6XM-T(S?9[RX$<?GO+B67
M!1@QS[<;Z]%U;P?H^M:WI>KWL+O>::<P,'(!Y##</XL, 1[U)KGABRUZ:VN9
M9KNUO+7<(;JSG,4JJV-RY'4' X/I0!G^ =+U'1]!N+/4+:&U47LSVMM#/YJP
M0L=P0-@< EAC' Q7/Z-X?T?6OB9XZ?5+&WOFCDM$2.X0.L8:W7) /0G &>OR
MUW6C:-9:#IJ6-BCB(,SLTCEWD=CEF9CRS$G))K&OO 6E7NJ7^IQW6I65]?E?
MM$UG=M$74*%"\<8PH^ASC&30!YCI<E]>:1X'TN/3H=8M8[C4O+M;NX\N.80N
M5BW$JP.U2V 1_#[5=U?2]<TO2I+*71;*WL-5\06NS28;W,6TH2\9<(-JNZ(<
M;<?,?6O2;CP5HLNAZ?I,,4UI#IQ#6<MK*T<L# $95^N2"<YSG)S3$\#Z*-#N
MM*E6YN$NY1//<S3LT[RC&V3S.H8;5QC&,4 <!K>C:M8:'XRO9=#L-$T^YT-E
M>TL[H2*TR[L2;0BA<J2#QSM%:6J:%IFB/\/[W3[.&"]?4X89;E$ EF62&0OO
M;JV2,G-=5%X$TE;#4[6XFO[U]3@^SW-S=W)DE,0SA Q^Z!DG@=36G>^'[&_3
M2TG60C3+A+BWPV,.JE1GU&&- '/_ !6EDC^'U[&LC1QSS6\$SJ<$1O,BOS[@
MD?C65K6@Z/HWQ,\"-IEE;63/)=HT=N@0.JV[8) ZD9QG_:KO-6TJRUS2KG3-
M1A$UI<H4DC)QD?4=#WS6%8> -)L=4L=3>YU*]OK$M]GGO;MI612A4J,\8PQ^
MIQG.* .2L&5?@QXUW$#][JPY]2TE1O\ \E-^&?\ V")O_1%=9<_#;0KN74?,
MDU 6FH.\MQ8I=L+=I''+[.F[//ID XX%:1\):6=8T?5-LOVK2(&M[4^9P$9=
MIR.YQ0!YW)J5QX-TGQ9X.M<BZ-PO]B)G&4O&VJ%_W'+_ )5Z?H6DV_A[P_8Z
M5;X$-G L0.,9P.6/N3D_C7'QZ7)XM^)-AK]QHMU8V6B021Q27D>R2YF8\87)
M^1!D@GNW%>A4 >'NL;V7A[7-,\.6=C9W.O6\D&I37>Z^G$D^&+ )T8%N"YP/
MI78^%F5#\068@!=6G))[#R(ZN#X8:!]D^RF74C;QN)+2,WC[;)@X<&$?PG(Z
M\G''0FK5SX T>ZU2YOFFU!!>!?MEM'=LL-T57:#(@^\<  ]CWSS0!YQI6E:=
M?GX1B\L+6X$UG<)*)H5?S%6#<H;(Y )) /0FNDT3PWH^L^*O'<NIZ?;WA%ZL
M2"= XC!@0DJ#]TGC)'/ ]*Z.Y\ :-<:5H]@DE];#1^+*>VN#'-&"NTC</4<&
MM;3M"LM,N=1GMQ)YFH2B6X+ONRP0)QZ<** /*/"D::]_PKK3M75;JQ32;BX6
M&<;DEE0JBY!X;:I.,]*/%%M!I4/Q,TK3HD@T[^S;:Y-O$-L<4S!@V%' W!5)
M^E>AOX"T4Z)IFEQ?:H!I>397,$Y2>'.<X<>H."#P:='X%T9-"U/2G%U,FJ?\
M?MQ-.7GG., ESZ 8 ' H X#XDZ'IVB_!1A8VL44D[VDEQ,%&^=]P)=VZL22>
M3ZUTGQ$M--OY+32+;2-.O/$>JCR()[BU25K:$??F)(SA03@=V(KIM>\+:9XC
M\/C1-065K(;.$?:WR$$<_A5+5/ NG:KKSZTU]JUI?/"L!>SO7A^0'(7Y>V>?
MK0!Q^LZ(=*\2>%?#6F:);:KI]AIMQ-%9WEP(XWD#(ID;*L&8!B<8_C)XJA<Z
M-?V=OH^B:Q8VUGI.H>* ZV$,_G1)%Y9?R2< ;3(I.W&.:]#NO!=A>:?8VTMY
MJ9N+!G:VO_MC?:D+9W#S.I!!Q@Y& /2F/X#T23P\='=+EHS<?:S<FX;[1]HS
MGS?,Z[_?TXZ4 8-EI6G:3\<%CTZWAM5E\/O))!"H1 WGH-VT< D #WVUV^E:
M18:'IZ6&FVRVUJA9EC4D@%B6/7U))K*T?P7IFC:S_;$4M[<ZBT#6\ES=W#2O
M(A93R3Z;1C& .?6IO"&BS>'_  [%I\\AD=9IG&9#)M5Y&95W'DX4@9]J -RB
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ*SO#_\ R+6E?]><7_H K!G\8:E-KNIV6C:$+^TTHJEY.UT(V+E=Q2)=IW,
M1U*C)Q0!U^<]*"0.M>5^!?$5QIOPZ\):;IE@+_5-0CG:**2;RHTC1V+.[8)
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MY;B\6(^3Y\MP[E9%/&]B1QGI3-?UV;Q#X7O-%MO FNS75U;M!']LLTBB1RN
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M CHPP581J""/4&N9\;I>6GC'PAKD.FWM]:6$EVMPME"99$\R(*IVCG&1U[4
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M,2&S@$D\  #U.>E5KSQQK"0:IK5GI5I+X?TNXDAG9YV%Q*L9VRR1J%VX4[L
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MAT. 2"K @$#TH ]#HK,T.;69[!I-<M+2UN6D)2&VE,@6/ P&8@?-USCBM.@
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M;(D+_8SI5[;2S@?+&TFP*#^1_*NTJ&>[MK4Q"XN(H3*XCC\QPN]CT49ZGVH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%/(Y#)D@$@!3C/0T ==X<\3:M?\ BS5= U:PMK>;3K>&0RV[LRRERW*YY"X
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M=0Q ;D$$9SSWK*7PMJ'B2Q\;7VH6,EC)KL,<-G:S,IDC$,9$;OM) )<YQGC
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M+#:Q[8X[BY(.6W*I(4 ],G)YZ5U?B&*5?#UA;7'AL:Y8D*E[:@(TB )PR*Q
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MGR9YV*["K$9"D."<\C!I-5UGQK8Z)KL=Y8:<EQ;Z<]W;W]JTGD?+G>A!^82
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M)#%*T;21H[1MO0LH)1L$9'H<$C\33Z /*/#>ARZY\&=3\%^8L6I:?)/8OOX
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ME@I7O@D&O5** /.TL/$&L>,-2UJXT62QM9] >QMXY98VDW^9N <*Q )R>A(
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MG6U6>;49PR^=<3O*8T)R4C#$A%SV&* ->&&.W@C@A0)%&H1%7HH P *?110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7.^,?$%SH&G6@L((IM1U"\BL;19B1&)'S\SXYV@ DX]*Z
M*N8\;Z+?:MI^G7.EI')?Z7?Q7\,,C[!-LR&3=VRK'!]<4 4[/7->TOQ5!H.O
MR6%U]NM);BSNK2%H?GCQO1D+-V8$$'\*B^'?B#Q+XLTFUUW4TTZWTZX@81P0
M(_F-(&P7)+$!>& 7D]#GM1;6&M>(?&5GKFI:0VE6NF6<T-O!-/')++++M#,=
MA("@+CKDDUH?#G1[[0/ &D:7J4(AO+>-EEC#AMI+L>H)!X(H J^*M9U[3[]U
ML[[0M,LHK?S$EU-MQNI><HH#KM  &6.?O<=*9I'C6YU?5O"T26\,=MK&E27L
MH()='79A5.<8^8]1Z=*HZIH.J_\ ":ZS=KX>MM334H(8K2^N'C*6(52K!E;Y
ML9._"@YSCCMF:5H?B?0[?PA?C0'N9](LY].NK1+J(.RMLVRHQ;:1E>A(//2@
M"3QSXFUJ;P_X^M+.2VMTTGR8ED"-YC120AGY###9;@XX'8]:;J9\0KXM\"J)
M=/FU62TO@)O*=844K$=Q7<6) [;AD^@IUUX3\2:MHOCX75E#;W>MB%[2(3JP
M^6-1L)[$;0"3@9Z<<UL6FGZWJ7B3PGJUYH[V"6%M=PW,<EQ&Y0LL84_*3D':
M>G3OB@"HWCO5M$TWQ3%K,%I>:EHLL$<+6JM$ER9P/+!4DE3D\\U>76O$V@Z]
MHUIXBDTNZM-6E:W$EE \1MYMA95^9FWJ=I&>#6?KG@K5=8N_&QC6.$Z@UC-I
M\KN"K20*#@@<@;E Y'?-6WM?$/BOQ!H,VI:$VD66DSF\E,MS'*TTNPJJIL)^
M4%B26Q]* #PEXC\3>);Z^N)8]-@TFPO;FSD C<RSE"0I7YL*!\N?4[N!Q7&S
M^)M;UGX.:'JEBNF:8UUJ<<,T5M;NB?\ 'P NT!^!E?F'.<GI7H/@;1+_ $72
M-7M[^$127&J7=Q$ X;=&[Y4\'C([5QEAX(\1V7P6TW138*VKV-^MV;3ST^<+
M.7P'SMR5/K0!V>E^(-7@\;R^&]<^Q,TM@EW9SVL31B0@[95(9FY!P0/0]ZL^
M%-?O/$5UK=PT<"Z9;7S6EBR*=\HC&)')S@@OD# '0]:YGXDRZA'X;T;Q-:VW
MV'Q!972I;6LCJ[L9OW3194D$G(;@_P -;GE2^ /A[9V]A;)>262PQ.K2;/,9
MW4.^?4EB<=R<4 :_BG7H_#'A?4-:EB,JVD1<1@XWMT5<]LD@5S;:YXKT"_T1
M_$3:7/9ZK=)9NEG"\;VLS@E!N9V#KD8)P/6M[QGH#>)_!^IZ-'*L4MS#B-VZ
M!P0RY]L@5SES;>)O%M]H%OJF@_V5;:;>QW]W.]U'()9(P=JQA"3@L<Y;& *
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M,V&'W\>9D?>QC&!CO7-^'M8\4:%\-+G6M/&F?V=IUS=R-;SQNTERHN'+D.&
M3&2 ,'D9[XKL[[3M9L_BO;Z[:Z6;W3KG3%L)I$G1#;L)BY<JQ!88/;)K/@\*
MZPGP;U3P^UJ!J<ZW@CA\Q<'S)79?FSCD,.] %G5?%^H77B"XTO1]1T;35L[6
M*>675,L97D!98U =< *,EN?O#BN@\->(X]>\(VFNR((5DB9YD#;@C(2K@'N
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB4()(T1&0-@= ^,'WJQJM]XENO!_B5=<T6SL(1I5P8W@O?/+-Y;<$;%QQWH
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MN&PH'85W/BC1[NWUW6=9M]+TOQ!8W%K'%?V,\@2X@5%8_NV((P5;.TX.>0:
M/1JP/%_B7_A%]%2ZCM?MEY<7$=K:6H?89I7; 7.#CC)Z=JT-$N;2\T'3KFP5
MELYK:.2!7SN$94%0<\YQBO.-<U/4];^*T1TO0YM8L?#,9WI'<1Q*+N5>I+D
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M2XN;=-6L&GM5+7$8N4+0@=2XS\H'O7CWB*UL[*R^+D%@B1PJED=D8PJL4RP
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MI,M[:S!;5OF(&UF)]AUZYJ[8ZYI.IE18:G9W1>+SE$,ZN3'DKNX/3((SZC%
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M4/V>6:ZNI)I#%S\@9V)5>>@Q4S^%=&D\-0^'GM"=-A1$BC\Q@R;3E2'SN!!
M(.<US_@7X@2>++ZYM+S3#ITIMTO;)6DW&>V9BH?IQR!GZBNHU+7]'T9X4U35
M;*R:8XB6YG6,O],GF@"#0_#.F^'VN)+-;A[BYV^=<7-P\\KA<[06<DX&3@=.
M:L:UH>G^(-/-EJ5OYT.]9%PQ1D<=&5E(*L/4&G'6]*$8D.IV0C-Q]E#&=<>=
MG'EYS]_/\/6J[>*- 32?[5;6M/&GES&+HW"^66!Q@-G!/!XH ;HGA?2_#\EQ
M-9QS/<W./.N;F=YY9 .@+N2<#TZ5-H.@:;X:TI--TJ P6B,SJA=GP6.3RQ)Z
MFI?[8TS^RO[5_M&T_L[;O^U^<OE;?7?G&*B@\0Z+=:4^JP:O8R:?&</=+<*8
MT/NV<#J.OK0 W7O#^F^)=.%CJ<+20K(LJ%)&1D=3E65E(((HT[P]IVEWK7MM
M'+]I:VCM6EEF>1FC3.T$L3D_,>>ISS34\4>'Y+F[MDUO3C/:*7N(Q<IF)1U+
M#/ '?/2I].UO2M7LGO=.U&TN[5"0\T$RNJD<G)!XXH S;KP/X?O-)FTN>R9K
M.:\:^D3SG&9BVXMD'/7MTI-7\$:)K=_)>W4=TDTR".X^S7<L*W"#@+($8!AC
MCGMQ6AIOB'1=929],U:RO5@_UIMYU?9]<'CI42>*_#LE[;V4>NZ:]S<JK01+
M=(6D!Z%1GG/;'6@#3@ABMK>.""-8X8E"(BC 50,  >F*HZ-H.G:!%=1Z= 8_
MM5P]U.S.SM)*WWF)8D]JSK;QOH=WXONO#<=];?;;=%.//3YY"6W1J,Y+*%R1
MVS71T 9NIZ#IVL76GW5[ 7GT^?[1;2*[*4?&.Q&0>X/!JJ?"&B'PS<>'3:-_
M9=P7:2'S7R2[EV^;.1\QSUJYJNO:1H4<;ZMJ=G8K*<(;F98]Q[XR>:+[7M'T
MRPBO[[5+*VM)<>7/+.JH^1D;23@Y'/% "W6C6-YJ>G:C/"6NM.,AMGWD;-Z[
M&X!P<CCFLD> O#PU7^T!:S;OM'VK[/\ :9/L_G9SYGE;MF[/.<=>>M=!:W5O
M>VL=S:3Q3V\J[HY8G#*P]01P:I:IXBT71)(H]5U:QL7F_P!6MS.L9;Z9/2@!
M]GHUC87&H3VT)234)?.N3O)WOM"YY/' '2LF?P'X?GTC3=,%M-##IF?L4D%S
M)'+!GKMD!W<]^:U[S6=+TX*;W4K.V#1M*OG3JF47&6&3R!D9/N*I/XQ\,QV$
M-^_B#2UM)W*13&Z0([#J <]1W]* *D?@#PW%IVIV"6#"WU-46\!GD)EV9P2Q
M;.>22<Y)/-:]SHUC>:CIU_/"6N=.+FV?>1L+KM;C.#QQS1J&MZ5I-DM[J.I6
MEI:N0$FFF5%;/(P2>:=_;&F"TM[LZC:"VN2%@F\]=DI() 4YPQP">/0T 5W\
M-Z1+<:M-+9K(VK1I'>AV++*J*548)P.">F*IZ7X)T32))I8(KF666 VWF75U
M),R0G_EFA=CM7V'H*T-+U_1]<$ITG5+.^\DXD^S3K)L/;.#Q7.^(/'VGVUO"
MNAZGIE]=_P!HVUK/$LPD,:22!&.%;((SUZ9H VW\+:1)X>M=":V)TZU\KR8O
M,;*^60R?-G)P5'4\TU_"NDMXG'B(131ZEL".\=PZ+* "%WH#M; )QD5/>>(M
M%T[4(=/O=6L;:\FQY<$UPJN^>!A2<\T[5-?T?1&A75=5LK%ICB,7,ZQ[_ID\
MT /U?2+'7=+GTW48?.M9@ Z;BIX((((Y!! ((]*QH? 'A^&:.<073W*QR1O/
M)>2M),L@ 82,6RXP!@'(&!C%2^$->N=?M]6EN5A'V35;FSB,0(#1QOM4G).3
MCJ>GM5?4O%J:3XX32[^XL[72AI3WLEQ.VPJXF5 -Q.,8;IC.: -.3PSI,NAV
M.C/;$V-B83;Q^8WR^404YSDXVCKU[U3U#P-H.I:Q+JEQ;3"><*+E8KF2..Y"
M\+YJ*P5\#CD=.#6E!K^C7-O:W$&K6,D-W)Y5LZW"D3/_ '5.?F;@\#GBK-Q?
M6EI)!'<W4$,EP_EPK)(%,K]=J@]3["@"+2-)LM"TJWTS3XC%:6Z[8D+%MHSG
MJ>3UJEJ/A72=3UZSUN>*9=0M%"1S0W#Q[D#;@C!2 R[N<'(J7Q)XAL?"^@W>
MK:A*B101LRHSA3*P!(1<]6., 5@7'CRT.L>&S:7NGMI&I0W4ES<F4,(O*16
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M%\BO;Q^'&FM5D&5,^V($@>H3\JP_&,4<$7Q0M;11':>7ITCI'PJS,1N(QT)
M4G\*]4U#PGHNIZ;96%U9DPV(46K1RO')#A=HVNI##CCKSWJ./P7X?BT&YT1=
M/'V"Z?S+A&E<M*V0=S.3N)R!R3VH Y[7]/LM+\=^ A9VT-LJ2W4(\M0O[O[.
MQVGVX!K,TBTD\+S:!97]AI>JZ*]Z$TS5[1\31R2;BAD7HV02"RG!ZD5Z+=Z3
M8WU_8WUS 'N;%W>V?<1L+*58X!P<@D<YK)L/ ?AS3=2CO[6P9)8G:2%#/(T4
M+'.2D98HIY/0#K0!5^)X)^&/B+'_ #Y/6;XKFC.H_#Y Z[GU-749ZJ('R1^8
M_.NYNK6"^M)K2ZB6:WG0QR1N,AU(P0?PKG]/^'_AG3);66VT]_-M)%EMWEN9
M9#$0" %+,<+AC\O3VX% '&:5I5A-X(^(UQ+:1232ZAJ@9W0$X7<5 )Z ')'N
M2:E\)*E]XXT+[<JS-%X/M9+<2#=AF;$C#/?A03Z5Z##X?TNWL-0L8K4+;:A)
M++=)O;]XTOWSG.1G/;&.U4M0\$^']3M]/AN+)P-.B$-J\-Q)%)''@#;O5@Q&
M .": /*)H%CL=:LM*CM#:R>.(HFAF)$!&U3L? /R>8%&,>U=!K>D:Q;6GC'4
MM3;1+<S^&YHI+73I'+.5#[)&5E'8NN?P[5W,/@OP[;Z1>Z5%I4*V%ZP>>#+%
M68!0#UX("KR,<C/7FDLO!6@6%CJ%G%9N\>HQ&&[::XDEDE3!7:79BV,$X /&
M: (O >F6>G>"M&^RV\<;RV,,DKJH#2,4#%F/4DDD\^M8OBZWAE^*?@+S(8WW
M&_#;E!R! ",UW%I:PV-E!9VR;(((UBC3).U5& ,GGH*S=>\+Z/XE%M_:MJTK
M6KEX)(YGB>,D8.&0@\CJ,T <CX:TJPN]>^($US:0S227YA8R(&^3R$..>W/\
MO2N4\,_VO=OX#2RBTZ=XO#\LD"ZDSB,/YB*Q7:#\P7:/H37L5GHUAI\E]):V
M_EM?2>;<G>Q\QMH7/)XX '%9T_@GP_<:/8Z6UBR6VG_\>ABGD22'L=LBL&&>
M_/- %3P'I5YI%CJD5Y-IS&7499EAT^1FBM]P7='R!@[MQQ_M5C^+/^2R_#__
M '-0_P#1(KM=)T>PT+3TL=-MU@MU);:"6)8G)8DDEB3U))-4/$'@[0?%$UK-
MK%D;B2U#"!UGDC*;L;ON,.N!0!I:H\\>DWKVH)N%@<Q8Z[MIQ^M>27=GIT?[
M-UO=P1Q"X6TAN8YU \S[474[@W7=O)'KVKT'2? /AO0]2BU#3[*:*ZBR$=KR
M9P,@@_*SD'@GM21_#_PQ%J*WJ:;AUF^T+#Y\A@67.=XBW; <\YVT <=XAEGU
M$>-)[+2]'AAMK86^I7E^SO),RP!L(HX4*& 'J><4[P[:P:CXZ\*RWD:SM'X0
MCF4R#=ARZ#=SWPQ_.NVN_!7A^^UF35;G3_,NI=IES*XCE*C"L\8.QB!T)!(P
M/2I=)\*:+HDUO-86C1R6]L;2)FFDD*0E]^SYF/&>GIT''% &%\/8DM]0\8V\
M*+'"FNR%448"YBC)P.W-4OBS?WEQI5EX3TF)I]2UR4QF)'"-]G0;I3N/ R,+
MSZFNWL=)LM-FO9;2#RGO9S<7!W$[Y" N>3QPHZ<<4PZ'IS:^NNM;!M22W^S+
M,78[8\Y("YP.>^,T >5^);W7M$U'0/%$OA(Z59:(1;73QWT<P-H^$*[5Y^7@
MCTKIM)AL]3^*_BB2\CAN=FGV26GF*&'DN)"^W/8MC-=M?V-MJ>GW%A>PK-:W
M$;12QMT92,$5P7B/PS%;ZGIXB\'/JVG6MD+:&2TOC%<1X/$;[I%WQXQU)QSQ
M0!PR6=C<> ;&Q@P^GR>.!"F&^]$964<_[M=MXFLKR+XB>'+/1K+2@D5C=2V\
M-X&CA$FZ,,5" _.%/''0FM+PIX*CA\,P6^NV4*W)U-]66VBD.RVE,A9%!7&=
MH('I]:Z+6_#VE^(888]2MS)Y#^9#)'*T4D;8QE70AAQZ'F@#RO4=(UG3ETZT
M=M"E%YXH,WV6*5S:Q2>02(W^7(RZ[MN.I%.\7Z3JUEX8\=7VHOH\37=A;^9:
M:=([;75R!(P8#!8'&>^WVKTD>#M 'A]M#_LY#I[/YC(78L9,YW[\[M^>=V<^
M]1P^!_#T.CWVE_86DMK_ !]K,L\CR38Z;I&8L<8XYXH Y?Q#H.EIXY^'MJMC
M (5:Z38$&&"0;U!]<,H//<5SOBI&M)/B;!9)'%$\FE>8OW4VOM$A..@*YW'T
MS7KUSI%C=ZA87\\ >YT\N;5]Q'EEUVMP#@Y7CG-0MX>TE[C5)Y+*-WU1$CO=
MY+"954JH()P."1Q0!QT.BZW%XIM=1OQX>LA%IUQ;F#3Y'\R>,A2/E91E48#Z
M;O>N8_LVRM?V>='NH;:);A6L[@3!1O$AN$&[=US@X^G%>FZ/X,T+0II9K&T<
M2R1>09)KB29EC_N*78E5]ABIV\+Z,WAR+P^;('2X@@2#S&X",&7YLYX(!ZT
M<QH5O#_PN3Q8WDQ[EL[)E.T9!(?)'N:[Q)$E3?&ZNOJIR*R)_"NCW'B.+Q ]
MJPU.- @F29TW*,X#*"%;&>X-+X8T-?#NAKIR;-JSSR@(20HDE9PHSR<!@,GT
MH YW6Y)[[QX]KI6F:7)?VFFJUQ>ZDSE$BD=L(J+U)*$EN.,"N6\*:9>ZEX/\
M)ZCH]SI4VI6"WPCL;PGRIH6G*DIC++MVJ <$8;!ZUZ/J_A#0]=U&*_U"S,EQ
M''Y6Y9G0/'G.QPI =<\X;(JI+\/?#,L(C%A)$%GDN$:&ZEC:-W^_L96!53CE
M1@>U #_ ]Y:W>@/]FTM=+>&[GAN;-'#+%.'/F;2.""Q)XQUZ5SFN227_ (F\
M2+IVF:.#8V4<.HWVIL[[D9&<(B#@*%)).1DGOBNZTK2;'1-.CL-.MU@MH\E4
M!)Y)R22<DDDDDGDUGWW@[0M2UD:M=61>[P@<B5U24*<KO0':^.VX&@#SCP];
MPZCJ/PL%XBSA-%N' D&X95(L9!ZX[>X'I6KH6BZ:VM_$@-8P,IG";2@( :W5
MFP.V2<GUX]*[/3?!^A:1+92V5D8WL1*MMF:1A$LF-X +'@X'';MBKL&BZ?;3
M:C-#;A9-18/='>Q\P[0N>O'R@#C% 'D/A[^V+NY\"I8Q:=<21>&VD@74F<(&
MWHK%=H/S!=H^A-6-0T":UTO1M/U1M-FBN?&22&VL7+PQ*R,6B((&/FWY7_:K
MT:Y\%:!=:38::]BRV^GC%H8IY(Y(1C'RR*P89'7GGO4L/A+0[>QL+**P58+"
MY%W;J';*S#/SDYRQ^8YW9SF@#A/%R'3O&>OR:;&L$S>#+A_W*[<NLF%/'<9X
MJOX@T_2+?X<^ Y+>&!&6^TW[.Z* 6+%2W/?(R3ZD9KT]]'L)-7.JO;*UZ;8V
MAD))S$6W%=N<=?;-85O\-O"=JZ-%I9Q%(LL*M<RLL+*P<>6I;"#< <#&>G2@
M#B(],UK6AX[B2#P^UO/J-Q!<7&HR2++&BHH0Y"D!53:P.>.36SX4LS-\1-6B
MUAH+R\M=%T^&*4_.KJ5?S67/52XZUT^J^!O#NM:C)?7U@7GE"B;9/(B3A?NB
M1%8*^/\ :!]*DUCP;H6NW<%W?6;&X@C\I)8)Y(6\O.=A*,,K['B@# ^$\=M%
MH.LQV6W[*FN7BP[>FP/\N/;&*9J5K977QQTH7D<<ACT.5X%D (\SS@,@'OM+
M5V&D:'IN@6LEMI=HEK!),TS1H3C>W4@'I]!Q535_"6B:Y?+>W]F9+M(?)CG2
M9XWC7=N^4J05.>XYZCH: /.+G0'U)?B#::.@C?3]3@U#3A&.$NTA1W"CU)&#
M_O5M:!JD/C_QQI^M0C-AH^FI(J_W;NX7+#W*QC'L6KI6LH_!GA\P^&O#\UZS
M2EOL\4ZAG=@29'DD;)Y !))/3CBHO /A=O"OAD6LZPK?7,SW=WY(P@E<Y*K[
M*,*/I0!!\4D5_ACX@W*&VVC$9&<'UK$U+3K.Y\8?#B"6VB:%;:[E\LJ-I80Q
MD$CH><'Z@5Z%?V%KJFGW%A>PK-:W$9CEC;HRD8(K*TWP?H>DMI[6EI(&T_S/
MLK27$DAC\P ,,LQR"% P>F.,4 <!K$,=M-\7(8(UCB.EP2;$&!N-O)DX]3@5
M/I&DW]WX9\$:EHTNF3ZE9:*J_P!GZ@3MEB=8]S*1DJP*@;L$<X->@3^&](N7
MU9IK0,VK1+#?'>P\U%4J!UXX8CC'6J=WX(\/WMCI]G)9ND>G1>3:-!<2121)
M@#:'5@Q& .">U ">"+RTO/#2&TTP:8(KB>&:R5@RPS+(PD"D<$;LD8XY[5T5
M5-+TNRT;3HK#3K=8+6($)&N3C)R22>22222>235N@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN
M8\?^(I/#7@^[N[8%M0FQ:V48ZO/)\J8]<=?PH Q;#XD27GCPZ2UC&NBRW4UA
M:ZAO.9+F)59E(Z8.6 /<BNTU#6--THQ_VA?V]KY@=D\Z0)N"#<Q&?0<FO(;S
MPUXP@^&]GH%MX4MXKG3&2[@ODU57D%PC;S($\ODL2W&?XNM;-WJUEXRUCX9:
MIY:/#=2W,K1GD+(L!)'_  %U_2@#L#X\\)C3!J1\0Z=]C,GE"7SUQOQG;ZYQ
MS]*T+SQ!H]AI*:K=ZG:0Z?(%*7+2C8^[IM/?/;%<EX=T^S?XL^.)6MHF?R;%
M<E0>'C;?^>U<^N!7$>&QJDFF?#:/3C8[UCU$PB_#-%YBO@?=YW!-V/QH ]DB
M\0Z-/IL&HQ:I:/97$BQ13K*"CN3@*#ZYXQZU'I/BC0M>N)X-)U>SO98/]8D$
MH8J.F>.WOTKR_7M$N8-(OH]4N=+N/M_B6P:>UT\MY<+DHKA@W(+#:Q^N>]=#
MXI1K7XB:=)8QB.Y.@7Z(8Q@G;L*#CT/2@"YXL^(>F:?HFHG1-6TZYU:TDB4V
M_F!R,S(C< \X#'Z&N@U/Q9X?T9IDU+6;*U>%D6199@&4L"5!'7D GZ"O+]6A
MTL?LZ:$RK#NVV30D 9\\RIYF/?\ UF?QKK-!L[>?XM^-9I84DD6VL8P67.%:
M-MP^AP,_2@#HF\8>&UOK2R.NZ?\ :;M5:WC%PI,@;[I'/?MZ]JEU;Q1H.A7$
M-OJNKV=E-,,QI/,%)&<9Y[9[]*\C@LK:W_9J26*%%E^TI+O ^;>+T*#GU"@#
MZ#%;ZVVNWGCCQO'9C0VC9H(IQJ22,WD&!< ;3C9R_P".: /0=1\0Z-I.?[1U
M2TM<0^>?.E"_N\A=W/;) ^I%8^M_$+P_I'A&3Q'%?VUY:YV0B&8?OI/[@/KU
M..P%<IX=TE+?QUX1M;JYM]1>R\-2&*ZB.]'(D15=3W^4]:P_%4:1>"_BA$BJ
ML:ZQ X4# !;[.2?QH ]HT_4;+5K&.]T^ZBNK67.R:%@RM@D'!'N"*L,RHI9B
M%4#)). !3#+!%)'"9(T>3/EH6 +8Y.!WQ7,_$MYT^&GB)K<L)/L4G*]=N/F_
M\=S0!1U7X@Z=)/H\7A[5=/OGN-7@L[I8W$A6-P^2,'U7@]*WM2\7^'-'U!;#
M4=;L+6[;!\J6=589Z9],^]<;XN@TJ*#X<_94A4KJ]HMKL SY.PYQ_L_<_2I?
M",-C-H'C=M32)G?5KY;XR@9V#[H.?X0F,>U 'HP(8 @@@\@BL;4O%_AS1VD7
M4=;L;9XY!$ZRS ,KX#8(Z]"#]"*S_AJUP_PU\/-=;C+]BC^]UVX^7_QW%9OA
M:QM9O'_CV:6".21[BWA8LH/R?9T)7Z'//KQ0!U=[KVD:=I2:I>:E:06#A2EP
M\H"/D9&T]\CIBLZ\\;^'[;PM=^(8=3M;FQMU;YHI@=S@9$?LQX '7D5YKX*"
MRR?#&.[PUNMG?M 'Y7SE;"_B%SC\:O>*$1-7^)B6JJ(3X?C>Y"CCS]DF"??9
MC]* /2_#^O6/B31H-3T^>*6*11N$;A_+? )0D=QG!IFI>)]"TB62+4=6L[62
M/86264*PWDA>.O.#CZ&CPN /"6C;0 #8P'C_ *YK7)V]A:W?QTU26X@25H=%
M@,>]00I,C D ]\<9]SZT =7=>*= LM8CTFZUBRAU"0@+;O,H<D]!CL3V'>EU
M7Q1H6AW,-MJNKV=G-/S''/,%+#.,\]L]^E>6V^F:YJ_ASQA;FX\/6]E/JEXM
MW/?"02Q,'.UBP.T;5V%?08KI_"D2O\0_&*ZB8I[I+>PBWL,AHC#EL9_A+[B:
M .PAU[29U@:+4;9A<3M;PD2#]Y*N=R#U(VGCVJ=]0M?MDMBMU"+Q(?/,1;YE
M0D@,1Z9!&?:O&/#'V9-#\#&V(^RCQ-=K$0>-I\\+_2NT\Z.7XP:RB.K-%X>B
M1P#]T^;(<'\"#^- &WH>OP?\(U8WVJZYI=TUQ*85O+5MD$KER%5<D\\8Z]0:
MF?QEX;CTA=6?6[$:>TAB6X,PV,XZJ#W/TKQG2;>.[^!'@JVF7=%-X@BC=?53
M<R C\C7>>([?4H_B=H4&C1Z7$8],N6MDO8V\H/OC#[ F/GVX_#- '?6-]::E
M917EC<Q7-M*-T<L3AE8>Q%4]9\2:+X>2)M8U2UL1*2(_/D"E\=<#OBLCP)IE
MUI=IJZ75YIT[S:E+,8]/)\N!F"[H\'D'<"Q'^U5+6+F\N?'LMKH]KI45Y9Z8
MKW-_J*N^(I';$:HK+Q\A))/H* .GGU_1[6WM[B?4[.*"Y1I(97F4+(JKN+*<
MX("\Y]*JVWC#PY>:;)J-OK=C)9Q2+%),)AM1B< $]B21C->6>&H8-0L/A?'.
ML4\/V[46 "_(=GFE< ]@5&!["NDNM!MM>\<^.-&D54BU#2;0.0/X_P!Z%?Z@
M@'\* /0;[4+/3+<7%]=16T)=4#RL%!9C@#GN35FO(M"U2?QQJ'A/1[T'S]$#
MWFL(W47$+&&('W+AGQZ"N^\</<IX#\0/9EA<#3YRA7J#L/3WH DLO&'AO4=4
M.F66N6$]Z"1Y,<ZEB1U ]<>U2W/B?0K.^^PW.K6<5WYR6_D-*-_F. 57'7)!
M!_&N#\1PV,/PK\*-IJ1"5+G3CIQC SYA9/N^Y7=GUYK0\,6%K-\7?'=W+ DD
M\36*QNZ@E 8 3CTSM7\A0!I^*O'FDZ1IFLPV6KZ>VMV5I+*EJTH+;U0M@KGD
M\=.N*T9O%FD:5I.G76N:I9V,EW"CJ)I FXE03@'L,_A7FMO'8R?LYZU+?+&;
MA_MDERS@;OM/GOM)_P!K.P#\*OZ;'KT_CBY&F?V09%T*Q5!J22,?)(?=LVGH
M6^]^% 'I%WK^CV$4$MWJ=I#'<1M+"[S*%D15W,RG/("\Y]*M65[;:E90WMG.
MD]M,H>.5#E64]"*\ACT*.'4OAII5[<66HP)=Z@P:U.^$@*SJHSU"D!<?[.*]
M@62".5;57C63;N6($ [>F0/2@![NL:,[L%102S,< #U-96D>*=!U^>:'2-7L
MKV6'F1()@Q4>N!V]^E8GQ6:5/AEK1C+ %(Q(5Z^69$$G_CFZCQ3#HEO:)-:+
M#'KBZ7=KI'D$JQ419(4+P5'RXSP.W- &O;^,/#=UJYTF#7+"2_#%/(6=2Q8=
M5'J?;K2ZEXN\.Z.TJ:CK5C:O%((W268!E8J& (Z]"#]"*\\UF&QB_9_T5]/2
M(3I%826;(!N^TF2/)7_:)+9_&NA\,65M+\2/'L\L$;R-+:1%F4'Y#;J2OT/?
MUP/2@#I]0\3Z%I6G0:A?ZO9V]G<8,,SS*%ER,C:?XN.>*6Y\2:)9Z/'J]QJM
MG'ITN/+N3,NQ\]-I[GKT]*\Q\':9?77A#PA?Z)?Z<NLV%M=K'97^62:!IMK$
M;3N7!51N /7!IJWE[J7B'PJ-(TW3-,N()-31K2ZW/;I=HZB0H4QD\N0?=J /
M4HO$&CS:;;ZC'J=H]E<2+%#.)04=R<!0?7/&/6JUEXQ\-:C'>26>N6$Z62&2
MY:.=2(D'5C_L^_2O-=<T2X@T:ZAU.YTNX%_XHL7GMM/+>7"S%%=2&Y!888C_
M &L]ZZW4(8H?C#H)CC1-^D74;;1C*J\9 /L,T :WA#QEI?C/3'N].FC+QNRR
MP"0,\8WLJE@.FX+N'L:Z*N ^$4L%M\*-*FFDCB0-/N=V"@?Z1(!DFN_H QY_
M%GA^VUI-'GUFQCU)R%%LTRA\GH,>I[#J:74_%6@:,TRZEK%E:O#L\Q99@K+O
MSMXZ\[3CZ&O*O%=[>7?@7Q)J5G;Z/I^CR:DXVNCO=3S),$,F[< K%ER!@X K
MK=+ALY/C;XA>58VNDTNU\K<,D*2V_'_COYT =:WB#1DL;:^?5+-;2Z.()S,N
MR3@MPV<'A2?P-1:9XHT'6;6YN=-U>SNH;89G>*4,(Q@G+>@P#S[5X^D-DUEI
M5M,L?]E+X]F2W0X\OR_GPH[;=V1Z5U?B1(X_B1J7V955I/"=P;H*,9Q( A/O
M]X#VH [:U\3Z%?23):ZO93&"!;F79,I$<3#(=CT (P<^E1Z;XO\ #FL&X&G:
MU8W1MT,DHBF!*J.K8]/?I7F=Q8VUG^S]HGEPI';3BQ:_<#!:-I4+[CZ<X^E=
M7XLBAC\>>!OLL<8N3/<1X0 9M_(.\'_9'R^V<4 =C%J5C/I@U**[A>Q,9F%P
MK@IL R6W=,8[UFWWC+PUIL%I->ZY801WB"2W:290)$/1A_L^_2O+I9)['P_J
M?PQ@=ENI=86QM2.JV,^9BWN @D4UTU\TH\0ZW9Z)9:+9P:5IT%O>W>HH\I:(
MHS+&JJR@(JYR2>2>G% &KXK\57FD>(O"-G8&W>UU>[:*9V&[*8!!4@^_7FNR
MKPR)V?3?@T68D^;C)]D45[>D\4DLD22HTD>-Z!@2N>1D=LT <G\2O$U_X3\*
MKJ6G"$SF[BA_?*67:QP>,CFM6XOYT\86E@-4T]()+9I&L7!^TR$$_.IS]T=^
M.U<E\</^1 C_ .PA;_\ H5&J_P#)P>@_]@6;_P!":@#L'\6>'HM;&C/K5BNI
M$A1;&9=^X]%QZ^W6EO\ Q3H&EZG%IM_K%E;7LN-D$LRJQSTX[9[9ZUPW@^'0
M)OA&LWB40^4;R:2_DD)5A<BY;!)7Y@V=H&.<8K.AT_7-4A\>0++H$=G/J-S%
M>2ZBLGFI&$78Q(. JIM*YZ<F@#TS4_$VAZ*95U/5K.T:)5=UFE"D!B0IQUYV
MMCZ&B3Q-H4.B)K4FKV2Z8_W+HS+Y;'., ]SD'CKQ7&^'[!5^*>Z[>*[N[;PU
M:)]H'S!F+N&=3[XZ^A]ZR-%TE[VTNH],O[*SU+3_ !7?S:=!=KNBEV[@R; 0
M<!6)RO(ZT >E1^)-$ET1M:35K-M,49:[$R^6.<8+=,YXQ4VDZUIFNV?VO2KZ
MWO+<,5+PN& 8=CZ'VKRC5KV^OKC3+-=*TO3M4A\2JE\C,TEI-<&V+Q2$C!.1
MMP#SN S78^&[#4-/\4Z[J>L:AHJR3V\'VB"Q9E$97?B1PYR,J<9[[?:@#M*Q
M]1\6>'](U&+3]1UFQM;N7&V&695;GIP>F?>M=65U#*P92,@@Y!%>2>*;JZOM
M'\?7-A:Z-9Z?$)+2]FNT>2>ZE2%1QA@$QN55Z\\XH ]4%]:'4&T\7$1O%B$S
M0;AO"$D!L>F01GVKG_$GCW0_#FE27LM[;S%+H6GE+, ?,W*'7ZJ&W'T K"\-
MR%_B5;EVR\GA2U;)/+?O6R?UKDM1EBN/ WB.:-E>-O&A*N.01YT?(- '>S>/
M;&V\6K%-J=@F@/HXOENV<89S-L&&S@@CMZUTEOKVD76CG5X-3M'TT*6-T)1Y
M8 ZY;H,5RTMI;S?'&"22)&:#P\7BR/N,;@C(]#@D?B:XN[CC6"_M9%4::WC^
M-;J,CY/+*H<,.FTOMS0!ZSH_B;0_$ E_LC5;2],7^L$,H8J.Q(ZX]ZJ2>+-%
MO+6YBTS7=-:[%E)=1L9 Z(@X\Q@#]T'K6+KBI'\7?"[6JJ)WL+U;O8.3" FS
M=[;^GO7.>"["UM_V=[NYC@03SZ;?-++M^9S^\ R?8*!] * .ZA\5:7IN@:;=
MZYK^EAKJ/*W*2".*<CJ4R>G([U=M/%.@7VF7&I6NL6,UC;'$]PDZE(^,_,V<
M#J*X71-<&B?!OPT+>V2[U:\MH[;3K9@#YDS="?15'S,?05:U#1K;PAX&L=*-
MG;ZIJ&HZE"LDET2L<UY(^[S9,<[05R!Z*!0!TQ\;^&VT"\UNWUBSGL;,?O9(
MY00K=E/H2< >N:S%\:6^M^%M+UC2-9TNQ%Q<PQS_ &M_,"LR[F@R"/WG(_PK
ME+DWX\0>/(M3GTZ6Z_X1I3*+&)HT! FV[@S,2P!'/H15/Q6 /@_\/-H S>:8
M3C_KD: /5-9\3Z%X>:)=7U:TLFEY19I0I8>H'7'O4TNNZ3#:6UW+J5HEM<_Z
MB8S+LD^4M\K9P?E!/T!KEO#Z1R_%;QFURJM<)#9);[QDB QDD+[%]V?>N'L;
M6WNK/0;0QI)I8\;72VB8RAA'FE0!TV[LT >NZ-XCT7Q"DKZ/JEK?"$A9/(D#
M;">F?K@_E5V\O+;3[26[O+B*WMHEW22RN%51ZDG@5R%O&D7QLO/+4+YOA^)W
MP,;B)W )]\<4WXE!7C\+Q7 !L9-?MEN0WW67#E0W^SO"]?:@#H](\3:'K\<S
MZ3JMI>"'_6>3*&*>Y'4"C3_$VAZK>"TT_5;2ZN#!]H$<,H8^7D#=QVR1^=<O
MKBI'\6]$-J%$\FDW@O-O4Q IY>[VWYQ2?!JPM;;X8:-/% BS3QN\LFWYG.]A
MR>IX 'T H [674;."_@L);J)+NX5FAA9@'D"_>*COCO22ZG8P7T=C-=PI=2Q
MM*D+. S(OWF ]!ZUR/Q+A>STW3?%$"DSZ!>)=/M'+6[?),O_ 'R<_P# :P9-
M1M+NX\<^-KRW^VZ=9VK:3:1!L"6-!F7!'9G;&1V!H [_ $GQ5H&O7,UMI.L6
M5[-",ND$P8@9QGCJ,]^E<IX=\8ZIK7A#Q)J%U>Z=83Z?J4]I#<SH1#&B;<%Q
MGG[Q[BJ%O'JMI\1O!MOJ;:/$PL[I8K;3HW4Q1^6N%9F8[ER!C@=#7+6/_)%/
MB+_V&+O^<= 'L-QXCTO1M%LKW6=7LH4G1,3EPJ3,5!R@)Y!Z_2LO0O%T>I:O
MXG,UY9_V3IKP-!=*X">6\*R%F?.",D\^E<[H@23QYX-6Z ,<?A8O:[NTQ,08
MK[[/TK)>XTZROO'\%OIUM?176LV-K';2,5A,[A 2Y'0"3)/TQ0!Z1!XT\-76
ME7>IVVMV4UG9@&XE28$1YZ9],]O6L2/QU;:]X+MM:TG6-+TZ1Y(UF^VOYBPL
MW)C;!'SD=*P@=17Q]KL.JSZ;+=?\(RQ=;")D4 .=H8,S989/IP1Q6!XC '[.
MWA@@#E[/./K0![!K/B31?#RQMJ^J6MEYN?+$T@4OCK@=34AUW25L;:^.I6GV
M2Z8)!/YR[)&() 5LX/0_D:Y;2E23XQ^(VNP#/'IMH+/=U$)+^9M]M^,UP[6M
MO<V*V7EH^F'X@B.&/'R&/!W*!TV[MXQTZT >N:/XFT/Q 9ETC5;2^,! D$$H
M8KGIG';WK0N;F"SMI+FZFC@@B4M)+(P55 ZDD\ 5QK1I%\;83&BJ9/#S[]HQ
MNQ<)C/TR:3XHA6T/2(Y\?8)-;LDO0WW3#YG.[_9SMH WM.\7^'-6@NI[#6K&
MXCM4,D[1S ^6@&2S>@]^E<AX,^(,_BWQ?J5NNJZ/'86]U+;VMD@+7%RB#B8-
MNQM/7A>F?K6AX@CCC^*_@TVRJ)WM[U+C8.3 (U*AO;?C'OFJ'PI\N-_&\C[5
M5/$MX2QX"CY>_I0!Z1138Y$EC62-U>-P&5E.00>X-.H **** "BBB@ HHHH
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M^N>,=<\4FE^*=#UN5(=-U2WN971I!'&WS;5(#$CJ,%EZ^HH ET30=-\.:?\
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M;16"H]U)YGRQ!_NY/3G'3KVJO+X\\.#PY?ZY;ZG!<6MD#YNUB"&Q\JD$9!/
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MFN$\Q;=6; 9ER.#R!S6?J/Q"T?1-;T;1KZ]@>:]A,DEP&VJ@"@JV,'[Y/'-
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MUH-0\SS?.V?Q_P!_'3=_M8S1JG@OPWK6H?;M1T>VN+D@!G93\X'0.!PV/?-
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M,VGANY-UXRAL&5+FW(P]L(L2,Y/\+-MV9_BQCO7?ZGX-\.ZUJ*W^HZ1;7-T
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MZ:""*UMXK>! D42!$1>BJ!@#\JK:KI&GZYI[V.IVD=U;.03&X[@Y!!Z@CU%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 444R26.&,R2NJ(.K,< ?C0 ^BD5E=0R,&4C((.0:6@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *YWQ!X4TS7]2M+[6G$]A8QN?L4V/(+
MG'[QP>"0 0,\#)KHJX'X@6^O:EJ6G6%OH5SJ>@!3-?16]S%$;AP?DC;>P.S^
M(@=>!0 _X96\<<&N3::C1>'I]09M+C.=OEA0'9 >B,X8C_Z]=W6-X>U#4+ZW
MD2]\/3:,L.U8HY)HG#+CMY9( &!6S0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5W*]P\?V58\2MMRP()XPO3WKHZ* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
@@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>svb-second_amendmentxtox003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 svb-second_amendmentxtox003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3W;[<TD>V3S+9XUV!6+<F0.VX#!7N: /2=/\0:/JMS+;:?JEI=31#+QPS*Q
MSC.!VSQGUK/USQ4NBWE[;FS,WV72)M4W"3;N$9QLZ<9]?TKG/"GA_5+?5-%:
M^LM4B&EVKQ%[FZMS"I*A=L2QC<RG&?FVXP.IK0\5Z#J6I:GJLUI;>9'/X<NK
M&,[U&Z9V!5>3W]>GO0!8A\6ZE;OI\FLZ$EG97\D<,=S!>"<(\GW XV*0"2!D
M9Y(KI[>[MKL2FVGCF$4C12;&!V.O53Z$>E<5+;Z]XAL=)T>XT"?3+2WGMIKJ
MXN;B%MPA97"HL;L22RJ,G&!FNRLY)9!/YMFUMMF95#,I\Q1T?Y2< ^AY]: .
M<T_QH]Y)87$NEF#2=1N&MK.[,X9W;YMI>/'RJVPX.2>F0,TFA^)M>UV"WO8/
M#UJFGS2LOFMJ7SA5<J6V>5UX)QG\:P[7PI>3:WIT)TR^LK6PU)KQM]ZLEHH!
M<KY"!MV6+ X8 *-P'7G5\%^";+2=+L[F^TU8M7CDE=G\TL03(Q!X)7[I% $^
MF>)M>U@R367AZU-DEW-;>;)J6UR(Y&C9MOE'NI.,U/)XIN[?5;>&ZT:2"PN;
MTV,%P\V)7D^;#>5C[AVG!W9Q@XQS5'PKX)LK))+W4M-5-3_M&ZN%D\TD[6G=
MHSP<?=*G'YU!JFGZQJVNV$CZ%]GU&ROU9-8CF01?9 Y)7&[>2R$H4*XR2<XQ
M0!I#Q9>1WMH;O1)+;3KR\-E!/)-B;?E@K-$5&U6*G!W$X() I=(\67&KWMN8
M=)/]F73,(;E;@-(%&=LCQ8^5&V\')ZC(&:RM.&O7_BE=0U[PUJ&(IF2R"W%L
M;>SC.5\P@2[FD*]3C@$@#J3G>'/!]UI4OAZQBT(6=QI-P[7.L!X\74.QU"@A
MM[;LIE6 "[?84 =;IWBVWU/7M2TRWM+A4L;=)O/E4H)LLZG8",E08R-W0\XX
MY.19^.]2;0K'7]1\/+;:-=)%(UQ#?"5X4DQAG0HO R,X)QUQ6N=,N_\ A--2
MU#RO]%FTF"VC?<.9%DF8C&<]'7GIS7)VNF>)+_X>6'@V;P[/8YM(;.ZO;BY@
M:-$4 .5".S,2 0!@=1DT =YKFKQ:%H\^H2QO*(]JI$F-TCLP5%&>Y9@/QKG[
M[QM=:99:DM[HRIJED;8BU6[W1RI/)Y:,)-@/#;@?EXV^X-/\1>&-2O+&]DMM
M6O+R4S17-O8W!B6%6CF24*I"!AG9M!9CUY]:Q=>T?7->35]6CT:XAF=+""VL
MI98A+(L-SYTC$AR@^\0 6_A]Q0!T=OXFOH-7MM.US1OL#W:N;66"Y^T)(R+N
M9#\JD-M!(&.<'FH(?&5Q#/9G6-'?3;6^AEFMW>??(HC3S")8]HV'8"< M@C!
MP:AF36]?US2[VYT*?3K/27DNA'/<1-+<2F-HU10C,JC#L221SCZUEZ=INN:Y
M)?-XCT&^@U"_M)K5;EI[=K>QC=3\D:K(6.>,MC+''0#  .@T?Q5<7]]96]_I
M1L%U&V:YL7\\2%U7:2K@ ;'PRG +#KSQ5_Q+X@M_#.ASZE/&\S("(H(_O3/@
MD*/R))[ $]!7-V6EZWJ]WHRWEG<Z/_95C+"]RLL3EYG54!BP6^4 ,<N!U''7
M"Z[X*UBZM99;?Q'<W<\=C/!$EY;Q.6:0')!4(JDC"YQP,\\F@#3USQI;Z)X<
MM-4>RN)Y;J)98[>%2< [<EGQA5&X<GKV!-6M7UK4[.]>VT[16O1%;_:)II9_
M(C R0$5BIW/\I.. !C)&169J&AZK-\+QHQQ<ZE]EBC(&U,D%3CKC@#&<\XJ+
MQ@->O]2BTR'1;ZZT!HMUVUE<01R7#$_ZHEY%*IC[Q'+9QD#.0!\/C6_U6]AA
MT'1([R*33;?4-]Q>>00DQ?:N-C<_(<\]ZZ#0-9CU_0[;4XH7A68',;D$HRL5
M89'!Y!Y'7K7#:KX>>[\4'4+OP1<:A92Z5;6\4$<]NAMG5I2R$&51P&4?+D<<
M5L^&O#.KVNB:=%=:O?:?]FD<K8V[Q2HL)D+1Q.[(Q;:F%R".GXT 2V7C5[O4
MK2-M,\O3[V]FL;:X%P&D,L6_=NBQ\JGRWP<D],@9HTGQJ^I:CI\;Z9Y-EJ<D
M\=E.+@.[&+<6\R/ V A6QR>P.":Y_2O"^I6^JZ=)_8TD&L07TDU]KAF0I<Q$
MMD##;VW J I4!<>PS'H_A/58+C3!#IDNF:S"TW]I:[YL;B[#(X) W%GW.4<!
ME&W;^! .M3QA;3>)=1T>WMWD^PVC7$EQNPC.I :,<<D9&3V/'4&J&F>-=1N8
M=$N]0T%+6QUDQK;S0WHF96D0NFY-BX&!R03BL[3O!FN:3KR;=06YT^+2);4'
M[.B%W9B=I.XG<2=Y8]3G/6LC0O"%];0>&DMO"<^D:I8/;_:M3DNXBK*H F 5
M)&+;QN&"!USQB@#U2\O+?3[*:\NY5BMX$,DCMT50,DUS%MXZCN?#%MJHTNX6
MZN[V2QMK L!(\JR.F&)X7A&8_P!T ]<<K?\ @_4;R.-/^$IOY52Y2XV7<$,B
M93)4854R Q#<D\HM8ECX5\166AVMQ(8[O4=.UNXU"&V.V/S8W>8, P) ++*7
M&>AP#B@#I(_$>I6CW:ZYHGV-8+1[M;BVG-Q RI]Y2Y1=K\C@C!&<'@T:#XEO
M-5M);V^TV"RM(X/-9X[T3LO&=K*J@@@9_*JUQ<>(M>BOH1H,=G8&REC^S:FZ
M,UU,PP%/E.P6/&X$YR=W3BJ_A_2)AXKCU2#P]_8%I#I[6LL.8@;B0NI7B)B-
MJ!6 8X)W],4 :FB>++;6=.U34'M;FSM]/N'A;SXV$C*J*^_9C<,AN%Z_B<"7
MP_XFAUW2[S4'MI;&&VN)86%U\K )U9@?N^N#T[TGAS3[JPN]?>YBV+=ZFUQ"
M=P.Z,Q1+GCIRK<'GBL=?"FH7^C:MI\MR; 7.L2W8.Q91-"6#!6&?NM@9'H,'
M@F@ 7X@"Y\.7.KV>E2.4U./3X(9I?*,N]XU5R=IV@^8#C!.*T+;Q/=P:M%IV
MOZ4NFR7$4DMO-'=">*38,NI;:I5@.>1@@'GBN7D\,>)K?1=6$H.HSOKUO?PP
MQK%$TD<<L3,X)? R%^Z2,;?>MBYT[5/%NM64VHZ3+I.GV45P,3SQO+-)+&8N
M!&S *%9CDG))'% $T'B[5KFR@U>'PU+)HLY4QR)<;KHQL0!)Y 3[N"#C=NQV
M[59O_%-WIU_^^T:1=,%Y%9?:GFVR.\A50R1X^9-S 9W9X) (%9NGW'BW3] L
M] @T+;?VT<=L-2>6,VFQ<+YN-_F$E1G9M'/?'-,\2Z?K&LW@MQH6+ZWNT?3M
M9BE0)!%N4LS9;?NP&4J%(;([$X +S^-7756B_LS.G+J2Z6US]H'F>>V #Y6/
MN9(&=V<<XQS5J[\706GC&VT!K9V25562[#_+%*X=HXR,=6$;=_[OK7*R^%]1
M;699?[&D;6FU<74>O><FQ+;S =N-V_B+,>S;@]<\YI\_@?6]4T75-0FU2\L]
M8O+IK^.R7R&C26,C[.I?86X5(P</CKZF@#?U'QG)97&JR1:4T^F:.P2_N_/"
MLAV*[;$P=^U64G)7VS75 A@"#D'D$5YEX@\.:KKJZE -$OK2;6+>)97AOT%L
M',85FG3=DLG3Y 0X5<YYQZ9'&(HDC7[J*%'T% #J*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ JE=:1IE]=0W5WIUI<7$/\ JI9H%=T[_*2,C\*NT4 %
M%%% !1110 4444 %,AABMH$@@B2**-0J1HH55 Z  =!3Z* "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K,U[5Y-&TX7
M$&GW-_<22I##;VXY9V.!DGA5'4L> *TZX[XB3W,&EZ;MEOH=-?4(UU*6Q#^:
MEOM;."GS %M@)7G!H CE^(!L=&U^ZU/1IK6^T1(Y+BS$ZN'23[C*XX(.#VXQ
M6YJWB&/2M0T6T:W>5M4G:!"& V$1L^3Z_=Q7DMUIGVBU\=V.D:9JJQ:GI=O+
MIPNEGD>Y6(R;R#)E@<GA202""!S737VOQ>)_$O@N32[*_>WMKUGN9I;22)86
M,#@(=P&3UR1D#CGD4 95WXK\0:YX%^('V^P>VBLY+F&*59T/D%%0>5\O)(RS
M;O?%=9IOC6YCO=$L[_0;JTL=3 BL[V29&WN$W /&.4W $C//J!VXV9I(O#'Q
M-T%[2\&HW%]>7D$?V:0B6)P@5E;&TY],Y]J[#Q1;3RS>!?+@D<0ZK$TFU"=@
M\B09/H,F@!;KQ_<@:G=Z;X<NK_2-,E>*YO$G1"3'_K/+0\N%YYR,X.,U)JGQ
M CMM2TRPTK2I]5GU2Q^VV0AD5!(,C@EN%&TELGTQUKF].U;_ (13POKGAB]L
M+^35?M%V+***TDD%XLK,T;*ZJ5Q\V#DC&#FK&@:%>Z/XU\'VMQ"Y^Q>&VMYI
M0I*+(&3*[NGKB@#6@U>U/Q'O[:+1KC^WDT1;ALW?R.-RXB SM!W8&_%9/ACX
MCZF?"=CK&O:7)]ENM1-K]M69-J*\TB@E0.%3"H2>O!YJY8VEROQ]U.[-O*+9
MM"1!,4.PMYB\;NF?:LWP1ID&N_"S4/!=]#<6]]%]ICG2:W=!&S3.T;!B,-@[
M6X)Z4 =WJOB*/3=?T;1EMWGNM3>3&U@!%'&NYG;VY ]R:VJ\R^&4FH>)-2NO
M$NKPLES96T>C1AN[Q\SO_P "? S_ +-=WH>MV^OV#7EM%/$BS20%)TVL&1BI
MXR>,B@#-UOQ3-8:W!H>EZ5)JFJ2P&Y:)9EB2*$';N9V]6X  .<&LRX^)-G9^
M%KS6;K3[B"6PO5L;VS=@7AD+*,Y&0PPP((ZBH=5N1X8^)C:[J$-Q_95]I:VO
MVF&!Y1#*DC-M8("0&#<''45R>LZ??:EX7\2ZPFGW21ZMKEI+:P/"PD:&-HT\
MPIC(!P3R.G- 'JVA:A?ZG8-<ZAI$NEN9"(X)I5=V3 (8[>%)R?EZC%8NI>,K
MRWU74;73?#MWJ<.F;!>RPRHK*60/MCC/,A"D' QUP,UUM>5^-)-.BUC5+FTC
MU[2?%,<8%G-80RNFHD(#&&"@QN,_*0V",>F* .[T_P 0Q:CXDU71DMY$?3XK
M>5I&XWB4,0,=01M[^M<+XC\7_P!H6_A35K:TN<+X@DMOLT; O,R++& .@^9@
M.O SS5JVU9_#/Q!U:ZURTNU.JZ?9&%K6UDF5Y8PX>,; <-EA@'M7-VD>I6?A
MKPK=3:1>F6W\37-Q<6Z0EWC0M,2<#K@'C'7C&<B@#O[/QR([O4[/7]+ETBZT
M^R.H,K3+,LEN,@NK+W!&"/I7+^(O%6IZK;>%);C0KO2[:]URQ>VF:X5_,0OG
M:X7E"5.<'(X/.>*BUNWF\>ZWK]WHL%RUI'X<ET^.::!X1-<.^\(H< G 4 GL
M32:GXA'B'2O!UC8:9J)N+35K"2_62RDC%IL8 ABR@$Y],\ F@#:;Q+IVE^*/
M'-Q::/=3:AI=M;SW;"Y)6X7R]PV*<A2%ST'.*WM8\8V>E^$[77X87NTO3 MI
M!&P#3-*0%4'UYS^!KG_#5A-_PM_QY+<6L@M;B*S5'>,[) (L, 3P?0UA^%M'
MU*3Q3IOA>]M;@:7X5N;BYCGD0[+C<?\ 1L'H2JNQXZ;: .E@\0Z+8>-_&$CV
M5S%=:;8Q7-]<>>SK(@CW (A.%( [8S6MHGB74M2NHX=0\-W>GQ7%N9X)_-69
M&48^5ROW&PP(!Z\X/%<I:V]Q!\4?B!>2Z3<7MM)IUN%A$?%UB(;D4G@D\C%+
MX2>VA\46]MX5N-:?0VM93>V=_'*(K-AM\M8S* 0V2P*@D8'M0!8\+>,=%T_X
M9:?JFF:7>)#=736MG8&<S2RS-(P"[W/<@G)/ %;ECXQG.J3Z5K.C2Z9J"VC7
MD*>>LR3QJ<-M=?X@<9!'?->;^%M*U*S^$OA&^;3KMGT?63>7-J(6\WR=\BLP
M3&20'#8] :ZJXNAXO\:0:II4%TVG:7I=TCW,MN\0DEE"@1J' +$!23@8'% %
MJW^)DLVF:7K3^'+N+0[Z2*(WK3IF-I"%!\OJ5#'&[CU (QGNYWDCMY7BB\V5
M4)2/<%WG' R>!GUKRVZL;L_ 70[06LYN4&G[H1&=ZXFC)RO7@ YKU:@#Q74/
M%NMZW\)-=U#4[62W6+44$5PDJD[1>(/+"IS\HXSW]Z[^Q\8W3^)+/2-5T"YT
MS^T(Y)+*62=)/,V %E95^XVTYQS7G2>:?A5KWA[['>C5+;51)) ;63E#>HP9
M6QAACG@G@9Z5WOBBTFN?B!X-9(I#$GVX22*I(CW08&3VR: &VWQ!,[6MZVB7
M,>@7=T+6#4S,GS,S;%8Q_>5&;@-[@X&:FM?&\^H>*;W1+#0KB?\ L^Z$-Y<F
M9$CA0J"'YY;.3\HY^4^U<#X<T31H=-TKP_JEGXFGUJ"=(9[)9[D6Z;'R)N3Y
M7EC <8/I@9KL_"5C/_PD/CL2Q21+<Z@HCD9" P\E1D'N* );3X@FY>SO'T2Y
MBT&^N1;6VIM,AW,S;49H_O*C-P#[C(&:?=^.+LW>J+HWAVYU2STJ0Q7=REPD
M?[Q1ETC5N7*@\].>*X;PUHVBQV&CZ#J5GXFFUNWFCBN+(3W/V>,QMGSN3Y7E
MC:&&#Z #-;VE:TG@EO$VEZE97[W4^I7%[8K!:22B\27YE"LJD;L_*02,4 9?
MQ(\17>MVWA"/2[6YFT;5KV!]T5V(#=!@?W!P05]R3C/TKU+1;?[+HMG!]C:S
M\N(+]G:;S3'_ +._)W?7->5W/AW4M)\._"[3IK:5[BRU2![D(I;RLY8[B.@&
M<9Z<5ZB-;M_^$E.A>5.+G[']L$A3]V4W[,!L_>!QQCH10!SGQ7NC9?#^ZN0[
MH([JU9F3.<?:(\]/:K-AXQNG\1V>CZOH%QI3ZA'))8R23I()=@W,K!?N,%.<
M<]^:K_%6&YN/ -TEG:R75Q]IM62&-<E\3QG'Z5GW&IQ^+O'_ (8.F6UZ(M*:
MXN;Z2>UDA$):(HL9W@98EN@SP* (M'\9:+HW@_Q+KEGIEU%;6.LO#<QO<-*T
MDA>-&=2<X'S@[1Z>];MEXQNG\266D:IH%SIHU".22QFDG1_,V ,RNJ_<;:<X
MR:\XM-,OQ\*_&UN;&Y$TOB4R1QF)MSIY\!W 8Y& >?8UZ%XFMIIOB#X+DCBD
M:*-KWS)%4D)F# R>V30!R_C/QQ=ZO\.M>O;+1;M-&>.2"WU-9URQ#;=_ECY@
MA88!Z]R .:Z/^T=,7XF:/I\EE.VJ2:098[H7#"-8\D%3'G!.<\XS7!RZA-9?
M!:]\%G2]1?7[6"6VDMULY"NT2$^8'QM*E>1SDG %=3+9W)^-V@W0MIOLZ:"R
M-+L.Q6W-P3T!]J )V^)T[:+<ZW;^&;R;2[*62.\G\]%,>QRK%%/+X !/0<XS
MD'&QJ7C&6/7$TC1='FU>Z%JMW.4F2)(HF.%Y;JQP<+^M<K:6-V/@9XAM3:SB
MX?\ M';%Y9WMF60C ZG/&*L6-X?"?C2XO=1L[YK/5=*LUAFM[22;$L093$0@
M)#'<",\4 ==X3\4P>+=.NKVWM9K=(+N2UV3<,2F,DCMUZ5#K?BF:PUN#0]+T
MJ35-4E@-R\0F6)(H@=NYG;U/  !Z&L?X5RRSZ3K\TT!MY9->O'>%L9C)8$J<
M<9'2DU6Y'ACXF/KNH0W']E7^EI:_:88'E$,L<C-M8("0&#<''44 3R_$BTM_
M#TNIW.FW44]KJ*:=>660TD,C,!QC(<88$8ZU=TOQ;=W'B5=#U;0I]+N)[=KF
MU9YTE$J*0&!V_=8;AQS]:X6ZL+[4-/U+6UL+J.'5/$]C/;Q20LLA@C:-?,*D
M94'!/(''-=GJUO,_Q5\.3K#(T*6%XKR!254DQX!/09P: +OCOQ!<>&O"5W?V
M4:R7S,D%JC]#+(P12?89S^%8Q^'NI?V?YP\::_\ VYLW?:?M1\CS/^N.-NS/
M\..E:WC_ $&[\1>#[NST\J+^-H[BUW' ,D;AP#]<8_&LE?B?;M8>7_8.M_V[
MMQ_9?V&3=YGIOQLVY_BSTYQ0!HWOB74-'72-(DL%U7Q'=PEWAM9!%$ @&^0L
MWW5R1CC))Q5[PYXE&NO?VL]C+8:EITJQ75I(X?9N7<K!APRL.A]C7+7L^HZ)
MXOT+Q1K]FRQ2Z2]C?-91/,EK,760$A06VG!7//-+H>DOXIUGQ7K&_5-.T[4W
MM8K2:)GM9Y%A4Y<9 8*2V!D<@4 6?BS?7%CX9T]H-1N-/675;:&:X@G,3+&Q
M(;YAT&/Y5SNI3QZ1?:2WA'QMJ.LZE-?11OI\FHK>I)"3\Y8<E !SNR,5=^(6
M@C2/!6GVR2ZKJT,>M6UQ,;IWNY?+!^8="2N!T]SZUG>*KK0_$&BM8^$?#%Z-
M>:1#9W4.DO:?9F# [S*57:,9[\T =[K/BJ>SUU-#TC2)-4U+[/\ :94$RPQP
MQ9V@L[=R0< #M6;<?$JRM?#!UF?3[J-X=173KRT)!DMY=V&Z9# 9!&.H(JI<
M71\)?$2[U;5TN&L-2TV"+[9#;O*J31%LHP0$KD-D<8ZUS-]IFH7GAR\U0Z?=
M1KJGBNWO(('A82" ,BAV7JN=I//;% '8W_CZ]TI-)CU#PQ=PWNJ3316]HMQ&
M[Y50R9(X&XD#K\O)-6;CQCJ*7MII-KX=EN-;DM?M=S:?:XU2U0G:-TO0DD'
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M$UU&ZW03&4W#A6&1P<CGK47PR\1ZOXG\+)J&K6AC+R2&*XWH1*/-<8"K]W:
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M5HI()\'D=U8<.IR,,/Z52UOQ!J-AJ46GZ5H%SJEPT)G=A*L,2(#C&]N"Q/\
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M)] 3C%=!K1*Z%J!!((MI""/]TUYCJUQ:1ZW/=>'8=<TOQ1)?+OL4AE-M>C>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.LOGL94M2OF%!(3N[%<YS@UM+H=OH/Q9T^"QEN!:MHETR0RSO+Y3;TR5+DD
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MHO,=I&SM '?.*Y/0M6D\+ZMXLTCRM5U.PTN>U>TAA5KJ>-9H\E!D[BJD9Y/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !15'6M271M"U#5'C,J65M)<-&IP6"*6QGWQ4NG7@U'2[2^5"BW,*3!2
M<E0R@X_6@"S16?:7M[/JM_;3Z7);VL&SR+II59;G(RV%'*[3QSUK0H **IZG
MJEGHU@]]?S"&V1E5G*DX+,%48'/)('XU3.OQCQB/#OD-YAT\WWG;N,"0)MQZ
M\YS0!L4444 %%8^MZ_'HMUI$#P-*=2O5LU*MC82C-N/K]W]:UI&98V9$+L 2
M%!QD^E #J*I:1=WE]I<-S?Z<^G7+YWVKRK(8\$@?,O!R #QZU=H *P_$'A;3
MM>T._P!-:&&!KR)HS.D*EDS_ !#WJ3Q%K\?AZSM;F2!IA<7D-H%5L8,CA0WX
M9JQ!>WLNM7=I+I<D5G$BM%>F52LQ(Y 4?,,>] $+:,Z76DO:7TEK;6&_S+6)
M0$N R[1N],'YOK33H$9\9#Q&;AC(NGFQ6';\H!DWEL^O 'X5L44 %%%% !16
M/JNOQZ7K.BZ:T#2-JDTD*N&P(RL9?)]?NXJ_J-X-.TN[OF0NMM"\Q4'!8*I.
M/TH LUAWGAN*\\8:9XA-PZR6%O+ L(48<28R2?;%5-,\5W6M>$]*UW3-$FN?
MM[J&MQ.BM"A)!<EL @8Z#GFNGH R-1T"/4?$6BZPT[(^EF<I&%R)/,38<GMC
MK5"^\&PWMSXFG:\D4Z]8I9R (/W05'7</4_.?RKIJIZIJEGHNFS:AJ$PAM80
M#)(5)QD@#@<GDB@#G8_!M[I^DZ-::/XBN;&;3;7[)O,*RQSIQRT9.-V5&"#D
M9(Y%;/A[0X_#^E_9%N)+F62:2XGN)  TLLC%G; X')Z#H*EO+V]@U2PMK?2Y
M+FVG+^?=+*JBVP,C*GELGCCI6A0!@6WA>*+QK>^)Y[IY[F:V2T@C90%MXP<L
M%]=S<T[Q;X9@\6:)_9\MQ);2I-'<6]S& 7AD1LAAGOU'XUNT4 8>F^&TT_5=
M<U W32R:NT32#8 $*1B/CZXS6;_P@EO_ ,(-IOA?[=+Y5C)"ZS[!N?RY XR/
M?&*ZZHKFXCM+6:YF.(H4:1SCH ,F@#E]0\&WDFJ:A=Z1XANM*BU/:;V&*%'W
M,%"[XV/,;%0 2,] >M:-OX:BMO%$>MK=3.Z::NG".0[B55]^\L>2WUJMX.\5
M3^+]..IKHUQ8Z?*-UK--*C&<9()VJ25QCOZU=\1>)]-\,6D4]^TKR3R"*WMK
M>,R33O\ W44=3^E &-=?#ZVN=.U.W&H3Q3W6K?VO!<HHW6TXV[< \$#;WZ@F
MGV'@JXB\2Q>(-3UV?4+];22T),"Q)L8@C:J],$$]R=W7@"EL/B!93ZM;:;J6
MDZOHUQ=G;:G4;<(DS?W5968;O8XKK: .1'@.W'@33_"WVZ7RK-X76?8-S>7(
M'&1[XQ6I>>'(+[Q19ZW+*2;>TFM3 5!5UD*DDG_@/ZUM5RVM^.K31?$2Z$ND
MZOJ-\UJ+O980+(%C+%,G+ ]1^HH ATCP7>Z5+8VX\37TFCV#[K:Q"*A  (5'
MD'S.BYZ<9P,YQ5VS\)0VFBZ[IHNG9=7N+J=W*C,9FZ@#OC-)H/C33M>U*?2Q
M;7]AJ4$8F>SO[<Q2&,G&\=01GC(-='0!QMQX$D$GARXT[69K*[T2T^QK+Y"R
M":(JJD%3T/R]?>NOEC\V%XR<!U*Y^M/HH Y-_ T#_#VV\(_;9!# L*BXV#<?
M+D5QQTYVXJ&]\!O=WVKB/7+JWTG5W\R]L8XDR[E AQ(>55@JY'?U&:[*B@#B
M[?P7K=C:6L-AXPNX&CM4M9=UJDB.J9",JDX1@IP2.#@$C-=-HNDVVA:+9:5:
M;_L]I"L2%SEB .I]SUJ]10!QUQX)OH]>UC6=(\1W&G76JM'YR_9TE0*D808#
M?Q#!(/N<@\4#P!!9Z1HMMH^HSV%[HX<6]X464OYG^M$BGA@QY/3!QBNQHH Y
M2;P7)=Z']EO-<OI]26\%_%J#!=T,R\+L3[JH!QLZ$$]SFH[GP5=ZIH&LZ?J_
MB&ZO9M3B6%I?*5(X57ILB!P#R<G.3QZ5U]% &-JOAZ/5+[1+I[AXSI5P;A%"
MY\P[&3!]/O9K3O+2&_LKBSN4WP7$;12+_>5A@C\C4U% 'GX^&MU+8:=IU[XH
MO+FPTN>&:RA-NBE/+8%0[#E\*-HZ=<X)QC1N?!5PVO:E?6&OW-C::J4-]:1P
MHV\JH3*.>4)4 '&?48J:P\9-JOC"_P!#T_2+B:WTZ017E^TJ(D;E20 I.YNF
M.*ZF@#B%^'%LND^%; :A+M\/72W,;>6,S%3G!YXK&\9VNG>._&>B:+9>;-+I
MUR[ZI*BL(XH!@M"[8P2[*H &>A->H44 %<SJ_A:[N=;?6-&UJ72;R:!;>Y*P
M),DR*25)5NC#<V#Z'I7344 <Q_PAL<MUH;7FI7=Y;:0"\<-RV\S3]II&/4C)
MP,8!-0R> ;*2+7K074R:;J[B=K5 !]GG!!,L;=B6"MC&,BM6_P!?CL?$VCZ*
MT#.^I).ZRAL!/*"DY'?.[]*L:]JJ:%X?U#5I(FE2RMWG:-3@L%4G&?PH RM/
M\,7PFN'UW7[C5TEMFM1 8E@BV-]XLB_>8XQN/09P!FJ&F> KBRGTR*[\1WM[
MI6E.'L;)XD3:5!5-[KRX4'@<=LYKI-!U5-=\/Z?JT<31)>VZ3K&QR5#*#C/X
MUH4 >?W'PREGTK4]$3Q)=Q:%>O+*MDL"9B9V+8\SJ5#'.WCT)(SG7N_!\K^)
M]-UZQU>6SN+6T%C,GD+(L\ </MY^Z21U%=310!QUOX'N[*;[-9^)+VVT,71N
MAI\4:JRDOO*"4?,(RV>.N"1G%+<^![@ZQJ5UIVOW6GV6JL'OK2.%&WMM"ED<
M\H648)&?7BNPHH R?#&A1^&?#=CHL4[3QVD?EK(RX+#)/3\:RK[P;-<Z_?:A
M:ZU<6=MJ21IJ%K'$I,P0%1M<\IE>#CGTP>:V](O;V^MY9+_2Y-.D29D2-Y5D
M+H.CY7@ ^G7BM"@#C]"\!KHMQH<K:I+<C1H)[:W5HE7,<FW )'==O7OFI-1\
M!6.JGQ+]INIMNN&!FV *8&A4!&4^N5!KK*IZ=JEGJT,LUC,)HXIY+=V"D8=&
M*L.>N"",]* .9M?!%ZWB'2-;UCQ'<:E=Z89!"#;I$FUT*'Y5[G()/^R.E=1J
M6GV^JZ9=:==IOMKJ%H95!QE6&#^AJMK_ (@T[PUI;:AJ<QCA#!$55+/(YZ(J
MCEF/I6!#\1K);RVAU71=;T:*ZD$4%SJ%J$B9ST4LK':3_M8H J)\.KR5-'AU
M'Q1=WMMH]U#<6436Z)CRSP'(Y<X&W/N>,FKMUX)NS>Z@=,\1WFFZ?J4QGN[:
M&)"V\@!S'(>8RV.>O.2,5V%% '.OX3A?QY;^*?M4GFP:>;$0$9!7<6W%NN>:
M7PMX3@\,)JZ1W+W(U+4);YPZ ;#)C*^XXJ/Q%XTM/#NJV.F/INIW]Y>H\D45
MA"LAPF-V<L/6FZ/XYT[5=971YK+4],U%XS+%;ZC;&(RJ.I0Y(./K0!'X,\"6
M?@Q[]K>ZFN3<LJH90!Y,*YV1K[#<:AL_ ]WI\L=K:>)+V#0XKG[2FGQQJK+\
M^_R_-'S>7N_AZXXSBNQHH Q=(\.QZ1K>N:FEP\C:M-'*Z%0!&40)@'OTS618
M^![O3I8;6U\27L6AP7/VB+3XXU5E^;?Y?FCYO+W?P^G&<5V-% '&7/@.<ZAJ
MK6&OW5CINK2&6]LHX4;<[*%<HYY3< ,X_ BN@\.Z,GAWP[8:/',TR6<*PK(P
MP6 [XK3HH Y*^\&W;^)[_P 0Z7KTVGWUW#% 1Y"RQA$!ZJW4DD$'C&/0FL[5
M+?0/!'@*?1-0EN+Y]02<%/++SWT\F2V HX8EACTX]*[ZB@#E?AWX<F\,>"[*
MRO"6U"4&XO'8Y)E?D@GO@87_ (#6]JNEV>M:7<Z;J$(FM+F,QRQGN#_(^_:K
ME% '!CX?ZP;'^R)/'&JOHFWRS;^3$)C'_<,^-V,<9QG%:5_X)A+Z5<:%>-HU
MYID!MK>2*)9$,)QF-T;[PR >N<\UM:=>WMU<WT=WI<EG'!-L@D>57%PG]\!>
M5'L>:T* ,/PYX;701>SRWDM]J-_,)KN[E4*9& "J HX50!@"HO&'A?\ X2O3
M+6U6_DL9;6\CO(IXXPY#IG;P>#R?TKH:* .&N_ .HZW$MIXD\77^IZ;O5Y+-
M;:&W67!R Y1<E<@<9K2U3PG<3:ZVM:)K$FDWTL"V]QBW6:.9%)*Y5NC+DX.>
MG%=/10!QW_"O;-=&TRP2]N"]GJJ:M-<2 ,]S.&+,6Z 9)[= !6OJ/AV/4?%&
MB:XUPZ2:4)PD04$2>:H4Y/;&*VJ* .9U;PI<W&O-K>C:S)I5_+ +>X(@6:.9
M%)*DJW1ADX.>AQ4)\!67_"%77AU;NX+W4AN);Y\&5K@N)/-/09W <>P%=96/
MINOQZEX@UO25@9'TIX4:0MD2>9&'&!VQG% &!JOPULM3\#Z9X9%_/;K88VW2
M*-[Y1DDS_OAVS]:U=9\+&]N=/OM*U!]*U"PC:&&:.)9%,38S&R'J/E4CD8(K
MHJ* .3G\$M>:9IEM>ZS>75Q9ZK'JCW$P!,CH2=@7HB<X '2KVM:%J=]J$5]I
M7B"XTR98C#(GE+/%(N<@[&X# Y^8=N#FMZB@#,\/Z+#X>T2#3()9)EB+,TLF
M-TCLQ=F...68GBM.BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "N5\?36:Z';VMXVH,+N\BA2UT\
M@2W;<MY6<C"D*=QR. >:ZJL7Q)X>'B"VM E[-8W=E<K=6US$JL8W *\JP(((
M8@@^M 'E-Y-<Z=X:^(FGP6-[I%M;65M/;V4UR)6@9]X8JRNV =@.,UTE]HD'
MAOQ5X.O[&:Z^V7]VUO?327#M]J#0LQ+@G'WE!&  .U:5Q\-(;I-7$VN7\CZQ
M:+;W[NL9,KJ25D'R_+@$J%&!C%=%J?AZ#5+S1KB2:1&TJX^T1A0,.=C)@^V&
MH \N&C6^O_"WQ+XLO9KC^V)TOW$_GN/+1&D01!<XV;5QC'?Z5ZIX9_Y%31_^
MO&#_ - %<U=?#5)[?5-.AU_4+?1=1>2673XUCVK(_)VN5W!=W.W./P)%=CI]
MFNG:9:V*,72VA2%6;J0H R?RH \PL5U;4?&OQ4L--O'BO#;VR6C-(0(G:%L$
M?W>>X^M:?@9=*L_$+6::;K&A:J;0F;3[N8R0W(#+F5')8.5/&00<,<@]MM?
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M\\$L; R-*P.78D$$[CN/&#T(QQ5BQ\%"%M7N=1U6YU'4=4MOLDEU(B)Y<0!
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M*%@.<?6@#CM'EG\9:IX*&K7-P8[O09I+R..5HQ<%7C'S;2#R<$XZ].A(KJ?
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M0A]BY^4'*YSC)!]J=XB\/Q>(+2!#<S6EU:SK<6MU!C?#( 1D @@@@D$$8(-
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MZBHS%-H5E=6!5@0H./4 BMG0M(;1K%X9=0NK^>65IIKBY8%F8]< 8"KP,*
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MQK$JA6100-V26.>M4M9\W4O&U]I>JZ1K'B"WTRPMDC6RE6)1(X8O,P,B?,<
M#&<8/2NHU3P#]LOM2DL==O\ 3+35CG4+6W6,K,=NTLI9248J,$CK5B\\%!;R
M"[T+5KG19X[1+)S!&DBR0I]P%7!^9<G#=>3UH L^!QJR^#["/6XYX[^,/&XN
M&#2%5=@A8@D%B@4GGK70U3TK3DTG2[>PCGN)U@3;YMQ(7D?U+,>I-7* "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?9NRP7K@XZ^E;-<5\7./A7KV#@^2G/\ VT6L?6?#NG^%/$?A.]TM9%N;Z_\
ML-\[2,QO(WB<L9,GYCE0<T >FT5X_%J]YX:\%>)/"$<COJME>#3],W,2TD=T
M?W#9]0&?Z;*]1T32HM#T.QTN$EH[2!(@QZM@8)/N3S^- #M7U :3HM_J)C\T
M6EO).8\XW;%+8SVSBC2-0&K:+8:B(_*%W;QSB,G.W>H;&>^,U2\8?\B1K_\
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MG33C<&,2P;(W>!7)^4$D\=/SJ"[O+"U\,WFE:);ZIH,MWJME9WUA.VTV:2L
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MF"D#DXQ77LZH,LP4>I.*H:G=:E;/9#3].2\66X5+@M<"+R8CU<9!W$?W>,T
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MTH;8@KF3:H4;^.>!VQ3M4\'B[UJ75]-UB_TB]N(EANGM!&RSJN=I975AN&2
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MC4#9_9/)NY;;9YN_.PCYLX'7/2ND5U==RL&![@YH 1$6.-44850 !G/ IES
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M$1G&?:MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME_/YGD1DY*I@#K@9)R3CK4%KX T2T\-76@H+EK2XN6NBS2XDCE+!@R, -I!
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M6I^TQ[/,*8^=.3E#G@]Z -"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y.+P9<6GC;4/$=CKD]O_:+
MP&ZM?L\;K(L2A0NXC(R,\CUKK** "BBB@ HHHH **** "BBB@ HHHH Y./P9
M</XUM?$M]KD]W):)+';VYMXT5$D[949./4^E=9110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK-J+P^7&TK2AA'&  ,*JY.,\MR<FNM\$>$HO!7AU='ANWND$SR^8Z!3\QSC
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M5'L&#WSUK/M/!TNG:-J5A8:S<6TM]J3Z@;B-!N3>X9D SR,#&?0T =51110
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M_$T^D_:KITM+"[6[>V"@B=U^X&/H#DX[UMSPQW,$D$R!XI%*.C#AE(P0: .
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MK[T?[ZNA."#QWX(!S5IO!DMQ::<E_K=W>7-KJJ:H\\JC#LH("*HX1,'H/ZT
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MUE#9V_F>3$NU?,E:1L>[,23^)KD[[X>P7N@ZSI@U&:)]1U0ZFDZQ@F"3<C
M'A@"GZUU>GP75M80PWMY]LN5&))_*$>\YZ[1P* .<\>SVJZ796MS<ZDHNKQ$
M%KIH/GWF 28@0054@9)R.!UYKSV]U&^L?!GCRSLQJFG16,MF]G#>S[YK;S"A
M8;@[':2,@;CU->H>)/#LNN-IUS::@VGZAI\YFM[@1"4#*E&5E.,@JQ[BN?N/
MAHUU!K<4VOW,HUF*'[6TD*EC-&X(D&,8&!MV] ,>E $%SI(\,?$#PJUE?7[M
MJ;W,-_\ :+IY!<;82X8JQ(4AA_" .<=*Y2XTPZ[\%]7\7W5_??VO>07,SO\
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M!W ,A(Y!)P0>^*IGX>6?_"-G3O[0NOMYOO[3_M/"^;]KSGS,8VX[;<8V\>]
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M)U%OM$Q'E!3+_J]@*XV]<FNDCT"V\3>-?'<.J3W<EM;26_V>!+AXUB=K927
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MQ'/M,4<+B(NA."WSXZ5M5X%?VJ:/^SGIEWI[S6\]U);/*ZS/DG?CC)^48[#
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M+D#C(Z<D8IVI^#I[C5[W4-*UZ\TEM014O4@CC<2[1M#*6!*/MXR/0<<5U5%
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M0))-1O+B72)Y9Q+.^]YWD5@VX]A\Q( P!P.E7[+0(;+Q-JNN+,[2ZC%!&\9
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M'&DBRQ9W!61A@X/(/&,FJ3?#RQ;P[_937UT\DFH)J5S=OM,D\P<,2>  #@#
M'  KL%)*@D8)'(]*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE/'\ME_8=M:7@U"87=Y%
M#'9V#!9+MN6\HDD80A26.1P.M=76-XC\/)XAMK51>3V5U9W"W-M<P!2T<@!'
M1@000Q!!'>@#R>YOK[P_H?CRRL+*XT*.**P,%J;E9/LQG<QNZ%6(7(P>#P1F
MNAU;PQI_A?Q=X*31VFMH)K]TG@\YF68B%R'()/S#G)[YYZ"M+4O -I:V&N7L
MT^JZNVH6'EWUL#'YEXZ9*.ORC:XSA0N!P!CBN<TNW&N^,/"\MI?Z]JKZ;))-
M<W&IVIA6TC\HJ(_N(&=F(R?F)V]<"@!?#UA''9^-O%4IEN-1TC4]3.GAY6V0
M;5).%S@D[L'(/ 'I3/#6G:G'/X9U+3/#.KV]V\D3:EJ5Q>1.MY"Z?O&<>82W
M)##C(Q7I.B^&;/1K;5;='DGBU*]FO)EFP1F7&Y1@?=XK-TCP0=*N;$'7]4N=
M.T\DV5C(R!(^"H#,JAG"@X 8G'O0!YKIT>L:UHBZ_8>&-6G\1RW;7$6K"[B5
M,+,?W>TR B/8"FW;^%=)%X<L/$WC;QY%JPFN+>"2V$$/FLJ1L;927 !'S<#!
M[<XZFNC3P&D-TR6^N:G!I#W7VMM,B9%C\PMO(#[=X0MR5!QR:U['P[;6&KZW
MJ,<TK2ZNT;3*V,)LC$8V\>@SS0!Y+!IR1_##PQXN>>YEU\75G_IKSN7*&81[
M.N-NWC&.>IR2:T=5BF\1>+?%"W7AS5=6-I*EI92VMU'&MEB)6W*&D4ARS;MV
M/09[5W \"V \%V'AC[5<_9;)XG27*[V,;AQGC')'I1JG@QKS5;O4-/US4-)>
M_14O4M?+(F"C:&&]24;;QN7L!Z4 <A::7>:]XUT+3_% F\T>&0]]:^;A995F
M53OVG!&3G&<9Q7.^(=-MH_ASXPT[:[VND^((X[%'D8^0C-#E1ST^=N#ZUZ_:
M^&+.SU^UU:*6?S+;3O[.2-WW Q[@V23R6^4<YK.O_ &G:AH_B#3I;FZ6/6KL
M7DKJ0&BD&S&WCH#&IYSWH YWQ5X9BL-5M))/#EYK'AJWLO)2TLIV,EI+O9FD
M"%@7R"!D'(VUW/AF>SN/#&FRZ?>SWMHUNGE7%P<R.N,9<X'S>O'6LB7P?J+-
M%<0^+M6AO?)\BXN%CA(G4,S*2A3:K#<0&4 XZYJ2W\-3:3J/AJWTN>[CTO38
M9XYXS/\ )+N4!2Z_Q-NRP.,#YNF10!U%<;X6D=O'_CA&=BJ7%IM!/ _T=>E=
ME7*WW@K[1X@O-5LM;U#3QJ"1I?P6^S;.$&T$%E)0[>,J0?H>: /.M#A;5M$^
M&EI/<W BN;C4%G,<K*9$ E)4D'."!CZ&I];=O!2_$"ST%Y+2VCTZTG@B61B(
M))&:-W3)^4XP>.XKOM+\!Z=I,/AZ*"XN"FA/.]N&*_/YH8$-QVWG&,=*L7O@
MW3=2O]:N;MI95U>SCLYXL@*$3=@KQD'YCS["@#C-=\(Z5X:UCP0VEK)#NU>-
M)E\UF$Y\IR)&!)RPYY_VC6 D6KZ]INHZU9>&M6NO$+WT[6>JQW<2I#Y<Q5(P
MK2 A %VD%><GKUKT"#X>YN])N=1\0ZIJ,FDSK+9B;RU"  C:=JC<3D98\\#I
MSF67P&AN[D6VN:G::7=W)NKC3H&14:0G<VU]N]%8C) (ZGIF@#G[71+?Q%\7
M/$:ZIYTEM:6]A.EKYS*@FVMACM(R5P?;FJECI\&B>)[<^)=-U.VU.74V-OK]
MO.7ANM\A\N*3D[%((385QQP1UKT.R\/6UCXFU378Y96N-1CACDC;&U1&"!CC
M/.[FL>/P'BZ@2;7M3N-)M[H7<.G2F,HLBMO4%]N]E#<A2>PZT <9X<T[0]#M
M/B'J4C7%BMK?W%JMS:N3+%$43A,Y&[)X)[XJSX=MCHOC[1[>ST"]T.VOM/N?
M.CN;I93=%/+*NRJ[8<9.2>?FQ737'PZM+BXUX'5+Y;#6B9+FR79M68@#S%;;
MN!&T'&<9]:D@\#.NL:?K-WX@U*[U.S+)Y\BQ /$PP8]@4 #C.1\V>_3 !YK!
MHMO;_ [3O%GF7#Z];K!+#>M.^Z,>>JA ,X"[3C&.>2>:[.TT:R\7?$'Q4VLK
M+.-,>WMK)!,R?9P8@[.NTC#%FSNZ\"MW_A!+#_A7\?@[[5<_8D1$$V5\S"R!
MQVQU'I1J/@O[3K]SJ^GZWJ&E2WL:17R6OED3A!A3\RDJP!QN'.* /*I7FM_A
M#X1"7#LW_"4[&D#8+CSY\YQZUW$VAV?B+XKZY::H)+BQCTVU?[*9&6-G+2 ,
M0",X&?;G/4#&BWPSTK_A%]+\/I=7:6FFZ@+^%@5+%@[L%)(^[\Y'KP.:Z"WT
M&WMO$U]KJRRFXO+>*W>,XVJ(RQ!'&<_,: /*;'S;W2= \*SW-P=,D\1WMG(#
M*VY[> R,D1;.2IP!UZ 5JR:!-I_Q!UK1/#]Y):B?PP[6<;2L5M96E*@KG)49
M&?8DXK3\2^&-/T3PTI UB7;K#:BMW8*KSV<DC,6D"X.Y!N((P3@_C69X;T2+
MQ#XNUF_6YU:ZTZXTD6,NI7:-;R3RLY8F,;5VA5"CA0,^O)(!=\#0Z7IOB*.R
M;1M3T#639L)+66;S+>] *[I%?)#LI[\'#G.>WI-<QIOA&:UU--1U+7M0U6Y@
M@>"U,ZQIY*OC<1L498[1\Q]*O^%+*_T_POI]KJ<\\U['%B5YY?,D)))PS=R
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M/)15*E-H3#;E."S9/ Z=P#BX_#MEJ7P]\7:S>M<2W]E=ZE)92^>X-J8W=EV
M' ^89)ZGIT K1ATJQU?XJ>&KV^@\VXN/#XO)7+L-TJM'AN#V].E=Q!X/LX/#
M.K:$MQ.;?4WN7ED.-RF<L6V\8XW'&:KW7@B*34M%U"SU6\LKK2[868>((WG0
M_+E6#*1SMZC'7Z4 >=C5[_3=.^*US:3S"XCU%(HF5OFCWML)7/0@,2*V='T7
M5+/Q!;C0?#6IZ#:S6<\%Y-=74<B.^S,4A"R,2X<=<9PU=9;^ M*B7Q)',\UQ
M#X@E,EU'(0 N01A2!D=<_A18>#9(I7;4_$&J:HHMGM8DG=8Q'&X 8GRU7<^
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M6.^)\Z ASF)L\C8?E .> .3UKH:S-!T2#P_IGV.&::=FE>>:><@O+([%F9L
M#))[ "M.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBN3^(#V+:):65[!>W?VR]BABLK214-T_+>
M6Y;@1D*2W(X% &GXIUX>&_"VH:V(/M(M(O,\H/MW\@8W8..OI6M'()$!&,D
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M,FRX+.6()V;E!S@A2,@#ODG,C5]6^-]C=6&GWB:?I.FRVLT\EL\40?<P"H6
M#=L8XQTKTH31-*8A(AD R4##('KBJ.OZO'H'A^_U>:)I8[.!IFC0X+!1G S0
M!A)X M(KL^5JVJ1Z8;K[7_9:2J(/,W;_ .[O"[OFV[L9_*EU;P#::EJ-]=P:
MMJFG+J*A;^"SE54N0!MR=RDJ2O!*D9%4H_B!J:V$>I77@C6DT]XQ+Y\#PSD(
M1D-L5]V,<]*ZW2M7L-;TJWU/3KE)[.=-\<J]".^<]"#D$'IB@#%F\#V']M:5
MJEA>7FFRZ=:K9(EJR[)+=6#"-@RGC([8/O6GKN@VOB"VM8+J29%MKN*[0Q$
MEXVW*#D'C/6M&*:*=-\4B2+TW(P(H$T32M$)$,BC)0,,@?2@#.;0;5_%,7B$
MR3?:X[-K()D;-C.')QC.<J._X5D7'@'3IK2[BBO;ZWGGU4ZNES&Z[X+@@+\F
M5QMP,8(/4UU6Y<$[A@=3GI36EC12S2*H W$DXP/6@#E(?A[IZ7-_/+J.I7#Z
ME9-9ZAYLBG[4#N =OEX8!B!MP ,#'%1-\.K>30-.TM]=U=GTRY6XLKPO'YL&
MU=BH/DP5QZ@GGK77FXA"HQFC D.$)8?-]/6EDECA3?+(B+G&6.!0!R]]X&CN
MKR6ZMM<U:PFN84@O7M9$!N@@VAFRAP^.-RXJ_%X4T^#6]-U6)ITETZR:Q@CW
MY3RSCKD9)^4<YK;+*,9(&>G/6J]QJ%I;:?/?/.AMH$9W=6! "C)H DNK:&]M
M)K6YC66"9&CD1NC*1@@_@:Y2Q^'MI:SZ>+C5]5OK'39%ELK&ZE0Q0LO"'(4,
MVW^'<3BNCL-5M-1TBVU2&4"UN84F1G(7"L 1GT."*N A@"""#R"* ,:V\,65
MKXNOO$J2SF\O+=+>1&8>6%7H0,9S^-+XG\-VOBG21874]Q;[)DN(I[=@KQ2(
M<JPR"/S%;-% &)IWAF'3]:.KO>W=U>M91V3R3LOSJC,P8A5'S$L?;VK+U'X=
M:1J?A[4]%FN;U;;4=0;4961U#K(S!B%)7&W([@GWKKZ* .:U?P>-3U*>]MM<
MU73'NHUBN4LY$VS*,@'#JVUL'&5Q6F-%MHO#G]AVCRVEJMK]EC:%AOC3;M!4
MD'D#N<UI44 9V@Z)9^'-"L]'L%86MI&(TW$%CZDX[DY)]S61JO@33-6U/5+^
M2>[@DU33SI]VD+J%=.SX*GYP. >F.U=110!BW7AFRNVT,R2SC^QY1+;[6'S$
M(4^;CD8/;'-,N/"6F7FIZM>W0DF_M6T2SN868;#&N[&,#(/S'G/ITK=HH YK
M1_!ZZ7?PW=QK>JZDUM$T-LEY*I6%3C/"JNYL #<V333X&TP^ U\(>?=_V>J!
M!)N7S<!]_7;CJ/3I73T4 <QJ?@J"^UV?5[35M3TRXNHDBO%LI%5;A5R%W;E)
M# '&Y<'%1V'P_P!(TVQT:SMI;H0:1>R7ML"ZGYGWY5OEY4;SCOP.:ZNB@#+@
MT&UM_$MYKJ23&ZN[>.W="1L"H6((&,Y^8]ZR/^$ TU-#M]-@N[Z"2UO)+VVO
M(W430RNS,V#MP1\[#!!!'6NKHH Y5_ EG<:'>:=>ZEJ-V][<17%Q=S2+YC-&
MRLH "[57Y ,!>F?K6M?:%;7^O:5K$LDHN-,$PA52-K>:H5MPQGH.,$5J44 <
M]X<\)0>&;F^:SU"^DM;J9YA9S,IBA=VW,4PH;KZDU%J/@NVO]<N-274M0M5O
M(TCOK:WD58[I4R%#94L."0=I&17344 <KHW@/3]%N-)EAO;Z;^R4GBM$F9"%
MCEVY4X4$@;1COR<YJ:^\$:3J3>(/M9GD775A%RN\ (8EVH4P,@C /.>17244
M <C9> 8(=:TS6+[6M6U*^TTO]GDNI$(560H5PJ =#DGJ2!D\8K7\3>';3Q3H
M<NEWDL\4;NDBRP,%>-U8,K D$=1Z5KT4 85CX8AL]9MM7FO[V\OH+%K$RSLG
M[Q&D#EF"J/FR .,#':JT_@;2[FVU>"26Z_XF=XM\TBR!7@F4*%:,@?*1L!&<
M]^W%=-10!AZ'X<_LBZN+RXU6_P!3O9T6-IKQU^5%R0JJBJH&23TR:K^*/!EK
MXIO-,O)=1U"PNM-:1K>6RD5&!< '.Y6[#]37244 <QI?A"XTW4H;M_%?B&]6
M,DFWNKB-HWR"/F C![YZ]15%OAIIQB:P_M34QH;3><VCB1/LY.[<5SMW[-W.
MW=BNUHH Y>^\#6=[K-Y??VAJ$$&H!!?6,,BK#<[%VC=\NX?* "%(R!S2Z'X'
MLM"NM-N([Z^N'TZS>RM_/9"!$S*0#M49QM !].N:Z>B@#+TS0K72M3U6_@DE
M:74YEGF#D%594"#;@<#"CKFLG7/ T&M>(X]=CUG5M-ODM/L>ZQE1 T>\O@[D
M;N?T%=510!S&C>!=-TG5QJ\]WJ&JZFJ%([O4I_->)3U"  *N?89J/4? L%WJ
M-]=V6LZII:ZCC[;#92($G.-N[YE)5B, E2,XKJZ* .:O_!&F7.GZ5;64MSID
MFDC;87-FX$D(*[2/F!# CJ"#FJC?#K2Y-#FL'O=0:ZEO%OWU(RC[3]H7&UP<
M;1@# &, 5V%% '*V/@6TM=6EU:XU/4;[4)K)[&6>YD0[HV8'@*H"XV\ 8')R
M"3FICX*TYO#&DZ 9[K[+IDL$L+[EWL8F#+N.W!!QS@#\*Z2B@#)G\.V5SXD3
M7)3(TZV3V)B)'EM&[!CD8SG*XZXQVK*TKP);Z5=V3#6-5N+*P8M96$TRF* X
M('10S  D ,3BNKHH Y^#PA80>&]6T-9KDVVIM<M,Y9=ZF?._:<8&-QQD'\:K
MW7@>TFO]&OK;4M0LKG2[<6B20.F98>/E?<I!^Z.F.OTQU%% '(P> +:*[M]^
ML:K-IMM<BZ@TV65#"D@;<O.W>55N0"Q' K:\0Z#:^)-);3;R29(6ECE+0D!L
MHX<=0>,J,UJ44 9=SH-K=>)+'7'DF%S902P1H"-A63;G(QG/RC'-9T_@?2KF
M#6X9GN6&KW*W4K"0*T,JA0K1D#Y2"BD9SS^5=+10!S%MX,B6WU);_6-3U*>_
MM&LWGN9$S'$01A%50H/.<D$DU'X@T"TM_AM)H:V%YJ=M:6D4,<$,@6X<1[=K
M*<8WC:&'')'3M75T4 >4:#8?VM\0-#U*S?7[V/38)S=7^LP-$1O38D2 HH)!
M+$D#ZD\5U-MX M+2ZB$.K:HNEPW/VJ+2Q*H@23=N'1=^T-SMW8S^5==10!GZ
MYI%OK^AWNDW3R)!>0M#(T1 8 C!QD$9_"J%MX1L+6?P[*DUR6T&V>UMLLN'5
MD5"7XY.$'3'.:WZ* .>NO!VFWLWB&2=[AAKL$<%TNX *J(R@IQP<,3SGFJ1\
M!0-I6G6KZUJK7FFN7LM1WQB>$%0I0?)M*D#!!!S7744 8F@>&;;09+RY^U75
M]?WS*US>7; R2;1A1\H "@9P !UJ'6_"4&LZWIVL)J%]87UBKQK):LHWQMC<
MK!E(QQ70T4 8=IX5L;/2]9T^.6X,6K3W%Q.68;E:888+QP!VSG\:J#P-IBWW
MAF[$]WYGAV!H+0;EPZF,(2_R\G"CICFNGHH Y'_A +8W0#ZQJKZ6MT+L:6TJ
M& 2!_,'.W?M#?-MW8S6KXF\-6?BO3(].U"6X6T$\<TD<+ "8(<A'R#\I.,XP
M>!S6S10   # X%<C;_#S2;5D$-Q>K#'K']L10[UV1S8(*K\N0AW$X_6NNHH
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M3MP ,\9!_&F:AX+ANKJVO+'5=1TN\AM5LVGM&3,T0Z*X96!(.2" ",FNFHH
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M(V<'D;<(?4#%/U;0]+T^]^(FDVMA;Q:<=!CO!:I&!$DRK+AU7H#\JGCN :]
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !117.^(O#EKJDGV^ZUK6=/C@A(<66H/;QA1DEF"\9YZ^
M@% '145Q7PTM+Q=!GU.YOM2N(-1F,]G%?W+S/%;](\ECU8?,?]X#M7:T %%%
M% !1110 445YRHU#Q[XPUNT;5K[3]!T:5;416$QADN9]N7+N.0HSC ZT >C4
M5R6D^%=5T#Q!#+8:_>76B21L+FSU*9IW1OX6B<\CGJ"<?TSY/B/<?V=<:[;^
M';B?PW;R,KZ@MP@=D5MK2+%C)0$'N#@9Q0!WM%85KXG@N_%\N@10EMFGQWZW
M(?Y65W*@ ?AG-9=_X_AL;/Q7<'3Y''AYT5U$@'G;E#<<<=?>@#L:*XB3Q]=V
MMSI4U]X<N+;1]3N([:WO6N$+AI/N%XARH/UR.X!XJA!XN\2S?%R]T)=*#:?;
MVB$Q?:4&U3)C[1G&3E2/DSVH ]&HKB3\09,'41H<Q\."[^RG5//7.=_E^9Y7
M7R]_&[.>^*35?B%)9>,[GPM8Z#<:AJ26Z3PK',J+)GKN+<( .Y]ACF@#MZ*X
MJZ\=7]OK]IX?'AN:76+G3EO?(2Z39&=Y5E9\8 &/O<YR !S5C2_' N[;7$OM
M'N[35-% -U81$3NX9=R&,K]_<!QT]Z .MHKD-/\ &.H-K>FZ;K?AV72SJ:N;
M.3[4LVYE7>4< #8VW)[],50_X6-=W?B+6-!T?PS<:AJ&FS!& N4BC*8^^788
M7G  Y)Y]#0!WU%>;V_B_Q/-\6;C0_P"QQ]BAL4=K?[5'\H,N//W8R?E.-E;.
ME>,[[5;FVGA\-W1T6ZN&@AOTF5VX9EWO$.50E3SGCC(% '7T444 %%>3>/O#
MDVAVVEW-EXF\3(][K%O:R@ZM+M$<C'<%&>/:K7CG1(_"W@2^N(]6UJ\#W=D6
M^VWCW!4+<)G8#TSGG'7B@#T^BN4T_P 77LGB:VT75] ETQ[V&2:RD:Y27S F
M-RL%^XP# XR1[UA>'/%NE6'AC4KS2=%N$=M=>Q2U-T7-Q<L57=O<X13D>PQ0
M!Z116/H6K:AJ1NH=3T6?3+FW905:02QR!AD%)  &[@C&1^--\6^((O"_A;4-
M8E 8V\1,:?WY#PB_BQ H VJ*\Q\#7&N^&_%$?A[Q+J5S>R:M8)?VTES(7\N=
M1B>%2>PR& '  ]ZZ'4/&5Y%XGOO#^E:#+J%]:V\5QG[0L491\YRQ'!!  '.<
M]@": .MHKSH?%.5_#R>(H_#5W_8\3B.^G>=%>!MP5@J=9 I/)X_0UO:MXIO(
M-:ETC1=$?5KNW@6XNL7"PI$K$A%R0<NVUB!QP.M '3T5Q4WQ$AD_L!=,TJYO
MI=<@FDMH@ZQLC1[=R/GA<9.3GC:>O%$?Q#BMM'UZZUC2YK&\T1T2XM$E68N9
M #%L88!W;@.@Q0!VM%>97^M:M>>/_!-OJNBRZ5*UQ<R*HN5F21?L[9!*XPP.
M,@CN,$\XLR_$^X72+S6(?#-S+I>GW,D%[/\ :44IL?:2BD9?C!/3KC)P< 'H
ME%<A9^-KB7Q#IFGWNA3V=IJRR'3[MYU8R;5WX=!RA*\C)/IP>D!^(,@#:B-#
MF/AQ;O[*=4\]<YW^69/*Z^7OXW9SWQ0!VU%<;<>-M0DUK6=*T?PW-J-SI3HL
MQ-TL*%6C#C!(^\<D!?\ 9Y(R,XNK?$'5;L^#;KP_IK2VFL2EV5YD1I,(^Z$Y
M!VX(!W?[.* /3**@GN#;V$ER\?S1Q&1DSW SC-<"GQ3F&CZ7KLWAF\31+]DB
M%RLZM(LC< "+&2NX;<Y&>N,$9 /1:*Y72O%]W<>(YM#U?0Y=,NA9F]@Q.LXE
MB#;3]T<,"1\O/UJO8>-K^;4--BU'PW<Z;:ZJS)9333J7+A2X62,#,9*J?7T-
M '945S6C^,[34_"%WX@G@>S6R\];RW=@S0O$3N4GUXS^(K4T'4Y-9T"QU.6T
M:T:[A6;R&;<4##(!.!SC% &C17D?A?Q=J>C>&M8N8?#]SJ-A8:E>O=W(N%0H
MHE9CL4\OM7!/0=AWKL;WQE-)?067A[26UB>2S2^<_:%@2.%_N99@<LV#@8[<
MD4 =716;H&M6_B'1+;5+9)$CG!S'(,-&RDJRM[A@1^%86J>-;JVOM3CTS0)]
M2M=) ^WW"3K'L;:'*QJ?OL%()&1UQUH Z^BN;7QE:#6].LY8C'9:I:?:;&_+
MCRYB!N*'^ZVT[AGJ,^E48_'\<WA\ZQ#I5Q)%<WHL]+C#@/?,20KC. BG#')[
M*30!V5%<@GCN.RM-8;Q!ITFF76E0+<RP+*)A)$^0C1L,;LLI7! P:+3QCJ2W
M?V?6?#-SIIEMI+FV<3K,KA!ED<J/W;8(X.1UYH Z^BN5F\;11>!]-\3FR<QW
MWV;$'F#*><RJ.<<XW?I6;I7BK7+GXEZ_I-SIZII5C%#ES<)B%2)&$O3+;P%X
MS\N/K0!WE%<58>/IKJ33;JXT&>UT75)A!97[3JQ9FSY9>,<H'QP<GJ,XS576
MO&MW=V/B--.T*>YTO3UFM;F_6X56$BI\^R,\L%SR<CH< T =_17/> F9_A[X
M<9B68Z9;DDG)/[M:P+#Q'I5AK/Q!N[72I4NM)CCGO)#<LPNB(G9=JG(3 4CC
MUH ] HKB+?Q_=//HL]UX=N+72-8EC@M;UKA2V]U)3=&!D*V.#GTR!TKK[^\7
M3].N;QHIIE@B:0QP(7=\#.%4=2>PH L45RND>+;ZZUNUTO6-!ETJ:]MWN+0F
MY642!-NY6P!M8!E..1UYK#@^*5Q-X<MO$O\ PC-RNA.RK<71N4W19?82J8RZ
MAC@GCOV&: /1J*P])\2)J?B#6M%DMFM[K3'CX9\B:-URKKQTZ@CL12^&?$2>
M)K:]NH+9HK6"\EM896;/GA#M+CC@$Y ^E &W17(7GC*^_P"$DU/0=)\/RZA>
MV"12.3<K#&5=2>6(X/8#G//3%&G>/K;4K7PW-'8S)_;5Q+;%'8 V[QARP/KR
MA'ZT =?17,ZIXQBTS4=<M&LWD.E:5_:;,' \P?/\@XX/R=?>L5OB5<P+I-U<
M>&+Q-.U<K'8SI.C222LNY%,?&T-C@D^YQ0!Z!17GVI^*[K4=!\8:/J.DOI>I
M6>D2W"H+A9EDC>-P&5@!R"I!%0^'_&]W8Z'X9^WZ#<0Z1>1V]G%J+7"DF1D
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7)?$E+NY\&3Z?91S/)J$\-FYB4L5C>11(
M3CMLW9/O76T4 9NJZA#X>T*6\%E<W$-JB@6]E%OD(R% 5<C.,_D*TAR,T44
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M/L W%?F!X'0BO9J* /)M0EN==U7QO?VNFWRVESX8,-H\MLZ&X($OW5(!SD\
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MCJ_@WQ3-8Z$9-$BM[NS%]]J D=@K(76+;R@;ONS@$X[5W7AG_D5-'_Z\8?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^8IU/:Y8Y&)),8-4[N1]:\2BQO\ 0=3URSL-(LS%;VDZQK')*&+2-ND3+':
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MV '.,'=G/J* (7\#VG_"*Z3HL-[=02:3Y;65['M\V-T! ;!&TY!(((P0:/\
MA"8;O1=3T_6M4OM4?4BIFGE94*%<;/+50%3:0#P.3US6S:W>HRZQ?6UQI@@L
M80GV:[^T*WV@D9;Y ,I@\<]:T* .7TCP<UGJW]J:KK5[K%XEN;:![E4188V(
M+85% +' RQYXK+L/AE%8^%-0\+C7K^71KF-XX;=TBS;AGW$A@N2<YZ\<]*[S
M(SC-!.!DT <]J7A&TU/P=!X<DN)XX[>.%(;F,@2QM%M*N#C .5'ZT1>#=+C\
M$)X382-8+;B'<&PY(.=^1T;=\V?6NAHH YK3O"MS!/-/J7B'4=4E>V:UC\X)
M&D:-C)VHH#,<#YCD\4G_  A5G_PKW_A#OM4_V3[-]F\_CS-OKTQG\*V4U:S?
M6Y='64F]BMUN73!P$9BH.>G53Q5W(SC/- ',:AX/::]M]0TO6;O2K^*U6SDF
MA2-Q-$#D!E=2,@Y((Y&339?!LT5OIXTOQ%JEC=6<30FX9EG,ZL=Q\Q9 03GD
M$ 8SCIQ74UQ4GQ#+ZQJ6G6'AC6M1;3I_(GEMEB*;L9XW.#T/I0!,G@5K*UM!
MI.OZE8WL!E,MT!'+]H,K[W,B,I4DMR" ,=*N6/A%-.L]/@MM5U!#;7CWEQ()
M #>.Y8OYN  02V< 8X%3^&O%-AXHM[E[6*YM[BTE\FYM;N+RY87QG##GMW!(
MK<!!Z&@ HHR,XSS6'9^(Q=^,M3\/?92IL;:&?S_,SO\ ,SQMQQC'K0!N5C:)
MX<M]#OM8NX9I9&U2[-U('QA&V@8&.W%;-!( R3@4 96G:#!INN:QJL<LCRZH
M\3R(V-J&.,(,?4#/-8 ^'&GC1?#VF?;;KR]$OQ?0O\N9&#L^UN.F6/2N@\1:
MY;^&_#M]K-TCR0VD1D9$^\WH!]3BH_#.K:AK>CQW^H:4--:8!XHOM(F+1E00
MQ( P>>GM0!DZIX'DU.>_B_X2'4H=*U!]]WIZB-E?( 8*[*616QR >YQC-=:J
MA%"J,*!@ =A5,ZM9C7%T;S3]N-L;KR\'_5A@N<_4U2\+>(!XET1=2%O]FW3S
M0^67W?ZN1DSG Z[<_C0 V\\,6U_XNT[Q!<SRO)IT,D=M;\>6C/PTGKNQQ5W6
M](M=?T2]TF]4FWNX6B?'49'4>X/(]Q22W>HIKD%K'I@DTYXBTE]]H4>6XZ)Y
M>,G/K6AGG% '.:/X1ATG5[;4C?7-S<0:7'I>9=OSHCE@QP/O<XIB>"[-/#>N
MZ(+F?R=8FN9I9.-R&8DL%XQQGC-=-7*>(/B!I/ASQ)8:)=QW#S700O+&H,=N
MKOL0R$G@%N* '7O@PO<VE[I6LWFEWT%HMD\\*1N)HEY 974C(.2".F34\'@^
MU@N] N/MEY+)HHF$;3R;VF,J[6+L><]^,#\*Z*C(YYZ4 <U?>"=-U.Z\02WC
MS21ZW;0V\\>0 @C#!2IQU^;//<"J-OX!D.I:3J&J>(M2U*?2I=]KYRQJJKM*
MD$*HW$Y&6.3\H]\]F#D9% (/0T <TG@NSC\.:[HHN9S#K$US-*_&Y#-G<%XQ
MQGC-6+OPO;78T //*O\ 8TRRPXQ^\*QE,-^!SQ6[D9QGFH+RY%I93W&W=Y43
M2;<XS@9Q0!R[^!,7=PMKKVI6FE75R;J?3H"@4R%MS;9-N]%8\D ]SC&:VK#0
M8-/U_6-7CED:75/)\Q&QM3RTVC'U%.\.ZN-?\-Z=JXA\@7MND_E;MVS<,XS@
M9_*M+(QG(Q0!QDOPZM3X;TS2;;5+RVETR]:^M;M%1G60L['((VD?.1C'85V%
MO&\-M%%+,T\B(%:5@ 7('+$   GKQQ4A( R:* ,/7- N=3O+>^T_6KS2KR!&
MCWP*DB2(Q!(9'!4G(&#U'-4K#P-96%UHURMW=2SZ9-<W!DD*DW$LX(D9\ =V
M)XQ74%E"EBP '4YZ53TG5;36]*MM3L9#):W*"2)RI4E?H: ,35? UAJ]QKLT
M]S<*=7@@ADV$#RC"2R,O'7)SSZ5%:^"98M>L-=NO$%_=ZG;*\3RR)&JRPMC]
MWL"@*,C.1SDGGIC3E\0"+QE;>'OLV3/8R7GG[_N['5=NW'?=G.>U;77I0!PZ
M_#+35^'U[X/%]=?9+N8S-/\ +YBGS%? XQU4#I7:6\(M[:*%22L:! 3WP,5)
M10!A^*?"]KXKL;6TN[BX@2WNX[I6@;:VY,XY[=>H]*IZ=X,6+5Y]4UC5;K6;
MJ2U-FAN8XT6.%CEE"HH&6XR?:NH!!Z&C(SC/- ')Z1X*DTJYL0WB'4[G3M/S
M]CL9"BK'P5 9E4-(%!P Q].M=91D9QGFL72O$ U/7M=TO[/Y7]E2Q1&0OGS=
M\8?.,<8SCO0!2U7P>]YX@;6M,UJ]TF[G@6WNC;)&XG122N0ZD!ADX854M_AS
MI]GH":7:7U[!);W[ZA:788&6"5B>Y!##!((8'(/-=E03@9- '+?\(3%=:-J-
MCJ^K7^HS7[(\ER[*C1,F"AB50%3:0#P.3US4ECX4N(C>R:GK^H:G/<VIM TH
M2-(HSUPB *6_VCD\=JZ6@'(R* .:?P79OX;T/1#<S^3H\UM-%)QN<PD%0W&.
M<<XJW<^&;.[\2MK4[.[/ISZ<\!QL:-G#$GOGC%7-3U>RTB&&6\EV+-<1VT>
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M5OXFN++3]/MY@#<1QKY@CD9S_JU!)//\(^E9^JF:P\"?$?34L&TJWM7M9(;
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MV,]@0UM=6SJ'4A=O((*L"#R"*?H'A^+08[IOM=S>W=Y+YUS=7)4O*VT*.%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHIDDL<,9DED6-!U9C@#\: 'T4BLKJ&1@RD9!!R#2T %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7)^,-$T.YEAUSQ,[SZ7I
MT3#[$\32Q;W8 2%%!+$=!P0,DUUE<SK][XETO6K:\TW3CJND- T=Q9PLB31R
M9RLBER PQP5S[T 8WPK6W>PUJYTK":#/J#-IMOO!\I-JA_ER=@+9(4X(]!FN
M_KCO!6EZG%JOB'7-2L!IIU:XC>*Q\Q7:-43;N8K\NYNIQZ5V- !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>svb-second_amendmentxtox004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 svb-second_amendmentxtox004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3W;[<TD>V3S+9XUV!6+<F0.VX#!7N: /2=/\0:/JMS+;:?JEI=31#+QPS*Q
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M',85FG3=DLG3Y 0X5<YYQZ9'&(HDC7[J*%'T% #J*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ JE=:1IE]=0W5WIUI<7$/\ JI9H%=T[_*2,C\*NT4 %
M%%% !1110 4444 %,AABMH$@@B2**-0J1HH55 Z  =!3Z* "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *\U^,NK:CI.D:!)IU]<VCRZQ#%(T$I0NA5LJ<=1P.*]*KS#XV6
M5U>Z-X>6TMIIV3687<11ERJA7Y..@]Z .FUWQK!H'BG3-(NK1S;WD9>2]#_+
M;_.$7<,="S*N<\$BM3^VA_PEO]A>0<_8?MGG;_\ IILVXQ^.<UAZOI$6K?$!
M+:]M6FL)]!N()25.T[IHN,]CC)'?C-9'A*/6(?B)-9:M%/(^G:3]D2^9#LND
M\T-&^[INVG##U4T =_J-J][IEU:QSR6\DT+QK-&Q5HR00&!'((ZUY]X>\:7-
MM\&;K6-1E9]4TF*:UN#(VYC<1DHH8GJ22F?K7I5>+ZOH>HK\2;GPS#9SMHNM
M:G:ZO+*L9,2K&K-,K-T!9XTH Z7X;:KJ-CHNL:3XEOII]0T6023SSN6;RI(Q
M(I)/)Q\X_P" UFZ#XPU'0?AHGBO5DN+^;5]2,D<$MP1Y$4K[45<@X4 9  [U
M6^*-CJ]KX@D.C6L\O_"2Z<-*F:)"RQN)5P[D=!Y;R#/M6O\ %#1V@^'.GZ9I
MMM+*EK=VD<<<2%B$0@=!Z 4 ;7B_Q3K/A:QOM230(+S3+2,2--_:'EN1QGY/
M+/<^M,U+Q7KNC>'+[5]1\-P*8/*$$$&H^89F>14QDQC;]X'O3OBA!-=?#37H
M+>*2:5[;"QQJ69CN'0#K4GCV":X\#310Q/)(9K0[$4D\3QD\#T )H EG\96@
M\)V?B"TA:>&YF@A\IFV,C22K$P;@X*ECD>JD56;Q5K=SXAU?3-)\/6]TFF2Q
MQ233:CY.XO&LG"^6W]['7M7-^-M*OM(O@FG6DUQI6M:E:32QPH6^S7*3QLSX
M'1'122>S+_M5!-'HUOX^\5R:W/KMJ9;F!H#8F\1)%%O&"?W'!Y!'/- '9WGB
M/5;&VTZ&;181K&H7#0P6HO<Q *C.6:79P-JG@*33)_%6H:=I-U/J>A/!>Q7,
M-K##'<!XKAY654*2E5P,M@Y48P>#65?W/AFZ\-6%O<6&JZAHJW#*UW*ERTUK
M( 65R6'G?Q$!QTSC.*HV,Z?V1K<-S::OKWA0R6Z0_;(G>8*<^:R[@)'1#L(.
M"<[L$XH [+2=3UB>_FL]7T5+-EC$L<]O<F>%QG!7<44AAQQCIWJYK-G/J&B7
MUG;7,EM<30.D4\3E6C<@[6!'(P<&N/\ "#HGB>2#0KO5KGP\+-C*+\2LD,^]
M=BQ-*-Q^7?D9(&!TKOJ /--.\;7*_ V379Y'.JVMJ]H^XY?[4I\I<^Y;:?QJ
MWX"UJ\TSPQK5CXCO9;F^\/3RBYGF<L[Q;?-5B3U^4D#_ ':Y>;0]13XF3>%T
MLY_[#N]9BUXSB,^5@1LSH3TYE5>*F^)6F:M'XIN+/2K6X>#Q7:065Q-$A98I
M(YE!=R.@\IV'/I0!L>"/$6I66@>&6U@SWEYXFNYIM\LY/V="K2(%!!^7:HP!
MC&:['6]?&C:AHMH;8S?VG>?90V_;Y?R,^[&#G[N,<=:YKQGH$=YJW@G3HH;E
M;&"[D1C:R/&8D$#!?G0@KT ZCTJKKOA*WTOQ-X1N;#^U)]NJ?O3/>SW*HOE2
M<X=F"\XY]Z -:S\6>(-5N-1&E^&K6:WLKZ:R\V74_++M&VTG;Y1QGZU/J?BC
M6+"]T338]!@FU+4HYW:$W^U(?*VDC?Y9W9#>@KB=*30;74/$*ZU<^(K6Y?6K
MN14M&ODC9#(=K 1#:<^M;6IV$>O>)/!;:;=:M%8QVUZHNT\Q)EP(U&]I%W9)
M4_>Y/6@#H+#Q3>'7#HVLZ/\ V?>/:O=0&*Y$\<J(0&&[:I##<O!'>J&B^+/%
M&O:-::K9^%+/[-=QB6/?J^&VGU'DU5T729=&\::M!J37VH7$]H6T[4KEVDQ!
MQO@/\*L&PW &X$>E<OX/_P"$8M/".DPZG>^*;>^CMU$T,3ZBJ(W<!4&T#V'%
M 'H>H^)[R/6%T32-)&H:FL"W%R'N!%#;*Q(7<^TDDD' "DX&>*AM_&,\<VHV
M&KZ4;'5+.S:]6%9Q+'<1+G+))@=#@$%01D=:SOMR^&O&VI:U=V]T^CZW;6SI
M=PVSR>1)&K+LD5064$,""1C.0:J7[2^*M;O-9L;2Z73+#1;JVBFF@:)KJ64
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M=U?3M;K9 A3%(A8/YC_=504//?C YJN?B(EO9":_TF>UEAU2/3+Z(RJPM6<
MK)N'#(=R\\=:XVT^U6'A[18-3.JV>B2:MJ)U!K195D_UCF$,8QO",2>G7BKN
M@Z!!K-AXY\.FROK./462>S%Z)6;88D$<A=\G.]0=I.1T(&* ._U?Q)%I6NZ-
MI @::YU-Y,;6 $4<:[G=O8<#\:QK+X@-=26%W)H=S!H>HW MK346E0[V8D(S
M1_>56(P#[C(&:P_ \&J>++^_U[6K6XM)X=-CTB!9XRIW[=T\@!]7( /H*Q_#
M&D:*MGH>B:A9>)IM;MI8H[BR,]S]G@:,Y\WD^5Y8*AA@]P * /::Y_Q!XF?2
M;^RTNPTV74]5O%>2.V258PL:8W.[MPHY [Y)KH*X7Q),?#_Q#TSQ+=07$FEO
MITUA/+!"TOV=BZR*S*H)P<$9 ZT 74\:W$VC+/#X=U!]4^VFP;3S@;)0,DM)
M]WR\<[^AR.]0R?$!;70M3O;[29K:]TR[AM+JR,JL0960*RN."I$@/X&L37O$
M5WK5MI5W=VFKZ7X:DU&6.XEMQ*L\T(C/E.P11)&C/QCK@#IFN9N;&0Z+XVM=
M.TG54$L]CJ%I!<)-)+-!&T99@SY);Y2=I.X=,#&  >N:EX@BTWQ#H^D/"S-J
M8G*RAL"/RD#'([YS63H?C.\UJ:QF_P"$<O8=)U#/V6^$B2<8+*9$7F,,!P3G
MD@'&:Q+G6T\2?$/PG>Z597TUC:QWN^XDM7B4NT0P@W@<\=>F2!GK6;HS6B>(
M=+B\*)KE@UQ.PU71KB&46UM&48NWSC:C!]N-C8.>F* .FM_B"9FMKXZ)<IX?
MNKH6L&J&9,,Q?8KF/[P1FX#>X..:34?&MQ+/K5OINA7-[8:9N@O+V.9%V2!-
MS!$/+[01G&#Z9KB/#NAZ-!IFF>'M5L_$T^M03I!/8K/<BW&R3(FY(B\L !Q@
M^F!FMS3]4/A>;Q?HEW87TFH7NHW%Y8)%:NZ72S*"N' VC!R#D@#% '3_  UD
M>7X;>'GD=G=K)"68Y)XJ3X@ZWJ'AWP/JFIZ9#YES#"VU]RCR<@@28;AL'''>
MF_#B&6W^'&@0SQ/%*EFBLCJ593CH0>E'Q'M+B_\ ASKUM:0O-.]H^R.,99L<
MX [GB@#E=4U_5E\3>!+N?2KC[;/;WP%C%.C&9MD6&+#"@=6YZ#/TK8N/%\.H
M^&/%<.M:-<6MQI$#?;K);D$O&T992DB8^\,\\$51MKQ-;\5^ K^RAN6MH+6^
MBE>2W>/RV\J(8.X#'((!Z'!QFJFO6-W)/\5"EK.PN--MUAQ&3YI%NX(7U.>.
M* -RS\5BWT3PW9Z!H<]Y/?::MU!:O=*ODP*J#YY'SD_.H[D\UU.CZB^JZ7#>
M2V-S8ROD/;7*[7C8$@CT(R.".",$=:\V:'1H_!?@Z#Q%9:M9O#I<9@U2R242
M6LNQ 8R8P64D=F&#M]17:>!9M3N/"EN^JO<23>9*(I;J/9-)"'81,ZX&&*;2
M>* .CKQWQ%XAUZXUW5_%6DWMR-#\,W4-M):1.?+O "?M)*]"5##!_P!G->A^
M--8NM"\(ZA?6%O+<7PC\NVBBC+L96^53@=@3D^PKE-$^%MWI_A>+2I/%FL11
MRQ'[5!$(#&SN,R?>C)())ZDT =3XB\76?A_0+76?*DN[6YFAC3R.25D( 8#O
MUSCO61_PGNI1ZVVAW'A.[CU:6#[1:0"ZC998\D,6<<)C'(Y[8SD5QL=MJMMX
M.B\*W5M=33:%XAM(H9O*8B:U\T-&X.,$!<@XZ8%=S<6\Q^,=A<B&0P+H<R&7
M:=H8S1D#/3..U "6_P 08)/#EQJ$VEW,>H0:@=+;30ZL[760 BM]T@Y!W=,9
M-#^.WL;#6VU;1IK+4-*M!>O:>>L@FA.<,CC@\J0<C@UQ=_H=W<Z9KUQ):7YA
MM/&1OI4M=Z3/;^6B,\>W#'&XGY?[IJ:\T[1KWPQXMNM M=>NY/[(>V6\OGG<
M2[LMY<:RG<2" 3@8YH ZZW\=SMJ>DQWF@75GINKOY=E>O,A+.5+*&C'*;@#C
M//J!6;X@\;7-[H?B;^S]#NIM+LH[BTEU%)D!$BH0Q6/[S*I/+#T. <59\36M
MQ);> Q'!*WDZM;-(%0G8HAD!)]!DCK7-V^I/H/A#Q3X3GT[4)-8>:^^RQ1VD
MC+<1REF60.!MVX;G)XP1UH W=)\83:=I?A;1+?2KC4=0O-#ANHMLJJ&*J@(9
MFZ<$G/MC!)%*GQ*O9],U"ZMO"EY)+I+R)JD1N8U%N4R2$;_EH<#/ Z8]153P
MS9W4?BOP?));3*D7A,12,T9 1\Q?*3V/!XZ\5-I=G<IH/Q(1K:4-/?WC1 H<
MR P( 5]<GCB@#<N_&9DDTVWT+2Y=5N[^S%^L7FK"L<!QAG9NA). !GH?2JUQ
M\1+2#1=*U!=-NY)+^_;3C:+M\V*X&\%",X)W)MZXY!SBN*&DV]C-X9U/7AK-
MKI\GANVLS-8/.C0SQ_-MD$7S#(<XR.JUJG2X([#P?+I6F:G!;R>(S=2+>EWF
MP4E'FON)*AN#\W//- &^OC?4 ^KV-UX=EM=7L;,7L=L;I'6>$DKN#C@8(.0:
ML_#O6M6U_P &:??ZO;E+B6%&$Q=#]H!'W]J_=^E9VJ65U/\ $O4GBMY&23PN
M84<*=I<S/\N>F>>E6/A9?13^ =+L?+N(KFPMTM[F.>W>(HX'(^8#/X9H ZC5
MKN>PTFZN[:U-U-#&76$.$WX]SP*X3PYX^U%/AYI>K:UITUQ?WSQV]HD3Q[KZ
M5\XP!@(.#G/0 FN_U"-YM-NHHQEWA=5'J2#BO'='DE/@+P=<Q6-_)-X9O8SJ
M5J;219$0JZ,54CYRN0?ESQ0!Z+HWBJ>\UZ30]6TB32]2%O\ :HD,RS)-%NVD
MJZ]P2,@CN*Z6N!T^Z7Q5\2[36=.AN?[+TW3I86NIK=XEEED=?D4. 3@*23C
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"N<?PJUWXJAUK4M4GO([1F>QLC&J16[,,%N!EVQD GIDUT=% !1110 4444
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M5+/ WE99"3@DL0.N3FNFHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY,95 3@L,G/8"F^!/$6GP?$77-%L7G&G:J3J5F)[:2#;-@"9 '4$YX;CC&:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWMSJ FB3*_,,(GWR,[02,F@#N=<\5:?H:V:NES>7%[G[+;6,1FDF &25 XP
M0220.:30?%ECK]U=6<=O>V5_:A6FL[Z Q2JK=& Y!4X/()K'U7PAJ4"Z#=^'
M-1MXM3T:U-I&M[&6BN(BJ@A]O*G**<BI?#OB&^N?$TVC^(=$@L-;6T\^.XMY
M!+'<0!\':V PPS#Y3ZYH ["BLO0=#A\/Z>UG!=7ERAE:3?=S>8^6[9]/05J4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[F\L89XH[>ZDM6$X )9,9(P3QS7"_";_ )'7XC_]A@_^ARU<^"G_ "*VL?\
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MG5G;P=H7BKP9<,?[.N=+O+K1)&/1/+8R6^?5"<C_ &37I7A?_D4M&_Z\8/\
MT6M $7A?Q-9^*](;4+.*>'RYGMYH+A0)(I$."K $C/0]>A%)=^)[.U\6V'AL
M0SS7UW ]P3& 4AC7C<Y)R 3P, \URUL5\'_%FZMW(CTKQ-";F,GA4NXA^\'M
MN3YL]S3_ (<QMKFH:WXYN%.=5F,%CN'W+2([5^FX@D_0&@#8\7>/M)\&3646
MHQW,K766/V= WDQ@J#(^2,*"PYYKH+Z^BL-,N=0<%X;>%IF"8)954MQ^ KQR
MRUVP\2>(?%&KZEHVMW]A>PMI-A)9:=)-']F7(=E8#&6?GVQ6UX.UR;4_A%K&
MFWPE34M'M)[*=)XRDFT1GRV*GD93'7N#0!WWAS7;;Q-X?L]9LXY8[>[3>B3
M!P,D<X)';UJOXI\4V7A*QM+N^AGE2ZNX[1!  2'?."<D<<5C_"7_ ))7X?\
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M&&25@2J*6('L*YC1/'NFZ[X'NO%=M;7:65M'-(\4BJ)"(P2V &([<<UT5_\
M\@^Y_P"N3?R->-_#K_DV_6O^O6__ /0&H ]1\*>*=.\8:''JNF^8L3,R/%,
M)(G'56 )P>A^A%,L?%^EWFD:GJDCO:6>FW,UM<27&  8CAB,$\'MW/I7#:?G
MP1'X>\3Q_+HNJV-I;:NH^[#+Y:B*X]A_"WU!YKG]5Q_PK;6C-_QX_P#"8R&]
M]/)^T#.?;.V@#O5^)+26G]HP^$?$<NE8WB[6W3YD_OB,OO*XYSCI76Z3JUCK
MNE6^IZ;<+<6=PF^.1>X_H0<@CL15Q=I1=F-N.,=,55TV33Y+%#I;6S6@)5?L
MQ4H"#@@;>.N<T 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#!\1>%K;Q!+9W0O+NPU&R+&VO;-PLB!AAE.00RG R".
MU0Z+X033=7;5[_5;_5M2\HP)/=E (D)!(1$4*,D#)QGBNDHH YWPYX.L?#.J
MZYJ%I/<22ZQ=&ZG64J51LL<+@#CYCUS6'8?# :0MQ'I?BW7[*&>=[AXH7AV[
MVZGF,^WY5WU% '.P^%6_X1[4]'O]<U/48]0B>%IKID,D:LI4[=J@=\\@\U+I
M'A+3-*\'Q>%V5KS3DA:%EN<$NK$DYP ._:MVB@#A8_ALUO:_V=:^+O$,&DXV
MBS2=#M3^XLA7>%[8STK;G\%Z!/X47PRVGHNE(H5(E)!0@Y#!NN[/.>N<^M;]
M% '#R?#J2ZM_L.H>+O$-YI9&UK22=%\Q?[KR*@=AZ\\UN:CX5TZ_M-'M%#6M
MOI-W#=VT<& H,0(53D'Y>>W/O6Y10!S_ (P\'Z;XUT4Z9J)EC4.'CF@(62,]
M#@D$<@D$8Z&MC3[--.TVUL8F9H[:%(59NI"@ 9]^*L44 <_XO\(6'C/24L+Z
M:XM_+E$L4]LP61&P0<$@]02#]:N/H5NOA@Z!:22V=L+7[)&\) >--NW()!&<
M=\5J44 9^AZ/:>']#LM(L5(MK2(1)NZG'4GW)R3[FLR?P;8S:YJ^JI<7,4FK
M6/V*[B0KL? ($G3.\ X!SC':NCHH X/3?AI+I&GPV&G^,_$5O:0+MCB22'"C
M.>/W?O5[6? 4.O>&;31M1UO5)C;72W:7A:/SBZ[L9.S;@;O3L*ZZB@#C?^$&
MU'_H>_$O_?R#_P"-5)JW@-=1\22:];:_JVFWDELEL_V-XP&122,[D/<UUU%
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M=[I%\I-M=Q&)]O49Z$>X."/<5FZ?X/M;#7-/U<WMW/=66F#35,K*=\>X-N;
M&6XZ]/:NBHH Q-9\,6FL:KI6J&:>VO\ 3)2\,\! +*1AHVR#E&[C\B*?9^'+
M6R\4ZGK\<LS7.H11121L1L41@@8XSGGG)K8HH YSPQX)TGPE<:I-IHEW:C.9
MG#D$1C)(1,#A068@>]9]G\-M*L]*\/Z9]KO9;/1+I[N&*1EQ+(69@7PO.TL<
M8Q[YKLZ* &2Q)-$\4J!XW4JRL,@@]0:Y"Q\'3:!%X;T_2M0U!K#3KN5Y1).
M#"R/A&  W@.5P.WX"NRHH 9-&)H9(F) =2I(]Q7,:)X"T[0O ]UX4M[FZ>RN
M8YHVED9?, E!#8( '&>.*ZJB@#,70K$^&DT"=#<6*VJVC+)U= NWG'? [5E>
M'_ >DZ#X4N?#A::_L+EY'F%X0S/OQD$@#TZ]:ZBB@#A8_AL\-I_9T'B[Q%%I
M.-HLUG3Y4_N"0IO"XXQGI6\GA>RM;'2+'39KG3K/3)EECAM)-JR@ C9)_>4D
MY.>IYK<HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBL'7;FZN=0L]"L+E[6:Z5YI[B,9>*%, [<\;B650>W)
MIQC=V%)V5S>HK '@OP]C]YIR3OWDG=I';W+,233AX+\-@Y&CVV?]TU5H=W]W
M_!)O+M^/_ )T\2:5)JS:8)Y!<K*8/FMY%0R!-Y02%=A;;S@'.,^E7%U*Q=(7
M6]MF6=BD)$JD2,.R\\G@]*YS4? T6JS7J76HS?8KJ>2Y,$2!&61X/)SOZX"D
MD# Y]>E0VGP^AM+U+U=08SF;S)O]%BV,,Q<(A&$/[A>1SR3UP1!9OWGB/2;&
M.)Y+P2><0(UMD:=WRK,"%C!)&U6.<8P#4D>N:7)"TWVZ%(E8*7D;8"3&)!@M
MC/R,#Q_0UR$'PTM18M;#5?M,2B&%%GM8I5581(B@@C[PWGY@005_"J?B'X97
M=W;&+3+U)7F1X9I;Y\E5:&WBW#Y&W-_HZG/RGYCSSP >@G4]/"S,;ZVVP?ZT
M^:N(^<?-SQR".?2FOJU@FI1:<;J,WDH++"IRV ,Y..G'KC/:N4O/AK8W4;;;
MR6*0R/+O1 -S-,\OS8(W >85Z]@:N:1X&MM&UBWOH+MVC@4A(FB7.3$D9RXY
MQB-2!VR?; !MV&N:7J<>^SOH9!YK0[=VUMZE@5VG!S\C=N0"1Q5JWNK>[0O;
M7$4RC&3&X8#(##I[$'Z$5P%[\,G%G<+I^HLMW-)B*<@1&W5IVE=AM4EV^=E&
M<<'&1DUW.GV":>DL4100EE\J-(POEJ$50N1][[O4^N.U %RBBB@ HHH) !).
M .IH **165U#*0RD9!!R"*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ***Y>2&3Q/KM];7$DJ:1I[K"8HG*?:92H9MY&#M4,!M[DG/2JC&Y,G
M8Z?</4?G3)9XH(9)I' 2-2['K@ 9-8W_  A?AC_H Z?^,"_X4Y?".@PB1K32
MK.VF:-T6:*%0R[E*G!^A-#4;:/\ K[P3EU7]?</T_P 5:+J<,DT%[L2-(Y6-
MS$\&$DSL;$@7*M@X/0X-:#WUG',T3W4"RH%+(T@! 8X7(]SP/4UR ^':-#;F
M;57EN;:.&&"1K="BQQ)(@4H<ALB5R23UQC&*>?AW;HDL=OJ4T<96(QEH8W=7
MC,)4ER-Q'^CI\N0.3[8DHWY?$>E1:@EB;HM.X4CRXG=%W%@NYU!5<E& R1DB
MIH=:TRXACE2_MPLD2S*'<*VQAD,5."!CU%<VGP^A6XL)FU&1GM,$2>0@D/[Q
MG(#@9"L6PR\@@=LFLBW^&$T5Q]C:[A.E):&!9, SN3!%"<C;P,1YQN/7Z8 /
M08]0LIC"(KRW<S@F(+*I\P#KMYYQWQ53_A(](,-W,M]&T5I(D4\B LJL^W:,
M@8/WUY&0,\]#7.CX:V U3[9]LG"%Y6:%0% #R22 +C[N#*PSWP.E36G@*&UT
M#4=+^WLWVZ2&1I!;HH7RUC484#!R(QG/7)H Z4:KIQC\P7]J8\*=PF7&""1S
MGN <?2K2L&4,I!!&01WKB[/P']DUN"Z6>/RHH)BS;1F6>1Y&5C'C:%033 #)
MSOP>F3V<:E(U4G)4 9 QG\* '4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 45S/BWQ7/X;GTFVM=*?4KK4YV@AB6=8OF"[NK#%4K?QQ>VVMZ?IGB'P
MU=:0=1D,-K/]ICGC:3&=I*'*D]N* .SHID4T4P8Q2)(%8JQ5@<$=0?>F?;+7
M_GYAYD\K[X^__=^OM0!-7.2?\E)M_P#L$2_^CHZZ.N<D_P"2D6__ &")?_1T
M=73Z^A$^GJ='7G6E^*]4U/XKWMAYRKH]LSV4<2K_ *R0)O9F/]X,A QV->BU
MY1H&AZ['H4&LV5@/[6;7;FZ:*<A,I(LD)9LXX#'?CKCIFH+/0]&UZSUX:B;'
M>18WDEE(SC :1 -V/4?-C/M4JWILK*%=4N;47IB9V6([ Y49;8K$G KA)$_X
M1WP[XI\/00WINY$D:SDC@8^8IM4'FEP-H^96!).<CU(S"6L+PZIJ<DPFN$T>
M#3]+5#N+>=$6S&.[.QQD=D],T =?X%$C>!](N)A^^NX!=R_[\Q,K?JYKH:\J
M\.^,["UO]/EN[EK?2K?1([6V)SB>X7RS*BKU9UW1J% SG>.QK.@\12:A\0+#
MQ2\M\NG03W%G<VV686HVND2-$N?WC21N2.3\\8[C(!Z_<7<-M9SW3N/*@1G<
M@] HR?Y5D^"[B\O/!FD7E_(TEU=6RW$A8YP9/GQ] & _"N'\*75M9^"=:TV2
M\:YU_4;F]DET]!NGCE8E=I3JHX4ECA?FZX(KL/!VOZ7JNCV%IILPF-O8PF7R
M^5A)4 (Q[/P?EZC'..,@%+XB:UJ&FZ=INGZ5.(+W5;U+03 9:*,@[W7W''YU
M;L/%MNMCX3BO"[WNO6ZM&8U&W<(1(S'T';CN16;K]C=:A\6/"Y^SN]E9VMS.
M\F/D5CM7D^N=F/QK(MM&U+0_^$<U#5+5Q!HER+)1$/-*VPAFC$V%R1N9X\CJ
M H)QS@ ],>XACFCA>:-99<^6C, SXY.!WQ7G7ACQ=JFN?$J^B>8#1_\ 2[2W
M@"\%[=X?WF>N2)6]L <<58@U2PG\8ZIXAO?/62SM8;33K6:,I(?-W,2L9YWR
M, HZ'"\XYK$\)^&]=C\'^&]2M+4V^JR/<>?YN%,,<Z;?.(/4CRXGV]\XH ](
MT'7[/Q%937=B)/*BN9;8EQC+(Q4D>QQD>QJEXYN6M?!.JE&*R30_9D8=0TI$
M:G\W%<W:ZU'X)\,ZOIB65TMQ82W+6VZ!O*\LDO$[28VA/F52<YX/I7'V<[V.
MG:O8W%W?7\$FI6.I0W4S-*)K:.5#-.6Z!,Q,WIAE]10![G%&D,211J%1%"J!
MV Z5$E[:R2R1)<PM)'((G42 E7(W!2.QP0<>AKSO3OB#:62>([Z[\^2[FNC/
MIU@H+236PA3RY$7LC;'8GH.<^_(Z<B:-:6>M3:H;VP34+34=6NXV\R);Q_-W
MA"..%>)3C_8[YH ]YHKSO1/%;:%/J@\57DL-W>&._M+*0[G"RC:((AU9E9=I
M4=SGO7H@Y .,4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !17!67CW7=6EU Z1X,EO+
M:RO);-IAJ,4>YHS@X5L'T_.M[PUXML?$FEO>*DEE+%=-9SVUUA7BG7JAYP3R
M.E &_13)9HH0IED2,,P4%F R3T'UHCFBE+B.1'*-M<*P.T^A]#0 ^L'PU_K]
M=_["DG_H$=;U8/AK_7Z[_P!A23_T".KC\+(?Q(WJQM"\4:3XDDOTTNY\\64W
ME2.!\K''53T9>HR.X-)XNU-M&\(:MJ$8)EAM7,8!QER,*/S(KS;P?')X:\,W
M=I:'9<W6A64MHPZ^9,]P,_\  2RD^U06>QT5R6AZXND_"_1=6U*::ZD.G6S$
MCYY9Y'10JC/WF9F 'J35"'XD0S>&M%\02VWV.TO+F>&XAD_>2)Y:3'"E<98O
M&H'!SNQ[T =C/J5G;:A:6$TZI=7@<P1D'+[ "V/H"*MUY5'?ZBWQ135/%:VF
MF6FCZ09D99<HIN'VA6)_B&UUXZE00.<5Z?9W<%_907EK)YEO/&LL3X(W*PR#
M@\]#0!7OM9T[3ED-U=Q1F,Q"1<Y9/-?9&2!R 6XSTX/H:O5X[XRUB )XVCMX
MY;G4([RS.V)24AB@$,H:1^BC>9!CJ>< \UUWB'QM<>#M.A?5K-;Z]E.\Q:>"
M$ABW*I9V<] 7 !P,D@8ZF@#?&KF3Q6^C1Q@B&R%U,YZ@NY6,#Z[)"?H*U:X3
M^UXM$\3^,=8ND9TB>PLHT3&YV*@JH^K3BMV^\1"P\4QZ9.D<=G_9L]_+<LV/
M+$;HIS[8<G\* -ZBLW0-;MO$>B6VJV:2I#/NPDR[74JQ5@1V(((K2H ****
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MW]NZU_T*&H_^!5K_ /':/[=UK_H4-1_\"K7_ ..T =#17/?V[K7_ $*&H_\
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M/7P_I:W5C=?9%,UC"8+=B3\B8QC&<'C(!/(R<=37-CXCP$9&G)C_ +"UE_\
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M_P"A0U'_ ,"K7_X[0!T-%<]_;NM?]"AJ/_@5:_\ QVC^W=:_Z%#4?_ JU_\
MCM '0T5SW]NZU_T*&H_^!5K_ /':/[=UK_H4-1_\"K7_ ..T =#17/?V[K7_
M $*&H_\ @5:__':/[=UK_H4-1_\  JU_^.T =#17/?V[K7_0H:C_ .!5K_\
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MZ&SC/M5N\U;3M/L!?7M_:VUF<$3S3*D9ST^8G'- %RBJ9U?3%TP:D=1M!8,
M1=&9?*()P/GSCD\=:N4 %%<_XV\1R>$O"5[K<5H+M[<QA8#)L#%Y%3K@X^]G
MIVJQX6U^+Q/X:LM7BC,1G3]Y"3DQ2 E70_1@10!L45Q'ASX@KXB\>:OX>AL
MEK8Q,\=YYN?.VN(VPN.!NW#.3]VH]6\7:KH_@:YUDSZ+?7<=]' ILF9X0C2J
MF#\V=X#'//7% '=T5!+>VEO<P6TUU#'/<9$,3R -)CD[0>3CVJM#KND7.IR:
M;!JEE+?QYWVR3JTBXZY4'(H T**S/$>K'0?#6IZNL(F-E;27 B+;=^U2<9YQ
MTK.\#>+%\9>'%U(VWV2Y25X;BVW[O*=3TS@9RI4].] '245Q$?Q!6X^*'_"'
MP6 >%8WWWOF])50.R!<<X#+GGJ:Z>37M'BU1=+DU6Q34&QMM6N$$ISTPF<T
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MMQ$+>^.Q_F4[$&W(/4# Q]!7IVI>#=#U;55U&[MI#<"-8I EQ(B3(IRJR*I
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /'](T"ZU7PMJ>HZ00FNZ5XAOKFP<_Q'S#NB/\ LNORG\*33/%F
MF:IK_BGQ&\4K6?\ PCD+W%L&*R*5,H>,D8(8$$9X]:]3TO1['189X;"'RDGN
M)+F0;RV9'.6/)/4]NE9\'@OP];7VKWD6FQK-K"%+[YF*S YSE<X&<G. ,YH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ^BB@#JZ*\PT+XA:K?\ B^VEND@7POJUS<66ERJF&\R+&UF;N'(D 'J*]/H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXYHGBE19(W4JR,,A@>H([BJ\&F6%M)%)!8VT4D47DQM'$JE(\YV @<+GMTH
M\SM]&C\/?%2PB\17^H:K;7,9.AW=_<%Q;W &'C(&%WD<JV/;K27N@1>)_'_C
M_1Y2%-QIMF(W_N2 ,4;\& ->H7-E:WJQK=6T,XC<2()8PVUQT89Z$>M*EI;1
MW4MTEO$MQ* LDJH [@= 3U.* /*_"&IWGC_Q)I4^HPNB^&;4B[1QC=J+%HSQ
MWVJI;V+BL?0]8N;#]G[1=,TT_P#$VUJXFTZT /(+W$@9O8!<\]CBO;(+2VMF
ME:WMXHC,YDE,:!=['JS8ZGW-01:/ID'V;R=.M(_LI8V^R!1Y);[VS ^7/?'6
M@#R_6?!/C9_ EOHD#^'ECTM8YK,VT<PF$D7*E221N.",D?Q&O0_"7B"'Q3X5
MT[68<#[3$#(@_@D'#K^# BMJH+6SM;&(Q6EM#;QEBY2) @+'J<#N: /,?#F@
MW^K>)O&<MKXDU+2T7664Q6BQ%6/EI\QWH3GM^%:WB/PW9>&?A3XI@M9+B>6X
MM+B>YN;E]\L\A3EF/'8 < "NZAM;>W>5X((HFF??*40*7;IEL=3P.32SP0W,
M#P7$22PR*5>.10RL#U!!ZB@#BO WBGP];> ?#\$^O:7%-'IT"O&]Y&K*0@R"
M">#6?XRU"WTWQ9X3\:K(MSH<'GVEU<P'S%B64 +)E<_+N!!-=A_PB/AK_H7M
M)_\  */_ .)K2ALK2WLQ9P6T,5J%*B%(PJ 'J-HXQ0!SNL?$+PYI6FBZBU&W
MU":7"VUI8RK++<.>BHH/Z]*W(]4M'U"/3FE6._>W^T_96(\Q8\[23CC@G'7K
M4-CX<T/3+DW-AHNG6EP>LL%JD;'\0,U>^RV_VO[7Y$7VD1^5YVP;]F<[=W7&
M><4 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117+R6[>*-;O
M[:Z>0:/8.L!@C<H+F4J&;>1@E5# ;>A.<YXJHQON3)V.C-S #@SQY_WQ39+V
MVCB>1ITVHI=L')  R>!60/!/A<#'_"/Z;_X#+_A3T\(>'X-[6FD65K,T;()H
M8%5U#*5.#CT)IM0MHW_7S!<U]4+8^+-#U"!YHKX11HD<C&ZC>W^23.QOW@7(
M;!P1QP:T&U*Q2=H&O;99D"EHS*H8!B I(SW) 'KFN73X>VXCMFDU2ZDN;6.&
M&"5HXR$CC21%785P>)7R3SG'3%./P]LDADA@O[J.(B(Q@I&S1O'Y.&WE=Q_X
M]X\C.#S[8@HVY/$>E1ZDFG_:B]PZA\11.ZJ"6 W.H*KDHPY(Y%2PZ[I,\22)
MJ-L \*SA7D"L$8;@Q4X(&.>17/CX>V7VG3YWO9WDLCE)#%&),[V<X<+N 8L0
MR@X('0<YR;?X9O%.+(W8_LA+8PJ2P:9F,$<))&P8XC!^\1[#L =W%JNG3& 1
M7]K(;@$PA)E/F ==O/..^*J#Q-HS6UY<IJ$3P6<B13RIEE5FV[1D<'[Z\C@9
MYZ&L/_A7.FG4WO#=W>)'E>2$, AWR22#&!Q@RM@_2I[7P+;6VBZAIOVZ=Q>R
M0R/*8XP5,2QJN %V](UZCUH WUU;37B\U=0M&CP#N$RD8()'.>^#^1JVK!E#
M*05(R".]<=:>!A::_!>I./+B@F+2$@O+<2/(P<IM"@)YTP YSYG3CGL$4JBJ
M3D@8SC&: '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7<J@'_?$A/X5JUP9U>+0_$WC'6+E&D2.2PLHT4_,[% 54?\  IZWK[Q$-/\
M%,>F7"1QV?\ 9D]_+<LV/+$;H#GVPY/X4 ;U%9GA_6[?Q'H=MJMM%-%%.&_=
MS+M="K%6!'J"IK3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN@#H:*Y[^RO$_P#T,\'_ (+%_P#BZ/[*\3_]#/!_X+%_^+H Z&BN>_LKQ/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%>4^#/&.LQ^*KRUUZZ,^EZCJ5U::=.R@>1-%(P\DD=F7!7/<$5TT.N
M7$/Q'UZTNKIAIEGI<%R(R.$)+[FX&>BC\J .PHKE='\<V^JZE9V<VD:GI_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >8^
M&O#L'B;P1XCTNY+1-)KEZ\,R\-#*)24D7W!P?T[UA:#K^OR:WXRO9;)E\0Z;
MH:02($RKW$9DPRC^(,-K >^*]KHH \7L=3TMO%_@S48?$6HZM%YLL=W=W,I,
M$4TD#!$ P%5V;(VCIP#U%#1G_AG;75V'<9KOC')_TIJ]G  &  *6@#A_$:'_
M (6!X!P. ]YT'3_1S7!Z#I^BKX?LO#6L^(/$']JQW(MI=$@D7[ZRY#!"G^KX
M#[LXQWKW2DP,YP,^M %"VUNQN];O=(AE8WMDD;SH4("AQE<'&#T[5H444 >7
M7.@Q^)?&_P 0M(F^5;K3[%4<_P #A7*M^# '\*R]%FU+Q7I'B+Q'K%N\4VF:
M++I,2..LXC)N' ]VVK] :]EHH \@BU8V7ASP%8:CK-SHNBSZ,'FN8&\MI)EC
MCV1%\';P6.!@G&*P_-AD\+7UB&N6F3QA;S&.\),YBD9"CN#S\P!//OZ5[T0#
MU -+B@#S7XEZ5-K7B_P5I\-]<6)GEO4:YMP-Z*8/FP3T)&1GMG-:?P]OI+"U
MD\&ZC!%;ZGHR!%\I-B74'\$R#W_B]&SGK7;T4 ><>/M+L]9^(_@.RU"TCNK.
M1K_S(I5W*<0J1D?4"LSXF>"/#6C^$1>Z7H5E:W:7ML%EAA 8 RJ#R/:O6J*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHIDJ>;$\>YDW*5W(<$9[CWH ?17DOB?P_?:/XA\,6%MXO\
M$YAU2\>"<O?Y(4(6^7Y>#D>]:_BRUTWP?X+=M7O-=UBVDO8N9KX^:K$X&&&W
M"]R* /0Z*X>X\5:VGQ8C\.Q:5))I_P#9XG8B6(9!E5?.Y.=J_,-O4]<=*P_!
MGB"/1Q\0]3U.>>2VLM=G"J"7;&["H@/<D@ >IH ]4HKF]'\4SWNL#2=5T6YT
MF]D@-S;I+*DBS1@@-AE)PP++E3Z]ZU-$U&?5M)BO+C3KG3I7+ VUR '3#$ G
M'KC/T- &A14-W<QV5G/=3$B*"-I'(]%&3_*O//#NB:OXVT6'Q'K'B36;%[\&
M:UL],N?(CMXC]P' ^=L8))]>E 'I-%>7^*3KWA_P79#6]2^VR6^NVOEW5NI$
MLUOYHP'4 9?&00,@\5U&E>+I[OQ)_8>IZ'=:5=2V[75L998Y!+&K -RA.UAD
M<4 =117GGACQ=HMCX'FU/3['4/*;47M8;22;SIIYV8*%4L>A)]<  UI-XQOW
MM=5M6\/W-OK=E LXLFGB.^)L@2*^=I (.1UXQWH [&BO+_@H+JZ\,IJM[:7[
M7-XC-)J-S?>:MR1(P^5-QV8QCH,U<UJUO-<^+!T?^W=7T^RCT-+H)87/E;I/
M/=<G@]L?D* /1**XC5=(M/"G@_7;S4-5U[5[0VV98KF]RX4?\\V 4J3GKGL*
M=_PF=MI=CX7L;+2KV[DU>P\VR@20%\(D9"NS'T?)8G^$T =K17(V?CI)=-UJ
M6]T>]M;_ $=U2YL$VS2,7 *;"IPP;(],=Z=9^,Y3/J%IJVB7.FWUI8F_6%YD
ME$T(R"593@$$8(/J* .LHKA;;XD&:'1[^3P_?0:-JDD4,5^\D?RR2<+E,[MN
M[C=^/0C-K5/'4EK?ZC#IV@7NJ6VE8%_<021J(CMW%55B#(P4@D#UQUH ["BN
M*.MZ/=_$?18HX+M[V[TIKFWG$K+$(B2<-'G[WN1D5(?'DB7L33Z!?PZ/->BQ
MCU&1D ,A?8"8\[@A;@,?8XH [&BO._#UQ._QO\80--(T,=G:%(RQ*J2BYP.@
MK6\=:SJ5F-(T719E@U/6;K[/'<,@;R(U4M)( >"0HX!]: .NHKSW5_"6LZ#H
M]QJ^B>+-<GU*SC:?R=0N1/!<;1DHR$ +D @%<8KFO'/BC4?$%MX*2ST^^&FZ
MO-%-(MO>+";G*Y,&X,&&,\DX'Y4 >ST5XGXEGU6Z\;^&/#KZ!JJ:='9R.--C
MU54:X(4<M(),G9C^)LG!QG-=IHVMZ+;^+?& \FZM9M-AMY+^:>X+QE?*+#:N
M3MPH.<=?>@#N**X_2_',M[>Z<EYX>O\ 3[+5,_8;N5T82?+N =5),9*C(S3+
M7X@I<RVMT=&O(]"O+D6MMJC.FUW+;58IG<J,PP&/J.F: .SHKD;7QP^H^*+S
M0]/T2[N'L;H07EP'18X4(!#G)R<Y/RCGY3774 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!PWCB":7Q?X&>.*1TCU*1G95)"CRCR?2JGQIMI[KP$L=O#),_P!NMSMC
M4L<!NN!7HE% 'GVI7<>D_&VRN[Q)DMKS1/L4$JPNZM-]HSLRH..#GGBN1BT/
M4+_PY\2((K2Z,K>(3=1QQ@J\R),KG8>Y(4XQWQ7M]% 'G/A.'P[?>*8+O2Y_
M$6HS6MM(?M5_-,T5OOV@Q_O<?.>N #]WGM7;:)K%OKVDQ:C;17$4,I8!+B,Q
MN-K%3E3TY%:%% %>^M$O]/N;.0D1W$31,1Z,"#_.O.O"WC"'P;H%OX;\56U[
M9W^FK]GBDCLY98KN->$:-D4@Y&.#CFO3:* /,_$%_J_B'POI]Y=Z--9(WB"S
M:V@=29O($JX>1?X2>3CL,5MZI#*WQ9\/3+$YB33;Q6<*=H):/ )KL:* /!M%
MT6\D^%<$DMMJ$:6/B1KRX2V#I.(02K,F/FR V[CTKL_#MKH5S=:Q?Z-)KM^Z
M:>;<WU_+*\;!LMY:>9R2" 3@8&[UKT:B@#B/A#!-;?"O0X9XGBE5)-R2*58?
MO7Z@UFZUX5T[Q+\8RNL:<UU9QZ A1B751)]H?C*D<X/2O2:* ///%G@[2/#_
M ,-O%$6@:889+NS(=(V=S(5SC@D^IZ>M5],M9UUOX9LT$@$.B3K(2A^1O)@&
M#Z'@UZ710!Y/KKZK8:M\0+NQ%W ))M,#W%O&3(L.P"5H^.2JENG2L^+[!'XI
MO9]+&L3V%[X>NK:WN[U[B;[1."K%5,F2!M^@)!Q7M%% 'F&H6EP?A'X+A6WE
M,L<NDET"'<N#'G([8[T^QU^+P+J?BJSU.TO7N+O49-0T]8;9Y!>"1%PB,JD;
M@R[3GI7IE% 'FDR7UU\:_#=_/82VY;0G,R_?6%R6)0N!@D9Q7(75P;[0+2\O
MWU^\\0VVI0W&J1.UQY-FB7 W8B_U9 &,  G&3V)'O5% 'G/AJ*5OC5XMO!%*
M+::RM#'*R$*_R+T)K3\?:=J'F:'XATNT>]N=$NS,]K']^6%U*2!!W;!R!WQ7
M9T4 >>:S\0[+6=$NM,\-VFHWVLW<301VQLI8O)9AC=(SJ%4+G)Y[5F:[X?FT
M5_ACI<*/.-.O4CED1"0,( 6/H"<]:]6HH \^UNWG?XW>%KA89#"FGW(:0*=J
MD@X!/05A'0[[5?%?Q8LX89%>^LK>*W=E*K(WD,, G@\X!KUZB@#@M$\9Q:G:
M:1H5CIM\U_)"(;])('A%@%CPQ<LN"=P  !YS7'^&]*T9-,TCP_JA\3S:S!/'
M#/IBSS^3&T;Y$N#B/RAM#@@^F.:]MHH XCP1;RP^*?&TDD+HLNJ*49E(#CRE
MY'J*[>BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227791604184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Verona Pharma plc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1489389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3 More London Riverside<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">SE1 2RE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">283 4200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, nominal value &#163;0.05 per share*<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VRNA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482,944,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001657312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227791879256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 132,764<span></span>
</td>
<td class="nump">$ 148,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">1,246<span></span>
</td>
<td class="nump">4,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_TaxCreditAndIncomeTaxesReceivableCurrent', window );">Tax and tax incentive receivable</a></td>
<td class="nump">16,420<span></span>
</td>
<td class="nump">15,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2,525<span></span>
</td>
<td class="nump">2,063<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">152,955<span></span>
</td>
<td class="nump">170,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Furniture and equipment, net</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">545<span></span>
</td>
<td class="nump">545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Equity interest</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">744<span></span>
</td>
<td class="nump">899<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">16,360<span></span>
</td>
<td class="nump">16,524<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">169,315<span></span>
</td>
<td class="nump">186,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,064<span></span>
</td>
<td class="nump">10,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">28,877<span></span>
</td>
<td class="nump">22,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">583<span></span>
</td>
<td class="nump">648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">37,903<span></span>
</td>
<td class="nump">33,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Term loan</a></td>
<td class="nump">4,928<span></span>
</td>
<td class="nump">4,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">5,105<span></span>
</td>
<td class="nump">5,160<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">43,008<span></span>
</td>
<td class="nump">38,582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary &#163;0.05 par value shares; 494,058,246 and 489,177,550 issued, and 482,944,390 and 480,082,966 outstanding, at March 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">32,182<span></span>
</td>
<td class="nump">31,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">388,204<span></span>
</td>
<td class="nump">385,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Ordinary shares held in treasury</a></td>
<td class="num">(739)<span></span>
</td>
<td class="num">(603)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(288,739)<span></span>
</td>
<td class="num">(263,716)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">126,307<span></span>
</td>
<td class="nump">148,005<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 169,315<span></span>
</td>
<td class="nump">$ 186,587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_TaxCreditAndIncomeTaxesReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit And Income Taxes Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_TaxCreditAndIncomeTaxesReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227790296312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - &#163; / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in pounds sterling per share)</a></td>
<td class="nump">&#163; 0.05<span></span>
</td>
<td class="nump">&#163; 0.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">494,058,246<span></span>
</td>
<td class="nump">489,177,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">482,944,390<span></span>
</td>
<td class="nump">480,082,966<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227790406216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 17,625<span></span>
</td>
<td class="nump">$ 13,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">7,440<span></span>
</td>
<td class="nump">9,282<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">25,065<span></span>
</td>
<td class="nump">22,856<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(25,065)<span></span>
</td>
<td class="num">(22,856)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income/(expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_GainLossFromResearchAndDevelopmentTaxCredit', window );">Research and development tax credit</a></td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">2,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_UnrealizedGainLossOnWarrants', window );">Fair value movement on warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(507)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases', window );">Foreign exchange (loss)/gain</a></td>
<td class="num">(923)<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">310<span></span>
</td>
<td class="nump">1,646<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(24,755)<span></span>
</td>
<td class="num">(21,210)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(82)<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (24,837)<span></span>
</td>
<td class="num">$ (21,290)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Profit/(loss) per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Profit/(loss) per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_GainLossFromResearchAndDevelopmentTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) From Research And Development Tax Credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_GainLossFromResearchAndDevelopmentTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_UnrealizedGainLossOnWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized Gain (Loss) On Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_UnrealizedGainLossOnWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227792785704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Ordinary shares</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Ordinary shares held in treasury</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Accumulated deficit</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">488,304,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 184,854<span></span>
</td>
<td class="nump">$ 31,794<span></span>
</td>
<td class="nump">$ 366,411<span></span>
</td>
<td class="num">$ (1,700)<span></span>
</td>
<td class="num">$ (4,601)<span></span>
</td>
<td class="num">$ (207,050)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,290)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,290)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted share units vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">8,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">488,304,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 172,414<span></span>
</td>
<td class="nump">$ 31,794<span></span>
</td>
<td class="nump">375,261<span></span>
</td>
<td class="num">(1,670)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(228,370)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">480,082,966<span></span>
</td>
<td class="nump">489,177,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 148,005<span></span>
</td>
<td class="nump">$ 31,855<span></span>
</td>
<td class="nump">385,070<span></span>
</td>
<td class="num">(603)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(263,716)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(24,837)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,837)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares under at-the-market sales agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares under at-the-market sales agreement</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted share units vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(186)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Issuance of ordinary shares to treasury (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Issuance of ordinary shares to treasury</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(322)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common shares withheld for taxes on vested stock awards</a></td>
<td class="num">(793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation', window );">Equity settled share-based compensation reclassified as cash-settled</a></td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 3,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="nump">482,944,390<span></span>
</td>
<td class="nump">494,058,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 126,307<span></span>
</td>
<td class="nump">$ 32,182<span></span>
</td>
<td class="nump">$ 388,204<span></span>
</td>
<td class="num">$ (739)<span></span>
</td>
<td class="num">$ (4,601)<span></span>
</td>
<td class="num">$ (288,739)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Reclassification from Share-based Compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227792929896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (24,837)<span></span>
</td>
<td class="num">$ (21,290)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange loss/(gain)</a></td>
<td class="nump">1,119<span></span>
</td>
<td class="num">(155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issue costs</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of redemption premium on debt</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value movement on warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">3,748<span></span>
</td>
<td class="nump">8,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">2,791<span></span>
</td>
<td class="num">(2,709)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent', window );">Tax incentive receivable</a></td>
<td class="num">(1,578)<span></span>
</td>
<td class="num">(2,012)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(462)<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,980)<span></span>
</td>
<td class="nump">363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">6,621<span></span>
</td>
<td class="num">(2,349)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(174)<span></span>
</td>
<td class="num">(210)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable', window );">Taxes payable</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="num">(65)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(14,512)<span></span>
</td>
<td class="num">(18,551)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments of withholding taxes from share-based awards</a></td>
<td class="num">(793)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from at-the-market sales agreement</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(726)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(378)<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(15,616)<span></span>
</td>
<td class="num">(18,388)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">148,380<span></span>
</td>
<td class="nump">187,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of the period</a></td>
<td class="nump">132,764<span></span>
</td>
<td class="nump">169,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Tax And Tax Credit Receivables, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227789606984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and description of business operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_OrganizationAndBusinessDescriptionTextBlock', window );">Organization and description of business operations</a></td>
<td class="text">Organization and description of business operations <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Verona Pharma plc (the &#8220;Company&#8221;) is incorporated and domiciled in the United Kingdom. Verona Pharma plc has one wholly-owned subsidiary, Verona Pharma, Inc., a Delaware corporatio</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">n. Rhinopharma Limited, a Canadian company that was previously a non-operating, wholly-owned subsidiary, was dissolved in June 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The address of the registered office is 1 Central Square, Cardiff, CF10 1FS, United Kingdom.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company is a clinical-stage biopharmaceutical group focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The Company&#8217;s American Depositary Shares (&#8220;ADSs&#8221;) are listed on the Nasdaq Global Market (&#8220;Nasdaq&#8221;) and trade under the symbol &#8220;VRNA&#8221;.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has incurred recurring losses and negative cash flows from operations since inception, and has an accumulated deficit of $288.7&#160;million as of March 31, 2022. The Company expects to incur additional losses and negative cash flows from operations until its products potentially gain regulatory approval and reach commercial profitability, if at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company expects that its cash and cash equivalents as of March 31, 2022, will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In March, 2021, the Company entered into an open market sale agreement with respect to an at-the-market offering program (the &#8220;ATM Program&#8221;) under which the Company may issue and sell its ordinary shares in the form of ADSs, with an aggregate offering price of up to $100.0&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During the three months ended March 31, 2022, the Company sold 80,696 ordinary shares (equivalent to 10,087 ADSs) under the ATM Program, at an average price of approximately $0.86 per share (equivalent to $6.86 per ADS), raising aggregate net proceeds of approximately $0.1&#160;million after deducting issuance costs. As of March 31, 2022, there remained ordinary shares, in the form of ADSs, with a value up to $99.2&#160;million available for sale under the ATM Program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s commercial revenue, if any, will be derived from sales of products that we do not expect to be commercially available for several years, if ever. Additionally we may enter into out-licensing transactions from time to time but there can be no assurance that the company can secure such transactions in the future. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives including to further advance clinical and regulatory activities, to fund prelaunch and launch related costs and to create an effective sales and marketing organization to commercialize ensifentrine. We will need to seek additional funding through public or private financings, debt financing, collaboration or licensing agreements and other arrangements. However, there is no guarantee that we will be successful in securing additional capital on acceptable terms, or at all.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_OrganizationAndBusinessDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Business Description</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_OrganizationAndBusinessDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227789491624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of presentation and summary of significant accounting policies</a></td>
<td class="text">Basis of presentation and summary of significant accounting policies<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Basis of presentation and consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The unaudited condensed consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiary Verona Pharma, Inc. All inter-company balances and transactions have been eliminated. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with accounting principles generally accepted in the U.S. (&#8220;U.S. GAAP&#8221;).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 3, 2022 (the &#8220;2021 Form 10-K&#8221;). The Consolidated Balance Sheet as of December 31, 2021, was derived from audited consolidated financial statements included in the 2021 Form 10-K but does not include all disclosures required by U.S. GAAP for complete financial statements. The Company&#8217;s significant accounting policies are described in Note 2 to those consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. The unaudited condensed consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and shareholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Segment reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has one operating and reportable segment, pharmaceutical development.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, the fair value of share-based compensation, the fair value of warrants, research and development tax credit and the carrying value of the equity interest in Nuance Pharma (as defined below). Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company&#8217;s estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Recently adopted accounting standards and recent accounting standards not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">There are no recently adopted accounting standards and recent accounting standards not yet adopted that the Company believes will have a material impact on the Company&#8217;s consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227789491624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_PrepaidExpenseDisclosureTextBlock', window );">Prepaid expenses</a></td>
<td class="text">Prepaid expenses <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Prepaid expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and other development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,037&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_PrepaidExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expense, Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_PrepaidExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227790214456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax and tax incentive receivable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Tax and tax incentive receivable</a></td>
<td class="text">Tax and tax incentive receivables<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Tax and tax incentive receivables consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit receivable - U.K.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total tax receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,420&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,583&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company conducts research and development activities including, but not limited to, developing ensifentrine for various indications and delivery methods, and as a result the Company benefits in the U.K. from the HM Revenue and Customs, or HMRC, small and medium sized enterprises research and development relief, or SME R&amp;D credit, which provides relief against U.K. Corporation Tax.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Effective for accounting periods starting after April 1, 2021, new rules were introduced whereby the amount of SME R&amp;D tax credit that a business can receive in any one year will be capped at &#163;20,000 plus three times the company&#8217;s total Pay As You Earn (&#8220;PAYE&#8221;) and National Insurance contributions (&#8220;NIC&#8221;) liability. Exemptions to the cap have been introduced which are available to companies that meet certain conditions. The Company believes it may be eligible for an exemption and has requested feedback from HMRC. If the cap does not apply the Company would have recorded $3.6 million relating to the quarter ended March 31, 2022 instead of the $1.3 million reported in the condensed consolidated statements of operations. Until we receive this feedback the Company is accounting for the credit as if the cap applied.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227790575448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued expenses</a></td>
<td class="text">Accrued expenses<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and other development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and general corporate costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,877&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,256&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227789479144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term loan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Term loan</a></td>
<td class="text">Term loan<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In November 2020, the Company entered into a term loan facility of up to $30.0&#160;million (the &#8220;Term Loan&#8221;), consisting of advances of $5.0&#160;million funded at closing and $10.0&#160;million and $15.0&#160;million&#160;contingent upon achievement of certain clinical development milestones and other specified conditions. As of March 31, 2022, the Company had $5.0&#160;million principal outstanding under the Term Loan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Term Loan is governed by a loan and security agreement, dated as of November 19, 2020, between the Borrowers and SVB, as amended (the &#8220;Loan Agreement&#8221;). The Term B Loan will be available, subject to and customary terms and conditions, only during the period commencing upon the achievement of a specific clinical milestone relating to ensifentrine through and including September 30, 2022. The Term C Loan will be available, subject to customary terms and conditions, only during the period commencing upon the achievement of an additional specific clinical milestone relating to ensifentrine through and including June 30, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Term Loan will mature on November 1, 2024. Each advance under the Term Loan accrues interest at a floating per annum rate equal to the greater of (a) the sum of the prime rate reported in The Wall Street Journal plus 1.00% and (b) four and one-quarter of one percent (4.25%). The Term Loan provides for interest-only payments on a monthly basis until the payment date immediately preceding December 1, 2023. Thereafter, amortization payments will be payable monthly in equal installments of principal plus monthly payments of accrued interest. Upon repayment (whether at maturity, upon acceleration or by prepayment or otherwise), the Borrowers shall make a final payment to SVB in the amount of 10% of the aggregate Term Loans advanced (the "Final Payment"). The Borrowers may prepay the Term Loan in full but not in part provided that the Borrowers (i) provide ten days&#8217; prior written notice to SVB, (ii) pays on the date of such prepayment (A) all outstanding principal plus accrued and unpaid interest, (B) a prepayment fee of $450,000 plus 3.0% of the Term C Loans advanced if paid on or before the </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">first anniversary of the closing date; $300,000 plus 2.00% of the Term C Loans advanced if paid after the first anniversary of the closing date and on or before the second anniversary of the closing date; and $150,000 plus 1.00% of the Term C Loans advanced if paid thereafter and prior to maturity, (C) the Final Payment and (D) all other sums, if any, that shall become due and payable with respect to the Term Loan Advances, including interest at the Default Rate with respect to any past due amounts. Amounts outstanding during an event of default are payable upon SVB's demand and shall accrue interest at an additional rate of 3.0% per annum.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Term Loan is secured by a lien on substantially all of the assets of the Borrowers, other than the equity interests of Verona U.S. and other than intellectual property, provided that such lien on substantially all assets includes any rights to payments and proceeds from the sale, licensing or disposition of intellectual property. The Borrowers have also granted SVB a negative pledge with respect to its intellectual property.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Loan Agreement contains customary covenants and representations, including but not limited to financial reporting obligations and limitations on dividends, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. The Loan Agreement also contains other customary provisions, such as expense reimbursement, non-disclosure obligations as well as indemnification rights for the benefit of SVB. The Loan Agreement includes a minimum cash covenant triggered when Borrowers' consolidated cash and cash equivalents drop below $45.0 million at any time after the earliest to occur of any of the following: (i) the release of negative data from ENHANCE-2 and/or ENHANCE-1, which in the reasonable business discretion Borrowers&#8217; senior management, would be considered insufficient to support submission of an NDA to the FDA, (ii) the FDA issues a complete response letter with respect to an NDA submitted for ensifentrine, or (iii) failure to achieve a specific regulatory milestone relating to ensifentrine by June 30, 2023 (extendable to March 31, 2024 upon the Borrowers receiving a specified amount of new cash proceeds after September 8, 2020 from the sale of equity securities in one or more public financings or other bona fide equity financings, subordinated debt and/or upfront/milestone payments from one or more collaboration agreements not prohibited in the Loan Agreement). Upon such trigger, Borrowers must cash collateralize an amount equal to the outstanding obligations to SVB plus the amount of any prepayment penalty and Final Payment which would be due in the event the Loan Agreement were prepaid in full with respect to the Term Loans advanced as of such time.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of March 31, 2022, the carrying value of the Term Loan was approximately $4.9&#160;million, of which all was due in more than 12 months. The debt balance has been categorized within Level 3 of the fair value hierarchy. The carrying amount of the debt approximates its fair value based on prevailing interest rates as of the balance sheet date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227879117864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Interest<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Equity interest</a></td>
<td class="text">Equity interest <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company entered into a collaboration and license agreement (the &#8220;Nuance Agreement&#8221;) with Nuance Pharma Limited (&#8220;Nuance Pharma&#8221;) effective June 9, 2021 (the &#8220;Effective Date&#8221;), under which the Company granted Nuance Pharma the exclusive rights to develop and commercialize ensifentrine in Greater China (China, Taiwan, Hong Kong and Macau). In return, the Company received an unconditional right to consideration aggregating $40.0&#160;million consisting of $25.0&#160;million in cash and an equity interest, valued at $15.0&#160;million as of the Effective Date, in Nuance Biotech, the parent company of Nuance Pharma.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company follows guidance from ASC 321-10-35-2 and uses the fair value measurement alternative and measures the securities at cost, which is deemed to be the value indicated by the last observable transaction in Nuance Biotech's stock, subject to impairment. The valuation will be adjusted for any observable price changes in orderly transactions for an identical or similar investment in Nuance Biotech, or if there is an indicator of impairment. As of March 31, 2022, there had been no observable transactions to indicate any price changes in the value of Nuance Biotech&#8217;s stock, nor had there been any indications of impairment. The equity interest is therefore recorded at a value of $15.0&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227790229064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Significant agreements</a></td>
<td class="text">Significant agreements<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Ligand agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In 2006 the Company acquired Rhinopharma and assumed contingent liabilities owed to Ligand UK Development Limited (&#8220;Ligand&#8221;) (formerly Vernalis Development Limited). The Company refers to the assignment and license agreement as the Ligand Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ligand&#160;assigned to the Company all of its rights to certain patents and patent applications relating to ensifentrine and related compounds (the &#8220;Ligand Patents&#8221;) and an exclusive, worldwide, royalty-bearing license under certain Ligand know-how to develop, manufacture and commercialize products (the &#8220;Ligand Licensed Products&#8221;) developed using Ligand Patents, Ligand know-how and the physical stock of certain compounds.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The contingent liability comprises a milestone payment (the &#8220;Milestone Payment&#8221;) on obtaining the first approval of any regulatory authority for the commercialization of a Ligand Licensed Product, low single digit royalties based on the future sales performance of all Ligand Licensed Products and a portion equal to a mid-twenty percent of any consideration received from any sub-licensees for the Ligand Patents and for Ligand know-how.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At the time of the acquisition the contingent liability was not recognized as part of the acquisition accounting as it was immaterial. The Company will therefore record as a research and development expense the Milestone Payment or royalties when they are probable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In March 2022 we entered into an Amendment Agreement (the &#8220;Amendment&#8221;) with Ligand whereby the Ligand Agreement was amended to clarify certain ambiguous terms in the Ligand Agreement. Pursuant to the Amendment:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the Company agreed to pay to Ligand (i) $2.0&#160;million within five business days of the date of the Amendment and (ii) $15.0&#160;million upon the first commercial sale of ensifentrine by the Company or a sub-licensee, which amount is payable in cash or, at the Company's discretion, by the issuance of Company equity of equivalent value, as determined based on the volume-weighted average price of the Company's American Depositary Shares on the Nasdaq Global Market over the ten (10) trading days including and prior to such milestone event;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the Ligand Agreement shall expire on March 24, 2042 unless terminated earlier by either party in accordance with its terms;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">upon termination of the Ligand Agreement, any Sub-licensee (as defined in the Amendment) shall have the right to enter into a direct license agreement with Ligand for the portion of the Program IP (as defined in the Amendment) that was sub-licensed by such Sub-licensee;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the Milestone Payment may be paid in cash or, at the Company&#8217;s discretion, by issuing to Ligand shares in the Company of equivalent value; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">each party&#8217;s right to terminate the Ligand Agreement is conditioned upon such party obtaining a final judgment of the English High Court declaring that the other party is in material breach of its obligations under the Ligand Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company accounted for the $2.0&#160;million payment at execution as selling, general and administrative expense in the condensed consolidated statements of operations as the payment is related to a contract modification.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Nuance agreement </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company entered into a collaboration and license agreement (the &#8220;Nuance Agreement&#8221;) with Nuance Pharma Limited (&#8220;Nuance Pharma&#8221;) effective June 9, 2021 (the &#8220;Effective Date&#8221;) under which the Company granted Nuance Pharma the exclusive rights to develop and commercialize ensifentrine in Greater China (China, Taiwan, Hong Kong and Macau). In return, the Company received an unconditional right to consideration aggregating $40.0&#160;million consisting of $25.0&#160;million in cash and an equity interest, valued at $15.0&#160;million as of the Effective Date, in Nuance Biotech, the parent company of Nuance Pharma. The Company is eligible to receive future milestone payments of up to $179.0&#160;million triggered upon achievement of certain clinical, regulatory, and commercial milestones, as well as tiered double-digit royalties as a percentage of net sales of the products in Greater China.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of March 31, 2022, the $25.0&#160;million cash payment and $15.0&#160;million equity interest had been received and the holding in Nuance Biotech was recorded as Equity Interest on our unaudited condensed consolidated balance sheets included elsewhere in this Quarterly Report on Form 10-Q. The Company follows guidance from ASC 321-10-35-2 and uses the fair value measurement alternative and measures the securities at cost, which is deemed to be the value indicated by the last observable transaction in Nuance Biotech's stock, subject to impairment. The valuation will be adjusted for any observable price changes in orderly transactions for an identical or similar investment in Nuance Biotech, or if there is an indicator of impairment. As of March 31, 2022, there had been no other transactions to indicate any price changes in the value of Nuance Biotech&#8217;s stock, nor had there been any indications of impairment. The Equity Interest is therefore recorded at a value of $15&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the terms of the Nuance Agreement, at any time until three months prior to the expected submission of the first New Drug Application in Greater China, if (i) a third party is interested in partnering with the Company, either globally or in territory covering at least the United States or Europe, for the development and/or commercialization of ensifentrine or (ii) the Company undergoes a change of control, the Company will have an exclusive option right to buy back the license granted to Nuance Pharma and all related assets. The price is agreed to be equal to the aggregate of (i) all prior amounts paid by Nuance Pharma to the Company in cash under the agreement and (ii) all development and regulatory costs incurred and paid by Nuance Pharma in connection with the development and commercialization of ensifentrine under the Nuance Agreement multiplied by a single-digit factor range dependent upon achievement of certain milestones, subject to a specified maximum amount.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Nuance Agreement will continue on a jurisdiction-by-jurisdiction and product-by-product basis until the expiration of royalty payment obligations with respect to such product in such jurisdiction unless earlier terminated by the parties. Either party may terminate the Nuance Agreement for an uncured material breach or bankruptcy of the other party. Nuance Pharma may also terminate the Nuance Agreement at will upon 90 days' prior written notice. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company reviewed the buy-back option and determined that because it is conditional on a third party the Company does not have the practical ability to exercise it and, accordingly, the contract is accounted for under ASC 606.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The transaction price at the Effective Date of the Nuance Agreement was $40.0&#160;million consisting of the $25.0&#160;million upfront cash payment and $15.0&#160;million equity interest. Developmental and regulatory milestones, and the manufacture and supply of ensifentrine drug product, were not included in the transaction price as management determined that it is not probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Commercial milestones and sales royalties were also excluded and will be recognized when the milestones are achieved or the sales occur in Greater China.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The performance obligations in the Nuance Agreement include the grant of the license (including the right to commercialize ensifentrine until the end of the term, the sharing of certain know how, and the sharing of certain clinical and regulatory data), and manufacture and supply of ensifentrine drug product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has determined that the license and the know how shared with Nuance Pharma constitutes functional intellectual property and that revenue relating to this should be recognized at a point in time. Consequently, the Company determined that it fulfilled its obligations to Nuance Pharma after it delivered the know how that will allow Nuance Pharma to file an investigational new drug application in Greater China. This know how was delivered in the year ended December 31, 2021, and the $40.0&#160;million revenue was therefore recognized as revenue in the year ended December 31, 2021. Revenue relating to the manufacture and supply obligations will be recognized when the drug product is delivered.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227790537704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share based compensation</a></td>
<td class="text">Share-based compensation<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows the allocation of share-based compensation between research and development and selling, general and administrative costs (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,748&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Share options</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows share option activity, in ordinary shares, in the period:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of share options outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average exercise price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,695,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at March 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,303,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.34&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Restricted stock units activity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows restricted stock unit (&#8220;RSU&#8221;) activity, in ordinary shares, in the period:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.241%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of RSUs outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term (years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,347,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,943,144)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at March 31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,872,432&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227789515768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net loss per share</a></td>
<td class="text">Net loss per share <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Net loss per share is calculated on an ordinary share basis. The Company&#8217;s ADSs that are listed on the Nasdaq Global Market each represent eight ordinary shares. The following table shows the computation of basic and diluted net loss per share for the periods ended March 31, 2022 and 2021 (net loss in thousands, loss per share in dollars):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,837)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481,941,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469,465,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During the three months ended March 31, 2022 and 2021, outstanding share options, RSUs and warrants over 60,576,894 and 77,584,846 ordinary shares, respectively, were not included in the computation of diluted earnings per ordinary share, because to do so would be antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227789479672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of presentation and consolidation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Basis of presentation and consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The unaudited condensed consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiary Verona Pharma, Inc. All inter-company balances and transactions have been eliminated. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with accounting principles generally accepted in the U.S. (&#8220;U.S. GAAP&#8221;).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 3, 2022 (the &#8220;2021 Form 10-K&#8221;). The Consolidated Balance Sheet as of December 31, 2021, was derived from audited consolidated financial statements included in the 2021 Form 10-K but does not include all disclosures required by U.S. GAAP for complete financial statements. The Company&#8217;s significant accounting policies are described in Note 2 to those consolidated financial statements.</span></div>Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. The unaudited condensed consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and shareholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Segment reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has one operating and reportable segment, pharmaceutical development.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, the fair value of share-based compensation, the fair value of warrants, research and development tax credit and the carrying value of the equity interest in Nuance Pharma (as defined below). Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company&#8217;s estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting standards and recent accounting standards not yet adopted</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Recently adopted accounting standards and recent accounting standards not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">There are no recently adopted accounting standards and recent accounting standards not yet adopted that the Company believes will have a material impact on the Company&#8217;s consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227789505864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Summary of Prepaid Expenses</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Prepaid expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and other development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,037&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227789467144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax and tax incentive receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_ScheduleOfNontradeReceivablesTableTextBlock', window );">Components of Taxes Receivable</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Tax and tax incentive receivables consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit receivable - U.K.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total tax receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,420&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,583&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ScheduleOfNontradeReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Nontrade Receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ScheduleOfNontradeReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227790228232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and other development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and general corporate costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,877&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,256&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227784485304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Allocation of Share Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows the allocation of share-based compensation between research and development and selling, general and administrative costs (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,748&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share Option Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows share option activity, in ordinary shares, in the period:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of share options outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average exercise price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,695,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at March 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,303,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.34&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Restricted Stock Unit Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows restricted stock unit (&#8220;RSU&#8221;) activity, in ordinary shares, in the period:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.241%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of RSUs outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term (years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,347,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,943,144)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at March 31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,872,432&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227789480744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Earning Per Share</a></td>
<td class="text">The following table shows the computation of basic and diluted net loss per share for the periods ended March 31, 2022 and 2021 (net loss in thousands, loss per share in dollars):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,837)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481,941,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469,465,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227791631864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Consolidation and Presentation of Financial Statements (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>subsidiary </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 19, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_NumberOfWhollyOwnedSubsidiaries', window );">Number of wholly owned subsidiaries | subsidiary</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 288,739<span></span>
</td>
<td class="nump">$ 263,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in sale | shares</a></td>
<td class="nump">80,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received from sale of stock</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=vrna_AmericanDepositorySharesMember', window );">American Depository Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_SaleOfStockMaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in sale | shares</a></td>
<td class="nump">10,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_CommonStockSharesAvailableForSaleValue', window );">Shares available for sale</a></td>
<td class="nump">$ 99,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_CommonStockSharesAvailableForSaleValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Shares Available For Sale, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_CommonStockSharesAvailableForSaleValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_NumberOfWhollyOwnedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Wholly Owned Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_NumberOfWhollyOwnedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_SaleOfStockMaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Aggregate Offering Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_SaleOfStockMaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=vrna_AmericanDepositorySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=vrna_AmericanDepositorySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227790684568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and summary of significant accounting policies (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227792891608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_PrepaidResearchAndDevelopmentFeesCurrent', window );">Clinical trial and other development costs</a></td>
<td class="nump">$ 452<span></span>
</td>
<td class="nump">$ 2,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurance</a></td>
<td class="nump">435<span></span>
</td>
<td class="nump">1,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">359<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Total prepaid expenses</a></td>
<td class="nump">$ 1,246<span></span>
</td>
<td class="nump">$ 4,037<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_PrepaidResearchAndDevelopmentFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Research And Development Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_PrepaidResearchAndDevelopmentFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227791624296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax and tax incentive receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent', window );">Research and development tax credit receivable - U.K.</a></td>
<td class="nump">$ 16,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,583<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_TaxCreditAndIncomeTaxesReceivableCurrent', window );">Total tax receivable</a></td>
<td class="nump">16,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_GainLossFromResearchAndDevelopmentTaxCreditExcludingAnnualCap', window );">Research and development tax credit excluding annual cap</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_GainLossFromResearchAndDevelopmentTaxCredit', window );">Research and development tax credit</a></td>
<td class="nump">$ 1,302<span></span>
</td>
<td class="nump">$ 2,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_GainLossFromResearchAndDevelopmentTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) From Research And Development Tax Credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_GainLossFromResearchAndDevelopmentTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_GainLossFromResearchAndDevelopmentTaxCreditExcludingAnnualCap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) From Research And Development Tax Credit, Excluding Annual Cap</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_GainLossFromResearchAndDevelopmentTaxCreditExcludingAnnualCap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Credit Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_TaxCreditAndIncomeTaxesReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit And Income Taxes Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_TaxCreditAndIncomeTaxesReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227792800552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_AccruedResearchAndDevelopmentFeesCurrent', window );">Clinical trial and other development costs</a></td>
<td class="nump">$ 27,520<span></span>
</td>
<td class="nump">$ 21,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent', window );">Professional fees and general corporate costs</a></td>
<td class="nump">846<span></span>
</td>
<td class="nump">919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">People related costs</a></td>
<td class="nump">511<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 28,877<span></span>
</td>
<td class="nump">$ 22,256<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Professional Fees, Listing, And General Corporate Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_AccruedResearchAndDevelopmentFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_AccruedResearchAndDevelopmentFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227790489912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term loan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Carrying value of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,928<span></span>
</td>
<td class="nump">$ 4,874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Funded advances</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Term B Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Term C Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_TermBLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_TermBLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_TermCLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_TermCLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227790671656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity Interest (Details) - Nuance (Shanghai) Pharma Co Ltd - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 09, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_EquityInterestReceivable', window );">Equity interest receivable</a></td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_EquityInterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Interest Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_EquityInterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vrna_NuanceShanghaiPharmaCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vrna_NuanceShanghaiPharmaCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227791988104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant agreements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>tradingDay</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 09, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vrna_LigandUKDevelopmentLimitedMember', window );">Ligand UK Development Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_SublicensePayment', window );">Sublicense payment</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays', window );">Sublicense payment, equity issuance, threshold trading days | tradingDay</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vrna_LigandUKDevelopmentLimitedMember', window );">Ligand UK Development Limited | First Commercial Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_SublicensePayment', window );">Sublicense payment</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vrna_LigandUKDevelopmentLimitedMember', window );">Ligand UK Development Limited | Selling, General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_SublicensePayment', window );">Sublicense payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vrna_NuanceShanghaiPharmaCoLtdMember', window );">Nuance (Shanghai) Pharma Co Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_EquityInterestReceivable', window );">Equity interest receivable</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrna_ContractWithCustomerFutureEligibleMilestonePayments', window );">Future eligible milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ContractWithCustomerFutureEligibleMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Future Eligible Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ContractWithCustomerFutureEligibleMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_EquityInterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Interest Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_EquityInterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_SublicensePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sublicense Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_SublicensePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sublicense Payment, Equity Issuance, Threshold Trading Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_SublicensePaymentEquityIssuanceThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vrna_LigandUKDevelopmentLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vrna_LigandUKDevelopmentLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_BenchmarkAchievementAxis=vrna_FirstCommercialSaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_BenchmarkAchievementAxis=vrna_FirstCommercialSaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vrna_NuanceShanghaiPharmaCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vrna_NuanceShanghaiPharmaCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227792988088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 3,748<span></span>
</td>
<td class="nump">$ 8,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">1,539<span></span>
</td>
<td class="nump">3,432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 2,209<span></span>
</td>
<td class="nump">$ 5,418<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227792894840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation - Share Option Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of share options outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance outstanding | shares</a></td>
<td class="nump">12,695,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted | shares</a></td>
<td class="nump">608,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance outstanding | shares</a></td>
<td class="nump">13,303,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning Balance, Weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weight average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">0.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending Balance, Weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227790528584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation - RSU Activity (Details) - Restricted Stock Units - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>RSU Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance</a></td>
<td class="nump">38,347,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">468,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(3,943,144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance</a></td>
<td class="nump">34,872,432<span></span>
</td>
<td class="nump">38,347,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Outstanding, Weighted average remaining contractual term</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140227791719992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share - Computation (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (24,837)<span></span>
</td>
<td class="num">$ (21,290)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic (in shares)</a></td>
<td class="nump">481,941,527<span></span>
</td>
<td class="nump">469,465,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted (in shares)</a></td>
<td class="nump">481,941,527<span></span>
</td>
<td class="nump">469,465,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share (in shares)</a></td>
<td class="nump">60,576,894<span></span>
</td>
<td class="nump">77,584,846<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>vrna-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:vrna="http://veronapharma.com/20220331"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vrna-20220331.xsd" xlink:type="simple"/>
    <context id="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i13a74a89113848ab9989e148e632f317_I20220429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="i568425c4e3c7431599d8b1aa195d0e85_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i43f3fd81e5634600b3df44427e14839e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3fd060aa5bbb47278b27ef1634cafe13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee10beb5614d4c36a49b38b0408c3c77_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie034936385eb4829a4a09ca135e0d332_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i487b969ea66c4193b79846ba2684834b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia76cefe1174549e7b4d4eb6f368d6bb9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a41f83bf2f147cca904ad371dd3c80f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i406e2d71f2494b7586c12bf94c99c19a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1c4f42981f7a4b07b3f072092f9d25ee_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8c8f3273cca84e1fb9b901be94b1d3de_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iccf8c5dacaee4f44963a79b7f359f4ea_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i27b5bd780a9d45798cffb2697ac8ade3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic919c5d0bdfd4afaa416dbe6e26c0669_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i14c4574a519449c29bf55707447cb27d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i00c370453f2b4f5db71678b478ddbbe0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ief871dca18cb4d72a122e673f25d7055_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5415b7e84bdf40e388391917c6fb0a3c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i17b773074fa84265a6b1dcd53b75176c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89039648129e48e19231c6fcf8cd7c46_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i84db4d73c9c5454584348de0514aa545_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i753d3703301043ad8197826c3029e966_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if8c845ed47cd447f83b0049bc8df056e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i62831f3f81ff424dbd8b50fd58c3cd6c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i764cecabbeee41a19da9bdf3d8c3566e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia488af7353324c8197666eef6a12f7bf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i87de327ddb3f41e7ba3457265e088033_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6a61756845fa41f2bdc2a4c25489a95a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie7370fb3dc73448d91fdc9fe7f5ffd30_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie94feae856cc4ea5ac4eff16299f3bbf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic509b8fcd7664f3594ed0ab72f0e609f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i22ba9f263b564af695f8fba5e244c5fa_I20210319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-19</instant>
        </period>
    </context>
    <context id="i14b59a9e0309440bbd87ed4bea74076d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9b1d9925838f4f4e8d46dce269a2578c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib5e3071b65394dcb9eeb62c562c7fadf_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i3e36e2a2c0ee4200aa8e95a2881303c4_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i9d316fcf04fa4e9886bc433d175709c7_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermBLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="ia5ebcd401a344004af7b7053e2853059_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i9e7ac21ebac441969276519788ca0689_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i47479f2645fe48afa643ac8df2b7b1c4_I20210609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:NuanceShanghaiPharmaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-09</instant>
        </period>
    </context>
    <context id="i85587e1e0a8f439d8aebd8e3ae70349a_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:LigandUKDevelopmentLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8ccfc42928504d8bb11c9856cb8aae45_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:LigandUKDevelopmentLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vrna:BenchmarkAchievementAxis">vrna:FirstCommercialSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if0331ecacba24ab991d409deb3d7c0d6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:LigandUKDevelopmentLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i26149cf54682400fabed175e2aa6fa8c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:NuanceShanghaiPharmaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idf656cb200bb45b582e522a818bd7960_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i08b14602cfda47eaa4b3fbe624c9a1cf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6f4ede3c3b79413cac4812d5477bb459_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3718066b40d6491eb81e069865deddc4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i82b2bb68605b4efca32316b1da619988_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia5bbf2f1a066455386dcb6d6e2137c08_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ica753976be2b4f4bae0fa0b52b8c63a0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1c92777eba5f49eca3791c762fd6c083_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="gbpPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:GBP</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="subsidiary">
        <measure>vrna:subsidiary</measure>
    </unit>
    <unit id="segment">
        <measure>vrna:segment</measure>
    </unit>
    <unit id="tradingday">
        <measure>vrna:tradingDay</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80L2ZyYWc6YzAxZTE2YWU3YzRjNGE3YWI5ZTliNmJhMzc5ZmVhN2IvdGFibGU6MGI4ZmI3OTRiYTM3NGIwY2JjMTA3YjIyNTRhY2YyMjIvdGFibGVyYW5nZTowYjhmYjc5NGJhMzc0YjBjYmMxMDdiMjI1NGFjZjIyMl8zLTEtMS0xLTUwOTQw_2b1d1f7c-8d8c-476d-bd37-86dd436126dc">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80L2ZyYWc6YzAxZTE2YWU3YzRjNGE3YWI5ZTliNmJhMzc5ZmVhN2IvdGFibGU6MGI4ZmI3OTRiYTM3NGIwY2JjMTA3YjIyNTRhY2YyMjIvdGFibGVyYW5nZTowYjhmYjc5NGJhMzc0YjBjYmMxMDdiMjI1NGFjZjIyMl80LTEtMS0xLTUwOTQw_7c952a29-2167-4f24-9155-15a4940e0927">2022</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80L2ZyYWc6YzAxZTE2YWU3YzRjNGE3YWI5ZTliNmJhMzc5ZmVhN2IvdGFibGU6MGI4ZmI3OTRiYTM3NGIwY2JjMTA3YjIyNTRhY2YyMjIvdGFibGVyYW5nZTowYjhmYjc5NGJhMzc0YjBjYmMxMDdiMjI1NGFjZjIyMl81LTEtMS0xLTUwOTQw_957df4fa-f6b1-42a0-a37d-5a623509ab93">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80L2ZyYWc6YzAxZTE2YWU3YzRjNGE3YWI5ZTliNmJhMzc5ZmVhN2IvdGFibGU6MGI4ZmI3OTRiYTM3NGIwY2JjMTA3YjIyNTRhY2YyMjIvdGFibGVyYW5nZTowYjhmYjc5NGJhMzc0YjBjYmMxMDdiMjI1NGFjZjIyMl82LTEtMS0xLTUwOTQw_b519558e-952b-4e0d-a4d9-25cb3354f98c">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80L2ZyYWc6YzAxZTE2YWU3YzRjNGE3YWI5ZTliNmJhMzc5ZmVhN2IvdGFibGU6MGI4ZmI3OTRiYTM3NGIwY2JjMTA3YjIyNTRhY2YyMjIvdGFibGVyYW5nZTowYjhmYjc5NGJhMzc0YjBjYmMxMDdiMjI1NGFjZjIyMl83LTEtMS0xLTUwOTQw_89e060c8-1951-42d2-8694-5a36bcd19763">0001657312</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yNTI1_5228f0ef-7804-4473-90c0-2bf0abfabd20">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yNTIy_bfa611e8-919e-4108-8fd2-5275d962c289">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yMTI_dbfe63bd-96c9-494c-9060-0cc6fae79e9a">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yNTI2_bff39252-e3f0-4e0c-8ba6-cb1b6988541f">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yNTI3_431387bd-77d5-4340-963f-884622930edc">001-38067</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yNTI4_2d6f40a4-8e4c-4b41-8b3b-ce031cecb90e">Verona Pharma plc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGFibGU6ZmNlOTEzNGVjNjFjNGY3YTk2NTJkNjQwZTc3M2I3YTUvdGFibGVyYW5nZTpmY2U5MTM0ZWM2MWM0ZjdhOTY1MmQ2NDBlNzczYjdhNV8wLTAtMS0xLTUwOTQw_7b984d7b-c037-47f3-b8a4-817530ab1119">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGFibGU6ZmNlOTEzNGVjNjFjNGY3YTk2NTJkNjQwZTc3M2I3YTUvdGFibGVyYW5nZTpmY2U5MTM0ZWM2MWM0ZjdhOTY1MmQ2NDBlNzczYjdhNV8wLTMtMS0xLTUwOTQw_7a2e0d29-6eea-40e6-a056-bb897ba019f2">98-1489389</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGFibGU6ZmNlOTEzNGVjNjFjNGY3YTk2NTJkNjQwZTc3M2I3YTUvdGFibGVyYW5nZTpmY2U5MTM0ZWM2MWM0ZjdhOTY1MmQ2NDBlNzczYjdhNV8zLTAtMS0xLTUwOTQwL3RleHRyZWdpb246ODZmNTU0MGY0ZDBiNDc5OThmNjkwODRiM2E3MWY3YmJfNQ_12c9579b-1171-4fda-acc8-469bf5ffbc05">3 More London Riverside</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGFibGU6ZmNlOTEzNGVjNjFjNGY3YTk2NTJkNjQwZTc3M2I3YTUvdGFibGVyYW5nZTpmY2U5MTM0ZWM2MWM0ZjdhOTY1MmQ2NDBlNzczYjdhNV8zLTAtMS0xLTUwOTQwL3RleHRyZWdpb246ODZmNTU0MGY0ZDBiNDc5OThmNjkwODRiM2E3MWY3YmJfOA_cdcfa3d5-4959-4812-843f-6935949afd79">London</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGFibGU6ZmNlOTEzNGVjNjFjNGY3YTk2NTJkNjQwZTc3M2I3YTUvdGFibGVyYW5nZTpmY2U5MTM0ZWM2MWM0ZjdhOTY1MmQ2NDBlNzczYjdhNV8zLTAtMS0xLTUwOTQwL3RleHRyZWdpb246ODZmNTU0MGY0ZDBiNDc5OThmNjkwODRiM2E3MWY3YmJfMTE_d633ddf4-6b99-455e-b02e-78fb7ebb4665">SE1 2RE</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGFibGU6ZmNlOTEzNGVjNjFjNGY3YTk2NTJkNjQwZTc3M2I3YTUvdGFibGVyYW5nZTpmY2U5MTM0ZWM2MWM0ZjdhOTY1MmQ2NDBlNzczYjdhNV8zLTAtMS0xLTUwOTQwL3RleHRyZWdpb246ODZmNTU0MGY0ZDBiNDc5OThmNjkwODRiM2E3MWY3YmJfMTQ_c11b99a3-89d8-4988-93d7-edf5662fb62a">GB</dei:EntityAddressCountry>
    <dei:CountryRegion
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yNTI5_1d38bca4-acc9-4e27-a107-f3aba0ddee50">44</dei:CountryRegion>
    <dei:CityAreaCode
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yNTMz_5b3ce4ce-b7ca-49e2-9977-133fdcb46347">203</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yNTM0_47952a8b-61b4-4666-8043-0130cc5ffa25">283 4200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGFibGU6MjIzNWRkMDgxNzQ0NDc2MzlkNmYzY2YxNzNmMDg2MTAvdGFibGVyYW5nZToyMjM1ZGQwODE3NDQ0NzYzOWQ2ZjNjZjE3M2YwODYxMF8xLTAtMS0xLTUwOTQw_d215cedc-fcd6-47fd-ae3d-04fb47914378">Ordinary shares, nominal value &#xa3;0.05 per share*</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGFibGU6MjIzNWRkMDgxNzQ0NDc2MzlkNmYzY2YxNzNmMDg2MTAvdGFibGVyYW5nZToyMjM1ZGQwODE3NDQ0NzYzOWQ2ZjNjZjE3M2YwODYxMF8xLTEtMS0xLTUwOTQw_4f3b9e96-3ad3-46e1-8910-f78f19407633">VRNA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGFibGU6MjIzNWRkMDgxNzQ0NDc2MzlkNmYzY2YxNzNmMDg2MTAvdGFibGVyYW5nZToyMjM1ZGQwODE3NDQ0NzYzOWQ2ZjNjZjE3M2YwODYxMF8xLTItMS0xLTUwOTQwL3RleHRyZWdpb246NGQ2NzJkZjFjZTExNDRhODk1ODg0NGQ2MzNkODEwNjFfMzM_0b69a915-470a-42fe-918d-b918fa5035d2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yNTMw_7b00e412-79d9-4cde-865f-9ee8c471d69b">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yNTMx_fec4ec8d-7358-4de6-a3f7-0c0c0e51d1f6">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGFibGU6NDZiMjBlNmI3ZTc1NDQ2ZWE4ZDQzYTAxMzlkM2EwZjMvdGFibGVyYW5nZTo0NmIyMGU2YjdlNzU0NDZlYThkNDNhMDEzOWQzYTBmM18xLTAtMS0xLTUwOTQw_bfabe132-1781-4719-b787-9303fd6b036e">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGFibGU6NDZiMjBlNmI3ZTc1NDQ2ZWE4ZDQzYTAxMzlkM2EwZjMvdGFibGVyYW5nZTo0NmIyMGU2YjdlNzU0NDZlYThkNDNhMDEzOWQzYTBmM18xLTQtMS0xLTUwOTQw_e3df6238-d512-4181-adce-e254b041b02d">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGFibGU6NDZiMjBlNmI3ZTc1NDQ2ZWE4ZDQzYTAxMzlkM2EwZjMvdGFibGVyYW5nZTo0NmIyMGU2YjdlNzU0NDZlYThkNDNhMDEzOWQzYTBmM18yLTQtMS0xLTUwOTQw_fd837bf9-eb86-4200-a596-dd430665fcef">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yNTI0_74e73cf3-82ca-4603-b904-c02645351f71">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yNTMy_c306c680-6d60-403a-b733-b8d2581cdace">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i13a74a89113848ab9989e148e632f317_I20220429"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8xL2ZyYWc6OWM4YzQzYTc4ZWQ2NGFkOWI1YWNjOGQ4MzMzMWQ5ZDMvdGV4dHJlZ2lvbjo5YzhjNDNhNzhlZDY0YWQ5YjVhY2M4ZDgzMzMxZDlkM18yMzI4_1c48bd1a-a592-41ef-9e2e-1fa36a476cad"
      unitRef="shares">482944390</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNC0yLTEtMS01MDk0MA_31513e44-54e9-4106-8fda-5e1c2b04f50d"
      unitRef="usd">132764000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNC00LTEtMS01MDk0MA_645b02a3-a49c-4467-ad42-a313f62741c5"
      unitRef="usd">148380000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNy0yLTEtMS01MDk0MA_da91cf90-2c19-4c94-b2a2-ccba65878a4e"
      unitRef="usd">1246000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNy00LTEtMS01MDk0MA_877aa5aa-a75e-4a03-8c8c-9360dc2e3e29"
      unitRef="usd">4037000</us-gaap:PrepaidExpenseCurrent>
    <vrna:TaxCreditAndIncomeTaxesReceivableCurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfOC0yLTEtMS01MDk0MA_401fbb38-07da-415b-8cf3-5629009b05ee"
      unitRef="usd">16420000</vrna:TaxCreditAndIncomeTaxesReceivableCurrent>
    <vrna:TaxCreditAndIncomeTaxesReceivableCurrent
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfOC00LTEtMS01MDk0MA_f14be353-f638-41dc-ab02-7ca5604edc87"
      unitRef="usd">15583000</vrna:TaxCreditAndIncomeTaxesReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTEtMi0xLTEtNTA5NDA_519136de-9860-40b7-8d53-3a3ab7d32612"
      unitRef="usd">2525000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTEtNC0xLTEtNTA5NDA_8edfedbb-651a-4c72-8695-b9123aaf43e5"
      unitRef="usd">2063000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTItMi0xLTEtNTA5NDA_859c2fbe-261e-463b-801c-8249a4a43e49"
      unitRef="usd">152955000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTItNC0xLTEtNTA5NDA_100ca487-57da-4346-a14f-802c71ad495d"
      unitRef="usd">170063000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTUtMi0xLTEtNTA5NDA_fc888ef8-4335-47cd-a2c4-0f62c121c40d"
      unitRef="usd">71000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTUtNC0xLTEtNTA5NDA_2ecb510a-1489-42b3-82ec-caf873990965"
      unitRef="usd">80000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTYtMi0xLTEtNTA5NDA_869f0f44-da9c-412a-b253-11f48a8443ee"
      unitRef="usd">545000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTYtNC0xLTEtNTA5NDA_f4b967b0-529d-482f-8ce6-6540a6e2c6ae"
      unitRef="usd">545000</us-gaap:Goodwill>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTctMi0xLTEtNTA5NDA_2afec541-cc54-4105-b190-33163e5fb154"
      unitRef="usd">15000000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTctNC0xLTEtNTA5NDA_ff2d908d-d53e-4971-8116-9948d50c56c2"
      unitRef="usd">15000000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTgtMi0xLTEtNTA5NDA_747756c9-8bd3-46d2-a75a-3177feb31627"
      unitRef="usd">744000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTgtNC0xLTEtNTA5NDA_8616c8bf-0299-45b4-8570-654c67c3a27f"
      unitRef="usd">899000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTktMi0xLTEtNTA5NDA_6cf6e88c-13c2-466a-b3e0-11ac8ad9bbcc"
      unitRef="usd">16360000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMTktNC0xLTEtNTA5NDA_d7f2552a-6b7b-4bf4-aefd-e4b51d1e2c5f"
      unitRef="usd">16524000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMjAtMi0xLTEtNTA5NDA_0bf7ec26-059f-4603-b4ea-cab897d7935b"
      unitRef="usd">169315000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMjAtNC0xLTEtNTA5NDA_e61de9b4-461d-4194-84a4-f70934ab8eda"
      unitRef="usd">186587000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMjQtMi0xLTEtNTA5NDA_22e0ac93-9365-49a7-b892-638985181b80"
      unitRef="usd">8064000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMjQtNC0xLTEtNTA5NDA_3207f28f-0f4d-41df-bbd4-f859ac3c78e9"
      unitRef="usd">10044000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMjUtMi0xLTEtNTA5NDA_a57d5ee5-30df-4af3-a143-b530e22543eb"
      unitRef="usd">28877000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMjUtNC0xLTEtNTA5NDA_266b49f4-2510-4112-96b5-c770dfece619"
      unitRef="usd">22256000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMjctMi0xLTEtNTA5NDA_f6855d1f-670c-4e42-86fd-6c7a68886d46"
      unitRef="usd">583000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMjctNC0xLTEtNTA5NDA_9f5d53ee-c555-48f5-aa6f-8ea57e0f25e1"
      unitRef="usd">648000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMjktMi0xLTEtNTA5NDA_b42afc02-331c-406a-9142-3f0546d6c608"
      unitRef="usd">235000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMjktNC0xLTEtNTA5NDA_f3f20243-d7d0-4dd7-bcd2-59bbaca9b21f"
      unitRef="usd">147000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMzAtMi0xLTEtNTA5NDA_fbe32614-57f3-4c0f-aa27-66e9a780eea6"
      unitRef="usd">144000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMzAtNC0xLTEtNTA5NDA_eafb6d09-d519-4bb9-a057-74ef8d1842fc"
      unitRef="usd">327000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMzEtMi0xLTEtNTA5NDA_40949909-2e3f-4a8c-9866-8c6606110eb5"
      unitRef="usd">37903000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMzEtNC0xLTEtNTA5NDA_86f5a000-03c3-4228-8cc8-2e787f8e262e"
      unitRef="usd">33422000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMzUtMi0xLTEtNTA5NDA_c88987be-4bfe-4a32-9149-f2f26ad41ddc"
      unitRef="usd">4928000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMzUtNC0xLTEtNTA5NDA_55a5164f-2971-4903-a4fc-83ef8ecc91f2"
      unitRef="usd">4874000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMzYtMi0xLTEtNTA5NDA_3cf319a6-60db-419d-afd9-bad7cd079d66"
      unitRef="usd">177000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMzYtNC0xLTEtNTA5NDA_47509077-6f2d-4b46-bbec-9fdd7ab57edc"
      unitRef="usd">286000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMzctMi0xLTEtNTA5NDA_b3862b9a-8428-4578-acee-c7fa73e04e52"
      unitRef="usd">5105000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMzctNC0xLTEtNTA5NDA_0b7d6359-851e-4004-8764-b0d8b22741cb"
      unitRef="usd">5160000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMzgtMi0xLTEtNTA5NDA_1660b7b2-952a-4ee3-99a0-c92586ccffb0"
      unitRef="usd">43008000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfMzgtNC0xLTEtNTA5NDA_4a1bad0b-52e2-4a2e-b99d-50a56a512103"
      unitRef="usd">38582000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDAtMi0xLTEtNTA5NDA_3dab0410-be52-4a03-98ab-5d902e729886"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDAtNC0xLTEtNTA5NDA_d9b5a678-0435-4181-ba1d-2aac1652df87"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDMtMC0xLTEtNTA5NDAvdGV4dHJlZ2lvbjoyNDhkZDgzNzhlMjQ0YzNiOGE0NTVkOTM0MzE4ZmE5YV8xMw_7635d412-c513-4e0d-bd4b-73b268d498cb"
      unitRef="gbpPerShare">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDMtMC0xLTEtNTA5NDAvdGV4dHJlZ2lvbjoyNDhkZDgzNzhlMjQ0YzNiOGE0NTVkOTM0MzE4ZmE5YV8xMw_bf678216-cf85-4afe-8b83-1dffe5852bb1"
      unitRef="gbpPerShare">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDMtMC0xLTEtNTA5NDAvdGV4dHJlZ2lvbjoyNDhkZDgzNzhlMjQ0YzNiOGE0NTVkOTM0MzE4ZmE5YV8zNA_58da56db-b641-45c4-9f03-eb1ea7e3f7f9"
      unitRef="shares">494058246</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDMtMC0xLTEtNTA5NDAvdGV4dHJlZ2lvbjoyNDhkZDgzNzhlMjQ0YzNiOGE0NTVkOTM0MzE4ZmE5YV80MQ_85b756d8-6f28-4528-9acc-e0ba57e61004"
      unitRef="shares">489177550</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDMtMC0xLTEtNTA5NDAvdGV4dHJlZ2lvbjoyNDhkZDgzNzhlMjQ0YzNiOGE0NTVkOTM0MzE4ZmE5YV81Ng_74dd5531-4552-4d4c-ab7d-ff0443a10db8"
      unitRef="shares">482944390</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDMtMC0xLTEtNTA5NDAvdGV4dHJlZ2lvbjoyNDhkZDgzNzhlMjQ0YzNiOGE0NTVkOTM0MzE4ZmE5YV82Mw_0aa263d3-0516-412a-8221-13895828f36e"
      unitRef="shares">480082966</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDMtMi0xLTEtNTA5NDA_e731554a-dd42-4950-987d-3c0b57644385"
      unitRef="usd">32182000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDMtNC0xLTEtNTA5NDA_6942a264-f495-4068-856d-5140f4b8bb8b"
      unitRef="usd">31855000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDQtMi0xLTEtNTA5NDA_e6a23ebf-214b-4a2b-8454-206160fe09c0"
      unitRef="usd">388204000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDQtNC0xLTEtNTA5NDA_12e30d83-07a4-4c46-b7e0-953ef9fa5798"
      unitRef="usd">385070000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockValue
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDUtMi0xLTEtNTA5NDA_519e6947-4a07-424a-90da-79b1dc9539da"
      unitRef="usd">739000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDUtNC0xLTEtNTA5NDA_2d35c83e-8c50-47f5-8ed1-35e99a1c2c96"
      unitRef="usd">603000</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDYtMi0xLTEtNTA5NDA_f4cc2969-d71d-4f98-9732-6b5c1df669f5"
      unitRef="usd">-4601000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDYtNC0xLTEtNTA5NDA_fc2eedf3-9905-4bc8-bfd8-4b2fa21b6d9e"
      unitRef="usd">-4601000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDctMi0xLTEtNTA5NDA_a735e4c3-1afb-4310-bcd6-4226e33ff220"
      unitRef="usd">-288739000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDctNC0xLTEtNTA5NDA_756faeb4-f649-4e81-ae17-696fad65ac91"
      unitRef="usd">-263716000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDgtMi0xLTEtNTA5NDA_2ee74dd6-8f9c-4d7f-a882-c1c53dea5eec"
      unitRef="usd">126307000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDgtNC0xLTEtNTA5NDA_8b721dff-f190-4bf6-81f7-ef6d7a704842"
      unitRef="usd">148005000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDktMi0xLTEtNTA5NDA_9b417e76-c5ab-4480-839b-b5cd83969e90"
      unitRef="usd">169315000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8yOC9mcmFnOmMyNjdiODhiNWJlMzQyMjFiYTljMjMzNDlmNmQ0NjdkL3RhYmxlOmVkMjU3MTU4YTYxMjRkYTk5NzM4ZjNmNjA4YmNiMTlhL3RhYmxlcmFuZ2U6ZWQyNTcxNThhNjEyNGRhOTk3MzhmM2Y2MDhiY2IxOWFfNDktNC0xLTEtNTA5NDA_b02f2810-67a8-42d8-9b10-5a168f76953f"
      unitRef="usd">186587000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfNi0yLTEtMS01MDk0MA_7c2c2c9d-1462-4d6a-8baa-5e7799379023"
      unitRef="usd">17625000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfNi00LTEtMS01MDk0MA_564cd20c-6622-4868-966e-49e2a978fd4d"
      unitRef="usd">13574000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfNy0yLTEtMS01MDk0MA_8a91c255-a264-4d44-8fd1-5f17fcd3b83b"
      unitRef="usd">7440000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfNy00LTEtMS01MDk0MA_cdebf955-1604-467f-ae26-3547124e24d0"
      unitRef="usd">9282000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfOC0yLTEtMS01MDk0MA_75cdb941-3080-4f11-9d36-900bcdab8f44"
      unitRef="usd">25065000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfOC00LTEtMS01MDk0MA_ca713ecd-b33a-42ac-b224-c7f9ed7a37ec"
      unitRef="usd">22856000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfOS0yLTEtMS01MDk0MA_5f6963f4-b48d-4957-ae1f-bea425741b5b"
      unitRef="usd">-25065000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfOS00LTEtMS01MDk0MA_683420f3-5aea-4989-a5e8-f46a7c7eb9cf"
      unitRef="usd">-22856000</us-gaap:OperatingIncomeLoss>
    <vrna:GainLossFromResearchAndDevelopmentTaxCredit
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTEtMi0xLTEtNTA5NDA_0723bf88-9ded-4d1b-bd32-420943649c1b"
      unitRef="usd">1302000</vrna:GainLossFromResearchAndDevelopmentTaxCredit>
    <vrna:GainLossFromResearchAndDevelopmentTaxCredit
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTEtNC0xLTEtNTA5NDA_877b6828-d8f6-4aac-a708-c1c3d3a51510"
      unitRef="usd">2070000</vrna:GainLossFromResearchAndDevelopmentTaxCredit>
    <us-gaap:InvestmentIncomeNet
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTItMi0xLTEtNTA5NDA_68e4f9d7-e1a8-49fc-aac8-bb90b216071a"
      unitRef="usd">15000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTItNC0xLTEtNTA5NDA_89cd4cdb-368e-4378-8a55-40f11c6352f0"
      unitRef="usd">4000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpense
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTMtMi0xLTEtNTA5NDA_473cb567-3ad5-4a65-a643-5b4a22f0ff48"
      unitRef="usd">84000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTMtNC0xLTEtNTA5NDA_e3ea9cd4-9c80-4015-b254-07f86c110316"
      unitRef="usd">84000</us-gaap:InterestExpense>
    <vrna:UnrealizedGainLossOnWarrants
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTQtMi0xLTEtNTA5NDA_3933ad74-6734-4fca-8e3e-f5e9dc98ebb9"
      unitRef="usd">0</vrna:UnrealizedGainLossOnWarrants>
    <vrna:UnrealizedGainLossOnWarrants
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTQtNC0xLTEtNTA5NDA_d7f63ba7-d673-4451-998f-6129014eec27"
      unitRef="usd">-507000</vrna:UnrealizedGainLossOnWarrants>
    <vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTUtMi0xLTEtNTA5NDA_a95de505-6558-49f2-aea4-47f9887f2e81"
      unitRef="usd">-923000</vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases>
    <vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTUtNC0xLTEtNTA5NDA_2142ee9d-cada-4d5e-909e-1ddf60d21826"
      unitRef="usd">163000</vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTYtMi0xLTEtNTA5NDA_572ab943-76f6-4e95-ac93-5e8a6936f9ed"
      unitRef="usd">310000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTYtNC0xLTEtNTA5NDA_32a7b012-20ee-4b22-a461-f2dd258a2216"
      unitRef="usd">1646000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTctMi0xLTEtNTA5NDA_948e264f-47da-4f12-b6e8-3ff6300bd70a"
      unitRef="usd">-24755000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTctNC0xLTEtNTA5NDA_b5f4fd20-f265-4f75-9512-92f427643b06"
      unitRef="usd">-21210000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTgtMi0xLTEtNTA5NDA_bbb31232-155b-404a-862f-3247c393c10f"
      unitRef="usd">82000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTgtNC0xLTEtNTA5NDA_24c213e1-70f7-4fbc-a7e1-3746df28f7cb"
      unitRef="usd">80000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTktMi0xLTEtNTA5NDA_44b02f1a-bd30-458a-83bf-b3fc35e602f2"
      unitRef="usd">-24837000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMTktNC0xLTEtNTA5NDA_6bacdebd-719d-4993-bb4f-9b7ff321a62a"
      unitRef="usd">-21290000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMjQtMi0xLTEtNTA5NDA_277ba617-86b8-4a05-96cf-910318484dab"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMjQtMi0xLTEtNTA5NDA_35ed8f25-4204-4c5a-a285-a26a9eef9ce2"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMjQtNC0xLTEtNTA5NDA_0a2e9213-74db-407e-ae22-2118f36f8705"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zMS9mcmFnOjI1ZDgyMjBiNTVhOTQ2YjFhODZjNTIwM2QxMmEwMDM1L3RhYmxlOjQzYTc2NTMyOGVkMzRlNjZiODAzMzkyZjVkYTBlZWUwL3RhYmxlcmFuZ2U6NDNhNzY1MzI4ZWQzNGU2NmI4MDMzOTJmNWRhMGVlZTBfMjQtNC0xLTEtNTA5NDA_5d8952db-d22f-4eed-8a60-b1835ff8016c"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3fd060aa5bbb47278b27ef1634cafe13_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMi0yLTEtMS01MDk0MA_24ff9b9d-a801-4e63-91c0-f50e135d2b67"
      unitRef="shares">489177550</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3fd060aa5bbb47278b27ef1634cafe13_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMi00LTEtMS01MDk0MA_70008bec-eaf7-4f32-b9ee-97ebeb183954"
      unitRef="usd">31855000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iee10beb5614d4c36a49b38b0408c3c77_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMi02LTEtMS01MDk0MA_7714ebde-70ad-4780-b5c2-5f5158f5c88e"
      unitRef="usd">385070000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie034936385eb4829a4a09ca135e0d332_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMi04LTEtMS01MDk0MA_ee182ece-81d7-482b-8601-971ab1af7205"
      unitRef="usd">-603000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i487b969ea66c4193b79846ba2684834b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMi0xMC0xLTEtNTA5NDA_411af8c5-7a99-4d80-8f56-2ffd1aa94302"
      unitRef="usd">-4601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia76cefe1174549e7b4d4eb6f368d6bb9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMi0xMi0xLTEtNTA5NDA_861d897e-6c92-4ac2-b8af-49d5e21db206"
      unitRef="usd">-263716000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMi0xNC0xLTEtNTA5NDA_48d62fb3-1814-4ea3-96f6-b5d3a627a0ab"
      unitRef="usd">148005000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i9a41f83bf2f147cca904ad371dd3c80f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMy0xMi0xLTEtNTA5NDA_41eef1b3-b2b7-4834-9d92-84ee7e917dc7"
      unitRef="usd">-24837000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMy0xNC0xLTEtNTA5NDA_752c7232-05d3-435e-a740-2f7120ce379d"
      unitRef="usd">-24837000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i406e2d71f2494b7586c12bf94c99c19a_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfNi0yLTEtMS01MDk0MA_80a59027-bd7e-4654-a62e-969e7d1b3b84"
      unitRef="shares">80696</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i406e2d71f2494b7586c12bf94c99c19a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfNi00LTEtMS01MDk0MA_c6f3c54f-6442-4d63-b852-fdbfc651b8f2"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1c4f42981f7a4b07b3f072092f9d25ee_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfNi02LTEtMS01MDk0MA_c1bc1fbe-aa5b-410e-b023-724750a51768"
      unitRef="usd">62000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfNi0xNC0xLTEtNTA5NDA_6729f378-931f-4c8a-b765-fb3d9b60c2ef"
      unitRef="usd">67000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i8c8f3273cca84e1fb9b901be94b1d3de_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfNy04LTEtMS01MDk0MA_93ebc91b-263d-4caf-891b-f23cc927f4e4"
      unitRef="usd">186000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i9a41f83bf2f147cca904ad371dd3c80f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfNy0xMi0xLTEtNTA5NDA_305dad92-b55a-4558-8f75-49a572defe91"
      unitRef="usd">-186000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i406e2d71f2494b7586c12bf94c99c19a_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfOC0yLTEtMS01MjM4MA_5de3db56-ba4c-4abe-98bf-35a37f2526c5"
      unitRef="shares">4800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i406e2d71f2494b7586c12bf94c99c19a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfOC00LTEtMS01MjM4MA_f24f4c02-6e70-4e52-9ef5-613ecea16d2c"
      unitRef="usd">322000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i8c8f3273cca84e1fb9b901be94b1d3de_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfOC04LTEtMS01MjM4MA_d472c535-9ae4-4fd0-9756-2ba4d05c91f1"
      unitRef="usd">-322000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1c4f42981f7a4b07b3f072092f9d25ee_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfOS02LTEtMS01MDk0MA_af545cab-a49d-4176-aff6-2323a675a69d"
      unitRef="usd">793000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfOS0xNC0xLTEtNTA5NDA_627a20ec-e403-4db6-b4df-0c2d667f3831"
      unitRef="usd">793000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation
      contextRef="i1c4f42981f7a4b07b3f072092f9d25ee_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMTAtNi0xLTEtNTA5NDA_782d19b1-5598-403b-8477-b8da7b5026df"
      unitRef="usd">-118000</vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation>
    <vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMTAtMTQtMS0xLTUwOTQw_0f3c8cc6-1da8-4c25-a065-64731b7a7eef"
      unitRef="usd">-118000</vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1c4f42981f7a4b07b3f072092f9d25ee_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMTEtNi0xLTEtNTA5NDA_45a5f57c-0501-4057-b992-222dd1ec5969"
      unitRef="usd">3747000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMTEtMTQtMS0xLTUwOTQw_d8cb6f8e-fe4b-455b-8486-aa5c64aa90b2"
      unitRef="usd">3747000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iccf8c5dacaee4f44963a79b7f359f4ea_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMTMtMi0xLTEtNTA5NDA_fb0f8dcd-b249-4c0d-a620-04d1d4c10264"
      unitRef="shares">494058246</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iccf8c5dacaee4f44963a79b7f359f4ea_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMTMtNC0xLTEtNTA5NDA_79b2a509-dd39-4ae0-8462-d11d66789c20"
      unitRef="usd">32182000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i27b5bd780a9d45798cffb2697ac8ade3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMTMtNi0xLTEtNTA5NDA_de1943c2-592f-405d-b339-212634823800"
      unitRef="usd">388204000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic919c5d0bdfd4afaa416dbe6e26c0669_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMTMtOC0xLTEtNTA5NDA_5a973849-ef7a-41ca-aa06-3ae0fa470566"
      unitRef="usd">-739000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i14c4574a519449c29bf55707447cb27d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMTMtMTAtMS0xLTUwOTQw_0b1c3d7d-780e-4fae-9e8e-2bfb06cd6288"
      unitRef="usd">-4601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i00c370453f2b4f5db71678b478ddbbe0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMTMtMTItMS0xLTUwOTQw_6a51a539-25fb-41fa-9715-c7a88a64893f"
      unitRef="usd">-288739000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjcxMDI2YzA4ZDRlZjRiZWFhZDc5ODA2ODlkZGUxZTIxL3RhYmxlcmFuZ2U6NzEwMjZjMDhkNGVmNGJlYWFkNzk4MDY4OWRkZTFlMjFfMTMtMTQtMS0xLTUwOTQw_dd7ac381-98b6-4abb-8d6e-9ae85c5eb7c3"
      unitRef="usd">126307000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ief871dca18cb4d72a122e673f25d7055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMi0yLTEtMS01MDk0MA_6dd3df2f-1e4a-4f1e-842a-908d4fe6c64d"
      unitRef="shares">488304446</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ief871dca18cb4d72a122e673f25d7055_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMi00LTEtMS01MDk0MA_139cff80-e832-49da-af28-351fdaac2fb9"
      unitRef="usd">31794000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5415b7e84bdf40e388391917c6fb0a3c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMi02LTEtMS01MDk0MA_0b78e914-6646-4a03-acf5-aa70bbc486f0"
      unitRef="usd">366411000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i17b773074fa84265a6b1dcd53b75176c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMi04LTEtMS01MDk0MA_dd1317a8-2336-4ddd-bb5b-b44097aafebe"
      unitRef="usd">-1700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i89039648129e48e19231c6fcf8cd7c46_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMi0xMC0xLTEtNTA5NDA_d1fc9089-a61b-42da-a6e3-2721be959739"
      unitRef="usd">-4601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i84db4d73c9c5454584348de0514aa545_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMi0xMi0xLTEtNTA5NDA_47785e3b-af74-4139-b6ff-f88a73ba36ce"
      unitRef="usd">-207050000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i753d3703301043ad8197826c3029e966_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMi0xNC0xLTEtNTA5NDA_cdab0647-8bb7-417d-9b5a-481c72edda9c"
      unitRef="usd">184854000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="if8c845ed47cd447f83b0049bc8df056e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMy0xMi0xLTEtNTA5NDA_3d9b7db5-8ba3-403b-8736-642985028c4d"
      unitRef="usd">-21290000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMy0xNC0xLTEtNTA5NDA_0130b8a6-1c63-49af-89ab-f247d67b56a3"
      unitRef="usd">-21290000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i62831f3f81ff424dbd8b50fd58c3cd6c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfNy04LTEtMS01MDk0MA_394e1f37-54b6-4f3f-a2ec-c1aa3dce012e"
      unitRef="usd">30000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="if8c845ed47cd447f83b0049bc8df056e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfNy0xMi0xLTEtNTA5NDA_d1b2975b-4408-442c-8e5a-8700c8cd68dd"
      unitRef="usd">-30000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i764cecabbeee41a19da9bdf3d8c3566e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMTEtNi0xLTEtNTA5NDA_ab801b96-7abb-47c8-a298-99cef6ad7ce2"
      unitRef="usd">8850000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMTEtMTQtMS0xLTUwOTQw_b5c392d9-0f73-4862-9eac-aca91635b421"
      unitRef="usd">8850000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia488af7353324c8197666eef6a12f7bf_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMTItMi0xLTEtNTA5NDA_da732570-de3e-451a-8c00-5f9e6adbb134"
      unitRef="shares">488304446</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia488af7353324c8197666eef6a12f7bf_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMTItNC0xLTEtNTA5NDA_fe15bccd-3bc8-485b-b993-4b11c2f91952"
      unitRef="usd">31794000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i87de327ddb3f41e7ba3457265e088033_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMTItNi0xLTEtNTA5NDA_73bcdc47-dc02-404c-a6de-9615a3ac2333"
      unitRef="usd">375261000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6a61756845fa41f2bdc2a4c25489a95a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMTItOC0xLTEtNTA5NDA_5f35098a-3dd0-4653-a8d1-384f10a4aeaa"
      unitRef="usd">-1670000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie7370fb3dc73448d91fdc9fe7f5ffd30_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMTItMTAtMS0xLTUwOTQw_f427e2f4-461f-4e29-bc63-a69ee1ca4f03"
      unitRef="usd">-4601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie94feae856cc4ea5ac4eff16299f3bbf_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMTItMTItMS0xLTUwOTQw_5d0846c2-e8cf-455c-81a2-f144e7e0556b"
      unitRef="usd">-228370000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic509b8fcd7664f3594ed0ab72f0e609f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV8zNC9mcmFnOjk0ZDRjNWQ2MjVlZDRjMDA4ZThkZjJiOWE0NTEyODlkL3RhYmxlOjg2ODJhYWMxMjVjMDQwNWM5MjQ4ZTA5YWMxMzU2MjZlL3RhYmxlcmFuZ2U6ODY4MmFhYzEyNWMwNDA1YzkyNDhlMDlhYzEzNTYyNmVfMTItMTQtMS0xLTUwOTQw_face36b4-1bf8-4c45-a1b4-7fe4cd8ef937"
      unitRef="usd">172414000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMy0yLTEtMS01MDk0MA_a173ddff-a3aa-45e3-8d89-ce56dc5631e3"
      unitRef="usd">-24837000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMy00LTEtMS01MDk0MA_5ffa51eb-2d05-43fe-9806-6d9bd17b7621"
      unitRef="usd">-21290000</us-gaap:NetIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNS0yLTEtMS01MDk0MA_b29d5384-0365-41e7-975e-73b53694e3e2"
      unitRef="usd">-1119000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNS00LTEtMS01MDk0MA_451ee0d3-6132-45ee-8bcd-e2e37f16d943"
      unitRef="usd">155000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNi0yLTEtMS01MDk0MA_400e09b9-a15a-4643-9c69-c52ca78fc2ed"
      unitRef="usd">23000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNi00LTEtMS01MDk0MA_f6ea796e-0917-41b0-afa0-5cc0f53dbf99"
      unitRef="usd">19000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNy0yLTEtMS01MDk0MA_aba668f1-2471-4f8f-8b85-6ecbf218b40b"
      unitRef="usd">31000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNy00LTEtMS01MDk0MA_01bb8b19-bf06-491d-bb57-b68763c19a11"
      unitRef="usd">31000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfOC0yLTEtMS01MDk0MA_f6e94328-d269-4b62-8205-f4f2792550ef"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfOC00LTEtMS01MDk0MA_80dd59dc-c245-4df9-be19-f7d158e88def"
      unitRef="usd">507000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ShareBasedCompensation
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMTAtMi0xLTEtNTA5NDA_35eee905-7a11-4d61-b30a-8a1a92828cd2"
      unitRef="usd">3748000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMTAtNC0xLTEtNTA5NDA_86986ee2-51f4-4843-8a08-ae6cecb8f564"
      unitRef="usd">8850000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMTEtMi0xLTEtNTA5NDA_7de35c95-ae2c-4fc2-94ff-7d573f2b6f8c"
      unitRef="usd">163000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMTEtNC0xLTEtNTA5NDA_8a70ffce-2327-44e3-a5dd-7711c7f45d2a"
      unitRef="usd">153000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMTYtMi0xLTEtNTA5NDA_20ce0a87-d64f-4527-9620-c250f9a18b96"
      unitRef="usd">-2791000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMTYtNC0xLTEtNTA5NDA_a3e4fb6a-0dc8-4573-81d2-e44000465e83"
      unitRef="usd">2709000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMTctMi0xLTEtNTA5NDA_842e2e77-edb1-49e8-985a-b86d71ceb1b0"
      unitRef="usd">1578000</vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent>
    <vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMTctNC0xLTEtNTA5NDA_aef4e07a-f4ec-4f7a-8310-a34e8b57446b"
      unitRef="usd">2012000</vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMTgtMi0xLTEtNTA5NDA_18078a11-2de0-4a69-8a33-4cf422e3c086"
      unitRef="usd">462000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMTgtNC0xLTEtNTA5NDA_b387a2c6-57a8-4a71-8b7a-f0977ba2b96d"
      unitRef="usd">-236000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjAtMi0xLTEtNTA5NDA_57aa804c-34e3-4054-bf9f-b3bb342d5048"
      unitRef="usd">-1980000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjAtNC0xLTEtNTA5NDA_3003ef0e-004c-4aec-b8e7-7c4dbd7b36aa"
      unitRef="usd">363000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjEtMi0xLTEtNTA5NDA_d45b1c1f-427c-44ad-81d1-7897ef52c5c6"
      unitRef="usd">6621000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjEtNC0xLTEtNTA5NDA_775e34f6-2c92-4d47-b0c6-fc0e866fb1c0"
      unitRef="usd">-2349000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <vrna:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjItMi0xLTEtNTA5NDA_d41a5231-9983-464b-8a1a-1f6fa0ad54f4"
      unitRef="usd">-174000</vrna:IncreaseDecreaseInOperatingLeaseLiabilities>
    <vrna:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjItNC0xLTEtNTA5NDA_3c0bd5a9-1390-4e1e-a3ec-203b1b80ce88"
      unitRef="usd">-210000</vrna:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjMtMi0xLTEtNTA5NDA_927c7cb5-4d20-4145-a533-08c69809fdde"
      unitRef="usd">88000</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjMtNC0xLTEtNTA5NDA_988197fd-a4d7-415b-8217-7ff9ca0d98c5"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjQtMi0xLTEtNTA5NDA_bca32496-2221-477d-94d6-11530424b750"
      unitRef="usd">-65000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjQtNC0xLTEtNTA5NDA_f7c3543b-a6c3-4c43-b68e-2bc4a9dd2be3"
      unitRef="usd">15000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjUtMi0xLTEtNTA5NDA_75f435e3-06fc-4c13-810e-1d469742ec46"
      unitRef="usd">-14512000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjUtNC0xLTEtNTA5NDA_db464314-1f6c-4b82-aeb0-011251058e51"
      unitRef="usd">-18551000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjktMi0xLTEtNTA5NDA_6ef9d32e-967c-4c7c-ad0f-708d44c1512c"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMjktNC0xLTEtNTA5NDA_bbfef4ab-ef1c-46d4-8996-ff5070f59016"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMzUtMi0xLTEtNTA5NDA_28e227b3-a2bd-471d-b6ff-9ca935da8d5f"
      unitRef="usd">793000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMzUtNC0xLTEtNTA5NDA_2630514f-79c5-475b-ba18-84de4f25383d"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMzctMi0xLTEtNTA5NDA_fbe8ce30-846d-4caf-ae92-f5507f2a9e68"
      unitRef="usd">67000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMzctNC0xLTEtNTA5NDA_41ed8aa2-2ac5-422b-a271-4dad76172fbb"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMzgtMi0xLTEtNTA5NDA_2c6caf4c-60ab-4c37-ac6c-45d62e7dfdb7"
      unitRef="usd">-726000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMzgtNC0xLTEtNTA5NDA_0bf23f69-112c-4d06-83cb-20cb9c82006e"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMzktMi0xLTEtNTA5NDA_b1ebf5a2-1625-42d6-b9ce-cb935108497d"
      unitRef="usd">-378000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfMzktNC0xLTEtNTA5NDA_7c728f44-1db7-4a7f-ab2c-3387a34acdcc"
      unitRef="usd">163000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNDAtMi0xLTEtNTA5NDA_51ea1dfe-bedb-4256-a839-55abdaec35d5"
      unitRef="usd">-15616000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNDAtNC0xLTEtNTA5NDA_a43a53e6-dc33-4883-8cb0-e661cd8cda00"
      unitRef="usd">-18388000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNDEtMi0xLTEtNTA5NDA_f561797b-d23e-42d5-8ae2-29ce69fef211"
      unitRef="usd">148380000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i753d3703301043ad8197826c3029e966_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNDEtNC0xLTEtNTA5NDA_d7818cbf-f6fe-4494-a31f-64a493065ca0"
      unitRef="usd">187986000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNDItMi0xLTEtNTA5NDA_a0e07492-3b81-4054-97fe-a62aa07438eb"
      unitRef="usd">132764000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic509b8fcd7664f3594ed0ab72f0e609f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNDItNC0xLTEtNTA5NDA_21bd89c6-844f-4fe0-bc21-0730fa75f654"
      unitRef="usd">169598000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNDQtMi0xLTEtNTA5NDA_b007797e-903a-47d9-92c0-4e94cf379855"
      unitRef="usd">1000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNDQtNC0xLTEtNTA5NDA_f317c673-7092-451d-afa8-2de354d1fc6d"
      unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNDUtMi0xLTEtNTA5NDA_5bca871e-fdd4-4412-b405-4f0fe62cc71e"
      unitRef="usd">53000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MC9mcmFnOmEzODQ0MzlmNDE4NzQyMjA5N2YwNGQxOTBkZThjZjEyL3RhYmxlOjEyMTQzMjJkYmM5NjQzOThiZjY5YzNkYzJjNTFkYjIzL3RhYmxlcmFuZ2U6MTIxNDMyMmRiYzk2NDM5OGJmNjljM2RjMmM1MWRiMjNfNDUtNC0xLTEtNTA5NDA_fa017807-cdbb-4070-9c1b-8a21694883ec"
      unitRef="usd">55000</us-gaap:InterestPaidNet>
    <vrna:OrganizationAndBusinessDescriptionTextBlock
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80Ni9mcmFnOmZhNGYxYTU1YzcwNjQ3NjY5MWZhZjAwOGM0NTZkYjhhL3RleHRyZWdpb246ZmE0ZjFhNTVjNzA2NDc2NjkxZmFmMDA4YzQ1NmRiOGFfMjA1OQ_197af163-f27e-45b6-a8cf-f8488076a61a">Organization and description of business operations &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Verona Pharma plc (the &#x201c;Company&#x201d;) is incorporated and domiciled in the United Kingdom. Verona Pharma plc has one wholly-owned subsidiary, Verona Pharma, Inc., a Delaware corporatio&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;n. Rhinopharma Limited, a Canadian company that was previously a non-operating, wholly-owned subsidiary, was dissolved in June 2021. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The address of the registered office is 1 Central Square, Cardiff, CF10 1FS, United Kingdom.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company is a clinical-stage biopharmaceutical group focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The Company&#x2019;s American Depositary Shares (&#x201c;ADSs&#x201d;) are listed on the Nasdaq Global Market (&#x201c;Nasdaq&#x201d;) and trade under the symbol &#x201c;VRNA&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company has incurred recurring losses and negative cash flows from operations since inception, and has an accumulated deficit of $288.7&#160;million as of March 31, 2022. The Company expects to incur additional losses and negative cash flows from operations until its products potentially gain regulatory approval and reach commercial profitability, if at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company expects that its cash and cash equivalents as of March 31, 2022, will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In March, 2021, the Company entered into an open market sale agreement with respect to an at-the-market offering program (the &#x201c;ATM Program&#x201d;) under which the Company may issue and sell its ordinary shares in the form of ADSs, with an aggregate offering price of up to $100.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;During the three months ended March 31, 2022, the Company sold 80,696 ordinary shares (equivalent to 10,087 ADSs) under the ATM Program, at an average price of approximately $0.86 per share (equivalent to $6.86 per ADS), raising aggregate net proceeds of approximately $0.1&#160;million after deducting issuance costs. As of March 31, 2022, there remained ordinary shares, in the form of ADSs, with a value up to $99.2&#160;million available for sale under the ATM Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company&#x2019;s commercial revenue, if any, will be derived from sales of products that we do not expect to be commercially available for several years, if ever. Additionally we may enter into out-licensing transactions from time to time but there can be no assurance that the company can secure such transactions in the future. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives including to further advance clinical and regulatory activities, to fund prelaunch and launch related costs and to create an effective sales and marketing organization to commercialize ensifentrine. We will need to seek additional funding through public or private financings, debt financing, collaboration or licensing agreements and other arrangements. However, there is no guarantee that we will be successful in securing additional capital on acceptable terms, or at all.&lt;/span&gt;&lt;/div&gt;</vrna:OrganizationAndBusinessDescriptionTextBlock>
    <vrna:NumberOfWhollyOwnedSubsidiaries
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80Ni9mcmFnOmZhNGYxYTU1YzcwNjQ3NjY5MWZhZjAwOGM0NTZkYjhhL3RleHRyZWdpb246ZmE0ZjFhNTVjNzA2NDc2NjkxZmFmMDA4YzQ1NmRiOGFfMjA2MA_7b2f9cce-460e-4771-a195-8def6398188e"
      unitRef="subsidiary">1</vrna:NumberOfWhollyOwnedSubsidiaries>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80Ni9mcmFnOmZhNGYxYTU1YzcwNjQ3NjY5MWZhZjAwOGM0NTZkYjhhL3RleHRyZWdpb246ZmE0ZjFhNTVjNzA2NDc2NjkxZmFmMDA4YzQ1NmRiOGFfOTI0_7e8a44bf-65e9-4e9b-9973-1a0685219598"
      unitRef="usd">-288700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <vrna:SaleOfStockMaximumAggregateOfferingPrice
      contextRef="i22ba9f263b564af695f8fba5e244c5fa_I20210319"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80Ni9mcmFnOmZhNGYxYTU1YzcwNjQ3NjY5MWZhZjAwOGM0NTZkYjhhL3RleHRyZWdpb246ZmE0ZjFhNTVjNzA2NDc2NjkxZmFmMDA4YzQ1NmRiOGFfMTYzNw_89b179af-57b2-4d9a-bc84-175ae21b9ca2"
      unitRef="usd">100000000</vrna:SaleOfStockMaximumAggregateOfferingPrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80Ni9mcmFnOmZhNGYxYTU1YzcwNjQ3NjY5MWZhZjAwOGM0NTZkYjhhL3RleHRyZWdpb246ZmE0ZjFhNTVjNzA2NDc2NjkxZmFmMDA4YzQ1NmRiOGFfMTcwNw_2219a8bf-be2f-4825-9fd8-8970292f1ecf"
      unitRef="shares">80696</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i14b59a9e0309440bbd87ed4bea74076d_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80Ni9mcmFnOmZhNGYxYTU1YzcwNjQ3NjY5MWZhZjAwOGM0NTZkYjhhL3RleHRyZWdpb246ZmE0ZjFhNTVjNzA2NDc2NjkxZmFmMDA4YzQ1NmRiOGFfMTc0MQ_215d8c19-65d8-4da4-b44c-733fca6167bb"
      unitRef="shares">10087</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80Ni9mcmFnOmZhNGYxYTU1YzcwNjQ3NjY5MWZhZjAwOGM0NTZkYjhhL3RleHRyZWdpb246ZmE0ZjFhNTVjNzA2NDc2NjkxZmFmMDA4YzQ1NmRiOGFfMTgxMA_831fb03f-03aa-4298-89ef-44cc3c8f955f"
      unitRef="usdPerShare">0.86</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i9b1d9925838f4f4e8d46dce269a2578c_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80Ni9mcmFnOmZhNGYxYTU1YzcwNjQ3NjY5MWZhZjAwOGM0NTZkYjhhL3RleHRyZWdpb246ZmE0ZjFhNTVjNzA2NDc2NjkxZmFmMDA4YzQ1NmRiOGFfMTgzOA_d6c8fd12-a3e8-40c9-a4d2-039c24bf002b"
      unitRef="usdPerShare">6.86</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80Ni9mcmFnOmZhNGYxYTU1YzcwNjQ3NjY5MWZhZjAwOGM0NTZkYjhhL3RleHRyZWdpb246ZmE0ZjFhNTVjNzA2NDc2NjkxZmFmMDA4YzQ1NmRiOGFfMTg5OQ_ebc263d0-2b03-4a51-b452-ee648b39e319"
      unitRef="usd">100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <vrna:CommonStockSharesAvailableForSaleValue
      contextRef="i9b1d9925838f4f4e8d46dce269a2578c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80Ni9mcmFnOmZhNGYxYTU1YzcwNjQ3NjY5MWZhZjAwOGM0NTZkYjhhL3RleHRyZWdpb246ZmE0ZjFhNTVjNzA2NDc2NjkxZmFmMDA4YzQ1NmRiOGFfMTk3NQ_939c526e-973a-4e28-9e0c-82e82a87d968"
      unitRef="usd">99200000</vrna:CommonStockSharesAvailableForSaleValue>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80OS9mcmFnOmU3NmUzNWZkZWI5YTQ2OTg5N2IxYzkyN2FlZGYyYzIwL3RleHRyZWdpb246ZTc2ZTM1ZmRlYjlhNDY5ODk3YjFjOTI3YWVkZjJjMjBfNzgzMw_c7042b24-86ac-4948-b31b-ab17cccdcd76">Basis of presentation and summary of significant accounting policies&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Basis of presentation and consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The unaudited condensed consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiary Verona Pharma, Inc. All inter-company balances and transactions have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The accompanying unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with accounting principles generally accepted in the U.S. (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March 3, 2022 (the &#x201c;2021 Form 10-K&#x201d;). The Consolidated Balance Sheet as of December 31, 2021, was derived from audited consolidated financial statements included in the 2021 Form 10-K but does not include all disclosures required by U.S. GAAP for complete financial statements. The Company&#x2019;s significant accounting policies are described in Note 2 to those consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. The unaudited condensed consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and shareholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Segment reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company has one operating and reportable segment, pharmaceutical development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, the fair value of share-based compensation, the fair value of warrants, research and development tax credit and the carrying value of the equity interest in Nuance Pharma (as defined below). Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Recently adopted accounting standards and recent accounting standards not yet adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;There are no recently adopted accounting standards and recent accounting standards not yet adopted that the Company believes will have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80OS9mcmFnOmU3NmUzNWZkZWI5YTQ2OTg5N2IxYzkyN2FlZGYyYzIwL3RleHRyZWdpb246ZTc2ZTM1ZmRlYjlhNDY5ODk3YjFjOTI3YWVkZjJjMjBfNzgzNA_d430cecf-ab87-43f2-8c6c-6fd1f6f5a71e">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Basis of presentation and consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The unaudited condensed consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiary Verona Pharma, Inc. All inter-company balances and transactions have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The accompanying unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with accounting principles generally accepted in the U.S. (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March 3, 2022 (the &#x201c;2021 Form 10-K&#x201d;). The Consolidated Balance Sheet as of December 31, 2021, was derived from audited consolidated financial statements included in the 2021 Form 10-K but does not include all disclosures required by U.S. GAAP for complete financial statements. The Company&#x2019;s significant accounting policies are described in Note 2 to those consolidated financial statements.&lt;/span&gt;&lt;/div&gt;Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. The unaudited condensed consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and shareholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80OS9mcmFnOmU3NmUzNWZkZWI5YTQ2OTg5N2IxYzkyN2FlZGYyYzIwL3RleHRyZWdpb246ZTc2ZTM1ZmRlYjlhNDY5ODk3YjFjOTI3YWVkZjJjMjBfNzgzNQ_8982d9a9-252d-4d9c-b8d7-71c7ec2b1256">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Segment reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company has one operating and reportable segment, pharmaceutical development.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80OS9mcmFnOmU3NmUzNWZkZWI5YTQ2OTg5N2IxYzkyN2FlZGYyYzIwL3RleHRyZWdpb246ZTc2ZTM1ZmRlYjlhNDY5ODk3YjFjOTI3YWVkZjJjMjBfOTM0NTg0ODg0OTA5MQ_5f457c82-a04c-4731-9e28-f78d117fc30a"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80OS9mcmFnOmU3NmUzNWZkZWI5YTQ2OTg5N2IxYzkyN2FlZGYyYzIwL3RleHRyZWdpb246ZTc2ZTM1ZmRlYjlhNDY5ODk3YjFjOTI3YWVkZjJjMjBfOTM0NTg0ODg0OTA5MQ_7862f634-e4ee-48ef-9586-f49e3b76951c"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80OS9mcmFnOmU3NmUzNWZkZWI5YTQ2OTg5N2IxYzkyN2FlZGYyYzIwL3RleHRyZWdpb246ZTc2ZTM1ZmRlYjlhNDY5ODk3YjFjOTI3YWVkZjJjMjBfNzgzNg_d982fbb6-f423-44b3-ae75-cc5a450d61a8">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, the fair value of share-based compensation, the fair value of warrants, research and development tax credit and the carrying value of the equity interest in Nuance Pharma (as defined below). Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80OS9mcmFnOmU3NmUzNWZkZWI5YTQ2OTg5N2IxYzkyN2FlZGYyYzIwL3RleHRyZWdpb246ZTc2ZTM1ZmRlYjlhNDY5ODk3YjFjOTI3YWVkZjJjMjBfNzgzNw_ebe2093b-9ac9-435c-9cd7-0f4cc5b67e85">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Recently adopted accounting standards and recent accounting standards not yet adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;There are no recently adopted accounting standards and recent accounting standards not yet adopted that the Company believes will have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <vrna:PrepaidExpenseDisclosureTextBlock
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81Mi9mcmFnOmQ0MzgyNDAyN2M3NTRjNzQ5MTg0ZThmZGM5ZjMwMjQ3L3RleHRyZWdpb246ZDQzODI0MDI3Yzc1NGM3NDkxODRlOGZkYzlmMzAyNDdfOTM_7abd3dc9-29ac-483a-8131-77b1d6fa808f">Prepaid expenses &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Prepaid expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial and other development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</vrna:PrepaidExpenseDisclosureTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81Mi9mcmFnOmQ0MzgyNDAyN2M3NTRjNzQ5MTg0ZThmZGM5ZjMwMjQ3L3RleHRyZWdpb246ZDQzODI0MDI3Yzc1NGM3NDkxODRlOGZkYzlmMzAyNDdfOTQ_791005d0-7858-4ded-955f-ca84afb005ad">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Prepaid expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial and other development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <vrna:PrepaidResearchAndDevelopmentFeesCurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81Mi9mcmFnOmQ0MzgyNDAyN2M3NTRjNzQ5MTg0ZThmZGM5ZjMwMjQ3L3RhYmxlOjNlMzhlZDkwMjU4NjRiMGE5NDUwM2Q4YjhiZmJmOTAxL3RhYmxlcmFuZ2U6M2UzOGVkOTAyNTg2NGIwYTk0NTAzZDhiOGJmYmY5MDFfMi0yLTEtMS01MDk0MA_e3aea34d-c209-4e51-a118-04925e8334c4"
      unitRef="usd">452000</vrna:PrepaidResearchAndDevelopmentFeesCurrent>
    <vrna:PrepaidResearchAndDevelopmentFeesCurrent
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81Mi9mcmFnOmQ0MzgyNDAyN2M3NTRjNzQ5MTg0ZThmZGM5ZjMwMjQ3L3RhYmxlOjNlMzhlZDkwMjU4NjRiMGE5NDUwM2Q4YjhiZmJmOTAxL3RhYmxlcmFuZ2U6M2UzOGVkOTAyNTg2NGIwYTk0NTAzZDhiOGJmYmY5MDFfMi00LTEtMS01MDk0MA_2f84e161-60df-45eb-94f7-82f25f74964f"
      unitRef="usd">2169000</vrna:PrepaidResearchAndDevelopmentFeesCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81Mi9mcmFnOmQ0MzgyNDAyN2M3NTRjNzQ5MTg0ZThmZGM5ZjMwMjQ3L3RhYmxlOjNlMzhlZDkwMjU4NjRiMGE5NDUwM2Q4YjhiZmJmOTAxL3RhYmxlcmFuZ2U6M2UzOGVkOTAyNTg2NGIwYTk0NTAzZDhiOGJmYmY5MDFfMy0yLTEtMS01MDk0MA_c91a7cae-efc9-428a-84a5-7891976134dd"
      unitRef="usd">435000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81Mi9mcmFnOmQ0MzgyNDAyN2M3NTRjNzQ5MTg0ZThmZGM5ZjMwMjQ3L3RhYmxlOjNlMzhlZDkwMjU4NjRiMGE5NDUwM2Q4YjhiZmJmOTAxL3RhYmxlcmFuZ2U6M2UzOGVkOTAyNTg2NGIwYTk0NTAzZDhiOGJmYmY5MDFfMy00LTEtMS01MDk0MA_598d1eac-b811-47aa-b652-68e74e6ef5e0"
      unitRef="usd">1555000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81Mi9mcmFnOmQ0MzgyNDAyN2M3NTRjNzQ5MTg0ZThmZGM5ZjMwMjQ3L3RhYmxlOjNlMzhlZDkwMjU4NjRiMGE5NDUwM2Q4YjhiZmJmOTAxL3RhYmxlcmFuZ2U6M2UzOGVkOTAyNTg2NGIwYTk0NTAzZDhiOGJmYmY5MDFfNC0yLTEtMS01MDk0MA_405945de-3628-49dd-be53-206f59ae12f0"
      unitRef="usd">359000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81Mi9mcmFnOmQ0MzgyNDAyN2M3NTRjNzQ5MTg0ZThmZGM5ZjMwMjQ3L3RhYmxlOjNlMzhlZDkwMjU4NjRiMGE5NDUwM2Q4YjhiZmJmOTAxL3RhYmxlcmFuZ2U6M2UzOGVkOTAyNTg2NGIwYTk0NTAzZDhiOGJmYmY5MDFfNC00LTEtMS01MDk0MA_f841ef7e-f7a8-4fac-aff0-53296723ccca"
      unitRef="usd">313000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81Mi9mcmFnOmQ0MzgyNDAyN2M3NTRjNzQ5MTg0ZThmZGM5ZjMwMjQ3L3RhYmxlOjNlMzhlZDkwMjU4NjRiMGE5NDUwM2Q4YjhiZmJmOTAxL3RhYmxlcmFuZ2U6M2UzOGVkOTAyNTg2NGIwYTk0NTAzZDhiOGJmYmY5MDFfNS0yLTEtMS01MDk0MA_507f0faa-3937-48c8-92ff-abcfc282df8e"
      unitRef="usd">1246000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81Mi9mcmFnOmQ0MzgyNDAyN2M3NTRjNzQ5MTg0ZThmZGM5ZjMwMjQ3L3RhYmxlOjNlMzhlZDkwMjU4NjRiMGE5NDUwM2Q4YjhiZmJmOTAxL3RhYmxlcmFuZ2U6M2UzOGVkOTAyNTg2NGIwYTk0NTAzZDhiOGJmYmY5MDFfNS00LTEtMS01MDk0MA_79d6428a-b30e-4372-917a-3328ccfe827e"
      unitRef="usd">4037000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81NS9mcmFnOjgyY2JiMzFiMWFiMjQ3YzViYTFhZWRjNzUxOGI1ODFmL3RleHRyZWdpb246ODJjYmIzMWIxYWIyNDdjNWJhMWFlZGM3NTE4YjU4MWZfMTI1_8cca2f87-0ac7-4578-914a-28207e92e64b">Tax and tax incentive receivables&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Tax and tax incentive receivables consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credit receivable - U.K.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company conducts research and development activities including, but not limited to, developing ensifentrine for various indications and delivery methods, and as a result the Company benefits in the U.K. from the HM Revenue and Customs, or HMRC, small and medium sized enterprises research and development relief, or SME R&amp;amp;D credit, which provides relief against U.K. Corporation Tax.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Effective for accounting periods starting after April 1, 2021, new rules were introduced whereby the amount of SME R&amp;amp;D tax credit that a business can receive in any one year will be capped at &#xa3;20,000 plus three times the company&#x2019;s total Pay As You Earn (&#x201c;PAYE&#x201d;) and National Insurance contributions (&#x201c;NIC&#x201d;) liability. Exemptions to the cap have been introduced which are available to companies that meet certain conditions. The Company believes it may be eligible for an exemption and has requested feedback from HMRC. If the cap does not apply the Company would have recorded $3.6 million relating to the quarter ended March 31, 2022 instead of the $1.3 million reported in the condensed consolidated statements of operations. Until we receive this feedback the Company is accounting for the credit as if the cap applied.&lt;/span&gt;&lt;/div&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <vrna:ScheduleOfNontradeReceivablesTableTextBlock
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81NS9mcmFnOjgyY2JiMzFiMWFiMjQ3YzViYTFhZWRjNzUxOGI1ODFmL3RleHRyZWdpb246ODJjYmIzMWIxYWIyNDdjNWJhMWFlZGM3NTE4YjU4MWZfMTI2_53669730-04d6-4462-b0b8-c59da10ea93d">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Tax and tax incentive receivables consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credit receivable - U.K.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</vrna:ScheduleOfNontradeReceivablesTableTextBlock>
    <vrna:ResearchAndDevelopmentTaxCreditReceivableCurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81NS9mcmFnOjgyY2JiMzFiMWFiMjQ3YzViYTFhZWRjNzUxOGI1ODFmL3RhYmxlOjA5NWRjNjIxMGQyZDRiOWJiYTlhNDcxNDRkYzMxNTBjL3RhYmxlcmFuZ2U6MDk1ZGM2MjEwZDJkNGI5YmJhOWE0NzE0NGRjMzE1MGNfMi0yLTEtMS01MDk0MA_73f9abec-0129-4b6e-8795-fd5019832e01"
      unitRef="usd">16420000</vrna:ResearchAndDevelopmentTaxCreditReceivableCurrent>
    <vrna:ResearchAndDevelopmentTaxCreditReceivableCurrent
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81NS9mcmFnOjgyY2JiMzFiMWFiMjQ3YzViYTFhZWRjNzUxOGI1ODFmL3RhYmxlOjA5NWRjNjIxMGQyZDRiOWJiYTlhNDcxNDRkYzMxNTBjL3RhYmxlcmFuZ2U6MDk1ZGM2MjEwZDJkNGI5YmJhOWE0NzE0NGRjMzE1MGNfMi00LTEtMS01MDk0MA_ca6e70e3-4e71-4083-a521-0d077914df06"
      unitRef="usd">15583000</vrna:ResearchAndDevelopmentTaxCreditReceivableCurrent>
    <vrna:TaxCreditAndIncomeTaxesReceivableCurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81NS9mcmFnOjgyY2JiMzFiMWFiMjQ3YzViYTFhZWRjNzUxOGI1ODFmL3RhYmxlOjA5NWRjNjIxMGQyZDRiOWJiYTlhNDcxNDRkYzMxNTBjL3RhYmxlcmFuZ2U6MDk1ZGM2MjEwZDJkNGI5YmJhOWE0NzE0NGRjMzE1MGNfNC0yLTEtMS01MDk0MA_37359eb5-82c4-48d4-835e-306e30cbc1d8"
      unitRef="usd">16420000</vrna:TaxCreditAndIncomeTaxesReceivableCurrent>
    <vrna:TaxCreditAndIncomeTaxesReceivableCurrent
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81NS9mcmFnOjgyY2JiMzFiMWFiMjQ3YzViYTFhZWRjNzUxOGI1ODFmL3RhYmxlOjA5NWRjNjIxMGQyZDRiOWJiYTlhNDcxNDRkYzMxNTBjL3RhYmxlcmFuZ2U6MDk1ZGM2MjEwZDJkNGI5YmJhOWE0NzE0NGRjMzE1MGNfNC00LTEtMS01MDk0MA_be4f0cc7-f24e-4e54-b9e9-a7c4c854df5f"
      unitRef="usd">15583000</vrna:TaxCreditAndIncomeTaxesReceivableCurrent>
    <vrna:GainLossFromResearchAndDevelopmentTaxCreditExcludingAnnualCap
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81NS9mcmFnOjgyY2JiMzFiMWFiMjQ3YzViYTFhZWRjNzUxOGI1ODFmL3RleHRyZWdpb246ODJjYmIzMWIxYWIyNDdjNWJhMWFlZGM3NTE4YjU4MWZfMjc0ODc3OTA3NzUzNQ_15e04386-5372-4138-a309-aed88fb6c7ee"
      unitRef="usd">3600000</vrna:GainLossFromResearchAndDevelopmentTaxCreditExcludingAnnualCap>
    <vrna:GainLossFromResearchAndDevelopmentTaxCredit
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV81NS9mcmFnOjgyY2JiMzFiMWFiMjQ3YzViYTFhZWRjNzUxOGI1ODFmL3RleHRyZWdpb246ODJjYmIzMWIxYWIyNDdjNWJhMWFlZGM3NTE4YjU4MWZfMjc0ODc3OTA3ODAwMA_008b86e9-3d43-47a5-ba99-9a3e238c9d70"
      unitRef="usd">1300000</vrna:GainLossFromResearchAndDevelopmentTaxCredit>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82MS9mcmFnOjg3YzI1YjlmMjYyNjQ1YjBiMDQ3NDg2NjE1MzQ4OGNiL3RleHRyZWdpb246ODdjMjViOWYyNjI2NDViMGIwNDc0ODY2MTUzNDg4Y2JfOTE_8010bb6b-2547-4f2f-abf3-25be7ff885e6">Accrued expenses&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial and other development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees and general corporate costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;People related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82MS9mcmFnOjg3YzI1YjlmMjYyNjQ1YjBiMDQ3NDg2NjE1MzQ4OGNiL3RleHRyZWdpb246ODdjMjViOWYyNjI2NDViMGIwNDc0ODY2MTUzNDg4Y2JfOTI_70eb7b5a-8386-4d92-9c4f-329a94dab638">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial and other development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees and general corporate costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;People related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <vrna:AccruedResearchAndDevelopmentFeesCurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82MS9mcmFnOjg3YzI1YjlmMjYyNjQ1YjBiMDQ3NDg2NjE1MzQ4OGNiL3RhYmxlOjY2OWY4YTg3YmNkNzQ0ODdhZTk0NDdhYzgzYTAwZGQwL3RhYmxlcmFuZ2U6NjY5ZjhhODdiY2Q3NDQ4N2FlOTQ0N2FjODNhMDBkZDBfMi0yLTEtMS01MDk0MA_6a52011e-e5c1-465b-a41d-0b3628182012"
      unitRef="usd">27520000</vrna:AccruedResearchAndDevelopmentFeesCurrent>
    <vrna:AccruedResearchAndDevelopmentFeesCurrent
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82MS9mcmFnOjg3YzI1YjlmMjYyNjQ1YjBiMDQ3NDg2NjE1MzQ4OGNiL3RhYmxlOjY2OWY4YTg3YmNkNzQ0ODdhZTk0NDdhYzgzYTAwZGQwL3RhYmxlcmFuZ2U6NjY5ZjhhODdiY2Q3NDQ4N2FlOTQ0N2FjODNhMDBkZDBfMi00LTEtMS01MDk0MA_86b2c6ea-8e6b-4e63-a96f-25e3388b062c"
      unitRef="usd">21336000</vrna:AccruedResearchAndDevelopmentFeesCurrent>
    <vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82MS9mcmFnOjg3YzI1YjlmMjYyNjQ1YjBiMDQ3NDg2NjE1MzQ4OGNiL3RhYmxlOjY2OWY4YTg3YmNkNzQ0ODdhZTk0NDdhYzgzYTAwZGQwL3RhYmxlcmFuZ2U6NjY5ZjhhODdiY2Q3NDQ4N2FlOTQ0N2FjODNhMDBkZDBfMy0yLTEtMS01MDk0MA_281432b8-04ac-49c0-a350-eb8aa9120a7b"
      unitRef="usd">846000</vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent>
    <vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82MS9mcmFnOjg3YzI1YjlmMjYyNjQ1YjBiMDQ3NDg2NjE1MzQ4OGNiL3RhYmxlOjY2OWY4YTg3YmNkNzQ0ODdhZTk0NDdhYzgzYTAwZGQwL3RhYmxlcmFuZ2U6NjY5ZjhhODdiY2Q3NDQ4N2FlOTQ0N2FjODNhMDBkZDBfMy00LTEtMS01MDk0MA_764d9aba-9c0d-4056-bb9d-5c8dea75cdaf"
      unitRef="usd">919000</vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82MS9mcmFnOjg3YzI1YjlmMjYyNjQ1YjBiMDQ3NDg2NjE1MzQ4OGNiL3RhYmxlOjY2OWY4YTg3YmNkNzQ0ODdhZTk0NDdhYzgzYTAwZGQwL3RhYmxlcmFuZ2U6NjY5ZjhhODdiY2Q3NDQ4N2FlOTQ0N2FjODNhMDBkZDBfNC0yLTEtMS01MDk0MA_d396f7a4-37f8-46b6-a99d-221739a0cf63"
      unitRef="usd">511000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82MS9mcmFnOjg3YzI1YjlmMjYyNjQ1YjBiMDQ3NDg2NjE1MzQ4OGNiL3RhYmxlOjY2OWY4YTg3YmNkNzQ0ODdhZTk0NDdhYzgzYTAwZGQwL3RhYmxlcmFuZ2U6NjY5ZjhhODdiY2Q3NDQ4N2FlOTQ0N2FjODNhMDBkZDBfNC00LTEtMS01MDk0MA_7347ccea-0fe7-48d4-ac51-73e007f9a89c"
      unitRef="usd">1000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82MS9mcmFnOjg3YzI1YjlmMjYyNjQ1YjBiMDQ3NDg2NjE1MzQ4OGNiL3RhYmxlOjY2OWY4YTg3YmNkNzQ0ODdhZTk0NDdhYzgzYTAwZGQwL3RhYmxlcmFuZ2U6NjY5ZjhhODdiY2Q3NDQ4N2FlOTQ0N2FjODNhMDBkZDBfNS0yLTEtMS01MDk0MA_9111ab61-2f3d-4a97-ba61-cc01dab0b23e"
      unitRef="usd">28877000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82MS9mcmFnOjg3YzI1YjlmMjYyNjQ1YjBiMDQ3NDg2NjE1MzQ4OGNiL3RhYmxlOjY2OWY4YTg3YmNkNzQ0ODdhZTk0NDdhYzgzYTAwZGQwL3RhYmxlcmFuZ2U6NjY5ZjhhODdiY2Q3NDQ4N2FlOTQ0N2FjODNhMDBkZDBfNS00LTEtMS01MDk0MA_f886a403-18ae-4d09-a96d-7e04b7de74d5"
      unitRef="usd">22256000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82Ny9mcmFnOmYwMTU3MmQwNzRlYjQ3M2VhNDk4ZGIwYzQ0Mzg0N2IxL3RleHRyZWdpb246ZjAxNTcyZDA3NGViNDczZWE0OThkYjBjNDQzODQ3YjFfNzA4_5082b112-6b05-478b-b18d-f20a90efd841">Term loan&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In November 2020, the Company entered into a term loan facility of up to $30.0&#160;million (the &#x201c;Term Loan&#x201d;), consisting of advances of $5.0&#160;million funded at closing and $10.0&#160;million and $15.0&#160;million&#160;contingent upon achievement of certain clinical development milestones and other specified conditions. As of March 31, 2022, the Company had $5.0&#160;million principal outstanding under the Term Loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Term Loan is governed by a loan and security agreement, dated as of November 19, 2020, between the Borrowers and SVB, as amended (the &#x201c;Loan Agreement&#x201d;). The Term B Loan will be available, subject to and customary terms and conditions, only during the period commencing upon the achievement of a specific clinical milestone relating to ensifentrine through and including September 30, 2022. The Term C Loan will be available, subject to customary terms and conditions, only during the period commencing upon the achievement of an additional specific clinical milestone relating to ensifentrine through and including June 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Term Loan will mature on November 1, 2024. Each advance under the Term Loan accrues interest at a floating per annum rate equal to the greater of (a) the sum of the prime rate reported in The Wall Street Journal plus 1.00% and (b) four and one-quarter of one percent (4.25%). The Term Loan provides for interest-only payments on a monthly basis until the payment date immediately preceding December 1, 2023. Thereafter, amortization payments will be payable monthly in equal installments of principal plus monthly payments of accrued interest. Upon repayment (whether at maturity, upon acceleration or by prepayment or otherwise), the Borrowers shall make a final payment to SVB in the amount of 10% of the aggregate Term Loans advanced (the "Final Payment"). The Borrowers may prepay the Term Loan in full but not in part provided that the Borrowers (i) provide ten days&#x2019; prior written notice to SVB, (ii) pays on the date of such prepayment (A) all outstanding principal plus accrued and unpaid interest, (B) a prepayment fee of $450,000 plus 3.0% of the Term C Loans advanced if paid on or before the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;first anniversary of the closing date; $300,000 plus 2.00% of the Term C Loans advanced if paid after the first anniversary of the closing date and on or before the second anniversary of the closing date; and $150,000 plus 1.00% of the Term C Loans advanced if paid thereafter and prior to maturity, (C) the Final Payment and (D) all other sums, if any, that shall become due and payable with respect to the Term Loan Advances, including interest at the Default Rate with respect to any past due amounts. Amounts outstanding during an event of default are payable upon SVB's demand and shall accrue interest at an additional rate of 3.0% per annum.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Term Loan is secured by a lien on substantially all of the assets of the Borrowers, other than the equity interests of Verona U.S. and other than intellectual property, provided that such lien on substantially all assets includes any rights to payments and proceeds from the sale, licensing or disposition of intellectual property. The Borrowers have also granted SVB a negative pledge with respect to its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Loan Agreement contains customary covenants and representations, including but not limited to financial reporting obligations and limitations on dividends, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. The Loan Agreement also contains other customary provisions, such as expense reimbursement, non-disclosure obligations as well as indemnification rights for the benefit of SVB. The Loan Agreement includes a minimum cash covenant triggered when Borrowers' consolidated cash and cash equivalents drop below $45.0 million at any time after the earliest to occur of any of the following: (i) the release of negative data from ENHANCE-2 and/or ENHANCE-1, which in the reasonable business discretion Borrowers&#x2019; senior management, would be considered insufficient to support submission of an NDA to the FDA, (ii) the FDA issues a complete response letter with respect to an NDA submitted for ensifentrine, or (iii) failure to achieve a specific regulatory milestone relating to ensifentrine by June 30, 2023 (extendable to March 31, 2024 upon the Borrowers receiving a specified amount of new cash proceeds after September 8, 2020 from the sale of equity securities in one or more public financings or other bona fide equity financings, subordinated debt and/or upfront/milestone payments from one or more collaboration agreements not prohibited in the Loan Agreement). Upon such trigger, Borrowers must cash collateralize an amount equal to the outstanding obligations to SVB plus the amount of any prepayment penalty and Final Payment which would be due in the event the Loan Agreement were prepaid in full with respect to the Term Loans advanced as of such time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;As of March 31, 2022, the carrying value of the Term Loan was approximately $4.9&#160;million, of which all was due in more than 12 months. The debt balance has been categorized within Level 3 of the fair value hierarchy. The carrying amount of the debt approximates its fair value based on prevailing interest rates as of the balance sheet date.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib5e3071b65394dcb9eeb62c562c7fadf_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82Ny9mcmFnOmYwMTU3MmQwNzRlYjQ3M2VhNDk4ZGIwYzQ0Mzg0N2IxL3RleHRyZWdpb246ZjAxNTcyZDA3NGViNDczZWE0OThkYjBjNDQzODQ3YjFfOTc_71f0a457-01ee-41f8-82dc-4bba1d4e4dee"
      unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i3e36e2a2c0ee4200aa8e95a2881303c4_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82Ny9mcmFnOmYwMTU3MmQwNzRlYjQ3M2VhNDk4ZGIwYzQ0Mzg0N2IxL3RleHRyZWdpb246ZjAxNTcyZDA3NGViNDczZWE0OThkYjBjNDQzODQ3YjFfMTQ1_6843a3e9-d346-46a2-b20f-3ca3e299cdb1"
      unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9d316fcf04fa4e9886bc433d175709c7_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82Ny9mcmFnOmYwMTU3MmQwNzRlYjQ3M2VhNDk4ZGIwYzQ0Mzg0N2IxL3RleHRyZWdpb246ZjAxNTcyZDA3NGViNDczZWE0OThkYjBjNDQzODQ3YjFfMTcw_8a56479e-f444-4c18-8d63-55756885ba92"
      unitRef="usd">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia5ebcd401a344004af7b7053e2853059_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82Ny9mcmFnOmYwMTU3MmQwNzRlYjQ3M2VhNDk4ZGIwYzQ0Mzg0N2IxL3RleHRyZWdpb246ZjAxNTcyZDA3NGViNDczZWE0OThkYjBjNDQzODQ3YjFfMTc3_0d7c3505-1ab6-439b-92a6-323f9911054e"
      unitRef="usd">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9e7ac21ebac441969276519788ca0689_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82Ny9mcmFnOmYwMTU3MmQwNzRlYjQ3M2VhNDk4ZGIwYzQ0Mzg0N2IxL3RleHRyZWdpb246ZjAxNTcyZDA3NGViNDczZWE0OThkYjBjNDQzODQ3YjFfMzI1_b48f7e06-4ca5-4993-9397-922f7bd9289e"
      unitRef="usd">5000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV82Ny9mcmFnOmYwMTU3MmQwNzRlYjQ3M2VhNDk4ZGIwYzQ0Mzg0N2IxL3RleHRyZWdpb246ZjAxNTcyZDA3NGViNDczZWE0OThkYjBjNDQzODQ3YjFfNDUx_cb7a6e9a-4a32-411e-be64-d9ea8a5a1ca7"
      unitRef="usd">4900000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MTIvZnJhZzoxYzQ0Mzc0YWRmZmQ0Mzc5YWQxNjg5OTNkMWM4MGVhYy90ZXh0cmVnaW9uOjFjNDQzNzRhZGZmZDQzNzlhZDE2ODk5M2QxYzgwZWFjXzEwOTk1MTE2MjgxOTI0_b08aff67-1d59-40a0-ae8d-19d6d2921e67">Equity interest &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company entered into a collaboration and license agreement (the &#x201c;Nuance Agreement&#x201d;) with Nuance Pharma Limited (&#x201c;Nuance Pharma&#x201d;) effective June 9, 2021 (the &#x201c;Effective Date&#x201d;), under which the Company granted Nuance Pharma the exclusive rights to develop and commercialize ensifentrine in Greater China (China, Taiwan, Hong Kong and Macau). In return, the Company received an unconditional right to consideration aggregating $40.0&#160;million consisting of $25.0&#160;million in cash and an equity interest, valued at $15.0&#160;million as of the Effective Date, in Nuance Biotech, the parent company of Nuance Pharma.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company follows guidance from ASC 321-10-35-2 and uses the fair value measurement alternative and measures the securities at cost, which is deemed to be the value indicated by the last observable transaction in Nuance Biotech's stock, subject to impairment. The valuation will be adjusted for any observable price changes in orderly transactions for an identical or similar investment in Nuance Biotech, or if there is an indicator of impairment. As of March 31, 2022, there had been no observable transactions to indicate any price changes in the value of Nuance Biotech&#x2019;s stock, nor had there been any indications of impairment. The equity interest is therefore recorded at a value of $15.0&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i47479f2645fe48afa643ac8df2b7b1c4_I20210609"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MTIvZnJhZzoxYzQ0Mzc0YWRmZmQ0Mzc5YWQxNjg5OTNkMWM4MGVhYy90ZXh0cmVnaW9uOjFjNDQzNzRhZGZmZDQzNzlhZDE2ODk5M2QxYzgwZWFjXzEwOTk1MTE2MjgxOTQx_11f5c28c-6fbd-4592-96a1-b00aaf606776"
      unitRef="usd">40000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i47479f2645fe48afa643ac8df2b7b1c4_I20210609"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MTIvZnJhZzoxYzQ0Mzc0YWRmZmQ0Mzc5YWQxNjg5OTNkMWM4MGVhYy90ZXh0cmVnaW9uOjFjNDQzNzRhZGZmZDQzNzlhZDE2ODk5M2QxYzgwZWFjXzEwOTk1MTE2MjgxOTU2_282d373a-0979-4606-afa6-43755cf9fb46"
      unitRef="usd">25000000</us-gaap:AccountsReceivableNetCurrent>
    <vrna:EquityInterestReceivable
      contextRef="i47479f2645fe48afa643ac8df2b7b1c4_I20210609"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MTIvZnJhZzoxYzQ0Mzc0YWRmZmQ0Mzc5YWQxNjg5OTNkMWM4MGVhYy90ZXh0cmVnaW9uOjFjNDQzNzRhZGZmZDQzNzlhZDE2ODk5M2QxYzgwZWFjXzEwOTk1MTE2MjgxOTI2_38c6d866-bc48-4ced-93ff-4018bcee5aa8"
      unitRef="usd">15000000</vrna:EquityInterestReceivable>
    <vrna:EquityInterestReceivable
      contextRef="i47479f2645fe48afa643ac8df2b7b1c4_I20210609"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV80MTIvZnJhZzoxYzQ0Mzc0YWRmZmQ0Mzc5YWQxNjg5OTNkMWM4MGVhYy90ZXh0cmVnaW9uOjFjNDQzNzRhZGZmZDQzNzlhZDE2ODk5M2QxYzgwZWFjXzEwOTk1MTE2MjgxOTcx_33b4258a-9cd2-4079-962d-07d229888c58"
      unitRef="usd">15000000</vrna:EquityInterestReceivable>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfNjk5OQ_d8af9b55-cac1-4f68-96d5-6101db650c01">Significant agreements&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Ligand agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In 2006 the Company acquired Rhinopharma and assumed contingent liabilities owed to Ligand UK Development Limited (&#x201c;Ligand&#x201d;) (formerly Vernalis Development Limited). The Company refers to the assignment and license agreement as the Ligand Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Ligand&#160;assigned to the Company all of its rights to certain patents and patent applications relating to ensifentrine and related compounds (the &#x201c;Ligand Patents&#x201d;) and an exclusive, worldwide, royalty-bearing license under certain Ligand know-how to develop, manufacture and commercialize products (the &#x201c;Ligand Licensed Products&#x201d;) developed using Ligand Patents, Ligand know-how and the physical stock of certain compounds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The contingent liability comprises a milestone payment (the &#x201c;Milestone Payment&#x201d;) on obtaining the first approval of any regulatory authority for the commercialization of a Ligand Licensed Product, low single digit royalties based on the future sales performance of all Ligand Licensed Products and a portion equal to a mid-twenty percent of any consideration received from any sub-licensees for the Ligand Patents and for Ligand know-how.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;At the time of the acquisition the contingent liability was not recognized as part of the acquisition accounting as it was immaterial. The Company will therefore record as a research and development expense the Milestone Payment or royalties when they are probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In March 2022 we entered into an Amendment Agreement (the &#x201c;Amendment&#x201d;) with Ligand whereby the Ligand Agreement was amended to clarify certain ambiguous terms in the Ligand Agreement. Pursuant to the Amendment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt"&gt;the Company agreed to pay to Ligand (i) $2.0&#160;million within five business days of the date of the Amendment and (ii) $15.0&#160;million upon the first commercial sale of ensifentrine by the Company or a sub-licensee, which amount is payable in cash or, at the Company's discretion, by the issuance of Company equity of equivalent value, as determined based on the volume-weighted average price of the Company's American Depositary Shares on the Nasdaq Global Market over the ten (10) trading days including and prior to such milestone event;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt"&gt;the Ligand Agreement shall expire on March 24, 2042 unless terminated earlier by either party in accordance with its terms;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt"&gt;upon termination of the Ligand Agreement, any Sub-licensee (as defined in the Amendment) shall have the right to enter into a direct license agreement with Ligand for the portion of the Program IP (as defined in the Amendment) that was sub-licensed by such Sub-licensee;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt"&gt;the Milestone Payment may be paid in cash or, at the Company&#x2019;s discretion, by issuing to Ligand shares in the Company of equivalent value; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt"&gt;each party&#x2019;s right to terminate the Ligand Agreement is conditioned upon such party obtaining a final judgment of the English High Court declaring that the other party is in material breach of its obligations under the Ligand Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company accounted for the $2.0&#160;million payment at execution as selling, general and administrative expense in the condensed consolidated statements of operations as the payment is related to a contract modification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Nuance agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company entered into a collaboration and license agreement (the &#x201c;Nuance Agreement&#x201d;) with Nuance Pharma Limited (&#x201c;Nuance Pharma&#x201d;) effective June 9, 2021 (the &#x201c;Effective Date&#x201d;) under which the Company granted Nuance Pharma the exclusive rights to develop and commercialize ensifentrine in Greater China (China, Taiwan, Hong Kong and Macau). In return, the Company received an unconditional right to consideration aggregating $40.0&#160;million consisting of $25.0&#160;million in cash and an equity interest, valued at $15.0&#160;million as of the Effective Date, in Nuance Biotech, the parent company of Nuance Pharma. The Company is eligible to receive future milestone payments of up to $179.0&#160;million triggered upon achievement of certain clinical, regulatory, and commercial milestones, as well as tiered double-digit royalties as a percentage of net sales of the products in Greater China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;As of March 31, 2022, the $25.0&#160;million cash payment and $15.0&#160;million equity interest had been received and the holding in Nuance Biotech was recorded as Equity Interest on our unaudited condensed consolidated balance sheets included elsewhere in this Quarterly Report on Form 10-Q. The Company follows guidance from ASC 321-10-35-2 and uses the fair value measurement alternative and measures the securities at cost, which is deemed to be the value indicated by the last observable transaction in Nuance Biotech's stock, subject to impairment. The valuation will be adjusted for any observable price changes in orderly transactions for an identical or similar investment in Nuance Biotech, or if there is an indicator of impairment. As of March 31, 2022, there had been no other transactions to indicate any price changes in the value of Nuance Biotech&#x2019;s stock, nor had there been any indications of impairment. The Equity Interest is therefore recorded at a value of $15&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Under the terms of the Nuance Agreement, at any time until three months prior to the expected submission of the first New Drug Application in Greater China, if (i) a third party is interested in partnering with the Company, either globally or in territory covering at least the United States or Europe, for the development and/or commercialization of ensifentrine or (ii) the Company undergoes a change of control, the Company will have an exclusive option right to buy back the license granted to Nuance Pharma and all related assets. The price is agreed to be equal to the aggregate of (i) all prior amounts paid by Nuance Pharma to the Company in cash under the agreement and (ii) all development and regulatory costs incurred and paid by Nuance Pharma in connection with the development and commercialization of ensifentrine under the Nuance Agreement multiplied by a single-digit factor range dependent upon achievement of certain milestones, subject to a specified maximum amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Nuance Agreement will continue on a jurisdiction-by-jurisdiction and product-by-product basis until the expiration of royalty payment obligations with respect to such product in such jurisdiction unless earlier terminated by the parties. Either party may terminate the Nuance Agreement for an uncured material breach or bankruptcy of the other party. Nuance Pharma may also terminate the Nuance Agreement at will upon 90 days' prior written notice. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company reviewed the buy-back option and determined that because it is conditional on a third party the Company does not have the practical ability to exercise it and, accordingly, the contract is accounted for under ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The transaction price at the Effective Date of the Nuance Agreement was $40.0&#160;million consisting of the $25.0&#160;million upfront cash payment and $15.0&#160;million equity interest. Developmental and regulatory milestones, and the manufacture and supply of ensifentrine drug product, were not included in the transaction price as management determined that it is not probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Commercial milestones and sales royalties were also excluded and will be recognized when the milestones are achieved or the sales occur in Greater China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The performance obligations in the Nuance Agreement include the grant of the license (including the right to commercialize ensifentrine until the end of the term, the sharing of certain know how, and the sharing of certain clinical and regulatory data), and manufacture and supply of ensifentrine drug product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company has determined that the license and the know how shared with Nuance Pharma constitutes functional intellectual property and that revenue relating to this should be recognized at a point in time. Consequently, the Company determined that it fulfilled its obligations to Nuance Pharma after it delivered the know how that will allow Nuance Pharma to file an investigational new drug application in Greater China. This know how was delivered in the year ended December 31, 2021, and the $40.0&#160;million revenue was therefore recognized as revenue in the year ended December 31, 2021. Revenue relating to the manufacture and supply obligations will be recognized when the drug product is delivered.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <vrna:SublicensePayment
      contextRef="i85587e1e0a8f439d8aebd8e3ae70349a_D20220301-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfMTA5OTUxMTYzMTg4MTk_7a799338-11e0-473c-bef4-8564e3a08776"
      unitRef="usd">2000000</vrna:SublicensePayment>
    <vrna:SublicensePayment
      contextRef="i8ccfc42928504d8bb11c9856cb8aae45_D20220301-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfMTA5OTUxMTYzMTg4MzM_6090abdc-e7b5-48c9-92c7-5a27df047752"
      unitRef="usd">15000000</vrna:SublicensePayment>
    <vrna:SublicensePaymentEquityIssuanceThresholdTradingDays
      contextRef="i85587e1e0a8f439d8aebd8e3ae70349a_D20220301-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfMTA5OTUxMTYzMTg4NDg_a4dc01b1-9874-4d04-93ab-f574000f9364"
      unitRef="tradingday">10</vrna:SublicensePaymentEquityIssuanceThresholdTradingDays>
    <vrna:SublicensePayment
      contextRef="if0331ecacba24ab991d409deb3d7c0d6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfMjc0ODc3OTExMDMxOA_f48390db-f1a0-41a5-844d-d0c72a3c54a8"
      unitRef="usd">2000000</vrna:SublicensePayment>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i47479f2645fe48afa643ac8df2b7b1c4_I20210609"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfMTg1MA_2593fc08-b17e-4379-9113-1b14af5534b3"
      unitRef="usd">40000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i47479f2645fe48afa643ac8df2b7b1c4_I20210609"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfMTg2Nw_b370b234-4085-44f8-82f2-251ce6cefe0b"
      unitRef="usd">25000000</us-gaap:AccountsReceivableNetCurrent>
    <vrna:EquityInterestReceivable
      contextRef="i47479f2645fe48afa643ac8df2b7b1c4_I20210609"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfMTkxMg_b0bec1db-c785-43f0-8c98-855a9c85e8f5"
      unitRef="usd">15000000</vrna:EquityInterestReceivable>
    <vrna:ContractWithCustomerFutureEligibleMilestonePayments
      contextRef="i47479f2645fe48afa643ac8df2b7b1c4_I20210609"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfMjA2Nw_97c4b340-95d9-420d-926c-8b539f9e867f"
      unitRef="usd">179000000</vrna:ContractWithCustomerFutureEligibleMilestonePayments>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i26149cf54682400fabed175e2aa6fa8c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfMjI5MQ_77e98360-fb11-4720-aaf2-86bc1283b256"
      unitRef="usd">25000000</us-gaap:ContractWithCustomerLiability>
    <vrna:EquityInterestReceivable
      contextRef="i26149cf54682400fabed175e2aa6fa8c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfMjMxMQ_5d424ca0-8439-47ab-92f8-56662da5e168"
      unitRef="usd">15000000</vrna:EquityInterestReceivable>
    <vrna:EquityInterestReceivable
      contextRef="i26149cf54682400fabed175e2aa6fa8c_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfMjg2NA_c79e634e-39b4-41aa-9da9-3e3989aa78b1"
      unitRef="usd">15000000</vrna:EquityInterestReceivable>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i47479f2645fe48afa643ac8df2b7b1c4_I20210609"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfNDYxMg_9be414ba-fae1-4fd7-9de6-56bfbaacaf97"
      unitRef="usd">40000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i47479f2645fe48afa643ac8df2b7b1c4_I20210609"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfNDYzMw_f0284409-425d-4479-a050-970f9a6aba95"
      unitRef="usd">25000000</us-gaap:ContractWithCustomerLiability>
    <vrna:EquityInterestReceivable
      contextRef="i47479f2645fe48afa643ac8df2b7b1c4_I20210609"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfNDY2MQ_d1236b73-96a3-4851-8176-929dd24997da"
      unitRef="usd">15000000</vrna:EquityInterestReceivable>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i47479f2645fe48afa643ac8df2b7b1c4_I20210609"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83MC9mcmFnOjg2YWY2ZjkwMzMzZTQ2Yjg4MGYyZjZkZTk3MTQzYzlhL3RleHRyZWdpb246ODZhZjZmOTAzMzNlNDZiODgwZjJmNmRlOTcxNDNjOWFfNTkzNg_2e8e4375-3e50-41c1-8ed1-019420802221"
      unitRef="usd">40000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RleHRyZWdpb246ZjExOTIzYTM1OGRmNDhiN2I1MmIzNzNlZDg2ZDg1MThfMzk5_112456bd-d996-4aa9-a629-4e11919d3dcd">Share-based compensation&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows the allocation of share-based compensation between research and development and selling, general and administrative costs (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Share options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows share option activity, in ordinary shares, in the period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of share options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average exercise price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,695,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at March 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,303,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Restricted stock units activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows restricted stock unit (&#x201c;RSU&#x201d;) activity, in ordinary shares, in the period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of RSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,347,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,943,144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at March 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,872,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RleHRyZWdpb246ZjExOTIzYTM1OGRmNDhiN2I1MmIzNzNlZDg2ZDg1MThfNDAx_0af59d18-55db-48cc-b70a-3b864a61f3d9">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows the allocation of share-based compensation between research and development and selling, general and administrative costs (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idf656cb200bb45b582e522a818bd7960_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjZjNWNhMzJlMjA2ZDQ4YTNhNzZjZjhjN2Q2NDlhNzVjL3RhYmxlcmFuZ2U6NmM1Y2EzMmUyMDZkNDhhM2E3NmNmOGM3ZDY0OWE3NWNfMi0yLTEtMS01MDk0MA_2af192fd-acd1-44e5-b473-49a0b0754e44"
      unitRef="usd">1539000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i08b14602cfda47eaa4b3fbe624c9a1cf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjZjNWNhMzJlMjA2ZDQ4YTNhNzZjZjhjN2Q2NDlhNzVjL3RhYmxlcmFuZ2U6NmM1Y2EzMmUyMDZkNDhhM2E3NmNmOGM3ZDY0OWE3NWNfMi00LTEtMS01MDk0MA_f8bbc804-627d-4923-9f01-38e55d5655e8"
      unitRef="usd">3432000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6f4ede3c3b79413cac4812d5477bb459_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjZjNWNhMzJlMjA2ZDQ4YTNhNzZjZjhjN2Q2NDlhNzVjL3RhYmxlcmFuZ2U6NmM1Y2EzMmUyMDZkNDhhM2E3NmNmOGM3ZDY0OWE3NWNfMy0yLTEtMS01MDk0MA_75490a55-5f24-494b-ba47-4ba67269d37e"
      unitRef="usd">2209000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3718066b40d6491eb81e069865deddc4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjZjNWNhMzJlMjA2ZDQ4YTNhNzZjZjhjN2Q2NDlhNzVjL3RhYmxlcmFuZ2U6NmM1Y2EzMmUyMDZkNDhhM2E3NmNmOGM3ZDY0OWE3NWNfMy00LTEtMS01MDk0MA_a1192aa8-9d23-4b6e-b850-47d14c903c10"
      unitRef="usd">5418000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjZjNWNhMzJlMjA2ZDQ4YTNhNzZjZjhjN2Q2NDlhNzVjL3RhYmxlcmFuZ2U6NmM1Y2EzMmUyMDZkNDhhM2E3NmNmOGM3ZDY0OWE3NWNfNC0yLTEtMS01MDk0MA_4bbaccb9-6f0a-42bf-9b38-445c74a2fe8a"
      unitRef="usd">3748000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjZjNWNhMzJlMjA2ZDQ4YTNhNzZjZjhjN2Q2NDlhNzVjL3RhYmxlcmFuZ2U6NmM1Y2EzMmUyMDZkNDhhM2E3NmNmOGM3ZDY0OWE3NWNfNC00LTEtMS01MDk0MA_ff28ab61-b0db-46e3-a558-de9396e34c60"
      unitRef="usd">8850000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RleHRyZWdpb246ZjExOTIzYTM1OGRmNDhiN2I1MmIzNzNlZDg2ZDg1MThfNDAy_14c05412-8429-4b18-ba24-8d26c29436ca">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows share option activity, in ordinary shares, in the period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of share options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average exercise price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,695,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at March 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,303,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjhhZjExNmNiYjdmZjQ4Y2E4ZTRkZjY2NTY1ZTg5N2E1L3RhYmxlcmFuZ2U6OGFmMTE2Y2JiN2ZmNDhjYThlNGRmNjY1NjVlODk3YTVfMi0yLTEtMS01MDk0MA_3e65f365-164f-4797-9299-e1eb4b91d407"
      unitRef="shares">12695200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i43f3fd81e5634600b3df44427e14839e_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjhhZjExNmNiYjdmZjQ4Y2E4ZTRkZjY2NTY1ZTg5N2E1L3RhYmxlcmFuZ2U6OGFmMTE2Y2JiN2ZmNDhjYThlNGRmNjY1NjVlODk3YTVfMi00LTEtMS01MDk0MA_8ae4f1f0-b1f1-4da4-b21a-9aeeffe3ab9d"
      unitRef="usdPerShare">1.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjhhZjExNmNiYjdmZjQ4Y2E4ZTRkZjY2NTY1ZTg5N2E1L3RhYmxlcmFuZ2U6OGFmMTE2Y2JiN2ZmNDhjYThlNGRmNjY1NjVlODk3YTVfMy0yLTEtMS01MDk0MA_dc44633d-8dc5-4914-9f51-f418675224d3"
      unitRef="shares">608000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjhhZjExNmNiYjdmZjQ4Y2E4ZTRkZjY2NTY1ZTg5N2E1L3RhYmxlcmFuZ2U6OGFmMTE2Y2JiN2ZmNDhjYThlNGRmNjY1NjVlODk3YTVfMy00LTEtMS01MDk0MA_c358cb21-bfd5-4ad6-8e1a-b7abd51ccee7"
      unitRef="usdPerShare">0.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjhhZjExNmNiYjdmZjQ4Y2E4ZTRkZjY2NTY1ZTg5N2E1L3RhYmxlcmFuZ2U6OGFmMTE2Y2JiN2ZmNDhjYThlNGRmNjY1NjVlODk3YTVfNy0yLTEtMS01MDk0MA_44cc24ae-8335-49f9-927c-76686f96f56b"
      unitRef="shares">13303200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i568425c4e3c7431599d8b1aa195d0e85_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjhhZjExNmNiYjdmZjQ4Y2E4ZTRkZjY2NTY1ZTg5N2E1L3RhYmxlcmFuZ2U6OGFmMTE2Y2JiN2ZmNDhjYThlNGRmNjY1NjVlODk3YTVfNy00LTEtMS01MDk0MA_a1f4fb0f-069f-4463-ad46-ec35ca2694d9"
      unitRef="usdPerShare">1.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RleHRyZWdpb246ZjExOTIzYTM1OGRmNDhiN2I1MmIzNzNlZDg2ZDg1MThfNDAz_7edccc1c-ff58-44f2-b68c-2d7e8f0e28e1">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows restricted stock unit (&#x201c;RSU&#x201d;) activity, in ordinary shares, in the period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of RSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,347,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,943,144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at March 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,872,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i82b2bb68605b4efca32316b1da619988_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjdkMzJkMzU5ZjcyZDQwMzE5YThlMjAwMjg5NTZkZWQwL3RhYmxlcmFuZ2U6N2QzMmQzNTlmNzJkNDAzMTlhOGUyMDAyODk1NmRlZDBfMi0yLTEtMS01MDk0MA_f4532747-e5b4-4c8b-bc67-0a9bfccead23"
      unitRef="shares">38347352</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="ia5bbf2f1a066455386dcb6d6e2137c08_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjdkMzJkMzU5ZjcyZDQwMzE5YThlMjAwMjg5NTZkZWQwL3RhYmxlcmFuZ2U6N2QzMmQzNTlmNzJkNDAzMTlhOGUyMDAyODk1NmRlZDBfMi00LTEtMS01MDk0MA_95d2e84e-d5d3-45b0-83ba-dfc262802188">P1Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ica753976be2b4f4bae0fa0b52b8c63a0_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjdkMzJkMzU5ZjcyZDQwMzE5YThlMjAwMjg5NTZkZWQwL3RhYmxlcmFuZ2U6N2QzMmQzNTlmNzJkNDAzMTlhOGUyMDAyODk1NmRlZDBfMy0yLTEtMS01MDk0MA_bb79361f-5a85-4c81-9019-79c1162e153a"
      unitRef="shares">468224</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ica753976be2b4f4bae0fa0b52b8c63a0_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjdkMzJkMzU5ZjcyZDQwMzE5YThlMjAwMjg5NTZkZWQwL3RhYmxlcmFuZ2U6N2QzMmQzNTlmNzJkNDAzMTlhOGUyMDAyODk1NmRlZDBfNS0yLTEtMS01MDk0MA_ff3e1d74-777f-4857-9d42-d6f1e0d9efe4"
      unitRef="shares">3943144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i1c92777eba5f49eca3791c762fd6c083_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjdkMzJkMzU5ZjcyZDQwMzE5YThlMjAwMjg5NTZkZWQwL3RhYmxlcmFuZ2U6N2QzMmQzNTlmNzJkNDAzMTlhOGUyMDAyODk1NmRlZDBfNi0yLTEtMS01MDk0MA_38259c55-5ce2-4c7c-ba6e-2eeebf85d7bd"
      unitRef="shares">34872432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="ica753976be2b4f4bae0fa0b52b8c63a0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83Ni9mcmFnOmYxMTkyM2EzNThkZjQ4YjdiNTJiMzczZWQ4NmQ4NTE4L3RhYmxlOjdkMzJkMzU5ZjcyZDQwMzE5YThlMjAwMjg5NTZkZWQwL3RhYmxlcmFuZ2U6N2QzMmQzNTlmNzJkNDAzMTlhOGUyMDAyODk1NmRlZDBfNi00LTEtMS01MDk0MA_fd07456c-82f8-4b0d-98c4-b4c275c70cbc">P1Y1M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RleHRyZWdpb246NDY0NDI0NjYyNTJlNDA3MmFhNzQxN2EzN2Q3ZGY3MDNfOTUx_a92aa1be-7113-401a-aa57-479933627848">Net loss per share &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Net loss per share is calculated on an ordinary share basis. The Company&#x2019;s ADSs that are listed on the Nasdaq Global Market each represent eight ordinary shares. The following table shows the computation of basic and diluted net loss per share for the periods ended March 31, 2022 and 2021 (net loss in thousands, loss per share in dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481,941,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469,465,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;During the three months ended March 31, 2022 and 2021, outstanding share options, RSUs and warrants over 60,576,894 and 77,584,846 ordinary shares, respectively, were not included in the computation of diluted earnings per ordinary share, because to do so would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RleHRyZWdpb246NDY0NDI0NjYyNTJlNDA3MmFhNzQxN2EzN2Q3ZGY3MDNfOTUy_0dc46810-943b-4ee0-82b3-fda13f75a842">The following table shows the computation of basic and diluted net loss per share for the periods ended March 31, 2022 and 2021 (net loss in thousands, loss per share in dollars):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481,941,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469,465,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RhYmxlOjZlYjY4NDUzMzlkNDQ1ZjdhMDg4Yjk4NzY2ZjE3YThlL3RhYmxlcmFuZ2U6NmViNjg0NTMzOWQ0NDVmN2EwODhiOTg3NjZmMTdhOGVfMy0yLTEtMS01MDk0MA_5145b1cb-735e-450d-b11c-a306eff8c39e"
      unitRef="usd">-24837000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RhYmxlOjZlYjY4NDUzMzlkNDQ1ZjdhMDg4Yjk4NzY2ZjE3YThlL3RhYmxlcmFuZ2U6NmViNjg0NTMzOWQ0NDVmN2EwODhiOTg3NjZmMTdhOGVfMy00LTEtMS01MDk0MA_2fad3338-1e5e-4ab7-835c-22ce0e03e123"
      unitRef="usd">-21290000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RhYmxlOjZlYjY4NDUzMzlkNDQ1ZjdhMDg4Yjk4NzY2ZjE3YThlL3RhYmxlcmFuZ2U6NmViNjg0NTMzOWQ0NDVmN2EwODhiOTg3NjZmMTdhOGVfNi0yLTEtMS01MDk0MA_53ce9628-05ba-4cb1-840e-04cf4f13c4de"
      unitRef="shares">481941527</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RhYmxlOjZlYjY4NDUzMzlkNDQ1ZjdhMDg4Yjk4NzY2ZjE3YThlL3RhYmxlcmFuZ2U6NmViNjg0NTMzOWQ0NDVmN2EwODhiOTg3NjZmMTdhOGVfNi0yLTEtMS01MDk0MA_73c9355d-9e98-458c-814b-afd1dd6bc8ad"
      unitRef="shares">481941527</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RhYmxlOjZlYjY4NDUzMzlkNDQ1ZjdhMDg4Yjk4NzY2ZjE3YThlL3RhYmxlcmFuZ2U6NmViNjg0NTMzOWQ0NDVmN2EwODhiOTg3NjZmMTdhOGVfNi00LTEtMS01MDk0MA_25a6adf2-648f-4c4d-b1ab-e9425ad32880"
      unitRef="shares">469465085</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RhYmxlOjZlYjY4NDUzMzlkNDQ1ZjdhMDg4Yjk4NzY2ZjE3YThlL3RhYmxlcmFuZ2U6NmViNjg0NTMzOWQ0NDVmN2EwODhiOTg3NjZmMTdhOGVfNi00LTEtMS01MDk0MA_b562caf5-175a-4702-bdd2-f9c58ae5acdb"
      unitRef="shares">469465085</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RhYmxlOjZlYjY4NDUzMzlkNDQ1ZjdhMDg4Yjk4NzY2ZjE3YThlL3RhYmxlcmFuZ2U6NmViNjg0NTMzOWQ0NDVmN2EwODhiOTg3NjZmMTdhOGVfNy0yLTEtMS01MDk0MA_277ba617-86b8-4a05-96cf-910318484dab"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RhYmxlOjZlYjY4NDUzMzlkNDQ1ZjdhMDg4Yjk4NzY2ZjE3YThlL3RhYmxlcmFuZ2U6NmViNjg0NTMzOWQ0NDVmN2EwODhiOTg3NjZmMTdhOGVfNy0yLTEtMS01MDk0MA_35ed8f25-4204-4c5a-a285-a26a9eef9ce2"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RhYmxlOjZlYjY4NDUzMzlkNDQ1ZjdhMDg4Yjk4NzY2ZjE3YThlL3RhYmxlcmFuZ2U6NmViNjg0NTMzOWQ0NDVmN2EwODhiOTg3NjZmMTdhOGVfNy00LTEtMS01MDk0MA_0a2e9213-74db-407e-ae22-2118f36f8705"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RhYmxlOjZlYjY4NDUzMzlkNDQ1ZjdhMDg4Yjk4NzY2ZjE3YThlL3RhYmxlcmFuZ2U6NmViNjg0NTMzOWQ0NDVmN2EwODhiOTg3NjZmMTdhOGVfNy00LTEtMS01MDk0MA_5d8952db-d22f-4eed-8a60-b1835ff8016c"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RleHRyZWdpb246NDY0NDI0NjYyNTJlNDA3MmFhNzQxN2EzN2Q3ZGY3MDNfNTI4_147c0918-f4d1-4584-bcfd-9262ea394d04"
      unitRef="shares">60576894</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7adca89580cd4d529346880a8aab0a59_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzODZiYmRhNmRiNzQxMDI4ZTJkMGFiNmQ2YTNkMGM5L3NlYzoxMzg2YmJkYTZkYjc0MTAyOGUyZDBhYjZkNmEzZDBjOV83OS9mcmFnOjQ2NDQyNDY2MjUyZTQwNzJhYTc0MTdhMzdkN2RmNzAzL3RleHRyZWdpb246NDY0NDI0NjYyNTJlNDA3MmFhNzQxN2EzN2Q3ZGY3MDNfNTM1_47188750-8d7c-4cc2-a980-18dc37eb4923"
      unitRef="shares">77584846</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>51
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MI9A=4^LV$(:O3W^%)IWIM!U";-E <@J9"2&<,N4C$$I[VNF%8BN)!UMR99G
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M1=5^W3!J8%L#\_N]$/KUP7:^N_]TK/\%4$L#!!0    ( !E#HU3:#A^-=P(
M  T&   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULE57+;MLP$/P50@6*
M!$BMMQVGLH#$0= >"A@QVAZ*'FAI;1&A2)6D[/3ONZ04P0GDI+E(?.S,SJS(
M57:0ZD%7 (8\UESHA5<9TUSYOBXJJ*F>R 8$[FREJJG!J=KYNE% 2P>JN1\%
MP=2O*1->GKFUE<HSV1K.!*P4T6U=4_7W!K@\++S0>UJX9[O*V 4_SQJZ@S68
M[\U*X<P?6$I6@]!,"J)@N_"NPZME:N-=P \&!WTT)M;)1LH'._E:+KS "@(.
MA;$,%%][6 +GE@AE_.DYO2&E!1Z/G]COG'?TLJ$:EI+_9*6I%MZE1TK8TI:;
M>WGX KT?)["07+LG.72QZ<PC1:N-K'LP*JB9Z-[TL:_#$2!,3@"B'A#]+R#N
M ;$SVBESMFZIH7FFY($H&XUL=N!JX]#HA@G[%==&X2Y#G,F74FC)64D-E.2&
M<BH*(&M+I\G9BBH0I@+#"LK/R2?R\4,XC3\3G^@*MW3F&Y1@B?RB3W?3I8M.
MI/M&U83$X06)@B@:@2]?A]]",<##YW ?C0_NH\%]Y/CB$WQK@[[Q3!HBM^2.
M"73/*"<KJ9D[9+^N-]HH/&J_7TD6#\EBERPY6>JZ1D[\I,7#!6FH(GO*6R!G
M3)!&MJ+4N <*83O2@.IJ?#Y6XR[/S.6QUW2?!Y,@S?S]<27?"'IF(1DL).^P
MP+1N\=18_=UY&!7;,:9'.I)Y$J2743)]H7@D\G(>SF9I&HS+3@?9Z3MD8R_3
MAHK2UOD-[>F(HFB>)/$\>*%]+#((,'@Z?:'=/[JLME'BE=@QH0F'+6*#R0Q)
M5-=\NHF1C;N_&VFP&[AAA?T:E W _:V4YFEB6\+P!\C_ 5!+ P04    "  9
M0Z-43LS<?#($  #9#@  &    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;)V7
M46^C.!" _XH5[4,KM06;!))5&FF;O=55NKVKVMW;9Q<F 2W@G.TDO7]_8T,A
M 4.[]Y)@F!E_,_9X/,NCD#]5"J#)2Y&7ZG:2:KW[Z'DJ3J'@ZD;LH,0O&R$+
MKG$HMY[:2>")52IRC_E^Z!4\*R>KI7WW(%=+L==Y5L*#)&I?%%S^>P>Y.-Y.
MZ.3UQ6.V3;5YX:V6.[Z%)]#?=P\21UYC)<D**%4F2B)A<SOY1#^NZ<(H6(F_
M,SBJDV=B7'D6XJ<9W">W$]\000ZQ-B8X_AU@#7EN+"''/[7123.G43Q]?K7^
MQ3J/SCQS!6N1_\@2G=Y.YA.2P(;O<_THCK]#[=#,V(M%KNPO.=:R_H3$>Z5%
M42LC09&5U3]_J0-QHH!VW JL5F!=A>F 0E K!-;1BLRZ]9EKOEI*<2322*,U
M\V!C8[71FZPTR_BD)7[-4$^OUJ)4(L\2KB$A3QK_<(VT(F)#_MJ!Y";6BO R
M(6M1X$9)S0H>@/PAE"+7Y/O39W+QX9)\(%E)OJ5BKU!4+3V-:&8"+ZXQ[BH,
M-H 1D*^BU*DBOY4)).?Z'KK4^,5>_;ICHP:_<GE# GI%F,^8@V?]?G4Z@A,T
M80ZLO6# 7AW+<DO@!3-0@1HQ.FV,3JW1Z8#11U# 99S:Y4G@@#FY,ZOG"G]E
M*;263&H?5C0*V6SI'4Z#XI *9M&TD3K#G#68LU',)\Q1]/R*;*'$*.06ER>X
MF3.E350.X"*NC,Y.6*+IU.\ ]X46;,[<O&'#&X[R?A,:(<4;*U9!AKWYV<P/
MNV%U2+'Y+'1C1@UF-(K9;JD<<]$%%_6FO7;1N<2&\>8-WGQ\Q^L4))X*L2C
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M$6Y@6?51U4"+G6U%GH7&QL8^IMA[@C0"^'TCA'X=F F:;G;U'U!+ P04
M"  90Z-4NZ(C"XH%  #:%@  &    'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;+U8VW+;-A#]%8R::9.9,B+ JU)9,[%E.WEHF[&3]J'3!X2$3(Q)0B$@*_G[
M+BB:(D&0LB>9ODB\G%T<+!9G%USN174O,\84^EKDI3R;94IMW\SG,LE80>5K
ML64EO-F(JJ *;JN[N=Q6C*:U49'/B>N&\X+R<K9:UL\^5*NEV*F<E^Q#A>2N
M*&CU[9SE8G\VP[/'!S?\+E/ZP7RUW-([=LO4I^V'"N[FK9>4%ZR47)2H8INS
MV5O\YIIXVJ!&_,797G:ND9[*9R'N]<W[]&SF:D8L9XG2+BC\/; +EN?:$_#X
MTCB=M6-JP^[UH_>K>O(PF<]4L@N1_\U3E9W-XAE*V8;N<G4C]N]8,Z% ^TM$
M+NM?M#]@(W^&DIU4HFB,@4'!R\,__=H$HF. O1$#TA@0TR <,? : \\P(-&(
M@=\8^(:!-T8I: P"TV!LA+ Q"$U*[HA!U!A$]6(=HELOS9HJNEI68H\JC09O
M^J)>W]H:5H27.A5O505O.=BIU84HI<AY2A5+T:V"/\@S)9'8H-N,5BP3><HJ
M^?-/,<'1;^CRRXZK;\A!GV[7Z.6+5^@%XB7ZF(F=I&4JEW,%G+3G>=*,?WX8
MGXR,_U$HFEO,+J;-_JQ27L+605*3M(V[GG;P-DVYW@LT1UO*4P=FD= MMY.Y
M?!89E+$\U6%1H UR5WVS>+PZP2Y)=L4NKQ=%J(Q5*!$%2$VF->"!H5Q(VYRO
MG^X5=BM/N.H[F4/RM!E$V@PBM5=_Q.LYN^-ER<L[D(2<E@E#+V'NAU"\0E2A
M-4M>(P__BHA+7-M2'_P'M7\MG0\K/XX]U_?]<#E_L%#S6FK>,ZD]@<[YP6?8
MH8-C/P[\ELN!]1#FX6AAH-865!CZ&/=AET.8@R/7[:.N+"@_= U?UQ84<2,W
M<.W!]-M@^K6A-Q+,]V6B\QF6%R)87[W227ZK1'+?J,0OC_KPSXW(<P2U8D^K
M]-^)) O:P8/)E?P#BO)(TI\'@_1Q""8+(WC7)V$]8F%++)PD=L.DJGBBMU2=
M\FA7<I#/!WC,4IN4A ,:GLET"'&\$9I12S.:I%EKN:-K=EI+">@(U?)GBV<T
M&#Z. X/C^@2H1S)N2<:3)"_+=$)&?J=5NV^Q34;BY\K(HN6U> ZO)W Y7PPU
M)"(^-C5D"+-IR&*8,E% 0E-#AC 'AY&I(1:414,L*$)B+QI98>P>VPWWQU4+
M:VB; ?KK[+HQ682A$5XK=(&C*!A+5=SIF_#WU18[>3Q,#,T^,)D/<1Z. P.V
M;F"]U(!M:"[ZI07GA*YGI(8-9<D-&XR$7H1'MAD^=A*8_/\E!A^[!3S=+DP5
MF<:T/VD?=H09G).X/KEC]<7^)+GW4N[J-(/.'!2\$(^[!BH.! :RSX%&T8'S
MY#U,0](<WM"[BM7]?'>369MM?RCG;K@86]!CU<;39?N[2%N785C%P\C<.\%@
M[PSVC<4-&9GLL1/ /[@5P,-"C^/03"A+-]!%]<D>^P$\W1!T5T88YQ<EVJ/+
MR<09]@%:SEQW3%^/O0">;@:>2-!**AZ*)R&F) [;!:>+ZM,^M@IXNE>XZ&7Y
MGJNL/@UN1(44_0J/X.4A(Y#4LH:HUB^[Y%B*<+3PS%0^@>J?Z8YUFDS7Z49E
M)5,J?TQH2_^(*I;D5$J^X?"&2CA$R\QIK&R3(L.2C'%LS.D$J#^E8\4FTQ7[
M.3TPL=3?R(],GI;RVT7UB78.U-,GZJ?WP<3*W7:>)@O?]\PST84-NO#=("9C
M/3,Y5E,R74VGNV8[<\O1&SH+UU1X"\XC.";F\EA@<4Q<H[^^M."<R%L8W9$-
M9>F.;# 2QUU_AX#..Q_M]%=?B YTE!+E; .6[NL(5J4Z?$@]W"BQK;_C?19*
MB:*^S!B%,JH!\'XCA'J\T9\&V\_9J_\ 4$L#!!0    ( !E#HU1:GM/^% 8
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M_L"E#= T"/2F%%+S_ZCM9E!N.5M!P)3:,Y0)I;T[G3HX2-2!ZHJ<>7,!=-H
MG8:!9IED3R@ERUFYLV] &R7?EP@>#78?WJD#)L(=O$&1"[RS!N\LG &42W2@
M!02R% ?;SPS&(Y625OZXSAP0XPY,5R(>IWZ<>-SVWG$0Z<.62C8T+)3#GI=
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MU;*^RF[-U#?K'ZF$2E*H8&LP.7Z;0J1D?5E=OVBQL_>]*Z&U*.WCEM&<22,
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M8'[0J T\B%@_E@JT+!)%!2K<<P<:)C R4:/T8F[L>O'D]MDH50=L-G]$NOK
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M4B?',F@8H*M^'P ]121A:?3<E$@SPH&)-[7.9#"-?2>Y+ARB;,"D=-+!"+M
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MU&\K>A11NP Z+Y6R1\-=,#RSBU]02P,$%     @ &4.C5( T*\*Z!   .PH
M !D   !X;"]W;W)K<VAE971S+W-H965T,3 N>&ULK59M;]LV$/XK![<(6L#S
MBYRD0=Z Q,W08$@1),V&8M@'2CI91"A1)2D[WJ_?<Y2M.$"3?=B^V.+Q[N'=
M<R_DZ<JZ1U\R!WJJ3.W/!F4(S?%X[+.2*^5'MN$:.X5UE0I8NL78-XY5'HTJ
M,TXFD\-QI70].#^-LEMW?FK;8'3-MXY\6U7*K2_9V-798#K8"N[TH@PB&)^?
M-FK!]QP>FEN'U;A'R77%M=>V)L?%V>!B>GRY+_I1X7?-*[_S31)):NVC+*[S
ML\%$'&+#61 $A;\ES]D8 8(;/S:8@_Y(,=S]WJ+_&F-'+*GR/+?F#YV'\FQP
M-*"<"]6:<&=77W@3SX'@9=;X^$NK3G<V&U#6^F"KC3$\J'3=_:NG#0\[!D>3
M5PR2C4$2_>X.BEY^5D&=GSJ[(B?:0)./&&JTAG.ZEJ3<!X==#;MP_DT]D:IS
M"OC7=<:UD 2V,]9+E1H^'0><(KKC;(-XV2$FKR#.Z,;6H?1T5>><O[0?P[O>
MQ63KXF7R)N"-<B.:38>43)+D#;Q9'_(LXLU>P;OK@_/TYT7J@T-I_/4&\'X/
MO!^!]_]'+O\;HJ=_U\@L.L@'SLD6%$JFPAJTHJX7]$'7D-C6 \%_/"8PG961
MZL\ J%)V/>_R,Z4[]AQUY,B<E^CI!AT:XO&9XUR'G;/I%WH8_3:B]S0]'.XG
M$_DX&!X<S>B;#<I$HQWMGZC!V[FM&E6O)8R\S8*'Q2L^Q ;702-F,&':'"$.
M*6T#U3:0T946$H(=;JV$ ADO!:P=F <SCI;*:3 "B%QG2B:'WYQDP*Q;4\6@
M+/?#*%78%(\P R*W6V]3KKG006"B//)0.%O%U9<;,+GDNN4(,H]M#D0<_^7F
M;CXD7RECXEX%3MN*O/X;OL-/=HW3GM^@P<%1+B+8_<T5W>VIJCGYO,G.D%:E
MAE'C[%+G$4:T22TPOWWH_)Q;UU@78Y?Z&M%547"<GI$AE66V19V!O89!5N[)
M!^6B0!7PD"[@HZ&N<O!;8S:[5FIQQ8Y!27 6N41 JQ*"=!U)496@2I'NNKU3
M6*%42#(2ZI$KC\)6]:9\!).$=HLDKD$+ABCX2QDZ38-S8+CW;GHX.TDFP\ED
M0HU!AD/IF"G@BO'1@:S+W=Z[HV3ZZ02R6*2W:DT7GK[;EJZ4J^F#[">3D]N+
M[U?Q<WKR,>;@:R0,%M>U;YU"+TK-HK!0@;&*MI9?K^>]H=$JU4:'-4A^XJKI
M-(/M'%(-E0K1I<SU2]HDAPI<JJ72)G8/;+H = P'$5=RIV?L E(;VT=']-&+
MMDHE_TMI&1@H61,D"RV0,=DU\=:Q&&:II&A^M!Q'2L&<IRI[[&I;BG=$UT7O
M?6Z!+-V'-)CUBPY9V=;D77A(HG6X*^C];'2(2\Z8[L8W*M;4AHT?+6H,Q<5R
MK>R,JCB=I'CQ)-F.N/?3T6P'"-4LSFYZ4:A VT,@H]$:G2O910T'E@[R@H)7
M3]<!X.L!Q8Y[F?MJ"Z7VSZ'O1@7Y3GL(@?'$KH#!G'[F1BC1G(]^=O&,=R[T
MBMTB/EMDE .XN]M[:?\RNN@>!,_JW;,*1"W #ADN8#H9?3H8D.N>*MTBV"8^
M#U(;,(7B9PDJV8D"]@MKPW8A!_3OQ?-_ %!+ P04    "  90Z-4+V"I_8D"
M  ![!0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6RE5,ENVS 0_96!
MT$,+&-'F+89MP$Y:M(< 1M+E4/1 2R.)"$6J)!4G?]\A):MN4_O2"S4<SGNS
M4(_+@]*/ID*T\%P+:59!96VS"$.355@S<Z4:E'12*%TS2UM=AJ;1R'(/JD68
M1-$TK!F7P7KI?3N]7JK6"BYQI\&T=<WTRQ:%.JR".#@Z[GE96><(U\N&E?B
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MA):Q G*:=D2<HQ=R44NX*F,#NXUXP72[U5X=31^PD]](QMX717C1',.T#_@
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MYX#*FEX5BB-#6<#9-8V9 4AHM!).*_^HWS@PO?,B_ 87,MA\/)JAALE W3<
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M*+?\<Z,D.)@6X'MI;>@>Z(#^;R07?P%02P,$%     @ &4.C5-+U7'MA!
MR0D  !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&ULE5;;<MLV$/V5'=73
M.C.R+I3=I+&L&=MUFK1UZXG3]J'3!XA<D4A 0 % R\[7]RQ(W9+8T[Y()';W
M[-F#78#3E?,?0L4<Z;XV-ISUJAB7+X?#D%=<JS!P2[:P+)RO5<2K+X=AZ5D5
M*:@VPVPT^GY8*VU[LVE:N_&SJ6NBT99O/(6FKI5_N&#C5F>]<6^]\%:7592%
MX6RZ5"7?<OQC>>/Q-MR@%+IF&[2SY'EQUCL?O[PX%O_D\*?F5=AY)JED[MP'
M>7E3G/5&0H@-YU$0%/[N^)*-$2#0^-AA]C8I)7#W>8W^*M6.6N8J\*4S?^DB
M5F>]%STJ>*$:$]^ZU6ONZCD1O-R9D'YIU?F.>I0W(;JZ"P:#6MOV7]UW.OR7
M@*P+R!+O-E%B^:.*:C;U;D5>O($F#ZG4% URVLJFW$8/JT9<G%U];'1\H#<V
MLN<0I\,(4#$-\P[@H@7('@&8T+6SL0IT90LN]N.'(+-AE*T9761/ EXK/Z#)
MN$_9*,N>P)ML*IPDO,DC>+_[4EG]24D3].G2V>",+E3;$[:@&]3--K8+;D&O
MM%4VU\K0+189#1@#_7T^#]&CA?YY@M'QAM%Q8G3\M.;Z"<W_%P"]JQB%U4ME
M'XC38B%&1XK0'T;-G=_6:W2.F6)2I>=4'1U&Q'_[S8LL&YW^UJ!XIO.U,2V/
M3Y^A+6-%G?6F4A@(^E77.B+5X7YL:]T$\F+!:?3HY\8R_9 V=KR7]&KC@A[F
M=62?&K24IU6E\XKB3HVE5U82[],1#[[/31,$R<LX!H((!=_A[%FFXG-7U^QE
M=_4G>.-L6:!(#WTA&/V$8PWJT66%'J##]->G=TJO%%KGM;,E_2(_@G2M<M4\
M&V!R<#;%QL-AEZ+GG$&C@"_*R)TMM.P NBH1$UY8#!H%=EM30O(2S\ _.!X-
M1IAV8\22_$(RH#T/LI,=&TCG*E2)$3+Q?F/TZ4Z91DA$.ACOQJD@6$)X7_N^
M(':R7F@7.:_:NI;*2ZOD77D(WA-_L->#"S2=6P4J&PR:."V\J^G\]I(FV?AH
M/#J:G!QEB7,3."3\A=*^94LUJ]#XMC650256)7[BW]G:F,!YXR$K7I50DX+;
M9M$!NPZ$0G2><_)NP34V(E?2//.'M&P4!LC- _L[-3=P16\%U5X97VCQ72"<
MR/F'/BZQ^7OH)O@:16LO=%L5)%&[IRNH+>E5\1XG.7+B$J4DWS;?TF,>*:^4
M+5$',CJ/GC /NT1"%TAH%QO!W\"+ L;/*(^8.^QUDNLKFP='G7;:L\@B(*T$
M,& 7=\F?IZ; ^0L%UP=POPNM%!1CMF3=(VJE65O+FZK\HK3M-FS[IR,J0S]^
M?KK1UX*>Y&RSI\P"V>&G=)^Q%^D_ZW\I. % /I:1%&W3-*@MC[W!&'SM>!_N
M7*\X/<KT$1'0<(V-[4V[6=U\IYRWU_/6O?W(@;BE!G?#"X2.!L]/>NV!L'Z)
M;IDNZ[F+N/K38X5O+?;B /O"0:[N11)LOMYF_P)02P,$%     @ &4.C5"NB
MM8_8#0  BB4  !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&ULI5K;<ALW
M$OT5E-:UD:HH2J)D.XDO5?(EB3=Q2K'B[,/6/H S((EX9C &9D0S7[^GNS$@
MAJ24W>R+1'* 1J/[].D+^7SM_*>P,J937^JJ"2^.5EW7?GMV%HJ5J768NM8T
M>+)POM8=WOKE66B]T25OJJNSV?GYD[-:V^;HY7/^[,:_?.[ZKK*-N?$J]'6M
M_>:5J=SZQ='%T?#!![M<=?3!V<OGK5Z:6]-];&\\WITE*:6M31.L:Y0WBQ='
MUQ??OKJB];S@-VO6(7NMZ"9SYS[1FW?EBZ-S4LA4INA(@L:_._/:5!4)@AJ?
MH\RC="1MS%\/TK_CN^,N<QW,:U?]TY;=ZL71UT>J- O=5]T'M_[!Q/L\)GF%
MJP+_56M9>_7T2!5]Z%P=-T.#VC;R7W^)=L@V?'U^SX99W#!CO>4@UO*-[O3+
MY]ZME:?5D$8O^*J\&\K9AIQRVWD\M=C7O;RUR\8N;*&;3NFE-P8&[\+SLPZR
M:<59$>6\$CFS>^1<JO>NZ59!O6U*4X[WGT&GI-AL4.S5[$&![[6?JLN+B9J=
MSV8/R+M,%[UD>9?WR/M@[DS3&[7PKE:OH:L'(&#L;J5>LYF-5_^ZG@?^_-\/
M''B5#KSB Z_^;\O^%3GJ)[O43;G]1+UK%$6BZE8&]ZM;W6R ^<^]]:94'U:V
M<>U* \>*MP5$(3XO8 C;+&E_9?7<5K:S)BBWQK/.#8=\_%&]@?DJU_))/]G:
M=EAP_/>_?3V;G3^35?SFXMF).B:J,+[:J-^,;W1EPZ'=)U/U:Z8I8M'X0&>2
M_E /M^;E='YE"]" R2ZK Z^+^ET/GT^365B 7&)DD*I2;J$L#.@I7OG$PO@.
M]*5:W;%I28"\5KIM<;@F L$.4VFR%NTA6EI@A8>W> ,_9(O6K>N;,JAC.GAD
M(G4C)R13L:J-,E^*J@]@IPEQ6%6" O#2NXVNNLWIW&A/IPY6@'!@=5 Z2O[4
MN/7I"@B%;J58>P*>:/H%X-Q[T1&ZP3&%A4_^,*KUKNR+[J"B/\E9T#@N2BI'
MX7@$C:'5^&:3/7WH#<EO5YL 2U8*L59\(B<,-T@6$T0<@.2&UW@; $T-%JP,
MA,#NK=XP&O(+O$]/;^1ITAPYP,WI1'8A=BRL#^QB[^XTXT*0N.SA2N>!EKY;
M.4_G ]*\);<@HX)WJ7NL-E'(>8K,5!E5VJ7MHE,IQBB7E*04J]*SDX*&\JHU
MGK-M4Q@6#\S>YQ9!D&J=9V7,YQX7 03(2N5IM\;]-R2O(#/%"\+  0#SHK\W
MA0'R2B%&>A[Z^6G$&I09;C[V,Y]+CW;</577'2_OD+GI0(YF8J%@^;CN/@^O
M$=*-ZT@?!\+[PU 0P\.^.R1&%P4@P\&(5; K;;>H*SKCX9PQMZPM+ @)X!@'
M(],)GJ5KO Z(KF+%]RDSEC)?6@XV.G@/4@H7WSIRO3)\+^#%<U3-];PR4R+D
M]RR;,IA:&W &M,.];$,>:M0U9)4L+Q'8",KI>8(PIZMH\C5=:+XYR(-L#DW;
MA0*+"A2RV*20T_7<+GO7@_Z,KV&YYAXZO>E]Z"GS1!Y-*GTK2CYY-J97VLDG
M(C2S!')L3]2CV?2<8K<B_]%%<.@"R%-S(A(3@BKU)@S.+N')X?763B*+A%T\
MSJ3U[1!&'-';(.6 (C$CNHY&&Y2&,_4(]&#AE25,U(0Q90F&&_(IV:G0884M
M$Z6[7,I74-^&PAN"YV0XP@:RGH3Q<!QBE/!.2N$5B(<NAG\]SH772D,NL92[
M1@QQYRID[-,UEYD4''>(X"7AS1;)4EME8#-/-0-2;^L0-"BXU2WR/R5W$?BS
M#J7^K+ZO@->*D/H)+8"#5(E?8/KXXOQ$H1XJ*<S8.;9!HN*WG".])7)P,!ZL
MM:5EJK2Z9R. [ $TK(C6$&4H3TBC&"E75.]=S9#C*D*$F(+S*L*TLE .EC66
M@IFY84,N(3+P)=N9 X2R.^-ZJX,@)$J+M'U(KPDSX&T&!G7,3EFP1V*<)$">
MQ'NLX U^PD6%U <X+48ZD '.Z0Z4,7D\#T0[<'G4$$R_]+I6[V[^1)-NI27N
M,RB79"[V3GZEL6OVV:U&[,XIN]KR <23C(NGS_9P3YB/15*\61#<1953V.T'
MP#.&U:"<T=";G9R.2N9-P#B,+H0LDDS)N8(J%?(^FT$PLRT#-"@#):KZO2^7
M=<R1)/$M4K;%M7_ @="X1Q8J#;,HUP[1$B['(5]P2$!J[EG]6&NZ>045I8J4
M\NTPW>99*Z8XLT7&B$&'VD=3KC)%+VD1WD>#"R4G"OD5#%%)A5#"6I9Z&^J!
M4W*S*1^7@A8J#5QE2XZXT.&?-!NX!DH^'V\0B^]! QM2\<MH+X;FJG8E-RZT
M:ZI^%B;<@C^_[#@U0D15Z;F+)<KA%B#/E%%VLN0X8<:G-]+^['8OHZ=IHUDL
M# \,U#]ZA,8WW(=>C Y]FY:@\S9II_A7,DB.=T0Q>W.L#:U(Y7_6D\1:Y$#9
M/DIE\.#W0!IQS6LD5*V.^=]$_:KM6B,@?W  [(\N,O9[7>C^A$L31&SOL2!7
M,=6"R!M]DR((($J!-RX>]1(67TI3].CJ/(,GKPO\ .!Y-,O3]< I0_<C"=$R
M! (HF+F@)&2/T[Q.U<'8]!.2&,WZRKK.%*M)1*@GI!1;QAD9?QQO@+%!E%K*
M\[AHM,50F>\U':Q+W]+21Q=/O\G4A&>62T8S\PYHP,*9 [NDK@=12OW0)&LX
M)CONWIX:N#98([8Y^BR++UT/94]W&PLN;&/-3Q4"#FV0VJ6WB 9,O=\N@%#
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MHH.$ [B[PO&Z_+T/0[KB<-N>)T5JL=+H^AASY%*R<J9(B!L5Z 6='8T*\#Z
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M    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;(U576^;,!3]*Q;J0RMM)9A
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M80 9+MBJ,+=R_1GKA/H6+Y6%=K^PKM=& :0K;619!Y."D@O_94^U$3L!R:&
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M^208!2R#E=@6^*3WOZ#VI^_X4EU8_V7[^FPO8.G6HBYK,"DHI:K^XKV.PPF
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M80&O("*- >POA="[B3F@?5=-_P)02P,$%     @ &4.C5)P>*T8; P  ,!$
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MU)L%Z,VH-PO0FU%O%J WH]XL0&]&O5F WHQZLP"]&?5F 7H;U-L(T-N@WD:
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MLR]02P$"% ,4    "  90Z-4!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( !E#HU1N7[^4[@   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( !E#HU297)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ &4.C5&@= +QD!0  ?A8  !@
M         ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( !E#HU0U2WJ-& 8  /48   8              " @:<-  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  90Z-4V@X?C7<"   -!@
M&               @('U$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ &4.C5$[,W'PR!   V0X  !@              ("!HA8  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( !E#HU2[HB,+B@4
M -H6   8              " @0H;  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    "  90Z-46I[3_A0&   ^&   &               @('*
M(   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ &4.C5.#A
MIBQ7!P  W!   !@              ("!%"<  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( !E#HU2[7&#GC08  ,X1   8
M  " @:$N  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  9
M0Z-45/7A#8T"  !R!0  &               @(%D-0  >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ &4.C5( T*\*Z!   .PH  !D
M         ("!)S@  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    "  90Z-4+V"I_8D"  ![!0  &0              @($8/0  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( !E#HU2S!+4W"0H  "\9
M   9              " @=@_  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ &4.C5-+U7'MA!   R0D  !D              ("!&$H
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  90Z-4*Z*U
MC]@-  "*)0  &0              @(&P3@  >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( !E#HU0ANY<&<P,  !D(   9
M  " @;]<  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
M&4.C5'B2D7]C P  K@<  !D              ("!:6   'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    "  90Z-4*]*= \@%  "2$   &0
M            @($#9   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( !E#HU1X!+QTG0(  '4%   9              " @0)J  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ &4.C5!LC.T1J @
M4 4  !D              ("!UFP  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    "  90Z-44H;^3YL"  !_!0  &0              @(%W
M;P  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( !E#HU3'
M(ZN$OP,  #@)   9              " @4ER  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ &4.C5+1I9#2S @  !08  !D
M     ("!/W8  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !E#HU0H;OP9A@(  '8&   9              "
M@2.%  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ &4.C
M5)F&[?$* P  *0H  !D              ("!X(<  'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    "  90Z-4J_8%Y&$"  "E!0  &0
M        @($ABP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( !E#HU1A#-IETP,  '8-   9              " @;F-  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ &4.C5*$?4G/6 @  7@@
M !D              ("!PY$  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    "  90Z-43\OV3<X"   _"   &0              @('0E
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( !E#HU1*\\V(
MQ (  ,0'   9              " @=67  !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ &4.C5/-\M.<4 P  8PD  !D
M ("!T)H  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  9
M0Z-4G!XK1AL#   P$0  #0              @ $;G@  >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( !E#HU27BKL<P    !,"   +              "  6&A
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( !E#HU2'_N[?/P,   @7   /
M          "  4JB  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  90Z-4
MC-]?K6X!  #=%   &@              @ &VI0  >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    "  90Z-4!E="=X\!  !P%0  $P
M        @ %<IP  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     *@ J %T+
(   <J0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>55</ContextCount>
  <ElementCount>169</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>17</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and description of business operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations</Role>
      <ShortName>Organization and description of business operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Basis of presentation and summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies</Role>
      <ShortName>Basis of presentation and summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Prepaid expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Prepaidexpenses</Role>
      <ShortName>Prepaid expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109104 - Disclosure - Tax and tax incentive receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Taxandtaxincentivereceivable</Role>
      <ShortName>Tax and tax incentive receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112105 - Disclosure - Accrued expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Accruedexpenses</Role>
      <ShortName>Accrued expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2115106 - Disclosure - Term loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Termloan</Role>
      <ShortName>Term loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2117107 - Disclosure - Equity Interest</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/EquityInterest</Role>
      <ShortName>Equity Interest</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2119108 - Disclosure - Significant agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Significantagreements</Role>
      <ShortName>Significant agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2121109 - Disclosure - Share based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Sharebasedcompensation</Role>
      <ShortName>Share based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2126110 - Disclosure - Net loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Netlosspershare</Role>
      <ShortName>Net loss per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Basis of presentation and summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies</Role>
      <ShortName>Basis of presentation and summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Prepaid expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/PrepaidexpensesTables</Role>
      <ShortName>Prepaid expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Prepaidexpenses</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Tax and tax incentive receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/TaxandtaxincentivereceivableTables</Role>
      <ShortName>Tax and tax incentive receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Taxandtaxincentivereceivable</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Accrued expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/AccruedexpensesTables</Role>
      <ShortName>Accrued expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Accruedexpenses</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - Share based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationTables</Role>
      <ShortName>Share based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Sharebasedcompensation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - Net loss per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/NetlosspershareTables</Role>
      <ShortName>Net loss per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Netlosspershare</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails</Role>
      <ShortName>Organization, Consolidation and Presentation of Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Basis of presentation and summary of significant accounting policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesDetails</Role>
      <ShortName>Basis of presentation and summary of significant accounting policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Prepaid expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/PrepaidexpensesDetails</Role>
      <ShortName>Prepaid expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/PrepaidexpensesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Tax and tax incentive receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/TaxandtaxincentivereceivableDetails</Role>
      <ShortName>Tax and tax incentive receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/TaxandtaxincentivereceivableTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2414405 - Disclosure - Accrued expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/AccruedexpensesDetails</Role>
      <ShortName>Accrued expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/AccruedexpensesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Term loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/TermloanDetails</Role>
      <ShortName>Term loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Termloan</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - Equity Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/EquityInterestDetails</Role>
      <ShortName>Equity Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/EquityInterest</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2420408 - Disclosure - Significant agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SignificantagreementsDetails</Role>
      <ShortName>Significant agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Significantagreements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2423409 - Disclosure - Share based compensation - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share based compensation - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2424410 - Disclosure - Share based compensation - Share Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails</Role>
      <ShortName>Share based compensation - Share Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2425411 - Disclosure - Share based compensation - RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails</Role>
      <ShortName>Share based compensation - RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="vrna-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2428412 - Disclosure - Net loss per share - Computation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/NetlosspershareComputationDetails</Role>
      <ShortName>Net loss per share - Computation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="vrna-20220331.htm">vrna-20220331.htm</File>
    <File>exhibit311q122.htm</File>
    <File>exhibit312q122.htm</File>
    <File>exhibit321q122.htm</File>
    <File>exhibit322q122.htm</File>
    <File>svb-second_amendmentxtox.htm</File>
    <File>vrna-20220331.xsd</File>
    <File>vrna-20220331_cal.xml</File>
    <File>vrna-20220331_def.xml</File>
    <File>vrna-20220331_lab.xml</File>
    <File>vrna-20220331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="263">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>56
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vrna-20220331.htm": {
   "axisCustom": 1,
   "axisStandard": 7,
   "contextCount": 55,
   "dts": {
    "calculationLink": {
     "local": [
      "vrna-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vrna-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "vrna-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vrna-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vrna-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "vrna-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 252,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 5
   },
   "keyCustom": 22,
   "keyStandard": 147,
   "memberCustom": 7,
   "memberStandard": 10,
   "nsprefix": "vrna",
   "nsuri": "http://veronapharma.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://veronapharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109104 - Disclosure - Tax and tax incentive receivable",
     "role": "http://veronapharma.com/role/Taxandtaxincentivereceivable",
     "shortName": "Tax and tax incentive receivable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112105 - Disclosure - Accrued expenses",
     "role": "http://veronapharma.com/role/Accruedexpenses",
     "shortName": "Accrued expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115106 - Disclosure - Term loan",
     "role": "http://veronapharma.com/role/Termloan",
     "shortName": "Term loan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117107 - Disclosure - Equity Interest",
     "role": "http://veronapharma.com/role/EquityInterest",
     "shortName": "Equity Interest",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119108 - Disclosure - Significant agreements",
     "role": "http://veronapharma.com/role/Significantagreements",
     "shortName": "Significant agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121109 - Disclosure - Share based compensation",
     "role": "http://veronapharma.com/role/Sharebasedcompensation",
     "shortName": "Share based compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126110 - Disclosure - Net loss per share",
     "role": "http://veronapharma.com/role/Netlosspershare",
     "shortName": "Net loss per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Basis of presentation and summary of significant accounting policies (Policies)",
     "role": "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies",
     "shortName": "Basis of presentation and summary of significant accounting policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Prepaid expenses (Tables)",
     "role": "http://veronapharma.com/role/PrepaidexpensesTables",
     "shortName": "Prepaid expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vrna:ScheduleOfNontradeReceivablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Tax and tax incentive receivable (Tables)",
     "role": "http://veronapharma.com/role/TaxandtaxincentivereceivableTables",
     "shortName": "Tax and tax incentive receivable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vrna:ScheduleOfNontradeReceivablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i568425c4e3c7431599d8b1aa195d0e85_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://veronapharma.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i568425c4e3c7431599d8b1aa195d0e85_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Accrued expenses (Tables)",
     "role": "http://veronapharma.com/role/AccruedexpensesTables",
     "shortName": "Accrued expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - Share based compensation (Tables)",
     "role": "http://veronapharma.com/role/SharebasedcompensationTables",
     "shortName": "Share based compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - Net loss per share (Tables)",
     "role": "http://veronapharma.com/role/NetlosspershareTables",
     "shortName": "Net loss per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "vrna:NumberOfWhollyOwnedSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Details)",
     "role": "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
     "shortName": "Organization, Consolidation and Presentation of Financial Statements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "vrna:NumberOfWhollyOwnedSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Basis of presentation and summary of significant accounting policies (Details)",
     "role": "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesDetails",
     "shortName": "Basis of presentation and summary of significant accounting policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i568425c4e3c7431599d8b1aa195d0e85_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:PrepaidResearchAndDevelopmentFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Prepaid expenses (Details)",
     "role": "http://veronapharma.com/role/PrepaidexpensesDetails",
     "shortName": "Prepaid expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i568425c4e3c7431599d8b1aa195d0e85_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:PrepaidResearchAndDevelopmentFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vrna:ScheduleOfNontradeReceivablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i568425c4e3c7431599d8b1aa195d0e85_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:ResearchAndDevelopmentTaxCreditReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - Tax and tax incentive receivable (Details)",
     "role": "http://veronapharma.com/role/TaxandtaxincentivereceivableDetails",
     "shortName": "Tax and tax incentive receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vrna:ScheduleOfNontradeReceivablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i568425c4e3c7431599d8b1aa195d0e85_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:ResearchAndDevelopmentTaxCreditReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i568425c4e3c7431599d8b1aa195d0e85_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:AccruedResearchAndDevelopmentFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414405 - Disclosure - Accrued expenses (Details)",
     "role": "http://veronapharma.com/role/AccruedexpensesDetails",
     "shortName": "Accrued expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i568425c4e3c7431599d8b1aa195d0e85_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:AccruedResearchAndDevelopmentFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i568425c4e3c7431599d8b1aa195d0e85_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - Term loan (Details)",
     "role": "http://veronapharma.com/role/TermloanDetails",
     "shortName": "Term loan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "ib5e3071b65394dcb9eeb62c562c7fadf_I20201130",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i47479f2645fe48afa643ac8df2b7b1c4_I20210609",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418407 - Disclosure - Equity Interest (Details)",
     "role": "http://veronapharma.com/role/EquityInterestDetails",
     "shortName": "Equity Interest (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i568425c4e3c7431599d8b1aa195d0e85_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "gbpPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i568425c4e3c7431599d8b1aa195d0e85_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "gbpPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i85587e1e0a8f439d8aebd8e3ae70349a_D20220301-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:SublicensePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420408 - Disclosure - Significant agreements (Details)",
     "role": "http://veronapharma.com/role/SignificantagreementsDetails",
     "shortName": "Significant agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i85587e1e0a8f439d8aebd8e3ae70349a_D20220301-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:SublicensePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423409 - Disclosure - Share based compensation - Share-Based Compensation Expense (Details)",
     "role": "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails",
     "shortName": "Share based compensation - Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i43f3fd81e5634600b3df44427e14839e_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424410 - Disclosure - Share based compensation - Share Option Activity (Details)",
     "role": "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails",
     "shortName": "Share based compensation - Share Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i43f3fd81e5634600b3df44427e14839e_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i82b2bb68605b4efca32316b1da619988_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425411 - Disclosure - Share based compensation - RSU Activity (Details)",
     "role": "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails",
     "shortName": "Share based compensation - RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "ica753976be2b4f4bae0fa0b52b8c63a0_D20220101-20220331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428412 - Disclosure - Net loss per share - Computation (Details)",
     "role": "http://veronapharma.com/role/NetlosspershareComputationDetails",
     "shortName": "Net loss per share - Computation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "ief871dca18cb4d72a122e673f25d7055_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Shareholders\u2019 Equity",
     "role": "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity",
     "shortName": "Consolidated Statements of Shareholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "ief871dca18cb4d72a122e673f25d7055_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vrna:OrganizationAndBusinessDescriptionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and description of business operations",
     "role": "http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations",
     "shortName": "Organization and description of business operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vrna:OrganizationAndBusinessDescriptionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Basis of presentation and summary of significant accounting policies",
     "role": "http://veronapharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies",
     "shortName": "Basis of presentation and summary of significant accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vrna:PrepaidExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Prepaid expenses",
     "role": "http://veronapharma.com/role/Prepaidexpenses",
     "shortName": "Prepaid expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20220331.htm",
      "contextRef": "i5d40c630d05a4e8f8b382ced82422130_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vrna:PrepaidExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 17,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region",
        "terseLabel": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r51",
      "r53",
      "r92",
      "r93",
      "r186",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/EquityInterestDetails",
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r52",
      "r53",
      "r92",
      "r93",
      "r186",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/EquityInterestDetails",
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/Accruedexpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r38",
      "r318"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r29",
      "r154",
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/EquityInterestDetails",
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://veronapharma.com/role/AccruedexpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesDetails",
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r32",
      "r55",
      "r56",
      "r57",
      "r337",
      "r350",
      "r351"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r54",
      "r57",
      "r60",
      "r61",
      "r62",
      "r96",
      "r97",
      "r98",
      "r290",
      "r346",
      "r347",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r30",
      "r272",
      "r318"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r269",
      "r270",
      "r271",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Common shares withheld for taxes on vested stock awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r252",
      "r254",
      "r274",
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r254",
      "r267",
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r72",
      "r81",
      "r205",
      "r309"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Accretion of redemption premium on debt"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r68",
      "r81",
      "r205",
      "r311"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issue costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r90",
      "r139",
      "r147",
      "r151",
      "r158",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r287",
      "r291",
      "r296",
      "r316",
      "r318",
      "r323",
      "r336"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r50",
      "r90",
      "r158",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r287",
      "r291",
      "r296",
      "r316",
      "r318"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r90",
      "r158",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r287",
      "r291",
      "r296",
      "r316"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r255",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of presentation and summary of significant accounting policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedContractCostLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Capitalized Contract Cost [Line Items]",
        "terseLabel": "Capitalized Contract Cost [Line Items]"
       }
      }
     },
     "localname": "CapitalizedContractCostLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostTable": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cost capitalized in obtaining or fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Table]",
        "terseLabel": "Capitalized Contract Cost [Table]"
       }
      }
     },
     "localname": "CapitalizedContractCostTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r36",
      "r83"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r77",
      "r83",
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of the period",
        "periodStartLabel": "Cash and cash equivalents at beginning of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r77",
      "r301"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r88",
      "r90",
      "r111",
      "r112",
      "r113",
      "r115",
      "r117",
      "r125",
      "r126",
      "r127",
      "r158",
      "r171",
      "r175",
      "r176",
      "r177",
      "r180",
      "r181",
      "r220",
      "r221",
      "r224",
      "r225",
      "r296",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r283",
      "r284",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Equity interest"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/EquityInterest"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/EquityInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r45",
      "r169",
      "r327",
      "r341"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r96",
      "r97",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in pounds sterling per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r28",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r28",
      "r318"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Ordinary \u00a30.05 par value shares; 494,058,246 and 489,177,550 issued, and 482,944,390 and 480,082,966 outstanding, at March 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r86",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation and consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetNoncurrent": {
     "auth_ref": [
      "r237",
      "r239",
      "r249"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Equity interest"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r237",
      "r238",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r87",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r199",
      "r206",
      "r207",
      "r209",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Term loan"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/Termloan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r89",
      "r94",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r211",
      "r212",
      "r213",
      "r214",
      "r312",
      "r324",
      "r325",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r24",
      "r210",
      "r325",
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal outstanding"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r182",
      "r211",
      "r212",
      "r310",
      "r312",
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r44",
      "r89",
      "r94",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r211",
      "r212",
      "r213",
      "r214",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r44",
      "r89",
      "r94",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r208",
      "r211",
      "r212",
      "r213",
      "r214",
      "r228",
      "r231",
      "r232",
      "r233",
      "r309",
      "r310",
      "r312",
      "r313",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Summary of Prepaid Expenses"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/PrepaidexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r81",
      "r137"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share based compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/Sharebasedcompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r66",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r109",
      "r111",
      "r115",
      "r116",
      "r117",
      "r121",
      "r122",
      "r294",
      "r295",
      "r330",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Profit/(loss) per share, basic (in dollars per share)",
        "verboseLabel": "Net loss per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r66",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r111",
      "r115",
      "r116",
      "r117",
      "r121",
      "r122",
      "r294",
      "r295",
      "r330",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Profit/(loss) per share, diluted (in dollars per share)",
        "verboseLabel": "Net loss per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/Netlosspershare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://veronapharma.com/role/AccruedexpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "People related costs"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r60",
      "r61",
      "r62",
      "r96",
      "r97",
      "r98",
      "r100",
      "r106",
      "r108",
      "r124",
      "r159",
      "r227",
      "r234",
      "r269",
      "r270",
      "r271",
      "r279",
      "r280",
      "r293",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r346",
      "r347",
      "r348",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r81",
      "r216"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Fair value movement on warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r300"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedTerseLabel": "Foreign exchange loss/(gain)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r164",
      "r165",
      "r318",
      "r322"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r64",
      "r139",
      "r146",
      "r149",
      "r150",
      "r152",
      "r321",
      "r328",
      "r332",
      "r344"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r167",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails",
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails",
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r91",
      "r107",
      "r108",
      "r138",
      "r278",
      "r281",
      "r282",
      "r345"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedTaxesPayable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.",
        "label": "Increase (Decrease) in Accrued Taxes Payable",
        "terseLabel": "Taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedTerseLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedTerseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r63",
      "r136",
      "r308",
      "r311",
      "r331"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r76",
      "r78",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r70",
      "r72"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r41",
      "r90",
      "r148",
      "r158",
      "r171",
      "r172",
      "r173",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r288",
      "r291",
      "r292",
      "r296",
      "r316",
      "r317"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r35",
      "r90",
      "r158",
      "r296",
      "r318",
      "r326",
      "r339"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r43",
      "r90",
      "r158",
      "r171",
      "r172",
      "r173",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r288",
      "r291",
      "r292",
      "r296",
      "r316",
      "r317",
      "r318"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r24",
      "r25",
      "r90",
      "r158",
      "r171",
      "r172",
      "r173",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r288",
      "r291",
      "r292",
      "r296",
      "r316",
      "r317"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "Tax and tax incentive receivable"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/Taxandtaxincentivereceivable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Term loan",
        "verboseLabel": "Carrying value of term loan"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r44",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "terseLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r77",
      "r79",
      "r82"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r58",
      "r59",
      "r62",
      "r65",
      "r82",
      "r90",
      "r99",
      "r101",
      "r102",
      "r103",
      "r104",
      "r107",
      "r108",
      "r114",
      "r139",
      "r146",
      "r149",
      "r150",
      "r152",
      "r158",
      "r171",
      "r172",
      "r173",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r295",
      "r296",
      "r329",
      "r342"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently adopted accounting standards and recent accounting standards not yet adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r139",
      "r146",
      "r149",
      "r150",
      "r152"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r49",
      "r318"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other income/(expense)"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r42",
      "r318"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r7",
      "r162"
     ],
     "calculation": {
      "http://veronapharma.com/role/PrepaidexpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/PrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Payments of withholding taxes from share-based awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r7",
      "r161",
      "r162"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://veronapharma.com/role/PrepaidexpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses",
        "totalLabel": "Total prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets",
      "http://veronapharma.com/role/PrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r5",
      "r7",
      "r160",
      "r162"
     ],
     "calculation": {
      "http://veronapharma.com/role/PrepaidexpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/PrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from at-the-market sales agreement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "verboseLabel": "Funded advances"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r166",
      "r318",
      "r333",
      "r340"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Furniture and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r277",
      "r319",
      "r352"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r31",
      "r234",
      "r272",
      "r318",
      "r338",
      "r349",
      "r351"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets",
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r96",
      "r97",
      "r98",
      "r100",
      "r106",
      "r108",
      "r159",
      "r269",
      "r270",
      "r271",
      "r279",
      "r280",
      "r293",
      "r346",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Significant agreements"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/Significantagreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/EquityInterestDetails",
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in sale"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/EquityInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of Basic and Diluted Earning Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/NetlosspershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r254",
      "r266",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r254",
      "r266",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Allocation of Share Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r255",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r257",
      "r263",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Share Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r46",
      "r88",
      "r125",
      "r126",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, ending balance",
        "periodStartLabel": "Outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Outstanding, Weighted average remaining contractual term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "verboseLabel": "RSU Activity"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r259",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance outstanding",
        "periodStartLabel": "Beginning balance outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of share options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, Ending Balance, Weighted average exercise price (in dollars per share)",
        "periodStartLabel": "Outstanding, Beginning Balance, Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r253",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted, Weight average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r88",
      "r90",
      "r111",
      "r112",
      "r113",
      "r115",
      "r117",
      "r125",
      "r126",
      "r127",
      "r158",
      "r171",
      "r175",
      "r176",
      "r177",
      "r180",
      "r181",
      "r220",
      "r221",
      "r224",
      "r225",
      "r227",
      "r296",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r48",
      "r60",
      "r61",
      "r62",
      "r96",
      "r97",
      "r98",
      "r100",
      "r106",
      "r108",
      "r124",
      "r159",
      "r227",
      "r234",
      "r269",
      "r270",
      "r271",
      "r279",
      "r280",
      "r293",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r346",
      "r347",
      "r348",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r124",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r27",
      "r28",
      "r227",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common shares under at-the-market sales agreement (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r27",
      "r28",
      "r227",
      "r234"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common shares under at-the-market sales agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r227",
      "r234"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted share units vested"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r28",
      "r33",
      "r34",
      "r90",
      "r156",
      "r158",
      "r296",
      "r318"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r47",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Ordinary shares held in treasury"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r28",
      "r227",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Issuance of ordinary shares to treasury (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r47",
      "r235",
      "r236"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Ordinary shares held in treasury"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r227",
      "r234",
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "terseLabel": "Issuance of ordinary shares to treasury"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r110",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r109",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/AccruedexpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Professional Fees, Listing, And General Corporate Costs, Current",
        "label": "Accrued Professional Fees, Listing, And General Corporate Costs, Current",
        "terseLabel": "Professional fees and general corporate costs"
       }
      }
     },
     "localname": "AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_AccruedResearchAndDevelopmentFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/AccruedexpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research And Development Fees, Current",
        "label": "Accrued Research And Development Fees, Current",
        "terseLabel": "Clinical trial and other development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentFeesCurrent",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Reclassification from Share-based Compensation",
        "label": "Adjustments to Additional Paid in Capital, Reclassification from Share-based Compensation",
        "negatedTerseLabel": "Equity settled share-based compensation reclassified as cash-settled"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_AmericanDepositorySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American Depository Shares",
        "label": "American Depository Shares [Member]",
        "terseLabel": "American Depository Shares"
       }
      }
     },
     "localname": "AmericanDepositorySharesMember",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_BenchmarkAchievementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Benchmark Achievement",
        "label": "Benchmark Achievement [Axis]",
        "terseLabel": "Benchmark Achievement [Axis]"
       }
      }
     },
     "localname": "BenchmarkAchievementAxis",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vrna_BenchmarkAchievementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Benchmark Achievement [Domain]",
        "label": "Benchmark Achievement [Domain]",
        "terseLabel": "Benchmark Achievement [Domain]"
       }
      }
     },
     "localname": "BenchmarkAchievementDomain",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_CommonStockSharesAvailableForSaleValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Shares Available For Sale, Value",
        "label": "Common Stock, Shares Available For Sale, Value",
        "terseLabel": "Shares available for sale"
       }
      }
     },
     "localname": "CommonStockSharesAvailableForSaleValue",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_ContractWithCustomerFutureEligibleMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Future Eligible Milestone Payments",
        "label": "Contract With Customer, Future Eligible Milestone Payments",
        "terseLabel": "Future eligible milestone payments"
       }
      }
     },
     "localname": "ContractWithCustomerFutureEligibleMilestonePayments",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_EquityInterestReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Interest Receivable",
        "label": "Equity Interest Receivable",
        "terseLabel": "Equity interest receivable"
       }
      }
     },
     "localname": "EquityInterestReceivable",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/EquityInterestDetails",
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_FirstCommercialSaleMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Commercial Sale",
        "label": "First Commercial Sale [Member]",
        "terseLabel": "First Commercial Sale"
       }
      }
     },
     "localname": "FirstCommercialSaleMember",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases",
        "label": "Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases",
        "terseLabel": "Foreign exchange (loss)/gain"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_GainLossFromResearchAndDevelopmentTaxCredit": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) From Research And Development Tax Credit",
        "label": "Gain (Loss) From Research And Development Tax Credit",
        "terseLabel": "Research and development tax credit"
       }
      }
     },
     "localname": "GainLossFromResearchAndDevelopmentTaxCredit",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://veronapharma.com/role/TaxandtaxincentivereceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_GainLossFromResearchAndDevelopmentTaxCreditExcludingAnnualCap": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) From Research And Development Tax Credit, Excluding Annual Cap",
        "label": "Gain (Loss) From Research And Development Tax Credit, Excluding Annual Cap",
        "terseLabel": "Research and development tax credit excluding annual cap"
       }
      }
     },
     "localname": "GainLossFromResearchAndDevelopmentTaxCreditExcludingAnnualCap",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/TaxandtaxincentivereceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Liabilities",
        "label": "Increase (Decrease) In Operating Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Tax And Tax Credit Receivables, Current",
        "label": "Increase (Decrease) in Tax And Tax Credit Receivables, Current",
        "negatedTerseLabel": "Tax incentive receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_LigandUKDevelopmentLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ligand UK Development Limited",
        "label": "Ligand UK Development Limited [Member]",
        "terseLabel": "Ligand UK Development Limited"
       }
      }
     },
     "localname": "LigandUKDevelopmentLimitedMember",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_NuanceShanghaiPharmaCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nuance (Shanghai) Pharma Co Ltd",
        "label": "Nuance (Shanghai) Pharma Co Ltd [Member]",
        "terseLabel": "Nuance (Shanghai) Pharma Co Ltd"
       }
      }
     },
     "localname": "NuanceShanghaiPharmaCoLtdMember",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/EquityInterestDetails",
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_NumberOfWhollyOwnedSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Wholly Owned Subsidiaries",
        "label": "Number of Wholly Owned Subsidiaries",
        "terseLabel": "Number of wholly owned subsidiaries"
       }
      }
     },
     "localname": "NumberOfWhollyOwnedSubsidiaries",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vrna_OrganizationAndBusinessDescriptionTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Business Description",
        "label": "Organization And Business Description [Text Block]",
        "terseLabel": "Organization and description of business operations"
       }
      }
     },
     "localname": "OrganizationAndBusinessDescriptionTextBlock",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vrna_PrepaidExpenseDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expense, Disclosure",
        "label": "Prepaid Expense, Disclosure [Text Block]",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseDisclosureTextBlock",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/Prepaidexpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vrna_PrepaidResearchAndDevelopmentFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/PrepaidexpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Research And Development Fees, Current",
        "label": "Prepaid Research And Development Fees, Current",
        "terseLabel": "Clinical trial and other development costs"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopmentFeesCurrent",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/PrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_ResearchAndDevelopmentTaxCreditReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/TaxandtaxincentivereceivableDetails": {
       "order": 1.0,
       "parentTag": "vrna_TaxCreditAndIncomeTaxesReceivableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Tax Credit Receivable, Current",
        "label": "Research And Development Tax Credit Receivable, Current",
        "terseLabel": "Research and development tax credit receivable - U.K."
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditReceivableCurrent",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/TaxandtaxincentivereceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_SaleOfStockMaximumAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Aggregate Offering Price",
        "label": "Sale Of Stock, Maximum Aggregate Offering Price",
        "terseLabel": "Maximum aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockMaximumAggregateOfferingPrice",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_ScheduleOfNontradeReceivablesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Nontrade Receivables",
        "label": "Schedule Of Nontrade Receivables [Table Text Block]",
        "terseLabel": "Components of Taxes Receivable"
       }
      }
     },
     "localname": "ScheduleOfNontradeReceivablesTableTextBlock",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/TaxandtaxincentivereceivableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vrna_SublicensePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublicense Payment",
        "label": "Sublicense Payment",
        "terseLabel": "Sublicense payment"
       }
      }
     },
     "localname": "SublicensePayment",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_SublicensePaymentEquityIssuanceThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublicense Payment, Equity Issuance, Threshold Trading Days",
        "label": "Sublicense Payment, Equity Issuance, Threshold Trading Days",
        "terseLabel": "Sublicense payment, equity issuance, threshold trading days"
       }
      }
     },
     "localname": "SublicensePaymentEquityIssuanceThresholdTradingDays",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vrna_SublicensePaymentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublicense Payment, Percentage",
        "label": "Sublicense Payment, Percentage",
        "terseLabel": "Sublicense payment percentage of payments received"
       }
      }
     },
     "localname": "SublicensePaymentPercentage",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vrna_TaxCreditAndIncomeTaxesReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://veronapharma.com/role/TaxandtaxincentivereceivableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit And Income Taxes Receivable, Current",
        "label": "Tax Credit And Income Taxes Receivable, Current",
        "totalLabel": "Total tax receivable",
        "verboseLabel": "Tax and tax incentive receivable"
       }
      }
     },
     "localname": "TaxCreditAndIncomeTaxesReceivableCurrent",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets",
      "http://veronapharma.com/role/TaxandtaxincentivereceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_TermBLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term B Loan",
        "label": "Term B Loan [Member]",
        "terseLabel": "Term B Loan"
       }
      }
     },
     "localname": "TermBLoanMember",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_TermCLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term C Loan",
        "label": "Term C Loan [Member]",
        "terseLabel": "Term C Loan"
       }
      }
     },
     "localname": "TermCLoanMember",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_TermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan Facility",
        "label": "Term Loan Facility [Member]",
        "terseLabel": "Term Loan Facility"
       }
      }
     },
     "localname": "TermLoanFacilityMember",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_UnrealizedGainLossOnWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized Gain (Loss) On Warrants",
        "label": "Unrealized Gain (Loss) On Warrants",
        "terseLabel": "Fair value movement on warrants"
       }
      }
     },
     "localname": "UnrealizedGainLossOnWarrants",
     "nsuri": "http://veronapharma.com/20220331",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/subtopic&trid=2196772"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r353": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r354": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r355": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r356": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r357": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r358": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r359": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>57
<FILENAME>0001657312-22-000016-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001657312-22-000016-xbrl.zip
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MHQ/40^H*1K,9R*(5>[Y:_QUI_Z]AO_6+_L<'_P<0^A\F_P-02P,$%     @
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M/7*'A6(P <0GG/277?P$M.)C&\#ITRS\7PD?C0E?,>$"#1H$;A"@6$.@B7"
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MT-UVV=[OS8E\(L"A((D)." JK-4*4NV(0,X1*V&80KQ@[@4U_6@&A=QC)U#
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M-:T1B. A*?,N>ATNNAYI'0-"JHR5+D#&_1228^9>5:>2NG--JAQ+@@()$H5
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M22KVWL>C?5$;MJ:Y<E?OM#O7=VKE)8*'(._N&)-B FNC* &"IYQ-KQC05A'
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M2P?[B+_=E(#Y)PV;]01[$Y&Y^B,L.,83%_BPHG+R^#T61M2'?73LMZ,AS%Y
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M>X035>T$C3%_WII8W7>'F<B8$5(0%C.#D5>:J,RD)*4ZM9HIRN+DJ9I,M5B
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MHPD\SY2__G[/6W7M7&K*R?J2P3[ ][2TOS<__ &&XFE?GO^>#_V[^"_]L?C
M^'2E6K!_8/7QK+SJ5EB56*U;6]1/KC_>\A\M53BN/DO95D+3*S\.M^@=/TO"
MNWWS6X.E=(M%XA$-EK,;W?::IB2W:)YWATLOJ51?E8+],17;LQO5AYWF3-V@
MB\E3G8/YN)F%:?@IXG/C'J'K/:G(,V[2&>?:MWU64T9O(W^/K*'KY1TC7C99
M2F-OA,[2<.9]A3X#Z2?V67IF3;]O]_)/IB/)'0O_19<9X>]KMS?833LS07YM
M;?D2JQ\.UZ8]R5TMI[H]2;??N>CU/^^<P-\_\N[Q^[SSYE7<W?EXUF'O^,%Q
M+_\\^&NPM[_]=:4]"?MXL??FGQ/X[+R[?\2Z;W;/#O9/PN[^-HRMEV.KDH/!
M0=S9>>TZ>7B.K4DZ'T+:V3D).]N'-I)61AQDEH58%S#&(L4T(R$7++99%''-
M-U[P^*K\WH=1AL?1:*F%L^< 9SQRD3,9M7$2\20,560<YYREEO(L$K:J.D?9
M/<'938H1M%AW(ZP+E[".N8Q;FE"2A,81'EM%!'<IR9ACL4NY2+@#^KA)$_$H
MT.Z>&LBO-3SM#NLJ @_1+WYZ#W:[2;L4V1\UR'TO9VO<WS7.35>MA:S;0-;Y
M"CW3@LI42TNLPR-OEDF2<1F3-!-4I D%YF: GD7?W3UN_=JJM\IY7PSD:N5L
MR<:]:>XRV8A%9JB5F)Y!*>&IE$0E,2-)9E-N$^MB&VZ\H)OQ]W=^7+_VXVM-
M*?P!;/ 0;K ;0=8E,_;T(.N^^(1?J\6 C-;Q<WM\ZKY<818\C 6/C251PC+"
MA3%$V3@B+$Q<+*2ES $^1?%]F4)KY-YIU?2^F46KIO>EILLTPF6<6I=:XE()
M:NJ 4$CG0A)'3"0IB[36$M241FNDID_++[%RR.B5;'\T]AUE%@-Z'L))<=WW
MOMWP^WFZJN]S:IX,V-^SCV<9YUM;\IXV@0\K7"T.4Q<ZL" C$:6$9SHC@CDL
MLZ:=9ADS#CN)TDW&5ZN'W\V6O _-^<G^HQ8W6]Q<*Y+<XN9#X^8R>4Z%2;S/
M7$78@3E*&1$T!1B-6*:ULQFLX<8+OAE&5S4]?$RXZ6GW;SY(^W;90_5+U?J1
M8L:/[T\+%_SNBU?G7^PLDOM_%Z/OZU<-9U^1"EYL,K[Z*RO1@S\> WR@8+:4
M:C7W[RV2JN)I4E6OF,6I'EFB"BM/B.^Y\+OLG\GS<N.WQ=#]?$CF)WU]YNOR
MP,J5LIM7)B6LRXB[OO#@>(1%_^JD\(7R?Z^G"7@?I@EX:_]2OTQSW7^]3( ?
M<VH??_@:XG^/8)!>+O:Q.7:3D%4UI4'L7,.LK&Z3;WU\='[ _LH[%Z_SSB?X
M'VRS!Q?_Y ?[KWN?/^%6_/'KWIM=NK?S>K"<E;6W\]?QP6#WHO-I]^O!IUW,
MOCKN?OJK!_?I?\8,K?U7L!5_Y)U/GUUG?Y<>P@XIF<M2$DH-1D><@M%!N21@
M;X2I%<PF7"VG_%E##74IMH:TP)!BF7 =@[DIH\2RQ*YD9^_+KU75 O@O-J(>
M^IIUQ6PM[I ">.T8'BH%L&HOJGO63+#Q41=NBQ(V)UG[^.\S%BIV&$=)(M(H
M)"$W">$\842%*B,Z%D;2T$H1/9%<OVM%NTW^:Y/_VN2_IY#XUB;_M<E_;?+?
MVDS9\TO^>W^#XF SY@$VUL>M_VRU>8!MXLQ:GS=Z>^KRC!D@UR^]6,^,JT?E
M3[^C[57[T[?C+GYVO/NU\^8=W/]]OO?I+_@.%E'37[L[[T\.+CI?N_M_'J_X
MTW=.*-AEK'/\ZNSSSE\GW3>[,8RYM_?I5=B]@/^]>7_<N7A%.V^ZER4+II$3
M4EE-0LH$X2JQ)$M%3)R)0RJRB-F0;KR@R29GX:/(H&EAKX6]=3LN;&'O9\/>
M\C&BEHE-0QL1;E-*>)A%1,:,DM"$:2HH-RY, /;BS3B[KS"\GYHXV'A^X#7L
MMY%R_:Y\/K&'R.UGI+Z-/%R/3:^-H'DH2V"Z^<&>N.L;.L%?;-ENA0^V%5Z2
M-1*E42RLBDG&-"<\,YQD46Q)%"8V"K72U&3W90&L04A-"Z0MD*X3D-Z+;=$"
MZ4\ TF6;0EGN0JU3XABW6'>)$R6L(#+57&<QV!2QNR^;8@V ] :QB8_SE'^N
M+#PV'IEHW_3R"G<\+M^7JJ=*U7D$IK7J/;+<=Z3^%L8"8 ]+!]\NX.&^5>,7
M6>2C23GM\H@=4:HG]7-8A/-@8,>]D2DWZ[XI@:Q[8BP5L1]:EU?=::KFR?_9
MFK7)^'<G> ]#&$ZLO\E+F.31 .X(C_]WY_W+S: <^):>\-D H&0R"'#63.#/
M@TZ+O+3?F(8"Z^<[?[,/G5?!^_]/#D[_V*D/*C;K!A^GQ>A+;OQM\.I 'LE\
M6(ZK<;X<%:>CNCT/@-=3:.W\RC?SP1@1W^ITKC%OW>BS',NJ68Z/* VV89;[
MP;1#\1!&44PPK.0,&R+D("\CD$;LFHP=$M1YU<K&-^3!>)/YB9\[):KZ"H%(
MEC# L@PT3$1E9%K?:A8$!XQMWR2TZGZ@L-W,Z2GV6A@'B$O1'RS<A*D*3OL3
M[%-46!N,_415S:,7VR&,O2G[5IX'VV5P,)H$KV0QG/;P?KM]\*IIWNREJ.N7
M'+XQK6'A]\<B!QWR>M!\L[O[<OK%II71.39KM=,.2J.Z5\[I7)O<A6E#*<3&
M$O*+S/O^X R^4[U ;IM6JM@V6M<]?J=-91<[+\_Z1>2SWJL@<3G>TB_V,+#-
MP/QK8B-([ ME?720L]8@J%?:B>JW%>RZZ>BGW:-A&?KG"SI^YEO@^->;]M/Y
MG]O8;=_7=)#$"[SC#<S1WZ.R? VO<8U_\]77&AVKGN OY>G-R$CR.,G(W6/J
M8#Q[.SK:V]^.X)[8();&-N11EI 8TQTXC3(BHQ"(!2Q;YE2B4VLW7D1;JYEB
M :!:'R6BBOG')EV5CORWZA0/X(X"-(UVJ=JN(RACN_@ZANU1B%<K3-<)T][.
M]AFPU##,5)8 +8T,C["(34R4%(((&5D695J8%(O8;*U2U#EAJIO!U3SCBO9L
M<TW9%EIY;P4?81OLPZXVW8?&O;R<@>(\WL'?YS;.IJUUTQT-\'>&F@B6N367
M=-NY:W>=A&Y<2T >00A^_/ A^'6KLQ*V?=Q604FWL<6>-7_/F@ZN71 ^Z\S4
M$=1OEQX<]P>=XX/S[O$[^/G/O+/S+NKN'+'N,1A]%^_XWIMNOJJ.YKAS_ \8
MF?B]7=;=^2?OO-D] V,35.^ =?8!PW>..*B[V]M_=9C!/"J5*,)BGA+N&.;\
MN@A^539U+LMBFRS'X#,N,AN'-%-2<<V5M$K36"EA3,I=3)?#J^NYGZMA<.N0
M^VL?^> -XZ=1]ZN2M$Y!]S]!B'8/T]"J5,629$@+N!&,",T=B9B0@AO L.CQ
MM*?]I@VU+,IMB'T;8M^&V#^%\/(VQ+X-L6]#[-=FRIY?B'W;7V?]CHB?:8#I
MO433U%3Y:32DN*M951\"'S PI?C!/GQWT#V!L8$997J?L<X,_/?@XNCB8'_[
M[/.;=V?+A\#=XX/X\W&O!]?G!PR?\8YCT_.]_7<A_/=X;Z?;Z^S\>0+CO"R>
M/I$QV+74$AMK2G@2*R(Y-2146)259O A [Q--^,VGKZ%NV<*=_<2\]+"W4^
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MSNGJJJE7^A=DL=Z"^0=-MSYP\$N^72>+S)RZ&)G5'-K#\&!"IW&PJWYU61F
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MH+XL+W?ITNMIL'AM8'7[YF#E9:-KWO%:W[C;D]<MUC2[ECW<H<4ZUKJO!9Q
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M',9Z54X]PWE;DU=O.0"$*%^V9,D7TK:?)/UZ.?,YPVZ$'\2Z#K 7232=G2-
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M!!.5. ,*S4?11 ,B1E/;S[ _(D7_NF?=CG94H,-.N%5'4<*T0"C<2,"VH4^
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M%4:X!^ELA(>N*'=99 ;">K!>.2QB)*.LH-"U1HFJ92Y>N2M<'NIES9/L:GN
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M<L%0;25JK./*27GUH[A:GCTZ@ST\LV:*2%G=(#6N)2Z169D"7L>!L@,@TU;
MO:.A*P8!'7-0WRY XQ)HB9RMC+6)+A&$9CE#M_N$9Y24ALX-?#U0W2K$$C1
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M*Z+_-4SC*&W!MU'PP6^U]@^Y'R$7""._4_F(\$+E.92YPBI@4'? Y;-\RN5
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M@["D,@]X(IY):9*&88X:]P7#TF(5JU-'BH9;-&WV800-.\*!=\4T*O5Q+'+
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MKG=V+'$[XOHN1_; (ZYW:ONW'V3]4#E6@#@;2K B31,U*5+!^+]%=,EB\BF
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M48_I1K>9;7U7UGD+BV;UZ83AHYV.V$C ?=FQ[ T%'/ N6 Y;:G9R005O-[Y
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MY(KQ\)+X. F )(F^)SB@/B4>^$% %-)+'0K-$O,)D9]Q2$2,75+!$F?O$%(
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MZ*UGA]?P"%A[99_>TD,UP&K.'*\ARCQQ[ ]^3+)HY<0!,VJ,J4=F,:Q1JV>
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M[*I ?N(QWT_87@!5H&Q(V7/N_3<14I]"/[!SS]-["SBXA=%?1T,<4XD#\/
M Z[JW%HUJ^5+^>'09@]Y93%-726J['[CZPV/3WA&PR0\GTPXF8#/W_@^4?GK
M%J9G0TE9F4%3HZ9L@KC4LU&=*26G:,(4.=2+&%=^I7(Z!#>&!2N_2B3$\\>
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M/%.E%<.N6%))I&*2."H8\3)"]*"MT&TV?MX8XI!JSP?AO;8U7T-VK8KHKR[
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MTW-VKX.KJ@.P"ME^7(!M-7<K$;84>_5LTB5\TGME:=G QCF<ZVBIMGGAB1#
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M;,V/FT<^+_Q(HXRB1A((.'') +/6&442)"-X DV5VV4>9;<EWJJ<&$KL#[8
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M1I722,K.V4U;<\,9P2X/]RBGAU+J3[\ #[^=#M !!G/;NI2A$,GWW@_D#P_
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M2IO!F!04$P5RP3F LB@ 8P0#*G,A,L41I72V>Y9U>9-_)-4'.".!B:O1S_&
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M6>34G-8=#2/1J.CFIUJ@G&5%S'.E)^\TEP RS@#-]4\LA5 4DD):\ %!FY[
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MM<FT43&J=8PZ)>WFTG,(]G.)!UQ"GP@Z06)-#Q<,/T$$E>1_OE]^_4G?67/
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M+BRA[?_(_0,6^)/OL&J5O8FVZD:_V6P;#\'0(7[:*Y8C14OW8.HI%-H:E=[
MY\M/&2_,V=JBO:!F^[L&T.PMYZMG*3[)2NH;'VX7XK5>5\R73W6%5;F3#B A
M*CC&H)!0<RPK$, F!8^J3'$<YS%55CEW3E*G1KIW^KDEI_-HO2KUGW0AHF5=
MFTILU7?)]G4; @M6#@%L8')N58XZG>MDBQVM(Z/VD*07^U?;GJE#X#L287O"
MV8W#7?'JI7+KAXW'Z*[V[1&[\\U#U\&W0N@WJ6KW4&<BBZ7,& *4LQ1 D7/
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MV:ND3.AU[RR):E-N]AV#UIR;VF5HVE<V)H7/R/6"K^?4W>MT&CG'UPN Q\G
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M--J" X88!7$F(:4I$9"IV5>Y8LO1\-Z5%M SE>O(H#TFV);3V[4 !IZDSN9
M>9QO^B#P.VN<E#0N]_<9>\3@O1<//5QL:I1]I*5I3#EC&<O25.JU?9)K3A 9
M 33A".020IE*4E#IU+_IX/E3X]Y.O<B$6KB>#NXC9WL0.!B/X&=^+10?Z_"D
M;=>,'5=S4V/Q9F=-?\O7Y=>Z&+7/L\"3,'D^]MN7,?()WTD#CP_S3E\VH-[.
MA1X:VMN3Y5<3K=Z>%,Z(9$K[!#%@."ZT>P!3@#G3JW)%*"\80BGGUD5W7*5/
MC2ALFC:M-D9$(/KES__KSPZ589Q'IY]N@F,>F(PL&OM$6_UONIB$D( [U.,)
M"?Q(17E\#X!;F9ZA /;6ZG%^Z'@%>X;:NU>U9_!#W"-'7[<OX1=]ZTS/$4E*
M* 60"K.,E&;1'B/]5PQS3N(<*F8;-;K[X*E- 9UND5'./DYT#ZM^UKX&@<"$
M;&>\4U3H*4L'1X3N/6RT:-!3)NQ&@I[\]V$+M4_ZDUX\RZXXM0G]_K5</]P]
M5^OEHUQMTS?SA'%"$P0RH;3;QD0!*.<4Y"Q1N92:$Z53MJZMX*E]KI_+^T6I
M2DY-]&<7:^5X3&L-NMWB+P24P1VQ6N5M;7ZC=/2[UCKJU+8KANB\!'0%R^O:
MT%KXJ(M&5T@.5Y/.]P^EJE..2'M\-8.2QS1/*1"2:GX2# (J<P)R6# I:5Q@
MA=SXJ4?:U$CIW#+2E9;Z +;E(D^PC;42I <+D4M5$P80C@4BGEFF3^+(U&)A
M_#&?V-PT<M6K-_]X+M??MVW0JSK\_<L#7;2E5WY>+K[*:BU%$Q0SXS+G.)<Y
M0 67 .8P RQ'*> J0;G$2<HR/'NJCT _K^EJ;4=+H^GO\JT>6A'NL_WPO*[6
M^I,M%_<W$9/WY:(N4\CHW(0#CU1$R_E58+A0LD "$%ID ,H, BQ5#B@E.9<L
MXS%#[:OP9B'^\"]"9\-(KX&L_SOU=\!N^ISDJ :>BCT476NLCW;,;Y/*UAJ
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M]V@OL<ES!<1!J'DE2#<-1J7$0> <DN"PA_BI=/NZG#]KT3/,55% :)JU<1.
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M+VU4CKAH]"%!7+[!5\'Q6_Z/YW)E2D%4Z[_)]<-2S+0+EU)%$R#31'L;C$C
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M ?0<-VD@'-!'Z08!10WL3CRTG?MQT_9/R_G\[7)E_G$F)8)2\ (H%A, &<L
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MG99!MG$N@Q%B7CXE[B6FWAZSS\RN?7=X39=L(H6WF7D)(B0W[78QY0I EBE
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M!0:(D *D*,L(YVDB&75C@M.")DH%W5GQ1MNH4=>5"\Z@:TL&UV,V#ALXPS6
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M'_S9AX_RD5\RK?NP+UXWS"EH6RI474\%.G=U77N>,*%WL]-RVT1$ZQG$F;7
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M]C4GS[N=W79M?+GA=,CQ?KEA'2D3?/SA=<L9#S, O9GEGD6.EW\>!JN]+/5
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MXL>NMN\(RXGR^JY/\!42\.&I+G^YN&\S>S8;^U10FD*E5RHH4WK-@B6@><9
M!H6(.218(NY"9O:BIT9F=P\F+KPR-+;L5&[+=-?QC/-M)0/'LMT.PV'':6%
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MW#L ?R.[]>11^-'LUGVHNJWQ %A%7NHU3''9KJ^@$#X\_]*\UU<4[@S4!V?
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M@I3G!0)8< :0+@M@+)4 F2XHU@7)6.G5]/MD]+D9HDJXAIW&RN<9ESY%SLW
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MHI;]W9.MT7RO?S<C/CR__[%2\M,3WR[EDFUL]H0Y[!*1:0$T33E J8" 0E*
M#*>9S@G3!73JX.LRV=S\Q5K<JMMY)7"RMA(GVY;('O78UY >-A"A\8M]BCU
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MUC_5W);\IXYPKZ?+-H#KV/#:#-TGCS!;%&?H.DB1(V\OXYA<5_MZ)"Y09E8
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MZOQ?KZ=SY).L9$"?!+#(R5!RJ\$7F:'8E)@7&AD.!9)[EM\)(+YW@!PKUY[
M\8*^?+/\L/AC/@E**F>4A,*Y(7P' X$5"K^#=(ZDQ5,X/J?UP.*[I;?8,T'&
M@4+M"1=O%ZMUF/V_T\_;,Y+[:*R.8%F@,U*05$(4AKPMF[465ED>AX7&C?5W
M0T?'V<^!1-L30,Y=J(E!SKA/"#9+#HK^0P /%IA/)61M%>%^8*NQ77DW4'2<
M!CU:G"/#X9SD&HDMYA,5LE!:)<C:2'*C)1V 'I'LGF"!HC-1S/&.Q8TE=P-
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MXFRU)F=^ZY(1P*]$- F&R XR@>><//DH$")C&3*Y\1@,?2YOX]KL1E\/X=7
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M K1#D6.T(I16(>B]!(WK-+8#X7&2'S^FN#P=<'TM3\PU2YSB'["V5B7F.I3
M440MR.](41;+3)NV53?(&-?[:X&9PZ7<@:FY>#MT4<7Z2UA-T\1QYBD*\I M
M)P?4L^J*&@DIHRJY9$NH;P*5>\D9UWMK 9GCI=Y! '";B9?3V1F9KPDQ3Z2B
M@YPII%8.)3@L!1"+2$H4QQO=X#Q T$[PL<\9/H=(_KF5=6X8O?EZ:L!2SGL^
MO6GYYO>X&?Y=S2/ONZ(HRF49Z8RJ%]+&23JRHH5H"HLV%<54FUJTG<@[_DWI
M^2(?:IOM24$I;5 19*D#U(4*X),+()4IRIN2HV]CG6[2T<U[F8%P<?=9Z<%2
M[^!HNZ1^*Y%:7[V8;WIK?9VN)BA$X2&1794R@=(J04#&P.<2#9+%1=OFA<RC
M9'6"J /T_1!TCA9^!TBZQ</+Q6F8SB>(C ND(]_5D6Y*208NLP(14TC<\AA2
M(Q?I/G(Z0<[QZK[M)ATM^PX =.T=S]_Q-.)RDKT3ED4',NG: *D^SY=! 0:=
MR,$+UC8:\G*'E'&!,X!Z'WXS=8"L.P#+ SVSSIEA 7/AQH/@3%#((>N04D$Q
M0M12"ZZD\6TJ$1XE:]Q:EN%!-)P..@#4C59:%WM".H^\)!"R#C<E$1'U64!)
M%'S&DK76C<8"W25FW&N0X<%SK+P[@,P.?;#.&5,E9,>%!UV,IKU %M9;+L'4
M4]T)@]ZUN2?>F<1Q+S@:V*8FNND =+=;89USH8M7#'T&*5T$%<GNAF(#6&L=
M1BZ<,FU,U?WTC'OW,3R<!I!Z!]BY#$!>$R^;6^1)B$([:SC0:4SHUP*)@TP.
M8-).:.U4R&V>T=VEI9/V%P.&]8>)N0.@D(&LQS.^Q.V_?YO?39Z]6\QFORZ6
M?X1E)AM*/#!#QW70K!9T<8A6,-!,TGEN;,FB33_$/0GM)/X_$!=W;_";*:D#
M##[:UD/56:/:&LC%$R_!)X@!%3&4H](I&9%\Z\S 87U66K8H: >'?5JN[*.;
M@W'V&9?31;UH6JZ;]>-4+'IO*?S(&DE F"%H[X%'DI4G;R+Y5D?C0>T36[[)
M>S)D':F';O!TLU1&>9UEK<4S?/.P)T6(=0HW3YB]")(GTR8?M7]!4LM*RB=#
MT>'2/QA 7W 9%T,V!]YV1WMYMB2;^G:+SHVI_1W_V/QH-4%O6 S6U]%M>=-\
M#X(1 4*T*NN2>&&M;N=VH6_TFLFG-5K#ZJL#!^P!KC:M(*^8<B5D'9,%D6M4
M':,%9^H(>&U#X3))+1IVK?X>>:/78(Z-P2.TU3D$W^%JO9RF3;D1_=9)E>!F
MY !)L^!T?;:L6\XEXR2!QUJ30"GR'3Q' 70<9!M9B-&U*O@YCO+1*T&[ .[@
M.NX TS<N/K9'Q$DBB1(E=$(4\DFP^B>Q]L4)&6IG<+!*N\29D\JW@>LC1(U>
M5/ID2!Q*,[V!;+.5+CAYL5BM_X[K3XL\<6A,L)9<$6WK#6WAX)/0D (F3U&7
MRZY-UFX7ZG:"G?OA8#>$KCK WTG^_\ZVW2U6[W!S"_=A\2%\_>=T_:G*L+X(
M7EP^",!-6U><KS;JG2BTR19K(0N2(.TK ]$K!19#I#T7M<8VL#R"Z)W0ZG\$
MM#Z59L=_6[9Y['Z-W0^+!PI>WF&:A=5J6J9IPV=]U?F !%)QL13%H*"5M(V9
MJY?- @)F[4J65O+=>A,,2]=NF6OVG/$[MC;'Q_,]._A!(6P8CK<9?H>DBM5T
MC>]Q^66:<.NID\ 6'^>;3]F.(-28?58V0*D/1U7B"@*)HL[CTL)%PUMU_&W-
MV6[;Y(>XX>D*)!TX-(_>>*%),9M0P#A-$6AB#)SQ''A,0:>B6<(V@#_^-O*'
MN#0:3#E'7A^]FN=6EY'"9$8[HX TIM!18T@\T2!(5B(Y3I+KTN8&Z<#+2/Y#
MW",=J8A!X?1$KT]?A-6G7V>+/P:='W+UH4W?FCY ^_!/3"\7NGQ!6 A2GBM)
MAY@*%*3S3%_E&JDK9$IZY['Q8\M[J!K@$KM^YMOEXLN4Y/?+MW_06?_;_+(U
M\TE:3[]L)QY>R,$EY%J;7"\8/*A,! ?4%E@IVGOFA=6-.F+M36LGQ6#'HNF>
MN^^62NO %[MUNQ\8L\4G$*@,*)83.&4\,!*;4,''X-H,2]R_MJ(9F%KK_/'R
MBCT4T %Z;D0V-2R9I^D,;[#T8;&O-*U.V123 +.KG>Y%K@,-(K!@O8["H2EM
MRN];<#-NM=D38WET.'2P)?;HZ#E1PADK*&1/WD:2M:.C2<1(/G7RM8+%.]/&
MT=F#R'&-\?B(6CR->CM*:9XNENOI?VU4?#EF<OZQWI^M)MQ@+D50L.8R!X68
MP$=I*(!SWG+,D;E&MOD1JL:UL=U!=# %=F!-;_+R$N/ZY725%F?S]=LEGD[/
M3B?&B\TT"-#"U!O=7" :[R'[HDPP0639QF7]+FGCE@AW#LMC5=D!-G\-T^6V
MQ.!2U&_*99]X;XW%8A,P4?MR1Q' :UX?O>7,,4IA<YOVP8^2-6X=<7>8'$Z%
M'>#Q@8M5CIX;KR6@$76L?%;@'<]@T')FLE$JMS&01UR/-ZLB[@Z! RBM ^B]
M1%HY33>TT]<SW.ASGJ_;_+J=N.6.@T#K0-E@H4ZKA\23C;D8HVV;#D2[4#=N
MC7!WL!Q<H1V ].YEUZ7TSB_A+T47)*)&2:(KM4)0605!YP")6.(NHD+7!JJ[
MTSAN*7%W@&VDW"YA2_[RYS"]& DR\1B3%1G!6B<K/QPB2P5<4L9F%Y65;=[6
M?H^RWMYP#X.([P+O"/6,GP7:E/;=Y>E#^$K6_W(R(^UXG'ZIS3U6VTP8R3!2
ME%:8!<OKP /N&80@"[G-12+'$J2]-67B@6K, Q;O[4GWH$![$HV,#[Q'I+GI
M.;5EZF2U0HK,F'*9:4P@H].U_5"&B,)!YCX5BME$<&U>Z^Y"76]/PY_([!VI
MIIX1>)(V>:K5V_!MT]!(V,*-M1*,(W$I:0SX$$AP,@;NI$W.MRG,^"YIO;T3
M?R+L':.@+ET\8FAY1G1,0YS.-E[RI&2!:3.-*G@.BB4)(08D 0:FC8XY\#9Y
MG%VHZ^UM^-/A[A@UC3T?]!&Y;:9+7N<KQF@9)VY(4!2<,9W)@Q4!+/.9>)8B
ME7R@?_?@HKT]W'X*OVX8#?1LU#9#^"XLM0[%.&X+,!?(-=4:H?())7+)@E<8
M8IL+Y9W(Z^V]]M.:M8,5U27ZKONGU[>543)R'@LD)FO)'9?@/&TP*V(NJ(OD
MN=EXQ-U([.WY]@@!Q:$*ZP")N]?@39QAQ6E!3%GR6%7-?4:N KBL618J97E[
M9ON3%WR/&]P^?6UN"]5U,,#Q <Y^FW_!U0."Y-%)F1P'8I,VM^7TE9$63%$F
M:O1:Y#9M0O>GM9/NQT_T&F$HI?5K*^_A<,*%%EP4#ER(2)SE1&=-8?1'EZRA
MB,LT&H:T.XU=OF,8#"T'@W,OU?4+RLO"RGL$R0(+=70OD,1J+WM-IP%]#YPJ
M,5AMC4MM[H_WIW7< _VI;>502NL EA28'=8Y)KD0"]<% @](8JT]WE!KD"9G
MB=IQ'=L\?SZ4XB[MZ&!(6HR@UGXN6TBL"3&O:F>8VKB09(ID"ZZ:$$RBUUD9
M5(2J6H5I2GU]'A)(\N?12,Y5H\N6[Y+6Y=NN9K@<5%$=V,_=Y3<Q#)5W/$ N
M15)P1__P63@HF=GDF$HQJ)&/\R[C\E98;*2Z#N+R5Z5@(F?HU=?T*<P_XCNR
MMF_FE=GZ_]HVXTN8;8^'BVZN]0<G\WSS&]=^<\**B#&S"%GQ1.ZV+>"C(>^;
M_FR=$\A\F\"] 3/CWF\W\U;'5GL'YO@H9K=]L>ZFD-/LK#I-U\6Z%?4D:N8+
M(_>(NU)K33%!U-F YT8K\J"D5FV\BJ?E<]Q[^6;[I6.P='"('&<W<HC)*RDA
M8>!T8E(PX8M.X%F10@K'50G][8QQ2P7Z!/I>JNQFVL]Q+'O:D-IX!JDHVJI"
M*XJ"F8?DI4S&*AU9FX;'[=';K,Z@4_3NH\I>F@V>??X\VX@RS"Y$^=N\+):G
M6V5>"%5@22Y% TFAH>#'&HCDD-'18F+A.?CLVKCD.Q(X;L5!,SRV4$\'KO/V
MS=5YM<ZT#O688!1!J8(@A*?HVM=J'<]"O=,Q0@GI<VE6('^+EI%;P[50^=W2
ME6/DWP6"Z+/($%^2GWE!- Q0,I)&HJ^\*778EH\E.F<$:U7@?H.0D2_RGP0[
MATM^,. ,W [US?)CF)\_$@[SG'&5EM//]4^+$L]6TSFN5HMM#<UB?E!OU#U7
M&*11ZC%<#=0U]3H)5WU;MR^SWUYC[++K3YA=M72]A&NR3EF1/ B-9)LP!XA1
M1D*<-@5942*WN?\;A/RC"MZO4T"+_G*NMI=7NOQ JOIE5J\S7!9!1]IZPF&F
M74W!4TBV0%!!6,-83+<+3!XH>-]CT7'/RJ>'UXU:^%;*>0YF\H:XPTUQ+^X3
M]TM<A^GL:.-Y\+J#F]1A)-"5H16T$7R@$US(3:$RQ2N!"0-%!8\2,:O0)I,V
MOJ']_>PTXO)-^>>GQ6SV[<T?<\SOS^)JFJ=A6:_E6$9?0M3 >7W+PM&#*\A!
MYR!1"H-X>]SN \;U.PO]" 9U'QC=,*A#*J&#(.5]^H3Y;(9ORJ;>X)=O+^IL
MH0^;URG1V<B-"V $IT-'A03!D;0<)AEC$ESS-L^('B%JW.!E/.P-K:\>H'<A
MF0T+YPR=?)W2'C+*&\T%L%I5H$*VX$L*%+1%IXIP1;HV;?X>)&GD?,M02K\S
M/60(#70 I>OTOUR<ANE\DK)G(7M5;^K)#IN<('(K0!;NI;51BM3&>-VEI9,Y
M#L<I^?8MQ'$2'_N1]LDI+J<IU#9LB]64?O';=B[3W[&>[I-@G>8FT]&M?0#E
MK0)?:SVBRED7%E 7MY,G]?@ZXP+C6!4NVLBS,W-"P1?^1AMH-9$L2B>B!S12
M4WC,R-)ZE:%$$X+/]#5OD_Z_EYR1L[B-3J3C)=\!?-[5()KB@E=A.9_./ZY.
M4CH[/=M4GK_$,DW3]02M5Y$L+*"TE2.,9'H9UC&#UDONBTEM[@*^3UL_1NE
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M8FET,S$Q<3$R,BYH=&U02P$"% ,4    "  90Z-4_=)\^?X'  #K(@  $@
M            @ $S"   97AH:6)I=#,Q,G$Q,C(N:'1M4$L! A0#%     @
M&4.C5%C_/M45!0   Q0  !(              ( !81   &5X:&EB:70S,C%Q
M,3(R+FAT;5!+ 0(4 Q0    ( !E#HU02ELE8%P4  * 4   2
M  "  :85  !E>&AI8FET,S(R<3$R,BYH=&U02P$"% ,4    "  90Z-4WU ?
M-]4+  !H(@  '               @ 'M&@  <W9B+7-E8V]N9%]A;65N9&UE
M;G1X=&]X+FAT;5!+ 0(4 Q0    ( !E#HU3SS@\U+/H  #7)"@ 1
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M '9R;F$M,C R,C S,S%?;&%B+GAM;%!+ 0(4 Q0    ( !E#HU22[\9%ZD
M  K5 @ 5              "  6G( 0!V<FYA+3(P,C(P,S,Q7W!R92YX;6Q0
52P4&      L "P#4 @  A@D"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
